{"nodes":[{"data":{"id":"Protein_a4ea751750dbaec26a64eb323da26369","class":"macromolecule","label":"EGF","parent":"extracellular_region","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":636.7977,"y":270.82645,"w":48,"h":25},"metadata":[["bp:displayName","EGF"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P01133",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01133"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01133"]]],["bp:standardName","Pro-epidermal growth factor"],["bp:xref",[["bp:id","P01133"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","EGF"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","EGF"],["bp:db","hgnc symbol"]]],["bp:displayName","EGF_HUMAN"],["bp:name","Epidermal growth factor"],["bp:name","EGF"],["bp:name","Urogastrone"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1JL9_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/1950"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5767N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1950"],["bp:comment","FUNCTION: EGF stimulates the growth of various epidermal andepithelial tissues in vivo and in vitro and of some fibroblasts incell culture. Magnesiotropic hormone that stimulates magnesiumreabsorption in the renal distal convoluted tubule via engagementof EGFR and activation of the magnesium channel TRPM6. Can induceneurite outgrowth in motoneurons of the pond snail Lymnaeastagnalis in vitro (PubMed:10964941).{ECO:0000269|PubMed:10964941, ECO:0000269|PubMed:17671655}.SUBUNIT: Interacts with EGFR and promotes EGFR dimerization.Interacts with RHBDF2 (By similarity). Interacts with RHBDF1; mayretain EGF in the endoplasmic reticulum and regulates itsdegradation through the endoplasmic reticulum-associateddegradation (ERAD). {ECO:0000250, ECO:0000269|PubMed:12297050,ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:20837704,ECO:0000269|PubMed:21029725, ECO:0000269|PubMed:21439629}.SUBCELLULAR LOCATION: Membrane; Single-pass type I membraneprotein.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P01133-1; Sequence=Displayed;Name=2;IsoId=P01133-2; Sequence=VSP_041586;Name=3;IsoId=P01133-3; Sequence=VSP_047190;Note=No experimental confirmation available. Gene predictionbased on cDNA data.;TISSUE SPECIFICITY: Expressed in kidney, salivary gland, cerebrumand prostate. {ECO:0000269|PubMed:17671655}.PTM: O-glycosylated with core 1-like and core 2-like glycans. Itis uncertain if Ser-954 or Thr-955 is O-glycosylated. Themodification here shows glycan heterogeneity: HexHexNAc (major)and Hex2HexNAc2 (minor). {ECO:0000269|PubMed:22171320}.DISEASE: Hypomagnesemia 4 (HOMG4) [MIM:611718]: A disordercharacterized by massive renal hypomagnesemia and normal levels ofserum calcium and calcium excretion. Clinical features includeseizures, mild-to moderate psychomotor retardation, and brisktendon reflexes. {ECO:0000269|PubMed:17671655}. Note=The diseaseis caused by mutations affecting the gene represented in thisentry.SEQUENCE CAUTION:Sequence=AAR84237.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/egf/\";WEB RESOURCE: Name=Wikipedia; Note=Epidermal growth factor entry;URL=\"https://en.wikipedia.org/wiki/Epidermal_growth_factor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1950"],["bp:comment","EGF_HUMAN Reviewed; 1207 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001954"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01133"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_3912"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_4b54a396195a7afb2d66e2623aef4725","class":"macromolecule","label":"TNF","parent":"extracellular_region","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":869.0652,"y":201.81824,"w":48,"h":25},"metadata":[["bp:displayName","TNF-alpha"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"]]}},{"data":{"id":"BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":758.6861,"y":1323.0951,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Akt1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8101"]]],["bp:entityReference_http://identifiers.org/uniprot/P31749",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:organism","RAC-alpha serine/threonine-protein kinase"],["bp:displayName","AKT1_HUMAN"],["bp:name","RAC-PK-alpha"],["bp:name","PKB"],["bp:name","RAC"],["bp:name","Protein kinase B"],["bp:name","PKB alpha"],["bp:name","2.7.11.1"],["bp:name","Proto-oncogene c-Akt"],["bp:name","Protein kinase B alpha"],["bp:name","AKT1"],["bp:comment","REPLACED http://identifiers.org/uniprot/B0LPE5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P31749-1"],["bp:comment","REPLACED http://identifiers.org/ncbigene/207"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005154"],["bp:comment","REPLACED ProteinRef_AKT1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005267458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24269N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_570"],["bp:comment","FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, andwhich regulate many processes including metabolism, proliferation,cell survival, growth and angiogenesis. This is mediated throughserine and/or threonine phosphorylation of a range of downstreamsubstrates. Over 100 substrate candidates have been reported sofar, but for most of them, no isoform specificity has beenreported. AKT is responsible of the regulation of glucose uptakeby mediating insulin-induced translocation of the SLC2A4/GLUT4glucose transporter to the cell surface. Phosphorylation of PTPN1at 'Ser-50' negatively modulates its phosphatase activitypreventing dephosphorylation of the insulin receptor and theattenuation of insulin signaling. Phosphorylation of TBC1D4triggers the binding of this effector to inhibitory 14-3-3proteins, which is required for insulin-stimulated glucosetransport. AKT regulates also the storage of glucose in the formof glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at'Ser-9', resulting in inhibition of its kinase activity.Phosphorylation of GSK3 isoforms by AKT is also thought to be onemechanism by which cell proliferation is driven. AKT regulatesalso cell survival via the phosphorylation of MAP3K5 (apoptosissignal-related kinase). Phosphorylation of 'Ser-83' decreasesMAP3K5 kinase activity stimulated by oxidative stress and therebyprevents apoptosis. AKT mediates insulin-stimulated proteinsynthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',thereby activating mTORC1 signaling and leading to bothphosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT isinvolved in the phosphorylation of members of the FOXO factors(Forkhead family of transcription factors), leading to binding of14-3-3 proteins and cytoplasmic localization. In particular, FOXO1is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 andFOXO4 are phosphorylated on equivalent sites. AKT has an importantrole in the regulation of NF-kappa-B-dependent gene transcriptionand positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1induces the binding of accessory proteins that are necessary forthe transcription of pro-survival genes such as BCL2 and MCL1. AKTphosphorylates 'Ser-454' on ATP citrate lyase (ACLY), therebypotentially regulating ACLY activity and fatty acid synthesis.Activates the 3B isoform of cyclic nucleotide phosphodiesterase(PDE3B) via phosphorylation of 'Ser-273', resulting in reducedcyclic AMP levels and inhibition of lipolysis. PhosphorylatesPIKFYVE on 'Ser-318', which results in increased PI(3)P-5activity. The Rho GTPase-activating protein DLC1 is anothersubstrate and its phosphorylation is implicated in the regulationcell proliferation and cell growth. AKT plays a role as keymodulator of the AKT-mTOR signaling pathway controlling the tempoof the process of newborn neurons integration during adultneurogenesis, including correct neuron positioning, dendriticdevelopment and synapse formation. Signals downstream ofphosphatidylinositol 3-kinase (PI(3)K) to mediate the effects ofvarious growth factors such as platelet-derived growth factor(PDGF), epidermal growth factor (EGF), insulin and insulin-likegrowth factor I (IGF-I). AKT mediates the antiapoptotic effects ofIGF-I. Essential for the SPATA13-mediated regulation of cellmigration and adhesion assembly and disassembly. May be involvedin the regulation of the placental development. PhosphorylatesSTK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its:kinase activity, nuclear translocation, autophosphorylation andability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinaseactivity, autophosphorylation at Thr-180, binding to RASSF1 andnuclear translocation. Phosphorylates SRPK2 and enhances itskinase activity towards SRSF2 and ACIN1 and promotes its nucleartranslocation. Phosphorylates RAF1 at 'Ser-259' and negativelyregulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and thisphosphorylation inhibits the interaction of KAT6A with PML andnegatively regulates its acetylation activity towards p53/TP53.FUNCTION: AKT1-specific substrates have been recently identified,including palladin (PALLD), which phosphorylation modulatescytoskeletal organization and cell motility; prohibitin (PHB),playing an important role in cell metabolism and proliferation;and CDKN1A, for which phosphorylation at 'Thr-145' induces itsrelease from CDK2 and cytoplasmic relocalization. These recentfindings indicate that the AKT1 isoform has a more specific rolein cell motility and proliferation. Phosphorylates CLK2 therebycontrolling cell survival to ionizing radiation.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748,ECO:0000269|PubMed:1851997}.ENZYME REGULATION: Three specific sites, one in the kinase domain(Thr-308) and the two other ones in the C-terminal regulatoryregion (Ser-473 and Tyr-474), need to be phosphorylated for itsfull activation. Inhibited by pyrrolopyrimidine inhibitors likeaniline triazole and spiroindoline. {ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20810279,ECO:0000269|PubMed:21392984, ECO:0000269|PubMed:9512493,ECO:0000269|PubMed:9736715}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=52.8 uM for ATP (for purified and in vitro activated AKT1){ECO:0000269|PubMed:16540465};KM=0.5 uM for peptide substrate (for purified and in vitroactivated AKT1) {ECO:0000269|PubMed:16540465};KM=143.3 uM for ATP (for recombinant myristoylated AKT1expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};KM=2.9 uM for peptide substrate (for recombinant myristoylatedAKT1 expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};SUBUNIT: Interacts with BTBD10 (By similarity). Interacts withKCTD20 (By similarity). Interacts (via the C-terminus) withCCDC88A (via its C-terminus). Interacts with GRB10; theinteraction leads to GRB10 phosphorylation thus promoting YWHAE-binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A);the interaction occurs in the presence of guanine nucleotides.Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1AAND TCL1B. Interacts with CDKN1B; the interaction phosphorylatesCDKN1B promoting 14-3-3 binding and cell-cycle progression.Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3and STK4. Interacts (via PH domain) with SIRT1. Interacts withSRPK2 in a phosphorylation-dependent manner. Interacts with RAF1.Interacts with TRIM13; the interaction ubiquitinates AKT1 leadingto its proteasomal degradation. Interacts with TNK2 and CLK2.Interacts (via the C-terminus) with THEM4 (via its C-terminus).Interacts with and phosphorylated by PDPK1. Interacts with PA2G4(By similarity). Interacts with KIF14; the interaction is detectedin the plasma membrane upon INS stimulation and promotes AKT1phosphorylation (PubMed:24784001). Interacts with FAM83B;activates the PI3K/AKT signaling cascade (PubMed:23676467).Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529). Formsa complex with WDFY2 and FOXO1 (By similarity). Interacts withFAM168A (PubMed:23251525). {ECO:0000250|UniProtKB:P31750,ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10716693, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:10983986, ECO:0000269|PubMed:11154276,ECO:0000269|PubMed:11598301, ECO:0000269|PubMed:11839817,ECO:0000269|PubMed:12042314, ECO:0000269|PubMed:12176338,ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:12964941,ECO:0000269|PubMed:14749367, ECO:0000269|PubMed:14761976,ECO:0000269|PubMed:15118108, ECO:0000269|PubMed:16139227,ECO:0000269|PubMed:16417524, ECO:0000269|PubMed:16792529,ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:19713527,ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768,ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377,ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392,ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23676467,ECO:0000269|PubMed:24784001}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.Note=Nucleus after activation by integrin-linked protein kinase 1(ILK1). Nuclear translocation is enhanced by interaction withTCL1A. Phosphorylation on Tyr-176 by TNK2 results in itslocalization to the cell membrane where it is targeted for furtherphosphorylations on Thr-308 and Ser-473 leading to its activationand the activated form translocates to the nucleus. Colocalizeswith WDFY2 in intracellular vesicles (PubMed:16792529).{ECO:0000269|PubMed:16792529}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P31749-1; Sequence=Displayed;Name=2;IsoId=P31749-2; Sequence=VSP_056180;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in prostate cancer and levelsincrease from the normal to the malignant state (at proteinlevel). Expressed in all human cell types so far analyzed. TheTyr-176 phosphorylated form shows a significant increase inexpression in breast cancers during the progressive stages i.e.normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS),invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM)stages. {ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:20333297}.DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to theplasma membrane. The PH domain mediates interaction with TNK2 andTyr-176 is also essential for this interaction.DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activatingphosphorylation at Thr-308 via disrupting the interaction betweenAKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probablyinterferes with phosphorylation at this site.{ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is requiredfor full activity. Activated TNK2 phosphorylates it on Tyr-176resulting in its binding to the anionic plasma membranephospholipid PA. This phosphorylated form localizes to the cellmembrane, where it is targeted by PDPK1 and PDPK2 for furtherphosphorylations on Thr-308 and Ser-473 leading to its activation.Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylationby PDPK1. Phosphorylated at Thr-308 and Ser-473 by IKBKE and TBK1.Ser-473 phosphorylation is enhanced by interaction with AGAP2isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focalcortical dysplasias with Taylor-type balloon cells. Ser-473phosphorylation is enhanced by signaling through activated FLT3.Dephosphorylated at Thr-308 and Ser-473 by PP2A phosphatase. Thephosphorylated form of PPP2R5B is required for bridging AKT1 withPP2A phosphatase. Ser-473 is dephosphorylated by CPPED1, leadingto termination of signaling. {ECO:0000269|PubMed:12149249,ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Ubiquitinated via 'Lys-48'-linked polyubiquitination byZNRF1, leading to its degradation by the proteasome (Bysimilarity). Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1ubiquitination is critical for phosphorylation and activation.When ubiquitinated, it translocates to the plasma membrane, whereit becomes phosphorylated. When fully phosphorylated andtranslocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradationby the proteasome. Also ubiquitinated by TRIM13 leading to itsproteasomal degradation. Phosphorylated, undergoes 'Lys-48'-linkedpolyubiquitination preferentially at Lys-284 catalyzed by MUL1,leading to its proteasomal degradation. {ECO:0000250,ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20059950,ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22410793}.PTM: Acetylated on Lys-14 and Lys-20 by the histoneacetyltransferases EP300 and KAT2B. Acetylation results in reducedphosphorylation and inhibition of activity. Deacetylated at Lys-14and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves theinhibition. {ECO:0000269|PubMed:21775285}.DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancyoriginating from breast epithelial tissue. Breast neoplasms can bedistinguished by their histologic pattern. Invasive ductalcarcinoma is by far the most common type. Breast cancer isetiologically and genetically heterogeneous. Important geneticfactors have been indicated by familial occurrence and bilateralinvolvement. Mutations at more than one locus can be involved indifferent families or even in the same case.{ECO:0000269|PubMed:17611497}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex diseasecharacterized by malignant lesions arising from the inner wall ofthe large intestine (the colon) and the rectum. Geneticalterations are often associated with progression frompremalignant lesion (adenoma) to invasive adenocarcinoma. Riskfactors for cancer of the colon and rectum include colon polyps,long-standing ulcerative colitis, and genetic family history.Note=The gene represented in this entry may be involved in diseasepathogenesis.DISEASE: Note=Genetic variations in AKT1 may play a role insusceptibility to ovarian cancer.DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highlyvariable, severe disorder of asymmetric and disproportionateovergrowth of body parts, connective tissue nevi, epidermal nevi,dysregulated adipose tissue, and vascular malformations. Manyfeatures of Proteus syndrome overlap with other overgrowthsyndromes. {ECO:0000269|PubMed:18954143,ECO:0000269|PubMed:21793738}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowdensyndrome, a hamartomatous polyposis syndrome with age-relatedpenetrance. Cowden syndrome is characterized by hamartomatouslesions affecting derivatives of ectodermal, mesodermal andendodermal layers, macrocephaly, facial trichilemmomas (benigntumors of the hair follicle infundibulum), acral keratoses,papillomatous papules, and elevated risk for development ofseveral types of malignancy, particularly breast carcinoma inwomen and thyroid carcinoma in both men and women. Colon cancerand renal cell carcinoma have also been reported. Hamartomas canbe found in virtually every organ, but most commonly in the skin,gastrointestinal tract, breast and thyroid.{ECO:0000269|PubMed:23246288}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. RAC subfamily. {ECO:0000305}.CAUTION: In light of strong homologies in the primary amino acidsequence, the 3 AKT kinases were long surmised to play redundantand overlapping roles. More recent studies has brought intoquestion the redundancy within AKT kinase isoforms and insteadpointed to isoform specific functions in different cellular eventsand diseases. AKT1 is more specifically involved in cellularsurvival pathways, by inhibiting apoptotic processes; whereas AKT2is more specific for the insulin receptor signaling pathway.Moreover, while AKT1 and AKT2 are often implicated in many aspectsof cellular transformation, the 2 isoforms act in a complementaryopposing manner. The role of AKT3 is less clear, though it appearsto be predominantly expressed in brain. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AKT1ID355ch14q32.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001014431"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_207"],["bp:comment","REPLACED ProteinRef_AKT1__9606"],["bp:comment","AKT1_HUMAN Reviewed; 480 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P31749_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01261_identity"]]],["bp:name","AKT1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80901"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Akt1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8101"]]],["bp:entityReference_http://identifiers.org/uniprot/P31749",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:organism","RAC-alpha serine/threonine-protein kinase"],["bp:displayName","AKT1_HUMAN"],["bp:name","RAC-PK-alpha"],["bp:name","PKB"],["bp:name","RAC"],["bp:name","Protein kinase B"],["bp:name","PKB alpha"],["bp:name","2.7.11.1"],["bp:name","Proto-oncogene c-Akt"],["bp:name","Protein kinase B alpha"],["bp:name","AKT1"],["bp:comment","REPLACED http://identifiers.org/uniprot/B0LPE5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P31749-1"],["bp:comment","REPLACED http://identifiers.org/ncbigene/207"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005154"],["bp:comment","REPLACED ProteinRef_AKT1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005267458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24269N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_570"],["bp:comment","FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, andwhich regulate many processes including metabolism, proliferation,cell survival, growth and angiogenesis. This is mediated throughserine and/or threonine phosphorylation of a range of downstreamsubstrates. Over 100 substrate candidates have been reported sofar, but for most of them, no isoform specificity has beenreported. AKT is responsible of the regulation of glucose uptakeby mediating insulin-induced translocation of the SLC2A4/GLUT4glucose transporter to the cell surface. Phosphorylation of PTPN1at 'Ser-50' negatively modulates its phosphatase activitypreventing dephosphorylation of the insulin receptor and theattenuation of insulin signaling. Phosphorylation of TBC1D4triggers the binding of this effector to inhibitory 14-3-3proteins, which is required for insulin-stimulated glucosetransport. AKT regulates also the storage of glucose in the formof glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at'Ser-9', resulting in inhibition of its kinase activity.Phosphorylation of GSK3 isoforms by AKT is also thought to be onemechanism by which cell proliferation is driven. AKT regulatesalso cell survival via the phosphorylation of MAP3K5 (apoptosissignal-related kinase). Phosphorylation of 'Ser-83' decreasesMAP3K5 kinase activity stimulated by oxidative stress and therebyprevents apoptosis. AKT mediates insulin-stimulated proteinsynthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',thereby activating mTORC1 signaling and leading to bothphosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT isinvolved in the phosphorylation of members of the FOXO factors(Forkhead family of transcription factors), leading to binding of14-3-3 proteins and cytoplasmic localization. In particular, FOXO1is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 andFOXO4 are phosphorylated on equivalent sites. AKT has an importantrole in the regulation of NF-kappa-B-dependent gene transcriptionand positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1induces the binding of accessory proteins that are necessary forthe transcription of pro-survival genes such as BCL2 and MCL1. AKTphosphorylates 'Ser-454' on ATP citrate lyase (ACLY), therebypotentially regulating ACLY activity and fatty acid synthesis.Activates the 3B isoform of cyclic nucleotide phosphodiesterase(PDE3B) via phosphorylation of 'Ser-273', resulting in reducedcyclic AMP levels and inhibition of lipolysis. PhosphorylatesPIKFYVE on 'Ser-318', which results in increased PI(3)P-5activity. The Rho GTPase-activating protein DLC1 is anothersubstrate and its phosphorylation is implicated in the regulationcell proliferation and cell growth. AKT plays a role as keymodulator of the AKT-mTOR signaling pathway controlling the tempoof the process of newborn neurons integration during adultneurogenesis, including correct neuron positioning, dendriticdevelopment and synapse formation. Signals downstream ofphosphatidylinositol 3-kinase (PI(3)K) to mediate the effects ofvarious growth factors such as platelet-derived growth factor(PDGF), epidermal growth factor (EGF), insulin and insulin-likegrowth factor I (IGF-I). AKT mediates the antiapoptotic effects ofIGF-I. Essential for the SPATA13-mediated regulation of cellmigration and adhesion assembly and disassembly. May be involvedin the regulation of the placental development. PhosphorylatesSTK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its:kinase activity, nuclear translocation, autophosphorylation andability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinaseactivity, autophosphorylation at Thr-180, binding to RASSF1 andnuclear translocation. Phosphorylates SRPK2 and enhances itskinase activity towards SRSF2 and ACIN1 and promotes its nucleartranslocation. Phosphorylates RAF1 at 'Ser-259' and negativelyregulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and thisphosphorylation inhibits the interaction of KAT6A with PML andnegatively regulates its acetylation activity towards p53/TP53.FUNCTION: AKT1-specific substrates have been recently identified,including palladin (PALLD), which phosphorylation modulatescytoskeletal organization and cell motility; prohibitin (PHB),playing an important role in cell metabolism and proliferation;and CDKN1A, for which phosphorylation at 'Thr-145' induces itsrelease from CDK2 and cytoplasmic relocalization. These recentfindings indicate that the AKT1 isoform has a more specific rolein cell motility and proliferation. Phosphorylates CLK2 therebycontrolling cell survival to ionizing radiation.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748,ECO:0000269|PubMed:1851997}.ENZYME REGULATION: Three specific sites, one in the kinase domain(Thr-308) and the two other ones in the C-terminal regulatoryregion (Ser-473 and Tyr-474), need to be phosphorylated for itsfull activation. Inhibited by pyrrolopyrimidine inhibitors likeaniline triazole and spiroindoline. {ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20810279,ECO:0000269|PubMed:21392984, ECO:0000269|PubMed:9512493,ECO:0000269|PubMed:9736715}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=52.8 uM for ATP (for purified and in vitro activated AKT1){ECO:0000269|PubMed:16540465};KM=0.5 uM for peptide substrate (for purified and in vitroactivated AKT1) {ECO:0000269|PubMed:16540465};KM=143.3 uM for ATP (for recombinant myristoylated AKT1expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};KM=2.9 uM for peptide substrate (for recombinant myristoylatedAKT1 expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};SUBUNIT: Interacts with BTBD10 (By similarity). Interacts withKCTD20 (By similarity). Interacts (via the C-terminus) withCCDC88A (via its C-terminus). Interacts with GRB10; theinteraction leads to GRB10 phosphorylation thus promoting YWHAE-binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A);the interaction occurs in the presence of guanine nucleotides.Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1AAND TCL1B. Interacts with CDKN1B; the interaction phosphorylatesCDKN1B promoting 14-3-3 binding and cell-cycle progression.Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3and STK4. Interacts (via PH domain) with SIRT1. Interacts withSRPK2 in a phosphorylation-dependent manner. Interacts with RAF1.Interacts with TRIM13; the interaction ubiquitinates AKT1 leadingto its proteasomal degradation. Interacts with TNK2 and CLK2.Interacts (via the C-terminus) with THEM4 (via its C-terminus).Interacts with and phosphorylated by PDPK1. Interacts with PA2G4(By similarity). Interacts with KIF14; the interaction is detectedin the plasma membrane upon INS stimulation and promotes AKT1phosphorylation (PubMed:24784001). Interacts with FAM83B;activates the PI3K/AKT signaling cascade (PubMed:23676467).Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529). Formsa complex with WDFY2 and FOXO1 (By similarity). Interacts withFAM168A (PubMed:23251525). {ECO:0000250|UniProtKB:P31750,ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10716693, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:10983986, ECO:0000269|PubMed:11154276,ECO:0000269|PubMed:11598301, ECO:0000269|PubMed:11839817,ECO:0000269|PubMed:12042314, ECO:0000269|PubMed:12176338,ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:12964941,ECO:0000269|PubMed:14749367, ECO:0000269|PubMed:14761976,ECO:0000269|PubMed:15118108, ECO:0000269|PubMed:16139227,ECO:0000269|PubMed:16417524, ECO:0000269|PubMed:16792529,ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:19713527,ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768,ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377,ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392,ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23676467,ECO:0000269|PubMed:24784001}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.Note=Nucleus after activation by integrin-linked protein kinase 1(ILK1). Nuclear translocation is enhanced by interaction withTCL1A. Phosphorylation on Tyr-176 by TNK2 results in itslocalization to the cell membrane where it is targeted for furtherphosphorylations on Thr-308 and Ser-473 leading to its activationand the activated form translocates to the nucleus. Colocalizeswith WDFY2 in intracellular vesicles (PubMed:16792529).{ECO:0000269|PubMed:16792529}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P31749-1; Sequence=Displayed;Name=2;IsoId=P31749-2; Sequence=VSP_056180;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in prostate cancer and levelsincrease from the normal to the malignant state (at proteinlevel). Expressed in all human cell types so far analyzed. TheTyr-176 phosphorylated form shows a significant increase inexpression in breast cancers during the progressive stages i.e.normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS),invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM)stages. {ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:20333297}.DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to theplasma membrane. The PH domain mediates interaction with TNK2 andTyr-176 is also essential for this interaction.DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activatingphosphorylation at Thr-308 via disrupting the interaction betweenAKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probablyinterferes with phosphorylation at this site.{ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is requiredfor full activity. Activated TNK2 phosphorylates it on Tyr-176resulting in its binding to the anionic plasma membranephospholipid PA. This phosphorylated form localizes to the cellmembrane, where it is targeted by PDPK1 and PDPK2 for furtherphosphorylations on Thr-308 and Ser-473 leading to its activation.Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylationby PDPK1. Phosphorylated at Thr-308 and Ser-473 by IKBKE and TBK1.Ser-473 phosphorylation is enhanced by interaction with AGAP2isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focalcortical dysplasias with Taylor-type balloon cells. Ser-473phosphorylation is enhanced by signaling through activated FLT3.Dephosphorylated at Thr-308 and Ser-473 by PP2A phosphatase. Thephosphorylated form of PPP2R5B is required for bridging AKT1 withPP2A phosphatase. Ser-473 is dephosphorylated by CPPED1, leadingto termination of signaling. {ECO:0000269|PubMed:12149249,ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Ubiquitinated via 'Lys-48'-linked polyubiquitination byZNRF1, leading to its degradation by the proteasome (Bysimilarity). Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1ubiquitination is critical for phosphorylation and activation.When ubiquitinated, it translocates to the plasma membrane, whereit becomes phosphorylated. When fully phosphorylated andtranslocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradationby the proteasome. Also ubiquitinated by TRIM13 leading to itsproteasomal degradation. Phosphorylated, undergoes 'Lys-48'-linkedpolyubiquitination preferentially at Lys-284 catalyzed by MUL1,leading to its proteasomal degradation. {ECO:0000250,ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20059950,ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22410793}.PTM: Acetylated on Lys-14 and Lys-20 by the histoneacetyltransferases EP300 and KAT2B. Acetylation results in reducedphosphorylation and inhibition of activity. Deacetylated at Lys-14and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves theinhibition. {ECO:0000269|PubMed:21775285}.DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancyoriginating from breast epithelial tissue. Breast neoplasms can bedistinguished by their histologic pattern. Invasive ductalcarcinoma is by far the most common type. Breast cancer isetiologically and genetically heterogeneous. Important geneticfactors have been indicated by familial occurrence and bilateralinvolvement. Mutations at more than one locus can be involved indifferent families or even in the same case.{ECO:0000269|PubMed:17611497}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex diseasecharacterized by malignant lesions arising from the inner wall ofthe large intestine (the colon) and the rectum. Geneticalterations are often associated with progression frompremalignant lesion (adenoma) to invasive adenocarcinoma. Riskfactors for cancer of the colon and rectum include colon polyps,long-standing ulcerative colitis, and genetic family history.Note=The gene represented in this entry may be involved in diseasepathogenesis.DISEASE: Note=Genetic variations in AKT1 may play a role insusceptibility to ovarian cancer.DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highlyvariable, severe disorder of asymmetric and disproportionateovergrowth of body parts, connective tissue nevi, epidermal nevi,dysregulated adipose tissue, and vascular malformations. Manyfeatures of Proteus syndrome overlap with other overgrowthsyndromes. {ECO:0000269|PubMed:18954143,ECO:0000269|PubMed:21793738}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowdensyndrome, a hamartomatous polyposis syndrome with age-relatedpenetrance. Cowden syndrome is characterized by hamartomatouslesions affecting derivatives of ectodermal, mesodermal andendodermal layers, macrocephaly, facial trichilemmomas (benigntumors of the hair follicle infundibulum), acral keratoses,papillomatous papules, and elevated risk for development ofseveral types of malignancy, particularly breast carcinoma inwomen and thyroid carcinoma in both men and women. Colon cancerand renal cell carcinoma have also been reported. Hamartomas canbe found in virtually every organ, but most commonly in the skin,gastrointestinal tract, breast and thyroid.{ECO:0000269|PubMed:23246288}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. RAC subfamily. {ECO:0000305}.CAUTION: In light of strong homologies in the primary amino acidsequence, the 3 AKT kinases were long surmised to play redundantand overlapping roles. More recent studies has brought intoquestion the redundancy within AKT kinase isoforms and insteadpointed to isoform specific functions in different cellular eventsand diseases. AKT1 is more specifically involved in cellularsurvival pathways, by inhibiting apoptotic processes; whereas AKT2is more specific for the insulin receptor signaling pathway.Moreover, while AKT1 and AKT2 are often implicated in many aspectsof cellular transformation, the 2 isoforms act in a complementaryopposing manner. The role of AKT3 is less clear, though it appearsto be predominantly expressed in brain. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AKT1ID355ch14q32.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001014431"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_207"],["bp:comment","REPLACED ProteinRef_AKT1__9606"],["bp:comment","AKT1_HUMAN Reviewed; 480 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P31749_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01261_identity"]]],["bp:name","AKT1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80901"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Akt1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8101"]]],["bp:entityReference_http://identifiers.org/uniprot/P31749",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:organism","RAC-alpha serine/threonine-protein kinase"],["bp:displayName","AKT1_HUMAN"],["bp:name","RAC-PK-alpha"],["bp:name","PKB"],["bp:name","RAC"],["bp:name","Protein kinase B"],["bp:name","PKB alpha"],["bp:name","2.7.11.1"],["bp:name","Proto-oncogene c-Akt"],["bp:name","Protein kinase B alpha"],["bp:name","AKT1"],["bp:comment","REPLACED http://identifiers.org/uniprot/B0LPE5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P31749-1"],["bp:comment","REPLACED http://identifiers.org/ncbigene/207"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005154"],["bp:comment","REPLACED ProteinRef_AKT1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005267458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24269N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_570"],["bp:comment","FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, andwhich regulate many processes including metabolism, proliferation,cell survival, growth and angiogenesis. This is mediated throughserine and/or threonine phosphorylation of a range of downstreamsubstrates. Over 100 substrate candidates have been reported sofar, but for most of them, no isoform specificity has beenreported. AKT is responsible of the regulation of glucose uptakeby mediating insulin-induced translocation of the SLC2A4/GLUT4glucose transporter to the cell surface. Phosphorylation of PTPN1at 'Ser-50' negatively modulates its phosphatase activitypreventing dephosphorylation of the insulin receptor and theattenuation of insulin signaling. Phosphorylation of TBC1D4triggers the binding of this effector to inhibitory 14-3-3proteins, which is required for insulin-stimulated glucosetransport. AKT regulates also the storage of glucose in the formof glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at'Ser-9', resulting in inhibition of its kinase activity.Phosphorylation of GSK3 isoforms by AKT is also thought to be onemechanism by which cell proliferation is driven. AKT regulatesalso cell survival via the phosphorylation of MAP3K5 (apoptosissignal-related kinase). Phosphorylation of 'Ser-83' decreasesMAP3K5 kinase activity stimulated by oxidative stress and therebyprevents apoptosis. AKT mediates insulin-stimulated proteinsynthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',thereby activating mTORC1 signaling and leading to bothphosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT isinvolved in the phosphorylation of members of the FOXO factors(Forkhead family of transcription factors), leading to binding of14-3-3 proteins and cytoplasmic localization. In particular, FOXO1is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 andFOXO4 are phosphorylated on equivalent sites. AKT has an importantrole in the regulation of NF-kappa-B-dependent gene transcriptionand positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1induces the binding of accessory proteins that are necessary forthe transcription of pro-survival genes such as BCL2 and MCL1. AKTphosphorylates 'Ser-454' on ATP citrate lyase (ACLY), therebypotentially regulating ACLY activity and fatty acid synthesis.Activates the 3B isoform of cyclic nucleotide phosphodiesterase(PDE3B) via phosphorylation of 'Ser-273', resulting in reducedcyclic AMP levels and inhibition of lipolysis. PhosphorylatesPIKFYVE on 'Ser-318', which results in increased PI(3)P-5activity. The Rho GTPase-activating protein DLC1 is anothersubstrate and its phosphorylation is implicated in the regulationcell proliferation and cell growth. AKT plays a role as keymodulator of the AKT-mTOR signaling pathway controlling the tempoof the process of newborn neurons integration during adultneurogenesis, including correct neuron positioning, dendriticdevelopment and synapse formation. Signals downstream ofphosphatidylinositol 3-kinase (PI(3)K) to mediate the effects ofvarious growth factors such as platelet-derived growth factor(PDGF), epidermal growth factor (EGF), insulin and insulin-likegrowth factor I (IGF-I). AKT mediates the antiapoptotic effects ofIGF-I. Essential for the SPATA13-mediated regulation of cellmigration and adhesion assembly and disassembly. May be involvedin the regulation of the placental development. PhosphorylatesSTK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its:kinase activity, nuclear translocation, autophosphorylation andability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinaseactivity, autophosphorylation at Thr-180, binding to RASSF1 andnuclear translocation. Phosphorylates SRPK2 and enhances itskinase activity towards SRSF2 and ACIN1 and promotes its nucleartranslocation. Phosphorylates RAF1 at 'Ser-259' and negativelyregulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and thisphosphorylation inhibits the interaction of KAT6A with PML andnegatively regulates its acetylation activity towards p53/TP53.FUNCTION: AKT1-specific substrates have been recently identified,including palladin (PALLD), which phosphorylation modulatescytoskeletal organization and cell motility; prohibitin (PHB),playing an important role in cell metabolism and proliferation;and CDKN1A, for which phosphorylation at 'Thr-145' induces itsrelease from CDK2 and cytoplasmic relocalization. These recentfindings indicate that the AKT1 isoform has a more specific rolein cell motility and proliferation. Phosphorylates CLK2 therebycontrolling cell survival to ionizing radiation.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748,ECO:0000269|PubMed:1851997}.ENZYME REGULATION: Three specific sites, one in the kinase domain(Thr-308) and the two other ones in the C-terminal regulatoryregion (Ser-473 and Tyr-474), need to be phosphorylated for itsfull activation. Inhibited by pyrrolopyrimidine inhibitors likeaniline triazole and spiroindoline. {ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20810279,ECO:0000269|PubMed:21392984, ECO:0000269|PubMed:9512493,ECO:0000269|PubMed:9736715}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=52.8 uM for ATP (for purified and in vitro activated AKT1){ECO:0000269|PubMed:16540465};KM=0.5 uM for peptide substrate (for purified and in vitroactivated AKT1) {ECO:0000269|PubMed:16540465};KM=143.3 uM for ATP (for recombinant myristoylated AKT1expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};KM=2.9 uM for peptide substrate (for recombinant myristoylatedAKT1 expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};SUBUNIT: Interacts with BTBD10 (By similarity). Interacts withKCTD20 (By similarity). Interacts (via the C-terminus) withCCDC88A (via its C-terminus). Interacts with GRB10; theinteraction leads to GRB10 phosphorylation thus promoting YWHAE-binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A);the interaction occurs in the presence of guanine nucleotides.Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1AAND TCL1B. Interacts with CDKN1B; the interaction phosphorylatesCDKN1B promoting 14-3-3 binding and cell-cycle progression.Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3and STK4. Interacts (via PH domain) with SIRT1. Interacts withSRPK2 in a phosphorylation-dependent manner. Interacts with RAF1.Interacts with TRIM13; the interaction ubiquitinates AKT1 leadingto its proteasomal degradation. Interacts with TNK2 and CLK2.Interacts (via the C-terminus) with THEM4 (via its C-terminus).Interacts with and phosphorylated by PDPK1. Interacts with PA2G4(By similarity). Interacts with KIF14; the interaction is detectedin the plasma membrane upon INS stimulation and promotes AKT1phosphorylation (PubMed:24784001). Interacts with FAM83B;activates the PI3K/AKT signaling cascade (PubMed:23676467).Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529). Formsa complex with WDFY2 and FOXO1 (By similarity). Interacts withFAM168A (PubMed:23251525). {ECO:0000250|UniProtKB:P31750,ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10716693, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:10983986, ECO:0000269|PubMed:11154276,ECO:0000269|PubMed:11598301, ECO:0000269|PubMed:11839817,ECO:0000269|PubMed:12042314, ECO:0000269|PubMed:12176338,ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:12964941,ECO:0000269|PubMed:14749367, ECO:0000269|PubMed:14761976,ECO:0000269|PubMed:15118108, ECO:0000269|PubMed:16139227,ECO:0000269|PubMed:16417524, ECO:0000269|PubMed:16792529,ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:19713527,ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768,ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377,ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392,ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23676467,ECO:0000269|PubMed:24784001}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.Note=Nucleus after activation by integrin-linked protein kinase 1(ILK1). Nuclear translocation is enhanced by interaction withTCL1A. Phosphorylation on Tyr-176 by TNK2 results in itslocalization to the cell membrane where it is targeted for furtherphosphorylations on Thr-308 and Ser-473 leading to its activationand the activated form translocates to the nucleus. Colocalizeswith WDFY2 in intracellular vesicles (PubMed:16792529).{ECO:0000269|PubMed:16792529}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P31749-1; Sequence=Displayed;Name=2;IsoId=P31749-2; Sequence=VSP_056180;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in prostate cancer and levelsincrease from the normal to the malignant state (at proteinlevel). Expressed in all human cell types so far analyzed. TheTyr-176 phosphorylated form shows a significant increase inexpression in breast cancers during the progressive stages i.e.normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS),invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM)stages. {ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:20333297}.DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to theplasma membrane. The PH domain mediates interaction with TNK2 andTyr-176 is also essential for this interaction.DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activatingphosphorylation at Thr-308 via disrupting the interaction betweenAKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probablyinterferes with phosphorylation at this site.{ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is requiredfor full activity. Activated TNK2 phosphorylates it on Tyr-176resulting in its binding to the anionic plasma membranephospholipid PA. This phosphorylated form localizes to the cellmembrane, where it is targeted by PDPK1 and PDPK2 for furtherphosphorylations on Thr-308 and Ser-473 leading to its activation.Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylationby PDPK1. Phosphorylated at Thr-308 and Ser-473 by IKBKE and TBK1.Ser-473 phosphorylation is enhanced by interaction with AGAP2isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focalcortical dysplasias with Taylor-type balloon cells. Ser-473phosphorylation is enhanced by signaling through activated FLT3.Dephosphorylated at Thr-308 and Ser-473 by PP2A phosphatase. Thephosphorylated form of PPP2R5B is required for bridging AKT1 withPP2A phosphatase. Ser-473 is dephosphorylated by CPPED1, leadingto termination of signaling. {ECO:0000269|PubMed:12149249,ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Ubiquitinated via 'Lys-48'-linked polyubiquitination byZNRF1, leading to its degradation by the proteasome (Bysimilarity). Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1ubiquitination is critical for phosphorylation and activation.When ubiquitinated, it translocates to the plasma membrane, whereit becomes phosphorylated. When fully phosphorylated andtranslocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradationby the proteasome. Also ubiquitinated by TRIM13 leading to itsproteasomal degradation. Phosphorylated, undergoes 'Lys-48'-linkedpolyubiquitination preferentially at Lys-284 catalyzed by MUL1,leading to its proteasomal degradation. {ECO:0000250,ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20059950,ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22410793}.PTM: Acetylated on Lys-14 and Lys-20 by the histoneacetyltransferases EP300 and KAT2B. Acetylation results in reducedphosphorylation and inhibition of activity. Deacetylated at Lys-14and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves theinhibition. {ECO:0000269|PubMed:21775285}.DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancyoriginating from breast epithelial tissue. Breast neoplasms can bedistinguished by their histologic pattern. Invasive ductalcarcinoma is by far the most common type. Breast cancer isetiologically and genetically heterogeneous. Important geneticfactors have been indicated by familial occurrence and bilateralinvolvement. Mutations at more than one locus can be involved indifferent families or even in the same case.{ECO:0000269|PubMed:17611497}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex diseasecharacterized by malignant lesions arising from the inner wall ofthe large intestine (the colon) and the rectum. Geneticalterations are often associated with progression frompremalignant lesion (adenoma) to invasive adenocarcinoma. Riskfactors for cancer of the colon and rectum include colon polyps,long-standing ulcerative colitis, and genetic family history.Note=The gene represented in this entry may be involved in diseasepathogenesis.DISEASE: Note=Genetic variations in AKT1 may play a role insusceptibility to ovarian cancer.DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highlyvariable, severe disorder of asymmetric and disproportionateovergrowth of body parts, connective tissue nevi, epidermal nevi,dysregulated adipose tissue, and vascular malformations. Manyfeatures of Proteus syndrome overlap with other overgrowthsyndromes. {ECO:0000269|PubMed:18954143,ECO:0000269|PubMed:21793738}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowdensyndrome, a hamartomatous polyposis syndrome with age-relatedpenetrance. Cowden syndrome is characterized by hamartomatouslesions affecting derivatives of ectodermal, mesodermal andendodermal layers, macrocephaly, facial trichilemmomas (benigntumors of the hair follicle infundibulum), acral keratoses,papillomatous papules, and elevated risk for development ofseveral types of malignancy, particularly breast carcinoma inwomen and thyroid carcinoma in both men and women. Colon cancerand renal cell carcinoma have also been reported. Hamartomas canbe found in virtually every organ, but most commonly in the skin,gastrointestinal tract, breast and thyroid.{ECO:0000269|PubMed:23246288}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. RAC subfamily. {ECO:0000305}.CAUTION: In light of strong homologies in the primary amino acidsequence, the 3 AKT kinases were long surmised to play redundantand overlapping roles. More recent studies has brought intoquestion the redundancy within AKT kinase isoforms and insteadpointed to isoform specific functions in different cellular eventsand diseases. AKT1 is more specifically involved in cellularsurvival pathways, by inhibiting apoptotic processes; whereas AKT2is more specific for the insulin receptor signaling pathway.Moreover, while AKT1 and AKT2 are often implicated in many aspectsof cellular transformation, the 2 isoforms act in a complementaryopposing manner. The role of AKT3 is less clear, though it appearsto be predominantly expressed in brain. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AKT1ID355ch14q32.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001014431"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_207"],["bp:comment","REPLACED ProteinRef_AKT1__9606"],["bp:comment","AKT1_HUMAN Reviewed; 480 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P31749_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01261_identity"]]],["bp:name","AKT1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80901"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Akt1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8101"]]],["bp:entityReference_http://identifiers.org/uniprot/P31749",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:organism","RAC-alpha serine/threonine-protein kinase"],["bp:displayName","AKT1_HUMAN"],["bp:name","RAC-PK-alpha"],["bp:name","PKB"],["bp:name","RAC"],["bp:name","Protein kinase B"],["bp:name","PKB alpha"],["bp:name","2.7.11.1"],["bp:name","Proto-oncogene c-Akt"],["bp:name","Protein kinase B alpha"],["bp:name","AKT1"],["bp:comment","REPLACED http://identifiers.org/uniprot/B0LPE5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P31749-1"],["bp:comment","REPLACED http://identifiers.org/ncbigene/207"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005154"],["bp:comment","REPLACED ProteinRef_AKT1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005267458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24269N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_570"],["bp:comment","FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, andwhich regulate many processes including metabolism, proliferation,cell survival, growth and angiogenesis. This is mediated throughserine and/or threonine phosphorylation of a range of downstreamsubstrates. Over 100 substrate candidates have been reported sofar, but for most of them, no isoform specificity has beenreported. AKT is responsible of the regulation of glucose uptakeby mediating insulin-induced translocation of the SLC2A4/GLUT4glucose transporter to the cell surface. Phosphorylation of PTPN1at 'Ser-50' negatively modulates its phosphatase activitypreventing dephosphorylation of the insulin receptor and theattenuation of insulin signaling. Phosphorylation of TBC1D4triggers the binding of this effector to inhibitory 14-3-3proteins, which is required for insulin-stimulated glucosetransport. AKT regulates also the storage of glucose in the formof glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at'Ser-9', resulting in inhibition of its kinase activity.Phosphorylation of GSK3 isoforms by AKT is also thought to be onemechanism by which cell proliferation is driven. AKT regulatesalso cell survival via the phosphorylation of MAP3K5 (apoptosissignal-related kinase). Phosphorylation of 'Ser-83' decreasesMAP3K5 kinase activity stimulated by oxidative stress and therebyprevents apoptosis. AKT mediates insulin-stimulated proteinsynthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',thereby activating mTORC1 signaling and leading to bothphosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT isinvolved in the phosphorylation of members of the FOXO factors(Forkhead family of transcription factors), leading to binding of14-3-3 proteins and cytoplasmic localization. In particular, FOXO1is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 andFOXO4 are phosphorylated on equivalent sites. AKT has an importantrole in the regulation of NF-kappa-B-dependent gene transcriptionand positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1induces the binding of accessory proteins that are necessary forthe transcription of pro-survival genes such as BCL2 and MCL1. AKTphosphorylates 'Ser-454' on ATP citrate lyase (ACLY), therebypotentially regulating ACLY activity and fatty acid synthesis.Activates the 3B isoform of cyclic nucleotide phosphodiesterase(PDE3B) via phosphorylation of 'Ser-273', resulting in reducedcyclic AMP levels and inhibition of lipolysis. PhosphorylatesPIKFYVE on 'Ser-318', which results in increased PI(3)P-5activity. The Rho GTPase-activating protein DLC1 is anothersubstrate and its phosphorylation is implicated in the regulationcell proliferation and cell growth. AKT plays a role as keymodulator of the AKT-mTOR signaling pathway controlling the tempoof the process of newborn neurons integration during adultneurogenesis, including correct neuron positioning, dendriticdevelopment and synapse formation. Signals downstream ofphosphatidylinositol 3-kinase (PI(3)K) to mediate the effects ofvarious growth factors such as platelet-derived growth factor(PDGF), epidermal growth factor (EGF), insulin and insulin-likegrowth factor I (IGF-I). AKT mediates the antiapoptotic effects ofIGF-I. Essential for the SPATA13-mediated regulation of cellmigration and adhesion assembly and disassembly. May be involvedin the regulation of the placental development. PhosphorylatesSTK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its:kinase activity, nuclear translocation, autophosphorylation andability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinaseactivity, autophosphorylation at Thr-180, binding to RASSF1 andnuclear translocation. Phosphorylates SRPK2 and enhances itskinase activity towards SRSF2 and ACIN1 and promotes its nucleartranslocation. Phosphorylates RAF1 at 'Ser-259' and negativelyregulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and thisphosphorylation inhibits the interaction of KAT6A with PML andnegatively regulates its acetylation activity towards p53/TP53.FUNCTION: AKT1-specific substrates have been recently identified,including palladin (PALLD), which phosphorylation modulatescytoskeletal organization and cell motility; prohibitin (PHB),playing an important role in cell metabolism and proliferation;and CDKN1A, for which phosphorylation at 'Thr-145' induces itsrelease from CDK2 and cytoplasmic relocalization. These recentfindings indicate that the AKT1 isoform has a more specific rolein cell motility and proliferation. Phosphorylates CLK2 therebycontrolling cell survival to ionizing radiation.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748,ECO:0000269|PubMed:1851997}.ENZYME REGULATION: Three specific sites, one in the kinase domain(Thr-308) and the two other ones in the C-terminal regulatoryregion (Ser-473 and Tyr-474), need to be phosphorylated for itsfull activation. Inhibited by pyrrolopyrimidine inhibitors likeaniline triazole and spiroindoline. {ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20810279,ECO:0000269|PubMed:21392984, ECO:0000269|PubMed:9512493,ECO:0000269|PubMed:9736715}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=52.8 uM for ATP (for purified and in vitro activated AKT1){ECO:0000269|PubMed:16540465};KM=0.5 uM for peptide substrate (for purified and in vitroactivated AKT1) {ECO:0000269|PubMed:16540465};KM=143.3 uM for ATP (for recombinant myristoylated AKT1expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};KM=2.9 uM for peptide substrate (for recombinant myristoylatedAKT1 expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};SUBUNIT: Interacts with BTBD10 (By similarity). Interacts withKCTD20 (By similarity). Interacts (via the C-terminus) withCCDC88A (via its C-terminus). Interacts with GRB10; theinteraction leads to GRB10 phosphorylation thus promoting YWHAE-binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A);the interaction occurs in the presence of guanine nucleotides.Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1AAND TCL1B. Interacts with CDKN1B; the interaction phosphorylatesCDKN1B promoting 14-3-3 binding and cell-cycle progression.Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3and STK4. Interacts (via PH domain) with SIRT1. Interacts withSRPK2 in a phosphorylation-dependent manner. Interacts with RAF1.Interacts with TRIM13; the interaction ubiquitinates AKT1 leadingto its proteasomal degradation. Interacts with TNK2 and CLK2.Interacts (via the C-terminus) with THEM4 (via its C-terminus).Interacts with and phosphorylated by PDPK1. Interacts with PA2G4(By similarity). Interacts with KIF14; the interaction is detectedin the plasma membrane upon INS stimulation and promotes AKT1phosphorylation (PubMed:24784001). Interacts with FAM83B;activates the PI3K/AKT signaling cascade (PubMed:23676467).Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529). Formsa complex with WDFY2 and FOXO1 (By similarity). Interacts withFAM168A (PubMed:23251525). {ECO:0000250|UniProtKB:P31750,ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10716693, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:10983986, ECO:0000269|PubMed:11154276,ECO:0000269|PubMed:11598301, ECO:0000269|PubMed:11839817,ECO:0000269|PubMed:12042314, ECO:0000269|PubMed:12176338,ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:12964941,ECO:0000269|PubMed:14749367, ECO:0000269|PubMed:14761976,ECO:0000269|PubMed:15118108, ECO:0000269|PubMed:16139227,ECO:0000269|PubMed:16417524, ECO:0000269|PubMed:16792529,ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:19713527,ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768,ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377,ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392,ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23676467,ECO:0000269|PubMed:24784001}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.Note=Nucleus after activation by integrin-linked protein kinase 1(ILK1). Nuclear translocation is enhanced by interaction withTCL1A. Phosphorylation on Tyr-176 by TNK2 results in itslocalization to the cell membrane where it is targeted for furtherphosphorylations on Thr-308 and Ser-473 leading to its activationand the activated form translocates to the nucleus. Colocalizeswith WDFY2 in intracellular vesicles (PubMed:16792529).{ECO:0000269|PubMed:16792529}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P31749-1; Sequence=Displayed;Name=2;IsoId=P31749-2; Sequence=VSP_056180;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in prostate cancer and levelsincrease from the normal to the malignant state (at proteinlevel). Expressed in all human cell types so far analyzed. TheTyr-176 phosphorylated form shows a significant increase inexpression in breast cancers during the progressive stages i.e.normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS),invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM)stages. {ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:20333297}.DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to theplasma membrane. The PH domain mediates interaction with TNK2 andTyr-176 is also essential for this interaction.DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activatingphosphorylation at Thr-308 via disrupting the interaction betweenAKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probablyinterferes with phosphorylation at this site.{ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is requiredfor full activity. Activated TNK2 phosphorylates it on Tyr-176resulting in its binding to the anionic plasma membranephospholipid PA. This phosphorylated form localizes to the cellmembrane, where it is targeted by PDPK1 and PDPK2 for furtherphosphorylations on Thr-308 and Ser-473 leading to its activation.Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylationby PDPK1. Phosphorylated at Thr-308 and Ser-473 by IKBKE and TBK1.Ser-473 phosphorylation is enhanced by interaction with AGAP2isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focalcortical dysplasias with Taylor-type balloon cells. Ser-473phosphorylation is enhanced by signaling through activated FLT3.Dephosphorylated at Thr-308 and Ser-473 by PP2A phosphatase. Thephosphorylated form of PPP2R5B is required for bridging AKT1 withPP2A phosphatase. Ser-473 is dephosphorylated by CPPED1, leadingto termination of signaling. {ECO:0000269|PubMed:12149249,ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Ubiquitinated via 'Lys-48'-linked polyubiquitination byZNRF1, leading to its degradation by the proteasome (Bysimilarity). Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1ubiquitination is critical for phosphorylation and activation.When ubiquitinated, it translocates to the plasma membrane, whereit becomes phosphorylated. When fully phosphorylated andtranslocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradationby the proteasome. Also ubiquitinated by TRIM13 leading to itsproteasomal degradation. Phosphorylated, undergoes 'Lys-48'-linkedpolyubiquitination preferentially at Lys-284 catalyzed by MUL1,leading to its proteasomal degradation. {ECO:0000250,ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20059950,ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22410793}.PTM: Acetylated on Lys-14 and Lys-20 by the histoneacetyltransferases EP300 and KAT2B. Acetylation results in reducedphosphorylation and inhibition of activity. Deacetylated at Lys-14and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves theinhibition. {ECO:0000269|PubMed:21775285}.DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancyoriginating from breast epithelial tissue. Breast neoplasms can bedistinguished by their histologic pattern. Invasive ductalcarcinoma is by far the most common type. Breast cancer isetiologically and genetically heterogeneous. Important geneticfactors have been indicated by familial occurrence and bilateralinvolvement. Mutations at more than one locus can be involved indifferent families or even in the same case.{ECO:0000269|PubMed:17611497}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex diseasecharacterized by malignant lesions arising from the inner wall ofthe large intestine (the colon) and the rectum. Geneticalterations are often associated with progression frompremalignant lesion (adenoma) to invasive adenocarcinoma. Riskfactors for cancer of the colon and rectum include colon polyps,long-standing ulcerative colitis, and genetic family history.Note=The gene represented in this entry may be involved in diseasepathogenesis.DISEASE: Note=Genetic variations in AKT1 may play a role insusceptibility to ovarian cancer.DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highlyvariable, severe disorder of asymmetric and disproportionateovergrowth of body parts, connective tissue nevi, epidermal nevi,dysregulated adipose tissue, and vascular malformations. Manyfeatures of Proteus syndrome overlap with other overgrowthsyndromes. {ECO:0000269|PubMed:18954143,ECO:0000269|PubMed:21793738}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowdensyndrome, a hamartomatous polyposis syndrome with age-relatedpenetrance. Cowden syndrome is characterized by hamartomatouslesions affecting derivatives of ectodermal, mesodermal andendodermal layers, macrocephaly, facial trichilemmomas (benigntumors of the hair follicle infundibulum), acral keratoses,papillomatous papules, and elevated risk for development ofseveral types of malignancy, particularly breast carcinoma inwomen and thyroid carcinoma in both men and women. Colon cancerand renal cell carcinoma have also been reported. Hamartomas canbe found in virtually every organ, but most commonly in the skin,gastrointestinal tract, breast and thyroid.{ECO:0000269|PubMed:23246288}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. RAC subfamily. {ECO:0000305}.CAUTION: In light of strong homologies in the primary amino acidsequence, the 3 AKT kinases were long surmised to play redundantand overlapping roles. More recent studies has brought intoquestion the redundancy within AKT kinase isoforms and insteadpointed to isoform specific functions in different cellular eventsand diseases. AKT1 is more specifically involved in cellularsurvival pathways, by inhibiting apoptotic processes; whereas AKT2is more specific for the insulin receptor signaling pathway.Moreover, while AKT1 and AKT2 are often implicated in many aspectsof cellular transformation, the 2 isoforms act in a complementaryopposing manner. The role of AKT3 is less clear, though it appearsto be predominantly expressed in brain. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AKT1ID355ch14q32.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001014431"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_207"],["bp:comment","REPLACED ProteinRef_AKT1__9606"],["bp:comment","AKT1_HUMAN Reviewed; 480 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P31749_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01261_identity"]]],["bp:name","AKT1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80901"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Akt1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8101"]]],["bp:entityReference_http://identifiers.org/uniprot/P31749",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:organism","RAC-alpha serine/threonine-protein kinase"],["bp:displayName","AKT1_HUMAN"],["bp:name","RAC-PK-alpha"],["bp:name","PKB"],["bp:name","RAC"],["bp:name","Protein kinase B"],["bp:name","PKB alpha"],["bp:name","2.7.11.1"],["bp:name","Proto-oncogene c-Akt"],["bp:name","Protein kinase B alpha"],["bp:name","AKT1"],["bp:comment","REPLACED http://identifiers.org/uniprot/B0LPE5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P31749-1"],["bp:comment","REPLACED http://identifiers.org/ncbigene/207"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005154"],["bp:comment","REPLACED ProteinRef_AKT1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005267458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24269N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_570"],["bp:comment","FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, andwhich regulate many processes including metabolism, proliferation,cell survival, growth and angiogenesis. This is mediated throughserine and/or threonine phosphorylation of a range of downstreamsubstrates. Over 100 substrate candidates have been reported sofar, but for most of them, no isoform specificity has beenreported. AKT is responsible of the regulation of glucose uptakeby mediating insulin-induced translocation of the SLC2A4/GLUT4glucose transporter to the cell surface. Phosphorylation of PTPN1at 'Ser-50' negatively modulates its phosphatase activitypreventing dephosphorylation of the insulin receptor and theattenuation of insulin signaling. Phosphorylation of TBC1D4triggers the binding of this effector to inhibitory 14-3-3proteins, which is required for insulin-stimulated glucosetransport. AKT regulates also the storage of glucose in the formof glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at'Ser-9', resulting in inhibition of its kinase activity.Phosphorylation of GSK3 isoforms by AKT is also thought to be onemechanism by which cell proliferation is driven. AKT regulatesalso cell survival via the phosphorylation of MAP3K5 (apoptosissignal-related kinase). Phosphorylation of 'Ser-83' decreasesMAP3K5 kinase activity stimulated by oxidative stress and therebyprevents apoptosis. AKT mediates insulin-stimulated proteinsynthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',thereby activating mTORC1 signaling and leading to bothphosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT isinvolved in the phosphorylation of members of the FOXO factors(Forkhead family of transcription factors), leading to binding of14-3-3 proteins and cytoplasmic localization. In particular, FOXO1is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 andFOXO4 are phosphorylated on equivalent sites. AKT has an importantrole in the regulation of NF-kappa-B-dependent gene transcriptionand positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1induces the binding of accessory proteins that are necessary forthe transcription of pro-survival genes such as BCL2 and MCL1. AKTphosphorylates 'Ser-454' on ATP citrate lyase (ACLY), therebypotentially regulating ACLY activity and fatty acid synthesis.Activates the 3B isoform of cyclic nucleotide phosphodiesterase(PDE3B) via phosphorylation of 'Ser-273', resulting in reducedcyclic AMP levels and inhibition of lipolysis. PhosphorylatesPIKFYVE on 'Ser-318', which results in increased PI(3)P-5activity. The Rho GTPase-activating protein DLC1 is anothersubstrate and its phosphorylation is implicated in the regulationcell proliferation and cell growth. AKT plays a role as keymodulator of the AKT-mTOR signaling pathway controlling the tempoof the process of newborn neurons integration during adultneurogenesis, including correct neuron positioning, dendriticdevelopment and synapse formation. Signals downstream ofphosphatidylinositol 3-kinase (PI(3)K) to mediate the effects ofvarious growth factors such as platelet-derived growth factor(PDGF), epidermal growth factor (EGF), insulin and insulin-likegrowth factor I (IGF-I). AKT mediates the antiapoptotic effects ofIGF-I. Essential for the SPATA13-mediated regulation of cellmigration and adhesion assembly and disassembly. May be involvedin the regulation of the placental development. PhosphorylatesSTK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its:kinase activity, nuclear translocation, autophosphorylation andability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinaseactivity, autophosphorylation at Thr-180, binding to RASSF1 andnuclear translocation. Phosphorylates SRPK2 and enhances itskinase activity towards SRSF2 and ACIN1 and promotes its nucleartranslocation. Phosphorylates RAF1 at 'Ser-259' and negativelyregulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and thisphosphorylation inhibits the interaction of KAT6A with PML andnegatively regulates its acetylation activity towards p53/TP53.FUNCTION: AKT1-specific substrates have been recently identified,including palladin (PALLD), which phosphorylation modulatescytoskeletal organization and cell motility; prohibitin (PHB),playing an important role in cell metabolism and proliferation;and CDKN1A, for which phosphorylation at 'Thr-145' induces itsrelease from CDK2 and cytoplasmic relocalization. These recentfindings indicate that the AKT1 isoform has a more specific rolein cell motility and proliferation. Phosphorylates CLK2 therebycontrolling cell survival to ionizing radiation.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748,ECO:0000269|PubMed:1851997}.ENZYME REGULATION: Three specific sites, one in the kinase domain(Thr-308) and the two other ones in the C-terminal regulatoryregion (Ser-473 and Tyr-474), need to be phosphorylated for itsfull activation. Inhibited by pyrrolopyrimidine inhibitors likeaniline triazole and spiroindoline. {ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20810279,ECO:0000269|PubMed:21392984, ECO:0000269|PubMed:9512493,ECO:0000269|PubMed:9736715}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=52.8 uM for ATP (for purified and in vitro activated AKT1){ECO:0000269|PubMed:16540465};KM=0.5 uM for peptide substrate (for purified and in vitroactivated AKT1) {ECO:0000269|PubMed:16540465};KM=143.3 uM for ATP (for recombinant myristoylated AKT1expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};KM=2.9 uM for peptide substrate (for recombinant myristoylatedAKT1 expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};SUBUNIT: Interacts with BTBD10 (By similarity). Interacts withKCTD20 (By similarity). Interacts (via the C-terminus) withCCDC88A (via its C-terminus). Interacts with GRB10; theinteraction leads to GRB10 phosphorylation thus promoting YWHAE-binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A);the interaction occurs in the presence of guanine nucleotides.Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1AAND TCL1B. Interacts with CDKN1B; the interaction phosphorylatesCDKN1B promoting 14-3-3 binding and cell-cycle progression.Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3and STK4. Interacts (via PH domain) with SIRT1. Interacts withSRPK2 in a phosphorylation-dependent manner. Interacts with RAF1.Interacts with TRIM13; the interaction ubiquitinates AKT1 leadingto its proteasomal degradation. Interacts with TNK2 and CLK2.Interacts (via the C-terminus) with THEM4 (via its C-terminus).Interacts with and phosphorylated by PDPK1. Interacts with PA2G4(By similarity). Interacts with KIF14; the interaction is detectedin the plasma membrane upon INS stimulation and promotes AKT1phosphorylation (PubMed:24784001). Interacts with FAM83B;activates the PI3K/AKT signaling cascade (PubMed:23676467).Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529). Formsa complex with WDFY2 and FOXO1 (By similarity). Interacts withFAM168A (PubMed:23251525). {ECO:0000250|UniProtKB:P31750,ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10716693, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:10983986, ECO:0000269|PubMed:11154276,ECO:0000269|PubMed:11598301, ECO:0000269|PubMed:11839817,ECO:0000269|PubMed:12042314, ECO:0000269|PubMed:12176338,ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:12964941,ECO:0000269|PubMed:14749367, ECO:0000269|PubMed:14761976,ECO:0000269|PubMed:15118108, ECO:0000269|PubMed:16139227,ECO:0000269|PubMed:16417524, ECO:0000269|PubMed:16792529,ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:19713527,ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768,ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377,ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392,ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23676467,ECO:0000269|PubMed:24784001}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.Note=Nucleus after activation by integrin-linked protein kinase 1(ILK1). Nuclear translocation is enhanced by interaction withTCL1A. Phosphorylation on Tyr-176 by TNK2 results in itslocalization to the cell membrane where it is targeted for furtherphosphorylations on Thr-308 and Ser-473 leading to its activationand the activated form translocates to the nucleus. Colocalizeswith WDFY2 in intracellular vesicles (PubMed:16792529).{ECO:0000269|PubMed:16792529}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P31749-1; Sequence=Displayed;Name=2;IsoId=P31749-2; Sequence=VSP_056180;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in prostate cancer and levelsincrease from the normal to the malignant state (at proteinlevel). Expressed in all human cell types so far analyzed. TheTyr-176 phosphorylated form shows a significant increase inexpression in breast cancers during the progressive stages i.e.normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS),invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM)stages. {ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:20333297}.DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to theplasma membrane. The PH domain mediates interaction with TNK2 andTyr-176 is also essential for this interaction.DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activatingphosphorylation at Thr-308 via disrupting the interaction betweenAKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probablyinterferes with phosphorylation at this site.{ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is requiredfor full activity. Activated TNK2 phosphorylates it on Tyr-176resulting in its binding to the anionic plasma membranephospholipid PA. This phosphorylated form localizes to the cellmembrane, where it is targeted by PDPK1 and PDPK2 for furtherphosphorylations on Thr-308 and Ser-473 leading to its activation.Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylationby PDPK1. Phosphorylated at Thr-308 and Ser-473 by IKBKE and TBK1.Ser-473 phosphorylation is enhanced by interaction with AGAP2isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focalcortical dysplasias with Taylor-type balloon cells. Ser-473phosphorylation is enhanced by signaling through activated FLT3.Dephosphorylated at Thr-308 and Ser-473 by PP2A phosphatase. Thephosphorylated form of PPP2R5B is required for bridging AKT1 withPP2A phosphatase. Ser-473 is dephosphorylated by CPPED1, leadingto termination of signaling. {ECO:0000269|PubMed:12149249,ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Ubiquitinated via 'Lys-48'-linked polyubiquitination byZNRF1, leading to its degradation by the proteasome (Bysimilarity). Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1ubiquitination is critical for phosphorylation and activation.When ubiquitinated, it translocates to the plasma membrane, whereit becomes phosphorylated. When fully phosphorylated andtranslocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradationby the proteasome. Also ubiquitinated by TRIM13 leading to itsproteasomal degradation. Phosphorylated, undergoes 'Lys-48'-linkedpolyubiquitination preferentially at Lys-284 catalyzed by MUL1,leading to its proteasomal degradation. {ECO:0000250,ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20059950,ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22410793}.PTM: Acetylated on Lys-14 and Lys-20 by the histoneacetyltransferases EP300 and KAT2B. Acetylation results in reducedphosphorylation and inhibition of activity. Deacetylated at Lys-14and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves theinhibition. {ECO:0000269|PubMed:21775285}.DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancyoriginating from breast epithelial tissue. Breast neoplasms can bedistinguished by their histologic pattern. Invasive ductalcarcinoma is by far the most common type. Breast cancer isetiologically and genetically heterogeneous. Important geneticfactors have been indicated by familial occurrence and bilateralinvolvement. Mutations at more than one locus can be involved indifferent families or even in the same case.{ECO:0000269|PubMed:17611497}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex diseasecharacterized by malignant lesions arising from the inner wall ofthe large intestine (the colon) and the rectum. Geneticalterations are often associated with progression frompremalignant lesion (adenoma) to invasive adenocarcinoma. Riskfactors for cancer of the colon and rectum include colon polyps,long-standing ulcerative colitis, and genetic family history.Note=The gene represented in this entry may be involved in diseasepathogenesis.DISEASE: Note=Genetic variations in AKT1 may play a role insusceptibility to ovarian cancer.DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highlyvariable, severe disorder of asymmetric and disproportionateovergrowth of body parts, connective tissue nevi, epidermal nevi,dysregulated adipose tissue, and vascular malformations. Manyfeatures of Proteus syndrome overlap with other overgrowthsyndromes. {ECO:0000269|PubMed:18954143,ECO:0000269|PubMed:21793738}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowdensyndrome, a hamartomatous polyposis syndrome with age-relatedpenetrance. Cowden syndrome is characterized by hamartomatouslesions affecting derivatives of ectodermal, mesodermal andendodermal layers, macrocephaly, facial trichilemmomas (benigntumors of the hair follicle infundibulum), acral keratoses,papillomatous papules, and elevated risk for development ofseveral types of malignancy, particularly breast carcinoma inwomen and thyroid carcinoma in both men and women. Colon cancerand renal cell carcinoma have also been reported. Hamartomas canbe found in virtually every organ, but most commonly in the skin,gastrointestinal tract, breast and thyroid.{ECO:0000269|PubMed:23246288}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. RAC subfamily. {ECO:0000305}.CAUTION: In light of strong homologies in the primary amino acidsequence, the 3 AKT kinases were long surmised to play redundantand overlapping roles. More recent studies has brought intoquestion the redundancy within AKT kinase isoforms and insteadpointed to isoform specific functions in different cellular eventsand diseases. AKT1 is more specifically involved in cellularsurvival pathways, by inhibiting apoptotic processes; whereas AKT2is more specific for the insulin receptor signaling pathway.Moreover, while AKT1 and AKT2 are often implicated in many aspectsof cellular transformation, the 2 isoforms act in a complementaryopposing manner. The role of AKT3 is less clear, though it appearsto be predominantly expressed in brain. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AKT1ID355ch14q32.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001014431"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_207"],["bp:comment","REPLACED ProteinRef_AKT1__9606"],["bp:comment","AKT1_HUMAN Reviewed; 480 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P31749_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01261_identity"]]],["bp:name","AKT1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80901"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80898"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80898"]]}},{"data":{"id":"ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":949.32635,"y":1409.1335,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","I kappa B alpha (degradation)"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80832"],["bp:featureLocation",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_996"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:01240"],["bp:db","protein modification ontology"]]],["bp:term","ubiquitination"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80748"]]],["bp:entityReference_http://identifiers.org/uniprot/P25963",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:standardName","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:organism","NF-kappa-B inhibitor alpha"],["bp:displayName","IKBA_HUMAN"],["bp:name","IKBA"],["bp:name","MAD3"],["bp:name","IkB-alpha"],["bp:name","Major histocompatibility complex enhancer-binding protein MAD3"],["bp:name","NFKBI"],["bp:name","NFKBIA"],["bp:name","I-kappa-B-alpha"],["bp:name","IkappaBalpha"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q04207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25799_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25799"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-139N_identity"],["bp:comment","REPLACED ProteinRef_NFKBIA__9606"],["bp:comment","REPLACED ProteinRef_NFKBIA__40674"],["bp:comment","IKBA_HUMAN Reviewed; 317 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_990"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25963_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_065390"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01235_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4792"],["bp:comment","REPLACED ProteinRef_NFKBIA__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4792"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4792"],["bp:comment","FUNCTION: Inhibits the activity of dimeric NF-kappa-B/RELcomplexes by trapping REL dimers in the cytoplasm through maskingof their nuclear localization signals. On cellular stimulation byimmune and proinflammatory responses, becomes phosphorylatedpromoting ubiquitination and degradation, enabling the dimericRELA to translocate to the nucleus and activate transcription.{ECO:0000269|PubMed:7479976}.SUBUNIT: Interacts with RELA; the interaction requires the nuclearimport signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA,IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts withisoform 1 and isoform 2 of RWDD3; the interaction enhancessumoylation. Interacts (when phosphorylated at the 2 serineresidues in the destruction motif D-S-G-X(2,3,4)-S) with BTRC.Associates with the SCF(BTRC) complex, composed of SKP1, CUL1 andBTRC; the association is mediated via interaction with BTRC. Partof a SCF(BTRC)-like complex lacking CUL1, which is associated withRELA; RELA interacts directly with NFKBIA. Interacts with PRMT2.Interacts with PRKACA in platelets; this interaction is disruptedby thrombin and collagen. Interacts with HIF1AN. Interacts withMEFV. Interacts with DDRGK1; positively regulates NFKBIAphosphorylation and degradation. {ECO:0000269|PubMed:10454581,ECO:0000269|PubMed:10657303, ECO:0000269|PubMed:1493333,ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:18577712,ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:23469069,ECO:0000269|PubMed:23675531}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles betweenthe nucleus and the cytoplasm by a nuclear localization signal(NLS) and a CRM1-dependent nuclear export. {ECO:0000250}.INDUCTION: Induced in adherent monocytes.PTM: Phosphorylated; disables inhibition of NF-kappa-B DNA-bindingactivity. Phosphorylation at positions 32 and 36 is prerequisiteto recognition by UBE2D3 leading to polyubiquitination andsubsequent degradation. {ECO:0000269|PubMed:10329681,ECO:0000269|PubMed:10882136, ECO:0000269|PubMed:20504922}.PTM: Sumoylated; sumoylation requires the presence of the nuclearimport signal. Sumoylation blocks ubiquitination and proteasome-mediated degradation of the protein thereby increasing the proteinstability. {ECO:0000269|PubMed:11124955,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:20504922}.PTM: Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3.Ubiquitin chain elongation is then performed by CDC34 incooperation with the SCF(FBXW11) E3 ligase complex, buildingubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin.The resulting polyubiquitination leads to protein degradation.Also ubiquitinated by SCF(BTRC) following stimulus-dependentphosphorylation at Ser-32 and Ser-36.{ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10882136,ECO:0000269|PubMed:20347421, ECO:0000269|PubMed:20504922,ECO:0000269|PubMed:7479976}.PTM: Deubiquitinated by porcine reproductive and respiratorysyndrome virus Nsp2 protein, which thereby interferes with NFKBIAdegradation and impairs subsequent NF-kappa-B activation.DISEASE: Ectodermal dysplasia, anhidrotic, with T-cellimmunodeficiency autosomal dominant (ADEDAID) [MIM:612132]: A formof ectoderma dysplasia, a heterogeneous group of disorders due toabnormal development of two or more ectodermal structures. Thisform of ectodermal dysplasia is associated with decreasedproduction of pro-inflammatory cytokines and certain interferons,rendering patients susceptible to infection.{ECO:0000269|PubMed:14523047, ECO:0000269|PubMed:18412279}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the NF-kappa-B inhibitor family.{ECO:0000305}.WEB RESOURCE: Name=NFKBIAbase; Note=NFKBIA mutation db;URL=\"http://structure.bmc.lu.se/idbase/NFKBIAbase/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/nfkbia/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80834"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","I kappa B alpha (degradation)"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80832"],["bp:featureLocation",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_996"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:01240"],["bp:db","protein modification ontology"]]],["bp:term","ubiquitination"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80748"]]],["bp:entityReference_http://identifiers.org/uniprot/P25963",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:standardName","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:organism","NF-kappa-B inhibitor alpha"],["bp:displayName","IKBA_HUMAN"],["bp:name","IKBA"],["bp:name","MAD3"],["bp:name","IkB-alpha"],["bp:name","Major histocompatibility complex enhancer-binding protein MAD3"],["bp:name","NFKBI"],["bp:name","NFKBIA"],["bp:name","I-kappa-B-alpha"],["bp:name","IkappaBalpha"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q04207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25799_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25799"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-139N_identity"],["bp:comment","REPLACED ProteinRef_NFKBIA__9606"],["bp:comment","REPLACED ProteinRef_NFKBIA__40674"],["bp:comment","IKBA_HUMAN Reviewed; 317 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_990"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25963_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_065390"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01235_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4792"],["bp:comment","REPLACED ProteinRef_NFKBIA__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4792"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4792"],["bp:comment","FUNCTION: Inhibits the activity of dimeric NF-kappa-B/RELcomplexes by trapping REL dimers in the cytoplasm through maskingof their nuclear localization signals. On cellular stimulation byimmune and proinflammatory responses, becomes phosphorylatedpromoting ubiquitination and degradation, enabling the dimericRELA to translocate to the nucleus and activate transcription.{ECO:0000269|PubMed:7479976}.SUBUNIT: Interacts with RELA; the interaction requires the nuclearimport signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA,IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts withisoform 1 and isoform 2 of RWDD3; the interaction enhancessumoylation. Interacts (when phosphorylated at the 2 serineresidues in the destruction motif D-S-G-X(2,3,4)-S) with BTRC.Associates with the SCF(BTRC) complex, composed of SKP1, CUL1 andBTRC; the association is mediated via interaction with BTRC. Partof a SCF(BTRC)-like complex lacking CUL1, which is associated withRELA; RELA interacts directly with NFKBIA. Interacts with PRMT2.Interacts with PRKACA in platelets; this interaction is disruptedby thrombin and collagen. Interacts with HIF1AN. Interacts withMEFV. Interacts with DDRGK1; positively regulates NFKBIAphosphorylation and degradation. {ECO:0000269|PubMed:10454581,ECO:0000269|PubMed:10657303, ECO:0000269|PubMed:1493333,ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:18577712,ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:23469069,ECO:0000269|PubMed:23675531}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles betweenthe nucleus and the cytoplasm by a nuclear localization signal(NLS) and a CRM1-dependent nuclear export. {ECO:0000250}.INDUCTION: Induced in adherent monocytes.PTM: Phosphorylated; disables inhibition of NF-kappa-B DNA-bindingactivity. Phosphorylation at positions 32 and 36 is prerequisiteto recognition by UBE2D3 leading to polyubiquitination andsubsequent degradation. {ECO:0000269|PubMed:10329681,ECO:0000269|PubMed:10882136, ECO:0000269|PubMed:20504922}.PTM: Sumoylated; sumoylation requires the presence of the nuclearimport signal. Sumoylation blocks ubiquitination and proteasome-mediated degradation of the protein thereby increasing the proteinstability. {ECO:0000269|PubMed:11124955,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:20504922}.PTM: Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3.Ubiquitin chain elongation is then performed by CDC34 incooperation with the SCF(FBXW11) E3 ligase complex, buildingubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin.The resulting polyubiquitination leads to protein degradation.Also ubiquitinated by SCF(BTRC) following stimulus-dependentphosphorylation at Ser-32 and Ser-36.{ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10882136,ECO:0000269|PubMed:20347421, ECO:0000269|PubMed:20504922,ECO:0000269|PubMed:7479976}.PTM: Deubiquitinated by porcine reproductive and respiratorysyndrome virus Nsp2 protein, which thereby interferes with NFKBIAdegradation and impairs subsequent NF-kappa-B activation.DISEASE: Ectodermal dysplasia, anhidrotic, with T-cellimmunodeficiency autosomal dominant (ADEDAID) [MIM:612132]: A formof ectoderma dysplasia, a heterogeneous group of disorders due toabnormal development of two or more ectodermal structures. Thisform of ectodermal dysplasia is associated with decreasedproduction of pro-inflammatory cytokines and certain interferons,rendering patients susceptible to infection.{ECO:0000269|PubMed:14523047, ECO:0000269|PubMed:18412279}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the NF-kappa-B inhibitor family.{ECO:0000305}.WEB RESOURCE: Name=NFKBIAbase; Note=NFKBIA mutation db;URL=\"http://structure.bmc.lu.se/idbase/NFKBIAbase/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/nfkbia/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80834"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","I kappa B alpha (degradation)"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80832"],["bp:featureLocation",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_996"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:01240"],["bp:db","protein modification ontology"]]],["bp:term","ubiquitination"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80748"]]],["bp:entityReference_http://identifiers.org/uniprot/P25963",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:standardName","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:organism","NF-kappa-B inhibitor alpha"],["bp:displayName","IKBA_HUMAN"],["bp:name","IKBA"],["bp:name","MAD3"],["bp:name","IkB-alpha"],["bp:name","Major histocompatibility complex enhancer-binding protein MAD3"],["bp:name","NFKBI"],["bp:name","NFKBIA"],["bp:name","I-kappa-B-alpha"],["bp:name","IkappaBalpha"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q04207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25799_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25799"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-139N_identity"],["bp:comment","REPLACED ProteinRef_NFKBIA__9606"],["bp:comment","REPLACED ProteinRef_NFKBIA__40674"],["bp:comment","IKBA_HUMAN Reviewed; 317 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_990"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25963_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_065390"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01235_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4792"],["bp:comment","REPLACED ProteinRef_NFKBIA__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4792"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4792"],["bp:comment","FUNCTION: Inhibits the activity of dimeric NF-kappa-B/RELcomplexes by trapping REL dimers in the cytoplasm through maskingof their nuclear localization signals. On cellular stimulation byimmune and proinflammatory responses, becomes phosphorylatedpromoting ubiquitination and degradation, enabling the dimericRELA to translocate to the nucleus and activate transcription.{ECO:0000269|PubMed:7479976}.SUBUNIT: Interacts with RELA; the interaction requires the nuclearimport signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA,IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts withisoform 1 and isoform 2 of RWDD3; the interaction enhancessumoylation. Interacts (when phosphorylated at the 2 serineresidues in the destruction motif D-S-G-X(2,3,4)-S) with BTRC.Associates with the SCF(BTRC) complex, composed of SKP1, CUL1 andBTRC; the association is mediated via interaction with BTRC. Partof a SCF(BTRC)-like complex lacking CUL1, which is associated withRELA; RELA interacts directly with NFKBIA. Interacts with PRMT2.Interacts with PRKACA in platelets; this interaction is disruptedby thrombin and collagen. Interacts with HIF1AN. Interacts withMEFV. Interacts with DDRGK1; positively regulates NFKBIAphosphorylation and degradation. {ECO:0000269|PubMed:10454581,ECO:0000269|PubMed:10657303, ECO:0000269|PubMed:1493333,ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:18577712,ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:23469069,ECO:0000269|PubMed:23675531}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles betweenthe nucleus and the cytoplasm by a nuclear localization signal(NLS) and a CRM1-dependent nuclear export. {ECO:0000250}.INDUCTION: Induced in adherent monocytes.PTM: Phosphorylated; disables inhibition of NF-kappa-B DNA-bindingactivity. Phosphorylation at positions 32 and 36 is prerequisiteto recognition by UBE2D3 leading to polyubiquitination andsubsequent degradation. {ECO:0000269|PubMed:10329681,ECO:0000269|PubMed:10882136, ECO:0000269|PubMed:20504922}.PTM: Sumoylated; sumoylation requires the presence of the nuclearimport signal. Sumoylation blocks ubiquitination and proteasome-mediated degradation of the protein thereby increasing the proteinstability. {ECO:0000269|PubMed:11124955,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:20504922}.PTM: Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3.Ubiquitin chain elongation is then performed by CDC34 incooperation with the SCF(FBXW11) E3 ligase complex, buildingubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin.The resulting polyubiquitination leads to protein degradation.Also ubiquitinated by SCF(BTRC) following stimulus-dependentphosphorylation at Ser-32 and Ser-36.{ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10882136,ECO:0000269|PubMed:20347421, ECO:0000269|PubMed:20504922,ECO:0000269|PubMed:7479976}.PTM: Deubiquitinated by porcine reproductive and respiratorysyndrome virus Nsp2 protein, which thereby interferes with NFKBIAdegradation and impairs subsequent NF-kappa-B activation.DISEASE: Ectodermal dysplasia, anhidrotic, with T-cellimmunodeficiency autosomal dominant (ADEDAID) [MIM:612132]: A formof ectoderma dysplasia, a heterogeneous group of disorders due toabnormal development of two or more ectodermal structures. Thisform of ectodermal dysplasia is associated with decreasedproduction of pro-inflammatory cytokines and certain interferons,rendering patients susceptible to infection.{ECO:0000269|PubMed:14523047, ECO:0000269|PubMed:18412279}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the NF-kappa-B inhibitor family.{ECO:0000305}.WEB RESOURCE: Name=NFKBIAbase; Note=NFKBIA mutation db;URL=\"http://structure.bmc.lu.se/idbase/NFKBIAbase/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/nfkbia/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80834"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","I kappa B alpha (degradation)"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80832"],["bp:featureLocation",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_996"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:01240"],["bp:db","protein modification ontology"]]],["bp:term","ubiquitination"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80748"]]],["bp:entityReference_http://identifiers.org/uniprot/P25963",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:standardName","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:organism","NF-kappa-B inhibitor alpha"],["bp:displayName","IKBA_HUMAN"],["bp:name","IKBA"],["bp:name","MAD3"],["bp:name","IkB-alpha"],["bp:name","Major histocompatibility complex enhancer-binding protein MAD3"],["bp:name","NFKBI"],["bp:name","NFKBIA"],["bp:name","I-kappa-B-alpha"],["bp:name","IkappaBalpha"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q04207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25799_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25799"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-139N_identity"],["bp:comment","REPLACED ProteinRef_NFKBIA__9606"],["bp:comment","REPLACED ProteinRef_NFKBIA__40674"],["bp:comment","IKBA_HUMAN Reviewed; 317 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_990"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25963_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_065390"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01235_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4792"],["bp:comment","REPLACED ProteinRef_NFKBIA__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4792"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4792"],["bp:comment","FUNCTION: Inhibits the activity of dimeric NF-kappa-B/RELcomplexes by trapping REL dimers in the cytoplasm through maskingof their nuclear localization signals. On cellular stimulation byimmune and proinflammatory responses, becomes phosphorylatedpromoting ubiquitination and degradation, enabling the dimericRELA to translocate to the nucleus and activate transcription.{ECO:0000269|PubMed:7479976}.SUBUNIT: Interacts with RELA; the interaction requires the nuclearimport signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA,IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts withisoform 1 and isoform 2 of RWDD3; the interaction enhancessumoylation. Interacts (when phosphorylated at the 2 serineresidues in the destruction motif D-S-G-X(2,3,4)-S) with BTRC.Associates with the SCF(BTRC) complex, composed of SKP1, CUL1 andBTRC; the association is mediated via interaction with BTRC. Partof a SCF(BTRC)-like complex lacking CUL1, which is associated withRELA; RELA interacts directly with NFKBIA. Interacts with PRMT2.Interacts with PRKACA in platelets; this interaction is disruptedby thrombin and collagen. Interacts with HIF1AN. Interacts withMEFV. Interacts with DDRGK1; positively regulates NFKBIAphosphorylation and degradation. {ECO:0000269|PubMed:10454581,ECO:0000269|PubMed:10657303, ECO:0000269|PubMed:1493333,ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:18577712,ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:23469069,ECO:0000269|PubMed:23675531}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles betweenthe nucleus and the cytoplasm by a nuclear localization signal(NLS) and a CRM1-dependent nuclear export. {ECO:0000250}.INDUCTION: Induced in adherent monocytes.PTM: Phosphorylated; disables inhibition of NF-kappa-B DNA-bindingactivity. Phosphorylation at positions 32 and 36 is prerequisiteto recognition by UBE2D3 leading to polyubiquitination andsubsequent degradation. {ECO:0000269|PubMed:10329681,ECO:0000269|PubMed:10882136, ECO:0000269|PubMed:20504922}.PTM: Sumoylated; sumoylation requires the presence of the nuclearimport signal. Sumoylation blocks ubiquitination and proteasome-mediated degradation of the protein thereby increasing the proteinstability. {ECO:0000269|PubMed:11124955,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:20504922}.PTM: Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3.Ubiquitin chain elongation is then performed by CDC34 incooperation with the SCF(FBXW11) E3 ligase complex, buildingubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin.The resulting polyubiquitination leads to protein degradation.Also ubiquitinated by SCF(BTRC) following stimulus-dependentphosphorylation at Ser-32 and Ser-36.{ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10882136,ECO:0000269|PubMed:20347421, ECO:0000269|PubMed:20504922,ECO:0000269|PubMed:7479976}.PTM: Deubiquitinated by porcine reproductive and respiratorysyndrome virus Nsp2 protein, which thereby interferes with NFKBIAdegradation and impairs subsequent NF-kappa-B activation.DISEASE: Ectodermal dysplasia, anhidrotic, with T-cellimmunodeficiency autosomal dominant (ADEDAID) [MIM:612132]: A formof ectoderma dysplasia, a heterogeneous group of disorders due toabnormal development of two or more ectodermal structures. Thisform of ectodermal dysplasia is associated with decreasedproduction of pro-inflammatory cytokines and certain interferons,rendering patients susceptible to infection.{ECO:0000269|PubMed:14523047, ECO:0000269|PubMed:18412279}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the NF-kappa-B inhibitor family.{ECO:0000305}.WEB RESOURCE: Name=NFKBIAbase; Note=NFKBIA mutation db;URL=\"http://structure.bmc.lu.se/idbase/NFKBIAbase/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/nfkbia/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80834"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","I kappa B alpha (degradation)"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80832"],["bp:featureLocation",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_996"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:01240"],["bp:db","protein modification ontology"]]],["bp:term","ubiquitination"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80748"]]],["bp:entityReference_http://identifiers.org/uniprot/P25963",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation","MOD_RES 291 291 Phosphothreonine; by CK2."]]],["bp:standardName","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:organism","NF-kappa-B inhibitor alpha"],["bp:displayName","IKBA_HUMAN"],["bp:name","IKBA"],["bp:name","MAD3"],["bp:name","IkB-alpha"],["bp:name","Major histocompatibility complex enhancer-binding protein MAD3"],["bp:name","NFKBI"],["bp:name","NFKBIA"],["bp:name","I-kappa-B-alpha"],["bp:name","IkappaBalpha"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q04207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25799_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25799"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-139N_identity"],["bp:comment","REPLACED ProteinRef_NFKBIA__9606"],["bp:comment","REPLACED ProteinRef_NFKBIA__40674"],["bp:comment","IKBA_HUMAN Reviewed; 317 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_990"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25963_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_065390"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01235_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4792"],["bp:comment","REPLACED ProteinRef_NFKBIA__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4792"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4792"],["bp:comment","FUNCTION: Inhibits the activity of dimeric NF-kappa-B/RELcomplexes by trapping REL dimers in the cytoplasm through maskingof their nuclear localization signals. On cellular stimulation byimmune and proinflammatory responses, becomes phosphorylatedpromoting ubiquitination and degradation, enabling the dimericRELA to translocate to the nucleus and activate transcription.{ECO:0000269|PubMed:7479976}.SUBUNIT: Interacts with RELA; the interaction requires the nuclearimport signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA,IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts withisoform 1 and isoform 2 of RWDD3; the interaction enhancessumoylation. Interacts (when phosphorylated at the 2 serineresidues in the destruction motif D-S-G-X(2,3,4)-S) with BTRC.Associates with the SCF(BTRC) complex, composed of SKP1, CUL1 andBTRC; the association is mediated via interaction with BTRC. Partof a SCF(BTRC)-like complex lacking CUL1, which is associated withRELA; RELA interacts directly with NFKBIA. Interacts with PRMT2.Interacts with PRKACA in platelets; this interaction is disruptedby thrombin and collagen. Interacts with HIF1AN. Interacts withMEFV. Interacts with DDRGK1; positively regulates NFKBIAphosphorylation and degradation. {ECO:0000269|PubMed:10454581,ECO:0000269|PubMed:10657303, ECO:0000269|PubMed:1493333,ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:18577712,ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:23469069,ECO:0000269|PubMed:23675531}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles betweenthe nucleus and the cytoplasm by a nuclear localization signal(NLS) and a CRM1-dependent nuclear export. {ECO:0000250}.INDUCTION: Induced in adherent monocytes.PTM: Phosphorylated; disables inhibition of NF-kappa-B DNA-bindingactivity. Phosphorylation at positions 32 and 36 is prerequisiteto recognition by UBE2D3 leading to polyubiquitination andsubsequent degradation. {ECO:0000269|PubMed:10329681,ECO:0000269|PubMed:10882136, ECO:0000269|PubMed:20504922}.PTM: Sumoylated; sumoylation requires the presence of the nuclearimport signal. Sumoylation blocks ubiquitination and proteasome-mediated degradation of the protein thereby increasing the proteinstability. {ECO:0000269|PubMed:11124955,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:20504922}.PTM: Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3.Ubiquitin chain elongation is then performed by CDC34 incooperation with the SCF(FBXW11) E3 ligase complex, buildingubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin.The resulting polyubiquitination leads to protein degradation.Also ubiquitinated by SCF(BTRC) following stimulus-dependentphosphorylation at Ser-32 and Ser-36.{ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10882136,ECO:0000269|PubMed:20347421, ECO:0000269|PubMed:20504922,ECO:0000269|PubMed:7479976}.PTM: Deubiquitinated by porcine reproductive and respiratorysyndrome virus Nsp2 protein, which thereby interferes with NFKBIAdegradation and impairs subsequent NF-kappa-B activation.DISEASE: Ectodermal dysplasia, anhidrotic, with T-cellimmunodeficiency autosomal dominant (ADEDAID) [MIM:612132]: A formof ectoderma dysplasia, a heterogeneous group of disorders due toabnormal development of two or more ectodermal structures. Thisform of ectodermal dysplasia is associated with decreasedproduction of pro-inflammatory cytokines and certain interferons,rendering patients susceptible to infection.{ECO:0000269|PubMed:14523047, ECO:0000269|PubMed:18412279}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the NF-kappa-B inhibitor family.{ECO:0000305}.WEB RESOURCE: Name=NFKBIAbase; Note=NFKBIA mutation db;URL=\"http://structure.bmc.lu.se/idbase/NFKBIAbase/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/nfkbia/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80834"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80829"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80829"]]}},{"data":{"id":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":738.1889,"y":1393.5948,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28913"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28903"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28903"]]}},{"data":{"id":"BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":937.8619,"y":1046.0822,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF kappa B1/RelA/I kappa B alpha"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80753"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF kappa B1/RelA/I kappa B alpha"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80753"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","NF kappa B1/RelA/I kappa B alpha"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80753"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","NF kappa B1/RelA/I kappa B alpha"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80753"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80740"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80740"]]}},{"data":{"id":"BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1082.8726,"y":1400.0492,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","224"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:standardName","Caspase-8"],["bp:xref","Caspase-8"],["bp:xref","Caspase-8"],["bp:organism","Caspase-8"],["bp:displayName","CASP8_HUMAN"],["bp:name","ICE-like apoptotic protease 5"],["bp:name","CAP4"],["bp:name","FADD-homologous ICE/ced-3-like protease"],["bp:name","FLICE"],["bp:name","Apoptotic protease Mch-5"],["bp:name","CASP-8"],["bp:name","Apoptotic cysteine protease"],["bp:name","3.4.22.61"],["bp:name","MORT1-associated ced-3 homolog"],["bp:name","MACH"],["bp:name","FADD-like ICE"],["bp:name","Caspase-8 subunit p10"],["bp:name","MCH5"],["bp:name","Caspase-8 subunit p18"],["bp:name","CASP8"],["bp:comment","REPLACED http://identifiers.org/uniprot/P08160"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q14790_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_841"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-9"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_10835762_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-1"],["bp:comment","FUNCTION: Most upstream protease of the activation cascade ofcaspases responsible for the TNFRSF6/FAS mediated and TNFRSF1Ainduced cell death. Binding to the adapter molecule FADD recruitsit to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolyticactivation. The active dimeric enzyme is then liberated from theDISC and free to activate downstream apoptotic proteases.Proteolytic fragments of the N-terminal propeptide (termed CAP3,CAP5 and CAP6) are likely retained in the DISC. Cleaves andactivates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. Mayparticipate in the GZMB apoptotic pathways. Cleaves ADPRT.Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC.Likely target for the cowpox virus CRMA death inhibitory protein.Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalyticsite and may interfere with the pro-apoptotic activity of thecomplex. {ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9006941}.CATALYTIC ACTIVITY: Strict requirement for Asp at position P1 andhas a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp-|-(Gly/Ser/Ala). {ECO:0000269|PubMed:23516580}.ENZYME REGULATION: Inhibited by the effector protein NleF that isproduced by pathogenic E.coli; this inhibits apoptosis.{ECO:0000269|PubMed:23516580}.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 18 kDa (p18) and a 10kDa (p10) subunit. Interacts with FADD, CFLAR and PEA15. Isoform 9interacts at the endoplasmic reticulum with a complex containingBCAP31, BAP29, BCL2 and/or BCL2L1. Interacts with TNFAIP8L2 (Bysimilarity). Interacts with CASP8AP2. Interacts with RFFL andRNF34; negatively regulate CASP8 through proteasomal degradation.Interacts with human cytomegalovirus/HHV-5 protein vICA/UL36; thisinteraction inhibits CASP8 activation. Interacts with NleF frompathogenic E.coli. Interacts with NOL3; decreases CASP8 activityin a mitochondria localization- and phosphorylation-dependentmanner and this interaction is dissociated by calcium.{ECO:0000250|UniProtKB:O89110, ECO:0000250|UniProtKB:Q9JHX4,ECO:0000269|PubMed:10442631, ECO:0000269|PubMed:10508785,ECO:0000269|PubMed:11427719, ECO:0000269|PubMed:11917123,ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:15509781,ECO:0000269|PubMed:17245429, ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9334338}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Name=1; Synonyms=Alpha-1;IsoId=Q14790-1; Sequence=Displayed;Name=2; Synonyms=Alpha-2, MCH5-beta;IsoId=Q14790-2; Sequence=VSP_000810;Name=3; Synonyms=Alpha-3;IsoId=Q14790-3; Sequence=VSP_000813;Name=4; Synonyms=Alpha-4;IsoId=Q14790-4; Sequence=VSP_000809, VSP_000810;Name=5; Synonyms=Beta-1;IsoId=Q14790-5; Sequence=VSP_000814, VSP_000815;Name=6; Synonyms=Beta-2;IsoId=Q14790-6; Sequence=VSP_000811, VSP_000812;Name=7; Synonyms=Beta-3, 8L;IsoId=Q14790-7; Sequence=VSP_000816, VSP_000817;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=8; Synonyms=Beta-4;IsoId=Q14790-8; Sequence=VSP_000810, VSP_000816, VSP_000817;Name=9; Synonyms=8L;IsoId=Q14790-9; Sequence=VSP_000808;Note=Ref.8 (AAL87628) sequence is in conflict in position:14:K->R. {ECO:0000305};TISSUE SPECIFICITY: Isoform 1, isoform 5 and isoform 7 areexpressed in a wide variety of tissues. Highest expression inperipheral blood leukocytes, spleen, thymus and liver. Barelydetectable in brain, testis and skeletal muscle.DOMAIN: Isoform 9 contains a N-terminal extension that is requiredfor interaction with the BCAP31 complex.PTM: Generation of the subunits requires association with thedeath-inducing signaling complex (DISC), whereas additionalprocessing is likely due to the autocatalytic activity of theactivated protease. GZMB and CASP10 can be involved in theseprocessing events. {ECO:0000269|PubMed:8962078,ECO:0000269|PubMed:9184224}.PTM: Phosphorylation on Ser-387 during mitosis by CDK1 inhibitsactivation by proteolysis and prevents apoptosis. Thisphosphorylation occurs in cancer cell lines, as well as in primarybreast tissues and lymphocytes. {ECO:0000269|PubMed:20937773}.POLYMORPHISM: Genetic variations in CASP8 are associated withreduced risk of lung cancer [MIM:211980] in a population of HanChinese subjects. Genetic variations are also associated withdecreased risk of cancer of various other forms includingesophageal, gastric, colorectal, cervical, and breast, acting inan allele dose-dependent manner. {ECO:0000269|PubMed:17450141}.DISEASE: Caspase-8 deficiency (CASP8D) [MIM:607271]: Disorderresembling autoimmune lymphoproliferative syndrome (ALPS). It ischaracterized by lymphadenopathy, splenomegaly, and defectiveCD95-induced apoptosis of peripheral blood lymphocytes (PBLs). Itleads to defects in activation of T-lymphocytes, B-lymphocytes,and natural killer cells leading to immunodeficiency characterizedby recurrent sinopulmonary and herpes simplex virus infections andpoor responses to immunization. {ECO:0000269|PubMed:12353035}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA66858.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};Sequence=CAA66859.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};WEB RESOURCE: Name=CASP8base; Note=CASP8 mutation db;URL=\"http://structure.bmc.lu.se/idbase/CASP8base/\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/casp8/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QDU_see-also"],["bp:comment","REPLACED ProteinRef_CASP8__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001219"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203520"],["bp:comment","CASP8_HUMAN Reviewed; 479 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03459_identity"],["bp:comment","REPLACED ProteinRef_CASP8__9606"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_841"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203519"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1I4E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-30915N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1F9E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QTN_see-also"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4464"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246944"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_36111829"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80671"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","224"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:standardName","Caspase-8"],["bp:xref","Caspase-8"],["bp:xref","Caspase-8"],["bp:organism","Caspase-8"],["bp:displayName","CASP8_HUMAN"],["bp:name","ICE-like apoptotic protease 5"],["bp:name","CAP4"],["bp:name","FADD-homologous ICE/ced-3-like protease"],["bp:name","FLICE"],["bp:name","Apoptotic protease Mch-5"],["bp:name","CASP-8"],["bp:name","Apoptotic cysteine protease"],["bp:name","3.4.22.61"],["bp:name","MORT1-associated ced-3 homolog"],["bp:name","MACH"],["bp:name","FADD-like ICE"],["bp:name","Caspase-8 subunit p10"],["bp:name","MCH5"],["bp:name","Caspase-8 subunit p18"],["bp:name","CASP8"],["bp:comment","REPLACED http://identifiers.org/uniprot/P08160"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q14790_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_841"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-9"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_10835762_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-1"],["bp:comment","FUNCTION: Most upstream protease of the activation cascade ofcaspases responsible for the TNFRSF6/FAS mediated and TNFRSF1Ainduced cell death. Binding to the adapter molecule FADD recruitsit to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolyticactivation. The active dimeric enzyme is then liberated from theDISC and free to activate downstream apoptotic proteases.Proteolytic fragments of the N-terminal propeptide (termed CAP3,CAP5 and CAP6) are likely retained in the DISC. Cleaves andactivates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. Mayparticipate in the GZMB apoptotic pathways. Cleaves ADPRT.Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC.Likely target for the cowpox virus CRMA death inhibitory protein.Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalyticsite and may interfere with the pro-apoptotic activity of thecomplex. {ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9006941}.CATALYTIC ACTIVITY: Strict requirement for Asp at position P1 andhas a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp-|-(Gly/Ser/Ala). {ECO:0000269|PubMed:23516580}.ENZYME REGULATION: Inhibited by the effector protein NleF that isproduced by pathogenic E.coli; this inhibits apoptosis.{ECO:0000269|PubMed:23516580}.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 18 kDa (p18) and a 10kDa (p10) subunit. Interacts with FADD, CFLAR and PEA15. Isoform 9interacts at the endoplasmic reticulum with a complex containingBCAP31, BAP29, BCL2 and/or BCL2L1. Interacts with TNFAIP8L2 (Bysimilarity). Interacts with CASP8AP2. Interacts with RFFL andRNF34; negatively regulate CASP8 through proteasomal degradation.Interacts with human cytomegalovirus/HHV-5 protein vICA/UL36; thisinteraction inhibits CASP8 activation. Interacts with NleF frompathogenic E.coli. Interacts with NOL3; decreases CASP8 activityin a mitochondria localization- and phosphorylation-dependentmanner and this interaction is dissociated by calcium.{ECO:0000250|UniProtKB:O89110, ECO:0000250|UniProtKB:Q9JHX4,ECO:0000269|PubMed:10442631, ECO:0000269|PubMed:10508785,ECO:0000269|PubMed:11427719, ECO:0000269|PubMed:11917123,ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:15509781,ECO:0000269|PubMed:17245429, ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9334338}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Name=1; Synonyms=Alpha-1;IsoId=Q14790-1; Sequence=Displayed;Name=2; Synonyms=Alpha-2, MCH5-beta;IsoId=Q14790-2; Sequence=VSP_000810;Name=3; Synonyms=Alpha-3;IsoId=Q14790-3; Sequence=VSP_000813;Name=4; Synonyms=Alpha-4;IsoId=Q14790-4; Sequence=VSP_000809, VSP_000810;Name=5; Synonyms=Beta-1;IsoId=Q14790-5; Sequence=VSP_000814, VSP_000815;Name=6; Synonyms=Beta-2;IsoId=Q14790-6; Sequence=VSP_000811, VSP_000812;Name=7; Synonyms=Beta-3, 8L;IsoId=Q14790-7; Sequence=VSP_000816, VSP_000817;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=8; Synonyms=Beta-4;IsoId=Q14790-8; Sequence=VSP_000810, VSP_000816, VSP_000817;Name=9; Synonyms=8L;IsoId=Q14790-9; Sequence=VSP_000808;Note=Ref.8 (AAL87628) sequence is in conflict in position:14:K->R. {ECO:0000305};TISSUE SPECIFICITY: Isoform 1, isoform 5 and isoform 7 areexpressed in a wide variety of tissues. Highest expression inperipheral blood leukocytes, spleen, thymus and liver. Barelydetectable in brain, testis and skeletal muscle.DOMAIN: Isoform 9 contains a N-terminal extension that is requiredfor interaction with the BCAP31 complex.PTM: Generation of the subunits requires association with thedeath-inducing signaling complex (DISC), whereas additionalprocessing is likely due to the autocatalytic activity of theactivated protease. GZMB and CASP10 can be involved in theseprocessing events. {ECO:0000269|PubMed:8962078,ECO:0000269|PubMed:9184224}.PTM: Phosphorylation on Ser-387 during mitosis by CDK1 inhibitsactivation by proteolysis and prevents apoptosis. Thisphosphorylation occurs in cancer cell lines, as well as in primarybreast tissues and lymphocytes. {ECO:0000269|PubMed:20937773}.POLYMORPHISM: Genetic variations in CASP8 are associated withreduced risk of lung cancer [MIM:211980] in a population of HanChinese subjects. Genetic variations are also associated withdecreased risk of cancer of various other forms includingesophageal, gastric, colorectal, cervical, and breast, acting inan allele dose-dependent manner. {ECO:0000269|PubMed:17450141}.DISEASE: Caspase-8 deficiency (CASP8D) [MIM:607271]: Disorderresembling autoimmune lymphoproliferative syndrome (ALPS). It ischaracterized by lymphadenopathy, splenomegaly, and defectiveCD95-induced apoptosis of peripheral blood lymphocytes (PBLs). Itleads to defects in activation of T-lymphocytes, B-lymphocytes,and natural killer cells leading to immunodeficiency characterizedby recurrent sinopulmonary and herpes simplex virus infections andpoor responses to immunization. {ECO:0000269|PubMed:12353035}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA66858.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};Sequence=CAA66859.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};WEB RESOURCE: Name=CASP8base; Note=CASP8 mutation db;URL=\"http://structure.bmc.lu.se/idbase/CASP8base/\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/casp8/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QDU_see-also"],["bp:comment","REPLACED ProteinRef_CASP8__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001219"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203520"],["bp:comment","CASP8_HUMAN Reviewed; 479 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03459_identity"],["bp:comment","REPLACED ProteinRef_CASP8__9606"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_841"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203519"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1I4E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-30915N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1F9E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QTN_see-also"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4464"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246944"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_36111829"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80671"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","224"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:standardName","Caspase-8"],["bp:xref","Caspase-8"],["bp:xref","Caspase-8"],["bp:organism","Caspase-8"],["bp:displayName","CASP8_HUMAN"],["bp:name","ICE-like apoptotic protease 5"],["bp:name","CAP4"],["bp:name","FADD-homologous ICE/ced-3-like protease"],["bp:name","FLICE"],["bp:name","Apoptotic protease Mch-5"],["bp:name","CASP-8"],["bp:name","Apoptotic cysteine protease"],["bp:name","3.4.22.61"],["bp:name","MORT1-associated ced-3 homolog"],["bp:name","MACH"],["bp:name","FADD-like ICE"],["bp:name","Caspase-8 subunit p10"],["bp:name","MCH5"],["bp:name","Caspase-8 subunit p18"],["bp:name","CASP8"],["bp:comment","REPLACED http://identifiers.org/uniprot/P08160"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q14790_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_841"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-9"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_10835762_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-1"],["bp:comment","FUNCTION: Most upstream protease of the activation cascade ofcaspases responsible for the TNFRSF6/FAS mediated and TNFRSF1Ainduced cell death. Binding to the adapter molecule FADD recruitsit to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolyticactivation. The active dimeric enzyme is then liberated from theDISC and free to activate downstream apoptotic proteases.Proteolytic fragments of the N-terminal propeptide (termed CAP3,CAP5 and CAP6) are likely retained in the DISC. Cleaves andactivates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. Mayparticipate in the GZMB apoptotic pathways. Cleaves ADPRT.Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC.Likely target for the cowpox virus CRMA death inhibitory protein.Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalyticsite and may interfere with the pro-apoptotic activity of thecomplex. {ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9006941}.CATALYTIC ACTIVITY: Strict requirement for Asp at position P1 andhas a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp-|-(Gly/Ser/Ala). {ECO:0000269|PubMed:23516580}.ENZYME REGULATION: Inhibited by the effector protein NleF that isproduced by pathogenic E.coli; this inhibits apoptosis.{ECO:0000269|PubMed:23516580}.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 18 kDa (p18) and a 10kDa (p10) subunit. Interacts with FADD, CFLAR and PEA15. Isoform 9interacts at the endoplasmic reticulum with a complex containingBCAP31, BAP29, BCL2 and/or BCL2L1. Interacts with TNFAIP8L2 (Bysimilarity). Interacts with CASP8AP2. Interacts with RFFL andRNF34; negatively regulate CASP8 through proteasomal degradation.Interacts with human cytomegalovirus/HHV-5 protein vICA/UL36; thisinteraction inhibits CASP8 activation. Interacts with NleF frompathogenic E.coli. Interacts with NOL3; decreases CASP8 activityin a mitochondria localization- and phosphorylation-dependentmanner and this interaction is dissociated by calcium.{ECO:0000250|UniProtKB:O89110, ECO:0000250|UniProtKB:Q9JHX4,ECO:0000269|PubMed:10442631, ECO:0000269|PubMed:10508785,ECO:0000269|PubMed:11427719, ECO:0000269|PubMed:11917123,ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:15509781,ECO:0000269|PubMed:17245429, ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9334338}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Name=1; Synonyms=Alpha-1;IsoId=Q14790-1; Sequence=Displayed;Name=2; Synonyms=Alpha-2, MCH5-beta;IsoId=Q14790-2; Sequence=VSP_000810;Name=3; Synonyms=Alpha-3;IsoId=Q14790-3; Sequence=VSP_000813;Name=4; Synonyms=Alpha-4;IsoId=Q14790-4; Sequence=VSP_000809, VSP_000810;Name=5; Synonyms=Beta-1;IsoId=Q14790-5; Sequence=VSP_000814, VSP_000815;Name=6; Synonyms=Beta-2;IsoId=Q14790-6; Sequence=VSP_000811, VSP_000812;Name=7; Synonyms=Beta-3, 8L;IsoId=Q14790-7; Sequence=VSP_000816, VSP_000817;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=8; Synonyms=Beta-4;IsoId=Q14790-8; Sequence=VSP_000810, VSP_000816, VSP_000817;Name=9; Synonyms=8L;IsoId=Q14790-9; Sequence=VSP_000808;Note=Ref.8 (AAL87628) sequence is in conflict in position:14:K->R. {ECO:0000305};TISSUE SPECIFICITY: Isoform 1, isoform 5 and isoform 7 areexpressed in a wide variety of tissues. Highest expression inperipheral blood leukocytes, spleen, thymus and liver. Barelydetectable in brain, testis and skeletal muscle.DOMAIN: Isoform 9 contains a N-terminal extension that is requiredfor interaction with the BCAP31 complex.PTM: Generation of the subunits requires association with thedeath-inducing signaling complex (DISC), whereas additionalprocessing is likely due to the autocatalytic activity of theactivated protease. GZMB and CASP10 can be involved in theseprocessing events. {ECO:0000269|PubMed:8962078,ECO:0000269|PubMed:9184224}.PTM: Phosphorylation on Ser-387 during mitosis by CDK1 inhibitsactivation by proteolysis and prevents apoptosis. Thisphosphorylation occurs in cancer cell lines, as well as in primarybreast tissues and lymphocytes. {ECO:0000269|PubMed:20937773}.POLYMORPHISM: Genetic variations in CASP8 are associated withreduced risk of lung cancer [MIM:211980] in a population of HanChinese subjects. Genetic variations are also associated withdecreased risk of cancer of various other forms includingesophageal, gastric, colorectal, cervical, and breast, acting inan allele dose-dependent manner. {ECO:0000269|PubMed:17450141}.DISEASE: Caspase-8 deficiency (CASP8D) [MIM:607271]: Disorderresembling autoimmune lymphoproliferative syndrome (ALPS). It ischaracterized by lymphadenopathy, splenomegaly, and defectiveCD95-induced apoptosis of peripheral blood lymphocytes (PBLs). Itleads to defects in activation of T-lymphocytes, B-lymphocytes,and natural killer cells leading to immunodeficiency characterizedby recurrent sinopulmonary and herpes simplex virus infections andpoor responses to immunization. {ECO:0000269|PubMed:12353035}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA66858.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};Sequence=CAA66859.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};WEB RESOURCE: Name=CASP8base; Note=CASP8 mutation db;URL=\"http://structure.bmc.lu.se/idbase/CASP8base/\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/casp8/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QDU_see-also"],["bp:comment","REPLACED ProteinRef_CASP8__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001219"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203520"],["bp:comment","CASP8_HUMAN Reviewed; 479 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03459_identity"],["bp:comment","REPLACED ProteinRef_CASP8__9606"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_841"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203519"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1I4E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-30915N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1F9E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QTN_see-also"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4464"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246944"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_36111829"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80671"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","224"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation","MOD_RES 334 334 Phosphotyrosine."]]],["bp:standardName","Caspase-8"],["bp:xref","Caspase-8"],["bp:xref","Caspase-8"],["bp:organism","Caspase-8"],["bp:displayName","CASP8_HUMAN"],["bp:name","ICE-like apoptotic protease 5"],["bp:name","CAP4"],["bp:name","FADD-homologous ICE/ced-3-like protease"],["bp:name","FLICE"],["bp:name","Apoptotic protease Mch-5"],["bp:name","CASP-8"],["bp:name","Apoptotic cysteine protease"],["bp:name","3.4.22.61"],["bp:name","MORT1-associated ced-3 homolog"],["bp:name","MACH"],["bp:name","FADD-like ICE"],["bp:name","Caspase-8 subunit p10"],["bp:name","MCH5"],["bp:name","Caspase-8 subunit p18"],["bp:name","CASP8"],["bp:comment","REPLACED http://identifiers.org/uniprot/P08160"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q14790_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_841"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-9"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_10835762_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-1"],["bp:comment","FUNCTION: Most upstream protease of the activation cascade ofcaspases responsible for the TNFRSF6/FAS mediated and TNFRSF1Ainduced cell death. Binding to the adapter molecule FADD recruitsit to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolyticactivation. The active dimeric enzyme is then liberated from theDISC and free to activate downstream apoptotic proteases.Proteolytic fragments of the N-terminal propeptide (termed CAP3,CAP5 and CAP6) are likely retained in the DISC. Cleaves andactivates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. Mayparticipate in the GZMB apoptotic pathways. Cleaves ADPRT.Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC.Likely target for the cowpox virus CRMA death inhibitory protein.Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalyticsite and may interfere with the pro-apoptotic activity of thecomplex. {ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9006941}.CATALYTIC ACTIVITY: Strict requirement for Asp at position P1 andhas a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp-|-(Gly/Ser/Ala). {ECO:0000269|PubMed:23516580}.ENZYME REGULATION: Inhibited by the effector protein NleF that isproduced by pathogenic E.coli; this inhibits apoptosis.{ECO:0000269|PubMed:23516580}.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 18 kDa (p18) and a 10kDa (p10) subunit. Interacts with FADD, CFLAR and PEA15. Isoform 9interacts at the endoplasmic reticulum with a complex containingBCAP31, BAP29, BCL2 and/or BCL2L1. Interacts with TNFAIP8L2 (Bysimilarity). Interacts with CASP8AP2. Interacts with RFFL andRNF34; negatively regulate CASP8 through proteasomal degradation.Interacts with human cytomegalovirus/HHV-5 protein vICA/UL36; thisinteraction inhibits CASP8 activation. Interacts with NleF frompathogenic E.coli. Interacts with NOL3; decreases CASP8 activityin a mitochondria localization- and phosphorylation-dependentmanner and this interaction is dissociated by calcium.{ECO:0000250|UniProtKB:O89110, ECO:0000250|UniProtKB:Q9JHX4,ECO:0000269|PubMed:10442631, ECO:0000269|PubMed:10508785,ECO:0000269|PubMed:11427719, ECO:0000269|PubMed:11917123,ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:15509781,ECO:0000269|PubMed:17245429, ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9334338}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Name=1; Synonyms=Alpha-1;IsoId=Q14790-1; Sequence=Displayed;Name=2; Synonyms=Alpha-2, MCH5-beta;IsoId=Q14790-2; Sequence=VSP_000810;Name=3; Synonyms=Alpha-3;IsoId=Q14790-3; Sequence=VSP_000813;Name=4; Synonyms=Alpha-4;IsoId=Q14790-4; Sequence=VSP_000809, VSP_000810;Name=5; Synonyms=Beta-1;IsoId=Q14790-5; Sequence=VSP_000814, VSP_000815;Name=6; Synonyms=Beta-2;IsoId=Q14790-6; Sequence=VSP_000811, VSP_000812;Name=7; Synonyms=Beta-3, 8L;IsoId=Q14790-7; Sequence=VSP_000816, VSP_000817;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=8; Synonyms=Beta-4;IsoId=Q14790-8; Sequence=VSP_000810, VSP_000816, VSP_000817;Name=9; Synonyms=8L;IsoId=Q14790-9; Sequence=VSP_000808;Note=Ref.8 (AAL87628) sequence is in conflict in position:14:K->R. {ECO:0000305};TISSUE SPECIFICITY: Isoform 1, isoform 5 and isoform 7 areexpressed in a wide variety of tissues. Highest expression inperipheral blood leukocytes, spleen, thymus and liver. Barelydetectable in brain, testis and skeletal muscle.DOMAIN: Isoform 9 contains a N-terminal extension that is requiredfor interaction with the BCAP31 complex.PTM: Generation of the subunits requires association with thedeath-inducing signaling complex (DISC), whereas additionalprocessing is likely due to the autocatalytic activity of theactivated protease. GZMB and CASP10 can be involved in theseprocessing events. {ECO:0000269|PubMed:8962078,ECO:0000269|PubMed:9184224}.PTM: Phosphorylation on Ser-387 during mitosis by CDK1 inhibitsactivation by proteolysis and prevents apoptosis. Thisphosphorylation occurs in cancer cell lines, as well as in primarybreast tissues and lymphocytes. {ECO:0000269|PubMed:20937773}.POLYMORPHISM: Genetic variations in CASP8 are associated withreduced risk of lung cancer [MIM:211980] in a population of HanChinese subjects. Genetic variations are also associated withdecreased risk of cancer of various other forms includingesophageal, gastric, colorectal, cervical, and breast, acting inan allele dose-dependent manner. {ECO:0000269|PubMed:17450141}.DISEASE: Caspase-8 deficiency (CASP8D) [MIM:607271]: Disorderresembling autoimmune lymphoproliferative syndrome (ALPS). It ischaracterized by lymphadenopathy, splenomegaly, and defectiveCD95-induced apoptosis of peripheral blood lymphocytes (PBLs). Itleads to defects in activation of T-lymphocytes, B-lymphocytes,and natural killer cells leading to immunodeficiency characterizedby recurrent sinopulmonary and herpes simplex virus infections andpoor responses to immunization. {ECO:0000269|PubMed:12353035}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA66858.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};Sequence=CAA66859.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};WEB RESOURCE: Name=CASP8base; Note=CASP8 mutation db;URL=\"http://structure.bmc.lu.se/idbase/CASP8base/\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/casp8/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QDU_see-also"],["bp:comment","REPLACED ProteinRef_CASP8__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001219"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203520"],["bp:comment","CASP8_HUMAN Reviewed; 479 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03459_identity"],["bp:comment","REPLACED ProteinRef_CASP8__9606"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_841"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203519"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1I4E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-30915N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1F9E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QTN_see-also"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4464"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246944"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_36111829"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80671"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80666"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80666"]]}},{"data":{"id":"BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1027.87994,"y":1122.4275,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","BID"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80574"]]],["bp:entityReference_http://identifiers.org/uniprot/P55957",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:organism","BH3-interacting domain death agonist"],["bp:displayName","BID_HUMAN"],["bp:name","BH3-interacting domain death agonist p15"],["bp:name","BH3-interacting domain death agonist p13"],["bp:name","p22 BID"],["bp:name","BH3-interacting domain death agonist p11"],["bp:name","BID"],["bp:name","p15 BID"],["bp:name","p13 BID"],["bp:name","p11 BID"],["bp:comment","REPLACED ProteinRef_BID__10090"],["bp:comment","REPLACED ProteinRef_BID__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_637"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P55957-2"],["bp:comment","BID_HUMAN Reviewed; 195 AA."],["bp:comment","REPLACED ProteinRef_BID__40674"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1421"],["bp:comment","FUNCTION: The major proteolytic product p15 BID allows the releaseof cytochrome c (By similarity). Isoform 1, isoform 2 and isoform4 induce ICE-like proteases and apoptosis. Isoform 3 does notinduce apoptosis. Counters the protective effect of Bcl-2.{ECO:0000250, ECO:0000269|PubMed:14583606}.SUBUNIT: Forms heterodimers either with the pro-apoptotic proteinBAX or the anti-apoptotic protein Bcl-2 (By similarity). p15 BIDinteracts with ITCH. {ECO:0000250, ECO:0000269|PubMed:20392206}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Mitochondrionmembrane {ECO:0000250}. Note=When uncleaved, it is predominantlycytoplasmic. {ECO:0000269|PubMed:14583606}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p15:Mitochondrion membrane {ECO:0000250}. Note=Translocates tomitochondria as an integral membrane protein. {ECO:0000250}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p13:Mitochondrion membrane {ECO:0000250}. Note=Associated with themitochondrial membrane. {ECO:0000250}.SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.SUBCELLULAR LOCATION: Isoform 2: Mitochondrion membrane. Note=Asignificant proportion of isoform 2 localizes to mitochondria, itmay be cleaved constitutively.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=BID(L);IsoId=P55957-1; Sequence=Displayed;Name=2; Synonyms=BID(EL);IsoId=P55957-2; Sequence=VSP_017267;Name=3; Synonyms=BID(S);IsoId=P55957-3; Sequence=VSP_017268, VSP_017269;Name=4; Synonyms=BID(ES);IsoId=P55957-4; Sequence=VSP_017266;TISSUE SPECIFICITY: Isoform 2 and isoform 3 are expressed inspleen, bone marrow, cerebral and cerebellar cortex. Isoform 2 isexpressed in spleen, pancreas and placenta (at protein level).Isoform 3 is expressed in lung, pancreas and spleen (at proteinlevel). Isoform 4 is expressed in lung and pancreas (at proteinlevel). {ECO:0000269|PubMed:14583606}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: TNF-alpha induces a caspase-mediated cleavage of p22 BID intoa major p15 and minor p13 and p11 products. {ECO:0000250}.PTM: p15 BID is ubiquitinated by ITCH; ubiquitination results inproteasome-dependent degradation. {ECO:0000269|PubMed:20392206}.SEQUENCE CAUTION:Sequence=AAH22072.2; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bid/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001187"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34937N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_637"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_637_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_932070"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80576"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","BID"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80574"]]],["bp:entityReference_http://identifiers.org/uniprot/P55957",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:organism","BH3-interacting domain death agonist"],["bp:displayName","BID_HUMAN"],["bp:name","BH3-interacting domain death agonist p15"],["bp:name","BH3-interacting domain death agonist p13"],["bp:name","p22 BID"],["bp:name","BH3-interacting domain death agonist p11"],["bp:name","BID"],["bp:name","p15 BID"],["bp:name","p13 BID"],["bp:name","p11 BID"],["bp:comment","REPLACED ProteinRef_BID__10090"],["bp:comment","REPLACED ProteinRef_BID__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_637"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P55957-2"],["bp:comment","BID_HUMAN Reviewed; 195 AA."],["bp:comment","REPLACED ProteinRef_BID__40674"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1421"],["bp:comment","FUNCTION: The major proteolytic product p15 BID allows the releaseof cytochrome c (By similarity). Isoform 1, isoform 2 and isoform4 induce ICE-like proteases and apoptosis. Isoform 3 does notinduce apoptosis. Counters the protective effect of Bcl-2.{ECO:0000250, ECO:0000269|PubMed:14583606}.SUBUNIT: Forms heterodimers either with the pro-apoptotic proteinBAX or the anti-apoptotic protein Bcl-2 (By similarity). p15 BIDinteracts with ITCH. {ECO:0000250, ECO:0000269|PubMed:20392206}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Mitochondrionmembrane {ECO:0000250}. Note=When uncleaved, it is predominantlycytoplasmic. {ECO:0000269|PubMed:14583606}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p15:Mitochondrion membrane {ECO:0000250}. Note=Translocates tomitochondria as an integral membrane protein. {ECO:0000250}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p13:Mitochondrion membrane {ECO:0000250}. Note=Associated with themitochondrial membrane. {ECO:0000250}.SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.SUBCELLULAR LOCATION: Isoform 2: Mitochondrion membrane. Note=Asignificant proportion of isoform 2 localizes to mitochondria, itmay be cleaved constitutively.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=BID(L);IsoId=P55957-1; Sequence=Displayed;Name=2; Synonyms=BID(EL);IsoId=P55957-2; Sequence=VSP_017267;Name=3; Synonyms=BID(S);IsoId=P55957-3; Sequence=VSP_017268, VSP_017269;Name=4; Synonyms=BID(ES);IsoId=P55957-4; Sequence=VSP_017266;TISSUE SPECIFICITY: Isoform 2 and isoform 3 are expressed inspleen, bone marrow, cerebral and cerebellar cortex. Isoform 2 isexpressed in spleen, pancreas and placenta (at protein level).Isoform 3 is expressed in lung, pancreas and spleen (at proteinlevel). Isoform 4 is expressed in lung and pancreas (at proteinlevel). {ECO:0000269|PubMed:14583606}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: TNF-alpha induces a caspase-mediated cleavage of p22 BID intoa major p15 and minor p13 and p11 products. {ECO:0000250}.PTM: p15 BID is ubiquitinated by ITCH; ubiquitination results inproteasome-dependent degradation. {ECO:0000269|PubMed:20392206}.SEQUENCE CAUTION:Sequence=AAH22072.2; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bid/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001187"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34937N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_637"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_637_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_932070"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80576"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","BID"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80574"]]],["bp:entityReference_http://identifiers.org/uniprot/P55957",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:organism","BH3-interacting domain death agonist"],["bp:displayName","BID_HUMAN"],["bp:name","BH3-interacting domain death agonist p15"],["bp:name","BH3-interacting domain death agonist p13"],["bp:name","p22 BID"],["bp:name","BH3-interacting domain death agonist p11"],["bp:name","BID"],["bp:name","p15 BID"],["bp:name","p13 BID"],["bp:name","p11 BID"],["bp:comment","REPLACED ProteinRef_BID__10090"],["bp:comment","REPLACED ProteinRef_BID__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_637"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P55957-2"],["bp:comment","BID_HUMAN Reviewed; 195 AA."],["bp:comment","REPLACED ProteinRef_BID__40674"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1421"],["bp:comment","FUNCTION: The major proteolytic product p15 BID allows the releaseof cytochrome c (By similarity). Isoform 1, isoform 2 and isoform4 induce ICE-like proteases and apoptosis. Isoform 3 does notinduce apoptosis. Counters the protective effect of Bcl-2.{ECO:0000250, ECO:0000269|PubMed:14583606}.SUBUNIT: Forms heterodimers either with the pro-apoptotic proteinBAX or the anti-apoptotic protein Bcl-2 (By similarity). p15 BIDinteracts with ITCH. {ECO:0000250, ECO:0000269|PubMed:20392206}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Mitochondrionmembrane {ECO:0000250}. Note=When uncleaved, it is predominantlycytoplasmic. {ECO:0000269|PubMed:14583606}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p15:Mitochondrion membrane {ECO:0000250}. Note=Translocates tomitochondria as an integral membrane protein. {ECO:0000250}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p13:Mitochondrion membrane {ECO:0000250}. Note=Associated with themitochondrial membrane. {ECO:0000250}.SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.SUBCELLULAR LOCATION: Isoform 2: Mitochondrion membrane. Note=Asignificant proportion of isoform 2 localizes to mitochondria, itmay be cleaved constitutively.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=BID(L);IsoId=P55957-1; Sequence=Displayed;Name=2; Synonyms=BID(EL);IsoId=P55957-2; Sequence=VSP_017267;Name=3; Synonyms=BID(S);IsoId=P55957-3; Sequence=VSP_017268, VSP_017269;Name=4; Synonyms=BID(ES);IsoId=P55957-4; Sequence=VSP_017266;TISSUE SPECIFICITY: Isoform 2 and isoform 3 are expressed inspleen, bone marrow, cerebral and cerebellar cortex. Isoform 2 isexpressed in spleen, pancreas and placenta (at protein level).Isoform 3 is expressed in lung, pancreas and spleen (at proteinlevel). Isoform 4 is expressed in lung and pancreas (at proteinlevel). {ECO:0000269|PubMed:14583606}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: TNF-alpha induces a caspase-mediated cleavage of p22 BID intoa major p15 and minor p13 and p11 products. {ECO:0000250}.PTM: p15 BID is ubiquitinated by ITCH; ubiquitination results inproteasome-dependent degradation. {ECO:0000269|PubMed:20392206}.SEQUENCE CAUTION:Sequence=AAH22072.2; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bid/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001187"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34937N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_637"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_637_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_932070"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80576"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","BID"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80574"]]],["bp:entityReference_http://identifiers.org/uniprot/P55957",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:organism","BH3-interacting domain death agonist"],["bp:displayName","BID_HUMAN"],["bp:name","BH3-interacting domain death agonist p15"],["bp:name","BH3-interacting domain death agonist p13"],["bp:name","p22 BID"],["bp:name","BH3-interacting domain death agonist p11"],["bp:name","BID"],["bp:name","p15 BID"],["bp:name","p13 BID"],["bp:name","p11 BID"],["bp:comment","REPLACED ProteinRef_BID__10090"],["bp:comment","REPLACED ProteinRef_BID__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_637"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P55957-2"],["bp:comment","BID_HUMAN Reviewed; 195 AA."],["bp:comment","REPLACED ProteinRef_BID__40674"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1421"],["bp:comment","FUNCTION: The major proteolytic product p15 BID allows the releaseof cytochrome c (By similarity). Isoform 1, isoform 2 and isoform4 induce ICE-like proteases and apoptosis. Isoform 3 does notinduce apoptosis. Counters the protective effect of Bcl-2.{ECO:0000250, ECO:0000269|PubMed:14583606}.SUBUNIT: Forms heterodimers either with the pro-apoptotic proteinBAX or the anti-apoptotic protein Bcl-2 (By similarity). p15 BIDinteracts with ITCH. {ECO:0000250, ECO:0000269|PubMed:20392206}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Mitochondrionmembrane {ECO:0000250}. Note=When uncleaved, it is predominantlycytoplasmic. {ECO:0000269|PubMed:14583606}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p15:Mitochondrion membrane {ECO:0000250}. Note=Translocates tomitochondria as an integral membrane protein. {ECO:0000250}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p13:Mitochondrion membrane {ECO:0000250}. Note=Associated with themitochondrial membrane. {ECO:0000250}.SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.SUBCELLULAR LOCATION: Isoform 2: Mitochondrion membrane. Note=Asignificant proportion of isoform 2 localizes to mitochondria, itmay be cleaved constitutively.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=BID(L);IsoId=P55957-1; Sequence=Displayed;Name=2; Synonyms=BID(EL);IsoId=P55957-2; Sequence=VSP_017267;Name=3; Synonyms=BID(S);IsoId=P55957-3; Sequence=VSP_017268, VSP_017269;Name=4; Synonyms=BID(ES);IsoId=P55957-4; Sequence=VSP_017266;TISSUE SPECIFICITY: Isoform 2 and isoform 3 are expressed inspleen, bone marrow, cerebral and cerebellar cortex. Isoform 2 isexpressed in spleen, pancreas and placenta (at protein level).Isoform 3 is expressed in lung, pancreas and spleen (at proteinlevel). Isoform 4 is expressed in lung and pancreas (at proteinlevel). {ECO:0000269|PubMed:14583606}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: TNF-alpha induces a caspase-mediated cleavage of p22 BID intoa major p15 and minor p13 and p11 products. {ECO:0000250}.PTM: p15 BID is ubiquitinated by ITCH; ubiquitination results inproteasome-dependent degradation. {ECO:0000269|PubMed:20392206}.SEQUENCE CAUTION:Sequence=AAH22072.2; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bid/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001187"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34937N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_637"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_637_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_932070"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80576"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","BID"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80574"]]],["bp:entityReference_http://identifiers.org/uniprot/P55957",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:organism","BH3-interacting domain death agonist"],["bp:displayName","BID_HUMAN"],["bp:name","BH3-interacting domain death agonist p15"],["bp:name","BH3-interacting domain death agonist p13"],["bp:name","p22 BID"],["bp:name","BH3-interacting domain death agonist p11"],["bp:name","BID"],["bp:name","p15 BID"],["bp:name","p13 BID"],["bp:name","p11 BID"],["bp:comment","REPLACED ProteinRef_BID__10090"],["bp:comment","REPLACED ProteinRef_BID__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_637"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P55957-2"],["bp:comment","BID_HUMAN Reviewed; 195 AA."],["bp:comment","REPLACED ProteinRef_BID__40674"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1421"],["bp:comment","FUNCTION: The major proteolytic product p15 BID allows the releaseof cytochrome c (By similarity). Isoform 1, isoform 2 and isoform4 induce ICE-like proteases and apoptosis. Isoform 3 does notinduce apoptosis. Counters the protective effect of Bcl-2.{ECO:0000250, ECO:0000269|PubMed:14583606}.SUBUNIT: Forms heterodimers either with the pro-apoptotic proteinBAX or the anti-apoptotic protein Bcl-2 (By similarity). p15 BIDinteracts with ITCH. {ECO:0000250, ECO:0000269|PubMed:20392206}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Mitochondrionmembrane {ECO:0000250}. Note=When uncleaved, it is predominantlycytoplasmic. {ECO:0000269|PubMed:14583606}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p15:Mitochondrion membrane {ECO:0000250}. Note=Translocates tomitochondria as an integral membrane protein. {ECO:0000250}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p13:Mitochondrion membrane {ECO:0000250}. Note=Associated with themitochondrial membrane. {ECO:0000250}.SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.SUBCELLULAR LOCATION: Isoform 2: Mitochondrion membrane. Note=Asignificant proportion of isoform 2 localizes to mitochondria, itmay be cleaved constitutively.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=BID(L);IsoId=P55957-1; Sequence=Displayed;Name=2; Synonyms=BID(EL);IsoId=P55957-2; Sequence=VSP_017267;Name=3; Synonyms=BID(S);IsoId=P55957-3; Sequence=VSP_017268, VSP_017269;Name=4; Synonyms=BID(ES);IsoId=P55957-4; Sequence=VSP_017266;TISSUE SPECIFICITY: Isoform 2 and isoform 3 are expressed inspleen, bone marrow, cerebral and cerebellar cortex. Isoform 2 isexpressed in spleen, pancreas and placenta (at protein level).Isoform 3 is expressed in lung, pancreas and spleen (at proteinlevel). Isoform 4 is expressed in lung and pancreas (at proteinlevel). {ECO:0000269|PubMed:14583606}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: TNF-alpha induces a caspase-mediated cleavage of p22 BID intoa major p15 and minor p13 and p11 products. {ECO:0000250}.PTM: p15 BID is ubiquitinated by ITCH; ubiquitination results inproteasome-dependent degradation. {ECO:0000269|PubMed:20392206}.SEQUENCE CAUTION:Sequence=AAH22072.2; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bid/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001187"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34937N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_637"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_637_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_932070"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80576"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","BID"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80574"]]],["bp:entityReference_http://identifiers.org/uniprot/P55957",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:organism","BH3-interacting domain death agonist"],["bp:displayName","BID_HUMAN"],["bp:name","BH3-interacting domain death agonist p15"],["bp:name","BH3-interacting domain death agonist p13"],["bp:name","p22 BID"],["bp:name","BH3-interacting domain death agonist p11"],["bp:name","BID"],["bp:name","p15 BID"],["bp:name","p13 BID"],["bp:name","p11 BID"],["bp:comment","REPLACED ProteinRef_BID__10090"],["bp:comment","REPLACED ProteinRef_BID__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_637"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P55957-2"],["bp:comment","BID_HUMAN Reviewed; 195 AA."],["bp:comment","REPLACED ProteinRef_BID__40674"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1421"],["bp:comment","FUNCTION: The major proteolytic product p15 BID allows the releaseof cytochrome c (By similarity). Isoform 1, isoform 2 and isoform4 induce ICE-like proteases and apoptosis. Isoform 3 does notinduce apoptosis. Counters the protective effect of Bcl-2.{ECO:0000250, ECO:0000269|PubMed:14583606}.SUBUNIT: Forms heterodimers either with the pro-apoptotic proteinBAX or the anti-apoptotic protein Bcl-2 (By similarity). p15 BIDinteracts with ITCH. {ECO:0000250, ECO:0000269|PubMed:20392206}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Mitochondrionmembrane {ECO:0000250}. Note=When uncleaved, it is predominantlycytoplasmic. {ECO:0000269|PubMed:14583606}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p15:Mitochondrion membrane {ECO:0000250}. Note=Translocates tomitochondria as an integral membrane protein. {ECO:0000250}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p13:Mitochondrion membrane {ECO:0000250}. Note=Associated with themitochondrial membrane. {ECO:0000250}.SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.SUBCELLULAR LOCATION: Isoform 2: Mitochondrion membrane. Note=Asignificant proportion of isoform 2 localizes to mitochondria, itmay be cleaved constitutively.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=BID(L);IsoId=P55957-1; Sequence=Displayed;Name=2; Synonyms=BID(EL);IsoId=P55957-2; Sequence=VSP_017267;Name=3; Synonyms=BID(S);IsoId=P55957-3; Sequence=VSP_017268, VSP_017269;Name=4; Synonyms=BID(ES);IsoId=P55957-4; Sequence=VSP_017266;TISSUE SPECIFICITY: Isoform 2 and isoform 3 are expressed inspleen, bone marrow, cerebral and cerebellar cortex. Isoform 2 isexpressed in spleen, pancreas and placenta (at protein level).Isoform 3 is expressed in lung, pancreas and spleen (at proteinlevel). Isoform 4 is expressed in lung and pancreas (at proteinlevel). {ECO:0000269|PubMed:14583606}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: TNF-alpha induces a caspase-mediated cleavage of p22 BID intoa major p15 and minor p13 and p11 products. {ECO:0000250}.PTM: p15 BID is ubiquitinated by ITCH; ubiquitination results inproteasome-dependent degradation. {ECO:0000269|PubMed:20392206}.SEQUENCE CAUTION:Sequence=AAH22072.2; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bid/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001187"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34937N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_637"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_637_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_932070"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80576"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80572"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80572"]]}},{"data":{"id":"Protein_a5726d9b0e4bdae718169725939db78d","class":"macromolecule","label":"RIPK1","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1036.6838400000001,"y":768.35724,"w":48,"h":25},"metadata":[["bp:displayName","RIP"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q13546",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 166 166 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","166"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 384 384 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","384"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:standardName","Receptor-interacting serine/threonine-protein kinase 1"],["bp:xref","Receptor-interacting serine/threonine-protein kinase 1"],["bp:xref","Receptor-interacting serine/threonine-protein kinase 1"],["bp:organism","Receptor-interacting serine/threonine-protein kinase 1"],["bp:displayName","RIPK1_HUMAN"],["bp:name","Receptor-interacting protein 1"],["bp:name","Serine/threonine-protein kinase RIP"],["bp:name","RIP-1"],["bp:name","RIP1"],["bp:name","2.7.11.1"],["bp:name","Cell death protein RIP"],["bp:name","RIP"],["bp:name","RIPK1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-433N_identity"],["bp:comment","REPLACED ProteinRef_RIPK1__9606"],["bp:comment","RIPK1_HUMAN Reviewed; 671 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04583_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003795"],["bp:comment","REPLACED ProteinRef_RIPK1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13546_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8737"],["bp:comment","REPLACED ProteinRef_RIPK1__10090"],["bp:comment","FUNCTION: Serine-threonine kinase which transduces inflammatoryand cell-death signals (programmed necrosis) following deathreceptors ligation, activation of pathogen recognition receptors(PRRs), and DNA damage. Upon activation of TNFR1 by the TNF-alphafamily cytokines, TRADD and TRAF2 are recruited to the receptor.Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependentmanner, and thereby activates the MAP3K5-JNK apoptotic cascade.Ubiquitination by TRAF2 via 'Lys-63'-link chains acts as acritical enhancer of communication with downstream signaltransducers in the mitogen-activated protein kinase pathway andthe NF-kappa-B pathway, which in turn mediate downstream eventsincluding the activation of genes encoding inflammatory molecules.Polyubiquitinated protein binds to IKBKG/NEMO, the regulatorysubunit of the IKK complex, a critical event for NF-kappa-Bactivation. Interaction with other cellular RHIM-containingadapters initiates gene activation and cell death. RIPK1 and RIPK3association, in particular, forms a necrosis-inducing complex.{ECO:0000269|PubMed:11101870, ECO:0000269|PubMed:17389591,ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:19524513}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:23473668}.ENZYME REGULATION: Inhibited by necrostatins, includingnecrostatin-1, necrostatin-3 and necrostatin-4.{ECO:0000269|PubMed:23473668}.SUBUNIT: Interacts (via RIP homotypic interaction motif) withRIPK3 (via RIP homotypic interaction motif). Upon TNF-inducednecrosis, the RIPK1-RIPK3 dimer further interacts with PGAM5 andMLKL; the formation of this complex leads to PGAM5 phosphorylationand increase in PGAM5 phosphatase activity. Interacts (via thedeath domain) with TNFRSF6 (via the death domain) and TRADD (viathe death domain). Is recruited by TRADD to TNFRSF1A in a TNF-dependent process. Binds RNF216, EGFR, IKBKG, TRAF1, TRAF2 andTRAF3. Interacts with BNLF1. Interacts with SQSTM1 upon TNF-alphastimulation. May interact with MAVS/IPS1. Interacts with ZFAND5.Interacts with RBCK1 (By similarity). Interacts with ZBP1 (Bysimilarity). Interacts with BIRC2/c-IAP1, BIRC3/c-IAP2 andXIAP/BIRC4. Upon TNF-induced necrosis, forms in complex withPGAM5, RIPK3 and MLKL. Interacts (via kinase domain) with DAB2IP(via Ras-GAP domain); the interaction occurs in a TNF-alpha-dependent manner. Interacts with ARHGEF2. Interacts (via proteinkinase domain) with RFFL; involved in RIPK1 ubiquitination.Interacts with RNF34; involved in RIPK1 ubiquitination. Interactswith TICAM1 and this interaction is enhanced in the presence ofWDFY1 (PubMed:25736436). {ECO:0000250|UniProtKB:Q60855,ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:10358032,ECO:0000269|PubMed:10409763, ECO:0000269|PubMed:11116146,ECO:0000269|PubMed:11734559, ECO:0000269|PubMed:11854271,ECO:0000269|PubMed:14754897, ECO:0000269|PubMed:16127453,ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:17449468,ECO:0000269|PubMed:18442983, ECO:0000269|PubMed:18450452,ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:21887730,ECO:0000269|PubMed:21931591, ECO:0000269|PubMed:22265414,ECO:0000269|PubMed:25736436, ECO:0000269|PubMed:8612133,ECO:0000269|PubMed:9927690, ECO:0000269|Ref.32}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q13546-1; Sequence=Displayed;Name=2;IsoId=Q13546-2; Sequence=VSP_037690;Note=No experimental confirmation available.;DOMAIN: Contains a C-terminal death domain (DD) that engages otherDD-containing proteins as well as a central (intermediate) regionimportant for NF-kB activation and RHIM-dependent signaling.{ECO:0000269|PubMed:10356400}.PTM: Proteolytically cleaved by caspase-8 during TNF-inducedapoptosis. Cleavage abolishes NF-kappa-B activation and enhancespro-apoptotic signaling through the TRADD-FADD interaction.{ECO:0000269|PubMed:10521396}.PTM: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation. Phosphorylation of Ser-161 by RIPK3 is necessaryfor the formation of the necroptosis-inducing complex.{ECO:0000269|PubMed:18408713, ECO:0000269|PubMed:19524513}.PTM: Ubiquitinated by 'Lys-11'-, 'Lys-48'-, 'Lys-63'- and linear-linked type ubiquitin. Polyubiquitination with 'Lys-63'-linkedchains by TRAF2 induces association with the IKK complex.Deubiquitination of 'Lys-63'-linked chains and polyubiquitinationwith 'Lys-48'-linked chains by TNFAIP3 leads to RIPK1 proteasomaldegradation and consequently down-regulates TNF-alpha-inducedNFkappa-B signaling. 'Lys-48'-linked polyubiquitination by RFFL orRNF34 also promotes proteasomal degradation and negativelyregulates TNF-alpha-induced NFkappa-B signaling. Linearpolyubiquitinated; the head-to-tail polyubiquitination is mediatedby the LUBAC complex. LPS-mediated activation of NF-kappa-B. Alsoubiquitinated with 'Lys-11'-linked chains. Polyubiquitinated with'Lys-48' and 'Lys-63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation of NF-kappa-B.{ECO:0000269|PubMed:15258597, ECO:0000269|PubMed:16603398,ECO:0000269|PubMed:18450452, ECO:0000269|PubMed:21455173,ECO:0000269|PubMed:21931591, ECO:0000269|Ref.32}.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAG65471.1; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/ripk1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_750"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1574"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1574"]]}},{"data":{"id":"Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227","class":"complex","label":"NF kappa B1/RelA/I kappa B alpha","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":833.8459,"y":1121.0662,"w":52,"h":94},"metadata":[["bp:displayName","NF kappa B1/RelA/I kappa B alpha"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80744"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80741"]]}},{"data":{"id":"Protein_9733e0d5a4fe4b996e3a37b20284cea3_Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227","class":"macromolecule","label":"NFKB1","parent":"Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":833.8459,"y":1153.5662,"w":48,"h":25},"metadata":[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]}},{"data":{"id":"Protein_6649d417cf01db7afeba6341d9149288_Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227","class":"macromolecule","label":"NFKBIA","parent":"Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227","clonemarker":false,"stateVariables":[{"id":"Protein_6649d417cf01db7afeba6341d9149288_Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":833.8459,"y":1088.5662,"w":48,"h":25},"metadata":[["bp:displayName","I kappa B alpha"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_36859"]]],["bp:entityReference_http://identifiers.org/uniprot/P25963",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES (3S)-3-hydroxyasparagine"],["bp:term","(3S)-3-hydroxyasparagine"]]],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:standardName","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:organism","NF-kappa-B inhibitor alpha"],["bp:displayName","IKBA_HUMAN"],["bp:name","IKBA"],["bp:name","MAD3"],["bp:name","IkB-alpha"],["bp:name","Major histocompatibility complex enhancer-binding protein MAD3"],["bp:name","NFKBI"],["bp:name","NFKBIA"],["bp:name","I-kappa-B-alpha"],["bp:name","IkappaBalpha"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q04207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25799_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25799"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-139N_identity"],["bp:comment","REPLACED ProteinRef_NFKBIA__9606"],["bp:comment","REPLACED ProteinRef_NFKBIA__40674"],["bp:comment","IKBA_HUMAN Reviewed; 317 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_990"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25963_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_065390"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01235_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4792"],["bp:comment","REPLACED ProteinRef_NFKBIA__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4792"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4792"],["bp:comment","FUNCTION: Inhibits the activity of dimeric NF-kappa-B/RELcomplexes by trapping REL dimers in the cytoplasm through maskingof their nuclear localization signals. On cellular stimulation byimmune and proinflammatory responses, becomes phosphorylatedpromoting ubiquitination and degradation, enabling the dimericRELA to translocate to the nucleus and activate transcription.{ECO:0000269|PubMed:7479976}.SUBUNIT: Interacts with RELA; the interaction requires the nuclearimport signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA,IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts withisoform 1 and isoform 2 of RWDD3; the interaction enhancessumoylation. Interacts (when phosphorylated at the 2 serineresidues in the destruction motif D-S-G-X(2,3,4)-S) with BTRC.Associates with the SCF(BTRC) complex, composed of SKP1, CUL1 andBTRC; the association is mediated via interaction with BTRC. Partof a SCF(BTRC)-like complex lacking CUL1, which is associated withRELA; RELA interacts directly with NFKBIA. Interacts with PRMT2.Interacts with PRKACA in platelets; this interaction is disruptedby thrombin and collagen. Interacts with HIF1AN. Interacts withMEFV. Interacts with DDRGK1; positively regulates NFKBIAphosphorylation and degradation. {ECO:0000269|PubMed:10454581,ECO:0000269|PubMed:10657303, ECO:0000269|PubMed:1493333,ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:18577712,ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:23469069,ECO:0000269|PubMed:23675531}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles betweenthe nucleus and the cytoplasm by a nuclear localization signal(NLS) and a CRM1-dependent nuclear export. {ECO:0000250}.INDUCTION: Induced in adherent monocytes.PTM: Phosphorylated; disables inhibition of NF-kappa-B DNA-bindingactivity. Phosphorylation at positions 32 and 36 is prerequisiteto recognition by UBE2D3 leading to polyubiquitination andsubsequent degradation. {ECO:0000269|PubMed:10329681,ECO:0000269|PubMed:10882136, ECO:0000269|PubMed:20504922}.PTM: Sumoylated; sumoylation requires the presence of the nuclearimport signal. Sumoylation blocks ubiquitination and proteasome-mediated degradation of the protein thereby increasing the proteinstability. {ECO:0000269|PubMed:11124955,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:20504922}.PTM: Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3.Ubiquitin chain elongation is then performed by CDC34 incooperation with the SCF(FBXW11) E3 ligase complex, buildingubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin.The resulting polyubiquitination leads to protein degradation.Also ubiquitinated by SCF(BTRC) following stimulus-dependentphosphorylation at Ser-32 and Ser-36.{ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10882136,ECO:0000269|PubMed:20347421, ECO:0000269|PubMed:20504922,ECO:0000269|PubMed:7479976}.PTM: Deubiquitinated by porcine reproductive and respiratorysyndrome virus Nsp2 protein, which thereby interferes with NFKBIAdegradation and impairs subsequent NF-kappa-B activation.DISEASE: Ectodermal dysplasia, anhidrotic, with T-cellimmunodeficiency autosomal dominant (ADEDAID) [MIM:612132]: A formof ectoderma dysplasia, a heterogeneous group of disorders due toabnormal development of two or more ectodermal structures. Thisform of ectodermal dysplasia is associated with decreasedproduction of pro-inflammatory cytokines and certain interferons,rendering patients susceptible to infection.{ECO:0000269|PubMed:14523047, ECO:0000269|PubMed:18412279}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the NF-kappa-B inhibitor family.{ECO:0000305}.WEB RESOURCE: Name=NFKBIAbase; Note=NFKBIA mutation db;URL=\"http://structure.bmc.lu.se/idbase/NFKBIAbase/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/nfkbia/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_37148"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_37148"]]}},{"data":{"id":"Protein_f02a1f7ebcab04238d804d8ecc342e7e_Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227","class":"macromolecule","label":"RELA","parent":"Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":833.8459,"y":1123.5662,"w":48,"h":25},"metadata":[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","221"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]}},{"data":{"id":"Protein_bb16116cda922facd7903fd53727b854","class":"macromolecule","label":"TRAF2","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1009.65063,"y":786.8972,"w":48,"h":25},"metadata":[["bp:displayName","TRAF2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q12933",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 7 7 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","7"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 5 5 Phosphoserine."],["bp:featureLocation","MOD_RES 5 5 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 5 5 Phosphoserine."],["bp:featureLocation","MOD_RES 5 5 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 5 5 Phosphoserine."],["bp:featureLocation","MOD_RES 5 5 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 5 5 Phosphoserine."],["bp:featureLocation","MOD_RES 5 5 Phosphoserine."]]],["bp:standardName","TNF receptor-associated factor 2"],["bp:xref","TNF receptor-associated factor 2"],["bp:xref","TNF receptor-associated factor 2"],["bp:organism","TNF receptor-associated factor 2"],["bp:displayName","TRAF2_HUMAN"],["bp:name","E3 ubiquitin-protein ligase TRAF2"],["bp:name","TRAP3"],["bp:name","RING-type E3 ubiquitin transferase TRAF2"],["bp:name","2.3.2.27"],["bp:name","Tumor necrosis factor type 2 receptor-associated protein 3"],["bp:name","TRAF2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1CZY_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-6223N_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q12933-2"],["bp:comment","REPLACED ProteinRef_TRAF2__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20334"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7186"],["bp:comment","REPLACED ProteinRef_TRAF2__40674"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7186"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_066961"],["bp:comment","TRAF2_HUMAN Reviewed; 501 AA."],["bp:comment","FUNCTION: Regulates activation of NF-kappa-B and JNK and plays acentral role in the regulation of cell survival and apoptosis.Required for normal antibody isotype switching from IgM to IgG.Has E3 ubiquitin-protein ligase activity and promotes 'Lys-63'-linked ubiquitination of target proteins, such as BIRC3, RIPK1 andTICAM1. Is an essential constituent of several E3 ubiquitin-protein ligase complexes, where it promotes the ubiquitination oftarget proteins by bringing them into contact with other E3ubiquitin ligases. Regulates BIRC2 and BIRC3 protein levels byinhibiting their autoubiquitination and subsequent degradation;this does not depend on the TRAF2 RING-type zinc finger domain.Plays a role in mediating activation of NF-kappa-B by EIF2AK2/PKR.In complex with BIRC2 or BIRC3, promotes ubiquitination of IKBKE.{ECO:0000269|PubMed:10346818, ECO:0000269|PubMed:11907583,ECO:0000269|PubMed:12917689, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15383523, ECO:0000269|PubMed:18981220,ECO:0000269|PubMed:19150425, ECO:0000269|PubMed:19506082,ECO:0000269|PubMed:19810754, ECO:0000269|PubMed:19918265,ECO:0000269|PubMed:19937093, ECO:0000269|PubMed:20047764,ECO:0000269|PubMed:20064526, ECO:0000269|PubMed:20385093,ECO:0000269|PubMed:20577214, ECO:0000269|PubMed:23453969}.CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugatingenzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptorprotein]-L-lysine.ENZYME REGULATION: Has very low E3 ubiquitin ligase activity inthe absence of sphingosine-1-phosphate. E3 ubiquitin ligaseactivity is strongly activated by cytoplasmic sphingosine-1-phosphate. {ECO:0000269|PubMed:20577214}.PATHWAY: Protein modification; protein ubiquitination.SUBUNIT: Homotrimer, and heterotrimer with TRAF1 and TRAF3 (viaTRAF domain). The domain containing the RING-type and the firstTRAF-type zinc finger can also form homodimers (in vitro).Interacts with TNFRSF1B/TNFR2, TNFRSF4, TNFRSF5/CD40,CD27/TNFRSF7, TNFRSF8/CD30, TNFRSF9/CD137, TNFRSF11A/RANK,TNFRSF13B/TACI, TNFRSF14, TNFRSF16/NGFR, TNFRSF17/BCMA,TNFRSF18/AITR, TNFRSF19/TROY, TNFRSF19L/RELT, XEDAR, EDAR,Epstein-Barr virus BNFL1/LMP-1 and IL15RA. Interacts with CDK9,CSK, MAP3K1, MAP3K5, MAP3K11, MAP3K14, MAP4K2, RIPK1, RIPK2, TNIK,TBK1, SPHK1, TRADD, TRAFD1, TRAIP, TANK/ITRAF, TNFAIP3, TDP2,MAVS/IPS1, TICAM1 and TRPC4AP. Interacts with CASP8AP2, NFATC2IP,PEG3 and HIVEP3. Interacts with ERN1; the interaction requiresDAB2IP. Interacts with BIRC2 and BIRC3 N-terminus; a single BIRC2or BIRC3 molecule interacts with a heterotrimer formed by TRAF1and TRAF2, or a TRAF2 homotrimer. Identified in a complex composedof TRAF2, TRAF3, BIRC2 and BIRC3. Interaction with BIRC2 and/orBIRC3 is essential for ubiquitination of IKBKE, degradation ofNFKBIA and activation of NF-kappa-B. Interacts with CYLD, USP48,IKKA and IKKB. Identified in a complex with TNFRSF1A, RIPK1 andIKKB. Interacts (via 'Lys-63'-linked polyubiquitin chains) withTAB2 and TAB3. Interacts with ERN1 and TAOK3. Interaction withTAOK3 is facilitated under ER stress conditions, such as treatmentwith tunicamycin, and may promote TRAF2 phosphorylation. Interacts(via zinc fingers) with DAB2IP (via C-terminus PER domain); theinteraction occurs in a TNF-alpha-dependent manner. Interacts (viaC-terminus) with EIF2AK2/PKR (via the kinase catalytic domain).Interacts with CARD14. Interacts with PTPN2; probably involved intumor necrosis factor-mediated signaling.{ECO:0000269|PubMed:10037686, ECO:0000269|PubMed:10206649,ECO:0000269|PubMed:10346818, ECO:0000269|PubMed:10411888,ECO:0000269|PubMed:10463949, ECO:0000269|PubMed:10514511,ECO:0000269|PubMed:10521462, ECO:0000269|PubMed:10581243,ECO:0000269|PubMed:10764746, ECO:0000269|PubMed:10809768,ECO:0000269|PubMed:10880535, ECO:0000269|PubMed:10892748,ECO:0000269|PubMed:11278723, ECO:0000269|PubMed:11784851,ECO:0000269|PubMed:11907583, ECO:0000269|PubMed:12411493,ECO:0000269|PubMed:12917691, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15310755, ECO:0000269|PubMed:15383523,ECO:0000269|PubMed:15696169, ECO:0000269|PubMed:16153868,ECO:0000269|PubMed:16214042, ECO:0000269|PubMed:17389591,ECO:0000269|PubMed:18981220, ECO:0000269|PubMed:19150425,ECO:0000269|PubMed:19506082, ECO:0000269|PubMed:19810754,ECO:0000269|PubMed:19918265, ECO:0000269|PubMed:20047764,ECO:0000269|PubMed:20185725, ECO:0000269|PubMed:20385093,ECO:0000269|PubMed:20447407, ECO:0000269|PubMed:20577214,ECO:0000269|PubMed:21302310, ECO:0000269|PubMed:8069916,ECO:0000269|PubMed:8627180, ECO:0000269|PubMed:8710854,ECO:0000269|PubMed:9020361, ECO:0000269|PubMed:9104814,ECO:0000269|PubMed:9153189, ECO:0000269|PubMed:9418902,ECO:0000269|PubMed:9488716, ECO:0000269|PubMed:9607925,ECO:0000269|PubMed:9692890, ECO:0000269|PubMed:9705938,ECO:0000269|PubMed:9718306, ECO:0000269|PubMed:9774460,ECO:0000269|PubMed:9774977, ECO:0000269|PubMed:9827693}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15383523,ECO:0000269|PubMed:19150425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q12933-1; Sequence=Displayed;Name=2;IsoId=Q12933-2; Sequence=VSP_007401;Note=No experimental confirmation available.;Name=3;IsoId=Q12933-3; Sequence=VSP_039687;Note=No experimental confirmation available.;Name=4;IsoId=Q12933-4; Sequence=VSP_039688;Note=No experimental confirmation available.;DOMAIN: The coiled coil domain mediates homo- and hetero-oligomerization. {ECO:0000269|PubMed:20064526}.DOMAIN: The MATH/TRAF domain binds to receptor cytoplasmicdomains. {ECO:0000269|PubMed:20064526}.DOMAIN: The RING-type zinc finger domain is essential for E3ubiquitin-protein ligase activity. It is not essential for thestabilization of BIRC2, or for the ubiquitination of RIPK1 inresponse to TNFR1 signaling. {ECO:0000269|PubMed:20064526}.PTM: Phosphorylated at several serine residues within the first128 amino acid residues. Phosphorylated at Thr-117 in response tosignaling via TNF and TNFRSF1A. Phosphorylation at Thr-117 isrequired for 'Lys-63'-linked polyubiquitination, but not for 'Lys-48'-linked polyubiquitination. Phosphorylation at Thr-117 isimportant for interaction with IKKA and IKKB, activation of IKKand subsequent activation of NF-kappa-B.{ECO:0000269|PubMed:19150425}.PTM: Undergoes both 'Lys-48'-linked and 'Lys-63'-linkedpolyubiquitination. Polyubiquitinated via 'Lys-63'-linkedubiquitin in response to TNF signaling; this requires priorphosphorylation at Thr-117. 'Lys-63'-linked polyubiquitinationpromotes TRAF2-mediated activation of NF-kappa-B. Can bepolyubiquitinated at several Lys residues via 'Lys-48'-linkedubiquitin chains in response to TNF signaling, leading toproteasomal degradation. Autoubiquitinated, leading to itssubsequent proteasomal degradation. Polyubiquitinated by BIRC2 andSIAH2, leading to its subsequent proteasomal degradation.Deubiquitinated by CYLD, a protease that specifically cleaves'Lys-63'-linked polyubiquitin chains.{ECO:0000269|PubMed:19150425}.SIMILARITY: Belongs to the TNF receptor-associated factor family.A subfamily. {ECO:0000305}.WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/traf2/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03538_identity"],["bp:comment","REPLACED ProteinRef_TRAF2__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_7633"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QSC_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1D0J_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q12933_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P03230"],["bp:comment","REPLACED ProteinRef_TRAF2__10090"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]}},{"data":{"id":"Protein_f09a415a974418bd0b6bc65135e60760","class":"macromolecule","label":"MAPK3","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":823.139,"y":1402.8239,"w":48,"h":25},"metadata":[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 265 265 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","265"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 263 263 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","263"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 301 301 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","301"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 301 301 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","301"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 301 301 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","301"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 301 301 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","301"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 301 301 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","301"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 301 301 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","301"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 301 301 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","301"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 301 301 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","301"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Mitogen-activated protein kinase 3"],["bp:xref","Mitogen-activated protein kinase 3"],["bp:xref","Mitogen-activated protein kinase 3"],["bp:organism","Mitogen-activated protein kinase 3"],["bp:displayName","MK03_HUMAN"],["bp:name","ERK1"],["bp:name","Microtubule-associated protein 2 kinase"],["bp:name","PRKM3"],["bp:name","2.7.11.24"],["bp:name","p44-ERK1"],["bp:name","p44-MAPK"],["bp:name","ERK-1"],["bp:name","MAPK 3"],["bp:name","Insulin-stimulated MAP2 kinase"],["bp:name","MAP kinase 3"],["bp:name","Extracellular signal-regulated kinase 1"],["bp:name","MAP kinase isoform p44"],["bp:name","ERT2"],["bp:name","MAPK3"],["bp:comment","REPLACED ProteinRef_MAPK3__9606"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5595"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P27361"],["bp:comment","REPLACED ProteinRef_MAPK3__10090"],["bp:comment","FUNCTION: Serine/threonine kinase which acts as an essentialcomponent of the MAP kinase signal transduction pathway.MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an importantrole in the MAPK/ERK cascade. They participate also in a signalingcascade initiated by activated KIT and KITLG/SCF. Depending on thecellular context, the MAPK/ERK cascade mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation through the regulation of transcription,translation, cytoskeletal rearrangements. The MAPK/ERK cascadeplays also a role in initiation and regulation of meiosis,mitosis, and postmitotic functions in differentiated cells byphosphorylating a number of transcription factors. About 160substrates have already been discovered for ERKs. Many of thesesubstrates are localized in the nucleus, and seem to participatein the regulation of transcription upon stimulation. However,other substrates are found in the cytosol as well as in othercellular organelles, and those are responsible for processes suchas translation, mitosis and apoptosis. Moreover, the MAPK/ERKcascade is also involved in the regulation of the endosomaldynamics, including lysosome processing and endosome cyclingthrough the perinuclear recycling compartment (PNRC); as well asin the fragmentation of the Golgi apparatus during mitosis. Thesubstrates include transcription factors (such as ATF2, BCL6,ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such asCANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators ofapoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG),regulators of translation (such as EIF4EBP1) and a variety ofother signaling-related molecules (like ARHGEF2, FRS2 or GRB10).Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2,RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2,RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases(such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates whichenable the propagation the MAPK/ERK signal to additional cytosolicand nuclear targets, thereby extending the specificity of thecascade. {ECO:0000269|PubMed:10393181,ECO:0000269|PubMed:10617468, ECO:0000269|PubMed:12110590,ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:12974390,ECO:0000269|PubMed:15788397, ECO:0000269|PubMed:15952796,ECO:0000269|PubMed:16581800, ECO:0000269|PubMed:19265199,ECO:0000269|PubMed:8325880, ECO:0000269|PubMed:9155018,ECO:0000269|PubMed:9480836}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2on Thr-202 and Tyr-204 in response to external stimuli likeinsulin or NGF. Both phosphorylations are required for activity.This phosphorylation causes dramatic conformational changes, whichenable full activation and interaction of MAPK1/ERK2 with itssubstrates. Dephosphorylated and inactivated by DUSP3, DUSP6 andDUSP9. {ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:19060905}.SUBUNIT: Binds both upstream activators and downstream substratesin multimolecular complexes. Found in a complex with at leastBRAF, HRAS, MAP2K1/MEK1, MAPK3 and RGS14 (By similarity). Binds toHIV-1 Nef through its SH3 domain. This interaction inhibits itstyrosine-kinase activity. Interacts with ADAM15, ARRB2, CANX,DAPK1 (via death domain), HSF4, IER3, MAP2K1/MEK1, MORG1, NISCH,and SGK1. Interacts with PEA15 and MKNK2 (By similarity). MKNK2isoform 1 binding prevents from dephosphorylation and inactivation(By similarity). Interacts with TPR. Interacts with CDKN2AIP.Interacts with HSF1 (via D domain and preferentially withhyperphosphorylated form); this interaction occurs upon heat shock(PubMed:10747973). {ECO:0000250, ECO:0000269|PubMed:10393181,ECO:0000269|PubMed:10521408, ECO:0000269|PubMed:10747973,ECO:0000269|PubMed:11912194, ECO:0000269|PubMed:12356731,ECO:0000269|PubMed:15616583, ECO:0000269|PubMed:16581800,ECO:0000269|PubMed:18296648, ECO:0000269|PubMed:18435604,ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19060905,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:24825908,ECO:0000269|PubMed:8794306}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Autophosphorylationat Thr-207 promotes nuclear localization.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P27361-1; Sequence=Displayed;Name=2;IsoId=P27361-2; Sequence=VSP_041906;Name=3; Synonyms=ERK1b;IsoId=P27361-3; Sequence=VSP_041907;DOMAIN: The TXY motif contains the threonine and tyrosine residueswhose phosphorylation activates the MAP kinases.{ECO:0000269|PubMed:10521408}.PTM: Phosphorylated upon KIT and FLT3 signaling (By similarity).Dually phosphorylated on Thr-202 and Tyr-204, which activates theenzyme. Ligand-activated ALK induces tyrosine phosphorylation.Dephosphorylated by PTPRJ at Tyr-204. {ECO:0000250,ECO:0000269|PubMed:17274988, ECO:0000269|PubMed:18983981,ECO:0000269|PubMed:19060905, ECO:0000269|PubMed:19265199,ECO:0000269|PubMed:19494114}.SIMILARITY: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAPK3ID425ch16p11.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P27361-3"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002737"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_AAH13992_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5595"],["bp:comment","MK03_HUMAN Reviewed; 379 AA."],["bp:comment","REPLACED ProteinRef_MAPK3__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03479_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_595"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-30985N_identity"],["bp:comment","REPLACED ProteinRef_MAPK3__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_41344323"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P27361_identity"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28904"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28904"]]}},{"data":{"id":"Protein_ea4c64305171f853861236d92ecc10b0","class":"macromolecule","label":"AKT1","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_ea4c64305171f853861236d92ecc10b0.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":832.8667,"y":1343.5511,"w":48,"h":25},"metadata":[["bp:displayName","Akt1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8101"]]],["bp:entityReference_http://identifiers.org/uniprot/P31749",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation","MOD_RES 14 14 N6-acetyllysine."]]],["bp:standardName","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:organism","RAC-alpha serine/threonine-protein kinase"],["bp:displayName","AKT1_HUMAN"],["bp:name","RAC-PK-alpha"],["bp:name","PKB"],["bp:name","RAC"],["bp:name","Protein kinase B"],["bp:name","PKB alpha"],["bp:name","2.7.11.1"],["bp:name","Proto-oncogene c-Akt"],["bp:name","Protein kinase B alpha"],["bp:name","AKT1"],["bp:comment","REPLACED http://identifiers.org/uniprot/B0LPE5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P31749-1"],["bp:comment","REPLACED http://identifiers.org/ncbigene/207"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005154"],["bp:comment","REPLACED ProteinRef_AKT1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005267458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24269N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_570"],["bp:comment","FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, andwhich regulate many processes including metabolism, proliferation,cell survival, growth and angiogenesis. This is mediated throughserine and/or threonine phosphorylation of a range of downstreamsubstrates. Over 100 substrate candidates have been reported sofar, but for most of them, no isoform specificity has beenreported. AKT is responsible of the regulation of glucose uptakeby mediating insulin-induced translocation of the SLC2A4/GLUT4glucose transporter to the cell surface. Phosphorylation of PTPN1at 'Ser-50' negatively modulates its phosphatase activitypreventing dephosphorylation of the insulin receptor and theattenuation of insulin signaling. Phosphorylation of TBC1D4triggers the binding of this effector to inhibitory 14-3-3proteins, which is required for insulin-stimulated glucosetransport. AKT regulates also the storage of glucose in the formof glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at'Ser-9', resulting in inhibition of its kinase activity.Phosphorylation of GSK3 isoforms by AKT is also thought to be onemechanism by which cell proliferation is driven. AKT regulatesalso cell survival via the phosphorylation of MAP3K5 (apoptosissignal-related kinase). Phosphorylation of 'Ser-83' decreasesMAP3K5 kinase activity stimulated by oxidative stress and therebyprevents apoptosis. AKT mediates insulin-stimulated proteinsynthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',thereby activating mTORC1 signaling and leading to bothphosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT isinvolved in the phosphorylation of members of the FOXO factors(Forkhead family of transcription factors), leading to binding of14-3-3 proteins and cytoplasmic localization. In particular, FOXO1is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 andFOXO4 are phosphorylated on equivalent sites. AKT has an importantrole in the regulation of NF-kappa-B-dependent gene transcriptionand positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1induces the binding of accessory proteins that are necessary forthe transcription of pro-survival genes such as BCL2 and MCL1. AKTphosphorylates 'Ser-454' on ATP citrate lyase (ACLY), therebypotentially regulating ACLY activity and fatty acid synthesis.Activates the 3B isoform of cyclic nucleotide phosphodiesterase(PDE3B) via phosphorylation of 'Ser-273', resulting in reducedcyclic AMP levels and inhibition of lipolysis. PhosphorylatesPIKFYVE on 'Ser-318', which results in increased PI(3)P-5activity. The Rho GTPase-activating protein DLC1 is anothersubstrate and its phosphorylation is implicated in the regulationcell proliferation and cell growth. AKT plays a role as keymodulator of the AKT-mTOR signaling pathway controlling the tempoof the process of newborn neurons integration during adultneurogenesis, including correct neuron positioning, dendriticdevelopment and synapse formation. Signals downstream ofphosphatidylinositol 3-kinase (PI(3)K) to mediate the effects ofvarious growth factors such as platelet-derived growth factor(PDGF), epidermal growth factor (EGF), insulin and insulin-likegrowth factor I (IGF-I). AKT mediates the antiapoptotic effects ofIGF-I. Essential for the SPATA13-mediated regulation of cellmigration and adhesion assembly and disassembly. May be involvedin the regulation of the placental development. PhosphorylatesSTK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its:kinase activity, nuclear translocation, autophosphorylation andability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinaseactivity, autophosphorylation at Thr-180, binding to RASSF1 andnuclear translocation. Phosphorylates SRPK2 and enhances itskinase activity towards SRSF2 and ACIN1 and promotes its nucleartranslocation. Phosphorylates RAF1 at 'Ser-259' and negativelyregulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and thisphosphorylation inhibits the interaction of KAT6A with PML andnegatively regulates its acetylation activity towards p53/TP53.FUNCTION: AKT1-specific substrates have been recently identified,including palladin (PALLD), which phosphorylation modulatescytoskeletal organization and cell motility; prohibitin (PHB),playing an important role in cell metabolism and proliferation;and CDKN1A, for which phosphorylation at 'Thr-145' induces itsrelease from CDK2 and cytoplasmic relocalization. These recentfindings indicate that the AKT1 isoform has a more specific rolein cell motility and proliferation. Phosphorylates CLK2 therebycontrolling cell survival to ionizing radiation.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748,ECO:0000269|PubMed:1851997}.ENZYME REGULATION: Three specific sites, one in the kinase domain(Thr-308) and the two other ones in the C-terminal regulatoryregion (Ser-473 and Tyr-474), need to be phosphorylated for itsfull activation. Inhibited by pyrrolopyrimidine inhibitors likeaniline triazole and spiroindoline. {ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20810279,ECO:0000269|PubMed:21392984, ECO:0000269|PubMed:9512493,ECO:0000269|PubMed:9736715}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=52.8 uM for ATP (for purified and in vitro activated AKT1){ECO:0000269|PubMed:16540465};KM=0.5 uM for peptide substrate (for purified and in vitroactivated AKT1) {ECO:0000269|PubMed:16540465};KM=143.3 uM for ATP (for recombinant myristoylated AKT1expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};KM=2.9 uM for peptide substrate (for recombinant myristoylatedAKT1 expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};SUBUNIT: Interacts with BTBD10 (By similarity). Interacts withKCTD20 (By similarity). Interacts (via the C-terminus) withCCDC88A (via its C-terminus). Interacts with GRB10; theinteraction leads to GRB10 phosphorylation thus promoting YWHAE-binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A);the interaction occurs in the presence of guanine nucleotides.Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1AAND TCL1B. Interacts with CDKN1B; the interaction phosphorylatesCDKN1B promoting 14-3-3 binding and cell-cycle progression.Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3and STK4. Interacts (via PH domain) with SIRT1. Interacts withSRPK2 in a phosphorylation-dependent manner. Interacts with RAF1.Interacts with TRIM13; the interaction ubiquitinates AKT1 leadingto its proteasomal degradation. Interacts with TNK2 and CLK2.Interacts (via the C-terminus) with THEM4 (via its C-terminus).Interacts with and phosphorylated by PDPK1. Interacts with PA2G4(By similarity). Interacts with KIF14; the interaction is detectedin the plasma membrane upon INS stimulation and promotes AKT1phosphorylation (PubMed:24784001). Interacts with FAM83B;activates the PI3K/AKT signaling cascade (PubMed:23676467).Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529). Formsa complex with WDFY2 and FOXO1 (By similarity). Interacts withFAM168A (PubMed:23251525). {ECO:0000250|UniProtKB:P31750,ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10716693, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:10983986, ECO:0000269|PubMed:11154276,ECO:0000269|PubMed:11598301, ECO:0000269|PubMed:11839817,ECO:0000269|PubMed:12042314, ECO:0000269|PubMed:12176338,ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:12964941,ECO:0000269|PubMed:14749367, ECO:0000269|PubMed:14761976,ECO:0000269|PubMed:15118108, ECO:0000269|PubMed:16139227,ECO:0000269|PubMed:16417524, ECO:0000269|PubMed:16792529,ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:19713527,ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768,ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377,ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392,ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23676467,ECO:0000269|PubMed:24784001}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.Note=Nucleus after activation by integrin-linked protein kinase 1(ILK1). Nuclear translocation is enhanced by interaction withTCL1A. Phosphorylation on Tyr-176 by TNK2 results in itslocalization to the cell membrane where it is targeted for furtherphosphorylations on Thr-308 and Ser-473 leading to its activationand the activated form translocates to the nucleus. Colocalizeswith WDFY2 in intracellular vesicles (PubMed:16792529).{ECO:0000269|PubMed:16792529}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P31749-1; Sequence=Displayed;Name=2;IsoId=P31749-2; Sequence=VSP_056180;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in prostate cancer and levelsincrease from the normal to the malignant state (at proteinlevel). Expressed in all human cell types so far analyzed. TheTyr-176 phosphorylated form shows a significant increase inexpression in breast cancers during the progressive stages i.e.normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS),invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM)stages. {ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:20333297}.DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to theplasma membrane. The PH domain mediates interaction with TNK2 andTyr-176 is also essential for this interaction.DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activatingphosphorylation at Thr-308 via disrupting the interaction betweenAKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probablyinterferes with phosphorylation at this site.{ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is requiredfor full activity. Activated TNK2 phosphorylates it on Tyr-176resulting in its binding to the anionic plasma membranephospholipid PA. This phosphorylated form localizes to the cellmembrane, where it is targeted by PDPK1 and PDPK2 for furtherphosphorylations on Thr-308 and Ser-473 leading to its activation.Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylationby PDPK1. Phosphorylated at Thr-308 and Ser-473 by IKBKE and TBK1.Ser-473 phosphorylation is enhanced by interaction with AGAP2isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focalcortical dysplasias with Taylor-type balloon cells. Ser-473phosphorylation is enhanced by signaling through activated FLT3.Dephosphorylated at Thr-308 and Ser-473 by PP2A phosphatase. Thephosphorylated form of PPP2R5B is required for bridging AKT1 withPP2A phosphatase. Ser-473 is dephosphorylated by CPPED1, leadingto termination of signaling. {ECO:0000269|PubMed:12149249,ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Ubiquitinated via 'Lys-48'-linked polyubiquitination byZNRF1, leading to its degradation by the proteasome (Bysimilarity). Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1ubiquitination is critical for phosphorylation and activation.When ubiquitinated, it translocates to the plasma membrane, whereit becomes phosphorylated. When fully phosphorylated andtranslocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradationby the proteasome. Also ubiquitinated by TRIM13 leading to itsproteasomal degradation. Phosphorylated, undergoes 'Lys-48'-linkedpolyubiquitination preferentially at Lys-284 catalyzed by MUL1,leading to its proteasomal degradation. {ECO:0000250,ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20059950,ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22410793}.PTM: Acetylated on Lys-14 and Lys-20 by the histoneacetyltransferases EP300 and KAT2B. Acetylation results in reducedphosphorylation and inhibition of activity. Deacetylated at Lys-14and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves theinhibition. {ECO:0000269|PubMed:21775285}.DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancyoriginating from breast epithelial tissue. Breast neoplasms can bedistinguished by their histologic pattern. Invasive ductalcarcinoma is by far the most common type. Breast cancer isetiologically and genetically heterogeneous. Important geneticfactors have been indicated by familial occurrence and bilateralinvolvement. Mutations at more than one locus can be involved indifferent families or even in the same case.{ECO:0000269|PubMed:17611497}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex diseasecharacterized by malignant lesions arising from the inner wall ofthe large intestine (the colon) and the rectum. Geneticalterations are often associated with progression frompremalignant lesion (adenoma) to invasive adenocarcinoma. Riskfactors for cancer of the colon and rectum include colon polyps,long-standing ulcerative colitis, and genetic family history.Note=The gene represented in this entry may be involved in diseasepathogenesis.DISEASE: Note=Genetic variations in AKT1 may play a role insusceptibility to ovarian cancer.DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highlyvariable, severe disorder of asymmetric and disproportionateovergrowth of body parts, connective tissue nevi, epidermal nevi,dysregulated adipose tissue, and vascular malformations. Manyfeatures of Proteus syndrome overlap with other overgrowthsyndromes. {ECO:0000269|PubMed:18954143,ECO:0000269|PubMed:21793738}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowdensyndrome, a hamartomatous polyposis syndrome with age-relatedpenetrance. Cowden syndrome is characterized by hamartomatouslesions affecting derivatives of ectodermal, mesodermal andendodermal layers, macrocephaly, facial trichilemmomas (benigntumors of the hair follicle infundibulum), acral keratoses,papillomatous papules, and elevated risk for development ofseveral types of malignancy, particularly breast carcinoma inwomen and thyroid carcinoma in both men and women. Colon cancerand renal cell carcinoma have also been reported. Hamartomas canbe found in virtually every organ, but most commonly in the skin,gastrointestinal tract, breast and thyroid.{ECO:0000269|PubMed:23246288}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. RAC subfamily. {ECO:0000305}.CAUTION: In light of strong homologies in the primary amino acidsequence, the 3 AKT kinases were long surmised to play redundantand overlapping roles. More recent studies has brought intoquestion the redundancy within AKT kinase isoforms and insteadpointed to isoform specific functions in different cellular eventsand diseases. AKT1 is more specifically involved in cellularsurvival pathways, by inhibiting apoptotic processes; whereas AKT2is more specific for the insulin receptor signaling pathway.Moreover, while AKT1 and AKT2 are often implicated in many aspectsof cellular transformation, the 2 isoforms act in a complementaryopposing manner. The role of AKT3 is less clear, though it appearsto be predominantly expressed in brain. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AKT1ID355ch14q32.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001014431"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_207"],["bp:comment","REPLACED ProteinRef_AKT1__9606"],["bp:comment","AKT1_HUMAN Reviewed; 480 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P31749_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01261_identity"]]],["bp:name","AKT1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80899"]]}},{"data":{"id":"Protein_89f70a1844b25ec5984cf26a32b0e470","class":"macromolecule","label":"BAG4","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1132.5515,"y":825.01984,"w":48,"h":25},"metadata":[["bp:displayName","BAG4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95429",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Omega-N-methylarginine"],["bp:term","Omega-N-methylarginine"]]],["bp:comment","MOD_RES 185 185 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 53 53 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","53"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 108 108 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 108 108 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 108 108 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","BAG family molecular chaperone regulator 4"],["bp:xref","BAG family molecular chaperone regulator 4"],["bp:xref","BAG family molecular chaperone regulator 4"],["bp:organism","BAG family molecular chaperone regulator 4"],["bp:displayName","BAG4_HUMAN"],["bp:name","Bcl-2-associated athanogene 4"],["bp:name","BAG-4"],["bp:name","Silencer of death domains"],["bp:name","SODD"],["bp:name","BAG4"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9530"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9530"],["bp:comment","FUNCTION: Inhibits the chaperone activity of HSP70/HSC70 bypromoting substrate release (By similarity). Prevents constitutiveTNFRSF1A signaling. Negative regulator of PRKN translocation todamaged mitochondria. {ECO:0000250, ECO:0000269|PubMed:24270810}.SUBUNIT: Binds to the ATPase domain of HSP/HSC70 chaperones. Bindsto the death domain of TNFRSF1A in the absence of TNF and therebyprevents binding of adapter molecules such as TRADD or TRAF2.Binds to the death domain of TNFRSF12. Interacts with PRKN.{ECO:0000269|PubMed:12058034, ECO:0000269|PubMed:24270810,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=O95429-1; Sequence=Displayed;Name=2;IsoId=O95429-2; Sequence=VSP_042741;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004865"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04861_identity"],["bp:comment","BAG4_HUMAN Reviewed; 457 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80762"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80762"]]}},{"data":{"id":"Protein_7c70f237b0f19ba3db592f0ad84be0fd","class":"macromolecule","label":"AKT1","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":826.9595,"y":1288.8872,"w":48,"h":25},"metadata":[["bp:displayName","Akt1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P31749",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 124 124 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","124"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 14 14 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","14"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P31749"]]],["bp:standardName","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:xref","RAC-alpha serine/threonine-protein kinase"],["bp:organism","RAC-alpha serine/threonine-protein kinase"],["bp:displayName","AKT1_HUMAN"],["bp:name","RAC-PK-alpha"],["bp:name","PKB"],["bp:name","RAC"],["bp:name","Protein kinase B"],["bp:name","PKB alpha"],["bp:name","2.7.11.1"],["bp:name","Proto-oncogene c-Akt"],["bp:name","Protein kinase B alpha"],["bp:name","AKT1"],["bp:comment","REPLACED http://identifiers.org/uniprot/B0LPE5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P31749-1"],["bp:comment","REPLACED http://identifiers.org/ncbigene/207"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005154"],["bp:comment","REPLACED ProteinRef_AKT1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005267458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24269N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_570"],["bp:comment","FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, andwhich regulate many processes including metabolism, proliferation,cell survival, growth and angiogenesis. This is mediated throughserine and/or threonine phosphorylation of a range of downstreamsubstrates. Over 100 substrate candidates have been reported sofar, but for most of them, no isoform specificity has beenreported. AKT is responsible of the regulation of glucose uptakeby mediating insulin-induced translocation of the SLC2A4/GLUT4glucose transporter to the cell surface. Phosphorylation of PTPN1at 'Ser-50' negatively modulates its phosphatase activitypreventing dephosphorylation of the insulin receptor and theattenuation of insulin signaling. Phosphorylation of TBC1D4triggers the binding of this effector to inhibitory 14-3-3proteins, which is required for insulin-stimulated glucosetransport. AKT regulates also the storage of glucose in the formof glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at'Ser-9', resulting in inhibition of its kinase activity.Phosphorylation of GSK3 isoforms by AKT is also thought to be onemechanism by which cell proliferation is driven. AKT regulatesalso cell survival via the phosphorylation of MAP3K5 (apoptosissignal-related kinase). Phosphorylation of 'Ser-83' decreasesMAP3K5 kinase activity stimulated by oxidative stress and therebyprevents apoptosis. AKT mediates insulin-stimulated proteinsynthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',thereby activating mTORC1 signaling and leading to bothphosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT isinvolved in the phosphorylation of members of the FOXO factors(Forkhead family of transcription factors), leading to binding of14-3-3 proteins and cytoplasmic localization. In particular, FOXO1is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 andFOXO4 are phosphorylated on equivalent sites. AKT has an importantrole in the regulation of NF-kappa-B-dependent gene transcriptionand positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1induces the binding of accessory proteins that are necessary forthe transcription of pro-survival genes such as BCL2 and MCL1. AKTphosphorylates 'Ser-454' on ATP citrate lyase (ACLY), therebypotentially regulating ACLY activity and fatty acid synthesis.Activates the 3B isoform of cyclic nucleotide phosphodiesterase(PDE3B) via phosphorylation of 'Ser-273', resulting in reducedcyclic AMP levels and inhibition of lipolysis. PhosphorylatesPIKFYVE on 'Ser-318', which results in increased PI(3)P-5activity. The Rho GTPase-activating protein DLC1 is anothersubstrate and its phosphorylation is implicated in the regulationcell proliferation and cell growth. AKT plays a role as keymodulator of the AKT-mTOR signaling pathway controlling the tempoof the process of newborn neurons integration during adultneurogenesis, including correct neuron positioning, dendriticdevelopment and synapse formation. Signals downstream ofphosphatidylinositol 3-kinase (PI(3)K) to mediate the effects ofvarious growth factors such as platelet-derived growth factor(PDGF), epidermal growth factor (EGF), insulin and insulin-likegrowth factor I (IGF-I). AKT mediates the antiapoptotic effects ofIGF-I. Essential for the SPATA13-mediated regulation of cellmigration and adhesion assembly and disassembly. May be involvedin the regulation of the placental development. PhosphorylatesSTK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its:kinase activity, nuclear translocation, autophosphorylation andability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinaseactivity, autophosphorylation at Thr-180, binding to RASSF1 andnuclear translocation. Phosphorylates SRPK2 and enhances itskinase activity towards SRSF2 and ACIN1 and promotes its nucleartranslocation. Phosphorylates RAF1 at 'Ser-259' and negativelyregulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and thisphosphorylation inhibits the interaction of KAT6A with PML andnegatively regulates its acetylation activity towards p53/TP53.FUNCTION: AKT1-specific substrates have been recently identified,including palladin (PALLD), which phosphorylation modulatescytoskeletal organization and cell motility; prohibitin (PHB),playing an important role in cell metabolism and proliferation;and CDKN1A, for which phosphorylation at 'Thr-145' induces itsrelease from CDK2 and cytoplasmic relocalization. These recentfindings indicate that the AKT1 isoform has a more specific rolein cell motility and proliferation. Phosphorylates CLK2 therebycontrolling cell survival to ionizing radiation.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748,ECO:0000269|PubMed:1851997}.ENZYME REGULATION: Three specific sites, one in the kinase domain(Thr-308) and the two other ones in the C-terminal regulatoryregion (Ser-473 and Tyr-474), need to be phosphorylated for itsfull activation. Inhibited by pyrrolopyrimidine inhibitors likeaniline triazole and spiroindoline. {ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20810279,ECO:0000269|PubMed:21392984, ECO:0000269|PubMed:9512493,ECO:0000269|PubMed:9736715}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=52.8 uM for ATP (for purified and in vitro activated AKT1){ECO:0000269|PubMed:16540465};KM=0.5 uM for peptide substrate (for purified and in vitroactivated AKT1) {ECO:0000269|PubMed:16540465};KM=143.3 uM for ATP (for recombinant myristoylated AKT1expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};KM=2.9 uM for peptide substrate (for recombinant myristoylatedAKT1 expressed and immunoprecipitated from Rat-1 cells){ECO:0000269|PubMed:16540465};SUBUNIT: Interacts with BTBD10 (By similarity). Interacts withKCTD20 (By similarity). Interacts (via the C-terminus) withCCDC88A (via its C-terminus). Interacts with GRB10; theinteraction leads to GRB10 phosphorylation thus promoting YWHAE-binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A);the interaction occurs in the presence of guanine nucleotides.Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1AAND TCL1B. Interacts with CDKN1B; the interaction phosphorylatesCDKN1B promoting 14-3-3 binding and cell-cycle progression.Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3and STK4. Interacts (via PH domain) with SIRT1. Interacts withSRPK2 in a phosphorylation-dependent manner. Interacts with RAF1.Interacts with TRIM13; the interaction ubiquitinates AKT1 leadingto its proteasomal degradation. Interacts with TNK2 and CLK2.Interacts (via the C-terminus) with THEM4 (via its C-terminus).Interacts with and phosphorylated by PDPK1. Interacts with PA2G4(By similarity). Interacts with KIF14; the interaction is detectedin the plasma membrane upon INS stimulation and promotes AKT1phosphorylation (PubMed:24784001). Interacts with FAM83B;activates the PI3K/AKT signaling cascade (PubMed:23676467).Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529). Formsa complex with WDFY2 and FOXO1 (By similarity). Interacts withFAM168A (PubMed:23251525). {ECO:0000250|UniProtKB:P31750,ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10716693, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:10983986, ECO:0000269|PubMed:11154276,ECO:0000269|PubMed:11598301, ECO:0000269|PubMed:11839817,ECO:0000269|PubMed:12042314, ECO:0000269|PubMed:12176338,ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:12964941,ECO:0000269|PubMed:14749367, ECO:0000269|PubMed:14761976,ECO:0000269|PubMed:15118108, ECO:0000269|PubMed:16139227,ECO:0000269|PubMed:16417524, ECO:0000269|PubMed:16792529,ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:19713527,ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768,ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377,ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392,ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23676467,ECO:0000269|PubMed:24784001}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.Note=Nucleus after activation by integrin-linked protein kinase 1(ILK1). Nuclear translocation is enhanced by interaction withTCL1A. Phosphorylation on Tyr-176 by TNK2 results in itslocalization to the cell membrane where it is targeted for furtherphosphorylations on Thr-308 and Ser-473 leading to its activationand the activated form translocates to the nucleus. Colocalizeswith WDFY2 in intracellular vesicles (PubMed:16792529).{ECO:0000269|PubMed:16792529}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P31749-1; Sequence=Displayed;Name=2;IsoId=P31749-2; Sequence=VSP_056180;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in prostate cancer and levelsincrease from the normal to the malignant state (at proteinlevel). Expressed in all human cell types so far analyzed. TheTyr-176 phosphorylated form shows a significant increase inexpression in breast cancers during the progressive stages i.e.normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS),invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM)stages. {ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:17932490,ECO:0000269|PubMed:20333297}.DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to theplasma membrane. The PH domain mediates interaction with TNK2 andTyr-176 is also essential for this interaction.DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activatingphosphorylation at Thr-308 via disrupting the interaction betweenAKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probablyinterferes with phosphorylation at this site.{ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is requiredfor full activity. Activated TNK2 phosphorylates it on Tyr-176resulting in its binding to the anionic plasma membranephospholipid PA. This phosphorylated form localizes to the cellmembrane, where it is targeted by PDPK1 and PDPK2 for furtherphosphorylations on Thr-308 and Ser-473 leading to its activation.Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylationby PDPK1. Phosphorylated at Thr-308 and Ser-473 by IKBKE and TBK1.Ser-473 phosphorylation is enhanced by interaction with AGAP2isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focalcortical dysplasias with Taylor-type balloon cells. Ser-473phosphorylation is enhanced by signaling through activated FLT3.Dephosphorylated at Thr-308 and Ser-473 by PP2A phosphatase. Thephosphorylated form of PPP2R5B is required for bridging AKT1 withPP2A phosphatase. Ser-473 is dephosphorylated by CPPED1, leadingto termination of signaling. {ECO:0000269|PubMed:12149249,ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.PTM: Ubiquitinated via 'Lys-48'-linked polyubiquitination byZNRF1, leading to its degradation by the proteasome (Bysimilarity). Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1ubiquitination is critical for phosphorylation and activation.When ubiquitinated, it translocates to the plasma membrane, whereit becomes phosphorylated. When fully phosphorylated andtranslocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradationby the proteasome. Also ubiquitinated by TRIM13 leading to itsproteasomal degradation. Phosphorylated, undergoes 'Lys-48'-linkedpolyubiquitination preferentially at Lys-284 catalyzed by MUL1,leading to its proteasomal degradation. {ECO:0000250,ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20059950,ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22410793}.PTM: Acetylated on Lys-14 and Lys-20 by the histoneacetyltransferases EP300 and KAT2B. Acetylation results in reducedphosphorylation and inhibition of activity. Deacetylated at Lys-14and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves theinhibition. {ECO:0000269|PubMed:21775285}.DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancyoriginating from breast epithelial tissue. Breast neoplasms can bedistinguished by their histologic pattern. Invasive ductalcarcinoma is by far the most common type. Breast cancer isetiologically and genetically heterogeneous. Important geneticfactors have been indicated by familial occurrence and bilateralinvolvement. Mutations at more than one locus can be involved indifferent families or even in the same case.{ECO:0000269|PubMed:17611497}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex diseasecharacterized by malignant lesions arising from the inner wall ofthe large intestine (the colon) and the rectum. Geneticalterations are often associated with progression frompremalignant lesion (adenoma) to invasive adenocarcinoma. Riskfactors for cancer of the colon and rectum include colon polyps,long-standing ulcerative colitis, and genetic family history.Note=The gene represented in this entry may be involved in diseasepathogenesis.DISEASE: Note=Genetic variations in AKT1 may play a role insusceptibility to ovarian cancer.DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highlyvariable, severe disorder of asymmetric and disproportionateovergrowth of body parts, connective tissue nevi, epidermal nevi,dysregulated adipose tissue, and vascular malformations. Manyfeatures of Proteus syndrome overlap with other overgrowthsyndromes. {ECO:0000269|PubMed:18954143,ECO:0000269|PubMed:21793738}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowdensyndrome, a hamartomatous polyposis syndrome with age-relatedpenetrance. Cowden syndrome is characterized by hamartomatouslesions affecting derivatives of ectodermal, mesodermal andendodermal layers, macrocephaly, facial trichilemmomas (benigntumors of the hair follicle infundibulum), acral keratoses,papillomatous papules, and elevated risk for development ofseveral types of malignancy, particularly breast carcinoma inwomen and thyroid carcinoma in both men and women. Colon cancerand renal cell carcinoma have also been reported. Hamartomas canbe found in virtually every organ, but most commonly in the skin,gastrointestinal tract, breast and thyroid.{ECO:0000269|PubMed:23246288}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. RAC subfamily. {ECO:0000305}.CAUTION: In light of strong homologies in the primary amino acidsequence, the 3 AKT kinases were long surmised to play redundantand overlapping roles. More recent studies has brought intoquestion the redundancy within AKT kinase isoforms and insteadpointed to isoform specific functions in different cellular eventsand diseases. AKT1 is more specifically involved in cellularsurvival pathways, by inhibiting apoptotic processes; whereas AKT2is more specific for the insulin receptor signaling pathway.Moreover, while AKT1 and AKT2 are often implicated in many aspectsof cellular transformation, the 2 isoforms act in a complementaryopposing manner. The role of AKT3 is less clear, though it appearsto be predominantly expressed in brain. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AKT1ID355ch14q32.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001014431"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_207"],["bp:comment","REPLACED ProteinRef_AKT1__9606"],["bp:comment","AKT1_HUMAN Reviewed; 480 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P31749_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01261_identity"]]],["bp:name","AKT1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_13298"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_13298"]]}},{"data":{"id":"Protein_b54ed7eb0d63a83fb04431a4f179ecf2","class":"macromolecule","label":"MAP2K4","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":531.9933,"y":1044.6752,"w":48,"h":25},"metadata":[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 261 261 Phosphothreonine; by MAP3K."],["bp:featureLocation","MOD_RES 261 261 Phosphothreonine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 261 261 Phosphothreonine; by MAP3K."],["bp:featureLocation","MOD_RES 261 261 Phosphothreonine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 261 261 Phosphothreonine; by MAP3K."],["bp:featureLocation","MOD_RES 261 261 Phosphothreonine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 261 261 Phosphothreonine; by MAP3K."],["bp:featureLocation","MOD_RES 261 261 Phosphothreonine; by MAP3K."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]}},{"data":{"id":"Protein_41cbba05d068bb578a344033dfd6b9a0","class":"macromolecule","label":"BID","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_41cbba05d068bb578a344033dfd6b9a0.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":1117.0299,"y":1231.8666,"w":48,"h":25},"metadata":[["bp:displayName","BID"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80574"]]],["bp:entityReference_http://identifiers.org/uniprot/P55957",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 78 78 Phosphoserine."],["bp:featureLocation","MOD_RES 78 78 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 78 78 Phosphoserine."],["bp:featureLocation","MOD_RES 78 78 Phosphoserine."]]],["bp:standardName","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:organism","BH3-interacting domain death agonist"],["bp:displayName","BID_HUMAN"],["bp:name","BH3-interacting domain death agonist p15"],["bp:name","BH3-interacting domain death agonist p13"],["bp:name","p22 BID"],["bp:name","BH3-interacting domain death agonist p11"],["bp:name","BID"],["bp:name","p15 BID"],["bp:name","p13 BID"],["bp:name","p11 BID"],["bp:comment","REPLACED ProteinRef_BID__10090"],["bp:comment","REPLACED ProteinRef_BID__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_637"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P55957-2"],["bp:comment","BID_HUMAN Reviewed; 195 AA."],["bp:comment","REPLACED ProteinRef_BID__40674"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1421"],["bp:comment","FUNCTION: The major proteolytic product p15 BID allows the releaseof cytochrome c (By similarity). Isoform 1, isoform 2 and isoform4 induce ICE-like proteases and apoptosis. Isoform 3 does notinduce apoptosis. Counters the protective effect of Bcl-2.{ECO:0000250, ECO:0000269|PubMed:14583606}.SUBUNIT: Forms heterodimers either with the pro-apoptotic proteinBAX or the anti-apoptotic protein Bcl-2 (By similarity). p15 BIDinteracts with ITCH. {ECO:0000250, ECO:0000269|PubMed:20392206}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Mitochondrionmembrane {ECO:0000250}. Note=When uncleaved, it is predominantlycytoplasmic. {ECO:0000269|PubMed:14583606}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p15:Mitochondrion membrane {ECO:0000250}. Note=Translocates tomitochondria as an integral membrane protein. {ECO:0000250}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p13:Mitochondrion membrane {ECO:0000250}. Note=Associated with themitochondrial membrane. {ECO:0000250}.SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.SUBCELLULAR LOCATION: Isoform 2: Mitochondrion membrane. Note=Asignificant proportion of isoform 2 localizes to mitochondria, itmay be cleaved constitutively.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=BID(L);IsoId=P55957-1; Sequence=Displayed;Name=2; Synonyms=BID(EL);IsoId=P55957-2; Sequence=VSP_017267;Name=3; Synonyms=BID(S);IsoId=P55957-3; Sequence=VSP_017268, VSP_017269;Name=4; Synonyms=BID(ES);IsoId=P55957-4; Sequence=VSP_017266;TISSUE SPECIFICITY: Isoform 2 and isoform 3 are expressed inspleen, bone marrow, cerebral and cerebellar cortex. Isoform 2 isexpressed in spleen, pancreas and placenta (at protein level).Isoform 3 is expressed in lung, pancreas and spleen (at proteinlevel). Isoform 4 is expressed in lung and pancreas (at proteinlevel). {ECO:0000269|PubMed:14583606}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: TNF-alpha induces a caspase-mediated cleavage of p22 BID intoa major p15 and minor p13 and p11 products. {ECO:0000250}.PTM: p15 BID is ubiquitinated by ITCH; ubiquitination results inproteasome-dependent degradation. {ECO:0000269|PubMed:20392206}.SEQUENCE CAUTION:Sequence=AAH22072.2; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bid/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001187"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34937N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_637"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_637_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_932070"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80573"]]}},{"data":{"id":"Protein_c150eaef12b60ffe815e4a50b857c496","class":"macromolecule","label":"MAPK1","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":883.5027,"y":1382.6461,"w":48,"h":25},"metadata":[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 187 187 Phosphotyrosine; by MAP2K1 and MAP2K2."],["bp:featureLocation",[["bp:sequencePosition","187"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 29 29 Phosphoserine; by SGK1."],["bp:featureLocation",[["bp:sequencePosition","29"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:standardName","Mitogen-activated protein kinase 1"],["bp:xref","Mitogen-activated protein kinase 1"],["bp:xref","Mitogen-activated protein kinase 1"],["bp:organism","Mitogen-activated protein kinase 1"],["bp:displayName","MK01_HUMAN"],["bp:name","ERT1"],["bp:name","PRKM2"],["bp:name","PRKM1"],["bp:name","p42-MAPK"],["bp:name","2.7.11.24"],["bp:name","MAPK 2"],["bp:name","ERK-2"],["bp:name","ERK2"],["bp:name","Mitogen-activated protein kinase 2"],["bp:name","MAPK 1"],["bp:name","MAP kinase 2"],["bp:name","Extracellular signal-regulated kinase 2"],["bp:name","MAP kinase isoform p42"],["bp:name","MAPK1"],["bp:name","MAP kinase 1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P28482_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002736"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5594"],["bp:comment","REPLACED ProteinRef_MAPK1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_620407"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5594"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-519N_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P28482"],["bp:comment","REPLACED ProteinRef_MAPK1__40674"],["bp:comment","REPLACED ProteinRef_MAPK1__9606"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_832"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5594"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1WZY_see-also"],["bp:comment","MK01_HUMAN Reviewed; 360 AA."],["bp:comment","FUNCTION: Serine/threonine kinase which acts as an essentialcomponent of the MAP kinase signal transduction pathway.MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an importantrole in the MAPK/ERK cascade. They participate also in a signalingcascade initiated by activated KIT and KITLG/SCF. Depending on thecellular context, the MAPK/ERK cascade mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation through the regulation of transcription,translation, cytoskeletal rearrangements. The MAPK/ERK cascadeplays also a role in initiation and regulation of meiosis,mitosis, and postmitotic functions in differentiated cells byphosphorylating a number of transcription factors. About 160substrates have already been discovered for ERKs. Many of thesesubstrates are localized in the nucleus, and seem to participatein the regulation of transcription upon stimulation. However,other substrates are found in the cytosol as well as in othercellular organelles, and those are responsible for processes suchas translation, mitosis and apoptosis. Moreover, the MAPK/ERKcascade is also involved in the regulation of the endosomaldynamics, including lysosome processing and endosome cyclingthrough the perinuclear recycling compartment (PNRC); as well asin the fragmentation of the Golgi apparatus during mitosis. Thesubstrates include transcription factors (such as ATF2, BCL6,ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such asCANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators ofapoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG),regulators of translation (such as EIF4EBP1) and a variety ofother signaling-related molecules (like ARHGEF2, DCC, FRS2 orGRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2,RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2,RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases(such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates whichenable the propagation the MAPK/ERK signal to additional cytosolicand nuclear targets, thereby extending the specificity of thecascade. Mediates phosphorylation of TPR in respons to EGFstimulation. May play a role in the spindle assembly checkpoint.Phosphorylates PML and promotes its interaction with PIN1, leadingto PML degradation. Phosphorylates CDK2AP2 (By similarity).{ECO:0000250|UniProtKB:P63086, ECO:0000269|PubMed:10617468,ECO:0000269|PubMed:10637505, ECO:0000269|PubMed:11154262,ECO:0000269|PubMed:12110590, ECO:0000269|PubMed:12356731,ECO:0000269|PubMed:12792650, ECO:0000269|PubMed:12794087,ECO:0000269|PubMed:12974390, ECO:0000269|PubMed:15184391,ECO:0000269|PubMed:15241487, ECO:0000269|PubMed:15616583,ECO:0000269|PubMed:15664191, ECO:0000269|PubMed:15788397,ECO:0000269|PubMed:15952796, ECO:0000269|PubMed:16581800,ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19265199,ECO:0000269|PubMed:19879846, ECO:0000269|PubMed:22033920,ECO:0000269|PubMed:7588608, ECO:0000269|PubMed:8622688,ECO:0000269|PubMed:9480836, ECO:0000269|PubMed:9596579,ECO:0000269|PubMed:9649500, ECO:0000269|PubMed:9687510,ECO:0000303|PubMed:15526160, ECO:0000303|PubMed:16393692,ECO:0000303|PubMed:19565474, ECO:0000303|PubMed:21779493}.FUNCTION: Acts as a transcriptional repressor. Binds to a[GC]AAA[GC] consensus sequence. Repress the expression ofinterferon gamma-induced genes. Seems to bind to the promoter ofCCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 andSTAT1. Transcriptional activity is independent of kinase activity.{ECO:0000269|PubMed:19879846}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2on Thr-185 and Tyr-187 in response to external stimuli likeinsulin or NGF. Both phosphorylations are required for activity.This phosphorylation causes dramatic conformational changes, whichenable full activation and interaction of MAPK1/ERK2 with itssubstrates. Phosphorylation on Ser-29 by SGK1 results in itsactivation by enhancing its interaction with MAP2K1/MEK1 andMAP2K2/MEK2. Dephosphorylated and inactivated by DUSP3, DUSP6 andDUSP9. Inactivated by pyrimidylpyrrole inhibitors.{ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:19060905}.SUBUNIT: Binds both upstream activators and downstream substratesin multimolecular complexes. Binds to HIV-1 Nef through its SH3domain. This interaction inhibits its tyrosine-kinase activity.Interacts with ADAM15, ARHGEF2, ARRB2, DAPK1 (via death domain),HSF4, IER3, IPO7, DUSP6, NISCH, SGK1, and isoform 1 of NEK2.Interacts (phosphorylated form) with CAV2 ('Tyr-19'-phosphorylatedform); the interaction, promoted by insulin, leads to nuclearlocation and MAPK1 activation. Interacts with MORG1, PEA15 andMKNK2 (By similarity). MKNK2 isoform 1 binding prevents fromdephosphorylation and inactivation (By similarity). Interacts withDCC (By similarity). The phosphorylated form interacts with PML(isoform PML-4). Interacts with STYX. Interacts with CDK2AP2 (Bysimilarity). {ECO:0000250|UniProtKB:P63085,ECO:0000250|UniProtKB:P63086, ECO:0000269|PubMed:11912194,ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:15358203,ECO:0000269|PubMed:15616583, ECO:0000269|PubMed:16139248,ECO:0000269|PubMed:16242327, ECO:0000269|PubMed:16581800,ECO:0000269|PubMed:17194451, ECO:0000269|PubMed:17300186,ECO:0000269|PubMed:18211802, ECO:0000269|PubMed:18296648,ECO:0000269|PubMed:18435604, ECO:0000269|PubMed:18760948,ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19060905,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:19827834,ECO:0000269|PubMed:22033920, ECO:0000269|PubMed:23847209,ECO:0000269|PubMed:8794306, ECO:0000269|PubMed:9596579,ECO:0000269|PubMed:9827991}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, spindle{ECO:0000250}. Nucleus. Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome. Cytoplasm. Note=Associated with thespindle during prometaphase and metaphase (By similarity). PEA15-binding and phosphorylated DAPK1 promote its cytoplasmicretention. Phosphorylation at Ser- 246 and Ser-248 as well asautophosphorylation at Thr-190 promote nuclear localization.{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P28482-1; Sequence=Displayed;Name=2;IsoId=P28482-2; Sequence=VSP_047815;DOMAIN: The TXY motif contains the threonine and tyrosine residueswhose phosphorylation activates the MAP kinases.PTM: Phosphorylated upon KIT and FLT3 signaling (By similarity).Dually phosphorylated on Thr-185 and Tyr-187, which activates theenzyme. Undergoes regulatory phosphorylation on additionalresidues such as Ser-246 and Ser-248 in the kinase insert domain(KID) These phosphorylations, which are probably mediated by morethan one kinase, are important for binding of MAPK1/ERK2 toimportin-7 (IPO7) and its nuclear translocation. In addition,autophosphorylation of Thr-190 was shown to affect the subcellularlocalization of MAPK1/ERK2 as well. Ligand-activated ALK inducestyrosine phosphorylation. Dephosphorylated by PTPRJ at Tyr-187.Phosphorylation on Ser-29 by SGK1 results in its activation byenhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. DUSP3and DUSP6 dephosphorylate specifically MAPK1/ERK2 and MAPK3/ERK1whereas DUSP9 dephosphorylates a broader range of MAPKs.{ECO:0000250, ECO:0000269|PubMed:17274988,ECO:0000269|PubMed:18760948, ECO:0000269|PubMed:19053285,ECO:0000269|PubMed:19060905, ECO:0000269|PubMed:19265199,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:19494114}.PTM: ISGylated. {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA77753.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Extracellular signal-regulatedkinase entry;URL=\"https://en.wikipedia.org/wiki/Extracellular_signal-regulated_kinase\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAPK1ID41288ch22q11.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_MAPK1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01496_identity"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28905"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28905"]]}},{"data":{"id":"Protein_461233220923d236025748ff1e4a769d","class":"macromolecule","label":"MAPK1","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_461233220923d236025748ff1e4a769d.info.1","class":"state variable","state":{"variable":"185","value":"opthr"}},{"id":"Protein_461233220923d236025748ff1e4a769d.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_461233220923d236025748ff1e4a769d.info.3","class":"state variable","state":{"variable":"187","value":"optyr"}}],"unitsOfInformation":[],"bbox":{"x":682.13477,"y":1294.8898,"w":85,"h":25},"metadata":[["bp:displayName","Erk2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5166"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5167"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_5167"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5167"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_5167"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_5165"]]}},{"data":{"id":"Protein_bb8f0cd1124ca58baa10c0830e8a3bd3","class":"macromolecule","label":"BIRC3","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1103.3716,"y":778.7795,"w":48,"h":25},"metadata":[["bp:displayName","cIAP2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q13489",[["bp:standardName","Baculoviral IAP repeat-containing protein 3"],["bp:xref",[["bp:id","Q13489"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","BIRC3"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","BIRC3"],["bp:db","hgnc symbol"]]],["bp:displayName","BIRC3_HUMAN"],["bp:name","Apoptosis inhibitor 2"],["bp:name","TNFR2-TRAF-signaling complex protein 1"],["bp:name","hIAP1"],["bp:name","Cellular inhibitor of apoptosis 2"],["bp:name","RING finger protein 49"],["bp:name","C-IAP2"],["bp:name","RNF49"],["bp:name","RING-type E3 ubiquitin transferase BIRC3"],["bp:name","Inhibitor of apoptosis protein 1"],["bp:name","IAP homolog C"],["bp:name","BIRC3"],["bp:name","API2"],["bp:name","2.3.2.27"],["bp:name","MIHC"],["bp:name","hIAP-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-33720N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016873132"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_330"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_330"],["bp:comment","FUNCTION: Multi-functional protein which regulates not onlycaspases and apoptosis, but also modulates inflammatory signalingand immunity, mitogenic kinase signaling and cell proliferation,as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates bothcanonical and non-canonical NF-kappa-B signaling by acting inopposite directions: acts as a positive regulator of the canonicalpathway and suppresses constitutive activation of non-canonicalNF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4,CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an importantregulator of innate immune signaling via regulation of Toll-likereceptors (TLRs), Nodlike receptors (NLRs) and RIG-I likereceptors (RLRs), collectively referred to as pattern recognitionreceptors (PRRs). Protects cells from spontaneous formation of theripoptosome, a large multi-protein complex that has the capabilityto kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation byubiquitinating RIPK1 and CASP8. {ECO:0000269|PubMed:21931591,ECO:0000269|PubMed:23453969}.CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugatingenzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptorprotein]-L-lysine. {ECO:0000269|PubMed:21931591,ECO:0000269|PubMed:23453969}.ENZYME REGULATION: USP19 regulates the stability of BIRC3/c-IAP2by preventing its ubiquitination. {ECO:0000269|PubMed:21849505}.SUBUNIT: Interacts with DIABLO/SMAC and with PRSS25; theseinteractions inhibit apoptotic suppressor activity. The BIR motifsregion interacts with TNF receptor associated factors 1 and 2(TRAF1 and TRAF2) to form a heteromeric complex, which is thenrecruited to the tumor necrosis factor receptor 2 (TNFR2).Interaction with TRAF2 is required for ubiquitination of IKBKE,degradation of NFKBIA and activation of NF-kappa-B. Interacts withRIP1, RIP2, RIP3, RIP4 and USP19. {ECO:0000269|PubMed:21849505,ECO:0000269|PubMed:21931591}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15665297}.Nucleus {ECO:0000269|PubMed:15665297}.TISSUE SPECIFICITY: Highly expressed in fetal lung, and kidney. Inthe adult, expression is mainly seen in lymphoid tissues,including spleen, thymus and peripheral blood lymphocytes.PTM: Auto-ubiquitinated and degraded by the proteasome inapoptotic cells.DISEASE: Note=A chromosomal aberration involving BIRC3 isrecurrent in low-grade mucosa-associated lymphoid tissue (MALTlymphoma). Translocation t(11;18)(q21;q21) with MALT1. Thistranslocation is found in approximately 50% of cytogeneticallyabnormal low-grade MALT lymphoma.SIMILARITY: Belongs to the IAP family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BIRC3ID239.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/birc3/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_892007"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13489_identity"],["bp:comment","BIRC3_HUMAN Reviewed; 604 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001156"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1559"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_59946f19a491a0ccdfd10b86bf8a3b2c","class":"macromolecule","label":"CASP8","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1016.6449,"y":1397.3065,"w":48,"h":25},"metadata":[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","224"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 Phosphoserine."],["bp:featureLocation","MOD_RES 211 211 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 Phosphoserine."],["bp:featureLocation","MOD_RES 211 211 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 Phosphoserine."],["bp:featureLocation","MOD_RES 211 211 Phosphoserine."]]],["bp:standardName","Caspase-8"],["bp:xref","Caspase-8"],["bp:xref","Caspase-8"],["bp:organism","Caspase-8"],["bp:displayName","CASP8_HUMAN"],["bp:name","ICE-like apoptotic protease 5"],["bp:name","CAP4"],["bp:name","FADD-homologous ICE/ced-3-like protease"],["bp:name","FLICE"],["bp:name","Apoptotic protease Mch-5"],["bp:name","CASP-8"],["bp:name","Apoptotic cysteine protease"],["bp:name","3.4.22.61"],["bp:name","MORT1-associated ced-3 homolog"],["bp:name","MACH"],["bp:name","FADD-like ICE"],["bp:name","Caspase-8 subunit p10"],["bp:name","MCH5"],["bp:name","Caspase-8 subunit p18"],["bp:name","CASP8"],["bp:comment","REPLACED http://identifiers.org/uniprot/P08160"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q14790_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_841"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-9"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_10835762_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-1"],["bp:comment","FUNCTION: Most upstream protease of the activation cascade ofcaspases responsible for the TNFRSF6/FAS mediated and TNFRSF1Ainduced cell death. Binding to the adapter molecule FADD recruitsit to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolyticactivation. The active dimeric enzyme is then liberated from theDISC and free to activate downstream apoptotic proteases.Proteolytic fragments of the N-terminal propeptide (termed CAP3,CAP5 and CAP6) are likely retained in the DISC. Cleaves andactivates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. Mayparticipate in the GZMB apoptotic pathways. Cleaves ADPRT.Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC.Likely target for the cowpox virus CRMA death inhibitory protein.Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalyticsite and may interfere with the pro-apoptotic activity of thecomplex. {ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9006941}.CATALYTIC ACTIVITY: Strict requirement for Asp at position P1 andhas a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp-|-(Gly/Ser/Ala). {ECO:0000269|PubMed:23516580}.ENZYME REGULATION: Inhibited by the effector protein NleF that isproduced by pathogenic E.coli; this inhibits apoptosis.{ECO:0000269|PubMed:23516580}.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 18 kDa (p18) and a 10kDa (p10) subunit. Interacts with FADD, CFLAR and PEA15. Isoform 9interacts at the endoplasmic reticulum with a complex containingBCAP31, BAP29, BCL2 and/or BCL2L1. Interacts with TNFAIP8L2 (Bysimilarity). Interacts with CASP8AP2. Interacts with RFFL andRNF34; negatively regulate CASP8 through proteasomal degradation.Interacts with human cytomegalovirus/HHV-5 protein vICA/UL36; thisinteraction inhibits CASP8 activation. Interacts with NleF frompathogenic E.coli. Interacts with NOL3; decreases CASP8 activityin a mitochondria localization- and phosphorylation-dependentmanner and this interaction is dissociated by calcium.{ECO:0000250|UniProtKB:O89110, ECO:0000250|UniProtKB:Q9JHX4,ECO:0000269|PubMed:10442631, ECO:0000269|PubMed:10508785,ECO:0000269|PubMed:11427719, ECO:0000269|PubMed:11917123,ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:15509781,ECO:0000269|PubMed:17245429, ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9334338}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Name=1; Synonyms=Alpha-1;IsoId=Q14790-1; Sequence=Displayed;Name=2; Synonyms=Alpha-2, MCH5-beta;IsoId=Q14790-2; Sequence=VSP_000810;Name=3; Synonyms=Alpha-3;IsoId=Q14790-3; Sequence=VSP_000813;Name=4; Synonyms=Alpha-4;IsoId=Q14790-4; Sequence=VSP_000809, VSP_000810;Name=5; Synonyms=Beta-1;IsoId=Q14790-5; Sequence=VSP_000814, VSP_000815;Name=6; Synonyms=Beta-2;IsoId=Q14790-6; Sequence=VSP_000811, VSP_000812;Name=7; Synonyms=Beta-3, 8L;IsoId=Q14790-7; Sequence=VSP_000816, VSP_000817;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=8; Synonyms=Beta-4;IsoId=Q14790-8; Sequence=VSP_000810, VSP_000816, VSP_000817;Name=9; Synonyms=8L;IsoId=Q14790-9; Sequence=VSP_000808;Note=Ref.8 (AAL87628) sequence is in conflict in position:14:K->R. {ECO:0000305};TISSUE SPECIFICITY: Isoform 1, isoform 5 and isoform 7 areexpressed in a wide variety of tissues. Highest expression inperipheral blood leukocytes, spleen, thymus and liver. Barelydetectable in brain, testis and skeletal muscle.DOMAIN: Isoform 9 contains a N-terminal extension that is requiredfor interaction with the BCAP31 complex.PTM: Generation of the subunits requires association with thedeath-inducing signaling complex (DISC), whereas additionalprocessing is likely due to the autocatalytic activity of theactivated protease. GZMB and CASP10 can be involved in theseprocessing events. {ECO:0000269|PubMed:8962078,ECO:0000269|PubMed:9184224}.PTM: Phosphorylation on Ser-387 during mitosis by CDK1 inhibitsactivation by proteolysis and prevents apoptosis. Thisphosphorylation occurs in cancer cell lines, as well as in primarybreast tissues and lymphocytes. {ECO:0000269|PubMed:20937773}.POLYMORPHISM: Genetic variations in CASP8 are associated withreduced risk of lung cancer [MIM:211980] in a population of HanChinese subjects. Genetic variations are also associated withdecreased risk of cancer of various other forms includingesophageal, gastric, colorectal, cervical, and breast, acting inan allele dose-dependent manner. {ECO:0000269|PubMed:17450141}.DISEASE: Caspase-8 deficiency (CASP8D) [MIM:607271]: Disorderresembling autoimmune lymphoproliferative syndrome (ALPS). It ischaracterized by lymphadenopathy, splenomegaly, and defectiveCD95-induced apoptosis of peripheral blood lymphocytes (PBLs). Itleads to defects in activation of T-lymphocytes, B-lymphocytes,and natural killer cells leading to immunodeficiency characterizedby recurrent sinopulmonary and herpes simplex virus infections andpoor responses to immunization. {ECO:0000269|PubMed:12353035}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA66858.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};Sequence=CAA66859.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};WEB RESOURCE: Name=CASP8base; Note=CASP8 mutation db;URL=\"http://structure.bmc.lu.se/idbase/CASP8base/\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/casp8/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QDU_see-also"],["bp:comment","REPLACED ProteinRef_CASP8__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001219"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203520"],["bp:comment","CASP8_HUMAN Reviewed; 479 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03459_identity"],["bp:comment","REPLACED ProteinRef_CASP8__9606"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_841"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203519"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1I4E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-30915N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1F9E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QTN_see-also"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4464"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246944"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_36111829"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"]]}},{"data":{"id":"Protein_ee92ce16bb5ebd6a4c6ecf0c1e60f011","class":"macromolecule","label":"AIFM1","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":751.6215,"y":778.1033,"w":48,"h":25},"metadata":[["bp:displayName","AIF"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"]]}},{"data":{"id":"Protein_4e99ebac6e0007d47a4838b2ae773d07","class":"macromolecule","label":"MAPK8","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":560.0849,"y":1174.5718,"w":48,"h":25},"metadata":[["bp:displayName","Jnk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45983",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 183 183 Phosphothreonine; by MAP2K7."],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 185 185 Phosphotyrosine; by MAP2K4."],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P45983"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P45983"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P45983"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P45983"]]],["bp:standardName","Mitogen-activated protein kinase 8"],["bp:xref","Mitogen-activated protein kinase 8"],["bp:xref","Mitogen-activated protein kinase 8"],["bp:organism","Mitogen-activated protein kinase 8"],["bp:displayName","MK08_HUMAN"],["bp:name","PRKM8"],["bp:name","SAPK1c"],["bp:name","2.7.11.24"],["bp:name","Stress-activated protein kinase JNK1"],["bp:name","SAPK1"],["bp:name","MAPK 8"],["bp:name","JNK-46"],["bp:name","MAP kinase 8"],["bp:name","c-Jun N-terminal kinase 1"],["bp:name","JNK1"],["bp:name","MAPK8"],["bp:name","SAPK1C"],["bp:name","Stress-activated protein kinase 1c"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5599"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P45983-1"],["bp:comment","MK08_HUMAN Reviewed; 427 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03100_identity"],["bp:comment","REPLACED ProteinRef_MAPK8__10090"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q9WVI9"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5599"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_27724600"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3551"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_620637"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-249N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_620634"],["bp:comment","REPLACED ProteinRef_MAPK8__40674"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5599"],["bp:comment","REPLACED ProteinRef_MAPK8__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1UKI_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P45983_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002741"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_613"],["bp:comment","FUNCTION: Serine/threonine-protein kinase involved in variousprocesses such as cell proliferation, differentiation, migration,transformation and programmed cell death. Extracellular stimulisuch as proinflammatory cytokines or physical stress stimulate thestress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK)signaling pathway. In this cascade, two dual specificity kinasesMAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK8/JNK1.In turn, MAPK8/JNK1 phosphorylates a number of transcriptionfactors, primarily components of AP-1 such as JUN, JDP2 and ATF2and thus regulates AP-1 transcriptional activity. Phosphorylatesthe replication licensing factor CDT1, inhibiting the interactionbetween CDT1 and the histone H4 acetylase HBO1 to replicationorigins. Loss of this interaction abrogates the acetylationrequired for replication initiation. Promotes stressed cellapoptosis by phosphorylating key regulatory factors includingp53/TP53 and Yes-associates protein YAP1. In T-cells, MAPK8 andMAPK9 are required for polarized differentiation of T-helper cellsinto Th1 cells. Contributes to the survival of erythroid cells byphosphorylating the antagonist of cell death BAD upon EPOstimulation. Mediates starvation-induced BCL2 phosphorylation,BCL2 dissociation from BECN1, and thus activation of autophagy.Phosphorylates STMN2 and hence regulates microtubule dynamics,controlling neurite elongation in cortical neurons. In thedeveloping brain, through its cytoplasmic activity on STMN2,negatively regulates the rate of exit from multipolar stage and ofradial migration from the ventricular zone. Phosphorylates severalother substrates including heat shock factor protein 4 (HSF4), thedeacetylase SIRT1, ELK1, or the E3 ligase ITCH. Phosphorylates theCLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulationof the circadian clock (PubMed:22441692). Phosphorylates the heatshock transcription factor HSF1, suppressing HSF1-inducedtranscriptional activity (PubMed:10747973).{ECO:0000269|PubMed:10747973, ECO:0000269|PubMed:22441692}.FUNCTION: JNK1 isoforms display different binding patterns: beta-1preferentially binds to c-Jun, whereas alpha-1, alpha-2, and beta-2 have a similar low level of binding to both c-Jun or ATF2.However, there is no correlation between binding andphosphorylation, which is achieved at about the same efficiency byall isoforms.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:11062067};ENZYME REGULATION: Activated by threonine and tyrosinephosphorylation by either of two dual specificity kinases, MAP2K4and MAP2K7. MAP2K4 shows a strong preference for Tyr-185 whileMAP2K7 phosphorylates Tyr-183 preferentially. Inhibited by dualspecificity phosphatases, such as DUSP1. Inhibited by SERPINB3.{ECO:0000269|PubMed:19166818}.SUBUNIT: Binds to at least four scaffolding proteins,MAPK8IP1/JIP-1, MAPK8IP2/JIP-2, MAPK8IP3/JIP-3/JSAP1 andSPAG9/MAPK8IP4/JIP-4. These proteins also bind other components ofthe JNK signaling pathway. Interacts with TP53 and WWOX. Interactswith JAMP. Forms a complex with MAPK8IP1 and ARHGEF28 (Bysimilarity). Interacts with HSF1 (via D domain and preferentiallywith hyperphosphorylated form); this interaction occurs under bothnormal growth conditions and immediately upon heat shock(PubMed:10747973). Interacts (phosphorylated form) with NFE2; theinteraction phosphorylates NFE2 in undifferentiated cells (Bysimilarity). Interacts with NFATC4. Interacts with MECOM;regulates JNK signaling. Interacts with PIN1; this interactionmediates MAPK8 conformational changes leading to the binding ofMAPK8 to its substrates. {ECO:0000250,ECO:0000269|PubMed:10747973, ECO:0000269|PubMed:10856240,ECO:0000269|PubMed:12514174, ECO:0000269|PubMed:15693750,ECO:0000269|PubMed:16581800, ECO:0000269|PubMed:17875713,ECO:0000269|PubMed:19166818, ECO:0000269|PubMed:21660049}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21148294}.Nucleus {ECO:0000269|PubMed:21148294}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=2; Synonyms=JNK1-alpha-2;IsoId=P45983-1; Sequence=Displayed;Name=1; Synonyms=JNK1-alpha-1;IsoId=P45983-2; Sequence=VSP_004833;Note=Contains a phosphoserine at position 377.{ECO:0000244|PubMed:18691976, ECO:0000244|PubMed:19369195};Name=3; Synonyms=JNK1-beta-1;IsoId=P45983-3; Sequence=VSP_004831, VSP_004832, VSP_004833;Note=Contains a phosphoserine at position 377.{ECO:0000244|PubMed:18691976, ECO:0000244|PubMed:19369195};Name=4; Synonyms=JNK1-beta-2;IsoId=P45983-4; Sequence=VSP_004831, VSP_004832;Name=5;IsoId=P45983-5; Sequence=VSP_054554, VSP_004833;Note=Contains a phosphoserine at position 301.{ECO:0000244|PubMed:18691976, ECO:0000244|PubMed:19369195};DOMAIN: The TXY motif contains the threonine and tyrosine residueswhose phosphorylation activates the MAP kinases.PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K7 andMAP2K4, which activates the enzyme. Phosphorylated by TAOK2.{ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:17158878}.SIMILARITY: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/JNK1ID196.html\";WEB RESOURCE: Name=Wikipedia; Note=C-Jun N-terminal kinases entry;URL=\"https://en.wikipedia.org/wiki/C-Jun_N-terminal_kinases\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1UKH_see-also"]]],["bp:name","JNK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2056"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2056"]]}},{"data":{"id":"Protein_07241ca70aaa064dcd6380a81ff2bc8d","class":"macromolecule","label":"MAPK3","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_07241ca70aaa064dcd6380a81ff2bc8d.info.1","class":"state variable","state":{"variable":"202","value":"opthr"}},{"id":"Protein_07241ca70aaa064dcd6380a81ff2bc8d.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_07241ca70aaa064dcd6380a81ff2bc8d.info.3","class":"state variable","state":{"variable":"204","value":"optyr"}}],"unitsOfInformation":[],"bbox":{"x":607.8798,"y":1220.2893,"w":85,"h":25},"metadata":[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28909"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_28909"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28909"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_28909"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]}},{"data":{"id":"Complex_f59c961e9775137e7d6dabedebd36f0a","class":"complex","label":"NF kappa B1/RelA/I kappa B alpha","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Complex_f59c961e9775137e7d6dabedebd36f0a.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":918.50336,"y":1261.6371,"w":52,"h":94},"metadata":[["bp:displayName","NF kappa B1/RelA/I kappa B alpha"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80749"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80749"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80749"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80749"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80749"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80749"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80749"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80749"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80746"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80746"]]}},{"data":{"id":"Protein_9733e0d5a4fe4b996e3a37b20284cea3_Complex_f59c961e9775137e7d6dabedebd36f0a","class":"macromolecule","label":"NFKB1","parent":"Complex_f59c961e9775137e7d6dabedebd36f0a","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":918.50336,"y":1294.1371,"w":48,"h":25},"metadata":[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]}},{"data":{"id":"Protein_960ce83def5ac39b4fe48820a9835d6c_Complex_f59c961e9775137e7d6dabedebd36f0a","class":"macromolecule","label":"NFKBIA","parent":"Complex_f59c961e9775137e7d6dabedebd36f0a","clonemarker":false,"stateVariables":[{"id":"Protein_960ce83def5ac39b4fe48820a9835d6c_Complex_f59c961e9775137e7d6dabedebd36f0a.info.1","class":"state variable","state":{"variable":"","value":"Ub"}}],"unitsOfInformation":[],"bbox":{"x":918.50336,"y":1229.1371,"w":48,"h":25},"metadata":[["bp:displayName","I kappa B alpha"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:01240"],["bp:db","protein modification ontology"]]],["bp:term","ubiquitination"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80748"]]],["bp:entityReference_http://identifiers.org/uniprot/P25963",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."],["bp:featureLocation","MOD_RES 210 210 (3S)-3-hydroxyasparagine; by HIF1AN;partial."]]],["bp:standardName","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:organism","NF-kappa-B inhibitor alpha"],["bp:displayName","IKBA_HUMAN"],["bp:name","IKBA"],["bp:name","MAD3"],["bp:name","IkB-alpha"],["bp:name","Major histocompatibility complex enhancer-binding protein MAD3"],["bp:name","NFKBI"],["bp:name","NFKBIA"],["bp:name","I-kappa-B-alpha"],["bp:name","IkappaBalpha"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q04207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25799_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25799"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-139N_identity"],["bp:comment","REPLACED ProteinRef_NFKBIA__9606"],["bp:comment","REPLACED ProteinRef_NFKBIA__40674"],["bp:comment","IKBA_HUMAN Reviewed; 317 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_990"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25963_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_065390"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01235_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4792"],["bp:comment","REPLACED ProteinRef_NFKBIA__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4792"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4792"],["bp:comment","FUNCTION: Inhibits the activity of dimeric NF-kappa-B/RELcomplexes by trapping REL dimers in the cytoplasm through maskingof their nuclear localization signals. On cellular stimulation byimmune and proinflammatory responses, becomes phosphorylatedpromoting ubiquitination and degradation, enabling the dimericRELA to translocate to the nucleus and activate transcription.{ECO:0000269|PubMed:7479976}.SUBUNIT: Interacts with RELA; the interaction requires the nuclearimport signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA,IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts withisoform 1 and isoform 2 of RWDD3; the interaction enhancessumoylation. Interacts (when phosphorylated at the 2 serineresidues in the destruction motif D-S-G-X(2,3,4)-S) with BTRC.Associates with the SCF(BTRC) complex, composed of SKP1, CUL1 andBTRC; the association is mediated via interaction with BTRC. Partof a SCF(BTRC)-like complex lacking CUL1, which is associated withRELA; RELA interacts directly with NFKBIA. Interacts with PRMT2.Interacts with PRKACA in platelets; this interaction is disruptedby thrombin and collagen. Interacts with HIF1AN. Interacts withMEFV. Interacts with DDRGK1; positively regulates NFKBIAphosphorylation and degradation. {ECO:0000269|PubMed:10454581,ECO:0000269|PubMed:10657303, ECO:0000269|PubMed:1493333,ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:18577712,ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:23469069,ECO:0000269|PubMed:23675531}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles betweenthe nucleus and the cytoplasm by a nuclear localization signal(NLS) and a CRM1-dependent nuclear export. {ECO:0000250}.INDUCTION: Induced in adherent monocytes.PTM: Phosphorylated; disables inhibition of NF-kappa-B DNA-bindingactivity. Phosphorylation at positions 32 and 36 is prerequisiteto recognition by UBE2D3 leading to polyubiquitination andsubsequent degradation. {ECO:0000269|PubMed:10329681,ECO:0000269|PubMed:10882136, ECO:0000269|PubMed:20504922}.PTM: Sumoylated; sumoylation requires the presence of the nuclearimport signal. Sumoylation blocks ubiquitination and proteasome-mediated degradation of the protein thereby increasing the proteinstability. {ECO:0000269|PubMed:11124955,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:20504922}.PTM: Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3.Ubiquitin chain elongation is then performed by CDC34 incooperation with the SCF(FBXW11) E3 ligase complex, buildingubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin.The resulting polyubiquitination leads to protein degradation.Also ubiquitinated by SCF(BTRC) following stimulus-dependentphosphorylation at Ser-32 and Ser-36.{ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10882136,ECO:0000269|PubMed:20347421, ECO:0000269|PubMed:20504922,ECO:0000269|PubMed:7479976}.PTM: Deubiquitinated by porcine reproductive and respiratorysyndrome virus Nsp2 protein, which thereby interferes with NFKBIAdegradation and impairs subsequent NF-kappa-B activation.DISEASE: Ectodermal dysplasia, anhidrotic, with T-cellimmunodeficiency autosomal dominant (ADEDAID) [MIM:612132]: A formof ectoderma dysplasia, a heterogeneous group of disorders due toabnormal development of two or more ectodermal structures. Thisform of ectodermal dysplasia is associated with decreasedproduction of pro-inflammatory cytokines and certain interferons,rendering patients susceptible to infection.{ECO:0000269|PubMed:14523047, ECO:0000269|PubMed:18412279}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the NF-kappa-B inhibitor family.{ECO:0000305}.WEB RESOURCE: Name=NFKBIAbase; Note=NFKBIA mutation db;URL=\"http://structure.bmc.lu.se/idbase/NFKBIAbase/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/nfkbia/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80747"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80747"]]}},{"data":{"id":"Protein_f02a1f7ebcab04238d804d8ecc342e7e_Complex_f59c961e9775137e7d6dabedebd36f0a","class":"macromolecule","label":"RELA","parent":"Complex_f59c961e9775137e7d6dabedebd36f0a","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":918.50336,"y":1264.1371,"w":48,"h":25},"metadata":[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","221"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]}},{"data":{"id":"Protein_cc5c1bfad753f6f8b2a7d5a89e3118b8","class":"macromolecule","label":"CYCS","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":836.90424,"y":778.2764,"w":48,"h":25},"metadata":[["bp:displayName","Cytochrome C"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1069"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1069"]]}},{"data":{"id":"Protein_31a21d7f77c1a788543491fb2b184bbb","class":"macromolecule","label":"CASP8","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_31a21d7f77c1a788543491fb2b184bbb.info.1","class":"state variable","state":{"variable":"334","value":"optyr"}},{"id":"Protein_31a21d7f77c1a788543491fb2b184bbb.state.2","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":1133.2146,"y":1292.576,"w":48,"h":25},"metadata":[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation","MOD_RES 224 224 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation","MOD_RES 224 224 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation","MOD_RES 224 224 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation","MOD_RES 224 224 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation","MOD_RES 224 224 N6-acetyllysine."]]],["bp:standardName","Caspase-8"],["bp:xref","Caspase-8"],["bp:xref","Caspase-8"],["bp:organism","Caspase-8"],["bp:displayName","CASP8_HUMAN"],["bp:name","ICE-like apoptotic protease 5"],["bp:name","CAP4"],["bp:name","FADD-homologous ICE/ced-3-like protease"],["bp:name","FLICE"],["bp:name","Apoptotic protease Mch-5"],["bp:name","CASP-8"],["bp:name","Apoptotic cysteine protease"],["bp:name","3.4.22.61"],["bp:name","MORT1-associated ced-3 homolog"],["bp:name","MACH"],["bp:name","FADD-like ICE"],["bp:name","Caspase-8 subunit p10"],["bp:name","MCH5"],["bp:name","Caspase-8 subunit p18"],["bp:name","CASP8"],["bp:comment","REPLACED http://identifiers.org/uniprot/P08160"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q14790_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_841"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-9"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_10835762_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-1"],["bp:comment","FUNCTION: Most upstream protease of the activation cascade ofcaspases responsible for the TNFRSF6/FAS mediated and TNFRSF1Ainduced cell death. Binding to the adapter molecule FADD recruitsit to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolyticactivation. The active dimeric enzyme is then liberated from theDISC and free to activate downstream apoptotic proteases.Proteolytic fragments of the N-terminal propeptide (termed CAP3,CAP5 and CAP6) are likely retained in the DISC. Cleaves andactivates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. Mayparticipate in the GZMB apoptotic pathways. Cleaves ADPRT.Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC.Likely target for the cowpox virus CRMA death inhibitory protein.Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalyticsite and may interfere with the pro-apoptotic activity of thecomplex. {ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9006941}.CATALYTIC ACTIVITY: Strict requirement for Asp at position P1 andhas a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp-|-(Gly/Ser/Ala). {ECO:0000269|PubMed:23516580}.ENZYME REGULATION: Inhibited by the effector protein NleF that isproduced by pathogenic E.coli; this inhibits apoptosis.{ECO:0000269|PubMed:23516580}.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 18 kDa (p18) and a 10kDa (p10) subunit. Interacts with FADD, CFLAR and PEA15. Isoform 9interacts at the endoplasmic reticulum with a complex containingBCAP31, BAP29, BCL2 and/or BCL2L1. Interacts with TNFAIP8L2 (Bysimilarity). Interacts with CASP8AP2. Interacts with RFFL andRNF34; negatively regulate CASP8 through proteasomal degradation.Interacts with human cytomegalovirus/HHV-5 protein vICA/UL36; thisinteraction inhibits CASP8 activation. Interacts with NleF frompathogenic E.coli. Interacts with NOL3; decreases CASP8 activityin a mitochondria localization- and phosphorylation-dependentmanner and this interaction is dissociated by calcium.{ECO:0000250|UniProtKB:O89110, ECO:0000250|UniProtKB:Q9JHX4,ECO:0000269|PubMed:10442631, ECO:0000269|PubMed:10508785,ECO:0000269|PubMed:11427719, ECO:0000269|PubMed:11917123,ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:15509781,ECO:0000269|PubMed:17245429, ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9334338}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Name=1; Synonyms=Alpha-1;IsoId=Q14790-1; Sequence=Displayed;Name=2; Synonyms=Alpha-2, MCH5-beta;IsoId=Q14790-2; Sequence=VSP_000810;Name=3; Synonyms=Alpha-3;IsoId=Q14790-3; Sequence=VSP_000813;Name=4; Synonyms=Alpha-4;IsoId=Q14790-4; Sequence=VSP_000809, VSP_000810;Name=5; Synonyms=Beta-1;IsoId=Q14790-5; Sequence=VSP_000814, VSP_000815;Name=6; Synonyms=Beta-2;IsoId=Q14790-6; Sequence=VSP_000811, VSP_000812;Name=7; Synonyms=Beta-3, 8L;IsoId=Q14790-7; Sequence=VSP_000816, VSP_000817;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=8; Synonyms=Beta-4;IsoId=Q14790-8; Sequence=VSP_000810, VSP_000816, VSP_000817;Name=9; Synonyms=8L;IsoId=Q14790-9; Sequence=VSP_000808;Note=Ref.8 (AAL87628) sequence is in conflict in position:14:K->R. {ECO:0000305};TISSUE SPECIFICITY: Isoform 1, isoform 5 and isoform 7 areexpressed in a wide variety of tissues. Highest expression inperipheral blood leukocytes, spleen, thymus and liver. Barelydetectable in brain, testis and skeletal muscle.DOMAIN: Isoform 9 contains a N-terminal extension that is requiredfor interaction with the BCAP31 complex.PTM: Generation of the subunits requires association with thedeath-inducing signaling complex (DISC), whereas additionalprocessing is likely due to the autocatalytic activity of theactivated protease. GZMB and CASP10 can be involved in theseprocessing events. {ECO:0000269|PubMed:8962078,ECO:0000269|PubMed:9184224}.PTM: Phosphorylation on Ser-387 during mitosis by CDK1 inhibitsactivation by proteolysis and prevents apoptosis. Thisphosphorylation occurs in cancer cell lines, as well as in primarybreast tissues and lymphocytes. {ECO:0000269|PubMed:20937773}.POLYMORPHISM: Genetic variations in CASP8 are associated withreduced risk of lung cancer [MIM:211980] in a population of HanChinese subjects. Genetic variations are also associated withdecreased risk of cancer of various other forms includingesophageal, gastric, colorectal, cervical, and breast, acting inan allele dose-dependent manner. {ECO:0000269|PubMed:17450141}.DISEASE: Caspase-8 deficiency (CASP8D) [MIM:607271]: Disorderresembling autoimmune lymphoproliferative syndrome (ALPS). It ischaracterized by lymphadenopathy, splenomegaly, and defectiveCD95-induced apoptosis of peripheral blood lymphocytes (PBLs). Itleads to defects in activation of T-lymphocytes, B-lymphocytes,and natural killer cells leading to immunodeficiency characterizedby recurrent sinopulmonary and herpes simplex virus infections andpoor responses to immunization. {ECO:0000269|PubMed:12353035}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA66858.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};Sequence=CAA66859.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};WEB RESOURCE: Name=CASP8base; Note=CASP8 mutation db;URL=\"http://structure.bmc.lu.se/idbase/CASP8base/\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/casp8/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QDU_see-also"],["bp:comment","REPLACED ProteinRef_CASP8__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001219"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203520"],["bp:comment","CASP8_HUMAN Reviewed; 479 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03459_identity"],["bp:comment","REPLACED ProteinRef_CASP8__9606"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_841"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203519"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1I4E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-30915N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1F9E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QTN_see-also"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4464"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246944"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_36111829"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]}},{"data":{"id":"Protein_7469a828ff14fc3ff99290371d6053e0","class":"macromolecule","label":"BID","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1015.2557,"y":1230.8096,"w":48,"h":25},"metadata":[["bp:displayName","BID"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P55957",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 54 54 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","54"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 78 78 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","78"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:standardName","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:xref","BH3-interacting domain death agonist"],["bp:organism","BH3-interacting domain death agonist"],["bp:displayName","BID_HUMAN"],["bp:name","BH3-interacting domain death agonist p15"],["bp:name","BH3-interacting domain death agonist p13"],["bp:name","p22 BID"],["bp:name","BH3-interacting domain death agonist p11"],["bp:name","BID"],["bp:name","p15 BID"],["bp:name","p13 BID"],["bp:name","p11 BID"],["bp:comment","REPLACED ProteinRef_BID__10090"],["bp:comment","REPLACED ProteinRef_BID__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_637"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P55957-2"],["bp:comment","BID_HUMAN Reviewed; 195 AA."],["bp:comment","REPLACED ProteinRef_BID__40674"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1421"],["bp:comment","FUNCTION: The major proteolytic product p15 BID allows the releaseof cytochrome c (By similarity). Isoform 1, isoform 2 and isoform4 induce ICE-like proteases and apoptosis. Isoform 3 does notinduce apoptosis. Counters the protective effect of Bcl-2.{ECO:0000250, ECO:0000269|PubMed:14583606}.SUBUNIT: Forms heterodimers either with the pro-apoptotic proteinBAX or the anti-apoptotic protein Bcl-2 (By similarity). p15 BIDinteracts with ITCH. {ECO:0000250, ECO:0000269|PubMed:20392206}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Mitochondrionmembrane {ECO:0000250}. Note=When uncleaved, it is predominantlycytoplasmic. {ECO:0000269|PubMed:14583606}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p15:Mitochondrion membrane {ECO:0000250}. Note=Translocates tomitochondria as an integral membrane protein. {ECO:0000250}.SUBCELLULAR LOCATION: BH3-interacting domain death agonist p13:Mitochondrion membrane {ECO:0000250}. Note=Associated with themitochondrial membrane. {ECO:0000250}.SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.SUBCELLULAR LOCATION: Isoform 2: Mitochondrion membrane. Note=Asignificant proportion of isoform 2 localizes to mitochondria, itmay be cleaved constitutively.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=BID(L);IsoId=P55957-1; Sequence=Displayed;Name=2; Synonyms=BID(EL);IsoId=P55957-2; Sequence=VSP_017267;Name=3; Synonyms=BID(S);IsoId=P55957-3; Sequence=VSP_017268, VSP_017269;Name=4; Synonyms=BID(ES);IsoId=P55957-4; Sequence=VSP_017266;TISSUE SPECIFICITY: Isoform 2 and isoform 3 are expressed inspleen, bone marrow, cerebral and cerebellar cortex. Isoform 2 isexpressed in spleen, pancreas and placenta (at protein level).Isoform 3 is expressed in lung, pancreas and spleen (at proteinlevel). Isoform 4 is expressed in lung and pancreas (at proteinlevel). {ECO:0000269|PubMed:14583606}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: TNF-alpha induces a caspase-mediated cleavage of p22 BID intoa major p15 and minor p13 and p11 products. {ECO:0000250}.PTM: p15 BID is ubiquitinated by ITCH; ubiquitination results inproteasome-dependent degradation. {ECO:0000269|PubMed:20392206}.SEQUENCE CAUTION:Sequence=AAH22072.2; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bid/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001187"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34937N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_637"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_637_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_932070"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1770"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1770"]]}},{"data":{"id":"Protein_e2861ae7a61f3469a6509614275092e7","class":"macromolecule","label":"MAP2K2","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":610.1627,"y":1400.2423,"w":48,"h":25},"metadata":[["bp:displayName","MEK2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","306"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"]]}},{"data":{"id":"Protein_a56ed666236bbdbf9bd991c41754204f","class":"macromolecule","label":"MAP2K1","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":636.0808,"y":1350.0325,"w":48,"h":25},"metadata":[["bp:displayName","MEK1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 298 298 Phosphoserine; by PAK."],["bp:featureLocation",[["bp:sequencePosition","298"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_18627"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_18627"]]}},{"data":{"id":"Complex_0082d1d47f9d4db10237bfa0b048e1de","class":"complex","label":"NF kappa B1/RelA","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1018.03372,"y":1316.0822,"w":51.99994,"h":59},"metadata":[["bp:displayName","NF kappa B1/RelA"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80674"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80674"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80674"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80674"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation","MOD_RES 221 221 N6-acetyllysine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80674"],["bp:stoichiometricCoefficient","1.0"]]],["bp:name","NF kappa B1 p50/RelA"],["bp:name","RelA/NF kappa B1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80673"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80673"]]}},{"data":{"id":"Protein_9733e0d5a4fe4b996e3a37b20284cea3_Complex_0082d1d47f9d4db10237bfa0b048e1de","class":"macromolecule","label":"NFKB1","parent":"Complex_0082d1d47f9d4db10237bfa0b048e1de","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1018.03375,"y":1331.0822,"w":48,"h":25},"metadata":[["bp:displayName","NF KappaB"],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 937 937 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","937"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 759 759 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","759"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 337 337 Phosphoserine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","337"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","NF Kappa B1"],["bp:name","NF kappa B"],["bp:name","NF kappa B1"],["bp:name","NF-kappa-B"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67665"]]}},{"data":{"id":"Protein_f02a1f7ebcab04238d804d8ecc342e7e_Complex_0082d1d47f9d4db10237bfa0b048e1de","class":"macromolecule","label":"RELA","parent":"Complex_0082d1d47f9d4db10237bfa0b048e1de","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1018.03375,"y":1301.0822,"w":48,"h":25},"metadata":[["bp:displayName","RelA"],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","529"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 276 276 Phosphoserine; by RPS6KA4 and RPS6KA5."],["bp:featureLocation",[["bp:sequencePosition","276"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 221 221 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","221"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 254 254 Phosphothreonine."],["bp:featureLocation","MOD_RES 254 254 Phosphothreonine."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2008"]]}},{"data":{"id":"extracellular_region","class":"compartment","label":"extracellular region","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":752.93143,"y":236.322345,"w":284.26746,"h":98.00821},"metadata":null}},{"data":{"id":"cytoplasm","class":"compartment","label":"cytoplasm","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":832.6039499999999,"y":1086.24539,"w":653.2213,"h":664.7763},"metadata":null}},{"data":{"id":"SmallMolecule_b51a045e32b204d7820ae210c6a55006","class":"simple chemical","label":"OKADAIC ACID","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":132.90247,"y":492.32187,"w":48,"h":20},"metadata":[["bp:displayName","OKADAIC ACID"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:44658",[["bp:standardName","(2R)-2-hydroxy-3-{(2S,5R,6R,8S)-5-hydroxy-8-[(2R,3E)-4-((2R,4a'R,5R,6'S,8'R,8a'S)-8'-hydroxy-6'-{(1S,3S)-1-hydroxy-3-[(2S,3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]butyl}-7'-methylideneoctahydro-3H,3'H-spiro[furan-2,2'-pyrano[3,2-b]pyran]-5-yl)but-3-en-2-yl]-10-methyl-1,7-dioxaspiro[5.5]undec-10-en-2-yl}-2-methylpropanoic acid"],["bp:xref",[["bp:id","CHEBI:44658"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:7733"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:22986"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:36468"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:37153"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:44655"],["bp:db","chebi"]]],["bp:chemicalFormula","C44H68O13"],["bp:displayName","okadaic acid"],["bp:name","9,10-Deepithio-9,10-didehydroacanthifolicin"],["bp:name","[H][C@]1(CC[C@@H](O)[C@]2(O1)O[C@@]([H])(CC(C)=C2)[C@H](C)\\\\C=C\\\\[C@@]1([H])CC[C@@]2(CC[C@@]3([H])O[C@]([H])([C@@H](O)C[C@H](C)[C@@]4([H])O[C@@]5(CCCCO5)CC[C@H]4C)C(=C)[C@@H](O)[C@]3([H])O2)O1)C[C@@](C)(O)C(O)=O"],["bp:name","C44H68O13"],["bp:molecularWeight","805.0029"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d019319"],["bp:comment","has_role CHEBI:22986"],["bp:comment","has_role CHEBI:37153"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB02169"],["bp:comment","is_a CHEBI:36468"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80942"],["bp:structure",[["bp:structureFormat","InChI"],["bp:structureData","InChI=1S/C44H68O13/c1-25-21-34(55-44(23-25)35(46)12-11-31(54-44)24-41(6,50)40(48)49)26(2)9-10-30-14-18-43(53-30)19-15-33-39(57-43)36(47)29(5)38(52-33)32(45)22-28(4)37-27(3)13-17-42(56-37)16-7-8-20-51-42/h9-10,23,26-28,30-39,45-47,50H,5,7-8,11-22,24H2,1-4,6H3,(H,48,49)/b10-9+/t26-,27-,28+,30+,31+,32+,33-,34+,35-,36-,37+,38+,39-,41-,42+,43-,44-/m1/s1"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80941"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"SmallMolecule_8df6fbb2ccfd27d2ffb2483093c4ad97","class":"simple chemical","label":"glutathione","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1043.33203,"y":308.96252,"w":48,"h":20},"metadata":[["bp:displayName","glutathione"],["bp:entityReference_#SmallMoleculeReference_d2093539da38fc840e3053590f8d6fb4",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80707"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_f576ffc59d4746653266a7daef180870","class":"macromolecule","label":"PAWR","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":436.56384,"y":566.69476,"w":48,"h":25},"metadata":[["bp:displayName","PAR4"],["bp:entityReference_http://identifiers.org/uniprot/Q96IZ0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 163 163 Phosphothreonine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","163"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 108 108 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 231 231 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","231"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","PRKC apoptosis WT1 regulator protein"],["bp:xref",[["bp:id","Q96IZ0"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q96IZ0"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q96IZ0"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","PAWR_HUMAN"],["bp:name","Prostate apoptosis response 4 protein"],["bp:name","PAWR"],["bp:name","PAR4"],["bp:name","Par-4"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_8332"],["bp:comment","FUNCTION: Pro-apoptopic protein capable of selectively inducingapoptosis in cancer cells, sensitizing the cells to diverseapoptotic stimuli and causing regression of tumors in animalmodels. Induces apoptosis in certain cancer cells by activation ofthe Fas prodeath pathway and coparallel inhibition of NF-kappa-Btranscriptional activity. Inhibits the transcriptional activationand augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction withWT1. Seems also to be a transcriptional repressor by itself. Maybe directly involved in regulating the amyloid precursor protein(APP) cleavage activity of BACE1. {ECO:0000269|PubMed:11585763}.SUBUNIT: Interacts with WT1, via the C-terminal region.Homooligomer. Interacts also with a wide variety of proteins, suchas atypical PKCs, p62, DAPK3 kinase and THAP1. Interacts withactin, AATF, BACE1, SPSB1, SPSB2 AND SPSB4. Component of a ternarycomplex composed of SQSTM1 and PRKCZ.{ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:12717420,ECO:0000269|PubMed:14627703, ECO:0000269|PubMed:15671026,ECO:0000269|PubMed:17189197, ECO:0000269|PubMed:8943350}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Mainly cytoplasmicin absence of apoptosis signal and in normal cells. Nuclear inmost cancer cell lines. Nuclear entry seems to be essential butnot sufficient for apoptosis (By similarity). Nuclear localizationincludes nucleoplasm and PML nuclear bodies. {ECO:0000250}.TISSUE SPECIFICITY: Widely expressed. Expression is elevated invarious neurodegenerative diseases such as amyotrophic lateralsclerosis, Alzheimer, Parkinson and Huntington diseases andstroke. Down-regulated in several cancers.{ECO:0000269|PubMed:8943350}.INDUCTION: By apoptosis.DOMAIN: The leucine-zipper domain is not essential for apoptosis,but is required for sensitization of cells to exogenous apoptoticinsults and for interaction with its partners. {ECO:0000250}.DOMAIN: The SAC domain is a death-inducing domain selective forapoptosis induction in cancer cells. This domain is essential fornuclear entry, Fas activation, inhibition of NF-kappa-B activityand induction of apoptosis in cancer cells (By similarity).{ECO:0000250}.PTM: Preferentially phosphorylated at the Thr-163 by PKC in cancercells. {ECO:0000250}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PAWRID41641ch12q21.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pawr/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5074"],["bp:comment","PAWR_HUMAN Reviewed; 340 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29003N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5074"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"]]}},{"data":{"id":"Protein_8ef34d76e3b19562a5795cfa5dea9425","class":"macromolecule","label":"FADD","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1321.0868,"y":1210.4359,"w":48,"h":25},"metadata":[["bp:displayName","FADD"],["bp:entityReference_http://identifiers.org/uniprot/Q13158",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 194 194 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","FAS-associated death domain protein"],["bp:xref",[["bp:relationshipType",null],["bp:id","FADD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","Q13158"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q13158"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","FADD_HUMAN"],["bp:name","MORT1"],["bp:name","FADD"],["bp:name","FAS-associating death domain-containing protein"],["bp:name","Growth-inhibiting gene 3 protein"],["bp:name","Protein FADD"],["bp:name","Mediator of receptor induced toxicity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003815"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03909_identity"],["bp:comment","FUNCTION: Apoptotic adaptor molecule that recruits caspase-8 orcaspase-10 to the activated Fas (CD95) or TNFR-1 receptors. Theresulting aggregate called the death-inducing signaling complex(DISC) performs caspase-8 proteolytic activation. Active caspase-8initiates the subsequent cascade of caspases mediating apoptosis.Involved in interferon-mediated antiviral immune response, playinga role in the positive regulation of interferon signaling.{ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.SUBUNIT: Can self-associate. Interacts with CFLAR, PEA15 and MBD4.When phosphorylated, part of a complex containing HIPK3 and FAS.May interact with MAVS/IPS1. Interacts with MOCV v-CFLAR proteinand PIDD1. Interacts (via death domain) with FAS (via deathdomain). Interacts with CASP8. Interacts directly (via DED domain)with NOL3 (via CARD domain); inhibits death-inducing signalingcomplex (DISC) assembly by inhibiting the increase in FAS-FADDbinding induced by FAS activation (By similarity).{ECO:0000250|UniProtKB:Q61160, ECO:0000269|PubMed:10442631,ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11034606,ECO:0000269|PubMed:12702765, ECO:0000269|PubMed:16127453,ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues, exceptfor peripheral blood mononuclear leukocytes.DOMAIN: Contains a death domain involved in the binding of thecorresponding domain within Fas receptor.{ECO:0000269|PubMed:19118384}.DOMAIN: The interaction between the FAS and FADD death domains iscrucial for the formation of the death-inducing signaling complex(DISC). {ECO:0000269|PubMed:19118384}.DISEASE: Infections, recurrent, associated with encephalopathy,hepatic dysfunction and cardiovascular malformations (IEHDCM)[MIM:613759]: A condition with biological features of autoimmunelymphoproliferative syndrome such as high-circulatingCD4(-)CD8(-)TCR-alpha-beta(+) T-cell counts, and elevated IL10 andFASL levels. Affected individuals suffer from recurrent,stereotypical episodes of fever, encephalopathy, and mild liverdysfunction sometimes accompanied by generalized seizures. Theepisodes can be triggered by varicella zoster virus (VZV), measlesmumps rubella (MMR) attenuated vaccine, parainfluenza virus, andEpstein-Barr virus (EBV). {ECO:0000269|PubMed:21109225}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/fadd/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8772"],["bp:comment","FADD_HUMAN Reviewed; 208 AA."],["bp:comment","REPLACED ProteinRef_FADD__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-286N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8772"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1124"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25446"],["bp:comment","REPLACED ProteinRef_FADD__10090"],["bp:comment","REPLACED ProteinRef_FADD__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1628"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_468f9ef328c933c629513ba7495bc4d9","class":"macromolecule","label":"CYCS","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":796.9988,"y":428.06528,"w":48,"h":25},"metadata":[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 49 49 Phosphotyrosine."],["bp:featureLocation","MOD_RES 49 49 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 49 49 Phosphotyrosine."],["bp:featureLocation","MOD_RES 49 49 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 49 49 Phosphotyrosine."],["bp:featureLocation","MOD_RES 49 49 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 49 49 Phosphotyrosine."],["bp:featureLocation","MOD_RES 49 49 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 49 49 Phosphotyrosine."],["bp:featureLocation","MOD_RES 49 49 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 49 49 Phosphotyrosine."],["bp:featureLocation","MOD_RES 49 49 Phosphotyrosine."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]}},{"data":{"id":"Protein_01c69bf5214b03bc85d545a5d2e46676","class":"macromolecule","label":"NFKBIA","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_01c69bf5214b03bc85d545a5d2e46676.info.1","class":"state variable","state":{"variable":"","value":"Ub"}}],"unitsOfInformation":[],"bbox":{"x":1237.1719,"y":1562.1166,"w":48,"h":25},"metadata":[["bp:displayName","I kappa B alpha (degradation)"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80832"],["bp:featureLocation",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_996"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:01240"],["bp:db","protein modification ontology"]]],["bp:term","ubiquitination"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80748"]]],["bp:entityReference_http://identifiers.org/uniprot/P25963",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 291 291 Phosphothreonine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P25963"]]],["bp:standardName","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:xref","NF-kappa-B inhibitor alpha"],["bp:organism","NF-kappa-B inhibitor alpha"],["bp:displayName","IKBA_HUMAN"],["bp:name","IKBA"],["bp:name","MAD3"],["bp:name","IkB-alpha"],["bp:name","Major histocompatibility complex enhancer-binding protein MAD3"],["bp:name","NFKBI"],["bp:name","NFKBIA"],["bp:name","I-kappa-B-alpha"],["bp:name","IkappaBalpha"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q04207"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25799_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25799"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-139N_identity"],["bp:comment","REPLACED ProteinRef_NFKBIA__9606"],["bp:comment","REPLACED ProteinRef_NFKBIA__40674"],["bp:comment","IKBA_HUMAN Reviewed; 317 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_990"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P25963_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_065390"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01235_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4792"],["bp:comment","REPLACED ProteinRef_NFKBIA__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4792"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4792"],["bp:comment","FUNCTION: Inhibits the activity of dimeric NF-kappa-B/RELcomplexes by trapping REL dimers in the cytoplasm through maskingof their nuclear localization signals. On cellular stimulation byimmune and proinflammatory responses, becomes phosphorylatedpromoting ubiquitination and degradation, enabling the dimericRELA to translocate to the nucleus and activate transcription.{ECO:0000269|PubMed:7479976}.SUBUNIT: Interacts with RELA; the interaction requires the nuclearimport signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA,IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts withisoform 1 and isoform 2 of RWDD3; the interaction enhancessumoylation. Interacts (when phosphorylated at the 2 serineresidues in the destruction motif D-S-G-X(2,3,4)-S) with BTRC.Associates with the SCF(BTRC) complex, composed of SKP1, CUL1 andBTRC; the association is mediated via interaction with BTRC. Partof a SCF(BTRC)-like complex lacking CUL1, which is associated withRELA; RELA interacts directly with NFKBIA. Interacts with PRMT2.Interacts with PRKACA in platelets; this interaction is disruptedby thrombin and collagen. Interacts with HIF1AN. Interacts withMEFV. Interacts with DDRGK1; positively regulates NFKBIAphosphorylation and degradation. {ECO:0000269|PubMed:10454581,ECO:0000269|PubMed:10657303, ECO:0000269|PubMed:1493333,ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:18577712,ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:23469069,ECO:0000269|PubMed:23675531}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles betweenthe nucleus and the cytoplasm by a nuclear localization signal(NLS) and a CRM1-dependent nuclear export. {ECO:0000250}.INDUCTION: Induced in adherent monocytes.PTM: Phosphorylated; disables inhibition of NF-kappa-B DNA-bindingactivity. Phosphorylation at positions 32 and 36 is prerequisiteto recognition by UBE2D3 leading to polyubiquitination andsubsequent degradation. {ECO:0000269|PubMed:10329681,ECO:0000269|PubMed:10882136, ECO:0000269|PubMed:20504922}.PTM: Sumoylated; sumoylation requires the presence of the nuclearimport signal. Sumoylation blocks ubiquitination and proteasome-mediated degradation of the protein thereby increasing the proteinstability. {ECO:0000269|PubMed:11124955,ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:20504922}.PTM: Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3.Ubiquitin chain elongation is then performed by CDC34 incooperation with the SCF(FBXW11) E3 ligase complex, buildingubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin.The resulting polyubiquitination leads to protein degradation.Also ubiquitinated by SCF(BTRC) following stimulus-dependentphosphorylation at Ser-32 and Ser-36.{ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10882136,ECO:0000269|PubMed:20347421, ECO:0000269|PubMed:20504922,ECO:0000269|PubMed:7479976}.PTM: Deubiquitinated by porcine reproductive and respiratorysyndrome virus Nsp2 protein, which thereby interferes with NFKBIAdegradation and impairs subsequent NF-kappa-B activation.DISEASE: Ectodermal dysplasia, anhidrotic, with T-cellimmunodeficiency autosomal dominant (ADEDAID) [MIM:612132]: A formof ectoderma dysplasia, a heterogeneous group of disorders due toabnormal development of two or more ectodermal structures. Thisform of ectodermal dysplasia is associated with decreasedproduction of pro-inflammatory cytokines and certain interferons,rendering patients susceptible to infection.{ECO:0000269|PubMed:14523047, ECO:0000269|PubMed:18412279}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the NF-kappa-B inhibitor family.{ECO:0000305}.WEB RESOURCE: Name=NFKBIAbase; Note=NFKBIA mutation db;URL=\"http://structure.bmc.lu.se/idbase/NFKBIAbase/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/nfkbia/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80830"]]}},{"data":{"id":"ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":468.7597,"y":496.45844,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref",[["bp:relationshipType",null],["bp:id","CTSD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_23922"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80888"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref",[["bp:relationshipType",null],["bp:id","CTSD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_23922"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80888"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref",[["bp:relationshipType",null],["bp:id","CTSD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_23922"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80888"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref",[["bp:relationshipType",null],["bp:id","CTSD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_23922"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80888"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref",[["bp:relationshipType",null],["bp:id","CTSD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_23922"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80888"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref",[["bp:relationshipType",null],["bp:id","CTSD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_23922"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80888"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref",[["bp:relationshipType",null],["bp:id","CTSD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_23922"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80888"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80887"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80887"]]}},{"data":{"id":"ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":384.63382,"y":634.95306,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80639"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:left","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80629"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80629"]]}},{"data":{"id":"Protein_79cfbeed00aaf2ff3f85c67362751d30","class":"macromolecule","label":"MAP2K1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_79cfbeed00aaf2ff3f85c67362751d30.info.1","class":"state variable","state":{"variable":"222","value":"opser"}},{"id":"Protein_79cfbeed00aaf2ff3f85c67362751d30.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_79cfbeed00aaf2ff3f85c67362751d30.info.3","class":"state variable","state":{"variable":"218","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":379.7151,"y":1412.8939,"w":85,"h":25},"metadata":[["bp:displayName","MEK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8443"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_18629"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8441"],["bp:featureLocation",[["bp:sequencePosition","218"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8442"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22220"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22220"]]}},{"data":{"id":"SmallMolecule_b174942622c3e16fcf2959863bcf022d","class":"simple chemical","label":"Sphingosine","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":292.9603,"y":254.29623,"w":48,"h":20},"metadata":[["bp:displayName","Sphingosine"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:16393",[["bp:standardName","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref",[["bp:id","CHEBI:16393"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:9224"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:207585"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:46967"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:26743"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:57756"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:75771"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:15102"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:26741"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:26741"],["bp:db","chebi"]]],["bp:chemicalFormula","C18H37NO2"],["bp:displayName","sphingosine"],["bp:name","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-ene-1-ol"],["bp:name","D-(+)-erythro-1,3-dihydroxy-2-amino-4-trans-octadecene"],["bp:name","Sphingoid"],["bp:name","trans-4-sphingenine"],["bp:name","(4E)-sphingenine"],["bp:name","(2S,3R,E)-2-aminooctadec-4-ene-1,3-diol"],["bp:name","sphingosin"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)CO"],["bp:name","(E)-2-amino-4-octadecan-1,3-diol"],["bp:name","Sph"],["bp:name","C18 sphingosine"],["bp:name","(4E)-sphing-4-enine"],["bp:name","D-erythro-sphingosine"],["bp:name","2-amino-4-octadecene-1,3-diol"],["bp:name","Sphingosine d18:1"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol"],["bp:name","(2S,3R)-(E)-2-amino-1,3-dihydroxy-4-octadecene"],["bp:name","Sphingosine"],["bp:name","(E)-D-erythro-4-octadecene-1,3-diol"],["bp:name","Sphingenine"],["bp:name","trans-D-erythro-2-amino-4-octadecene-1,3-diol"],["bp:name","Sphing-4-enine"],["bp:name","C18H37NO2"],["bp:molecularWeight","299.4919"],["bp:comment","is_enantiomer_of CHEBI:46967"],["bp:comment","is_conjugate_base_of CHEBI:57756"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00252"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33981"],["bp:comment","has_role CHEBI:75771"],["bp:comment","is_a CHEBI:26743"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00319.eref"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB03203"],["bp:comment","A sphing-4-enine in which the double bond is trans."],["bp:structure","A sphing-4-enine in which the double bond is trans."]]],["bp:name","sphingosine"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"]]}},{"data":{"id":"SmallMolecule_69913dd701a4c1b21404a2aeee4d3fd9","class":"simple chemical","label":"Sphingosine-1-phosphate","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":378.41486,"y":278.5571,"w":48,"h":20},"metadata":[["bp:displayName","Sphingosine-1-phosphate"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:37550",[["bp:standardName","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:9225"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:62488"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77068"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:60119"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:16393"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:26742"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:37550"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:75771"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:75771"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:75771"],["bp:db","chebi"]]],["bp:chemicalFormula","C18H38NO5P"],["bp:displayName","sphingosine 1-phosphate"],["bp:name","CHEBI:37550"],["bp:name","Sphing-4-enine 1-phosphate"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)COP(O)(O)=O"],["bp:name","C18H38NO5P"],["bp:name","sphingosine-1-phosphate"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol 1-(dihydrogen phosphate)"],["bp:name","(2-amino-3-hydroxy-octadec-4-enoxy)phosphonic acid"],["bp:name","D-erythro-sphingosine 1-phosphate"],["bp:name","Sphingosine 1-phosphate"],["bp:name","C18-Sphingosine 1-phosphate"],["bp:name","S1P"],["bp:name","Sphingosine 1-phosphic acid"],["bp:molecularWeight","379.249"],["bp:comment","REPLACED http://identifiers.org/chebi/CHEBI:392583"],["bp:comment","has_role CHEBI:35620"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_242"],["bp:comment","has_role CHEBI:62488"],["bp:comment","has_functional_parent CHEBI:16393"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC06124.eref"],["bp:comment","is_conjugate_acid_of CHEBI:60119"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28959"],["bp:comment","has_role CHEBI:63114"],["bp:comment","A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1"],["bp:comment","REPLACED http://identifiers.org/pubchem.substance/25244490"],["bp:comment","has_role CHEBI:63173"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_c060506"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00277"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bind_2131_identity"],["bp:comment","is_a CHEBI:77068"],["bp:structure","is_a CHEBI:77068"]]],["bp:name","S1P"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"]]}},{"data":{"id":"BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":69.220997,"y":451.00482,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","BCL2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11512"],["bp:featureLocation",[["bp:sequencePosition","70"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11513"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P10415",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:organism","Apoptosis regulator Bcl-2"],["bp:displayName","BCL2_HUMAN"],["bp:name","BCL2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YSW_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10415-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000624"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q07813"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_596"],["bp:comment","REPLACED ProteinRef_BCL2__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01045_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1043N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10415_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_596"],["bp:comment","REPLACED ProteinRef_BCL2__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000648"],["bp:comment","FUNCTION: Suppresses apoptosis in a variety of cell systemsincluding factor-dependent lymphohematopoietic and neural cells.Regulates cell death by controlling the mitochondrial membranepermeability. Appears to function in a feedback loop system withcaspases. Inhibits caspase activity either by preventing therelease of cytochrome c from the mitochondria and/or by binding tothe apoptosis-activating factor (APAF-1). May attenuateinflammation by impairing NLRP1-inflammasome activation, henceCASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18570871}.SUBUNIT: Forms homodimers, and heterodimers with BAX, BAD, BAK andBcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2motifs, and is necessary for anti-apoptotic activity(PubMed:8183370). Interacts with EI24 (By similarity). Alsointeracts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2.Binding to FKBP8 seems to target BCL2 to the mitochondria andprobably interferes with the binding of BCL2 to its targets.Interacts with BAG1 in an ATP-dependent manner. Interacts withRAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts(via the BH4 domain) with EGLN3; the interaction prevents theformation of the BAX-BCL2 complex and inhibits the anti-apoptoticactivity of BCL2. Interacts with G0S2; this interaction alsoprevents the formation of the anti-apoptotic BAX-BCL2 complex.Interacts with BOP. Interacts with the SCF(FBXO10) complex.Interacts (via the loop between motifs BH4 and BH3) with NLRP1(via LRR repeats), but not with NLRP2, NLRP3, NLRP4, PYCARD, norMEFV (PubMed:17418785). {ECO:0000250, ECO:0000269|PubMed:11463391,ECO:0000269|PubMed:12901880, ECO:0000269|PubMed:15547950,ECO:0000269|PubMed:15733859, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:17090549, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:19228691, ECO:0000269|PubMed:19706769,ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:23055042,ECO:0000269|PubMed:23431138, ECO:0000269|PubMed:8183370,ECO:0000269|PubMed:8668206, ECO:0000269|PubMed:9305631}.SUBCELLULAR LOCATION: Mitochondrion outer membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Nucleus membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Alpha;IsoId=P10415-1; Sequence=Displayed;Name=Beta;IsoId=P10415-2; Sequence=VSP_000512;Note=Ref.1 (AAA51814) sequence is in conflict in position:199:L->S. {ECO:0000305};TISSUE SPECIFICITY: Expressed in a variety of tissues.DOMAIN: BH1 and BH2 domains are required for the interaction withBAX and for anti-apoptotic activity. {ECO:0000269|PubMed:8183370}.DOMAIN: The BH4 motif is required for anti-apoptotic activity andfor interaction with RAF1 and EGLN3.DOMAIN: The loop between motifs BH4 and BH3 is required for theinteraction with NLRP1. {ECO:0000269|PubMed:17418785}.PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation onSer-70 by PKC is required for the anti-apoptosis activity andoccurs during the G2/M phase of the cell cycle. In the absence ofgrowth factors, BCL2 appears to be phosphorylated by other proteinkinases such as ERKs and stress-activated kinases. Phosphorylatedby MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulatesstarvation-induced autophagy. Dephosphorylated by proteinphosphatase 2A (PP2A) (By similarity). {ECO:0000250}.PTM: Proteolytically cleaved by caspases during apoptosis. Thecleaved protein, lacking the BH4 motif, has pro-apoptoticactivity, causes the release of cytochrome c into the cytosolpromoting further caspase activity. {ECO:0000269|PubMed:9395403}.PTM: Monoubiquitinated by PRKN, leading to increase its stability.Ubiquitinated by SCF(FBXO10), leading to its degradation by theproteasome. {ECO:0000269|PubMed:20889974,ECO:0000269|PubMed:23431138}.DISEASE: Note=A chromosomal aberration involving BCL2 has beenfound in chronic lymphatic leukemia. Translocationt(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutationsfound in non-Hodgkin lymphomas carrying the chromosomaltranslocation could be attributed to the Ig somatic hypermutationmechanism resulting in nucleotide transitions.{ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL2ID49.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bcl2/\";WEB RESOURCE: Name=Wikipedia; Note=Bcl-2 entry;URL=\"https://en.wikipedia.org/wiki/Bcl-2\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_925"],["bp:comment","REPLACED http://identifiers.org/ncbigene/596"],["bp:comment","BCL2_HUMAN Reviewed; 239 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80907"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","BCL2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11512"],["bp:featureLocation",[["bp:sequencePosition","70"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11513"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P10415",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:organism","Apoptosis regulator Bcl-2"],["bp:displayName","BCL2_HUMAN"],["bp:name","BCL2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YSW_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10415-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000624"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q07813"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_596"],["bp:comment","REPLACED ProteinRef_BCL2__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01045_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1043N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10415_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_596"],["bp:comment","REPLACED ProteinRef_BCL2__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000648"],["bp:comment","FUNCTION: Suppresses apoptosis in a variety of cell systemsincluding factor-dependent lymphohematopoietic and neural cells.Regulates cell death by controlling the mitochondrial membranepermeability. Appears to function in a feedback loop system withcaspases. Inhibits caspase activity either by preventing therelease of cytochrome c from the mitochondria and/or by binding tothe apoptosis-activating factor (APAF-1). May attenuateinflammation by impairing NLRP1-inflammasome activation, henceCASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18570871}.SUBUNIT: Forms homodimers, and heterodimers with BAX, BAD, BAK andBcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2motifs, and is necessary for anti-apoptotic activity(PubMed:8183370). Interacts with EI24 (By similarity). Alsointeracts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2.Binding to FKBP8 seems to target BCL2 to the mitochondria andprobably interferes with the binding of BCL2 to its targets.Interacts with BAG1 in an ATP-dependent manner. Interacts withRAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts(via the BH4 domain) with EGLN3; the interaction prevents theformation of the BAX-BCL2 complex and inhibits the anti-apoptoticactivity of BCL2. Interacts with G0S2; this interaction alsoprevents the formation of the anti-apoptotic BAX-BCL2 complex.Interacts with BOP. Interacts with the SCF(FBXO10) complex.Interacts (via the loop between motifs BH4 and BH3) with NLRP1(via LRR repeats), but not with NLRP2, NLRP3, NLRP4, PYCARD, norMEFV (PubMed:17418785). {ECO:0000250, ECO:0000269|PubMed:11463391,ECO:0000269|PubMed:12901880, ECO:0000269|PubMed:15547950,ECO:0000269|PubMed:15733859, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:17090549, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:19228691, ECO:0000269|PubMed:19706769,ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:23055042,ECO:0000269|PubMed:23431138, ECO:0000269|PubMed:8183370,ECO:0000269|PubMed:8668206, ECO:0000269|PubMed:9305631}.SUBCELLULAR LOCATION: Mitochondrion outer membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Nucleus membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Alpha;IsoId=P10415-1; Sequence=Displayed;Name=Beta;IsoId=P10415-2; Sequence=VSP_000512;Note=Ref.1 (AAA51814) sequence is in conflict in position:199:L->S. {ECO:0000305};TISSUE SPECIFICITY: Expressed in a variety of tissues.DOMAIN: BH1 and BH2 domains are required for the interaction withBAX and for anti-apoptotic activity. {ECO:0000269|PubMed:8183370}.DOMAIN: The BH4 motif is required for anti-apoptotic activity andfor interaction with RAF1 and EGLN3.DOMAIN: The loop between motifs BH4 and BH3 is required for theinteraction with NLRP1. {ECO:0000269|PubMed:17418785}.PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation onSer-70 by PKC is required for the anti-apoptosis activity andoccurs during the G2/M phase of the cell cycle. In the absence ofgrowth factors, BCL2 appears to be phosphorylated by other proteinkinases such as ERKs and stress-activated kinases. Phosphorylatedby MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulatesstarvation-induced autophagy. Dephosphorylated by proteinphosphatase 2A (PP2A) (By similarity). {ECO:0000250}.PTM: Proteolytically cleaved by caspases during apoptosis. Thecleaved protein, lacking the BH4 motif, has pro-apoptoticactivity, causes the release of cytochrome c into the cytosolpromoting further caspase activity. {ECO:0000269|PubMed:9395403}.PTM: Monoubiquitinated by PRKN, leading to increase its stability.Ubiquitinated by SCF(FBXO10), leading to its degradation by theproteasome. {ECO:0000269|PubMed:20889974,ECO:0000269|PubMed:23431138}.DISEASE: Note=A chromosomal aberration involving BCL2 has beenfound in chronic lymphatic leukemia. Translocationt(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutationsfound in non-Hodgkin lymphomas carrying the chromosomaltranslocation could be attributed to the Ig somatic hypermutationmechanism resulting in nucleotide transitions.{ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL2ID49.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bcl2/\";WEB RESOURCE: Name=Wikipedia; Note=Bcl-2 entry;URL=\"https://en.wikipedia.org/wiki/Bcl-2\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_925"],["bp:comment","REPLACED http://identifiers.org/ncbigene/596"],["bp:comment","BCL2_HUMAN Reviewed; 239 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80907"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","BCL2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11512"],["bp:featureLocation",[["bp:sequencePosition","70"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11513"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P10415",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:organism","Apoptosis regulator Bcl-2"],["bp:displayName","BCL2_HUMAN"],["bp:name","BCL2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YSW_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10415-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000624"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q07813"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_596"],["bp:comment","REPLACED ProteinRef_BCL2__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01045_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1043N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10415_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_596"],["bp:comment","REPLACED ProteinRef_BCL2__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000648"],["bp:comment","FUNCTION: Suppresses apoptosis in a variety of cell systemsincluding factor-dependent lymphohematopoietic and neural cells.Regulates cell death by controlling the mitochondrial membranepermeability. Appears to function in a feedback loop system withcaspases. Inhibits caspase activity either by preventing therelease of cytochrome c from the mitochondria and/or by binding tothe apoptosis-activating factor (APAF-1). May attenuateinflammation by impairing NLRP1-inflammasome activation, henceCASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18570871}.SUBUNIT: Forms homodimers, and heterodimers with BAX, BAD, BAK andBcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2motifs, and is necessary for anti-apoptotic activity(PubMed:8183370). Interacts with EI24 (By similarity). Alsointeracts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2.Binding to FKBP8 seems to target BCL2 to the mitochondria andprobably interferes with the binding of BCL2 to its targets.Interacts with BAG1 in an ATP-dependent manner. Interacts withRAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts(via the BH4 domain) with EGLN3; the interaction prevents theformation of the BAX-BCL2 complex and inhibits the anti-apoptoticactivity of BCL2. Interacts with G0S2; this interaction alsoprevents the formation of the anti-apoptotic BAX-BCL2 complex.Interacts with BOP. Interacts with the SCF(FBXO10) complex.Interacts (via the loop between motifs BH4 and BH3) with NLRP1(via LRR repeats), but not with NLRP2, NLRP3, NLRP4, PYCARD, norMEFV (PubMed:17418785). {ECO:0000250, ECO:0000269|PubMed:11463391,ECO:0000269|PubMed:12901880, ECO:0000269|PubMed:15547950,ECO:0000269|PubMed:15733859, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:17090549, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:19228691, ECO:0000269|PubMed:19706769,ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:23055042,ECO:0000269|PubMed:23431138, ECO:0000269|PubMed:8183370,ECO:0000269|PubMed:8668206, ECO:0000269|PubMed:9305631}.SUBCELLULAR LOCATION: Mitochondrion outer membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Nucleus membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Alpha;IsoId=P10415-1; Sequence=Displayed;Name=Beta;IsoId=P10415-2; Sequence=VSP_000512;Note=Ref.1 (AAA51814) sequence is in conflict in position:199:L->S. {ECO:0000305};TISSUE SPECIFICITY: Expressed in a variety of tissues.DOMAIN: BH1 and BH2 domains are required for the interaction withBAX and for anti-apoptotic activity. {ECO:0000269|PubMed:8183370}.DOMAIN: The BH4 motif is required for anti-apoptotic activity andfor interaction with RAF1 and EGLN3.DOMAIN: The loop between motifs BH4 and BH3 is required for theinteraction with NLRP1. {ECO:0000269|PubMed:17418785}.PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation onSer-70 by PKC is required for the anti-apoptosis activity andoccurs during the G2/M phase of the cell cycle. In the absence ofgrowth factors, BCL2 appears to be phosphorylated by other proteinkinases such as ERKs and stress-activated kinases. Phosphorylatedby MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulatesstarvation-induced autophagy. Dephosphorylated by proteinphosphatase 2A (PP2A) (By similarity). {ECO:0000250}.PTM: Proteolytically cleaved by caspases during apoptosis. Thecleaved protein, lacking the BH4 motif, has pro-apoptoticactivity, causes the release of cytochrome c into the cytosolpromoting further caspase activity. {ECO:0000269|PubMed:9395403}.PTM: Monoubiquitinated by PRKN, leading to increase its stability.Ubiquitinated by SCF(FBXO10), leading to its degradation by theproteasome. {ECO:0000269|PubMed:20889974,ECO:0000269|PubMed:23431138}.DISEASE: Note=A chromosomal aberration involving BCL2 has beenfound in chronic lymphatic leukemia. Translocationt(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutationsfound in non-Hodgkin lymphomas carrying the chromosomaltranslocation could be attributed to the Ig somatic hypermutationmechanism resulting in nucleotide transitions.{ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL2ID49.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bcl2/\";WEB RESOURCE: Name=Wikipedia; Note=Bcl-2 entry;URL=\"https://en.wikipedia.org/wiki/Bcl-2\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_925"],["bp:comment","REPLACED http://identifiers.org/ncbigene/596"],["bp:comment","BCL2_HUMAN Reviewed; 239 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80907"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","BCL2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11512"],["bp:featureLocation",[["bp:sequencePosition","70"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11513"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P10415",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:organism","Apoptosis regulator Bcl-2"],["bp:displayName","BCL2_HUMAN"],["bp:name","BCL2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YSW_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10415-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000624"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q07813"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_596"],["bp:comment","REPLACED ProteinRef_BCL2__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01045_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1043N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10415_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_596"],["bp:comment","REPLACED ProteinRef_BCL2__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000648"],["bp:comment","FUNCTION: Suppresses apoptosis in a variety of cell systemsincluding factor-dependent lymphohematopoietic and neural cells.Regulates cell death by controlling the mitochondrial membranepermeability. Appears to function in a feedback loop system withcaspases. Inhibits caspase activity either by preventing therelease of cytochrome c from the mitochondria and/or by binding tothe apoptosis-activating factor (APAF-1). May attenuateinflammation by impairing NLRP1-inflammasome activation, henceCASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18570871}.SUBUNIT: Forms homodimers, and heterodimers with BAX, BAD, BAK andBcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2motifs, and is necessary for anti-apoptotic activity(PubMed:8183370). Interacts with EI24 (By similarity). Alsointeracts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2.Binding to FKBP8 seems to target BCL2 to the mitochondria andprobably interferes with the binding of BCL2 to its targets.Interacts with BAG1 in an ATP-dependent manner. Interacts withRAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts(via the BH4 domain) with EGLN3; the interaction prevents theformation of the BAX-BCL2 complex and inhibits the anti-apoptoticactivity of BCL2. Interacts with G0S2; this interaction alsoprevents the formation of the anti-apoptotic BAX-BCL2 complex.Interacts with BOP. Interacts with the SCF(FBXO10) complex.Interacts (via the loop between motifs BH4 and BH3) with NLRP1(via LRR repeats), but not with NLRP2, NLRP3, NLRP4, PYCARD, norMEFV (PubMed:17418785). {ECO:0000250, ECO:0000269|PubMed:11463391,ECO:0000269|PubMed:12901880, ECO:0000269|PubMed:15547950,ECO:0000269|PubMed:15733859, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:17090549, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:19228691, ECO:0000269|PubMed:19706769,ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:23055042,ECO:0000269|PubMed:23431138, ECO:0000269|PubMed:8183370,ECO:0000269|PubMed:8668206, ECO:0000269|PubMed:9305631}.SUBCELLULAR LOCATION: Mitochondrion outer membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Nucleus membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Alpha;IsoId=P10415-1; Sequence=Displayed;Name=Beta;IsoId=P10415-2; Sequence=VSP_000512;Note=Ref.1 (AAA51814) sequence is in conflict in position:199:L->S. {ECO:0000305};TISSUE SPECIFICITY: Expressed in a variety of tissues.DOMAIN: BH1 and BH2 domains are required for the interaction withBAX and for anti-apoptotic activity. {ECO:0000269|PubMed:8183370}.DOMAIN: The BH4 motif is required for anti-apoptotic activity andfor interaction with RAF1 and EGLN3.DOMAIN: The loop between motifs BH4 and BH3 is required for theinteraction with NLRP1. {ECO:0000269|PubMed:17418785}.PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation onSer-70 by PKC is required for the anti-apoptosis activity andoccurs during the G2/M phase of the cell cycle. In the absence ofgrowth factors, BCL2 appears to be phosphorylated by other proteinkinases such as ERKs and stress-activated kinases. Phosphorylatedby MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulatesstarvation-induced autophagy. Dephosphorylated by proteinphosphatase 2A (PP2A) (By similarity). {ECO:0000250}.PTM: Proteolytically cleaved by caspases during apoptosis. Thecleaved protein, lacking the BH4 motif, has pro-apoptoticactivity, causes the release of cytochrome c into the cytosolpromoting further caspase activity. {ECO:0000269|PubMed:9395403}.PTM: Monoubiquitinated by PRKN, leading to increase its stability.Ubiquitinated by SCF(FBXO10), leading to its degradation by theproteasome. {ECO:0000269|PubMed:20889974,ECO:0000269|PubMed:23431138}.DISEASE: Note=A chromosomal aberration involving BCL2 has beenfound in chronic lymphatic leukemia. Translocationt(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutationsfound in non-Hodgkin lymphomas carrying the chromosomaltranslocation could be attributed to the Ig somatic hypermutationmechanism resulting in nucleotide transitions.{ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL2ID49.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bcl2/\";WEB RESOURCE: Name=Wikipedia; Note=Bcl-2 entry;URL=\"https://en.wikipedia.org/wiki/Bcl-2\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_925"],["bp:comment","REPLACED http://identifiers.org/ncbigene/596"],["bp:comment","BCL2_HUMAN Reviewed; 239 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80907"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","BCL2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11512"],["bp:featureLocation",[["bp:sequencePosition","70"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11513"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P10415",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:organism","Apoptosis regulator Bcl-2"],["bp:displayName","BCL2_HUMAN"],["bp:name","BCL2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YSW_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10415-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000624"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q07813"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_596"],["bp:comment","REPLACED ProteinRef_BCL2__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01045_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1043N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10415_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_596"],["bp:comment","REPLACED ProteinRef_BCL2__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000648"],["bp:comment","FUNCTION: Suppresses apoptosis in a variety of cell systemsincluding factor-dependent lymphohematopoietic and neural cells.Regulates cell death by controlling the mitochondrial membranepermeability. Appears to function in a feedback loop system withcaspases. Inhibits caspase activity either by preventing therelease of cytochrome c from the mitochondria and/or by binding tothe apoptosis-activating factor (APAF-1). May attenuateinflammation by impairing NLRP1-inflammasome activation, henceCASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18570871}.SUBUNIT: Forms homodimers, and heterodimers with BAX, BAD, BAK andBcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2motifs, and is necessary for anti-apoptotic activity(PubMed:8183370). Interacts with EI24 (By similarity). Alsointeracts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2.Binding to FKBP8 seems to target BCL2 to the mitochondria andprobably interferes with the binding of BCL2 to its targets.Interacts with BAG1 in an ATP-dependent manner. Interacts withRAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts(via the BH4 domain) with EGLN3; the interaction prevents theformation of the BAX-BCL2 complex and inhibits the anti-apoptoticactivity of BCL2. Interacts with G0S2; this interaction alsoprevents the formation of the anti-apoptotic BAX-BCL2 complex.Interacts with BOP. Interacts with the SCF(FBXO10) complex.Interacts (via the loop between motifs BH4 and BH3) with NLRP1(via LRR repeats), but not with NLRP2, NLRP3, NLRP4, PYCARD, norMEFV (PubMed:17418785). {ECO:0000250, ECO:0000269|PubMed:11463391,ECO:0000269|PubMed:12901880, ECO:0000269|PubMed:15547950,ECO:0000269|PubMed:15733859, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:17090549, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:19228691, ECO:0000269|PubMed:19706769,ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:23055042,ECO:0000269|PubMed:23431138, ECO:0000269|PubMed:8183370,ECO:0000269|PubMed:8668206, ECO:0000269|PubMed:9305631}.SUBCELLULAR LOCATION: Mitochondrion outer membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Nucleus membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Alpha;IsoId=P10415-1; Sequence=Displayed;Name=Beta;IsoId=P10415-2; Sequence=VSP_000512;Note=Ref.1 (AAA51814) sequence is in conflict in position:199:L->S. {ECO:0000305};TISSUE SPECIFICITY: Expressed in a variety of tissues.DOMAIN: BH1 and BH2 domains are required for the interaction withBAX and for anti-apoptotic activity. {ECO:0000269|PubMed:8183370}.DOMAIN: The BH4 motif is required for anti-apoptotic activity andfor interaction with RAF1 and EGLN3.DOMAIN: The loop between motifs BH4 and BH3 is required for theinteraction with NLRP1. {ECO:0000269|PubMed:17418785}.PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation onSer-70 by PKC is required for the anti-apoptosis activity andoccurs during the G2/M phase of the cell cycle. In the absence ofgrowth factors, BCL2 appears to be phosphorylated by other proteinkinases such as ERKs and stress-activated kinases. Phosphorylatedby MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulatesstarvation-induced autophagy. Dephosphorylated by proteinphosphatase 2A (PP2A) (By similarity). {ECO:0000250}.PTM: Proteolytically cleaved by caspases during apoptosis. Thecleaved protein, lacking the BH4 motif, has pro-apoptoticactivity, causes the release of cytochrome c into the cytosolpromoting further caspase activity. {ECO:0000269|PubMed:9395403}.PTM: Monoubiquitinated by PRKN, leading to increase its stability.Ubiquitinated by SCF(FBXO10), leading to its degradation by theproteasome. {ECO:0000269|PubMed:20889974,ECO:0000269|PubMed:23431138}.DISEASE: Note=A chromosomal aberration involving BCL2 has beenfound in chronic lymphatic leukemia. Translocationt(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutationsfound in non-Hodgkin lymphomas carrying the chromosomaltranslocation could be attributed to the Ig somatic hypermutationmechanism resulting in nucleotide transitions.{ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL2ID49.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bcl2/\";WEB RESOURCE: Name=Wikipedia; Note=Bcl-2 entry;URL=\"https://en.wikipedia.org/wiki/Bcl-2\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_925"],["bp:comment","REPLACED http://identifiers.org/ncbigene/596"],["bp:comment","BCL2_HUMAN Reviewed; 239 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80907"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","BCL2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11512"],["bp:featureLocation",[["bp:sequencePosition","70"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11513"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P10415",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:organism","Apoptosis regulator Bcl-2"],["bp:displayName","BCL2_HUMAN"],["bp:name","BCL2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YSW_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10415-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000624"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q07813"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_596"],["bp:comment","REPLACED ProteinRef_BCL2__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01045_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1043N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10415_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_596"],["bp:comment","REPLACED ProteinRef_BCL2__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000648"],["bp:comment","FUNCTION: Suppresses apoptosis in a variety of cell systemsincluding factor-dependent lymphohematopoietic and neural cells.Regulates cell death by controlling the mitochondrial membranepermeability. Appears to function in a feedback loop system withcaspases. Inhibits caspase activity either by preventing therelease of cytochrome c from the mitochondria and/or by binding tothe apoptosis-activating factor (APAF-1). May attenuateinflammation by impairing NLRP1-inflammasome activation, henceCASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18570871}.SUBUNIT: Forms homodimers, and heterodimers with BAX, BAD, BAK andBcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2motifs, and is necessary for anti-apoptotic activity(PubMed:8183370). Interacts with EI24 (By similarity). Alsointeracts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2.Binding to FKBP8 seems to target BCL2 to the mitochondria andprobably interferes with the binding of BCL2 to its targets.Interacts with BAG1 in an ATP-dependent manner. Interacts withRAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts(via the BH4 domain) with EGLN3; the interaction prevents theformation of the BAX-BCL2 complex and inhibits the anti-apoptoticactivity of BCL2. Interacts with G0S2; this interaction alsoprevents the formation of the anti-apoptotic BAX-BCL2 complex.Interacts with BOP. Interacts with the SCF(FBXO10) complex.Interacts (via the loop between motifs BH4 and BH3) with NLRP1(via LRR repeats), but not with NLRP2, NLRP3, NLRP4, PYCARD, norMEFV (PubMed:17418785). {ECO:0000250, ECO:0000269|PubMed:11463391,ECO:0000269|PubMed:12901880, ECO:0000269|PubMed:15547950,ECO:0000269|PubMed:15733859, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:17090549, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:19228691, ECO:0000269|PubMed:19706769,ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:23055042,ECO:0000269|PubMed:23431138, ECO:0000269|PubMed:8183370,ECO:0000269|PubMed:8668206, ECO:0000269|PubMed:9305631}.SUBCELLULAR LOCATION: Mitochondrion outer membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Nucleus membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Alpha;IsoId=P10415-1; Sequence=Displayed;Name=Beta;IsoId=P10415-2; Sequence=VSP_000512;Note=Ref.1 (AAA51814) sequence is in conflict in position:199:L->S. {ECO:0000305};TISSUE SPECIFICITY: Expressed in a variety of tissues.DOMAIN: BH1 and BH2 domains are required for the interaction withBAX and for anti-apoptotic activity. {ECO:0000269|PubMed:8183370}.DOMAIN: The BH4 motif is required for anti-apoptotic activity andfor interaction with RAF1 and EGLN3.DOMAIN: The loop between motifs BH4 and BH3 is required for theinteraction with NLRP1. {ECO:0000269|PubMed:17418785}.PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation onSer-70 by PKC is required for the anti-apoptosis activity andoccurs during the G2/M phase of the cell cycle. In the absence ofgrowth factors, BCL2 appears to be phosphorylated by other proteinkinases such as ERKs and stress-activated kinases. Phosphorylatedby MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulatesstarvation-induced autophagy. Dephosphorylated by proteinphosphatase 2A (PP2A) (By similarity). {ECO:0000250}.PTM: Proteolytically cleaved by caspases during apoptosis. Thecleaved protein, lacking the BH4 motif, has pro-apoptoticactivity, causes the release of cytochrome c into the cytosolpromoting further caspase activity. {ECO:0000269|PubMed:9395403}.PTM: Monoubiquitinated by PRKN, leading to increase its stability.Ubiquitinated by SCF(FBXO10), leading to its degradation by theproteasome. {ECO:0000269|PubMed:20889974,ECO:0000269|PubMed:23431138}.DISEASE: Note=A chromosomal aberration involving BCL2 has beenfound in chronic lymphatic leukemia. Translocationt(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutationsfound in non-Hodgkin lymphomas carrying the chromosomaltranslocation could be attributed to the Ig somatic hypermutationmechanism resulting in nucleotide transitions.{ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL2ID49.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bcl2/\";WEB RESOURCE: Name=Wikipedia; Note=Bcl-2 entry;URL=\"https://en.wikipedia.org/wiki/Bcl-2\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_925"],["bp:comment","REPLACED http://identifiers.org/ncbigene/596"],["bp:comment","BCL2_HUMAN Reviewed; 239 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80907"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80905"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80905"]]}},{"data":{"id":"Complex_57c85addb9c870fb650f24c45f6cb935","class":"complex","label":"TNF-alpha/TNFR1A/TRADD/MADD/cIAP2/RIP/TRAF2/RAIDD","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1275.027,"y":636.76984,"w":105,"h":119},"metadata":[["bp:displayName","TNF-alpha/TNFR1A/TRADD/MADD/cIAP2/RIP/TRAF2/RAIDD"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80540"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80540"]]}},{"data":{"id":"Protein_12ce91dd41f0737ffb0898c71af2f854_Complex_57c85addb9c870fb650f24c45f6cb935","class":"macromolecule","label":"TNF","parent":"Complex_57c85addb9c870fb650f24c45f6cb935","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1301.527,"y":681.76984,"w":48,"h":25},"metadata":[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNF"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P01375"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P01375"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]}},{"data":{"id":"Protein_bb16116cda922facd7903fd53727b854_Complex_57c85addb9c870fb650f24c45f6cb935","class":"macromolecule","label":"TRAF2","parent":"Complex_57c85addb9c870fb650f24c45f6cb935","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1301.527,"y":651.76984,"w":48,"h":25},"metadata":[["bp:displayName","TRAF2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q12933",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 7 7 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","7"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 5 5 Phosphoserine."],["bp:featureLocation","MOD_RES 5 5 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 5 5 Phosphoserine."],["bp:featureLocation","MOD_RES 5 5 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 5 5 Phosphoserine."],["bp:featureLocation","MOD_RES 5 5 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 5 5 Phosphoserine."],["bp:featureLocation","MOD_RES 5 5 Phosphoserine."]]],["bp:standardName","TNF receptor-associated factor 2"],["bp:xref","TNF receptor-associated factor 2"],["bp:xref","TNF receptor-associated factor 2"],["bp:organism","TNF receptor-associated factor 2"],["bp:displayName","TRAF2_HUMAN"],["bp:name","E3 ubiquitin-protein ligase TRAF2"],["bp:name","TRAP3"],["bp:name","RING-type E3 ubiquitin transferase TRAF2"],["bp:name","2.3.2.27"],["bp:name","Tumor necrosis factor type 2 receptor-associated protein 3"],["bp:name","TRAF2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1CZY_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-6223N_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q12933-2"],["bp:comment","REPLACED ProteinRef_TRAF2__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20334"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7186"],["bp:comment","REPLACED ProteinRef_TRAF2__40674"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7186"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_066961"],["bp:comment","TRAF2_HUMAN Reviewed; 501 AA."],["bp:comment","FUNCTION: Regulates activation of NF-kappa-B and JNK and plays acentral role in the regulation of cell survival and apoptosis.Required for normal antibody isotype switching from IgM to IgG.Has E3 ubiquitin-protein ligase activity and promotes 'Lys-63'-linked ubiquitination of target proteins, such as BIRC3, RIPK1 andTICAM1. Is an essential constituent of several E3 ubiquitin-protein ligase complexes, where it promotes the ubiquitination oftarget proteins by bringing them into contact with other E3ubiquitin ligases. Regulates BIRC2 and BIRC3 protein levels byinhibiting their autoubiquitination and subsequent degradation;this does not depend on the TRAF2 RING-type zinc finger domain.Plays a role in mediating activation of NF-kappa-B by EIF2AK2/PKR.In complex with BIRC2 or BIRC3, promotes ubiquitination of IKBKE.{ECO:0000269|PubMed:10346818, ECO:0000269|PubMed:11907583,ECO:0000269|PubMed:12917689, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15383523, ECO:0000269|PubMed:18981220,ECO:0000269|PubMed:19150425, ECO:0000269|PubMed:19506082,ECO:0000269|PubMed:19810754, ECO:0000269|PubMed:19918265,ECO:0000269|PubMed:19937093, ECO:0000269|PubMed:20047764,ECO:0000269|PubMed:20064526, ECO:0000269|PubMed:20385093,ECO:0000269|PubMed:20577214, ECO:0000269|PubMed:23453969}.CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugatingenzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptorprotein]-L-lysine.ENZYME REGULATION: Has very low E3 ubiquitin ligase activity inthe absence of sphingosine-1-phosphate. E3 ubiquitin ligaseactivity is strongly activated by cytoplasmic sphingosine-1-phosphate. {ECO:0000269|PubMed:20577214}.PATHWAY: Protein modification; protein ubiquitination.SUBUNIT: Homotrimer, and heterotrimer with TRAF1 and TRAF3 (viaTRAF domain). The domain containing the RING-type and the firstTRAF-type zinc finger can also form homodimers (in vitro).Interacts with TNFRSF1B/TNFR2, TNFRSF4, TNFRSF5/CD40,CD27/TNFRSF7, TNFRSF8/CD30, TNFRSF9/CD137, TNFRSF11A/RANK,TNFRSF13B/TACI, TNFRSF14, TNFRSF16/NGFR, TNFRSF17/BCMA,TNFRSF18/AITR, TNFRSF19/TROY, TNFRSF19L/RELT, XEDAR, EDAR,Epstein-Barr virus BNFL1/LMP-1 and IL15RA. Interacts with CDK9,CSK, MAP3K1, MAP3K5, MAP3K11, MAP3K14, MAP4K2, RIPK1, RIPK2, TNIK,TBK1, SPHK1, TRADD, TRAFD1, TRAIP, TANK/ITRAF, TNFAIP3, TDP2,MAVS/IPS1, TICAM1 and TRPC4AP. Interacts with CASP8AP2, NFATC2IP,PEG3 and HIVEP3. Interacts with ERN1; the interaction requiresDAB2IP. Interacts with BIRC2 and BIRC3 N-terminus; a single BIRC2or BIRC3 molecule interacts with a heterotrimer formed by TRAF1and TRAF2, or a TRAF2 homotrimer. Identified in a complex composedof TRAF2, TRAF3, BIRC2 and BIRC3. Interaction with BIRC2 and/orBIRC3 is essential for ubiquitination of IKBKE, degradation ofNFKBIA and activation of NF-kappa-B. Interacts with CYLD, USP48,IKKA and IKKB. Identified in a complex with TNFRSF1A, RIPK1 andIKKB. Interacts (via 'Lys-63'-linked polyubiquitin chains) withTAB2 and TAB3. Interacts with ERN1 and TAOK3. Interaction withTAOK3 is facilitated under ER stress conditions, such as treatmentwith tunicamycin, and may promote TRAF2 phosphorylation. Interacts(via zinc fingers) with DAB2IP (via C-terminus PER domain); theinteraction occurs in a TNF-alpha-dependent manner. Interacts (viaC-terminus) with EIF2AK2/PKR (via the kinase catalytic domain).Interacts with CARD14. Interacts with PTPN2; probably involved intumor necrosis factor-mediated signaling.{ECO:0000269|PubMed:10037686, ECO:0000269|PubMed:10206649,ECO:0000269|PubMed:10346818, ECO:0000269|PubMed:10411888,ECO:0000269|PubMed:10463949, ECO:0000269|PubMed:10514511,ECO:0000269|PubMed:10521462, ECO:0000269|PubMed:10581243,ECO:0000269|PubMed:10764746, ECO:0000269|PubMed:10809768,ECO:0000269|PubMed:10880535, ECO:0000269|PubMed:10892748,ECO:0000269|PubMed:11278723, ECO:0000269|PubMed:11784851,ECO:0000269|PubMed:11907583, ECO:0000269|PubMed:12411493,ECO:0000269|PubMed:12917691, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15310755, ECO:0000269|PubMed:15383523,ECO:0000269|PubMed:15696169, ECO:0000269|PubMed:16153868,ECO:0000269|PubMed:16214042, ECO:0000269|PubMed:17389591,ECO:0000269|PubMed:18981220, ECO:0000269|PubMed:19150425,ECO:0000269|PubMed:19506082, ECO:0000269|PubMed:19810754,ECO:0000269|PubMed:19918265, ECO:0000269|PubMed:20047764,ECO:0000269|PubMed:20185725, ECO:0000269|PubMed:20385093,ECO:0000269|PubMed:20447407, ECO:0000269|PubMed:20577214,ECO:0000269|PubMed:21302310, ECO:0000269|PubMed:8069916,ECO:0000269|PubMed:8627180, ECO:0000269|PubMed:8710854,ECO:0000269|PubMed:9020361, ECO:0000269|PubMed:9104814,ECO:0000269|PubMed:9153189, ECO:0000269|PubMed:9418902,ECO:0000269|PubMed:9488716, ECO:0000269|PubMed:9607925,ECO:0000269|PubMed:9692890, ECO:0000269|PubMed:9705938,ECO:0000269|PubMed:9718306, ECO:0000269|PubMed:9774460,ECO:0000269|PubMed:9774977, ECO:0000269|PubMed:9827693}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15383523,ECO:0000269|PubMed:19150425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q12933-1; Sequence=Displayed;Name=2;IsoId=Q12933-2; Sequence=VSP_007401;Note=No experimental confirmation available.;Name=3;IsoId=Q12933-3; Sequence=VSP_039687;Note=No experimental confirmation available.;Name=4;IsoId=Q12933-4; Sequence=VSP_039688;Note=No experimental confirmation available.;DOMAIN: The coiled coil domain mediates homo- and hetero-oligomerization. {ECO:0000269|PubMed:20064526}.DOMAIN: The MATH/TRAF domain binds to receptor cytoplasmicdomains. {ECO:0000269|PubMed:20064526}.DOMAIN: The RING-type zinc finger domain is essential for E3ubiquitin-protein ligase activity. It is not essential for thestabilization of BIRC2, or for the ubiquitination of RIPK1 inresponse to TNFR1 signaling. {ECO:0000269|PubMed:20064526}.PTM: Phosphorylated at several serine residues within the first128 amino acid residues. Phosphorylated at Thr-117 in response tosignaling via TNF and TNFRSF1A. Phosphorylation at Thr-117 isrequired for 'Lys-63'-linked polyubiquitination, but not for 'Lys-48'-linked polyubiquitination. Phosphorylation at Thr-117 isimportant for interaction with IKKA and IKKB, activation of IKKand subsequent activation of NF-kappa-B.{ECO:0000269|PubMed:19150425}.PTM: Undergoes both 'Lys-48'-linked and 'Lys-63'-linkedpolyubiquitination. Polyubiquitinated via 'Lys-63'-linkedubiquitin in response to TNF signaling; this requires priorphosphorylation at Thr-117. 'Lys-63'-linked polyubiquitinationpromotes TRAF2-mediated activation of NF-kappa-B. Can bepolyubiquitinated at several Lys residues via 'Lys-48'-linkedubiquitin chains in response to TNF signaling, leading toproteasomal degradation. Autoubiquitinated, leading to itssubsequent proteasomal degradation. Polyubiquitinated by BIRC2 andSIAH2, leading to its subsequent proteasomal degradation.Deubiquitinated by CYLD, a protease that specifically cleaves'Lys-63'-linked polyubiquitin chains.{ECO:0000269|PubMed:19150425}.SIMILARITY: Belongs to the TNF receptor-associated factor family.A subfamily. {ECO:0000305}.WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/traf2/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03538_identity"],["bp:comment","REPLACED ProteinRef_TRAF2__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_7633"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QSC_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1D0J_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q12933_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P03230"],["bp:comment","REPLACED ProteinRef_TRAF2__10090"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]}},{"data":{"id":"Protein_12bcf51c75aae38cdb2620e757a2f48e_Complex_57c85addb9c870fb650f24c45f6cb935","class":"macromolecule","label":"TNFRSF1A","parent":"Complex_57c85addb9c870fb650f24c45f6cb935","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1301.527,"y":621.76984,"w":48,"h":25},"metadata":[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_5baa21cbcb67644b7ea848eb02cc8edd_Complex_57c85addb9c870fb650f24c45f6cb935","class":"macromolecule","label":"CRADD","parent":"Complex_57c85addb9c870fb650f24c45f6cb935","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1301.527,"y":591.76984,"w":48,"h":25},"metadata":[["bp:displayName","RAIDD"],["bp:entityReference_http://identifiers.org/uniprot/P78560",[["bp:standardName","Death domain-containing protein CRADD"],["bp:xref",[["bp:id","P78560"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CRADD"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","CRADD"],["bp:db","hgnc symbol"]]],["bp:displayName","CRADD_HUMAN"],["bp:name","CRADD"],["bp:name","RIP-associated protein with a death domain"],["bp:name","RAIDD"],["bp:name","Caspase and RIP adapter with death domain"],["bp:comment","CRADD_HUMAN Reviewed; 199 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003796"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8738"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8738"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04584_identity"],["bp:comment","FUNCTION: Apoptotic adaptor molecule specific for caspase-2 andFASL/TNF receptor-interacting protein RIP. In the presence of RIPand TRADD, CRADD recruits caspase-2 to the TNFR-1 signallingcomplex.SUBUNIT: Interacts with PIDD. {ECO:0000269|PubMed:15073321,ECO:0000269|PubMed:16652156}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P78560-1; Sequence=Displayed;Name=2;IsoId=P78560-2; Sequence=VSP_056892;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Constitutively expressed in most tissues, withparticularly high expression in adult heart, testis, liver,skeletal muscle, fetal liver and kidney.DOMAIN: Contains a death domain involved in the binding of RIPprotein.DOMAIN: The CARD domain mediates the interaction with caspase-2.DISEASE: Mental retardation, autosomal recessive 34, with variantlissencephaly (MRT34) [MIM:614499]: A disorder characterized bysignificantly below average general intellectual functioningassociated with impairments in adaptive behavior and manifestedduring the developmental period. MRT34 is a non-syndromic form.Affected individuals have mildly delayed development andsignificantly impaired cognitive function, precluding independentliving and self-care. Speech is rudimentary, but articulate;autism is not present. {ECO:0000269|PubMed:22279524}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1556"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_54746a7dd41afff1181c13d616c2ce5a_Complex_57c85addb9c870fb650f24c45f6cb935","class":"macromolecule","label":"MADD","parent":"Complex_57c85addb9c870fb650f24c45f6cb935","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1248.527,"y":681.76984,"w":48,"h":25},"metadata":[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]}},{"data":{"id":"Protein_1860f53d1b97dd11d29408c4f2f846d8_Complex_57c85addb9c870fb650f24c45f6cb935","class":"macromolecule","label":"TRADD","parent":"Complex_57c85addb9c870fb650f24c45f6cb935","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1248.527,"y":651.76984,"w":48,"h":25},"metadata":[["bp:displayName","TRADD"],["bp:entityReference_http://identifiers.org/uniprot/Q15628",[["bp:standardName","Tumor necrosis factor receptor type 1-associated DEATH domain protein"],["bp:xref",[["bp:relationshipType",null],["bp:id","TRADD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","Q15628"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q15628"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TRADD_HUMAN"],["bp:name","TNFRSF1A-associated via death domain"],["bp:name","TNFR1-associated DEATH domain protein"],["bp:name","TRADD"],["bp:comment","REPLACED ProteinRef_TRADD__10116"],["bp:comment","REPLACED ProteinRef_TRADD__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016879304"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003780"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04610_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_8717_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-285N_identity"],["bp:comment","REPLACED ProteinRef_TRADD__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8717"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8717"],["bp:comment","FUNCTION: The nuclear form acts as a tumor suppressor bypreventing ubiquitination and degradation of isoform p19ARF/ARF ofCDKN2A by TRIP12: acts by interacting with TRIP12, leading todisrupt interaction between TRIP12 and isoform p19ARF/ARF ofCDKN2A (By similarity). Adapter molecule for TNFRSF1A/TNFR1 thatspecifically associates with the cytoplasmic domain of activatedTNFRSF1A/TNFR1 mediating its interaction with FADD. Overexpressionof TRADD leads to two major TNF-induced responses, apoptosis andactivation of NF-kappa-B. {ECO:0000250}.SUBUNIT: Interacts with TRIP12 (By similarity). Heterodimer withTNFRSF1A/TNFR1. Interacts with DAB2IP, FADD, HIPK2, KRT14, KRT16,KRT17, KRT18, RIPK1, SQSTM1, TRAF1, TRAF2 and TRPC4AP.{ECO:0000250, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10892748, ECO:0000269|PubMed:11032752,ECO:0000269|PubMed:11684708, ECO:0000269|PubMed:15310755,ECO:0000269|PubMed:8612133}.SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm{ECO:0000250}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:11684708}. Note=Shuttles between the cytoplasmand the nucleus. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q15628-1; Sequence=Displayed;Name=2;IsoId=Q15628-2; Sequence=VSP_056526;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Found in all examined tissues.DOMAIN: Requires the intact death domain to associate withTNFRSF1A/TNFR1.SEQUENCE CAUTION:Sequence=AAA98482.1; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tradd/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TRADD_HUMAN Reviewed; 312 AA."],["bp:comment","REPLACED ProteinRef_TRADD__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1577"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_a5726d9b0e4bdae718169725939db78d_Complex_57c85addb9c870fb650f24c45f6cb935","class":"macromolecule","label":"RIPK1","parent":"Complex_57c85addb9c870fb650f24c45f6cb935","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1248.527,"y":621.76984,"w":48,"h":25},"metadata":[["bp:displayName","RIP"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q13546",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 166 166 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","166"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 384 384 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","384"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 6 6 Phosphoserine."],["bp:featureLocation","MOD_RES 6 6 Phosphoserine."]]],["bp:standardName","Receptor-interacting serine/threonine-protein kinase 1"],["bp:xref","Receptor-interacting serine/threonine-protein kinase 1"],["bp:xref","Receptor-interacting serine/threonine-protein kinase 1"],["bp:organism","Receptor-interacting serine/threonine-protein kinase 1"],["bp:displayName","RIPK1_HUMAN"],["bp:name","Receptor-interacting protein 1"],["bp:name","Serine/threonine-protein kinase RIP"],["bp:name","RIP-1"],["bp:name","RIP1"],["bp:name","2.7.11.1"],["bp:name","Cell death protein RIP"],["bp:name","RIP"],["bp:name","RIPK1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-433N_identity"],["bp:comment","REPLACED ProteinRef_RIPK1__9606"],["bp:comment","RIPK1_HUMAN Reviewed; 671 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04583_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003795"],["bp:comment","REPLACED ProteinRef_RIPK1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13546_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8737"],["bp:comment","REPLACED ProteinRef_RIPK1__10090"],["bp:comment","FUNCTION: Serine-threonine kinase which transduces inflammatoryand cell-death signals (programmed necrosis) following deathreceptors ligation, activation of pathogen recognition receptors(PRRs), and DNA damage. Upon activation of TNFR1 by the TNF-alphafamily cytokines, TRADD and TRAF2 are recruited to the receptor.Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependentmanner, and thereby activates the MAP3K5-JNK apoptotic cascade.Ubiquitination by TRAF2 via 'Lys-63'-link chains acts as acritical enhancer of communication with downstream signaltransducers in the mitogen-activated protein kinase pathway andthe NF-kappa-B pathway, which in turn mediate downstream eventsincluding the activation of genes encoding inflammatory molecules.Polyubiquitinated protein binds to IKBKG/NEMO, the regulatorysubunit of the IKK complex, a critical event for NF-kappa-Bactivation. Interaction with other cellular RHIM-containingadapters initiates gene activation and cell death. RIPK1 and RIPK3association, in particular, forms a necrosis-inducing complex.{ECO:0000269|PubMed:11101870, ECO:0000269|PubMed:17389591,ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:19524513}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:23473668}.ENZYME REGULATION: Inhibited by necrostatins, includingnecrostatin-1, necrostatin-3 and necrostatin-4.{ECO:0000269|PubMed:23473668}.SUBUNIT: Interacts (via RIP homotypic interaction motif) withRIPK3 (via RIP homotypic interaction motif). Upon TNF-inducednecrosis, the RIPK1-RIPK3 dimer further interacts with PGAM5 andMLKL; the formation of this complex leads to PGAM5 phosphorylationand increase in PGAM5 phosphatase activity. Interacts (via thedeath domain) with TNFRSF6 (via the death domain) and TRADD (viathe death domain). Is recruited by TRADD to TNFRSF1A in a TNF-dependent process. Binds RNF216, EGFR, IKBKG, TRAF1, TRAF2 andTRAF3. Interacts with BNLF1. Interacts with SQSTM1 upon TNF-alphastimulation. May interact with MAVS/IPS1. Interacts with ZFAND5.Interacts with RBCK1 (By similarity). Interacts with ZBP1 (Bysimilarity). Interacts with BIRC2/c-IAP1, BIRC3/c-IAP2 andXIAP/BIRC4. Upon TNF-induced necrosis, forms in complex withPGAM5, RIPK3 and MLKL. Interacts (via kinase domain) with DAB2IP(via Ras-GAP domain); the interaction occurs in a TNF-alpha-dependent manner. Interacts with ARHGEF2. Interacts (via proteinkinase domain) with RFFL; involved in RIPK1 ubiquitination.Interacts with RNF34; involved in RIPK1 ubiquitination. Interactswith TICAM1 and this interaction is enhanced in the presence ofWDFY1 (PubMed:25736436). {ECO:0000250|UniProtKB:Q60855,ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:10358032,ECO:0000269|PubMed:10409763, ECO:0000269|PubMed:11116146,ECO:0000269|PubMed:11734559, ECO:0000269|PubMed:11854271,ECO:0000269|PubMed:14754897, ECO:0000269|PubMed:16127453,ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:17449468,ECO:0000269|PubMed:18442983, ECO:0000269|PubMed:18450452,ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:21887730,ECO:0000269|PubMed:21931591, ECO:0000269|PubMed:22265414,ECO:0000269|PubMed:25736436, ECO:0000269|PubMed:8612133,ECO:0000269|PubMed:9927690, ECO:0000269|Ref.32}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q13546-1; Sequence=Displayed;Name=2;IsoId=Q13546-2; Sequence=VSP_037690;Note=No experimental confirmation available.;DOMAIN: Contains a C-terminal death domain (DD) that engages otherDD-containing proteins as well as a central (intermediate) regionimportant for NF-kB activation and RHIM-dependent signaling.{ECO:0000269|PubMed:10356400}.PTM: Proteolytically cleaved by caspase-8 during TNF-inducedapoptosis. Cleavage abolishes NF-kappa-B activation and enhancespro-apoptotic signaling through the TRADD-FADD interaction.{ECO:0000269|PubMed:10521396}.PTM: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation. Phosphorylation of Ser-161 by RIPK3 is necessaryfor the formation of the necroptosis-inducing complex.{ECO:0000269|PubMed:18408713, ECO:0000269|PubMed:19524513}.PTM: Ubiquitinated by 'Lys-11'-, 'Lys-48'-, 'Lys-63'- and linear-linked type ubiquitin. Polyubiquitination with 'Lys-63'-linkedchains by TRAF2 induces association with the IKK complex.Deubiquitination of 'Lys-63'-linked chains and polyubiquitinationwith 'Lys-48'-linked chains by TNFAIP3 leads to RIPK1 proteasomaldegradation and consequently down-regulates TNF-alpha-inducedNFkappa-B signaling. 'Lys-48'-linked polyubiquitination by RFFL orRNF34 also promotes proteasomal degradation and negativelyregulates TNF-alpha-induced NFkappa-B signaling. Linearpolyubiquitinated; the head-to-tail polyubiquitination is mediatedby the LUBAC complex. LPS-mediated activation of NF-kappa-B. Alsoubiquitinated with 'Lys-11'-linked chains. Polyubiquitinated with'Lys-48' and 'Lys-63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation of NF-kappa-B.{ECO:0000269|PubMed:15258597, ECO:0000269|PubMed:16603398,ECO:0000269|PubMed:18450452, ECO:0000269|PubMed:21455173,ECO:0000269|PubMed:21931591, ECO:0000269|Ref.32}.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAG65471.1; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/ripk1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_750"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1574"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1574"]]}},{"data":{"id":"Protein_bb8f0cd1124ca58baa10c0830e8a3bd3_Complex_57c85addb9c870fb650f24c45f6cb935","class":"macromolecule","label":"BIRC3","parent":"Complex_57c85addb9c870fb650f24c45f6cb935","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1248.527,"y":591.76984,"w":48,"h":25},"metadata":[["bp:displayName","cIAP2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q13489",[["bp:standardName","Baculoviral IAP repeat-containing protein 3"],["bp:xref",[["bp:id","Q13489"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","BIRC3"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","BIRC3"],["bp:db","hgnc symbol"]]],["bp:displayName","BIRC3_HUMAN"],["bp:name","Apoptosis inhibitor 2"],["bp:name","TNFR2-TRAF-signaling complex protein 1"],["bp:name","hIAP1"],["bp:name","Cellular inhibitor of apoptosis 2"],["bp:name","RING finger protein 49"],["bp:name","C-IAP2"],["bp:name","RNF49"],["bp:name","RING-type E3 ubiquitin transferase BIRC3"],["bp:name","Inhibitor of apoptosis protein 1"],["bp:name","IAP homolog C"],["bp:name","BIRC3"],["bp:name","API2"],["bp:name","2.3.2.27"],["bp:name","MIHC"],["bp:name","hIAP-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-33720N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016873132"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_330"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_330"],["bp:comment","FUNCTION: Multi-functional protein which regulates not onlycaspases and apoptosis, but also modulates inflammatory signalingand immunity, mitogenic kinase signaling and cell proliferation,as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates bothcanonical and non-canonical NF-kappa-B signaling by acting inopposite directions: acts as a positive regulator of the canonicalpathway and suppresses constitutive activation of non-canonicalNF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4,CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an importantregulator of innate immune signaling via regulation of Toll-likereceptors (TLRs), Nodlike receptors (NLRs) and RIG-I likereceptors (RLRs), collectively referred to as pattern recognitionreceptors (PRRs). Protects cells from spontaneous formation of theripoptosome, a large multi-protein complex that has the capabilityto kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation byubiquitinating RIPK1 and CASP8. {ECO:0000269|PubMed:21931591,ECO:0000269|PubMed:23453969}.CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugatingenzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptorprotein]-L-lysine. {ECO:0000269|PubMed:21931591,ECO:0000269|PubMed:23453969}.ENZYME REGULATION: USP19 regulates the stability of BIRC3/c-IAP2by preventing its ubiquitination. {ECO:0000269|PubMed:21849505}.SUBUNIT: Interacts with DIABLO/SMAC and with PRSS25; theseinteractions inhibit apoptotic suppressor activity. The BIR motifsregion interacts with TNF receptor associated factors 1 and 2(TRAF1 and TRAF2) to form a heteromeric complex, which is thenrecruited to the tumor necrosis factor receptor 2 (TNFR2).Interaction with TRAF2 is required for ubiquitination of IKBKE,degradation of NFKBIA and activation of NF-kappa-B. Interacts withRIP1, RIP2, RIP3, RIP4 and USP19. {ECO:0000269|PubMed:21849505,ECO:0000269|PubMed:21931591}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15665297}.Nucleus {ECO:0000269|PubMed:15665297}.TISSUE SPECIFICITY: Highly expressed in fetal lung, and kidney. Inthe adult, expression is mainly seen in lymphoid tissues,including spleen, thymus and peripheral blood lymphocytes.PTM: Auto-ubiquitinated and degraded by the proteasome inapoptotic cells.DISEASE: Note=A chromosomal aberration involving BIRC3 isrecurrent in low-grade mucosa-associated lymphoid tissue (MALTlymphoma). Translocation t(11;18)(q21;q21) with MALT1. Thistranslocation is found in approximately 50% of cytogeneticallyabnormal low-grade MALT lymphoma.SIMILARITY: Belongs to the IAP family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BIRC3ID239.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/birc3/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_892007"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13489_identity"],["bp:comment","BIRC3_HUMAN Reviewed; 604 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001156"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1559"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":888.0622,"y":466.69333,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80604"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80604"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80604"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80604"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80604"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80603"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80603"]]}},{"data":{"id":"BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":209.74518,"y":534.6283,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PP2A Heterotrimer"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80688"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80687"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80937"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PP2A Heterotrimer"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80935"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80935"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80936"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PP2A Heterotrimer"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80935"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80935"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80936"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80946"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:evidence",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80946"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:right",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80946"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:left",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80946"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80934"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80934"]]}},{"data":{"id":"BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1102.9672,"y":412.39273,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80532"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80532"]]}},{"data":{"id":"BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1419.7286,"y":564.6143,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MAP4K4"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80783"],["bp:featureLocation",[["bp:sequencePosition","631"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63759"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80782"],["bp:featureLocation",[["bp:sequencePosition","629"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12745"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:entityReference_http://identifiers.org/uniprot/O95819",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80885"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MAP4K4"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80783"],["bp:featureLocation",[["bp:sequencePosition","631"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63759"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80782"],["bp:featureLocation",[["bp:sequencePosition","629"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12745"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:entityReference_http://identifiers.org/uniprot/O95819",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80885"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MAP4K4"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80783"],["bp:featureLocation",[["bp:sequencePosition","631"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63759"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80782"],["bp:featureLocation",[["bp:sequencePosition","629"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12745"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:entityReference_http://identifiers.org/uniprot/O95819",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80885"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MAP4K4"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80783"],["bp:featureLocation",[["bp:sequencePosition","631"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63759"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80782"],["bp:featureLocation",[["bp:sequencePosition","629"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12745"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:entityReference_http://identifiers.org/uniprot/O95819",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80885"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80883"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80883"]]}},{"data":{"id":"Protein_be0a2c4a2b3747d87c5a2d76568a200b","class":"macromolecule","label":"NSMAF","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":956.51514,"y":198.82304,"w":48,"h":25},"metadata":[["bp:displayName","FAN"],["bp:entityReference_http://identifiers.org/uniprot/Q92636",[["bp:standardName","Protein FAN"],["bp:xref",[["bp:id","Q92636"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","NSMAF"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","NSMAF"],["bp:db","hgnc symbol"]]],["bp:displayName","FAN_HUMAN"],["bp:name","Factor associated with N-SMase activation"],["bp:name","FAN"],["bp:name","NSMAF"],["bp:name","Factor associated with neutral sphingomyelinase activation"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8439"],["bp:comment","REPLACED ProteinRef_NSMAF__40674"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8IW26"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-44106N_identity"],["bp:comment","FAN_HUMAN Reviewed; 917 AA."],["bp:comment","FUNCTION: Couples the p55 TNF-receptor (TNF-R55 / TNFR1) toneutral sphingomyelinase (N-SMASE). Specifically binds to the N-smase activation domain of TNF-R55. May regulate ceramideproduction by N-SMASE.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q92636-1; Sequence=Displayed;Name=2;IsoId=Q92636-2; Sequence=VSP_042036;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_09117_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8439"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003571"],["bp:comment","REPLACED ProteinRef_NSMAF__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21820"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":353.69458,"y":200.93651,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Sphingosine-1-phosphate"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:37550",[["bp:standardName","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:9225"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:62488"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77068"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:60119"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:16393"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:26742"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:chemicalFormula","C18H38NO5P"],["bp:displayName","sphingosine 1-phosphate"],["bp:name","CHEBI:37550"],["bp:name","Sphing-4-enine 1-phosphate"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)COP(O)(O)=O"],["bp:name","C18H38NO5P"],["bp:name","sphingosine-1-phosphate"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol 1-(dihydrogen phosphate)"],["bp:name","(2-amino-3-hydroxy-octadec-4-enoxy)phosphonic acid"],["bp:name","D-erythro-sphingosine 1-phosphate"],["bp:name","Sphingosine 1-phosphate"],["bp:name","C18-Sphingosine 1-phosphate"],["bp:name","S1P"],["bp:name","Sphingosine 1-phosphic acid"],["bp:molecularWeight","379.249"],["bp:comment","REPLACED http://identifiers.org/chebi/CHEBI:392583"],["bp:comment","has_role CHEBI:35620"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_242"],["bp:comment","has_role CHEBI:62488"],["bp:comment","has_functional_parent CHEBI:16393"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC06124.eref"],["bp:comment","is_conjugate_acid_of CHEBI:60119"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28959"],["bp:comment","has_role CHEBI:63114"],["bp:comment","A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1"],["bp:comment","REPLACED http://identifiers.org/pubchem.substance/25244490"],["bp:comment","has_role CHEBI:63173"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_c060506"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00277"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bind_2131_identity"],["bp:comment","is_a CHEBI:77068"],["bp:structure","is_a CHEBI:77068"]]],["bp:name","S1P"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Sphingosine-1-phosphate"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:37550",[["bp:standardName","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:9225"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:62488"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77068"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:60119"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:16393"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:26742"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:chemicalFormula","C18H38NO5P"],["bp:displayName","sphingosine 1-phosphate"],["bp:name","CHEBI:37550"],["bp:name","Sphing-4-enine 1-phosphate"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)COP(O)(O)=O"],["bp:name","C18H38NO5P"],["bp:name","sphingosine-1-phosphate"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol 1-(dihydrogen phosphate)"],["bp:name","(2-amino-3-hydroxy-octadec-4-enoxy)phosphonic acid"],["bp:name","D-erythro-sphingosine 1-phosphate"],["bp:name","Sphingosine 1-phosphate"],["bp:name","C18-Sphingosine 1-phosphate"],["bp:name","S1P"],["bp:name","Sphingosine 1-phosphic acid"],["bp:molecularWeight","379.249"],["bp:comment","REPLACED http://identifiers.org/chebi/CHEBI:392583"],["bp:comment","has_role CHEBI:35620"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_242"],["bp:comment","has_role CHEBI:62488"],["bp:comment","has_functional_parent CHEBI:16393"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC06124.eref"],["bp:comment","is_conjugate_acid_of CHEBI:60119"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28959"],["bp:comment","has_role CHEBI:63114"],["bp:comment","A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1"],["bp:comment","REPLACED http://identifiers.org/pubchem.substance/25244490"],["bp:comment","has_role CHEBI:63173"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_c060506"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00277"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bind_2131_identity"],["bp:comment","is_a CHEBI:77068"],["bp:structure","is_a CHEBI:77068"]]],["bp:name","S1P"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Sphingosine-1-phosphate"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:37550",[["bp:standardName","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:9225"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:62488"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77068"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:60119"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:16393"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:26742"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:chemicalFormula","C18H38NO5P"],["bp:displayName","sphingosine 1-phosphate"],["bp:name","CHEBI:37550"],["bp:name","Sphing-4-enine 1-phosphate"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)COP(O)(O)=O"],["bp:name","C18H38NO5P"],["bp:name","sphingosine-1-phosphate"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol 1-(dihydrogen phosphate)"],["bp:name","(2-amino-3-hydroxy-octadec-4-enoxy)phosphonic acid"],["bp:name","D-erythro-sphingosine 1-phosphate"],["bp:name","Sphingosine 1-phosphate"],["bp:name","C18-Sphingosine 1-phosphate"],["bp:name","S1P"],["bp:name","Sphingosine 1-phosphic acid"],["bp:molecularWeight","379.249"],["bp:comment","REPLACED http://identifiers.org/chebi/CHEBI:392583"],["bp:comment","has_role CHEBI:35620"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_242"],["bp:comment","has_role CHEBI:62488"],["bp:comment","has_functional_parent CHEBI:16393"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC06124.eref"],["bp:comment","is_conjugate_acid_of CHEBI:60119"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28959"],["bp:comment","has_role CHEBI:63114"],["bp:comment","A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1"],["bp:comment","REPLACED http://identifiers.org/pubchem.substance/25244490"],["bp:comment","has_role CHEBI:63173"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_c060506"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00277"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bind_2131_identity"],["bp:comment","is_a CHEBI:77068"],["bp:structure","is_a CHEBI:77068"]]],["bp:name","S1P"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Sphingosine-1-phosphate"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:37550",[["bp:standardName","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:9225"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:62488"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77068"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:60119"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:16393"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:26742"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63114"],["bp:db","chebi"]]],["bp:chemicalFormula","C18H38NO5P"],["bp:displayName","sphingosine 1-phosphate"],["bp:name","CHEBI:37550"],["bp:name","Sphing-4-enine 1-phosphate"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)COP(O)(O)=O"],["bp:name","C18H38NO5P"],["bp:name","sphingosine-1-phosphate"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol 1-(dihydrogen phosphate)"],["bp:name","(2-amino-3-hydroxy-octadec-4-enoxy)phosphonic acid"],["bp:name","D-erythro-sphingosine 1-phosphate"],["bp:name","Sphingosine 1-phosphate"],["bp:name","C18-Sphingosine 1-phosphate"],["bp:name","S1P"],["bp:name","Sphingosine 1-phosphic acid"],["bp:molecularWeight","379.249"],["bp:comment","REPLACED http://identifiers.org/chebi/CHEBI:392583"],["bp:comment","has_role CHEBI:35620"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_242"],["bp:comment","has_role CHEBI:62488"],["bp:comment","has_functional_parent CHEBI:16393"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC06124.eref"],["bp:comment","is_conjugate_acid_of CHEBI:60119"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28959"],["bp:comment","has_role CHEBI:63114"],["bp:comment","A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1"],["bp:comment","REPLACED http://identifiers.org/pubchem.substance/25244490"],["bp:comment","has_role CHEBI:63173"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_c060506"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00277"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bind_2131_identity"],["bp:comment","is_a CHEBI:77068"],["bp:structure","is_a CHEBI:77068"]]],["bp:name","S1P"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_67804"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80643"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80643"]]}},{"data":{"id":"Protein_752f949acd24a9eb8567d88a0935b28a","class":"macromolecule","label":"MAP3K1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_752f949acd24a9eb8567d88a0935b28a.info.1","class":"state variable","state":{"variable":"1412","value":"opthr"}},{"id":"Protein_752f949acd24a9eb8567d88a0935b28a.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_752f949acd24a9eb8567d88a0935b28a.info.3","class":"state variable","state":{"variable":"1400","value":"opthr"}}],"unitsOfInformation":[],"bbox":{"x":251.9802,"y":773.73505,"w":85,"h":25},"metadata":[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation","MOD_RES 1043 1043 Phosphoserine."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 1"],["bp:xref","Mitogen-activated protein kinase kinase kinase 1"],["bp:xref","Mitogen-activated protein kinase kinase kinase 1"],["bp:organism","Mitogen-activated protein kinase kinase kinase 1"],["bp:displayName","M3K1_HUMAN"],["bp:name","MAP3K1"],["bp:name","MAPKKK1"],["bp:name","MEKK1"],["bp:name","MEK kinase 1"],["bp:name","2.7.11.25"],["bp:name","MEKK"],["bp:name","MAPK/ERK kinase kinase 1"],["bp:name","MEKK 1"],["bp:comment","REPLACED ProteinRef_MAP3K1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4214"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005912"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_AAC97073_see-also"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1736"],["bp:comment","REPLACED ProteinRef_MAP3K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-27520N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_19599_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_042066"],["bp:comment","REPLACED ProteinRef_MAP3K1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13233_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4214"],["bp:comment","M3K1_HUMAN Reviewed; 1512 AA."],["bp:comment","FUNCTION: Component of a protein kinase signal transductioncascade. Activates the ERK and JNK kinase pathways byphosphorylation of MAP2K1 and MAP2K4. Activates CHUK and IKBKB,the central protein kinases of the NF-kappa-B pathway.{ECO:0000269|PubMed:9808624}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by autophosphorylation on Thr-1400and Thr-1412 following oligomerization.SUBUNIT: Binds both upstream activators and downstream substratesin multimolecular complexes through its N-terminus. Oligomerizesafter binding MAP4K2 or TRAF2. Interacts with AXIN1. Interacts(via the kinase catalytic domain) with STK38.{ECO:0000269|PubMed:12223491, ECO:0000269|PubMed:15262978,ECO:0000269|PubMed:17906693, ECO:0000269|PubMed:9808624}.PTM: Autophosphorylated. {ECO:0000250}.DISEASE: 46,XY sex reversal 6 (SRXY6) [MIM:613762]: A disorder ofsex development. Affected individuals have a 46,XY karyotype butpresent as phenotypically normal females.{ECO:0000269|PubMed:21129722}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_MAP3K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]}},{"data":{"id":"Protein_6e31848cbf98ad57cabd5419ce8299a5","class":"macromolecule","label":"SMPD3","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1116.0791,"y":328.41028,"w":48,"h":25},"metadata":[["bp:displayName","Neutral sphingomyelinase II"],["bp:entityReference_http://identifiers.org/uniprot/Q9NY59",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q9NY59"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 291 291 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q9NY59"]]],["bp:standardName","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:organism","Sphingomyelin phosphodiesterase 3"],["bp:displayName","NSMA2_HUMAN"],["bp:name","Neutral sphingomyelinase 2"],["bp:name","SMPD3"],["bp:name","Neutral sphingomyelinase II"],["bp:name","nSMase-2"],["bp:name","nSMase2"],["bp:name","3.1.4.12"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_55512"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-60431N_identity"],["bp:comment","FUNCTION: Catalyzes the hydrolysis of sphingomyelin to formceramide and phosphocholine. Ceramide mediates numerous cellularfunctions, such as apoptosis and growth arrest, and is capable ofregulating these 2 cellular events independently. Also hydrolyzessphingosylphosphocholine. Regulates the cell cycle by acting as agrowth suppressor in confluent cells. Probably acts as a regulatorof postnatal development and participates in bone and dentinmineralization. {ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:14741383, ECO:0000269|PubMed:15051724}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:15051724};ENZYME REGULATION: Activated by unsaturated fatty acids andphosphatidylserine. {ECO:0000269|PubMed:10823942}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 7.5.;PATHWAY: Lipid metabolism; sphingolipid metabolism.SUBCELLULAR LOCATION: Golgi apparatus membrane{ECO:0000269|PubMed:10823942}; Lipid-anchor{ECO:0000269|PubMed:10823942}. Cell membrane{ECO:0000269|PubMed:15051724}; Lipid-anchor{ECO:0000269|PubMed:15051724}. Note=May localize to detergent-resistant subdomains of Golgi membranes of hypothalamicneurosecretory neurons (PubMed:10823942). Localizes to plasmamembrane in confluent contact-inhaibited cells (PubMed:15051724).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q9NY59-1; Sequence=Displayed;Name=2;IsoId=Q9NY59-2; Sequence=VSP_054334;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Predominantly expressed in brain.{ECO:0000269|PubMed:10823942}.DEVELOPMENTAL STAGE: Up-regulated during G0/G1 phases.PTM: Palmitoylated, palmitoylation-deficient proteins are targetedfor lysosomal degradation. {ECO:0000250}.SIMILARITY: Belongs to the neutral sphingomyelinase family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","NSMA2_HUMAN Reviewed; 655 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_55512"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"]]}},{"data":{"id":"ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1014.49756,"y":239.92111,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80769"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80769"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80769"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80769"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80760"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80760"]]}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","class":"simple chemical","label":"ceramide","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":372.15384,"y":515.2377,"w":48,"h":20},"metadata":[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":685.83014,"y":495.49957,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Cytochrome C"],["bp:entityReference_http://identifiers.org/uniprot/P99999",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P99999"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 73 73 N6-acetyllysine; alternate."],["bp:featureLocation",[["bp:sequencePosition","73"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-succinyllysine"],["bp:term","MOD_RES N6-succinyllysine"]]],["bp:comment","MOD_RES 73 73 N6-succinyllysine; alternate."],["bp:featureLocation","MOD_RES 73 73 N6-succinyllysine; alternate."]]],["bp:standardName","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:xref","Cytochrome c"],["bp:organism","Cytochrome c"],["bp:displayName","CYC_HUMAN"],["bp:name","CYC"],["bp:name","CYCS"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29683N_identity"],["bp:comment","FUNCTION: Electron carrier protein. The oxidized form of thecytochrome c heme group can accept an electron from the heme groupof the cytochrome c1 subunit of cytochrome reductase. Cytochrome cthen transfers this electron to the cytochrome oxidase complex,the final protein carrier in the mitochondrial electron-transportchain.FUNCTION: Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members ofthe Bcl-2 family leads to altered mitochondrial membranepermeability resulting in release of cytochrome c into thecytosol. Binding of cytochrome c to Apaf-1 triggers the activationof caspase-9, which then accelerates apoptosis by activating othercaspases.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Note=Loosely associated with the inner membrane.PTM: Binds 1 heme group per subunit.PTM: Phosphorylation at Tyr-49 and Tyr-98 both reduce by half theturnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration. {ECO:0000250}.DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopeniais defined by a decrease in the number of platelets in circulatingblood, resulting in the potential for increased bleeding anddecreased ability for clotting. {ECO:0000269|PubMed:18345000}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the cytochrome c family. {ECO:0000305}.WEB RESOURCE: Name=Protein Spotlight; Note=Life shuttle - Issue 76of November 2006;URL=\"http://web.expasy.org/spotlight/back_issues/076\";WEB RESOURCE: Name=Protein Spotlight; Note=An unexpected place -Issue 88 of November 2007;URL=\"http://web.expasy.org/spotlight/back_issues/088/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061820"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1J3S_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_54205"],["bp:comment","CYC_HUMAN Reviewed; 105 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot/P99998"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_54205"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1066"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10268"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10267"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_10267"]]}},{"data":{"id":"Protein_a0b3d7ab91cab515a09792dabb8361e6","class":"macromolecule","label":"SMPD1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_a0b3d7ab91cab515a09792dabb8361e6.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":861.88654,"y":362.3252,"w":48,"h":25},"metadata":[["bp:displayName","Acid Sphingomyelinase"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80536"]]],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80535"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_dec3540e8c049a00271de9871a91f002","class":"macromolecule","label":"EIF2AK2","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":563.1116,"y":148.89442,"w":48,"h":25},"metadata":[["bp:displayName","PKR"],["bp:entityReference_http://identifiers.org/uniprot/P19525",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 293 293 Phosphotyrosine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","293"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","255"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","242"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:organism","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:displayName","E2AK2_HUMAN"],["bp:name","PKR"],["bp:name","2.7.11.1"],["bp:name","p68 kinase"],["bp:name","Protein kinase RNA-activated"],["bp:name","Eukaryotic translation initiation factor 2-alpha kinase 2"],["bp:name","Tyrosine-protein kinase EIF2AK2"],["bp:name","EIF2AK2"],["bp:name","Protein kinase R"],["bp:name","PRKR"],["bp:name","P1/eIF-2A protein kinase"],["bp:name","2.7.10.2"],["bp:name","Interferon-inducible RNA-dependent protein kinase"],["bp:name","eIF-2A protein kinase 2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002750"],["bp:comment","E2AK2_HUMAN Reviewed; 551 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P19525_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A19_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5610"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2657N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011531289"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5610"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20459"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01468_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_646"],["bp:comment","FUNCTION: IFN-induced dsRNA-dependent serine/threonine-proteinkinase which plays a key role in the innate immune response toviral infection and is also involved in the regulation of signaltransduction, apoptosis, cell proliferation and differentiation.Exerts its antiviral activity on a wide range of DNA and RNAviruses including hepatitis C virus (HCV), hepatitis B virus(HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1).Inhibits viral replication via phosphorylation of the alphasubunit of eukaryotic initiation factor 2 (EIF2S1), thisphosphorylation impairs the recycling of EIF2S1 between successiverounds of initiation leading to inhibition of translation whicheventually results in shutdown of cellular and viral proteinsynthesis. Also phosphorylates other substrates includingp53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral proteinUS11. In addition to serine/threonine-protein kinase activity,also has tyrosine-protein kinase activity and phosphorylates CDK1at 'Tyr-4' upon DNA damage, facilitating its ubiquitination andproteosomal degradation. Either as an adapter protein and/or viaits kinase activity, can regulate various signaling pathways (p38MAP kinase, NF-kappa-B and insulin signaling pathways) andtranscription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved inthe expression of genes encoding proinflammatory cytokines andIFNs. Activates the NF-kappa-B pathway via interaction with IKBKBand TRAF family of proteins and activates the p38 MAP kinasepathway via interaction with MAP2K6. Can act as both a positiveand negative regulator of the insulin signaling pathway (ISP).Negatively regulates ISP by inducing the inhibitoryphosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5Awhich activates FOXO1, which in turn up-regulates the expressionof insulin receptor substrate 2 (IRS2). Can regulate NLRP3inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 andNLRC4 inflammasomes. Can trigger apoptosis via FADD-mediatedactivation of CASP8. Plays a role in the regulation of thecytoskeleton by binding to gelsolin (GSN), sequestering theprotein in an inactive conformation away from actin.{ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Initially produced in an inactive form and isactivated by binding to viral dsRNA, which causes dimerization andautophosphorylation in the activation loop and stimulation offunction. ISGylation can activate it in the absence of viralinfection. Can also be activated by heparin, proinflammatorystimuli, growth factors, cytokines, oxidative stress and thecellular protein PRKRA. Activity is markedly stimulated bymanganese ions. Activation is blocked by the viral components HIV-1 Tat protein and large amounts of HIV-1 trans-activation response(TAR) RNA element as well as by the cellular proteins TARBP2,DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana virus (TOS)and Rift valley fever virus (RVFV) NSS which promote itsproteasomal degradation. Inhibited by vaccinia virus protein E3,probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.SUBUNIT: Homodimer. Interacts with STRBP (By similarity).Interacts with DNAJC3. Forms a complex with FANCA, FANCC, FANCGand HSP70. Interacts with ADAR/ADAR1. Interacts with IRS1 (Bysimilarity). The inactive form interacts with NCK1 and GSN.Interacts (via the kinase catalytic domain) with STAT3 (via SH2domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1,NLRP3, NLRC4 and AIM2. Interacts (via DRBM 1 domain) with DUS2L(via DRBM domain). Interacts with DHX9 (via N-terminus) and thisinteraction is dependent upon activation of the kinase.{ECO:0000250, ECO:0000269|PubMed:10390359,ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11438532,ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25740987,ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.SUBUNIT: (Microbial infection) Interacts with human herpes simplexvirus 1 (HHV-1) protein US11 in an RNA-dependent manner(PubMed:11836380). The inactive form interacts with Toscana virus(TOS) NSS (PubMed:23325696). Interacts with herpes virus 8 proteinv-IRF2; this interaction inhibits EIF2AK2 activation(PubMed:11160738). Interacts with vaccinia protein E3(PubMed:25740987). {ECO:0000269|PubMed:11160738,ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:23325696,ECO:0000269|PubMed:25740987}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, perinuclearregion. Note=Nuclear localization is elevated in acute leukemia,myelodysplastic syndrome (MDS), melanoma, breast, colon, prostateand lung cancer patient samples or cell lines as well asneurocytes from advanced Creutzfeldt-Jakob disease patients.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P19525-1; Sequence=Displayed;Name=2;IsoId=P19525-2; Sequence=VSP_046177;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bonemarrow compared to non-hematopoietic tissues such as smallintestine, liver, or kidney tissues. Colocalizes with GSK3B andTAU in the Alzheimer disease (AD) brain. Elevated levels seen inbreast and colon carcinomas,and which correlates with tumorprogression and invasiveness or risk of progression.{ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:23403623}.INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.PTM: Autophosphorylated on several Ser, Thr and Tyr residues.Autophosphorylation of Thr-451 is dependent on Thr-446 and isstimulated by dsRNA binding and dimerization. Autophosphorylationapparently leads to the activation of the kinase. Tyrosineautophosphorylation is essential for efficient dsRNA-binding,dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/prkr/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_37502"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_37502"]]}},{"data":{"id":"BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":363.21988,"y":1298.9758,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80863"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80859"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80859"]]}},{"data":{"id":"Protein_df21ab8fde712730f509baed7c0e97f1","class":"macromolecule","label":"EIF2AK2","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_df21ab8fde712730f509baed7c0e97f1.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":489.1102,"y":94.07639,"w":48,"h":25},"metadata":[["bp:displayName","PKR"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63229"]]],["bp:entityReference_http://identifiers.org/uniprot/P19525",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 293 293 Phosphotyrosine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","293"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","255"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 242 242 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 242 242 Phosphoserine; by autocatalysis."]]],["bp:standardName","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:organism","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:displayName","E2AK2_HUMAN"],["bp:name","PKR"],["bp:name","2.7.11.1"],["bp:name","p68 kinase"],["bp:name","Protein kinase RNA-activated"],["bp:name","Eukaryotic translation initiation factor 2-alpha kinase 2"],["bp:name","Tyrosine-protein kinase EIF2AK2"],["bp:name","EIF2AK2"],["bp:name","Protein kinase R"],["bp:name","PRKR"],["bp:name","P1/eIF-2A protein kinase"],["bp:name","2.7.10.2"],["bp:name","Interferon-inducible RNA-dependent protein kinase"],["bp:name","eIF-2A protein kinase 2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002750"],["bp:comment","E2AK2_HUMAN Reviewed; 551 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P19525_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A19_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5610"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2657N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011531289"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5610"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20459"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01468_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_646"],["bp:comment","FUNCTION: IFN-induced dsRNA-dependent serine/threonine-proteinkinase which plays a key role in the innate immune response toviral infection and is also involved in the regulation of signaltransduction, apoptosis, cell proliferation and differentiation.Exerts its antiviral activity on a wide range of DNA and RNAviruses including hepatitis C virus (HCV), hepatitis B virus(HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1).Inhibits viral replication via phosphorylation of the alphasubunit of eukaryotic initiation factor 2 (EIF2S1), thisphosphorylation impairs the recycling of EIF2S1 between successiverounds of initiation leading to inhibition of translation whicheventually results in shutdown of cellular and viral proteinsynthesis. Also phosphorylates other substrates includingp53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral proteinUS11. In addition to serine/threonine-protein kinase activity,also has tyrosine-protein kinase activity and phosphorylates CDK1at 'Tyr-4' upon DNA damage, facilitating its ubiquitination andproteosomal degradation. Either as an adapter protein and/or viaits kinase activity, can regulate various signaling pathways (p38MAP kinase, NF-kappa-B and insulin signaling pathways) andtranscription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved inthe expression of genes encoding proinflammatory cytokines andIFNs. Activates the NF-kappa-B pathway via interaction with IKBKBand TRAF family of proteins and activates the p38 MAP kinasepathway via interaction with MAP2K6. Can act as both a positiveand negative regulator of the insulin signaling pathway (ISP).Negatively regulates ISP by inducing the inhibitoryphosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5Awhich activates FOXO1, which in turn up-regulates the expressionof insulin receptor substrate 2 (IRS2). Can regulate NLRP3inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 andNLRC4 inflammasomes. Can trigger apoptosis via FADD-mediatedactivation of CASP8. Plays a role in the regulation of thecytoskeleton by binding to gelsolin (GSN), sequestering theprotein in an inactive conformation away from actin.{ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Initially produced in an inactive form and isactivated by binding to viral dsRNA, which causes dimerization andautophosphorylation in the activation loop and stimulation offunction. ISGylation can activate it in the absence of viralinfection. Can also be activated by heparin, proinflammatorystimuli, growth factors, cytokines, oxidative stress and thecellular protein PRKRA. Activity is markedly stimulated bymanganese ions. Activation is blocked by the viral components HIV-1 Tat protein and large amounts of HIV-1 trans-activation response(TAR) RNA element as well as by the cellular proteins TARBP2,DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana virus (TOS)and Rift valley fever virus (RVFV) NSS which promote itsproteasomal degradation. Inhibited by vaccinia virus protein E3,probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.SUBUNIT: Homodimer. Interacts with STRBP (By similarity).Interacts with DNAJC3. Forms a complex with FANCA, FANCC, FANCGand HSP70. Interacts with ADAR/ADAR1. Interacts with IRS1 (Bysimilarity). The inactive form interacts with NCK1 and GSN.Interacts (via the kinase catalytic domain) with STAT3 (via SH2domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1,NLRP3, NLRC4 and AIM2. Interacts (via DRBM 1 domain) with DUS2L(via DRBM domain). Interacts with DHX9 (via N-terminus) and thisinteraction is dependent upon activation of the kinase.{ECO:0000250, ECO:0000269|PubMed:10390359,ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11438532,ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25740987,ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.SUBUNIT: (Microbial infection) Interacts with human herpes simplexvirus 1 (HHV-1) protein US11 in an RNA-dependent manner(PubMed:11836380). The inactive form interacts with Toscana virus(TOS) NSS (PubMed:23325696). Interacts with herpes virus 8 proteinv-IRF2; this interaction inhibits EIF2AK2 activation(PubMed:11160738). Interacts with vaccinia protein E3(PubMed:25740987). {ECO:0000269|PubMed:11160738,ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:23325696,ECO:0000269|PubMed:25740987}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, perinuclearregion. Note=Nuclear localization is elevated in acute leukemia,myelodysplastic syndrome (MDS), melanoma, breast, colon, prostateand lung cancer patient samples or cell lines as well asneurocytes from advanced Creutzfeldt-Jakob disease patients.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P19525-1; Sequence=Displayed;Name=2;IsoId=P19525-2; Sequence=VSP_046177;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bonemarrow compared to non-hematopoietic tissues such as smallintestine, liver, or kidney tissues. Colocalizes with GSK3B andTAU in the Alzheimer disease (AD) brain. Elevated levels seen inbreast and colon carcinomas,and which correlates with tumorprogression and invasiveness or risk of progression.{ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:23403623}.INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.PTM: Autophosphorylated on several Ser, Thr and Tyr residues.Autophosphorylation of Thr-451 is dependent on Thr-446 and isstimulated by dsRNA binding and dimerization. Autophosphorylationapparently leads to the activation of the kinase. Tyrosineautophosphorylation is essential for efficient dsRNA-binding,dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/prkr/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"]]}},{"data":{"id":"Protein_e182e050a948953a2b7fe086f9bf09f1","class":"macromolecule","label":"PRKCD","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":391.84915,"y":1043.5088,"w":48,"h":25},"metadata":[["bp:displayName","PKC delta"],["bp:entityReference_http://identifiers.org/uniprot/Q05655",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 654 654 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","654"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 307 307 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","307"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","374"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:standardName","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:organism","Protein kinase C delta type"],["bp:displayName","KPCD_HUMAN"],["bp:name","Protein kinase C delta type regulatory subunit"],["bp:name","nPKC-delta"],["bp:name","Protein kinase C delta type catalytic subunit"],["bp:name","2.7.10.2"],["bp:name","2.7.11.13"],["bp:name","Tyrosine-protein kinase PRKCD"],["bp:name","SDK1"],["bp:name","Sphingosine-dependent protein kinase-1"],["bp:name","PRKCD"],["bp:comment","REPLACED ProteinRef_PRKCD__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01501_identity"],["bp:comment","KPCD_HUMAN Reviewed; 676 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_882"],["bp:comment","REPLACED ProteinRef_PRKCD__10090"],["bp:comment","FUNCTION: Calcium-independent, phospholipid- and diacylglycerol(DAG)-dependent serine/threonine-protein kinase that playscontrasting roles in cell death and cell survival by functioningas a pro-apoptotic protein during DNA damage-induced apoptosis,but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well assurvival of several cancers, is required for oxygen radicalproduction by NADPH oxidase and acts as positive or negativeregulator in platelet functional responses. Negatively regulates Bcell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage,activates the promoter of the death-promoting transcription factorBCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcriptionand apoptosis. In response to oxidative stress, interact with andactivate CHUK/IKKA in the nucleus, causing the phosphorylation ofp53/TP53. In the case of ER stress or DNA damage-inducedapoptosis, can form a complex with the tyrosine-protein kinaseABL1 which trigger apoptosis independently of p53/TP53. In cytosolcan trigger apoptosis by activating MAPK11 or MAPK14, inhibitingAKT1 and decreasing the level of X-linked inhibitor of apoptosisprotein (XIAP), whereas in nucleus induces apoptosis via theactivation of MAPK8 or MAPK9. Upon ionizing radiation treatment,is required for the activation of the apoptosis regulators BAX andBAK, which trigger the mitochondrial cell death pathway. Canphosphorylate MCL1 and target it for degradation which issufficient to trigger for BAX activation and apoptosis. Isrequired for the control of cell cycle progression both at G1/Sand G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclinCCNA2 promoter activity. In response to UV irradiation canphosphorylate CDK1, which is important for the G2/M DNA damagecheckpoint activation. Can protect glioma cells from the apoptosisinduced by TNFSF10/TRAIL, probably by inducing increasedphosphorylation and subsequent activation of AKT1. Is highlyexpressed in a number of cancer cells and promotes cell survivaland resistance against chemotherapeutic drugs by inducing cyclinD1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3(ERK1/2). Can also act as tumor suppressor upon mitogenicstimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity,and regulates TNF-elicited superoxide anion production inneutrophils, by direct phosphorylation and activation of NCF1 orindirectly through MAPK1/3 (ERK1/2) signaling pathways. May alsoplay a role in the regulation of NADPH oxidase activity ineosinophil after stimulation with IL5, leukotriene B4 or PMA. Incollagen-induced platelet aggregation, acts a negative regulatorof filopodia formation and actin polymerization by interactingwith and negatively regulating VASP phosphorylation. Downstream ofPAR1, PAR4 and CD36/GP4 receptors, regulates differentiallyplatelet dense granule secretion; acts as a positive regulator inPAR-mediated granule secretion, whereas it negatively regulatesCD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins(YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (Bysimilarity). Phosphorylates ELAVL1 in response to angiotensin-2treatment (PubMed:18285462). {ECO:0000250,ECO:0000269|PubMed:11748588, ECO:0000269|PubMed:11877440,ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:16940418,ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19587372,ECO:0000269|PubMed:19801500}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:18285462}.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) arecalcium-insensitive, but activated by diacylglycerol (DAG) andphosphatidylserine. Three specific sites; Thr-507 (activation loopof the kinase domain), Ser-645 (turn motif) and Ser-664(hydrophobic region), need to be phosphorylated for its fullactivation. Activated by caspase-3 (CASP3) cleavage duringapoptosis. After cleavage, the pseudosubstrate motif in theregulatory subunit is released from the substrate recognition siteof the catalytic subunit, which enables PRKCD to becomeconstitutively activated. The catalytic subunit which displaysproperties of a sphingosine-dependent protein kinase is activatedby D-erythro-sphingosine (Sph) or N,N-dimethyl-D-erythrosphingosine (DMS) or N,N,N-trimethyl-D-erythrosphingosine(TMS), but not by ceramide or Sph-1-P and is strongly inhibited byphosphatidylserine (By similarity). {ECO:0000250}.SUBUNIT: Interacts with PDPK1 (via N-terminal region), RAD9A,CDCP1, MUC1 and VASP. {ECO:0000269|PubMed:11781095,ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12628935,ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16940418}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046, ECO:0000269|PubMed:18285462}.Cytoplasm, perinuclear region {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046}. Nucleus{ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:18285462}. Cell membrane{ECO:0000269|PubMed:17603046}; Peripheral membrane protein{ECO:0000305|PubMed:17603046}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q05655-1; Sequence=Displayed;Name=2; Synonyms=PKCdeltaVIII;IsoId=Q05655-2; Sequence=VSP_043899;Note=Antiapoptotic isoform, resistant to caspase-3 cleavage.;DOMAIN: The C1 domain, containing the phorbol ester/DAG-typeregion 1 (C1A) and 2 (C1B), is the diacylglycerol sensor.DOMAIN: The C2 domain is a non-calcium binding domain. It bindsproteins containing phosphotyrosine in a sequence-specific manner.PTM: Autophosphorylated and/or phosphorylated at Thr-507, withinthe activation loop; phosphorylation at Thr-507 is not aprerequisite for enzymatic activity. Autophosphorylated at Ser-299, Ser-302 and Ser-304. Upon TNFSF10/TRAIL treatment,phosphorylated at Tyr-155; phosphorylation is required for itstranslocation to the endoplasmic reticulum and cleavage bycaspase-3. Phosphorylated at Tyr-313, Tyr-334 and Tyr-567;phosphorylation of Tyr-313 and Tyr-567 following thrombinstimulation potentiates its kinase activity. Phosphorylated byprotein kinase PDPK1; phosphorylation is inhibited by theapoptotic C-terminal cleavage product of PKN2.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17570831, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:19801500}.PTM: Proteolytically cleaved into a catalytic subunit and aregulatory subunit by caspase-3 during apoptosis which results inkinase activation. {ECO:0000250}.DISEASE: Autoimmune lymphoproliferative syndrome 3 (ALPS3)[MIM:615559]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen. Thedefect results from a failure of B-cell differentiation andimpaired secretion of immunoglobulins; the numbers of circulatingB-cells is usually in the normal range, but can be low. CVID9patients have B-cell deficiency and severe autoimmunity.{ECO:0000269|PubMed:23319571}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PRKCDID42901ch3p21.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29954N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_006245"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_ddbj_embl_genbank_BAA01381_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_997704"],["bp:comment","REPLACED ProteinRef_PRKCD__40674"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5580"]]],["bp:name","nPKC-delta"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"]]}},{"data":{"id":"BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":225.53836,"y":189.17905,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","SPHK2"],["bp:entityReference_http://identifiers.org/uniprot/Q9NRA0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 399 399 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","399"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 387 387 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","387"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:organism","Sphingosine kinase 2"],["bp:displayName","SPHK2_HUMAN"],["bp:name","2.7.1.91"],["bp:name","SPHK2"],["bp:name","SK 2"],["bp:name","SPK 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_56848"],["bp:comment","FUNCTION: Catalyzes the phosphorylation of sphingosine to formsphingosine 1-phosphate (SPP), a lipid mediator with both intra-and extracellular functions. Also acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides.{ECO:0000269|PubMed:19168031}.CATALYTIC ACTIVITY: ATP + a sphingoid base = ADP + a sphingoidbase 1-phosphate. {ECO:0000269|PubMed:10751414}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Inhibited by sulfatide.{ECO:0000269|PubMed:19168031}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=3.4 uM for sphingosine {ECO:0000269|PubMed:10751414};pH dependence:Optimum pH is 7.5. {ECO:0000269|PubMed:10751414};SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Membrane.SUBCELLULAR LOCATION: Isoform 2: Lysosome membrane.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9NRA0-1; Sequence=Displayed;Name=2;IsoId=Q9NRA0-2; Sequence=VSP_006217;Name=3;IsoId=Q9NRA0-3; Sequence=VSP_006217, VSP_006218;Name=4;IsoId=Q9NRA0-4; Sequence=VSP_046910;Note=No experimental confirmation available.;Name=5;IsoId=Q9NRA0-5; Sequence=VSP_047721, VSP_047722; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06157_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16804"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006723355"],["bp:comment","SPHK2_HUMAN Reviewed; 654 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_56848"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80925"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","SPHK2"],["bp:entityReference_http://identifiers.org/uniprot/Q9NRA0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 399 399 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","399"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 387 387 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","387"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:organism","Sphingosine kinase 2"],["bp:displayName","SPHK2_HUMAN"],["bp:name","2.7.1.91"],["bp:name","SPHK2"],["bp:name","SK 2"],["bp:name","SPK 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_56848"],["bp:comment","FUNCTION: Catalyzes the phosphorylation of sphingosine to formsphingosine 1-phosphate (SPP), a lipid mediator with both intra-and extracellular functions. Also acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides.{ECO:0000269|PubMed:19168031}.CATALYTIC ACTIVITY: ATP + a sphingoid base = ADP + a sphingoidbase 1-phosphate. {ECO:0000269|PubMed:10751414}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Inhibited by sulfatide.{ECO:0000269|PubMed:19168031}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=3.4 uM for sphingosine {ECO:0000269|PubMed:10751414};pH dependence:Optimum pH is 7.5. {ECO:0000269|PubMed:10751414};SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Membrane.SUBCELLULAR LOCATION: Isoform 2: Lysosome membrane.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9NRA0-1; Sequence=Displayed;Name=2;IsoId=Q9NRA0-2; Sequence=VSP_006217;Name=3;IsoId=Q9NRA0-3; Sequence=VSP_006217, VSP_006218;Name=4;IsoId=Q9NRA0-4; Sequence=VSP_046910;Note=No experimental confirmation available.;Name=5;IsoId=Q9NRA0-5; Sequence=VSP_047721, VSP_047722; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06157_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16804"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006723355"],["bp:comment","SPHK2_HUMAN Reviewed; 654 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_56848"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80925"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","SPHK2"],["bp:entityReference_http://identifiers.org/uniprot/Q9NRA0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 399 399 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","399"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 387 387 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","387"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:organism","Sphingosine kinase 2"],["bp:displayName","SPHK2_HUMAN"],["bp:name","2.7.1.91"],["bp:name","SPHK2"],["bp:name","SK 2"],["bp:name","SPK 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_56848"],["bp:comment","FUNCTION: Catalyzes the phosphorylation of sphingosine to formsphingosine 1-phosphate (SPP), a lipid mediator with both intra-and extracellular functions. Also acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides.{ECO:0000269|PubMed:19168031}.CATALYTIC ACTIVITY: ATP + a sphingoid base = ADP + a sphingoidbase 1-phosphate. {ECO:0000269|PubMed:10751414}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Inhibited by sulfatide.{ECO:0000269|PubMed:19168031}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=3.4 uM for sphingosine {ECO:0000269|PubMed:10751414};pH dependence:Optimum pH is 7.5. {ECO:0000269|PubMed:10751414};SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Membrane.SUBCELLULAR LOCATION: Isoform 2: Lysosome membrane.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9NRA0-1; Sequence=Displayed;Name=2;IsoId=Q9NRA0-2; Sequence=VSP_006217;Name=3;IsoId=Q9NRA0-3; Sequence=VSP_006217, VSP_006218;Name=4;IsoId=Q9NRA0-4; Sequence=VSP_046910;Note=No experimental confirmation available.;Name=5;IsoId=Q9NRA0-5; Sequence=VSP_047721, VSP_047722; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06157_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16804"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006723355"],["bp:comment","SPHK2_HUMAN Reviewed; 654 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_56848"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80925"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","SPHK2"],["bp:entityReference_http://identifiers.org/uniprot/Q9NRA0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 399 399 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","399"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 387 387 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","387"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:organism","Sphingosine kinase 2"],["bp:displayName","SPHK2_HUMAN"],["bp:name","2.7.1.91"],["bp:name","SPHK2"],["bp:name","SK 2"],["bp:name","SPK 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_56848"],["bp:comment","FUNCTION: Catalyzes the phosphorylation of sphingosine to formsphingosine 1-phosphate (SPP), a lipid mediator with both intra-and extracellular functions. Also acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides.{ECO:0000269|PubMed:19168031}.CATALYTIC ACTIVITY: ATP + a sphingoid base = ADP + a sphingoidbase 1-phosphate. {ECO:0000269|PubMed:10751414}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Inhibited by sulfatide.{ECO:0000269|PubMed:19168031}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=3.4 uM for sphingosine {ECO:0000269|PubMed:10751414};pH dependence:Optimum pH is 7.5. {ECO:0000269|PubMed:10751414};SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Membrane.SUBCELLULAR LOCATION: Isoform 2: Lysosome membrane.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9NRA0-1; Sequence=Displayed;Name=2;IsoId=Q9NRA0-2; Sequence=VSP_006217;Name=3;IsoId=Q9NRA0-3; Sequence=VSP_006217, VSP_006218;Name=4;IsoId=Q9NRA0-4; Sequence=VSP_046910;Note=No experimental confirmation available.;Name=5;IsoId=Q9NRA0-5; Sequence=VSP_047721, VSP_047722; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06157_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16804"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006723355"],["bp:comment","SPHK2_HUMAN Reviewed; 654 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_56848"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80925"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80924"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80924"]]}},{"data":{"id":"Protein_26c29bc263b3ec949832ea6c307b3fe1","class":"macromolecule","label":"CHUK","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_26c29bc263b3ec949832ea6c307b3fe1.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":1143.332,"y":632.89703,"w":48,"h":25},"metadata":[["bp:displayName","IKKs"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80758"]]],["bp:entityReference_http://identifiers.org/uniprot/O15111",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 23 23 Phosphothreonine; by PKB/AKT1 and SGK1."],["bp:featureLocation",[["bp:sequencePosition","23"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES O-acetylthreonine"],["bp:term","O-acetylthreonine"]]],["bp:comment","MOD_RES 179 179 O-acetylthreonine; by Yersinia yopJ."],["bp:featureLocation",[["bp:sequencePosition","179"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:standardName","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:organism","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:displayName","IKKA_HUMAN"],["bp:name","Transcription factor 16"],["bp:name","TCF16"],["bp:name","CHUK"],["bp:name","IKK-alpha"],["bp:name","TCF-16"],["bp:name","Nuclear factor NF-kappa-B inhibitor kinase alpha"],["bp:name","I-kappa-B kinase alpha"],["bp:name","Conserved helix-loop-helix ubiquitous kinase"],["bp:name","IKKA"],["bp:name","I-kappa-B kinase 1"],["bp:name","IkappaB kinase"],["bp:name","IkBKA"],["bp:name","IKK-A"],["bp:name","IKK1"],["bp:name","2.7.11.10"],["bp:name","NFKBIKA"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-27526N_identity"],["bp:comment","IKKA_HUMAN Reviewed; 745 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1147"],["bp:comment","REPLACED ProteinRef_CHUK__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001269"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_461"],["bp:comment","REPLACED http://identifiers.org/ncbigene/1147"],["bp:comment","REPLACED ProteinRef_CHUK__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_O15111_identity"],["bp:comment","FUNCTION: Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimulisuch as inflammatory cytokines, bacterial or viral products, DNAdamages or other cellular stresses. Acts as part of the canonicalIKK complex in the conventional pathway of NF-kappa-B activationand phosphorylates inhibitors of NF-kappa-B on serine residues.These modifications allow polyubiquitination of the inhibitors andsubsequent degradation by the proteasome. In turn, free NF-kappa-Bis translocated into the nucleus and activates the transcriptionof hundreds of genes involved in immune response, growth control,or protection against apoptosis. Negatively regulates the pathwayby phosphorylating the scaffold protein TAXBP1 and thus promotingthe assembly of the A20/TNFAIP3 ubiquitin-editing complex(composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH andRNF11). Therefore, CHUK plays a key role in the negative feedbackof NF-kappa-B canonical signaling to limit inflammatory geneactivation. As part of the non-canonical pathway of NF-kappa-Bactivation, the MAP3K14-activated CHUK/IKKA homodimerphosphorylates NFKB2/p100 associated with RelB, inducing itsproteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genesencoding molecules involved in B-cell survival and lymphoidorganogenesis. Participates also in the negative feedback of thenon-canonical NF-kappa-B signaling pathway by phosphorylating anddestabilizing MAP3K14/NIK. Within the nucleus, phosphorylatesCREBBP and consequently increases both its transcriptional andhistone acetyltransferase activities. Modulates chromatinaccessibility at NF-kappa-B-responsive promoters byphosphorylating histones H3 at 'Ser-10' that are subsequentlyacetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates theCREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 andmay regulate this pro-apoptotic transcription factor(PubMed:15084260). {ECO:0000269|PubMed:12789342,ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:17434128,ECO:0000269|PubMed:20434986, ECO:0000269|PubMed:20501937,ECO:0000269|PubMed:21765415}.CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-Bphosphoprotein].ENZYME REGULATION: Activated when phosphorylated and inactivatedwhen dephosphorylated.SUBUNIT: Component of the I-kappa-B-kinase (IKK) core complexconsisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits.The IKK core complex seems to associate with regulatory or adapterproteins to form a IKK-signalosome holo-complex (PubMed:10195894,PubMed:12612076). The IKK complex associates with TERF2IP/RAP1,leading to promote IKK-mediated phosphorylation of RELA/p65 (Bysimilarity). Part of a complex composed of NCOA2, NCOA3,CHUK/IKKA, IKBKB, IKBKG and CREBBP (PubMed:11971985). Part of a70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA,RELA, IKBKAP and MAP3K14 (PubMed:9751059). Directly interacts withTRPC4AP (By similarity). May interact with TRAF2(PubMed:19150425). Interacts with NALP2 (PubMed:15456791). Mayinteract with MAVS/IPS1 (PubMed:16177806). Interacts with ARRB1and ARRB2 (PubMed:15173580). Interacts with NLRC5; prevents CHUKphosphorylation and kinase activity (PubMed:20434986). Interactswith PIAS1; this interaction induces PIAS1 phosphorylation(PubMed:17540171). Interacts with ZNF268 isoform 2; theinteraction is further increased in a TNF-alpha-dependent manner(PubMed:23091055). Interacts with FOXO3 (PubMed:15084260).Interacts with IFIT5; the interaction synergizes the recruitmentof IKK to MAP3K7 and enhances IKK phosphorylation(PubMed:26334375). {ECO:0000250|UniProtKB:Q60680,ECO:0000269|PubMed:10195894, ECO:0000269|PubMed:11971985,ECO:0000269|PubMed:12612076, ECO:0000269|PubMed:15084260,ECO:0000269|PubMed:15173580, ECO:0000269|PubMed:15456791,ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:17540171,ECO:0000269|PubMed:19150425, ECO:0000269|PubMed:20434986,ECO:0000269|PubMed:23091055, ECO:0000269|PubMed:26334375,ECO:0000269|PubMed:9751059}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12789342}.Nucleus {ECO:0000269|PubMed:12789342}. Note=Shuttles between thecytoplasm and the nucleus.TISSUE SPECIFICITY: Widely expressed.DOMAIN: The kinase domain is located in the N-terminal region. Theleucine zipper is important to allow homo- and hetero-dimerization. At the C-terminal region is located the regionresponsible for the interaction with NEMO/IKBKG.{ECO:0000269|PubMed:18626576}.PTM: Phosphorylated by MAP3K14/NIK, AKT and to a lesser extent byMEKK1, and dephosphorylated by PP2A. Autophosphorylated.PTM: (Microbial infection) Acetylation of Thr-179 by Yersinia yopJprevents phosphorylation and activation, thus blocking the I-kappa-B signaling pathway. {ECO:0000269|PubMed:17116858}.DISEASE: Cocoon syndrome (COCOS) [MIM:613630]: A lethal syndromecharacterized by multiple fetal malformations including defectiveface and seemingly absent limbs, which are bound to the trunk andencased under the skin. {ECO:0000269|PubMed:20961246}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. I-kappa-B kinase subfamily.{ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/chuk/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_CHUK__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1147"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-5773277_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80756"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80756"]]}},{"data":{"id":"Protein_057774005557cf4d75730302aebee51c","class":"macromolecule","label":"PRKCZ","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":382.72626,"y":482.41086,"w":48,"h":25},"metadata":[["bp:displayName","PKC zeta"],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q05513"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 591 591 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","591"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 410 410 Phosphothreonine; by PDPK1 and PI3K."],["bp:featureLocation","MOD_RES 410 410 Phosphothreonine; by PDPK1 and PI3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 410 410 Phosphothreonine; by PDPK1 and PI3K."],["bp:featureLocation","MOD_RES 410 410 Phosphothreonine; by PDPK1 and PI3K."]]],["bp:standardName","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:organism","Protein kinase C zeta type"],["bp:displayName","KPCZ_HUMAN"],["bp:name","nPKC-zeta"],["bp:name","PRKCZ"],["bp:name","2.7.11.13"],["bp:name","PKC2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_457"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01504_identity"],["bp:comment","REPLACED ProteinRef_PRKCZ__9606"],["bp:comment","FUNCTION: Calcium- and diacylglycerol-independentserine/threonine-protein kinase that functions inphosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activatedprotein (MAP) kinase cascade, and is involved in NF-kappa-Bactivation, mitogenic signaling, cell proliferation, cellpolarity, inflammatory response and maintenance of long-termpotentiation (LTP). Upon lipopolysaccharide (LPS) treatment inmacrophages, or following mitogenic stimuli, functions downstreamof PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascadeindependently of RAF1 activation. Required for insulin-dependentactivation of AKT3, but may function as an adapter rather than adirect activator. Upon insulin treatment may act as a downstreameffector of PI3K and contribute to the activation of translocationof the glucose transporter SLC2A4/GLUT4 and subsequent glucosetransport in adipocytes. In EGF-induced cells, binds and activatesMAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity andcan activate JUN promoter through MEF2C. Through binding withSQSTM1/p62, functions in interleukin-1 signaling and activation ofNF-kappa-B with the specific adapters RIPK1 and TRAF6.Participates in TNF-dependent transactivation of NF-kappa-B byphosphorylating and activating IKBKB kinase, which in turn leadsto the degradation of NF-kappa-B inhibitors. In migratingastrocytes, forms a cytoplasmic complex with PARD6A and isrecruited by CDC42 to function in the establishment of cellpolarity along with the microtubule motor and dynein. Inassociation with FEZ1, stimulates neuronal differentiation in PC12cells. In the inflammatory response, is required for the T-helper2 (Th2) differentiation process, including interleukin production,efficient activation of JAK1 and the subsequent phosphorylationand nuclear translocation of STAT6. May be involved in developmentof allergic airway inflammation (asthma), a process dependent onTh2 immune response. In the NF-kappa-B-mediated inflammatoryresponse, can relieve SETD6-dependent repression of NF-kappa-Btarget genes by phosphorylating the RELA subunit at 'Ser-311'.Necessary and sufficient for LTP maintenance in hippocampal CA1pyramidal cells. In vein endothelial cells treated with theoxidant peroxynitrite, phosphorylates STK11 leading to nuclearexport of STK11, subsequent inhibition of PI3K/Akt signaling, andincreased apoptosis. Phosphorylates VAMP2 in vitro(PubMed:17313651). {ECO:0000269|PubMed:11035106,ECO:0000269|PubMed:12162751, ECO:0000269|PubMed:15084291,ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:9447975}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit anelevated basal enzymatic activity (that may be due to theinteraction with SMG1 or SQSTM1) and are not regulated bydiacylglycerol, phosphatidylserine, phorbol esters or calciumions. Two specific sites, Thr-410 (activation loop of the kinasedomain) and Thr-560 (turn motif), need to be phosphorylated forits full activation. Phosphatidylinositol 3,4,5-trisphosphatemight be a physiological activator (By similarity). {ECO:0000250}.SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Formsanother ternary complex with SQSTM1 and GABRR3. Forms a complexwith SQSTM1 and MAP2K5 (By similarity). Interacts with PARD6A,PARD6B, PARD6G and SQSTM1. Part of a complex with PARD3, PARD6A orPARD6B or PARD6G and CDC42 or RAC1. Interacts with ADAP1/CENTA1.Forms a ternary complex composed of SQSTM1 and PAWR. Interactsdirectly with SQSTM1 (Probable). Interacts with IKBKB. Interacts(via the protein kinase domain) with WWC1. Forms a tripartitecomplex with WWC1 and DDR1, but predominantly in the absence ofcollagen. Component of the Par polarity complex, composed of atleast phosphorylated PRKCZ, PARD3 and TIAM1. Interacts with PDPK1(via N-terminal region). Interacts with WDFY2 (via WD repeats 1-3)(PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). Forms acomplex with WDFY2 and VAMP2 (PubMed:17313651).{ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:11260256, ECO:0000269|PubMed:11755531,ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:12234671,ECO:0000269|PubMed:12887891, ECO:0000269|PubMed:12893243,ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:20332120,ECO:0000269|PubMed:9566925, ECO:0000305}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:9566925}. Endosome{ECO:0000269|PubMed:9566925}. Cell junction{ECO:0000269|PubMed:7597083}. Note=In the retina, localizes in theterminals of the rod bipolar cells. Associates with endosomes.Presence of KRIT1, CDH5 and RAP1B is required for its localizationto the cell junction. Colocalizes with VAMP2 and WDFY2 inintracellular vesicles. {ECO:0000269|PubMed:17313651}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=Q05513-1; Sequence=Displayed;Name=2;IsoId=Q05513-2; Sequence=VSP_041904;Name=3;IsoId=Q05513-3; Sequence=VSP_046347;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent inlung, kidney and testis.DOMAIN: The PB1 domain mediate mutually exclusive interactionswith SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}.DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).{ECO:0000269|PubMed:12887891}.PTM: CDH5 is required for its phosphorylation at Thr-410.Phosphorylated by protein kinase PDPK1; phosphorylation isinhibited by the apoptotic C-terminal cleavage product of PKN2.Phosphorylation at Thr-410 by PI3K activates the kinase.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15314172,ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361}.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA78813.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5590"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002735"],["bp:comment","REPLACED ProteinRef_PRKCZ__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5590"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-1"],["bp:comment","REPLACED ProteinRef_PRKCZ__40674"],["bp:comment","KPCZ_HUMAN Reviewed; 592 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9156"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_9156"]]}},{"data":{"id":"BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":571.695,"y":348.5379,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","sphingomyelin"],["bp:entityReference_#SmallMoleculeReference_218aa1729347498918c05a239eb03b03",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20069"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21951"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21957"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:evidence",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21957"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:evidence",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21957"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:evidence",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21957"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:evidence",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21957"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:evidence",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21957"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:evidence",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21957"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:right",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21957"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:left",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21957"],["bp:evidenceCode",[["bp:xref",[["bp:id","ECO:0000201"],["bp:db","evidence code ontology"]]],["bp:term","inferred from sequence orthology"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21950"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_21950"]]}},{"data":{"id":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1248.1545,"y":513.6086399999999,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","cIAP2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q13489",[["bp:standardName","Baculoviral IAP repeat-containing protein 3"],["bp:xref",[["bp:id","Q13489"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","BIRC3"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","BIRC3"],["bp:db","hgnc symbol"]]],["bp:displayName","BIRC3_HUMAN"],["bp:name","Apoptosis inhibitor 2"],["bp:name","TNFR2-TRAF-signaling complex protein 1"],["bp:name","hIAP1"],["bp:name","Cellular inhibitor of apoptosis 2"],["bp:name","RING finger protein 49"],["bp:name","C-IAP2"],["bp:name","RNF49"],["bp:name","RING-type E3 ubiquitin transferase BIRC3"],["bp:name","Inhibitor of apoptosis protein 1"],["bp:name","IAP homolog C"],["bp:name","BIRC3"],["bp:name","API2"],["bp:name","2.3.2.27"],["bp:name","MIHC"],["bp:name","hIAP-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-33720N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016873132"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_330"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_330"],["bp:comment","FUNCTION: Multi-functional protein which regulates not onlycaspases and apoptosis, but also modulates inflammatory signalingand immunity, mitogenic kinase signaling and cell proliferation,as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates bothcanonical and non-canonical NF-kappa-B signaling by acting inopposite directions: acts as a positive regulator of the canonicalpathway and suppresses constitutive activation of non-canonicalNF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4,CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an importantregulator of innate immune signaling via regulation of Toll-likereceptors (TLRs), Nodlike receptors (NLRs) and RIG-I likereceptors (RLRs), collectively referred to as pattern recognitionreceptors (PRRs). Protects cells from spontaneous formation of theripoptosome, a large multi-protein complex that has the capabilityto kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation byubiquitinating RIPK1 and CASP8. {ECO:0000269|PubMed:21931591,ECO:0000269|PubMed:23453969}.CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugatingenzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptorprotein]-L-lysine. {ECO:0000269|PubMed:21931591,ECO:0000269|PubMed:23453969}.ENZYME REGULATION: USP19 regulates the stability of BIRC3/c-IAP2by preventing its ubiquitination. {ECO:0000269|PubMed:21849505}.SUBUNIT: Interacts with DIABLO/SMAC and with PRSS25; theseinteractions inhibit apoptotic suppressor activity. The BIR motifsregion interacts with TNF receptor associated factors 1 and 2(TRAF1 and TRAF2) to form a heteromeric complex, which is thenrecruited to the tumor necrosis factor receptor 2 (TNFR2).Interaction with TRAF2 is required for ubiquitination of IKBKE,degradation of NFKBIA and activation of NF-kappa-B. Interacts withRIP1, RIP2, RIP3, RIP4 and USP19. {ECO:0000269|PubMed:21849505,ECO:0000269|PubMed:21931591}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15665297}.Nucleus {ECO:0000269|PubMed:15665297}.TISSUE SPECIFICITY: Highly expressed in fetal lung, and kidney. Inthe adult, expression is mainly seen in lymphoid tissues,including spleen, thymus and peripheral blood lymphocytes.PTM: Auto-ubiquitinated and degraded by the proteasome inapoptotic cells.DISEASE: Note=A chromosomal aberration involving BIRC3 isrecurrent in low-grade mucosa-associated lymphoid tissue (MALTlymphoma). Translocation t(11;18)(q21;q21) with MALT1. Thistranslocation is found in approximately 50% of cytogeneticallyabnormal low-grade MALT lymphoma.SIMILARITY: Belongs to the IAP family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BIRC3ID239.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/birc3/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_892007"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13489_identity"],["bp:comment","BIRC3_HUMAN Reviewed; 604 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001156"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1559"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80793"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","TRAF2"],["bp:cellularLocation","TRAF2"],["bp:entityReference_http://identifiers.org/uniprot/Q12933","TRAF2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1580"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80795"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:left","true"],["bp:left","true"],["bp:left","true"],["bp:left","true"],["bp:left","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80791"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80791"]]}},{"data":{"id":"Protein_7df2a04ff77beff2263dd05591458a72","class":"macromolecule","label":"EIF2A","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":686.89813,"y":41.312965,"w":48,"h":25},"metadata":[["bp:displayName","EIF2A"],["bp:entityReference_http://identifiers.org/uniprot/Q9BY44",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 506 506 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","506"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 518 518 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","518"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:organism","Eukaryotic translation initiation factor 2A"],["bp:displayName","EIF2A_HUMAN"],["bp:name","65 kDa eukaryotic translation initiation factor 2A"],["bp:name","EIF2A"],["bp:name","eIF-2A"],["bp:name","Eukaryotic translation initiation factor 2A, N-terminally processed"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NFM1"],["bp:comment","EIF2A_HUMAN Reviewed; 585 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_83939"],["bp:comment","FUNCTION: Functions in the early steps of protein synthesis of asmall number of specific mRNAs. Acts by directing the binding ofmethionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF-2 complex, it binds methionyl-tRNAi to 40 S subunits in a codon-dependent manner, whereas the eIF-2 complex binds methionyl-tRNAito 40 S subunits in a GTP-dependent manner. May act by impigingthe expression of specific proteins.{ECO:0000269|PubMed:12133843}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q9BY44-1; Sequence=Displayed;Name=2;IsoId=Q9BY44-2; Sequence=VSP_024975, VSP_024976;Note=No experimental confirmation available.;Name=3;IsoId=Q9BY44-3; Sequence=VSP_056047;Note=No experimental confirmation available.;Name=4;IsoId=Q9BY44-4; Sequence=VSP_056048;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Widely expressed. Expressed at higher level inpancreas, heart, brain and placenta.{ECO:0000269|PubMed:12133843}.SIMILARITY: Belongs to the WD repeat EIF2A family. {ECO:0000305}.CAUTION: Was initially thought to constitute the ortholog ofprokaryotic IF-2 (infB) protein. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAK14926.1; Type=Erroneous initiation; Evidence={ECO:0000305};Sequence=AAM83402.1; Type=Frameshift; Positions=82, 90; Evidence={ECO:0000305};Sequence=AAQ13506.1; Type=Frameshift; Positions=513; Evidence={ECO:0000305};Sequence=AAQ13612.1; Type=Erroneous initiation; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-40272N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011511526"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_83939"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_5355"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9BY44-2"]]],["bp:name","eIF2A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"]]}},{"data":{"id":"Protein_f5c36b1f964edd8213ea3babcf3d02e1","class":"macromolecule","label":"SMPD3","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_f5c36b1f964edd8213ea3babcf3d02e1.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":779.4574,"y":364.57132,"w":48,"h":25},"metadata":[["bp:displayName","Neutral sphingomyelinase II"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80700"]]],["bp:entityReference_http://identifiers.org/uniprot/Q9NY59",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q9NY59"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 291 291 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:organism","Sphingomyelin phosphodiesterase 3"],["bp:displayName","NSMA2_HUMAN"],["bp:name","Neutral sphingomyelinase 2"],["bp:name","SMPD3"],["bp:name","Neutral sphingomyelinase II"],["bp:name","nSMase-2"],["bp:name","nSMase2"],["bp:name","3.1.4.12"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_55512"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-60431N_identity"],["bp:comment","FUNCTION: Catalyzes the hydrolysis of sphingomyelin to formceramide and phosphocholine. Ceramide mediates numerous cellularfunctions, such as apoptosis and growth arrest, and is capable ofregulating these 2 cellular events independently. Also hydrolyzessphingosylphosphocholine. Regulates the cell cycle by acting as agrowth suppressor in confluent cells. Probably acts as a regulatorof postnatal development and participates in bone and dentinmineralization. {ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:14741383, ECO:0000269|PubMed:15051724}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:15051724};ENZYME REGULATION: Activated by unsaturated fatty acids andphosphatidylserine. {ECO:0000269|PubMed:10823942}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 7.5.;PATHWAY: Lipid metabolism; sphingolipid metabolism.SUBCELLULAR LOCATION: Golgi apparatus membrane{ECO:0000269|PubMed:10823942}; Lipid-anchor{ECO:0000269|PubMed:10823942}. Cell membrane{ECO:0000269|PubMed:15051724}; Lipid-anchor{ECO:0000269|PubMed:15051724}. Note=May localize to detergent-resistant subdomains of Golgi membranes of hypothalamicneurosecretory neurons (PubMed:10823942). Localizes to plasmamembrane in confluent contact-inhaibited cells (PubMed:15051724).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q9NY59-1; Sequence=Displayed;Name=2;IsoId=Q9NY59-2; Sequence=VSP_054334;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Predominantly expressed in brain.{ECO:0000269|PubMed:10823942}.DEVELOPMENTAL STAGE: Up-regulated during G0/G1 phases.PTM: Palmitoylated, palmitoylation-deficient proteins are targetedfor lysosomal degradation. {ECO:0000250}.SIMILARITY: Belongs to the neutral sphingomyelinase family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","NSMA2_HUMAN Reviewed; 655 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_55512"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80699"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80699"]]}},{"data":{"id":"Protein_3c65bb885bc05136445eb41a1409f50c","class":"macromolecule","label":"SPHK2","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":134.63306,"y":198.3717,"w":48,"h":25},"metadata":[["bp:displayName","SPHK2"],["bp:entityReference_http://identifiers.org/uniprot/Q9NRA0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 399 399 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","399"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 387 387 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","387"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 393 393 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","393"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:organism","Sphingosine kinase 2"],["bp:displayName","SPHK2_HUMAN"],["bp:name","2.7.1.91"],["bp:name","SPHK2"],["bp:name","SK 2"],["bp:name","SPK 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_56848"],["bp:comment","FUNCTION: Catalyzes the phosphorylation of sphingosine to formsphingosine 1-phosphate (SPP), a lipid mediator with both intra-and extracellular functions. Also acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides.{ECO:0000269|PubMed:19168031}.CATALYTIC ACTIVITY: ATP + a sphingoid base = ADP + a sphingoidbase 1-phosphate. {ECO:0000269|PubMed:10751414}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Inhibited by sulfatide.{ECO:0000269|PubMed:19168031}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=3.4 uM for sphingosine {ECO:0000269|PubMed:10751414};pH dependence:Optimum pH is 7.5. {ECO:0000269|PubMed:10751414};SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Membrane.SUBCELLULAR LOCATION: Isoform 2: Lysosome membrane.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9NRA0-1; Sequence=Displayed;Name=2;IsoId=Q9NRA0-2; Sequence=VSP_006217;Name=3;IsoId=Q9NRA0-3; Sequence=VSP_006217, VSP_006218;Name=4;IsoId=Q9NRA0-4; Sequence=VSP_046910;Note=No experimental confirmation available.;Name=5;IsoId=Q9NRA0-5; Sequence=VSP_047721, VSP_047722; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06157_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16804"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006723355"],["bp:comment","SPHK2_HUMAN Reviewed; 654 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_56848"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_71137"]]}},{"data":{"id":"Protein_ae6bb14892c00e5f2d82a78899eabf25","class":"macromolecule","label":"BCL2","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_ae6bb14892c00e5f2d82a78899eabf25.info.1","class":"state variable","state":{"variable":"70","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":34.192059,"y":524.2937999999999,"w":48,"h":25},"metadata":[["bp:displayName","BCL2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11512"],["bp:featureLocation",[["bp:sequencePosition","70"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11513"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P10415",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P10415"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P10415"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P10415"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P10415"]]],["bp:standardName","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:organism","Apoptosis regulator Bcl-2"],["bp:displayName","BCL2_HUMAN"],["bp:name","BCL2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YSW_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10415-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000624"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q07813"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_596"],["bp:comment","REPLACED ProteinRef_BCL2__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01045_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1043N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10415_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_596"],["bp:comment","REPLACED ProteinRef_BCL2__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000648"],["bp:comment","FUNCTION: Suppresses apoptosis in a variety of cell systemsincluding factor-dependent lymphohematopoietic and neural cells.Regulates cell death by controlling the mitochondrial membranepermeability. Appears to function in a feedback loop system withcaspases. Inhibits caspase activity either by preventing therelease of cytochrome c from the mitochondria and/or by binding tothe apoptosis-activating factor (APAF-1). May attenuateinflammation by impairing NLRP1-inflammasome activation, henceCASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18570871}.SUBUNIT: Forms homodimers, and heterodimers with BAX, BAD, BAK andBcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2motifs, and is necessary for anti-apoptotic activity(PubMed:8183370). Interacts with EI24 (By similarity). Alsointeracts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2.Binding to FKBP8 seems to target BCL2 to the mitochondria andprobably interferes with the binding of BCL2 to its targets.Interacts with BAG1 in an ATP-dependent manner. Interacts withRAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts(via the BH4 domain) with EGLN3; the interaction prevents theformation of the BAX-BCL2 complex and inhibits the anti-apoptoticactivity of BCL2. Interacts with G0S2; this interaction alsoprevents the formation of the anti-apoptotic BAX-BCL2 complex.Interacts with BOP. Interacts with the SCF(FBXO10) complex.Interacts (via the loop between motifs BH4 and BH3) with NLRP1(via LRR repeats), but not with NLRP2, NLRP3, NLRP4, PYCARD, norMEFV (PubMed:17418785). {ECO:0000250, ECO:0000269|PubMed:11463391,ECO:0000269|PubMed:12901880, ECO:0000269|PubMed:15547950,ECO:0000269|PubMed:15733859, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:17090549, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:19228691, ECO:0000269|PubMed:19706769,ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:23055042,ECO:0000269|PubMed:23431138, ECO:0000269|PubMed:8183370,ECO:0000269|PubMed:8668206, ECO:0000269|PubMed:9305631}.SUBCELLULAR LOCATION: Mitochondrion outer membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Nucleus membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Alpha;IsoId=P10415-1; Sequence=Displayed;Name=Beta;IsoId=P10415-2; Sequence=VSP_000512;Note=Ref.1 (AAA51814) sequence is in conflict in position:199:L->S. {ECO:0000305};TISSUE SPECIFICITY: Expressed in a variety of tissues.DOMAIN: BH1 and BH2 domains are required for the interaction withBAX and for anti-apoptotic activity. {ECO:0000269|PubMed:8183370}.DOMAIN: The BH4 motif is required for anti-apoptotic activity andfor interaction with RAF1 and EGLN3.DOMAIN: The loop between motifs BH4 and BH3 is required for theinteraction with NLRP1. {ECO:0000269|PubMed:17418785}.PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation onSer-70 by PKC is required for the anti-apoptosis activity andoccurs during the G2/M phase of the cell cycle. In the absence ofgrowth factors, BCL2 appears to be phosphorylated by other proteinkinases such as ERKs and stress-activated kinases. Phosphorylatedby MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulatesstarvation-induced autophagy. Dephosphorylated by proteinphosphatase 2A (PP2A) (By similarity). {ECO:0000250}.PTM: Proteolytically cleaved by caspases during apoptosis. Thecleaved protein, lacking the BH4 motif, has pro-apoptoticactivity, causes the release of cytochrome c into the cytosolpromoting further caspase activity. {ECO:0000269|PubMed:9395403}.PTM: Monoubiquitinated by PRKN, leading to increase its stability.Ubiquitinated by SCF(FBXO10), leading to its degradation by theproteasome. {ECO:0000269|PubMed:20889974,ECO:0000269|PubMed:23431138}.DISEASE: Note=A chromosomal aberration involving BCL2 has beenfound in chronic lymphatic leukemia. Translocationt(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutationsfound in non-Hodgkin lymphomas carrying the chromosomaltranslocation could be attributed to the Ig somatic hypermutationmechanism resulting in nucleotide transitions.{ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL2ID49.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bcl2/\";WEB RESOURCE: Name=Wikipedia; Note=Bcl-2 entry;URL=\"https://en.wikipedia.org/wiki/Bcl-2\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_925"],["bp:comment","REPLACED http://identifiers.org/ncbigene/596"],["bp:comment","BCL2_HUMAN Reviewed; 239 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80906"]]}},{"data":{"id":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":256.4459,"y":353.4651,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80719"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Free Fatty acid"],["bp:entityReference_#SmallMoleculeReference_1438d1171ba27edc8c609fd96d7b2a8c",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80717"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80717"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80721"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Sphingosine"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:16393",[["bp:standardName","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:chemicalFormula","C18H37NO2"],["bp:displayName","sphingosine"],["bp:name","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-ene-1-ol"],["bp:name","D-(+)-erythro-1,3-dihydroxy-2-amino-4-trans-octadecene"],["bp:name","Sphingoid"],["bp:name","trans-4-sphingenine"],["bp:name","(4E)-sphingenine"],["bp:name","(2S,3R,E)-2-aminooctadec-4-ene-1,3-diol"],["bp:name","sphingosin"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)CO"],["bp:name","(E)-2-amino-4-octadecan-1,3-diol"],["bp:name","Sph"],["bp:name","C18 sphingosine"],["bp:name","(4E)-sphing-4-enine"],["bp:name","D-erythro-sphingosine"],["bp:name","2-amino-4-octadecene-1,3-diol"],["bp:name","Sphingosine d18:1"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol"],["bp:name","(2S,3R)-(E)-2-amino-1,3-dihydroxy-4-octadecene"],["bp:name","Sphingosine"],["bp:name","(E)-D-erythro-4-octadecene-1,3-diol"],["bp:name","Sphingenine"],["bp:name","trans-D-erythro-2-amino-4-octadecene-1,3-diol"],["bp:name","Sphing-4-enine"],["bp:name","C18H37NO2"],["bp:molecularWeight","299.4919"],["bp:comment","is_enantiomer_of CHEBI:46967"],["bp:comment","is_conjugate_base_of CHEBI:57756"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00252"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33981"],["bp:comment","has_role CHEBI:75771"],["bp:comment","is_a CHEBI:26743"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00319.eref"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB03203"],["bp:comment","A sphing-4-enine in which the double bond is trans."],["bp:structure","A sphing-4-enine in which the double bond is trans."]]],["bp:name","sphingosine"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80720"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Sphingosine"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:16393",[["bp:standardName","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:chemicalFormula","C18H37NO2"],["bp:displayName","sphingosine"],["bp:name","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-ene-1-ol"],["bp:name","D-(+)-erythro-1,3-dihydroxy-2-amino-4-trans-octadecene"],["bp:name","Sphingoid"],["bp:name","trans-4-sphingenine"],["bp:name","(4E)-sphingenine"],["bp:name","(2S,3R,E)-2-aminooctadec-4-ene-1,3-diol"],["bp:name","sphingosin"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)CO"],["bp:name","(E)-2-amino-4-octadecan-1,3-diol"],["bp:name","Sph"],["bp:name","C18 sphingosine"],["bp:name","(4E)-sphing-4-enine"],["bp:name","D-erythro-sphingosine"],["bp:name","2-amino-4-octadecene-1,3-diol"],["bp:name","Sphingosine d18:1"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol"],["bp:name","(2S,3R)-(E)-2-amino-1,3-dihydroxy-4-octadecene"],["bp:name","Sphingosine"],["bp:name","(E)-D-erythro-4-octadecene-1,3-diol"],["bp:name","Sphingenine"],["bp:name","trans-D-erythro-2-amino-4-octadecene-1,3-diol"],["bp:name","Sphing-4-enine"],["bp:name","C18H37NO2"],["bp:molecularWeight","299.4919"],["bp:comment","is_enantiomer_of CHEBI:46967"],["bp:comment","is_conjugate_base_of CHEBI:57756"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00252"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33981"],["bp:comment","has_role CHEBI:75771"],["bp:comment","is_a CHEBI:26743"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00319.eref"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB03203"],["bp:comment","A sphing-4-enine in which the double bond is trans."],["bp:structure","A sphing-4-enine in which the double bond is trans."]]],["bp:name","sphingosine"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80720"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Sphingosine"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:16393",[["bp:standardName","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:chemicalFormula","C18H37NO2"],["bp:displayName","sphingosine"],["bp:name","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-ene-1-ol"],["bp:name","D-(+)-erythro-1,3-dihydroxy-2-amino-4-trans-octadecene"],["bp:name","Sphingoid"],["bp:name","trans-4-sphingenine"],["bp:name","(4E)-sphingenine"],["bp:name","(2S,3R,E)-2-aminooctadec-4-ene-1,3-diol"],["bp:name","sphingosin"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)CO"],["bp:name","(E)-2-amino-4-octadecan-1,3-diol"],["bp:name","Sph"],["bp:name","C18 sphingosine"],["bp:name","(4E)-sphing-4-enine"],["bp:name","D-erythro-sphingosine"],["bp:name","2-amino-4-octadecene-1,3-diol"],["bp:name","Sphingosine d18:1"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol"],["bp:name","(2S,3R)-(E)-2-amino-1,3-dihydroxy-4-octadecene"],["bp:name","Sphingosine"],["bp:name","(E)-D-erythro-4-octadecene-1,3-diol"],["bp:name","Sphingenine"],["bp:name","trans-D-erythro-2-amino-4-octadecene-1,3-diol"],["bp:name","Sphing-4-enine"],["bp:name","C18H37NO2"],["bp:molecularWeight","299.4919"],["bp:comment","is_enantiomer_of CHEBI:46967"],["bp:comment","is_conjugate_base_of CHEBI:57756"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00252"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33981"],["bp:comment","has_role CHEBI:75771"],["bp:comment","is_a CHEBI:26743"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00319.eref"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB03203"],["bp:comment","A sphing-4-enine in which the double bond is trans."],["bp:structure","A sphing-4-enine in which the double bond is trans."]]],["bp:name","sphingosine"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80720"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Sphingosine"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:16393",[["bp:standardName","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:xref","(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol"],["bp:chemicalFormula","C18H37NO2"],["bp:displayName","sphingosine"],["bp:name","(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-ene-1-ol"],["bp:name","D-(+)-erythro-1,3-dihydroxy-2-amino-4-trans-octadecene"],["bp:name","Sphingoid"],["bp:name","trans-4-sphingenine"],["bp:name","(4E)-sphingenine"],["bp:name","(2S,3R,E)-2-aminooctadec-4-ene-1,3-diol"],["bp:name","sphingosin"],["bp:name","CCCCCCCCCCCCC\\\\C=C\\\\[C@@H](O)[C@@H](N)CO"],["bp:name","(E)-2-amino-4-octadecan-1,3-diol"],["bp:name","Sph"],["bp:name","C18 sphingosine"],["bp:name","(4E)-sphing-4-enine"],["bp:name","D-erythro-sphingosine"],["bp:name","2-amino-4-octadecene-1,3-diol"],["bp:name","Sphingosine d18:1"],["bp:name","(2S,3R,4E)-2-amino-4-octadecene-1,3-diol"],["bp:name","(2S,3R)-(E)-2-amino-1,3-dihydroxy-4-octadecene"],["bp:name","Sphingosine"],["bp:name","(E)-D-erythro-4-octadecene-1,3-diol"],["bp:name","Sphingenine"],["bp:name","trans-D-erythro-2-amino-4-octadecene-1,3-diol"],["bp:name","Sphing-4-enine"],["bp:name","C18H37NO2"],["bp:molecularWeight","299.4919"],["bp:comment","is_enantiomer_of CHEBI:46967"],["bp:comment","is_conjugate_base_of CHEBI:57756"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00252"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33981"],["bp:comment","has_role CHEBI:75771"],["bp:comment","is_a CHEBI:26743"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00319.eref"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB03203"],["bp:comment","A sphing-4-enine in which the double bond is trans."],["bp:structure","A sphing-4-enine in which the double bond is trans."]]],["bp:name","sphingosine"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33980"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80720"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80716"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80716"]]}},{"data":{"id":"Protein_48d9d24ed3c5ef9554008bb878f042a8","class":"macromolecule","label":"MAP4K4","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1421.4872,"y":650.354,"w":48,"h":25},"metadata":[["bp:displayName","MAP4K4"],["bp:entityReference_http://identifiers.org/uniprot/O95819",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 715 715 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","715"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 712 712 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","712"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 852 852 Phosphoserine."],["bp:featureLocation","MOD_RES 852 852 Phosphoserine."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase kinase 4"],["bp:xref","Mitogen-activated protein kinase kinase kinase kinase 4"],["bp:xref","Mitogen-activated protein kinase kinase kinase kinase 4"],["bp:organism","Mitogen-activated protein kinase kinase kinase kinase 4"],["bp:displayName","M4K4_HUMAN"],["bp:name","2.7.11.1"],["bp:name","HPK/GCK-like kinase HGK"],["bp:name","NIK"],["bp:name","MAPK/ERK kinase kinase kinase 4"],["bp:name","MAP4K4"],["bp:name","MEKKK 4"],["bp:name","HGK"],["bp:name","Nck-interacting kinase"],["bp:name","MEK kinase kinase 4"],["bp:name","KIAA0687"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_2496"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05235_identity"],["bp:comment","FUNCTION: Serine/threonine kinase that may play a role in theresponse to environmental stress and cytokines such as TNF-alpha.Appears to act upstream of the JUN N-terminal pathway.Phosphorylates SMAD1 on Thr-322. {ECO:0000269|PubMed:21690388,ECO:0000269|PubMed:9890973}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:9890973}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:9890973};SUBUNIT: Interacts with the SH3 domain of the adapter proteins Nck(By similarity). Interacts (via its CNH regulatory domain) withATL1 (via the N-terminal region). Interacts with RAP2A (GTP-boundform preferentially). {ECO:0000250, ECO:0000269|PubMed:12387898,ECO:0000269|PubMed:14966141}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14966141}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1 {ECO:0000269|PubMed:9890973}; Synonyms=Tumor-associated;IsoId=O95819-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:9890973};IsoId=O95819-2; Sequence=VSP_007054, VSP_007057;Name=3 {ECO:0000269|PubMed:9890973};IsoId=O95819-3; Sequence=VSP_007056, VSP_007057;Note=Variant in position: 682:D->V.;Name=4 {ECO:0000269|PubMed:9890973}; Synonyms=HGK-S{ECO:0000269|PubMed:9890973};IsoId=O95819-4; Sequence=VSP_007054, VSP_007055, VSP_007057,VSP_007058;Name=5 {ECO:0000269|PubMed:9890973}; Synonyms=HGK-L{ECO:0000269|PubMed:9890973};IsoId=O95819-5; Sequence=VSP_007054, VSP_007055, VSP_007056,VSP_007057, VSP_007058;Name=6;IsoId=O95819-6; Sequence=VSP_007054, VSP_058855, VSP_058856;Note=Gene prediction based on EST data.;TISSUE SPECIFICITY: Widely expressed. Isoform 5 is abundant in thebrain. Isoform 4 is predominant in the liver, skeletal muscle andplacenta. {ECO:0000269|PubMed:9890973}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. STE20 subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","M4K4_HUMAN Reviewed; 1239 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_9448_gene_product"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9448"],["bp:comment","REPLACED http://identifiers.org/uniprot/E7EN19"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21680"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_21680"]]}},{"data":{"id":"TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":53.598152,"y":623.65625,"w":15,"h":15},"metadata":[["bp:product",[["bp:displayName","MYC"],["bp:entityReference_http://identifiers.org/uniprot/P01106",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 323 323 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","323"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 58 58 Phosphothreonine; by GSK3; alternate."],["bp:featureLocation",[["bp:sequencePosition","58"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:organism","Myc proto-oncogene protein"],["bp:displayName","MYC_HUMAN"],["bp:name","Proto-oncogene c-Myc"],["bp:name","BHLHE39"],["bp:name","Class E basic helix-loop-helix protein 39"],["bp:name","Transcription factor p64"],["bp:name","bHLHe39"],["bp:name","MYC"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A93_see-also"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/koK01906.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A93_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1EE4_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01818_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P01106_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_947"],["bp:comment","MYC_HUMAN Reviewed; 439 AA."],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_4609"],["bp:comment","FUNCTION: Transcription factor that binds DNA in a non-specificmanner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.SUBUNIT: Efficient DNA binding requires dimerization with anotherbHLH protein. Binds DNA as a heterodimer with MAX. Interacts withTAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A andKDM5B. Interacts (when phosphorylated at Thr-58 and Ser-62) withFBXW7. Interacts with PIM2. Interacts with RIOX1. The heterodimerMYC:MAX interacts with ABI1; the interaction may enhance MYC:MAXtranscriptional activity. Interacts with TRIM6 (By similarity).{ECO:0000250|UniProtKB:P01108, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:15674325, ECO:0000269|PubMed:15723054,ECO:0000269|PubMed:17308053, ECO:0000269|PubMed:17311883,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:17873522,ECO:0000269|PubMed:9680483}.SUBCELLULAR LOCATION: Nucleus, nucleoplasm{ECO:0000269|PubMed:17558397}. Nucleus, nucleolus{ECO:0000269|PubMed:17558397}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P01106-1; Sequence=Displayed;Name=2;IsoId=P01106-2; Sequence=VSP_037813;Note=Initiates from CTG codon. Ref.7 (BAA01374) sequence is inconflict in position: 2:D->N. Ref.7 (BAA01374) sequence is inconflict in position: 6:V->E. {ECO:0000305};PTM: Phosphorylated by PRKDC. Phosphorylation at Ser-329 by PIM2leads to the stabilization of MYC (By similarity). Phosphorylationat Ser-62 by CDK2 prevents Ras-induced senescence. Phosphorylatedat Ser-62 by DYRK2; this primes the protein for subsequentphosphorylation by GSK3B at Thr-58. Phosphorylation at Thr-58 andSer-62 by GSK3 is required for ubiquitination and degradation bythe proteasome. {ECO:0000250, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:19966300,ECO:0000269|PubMed:20713526, ECO:0000269|PubMed:22307329,ECO:0000269|PubMed:8386367}.PTM: Ubiquitinated by the SCF(FBXW7) complex when phosphorylatedat Thr-58 and Ser-62, leading to its degradation by theproteasome. In the nucleoplasm, ubiquitination is counteracted byUSP28, which interacts with isoform 1 of FBXW7 (FBW7alpha),leading to its deubiquitination and preventing degradation. In thenucleolus, however, ubiquitination is not counteracted by USP28,due to the lack of interaction between isoform 4 of FBXW7(FBW7gamma) and USP28, explaining the selective MYC degradation inthe nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.Ubiquitinated by TRIM6 in a phosphorylation-independent manner (Bysimilarity). {ECO:0000250|UniProtKB:P01108,ECO:0000269|PubMed:15103331, ECO:0000269|PubMed:17558397,ECO:0000269|PubMed:19966300, ECO:0000269|PubMed:20713526,ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:8386367}.DISEASE: Note=A chromosomal aberration involving MYC may be acause of a form of B-cell chronic lymphocytic leukemia.Translocation t(8;12)(q24;q22) with BTG1.{ECO:0000269|PubMed:2069907}.DISEASE: Burkitt lymphoma (BL) [MIM:113970]: A form ofundifferentiated malignant lymphoma commonly manifested as a largeosteolytic lesion in the jaw or as an abdominal mass.{ECO:0000269|PubMed:2166998, ECO:0000269|PubMed:8220424}. Note=Thegene represented in this entry is involved in diseasepathogenesis. Chromosomal aberrations involving MYC are usuallyfound in Burkitt lymphoma. Translocations t(8;14), t(8;22) ort(2;8) which juxtapose MYC to one of the heavy or light chainimmunoglobulin gene loci.BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the fourYamanaka factors. When combined, these factors are sufficient toreprogram differentiated cells to an embryonic-like statedesignated iPS (induced pluripotent stem) cells. iPS cells exhibitthe morphology and growth properties of ES cells and express EScell marker genes. {ECO:0000269|PubMed:18035408}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MYCID27.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/myc/\";WEB RESOURCE: Name=Wikipedia; Note=Myc entry;URL=\"https://en.wikipedia.org/wiki/Myc\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-28143N_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q02821"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"]]],["bp:xref",[["bp:displayName","MYC"],["bp:entityReference_http://identifiers.org/uniprot/P01106",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 323 323 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","323"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 58 58 Phosphothreonine; by GSK3; alternate."],["bp:featureLocation",[["bp:sequencePosition","58"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:organism","Myc proto-oncogene protein"],["bp:displayName","MYC_HUMAN"],["bp:name","Proto-oncogene c-Myc"],["bp:name","BHLHE39"],["bp:name","Class E basic helix-loop-helix protein 39"],["bp:name","Transcription factor p64"],["bp:name","bHLHe39"],["bp:name","MYC"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A93_see-also"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/koK01906.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A93_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1EE4_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01818_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P01106_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_947"],["bp:comment","MYC_HUMAN Reviewed; 439 AA."],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_4609"],["bp:comment","FUNCTION: Transcription factor that binds DNA in a non-specificmanner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.SUBUNIT: Efficient DNA binding requires dimerization with anotherbHLH protein. Binds DNA as a heterodimer with MAX. Interacts withTAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A andKDM5B. Interacts (when phosphorylated at Thr-58 and Ser-62) withFBXW7. Interacts with PIM2. Interacts with RIOX1. The heterodimerMYC:MAX interacts with ABI1; the interaction may enhance MYC:MAXtranscriptional activity. Interacts with TRIM6 (By similarity).{ECO:0000250|UniProtKB:P01108, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:15674325, ECO:0000269|PubMed:15723054,ECO:0000269|PubMed:17308053, ECO:0000269|PubMed:17311883,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:17873522,ECO:0000269|PubMed:9680483}.SUBCELLULAR LOCATION: Nucleus, nucleoplasm{ECO:0000269|PubMed:17558397}. Nucleus, nucleolus{ECO:0000269|PubMed:17558397}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P01106-1; Sequence=Displayed;Name=2;IsoId=P01106-2; Sequence=VSP_037813;Note=Initiates from CTG codon. Ref.7 (BAA01374) sequence is inconflict in position: 2:D->N. Ref.7 (BAA01374) sequence is inconflict in position: 6:V->E. {ECO:0000305};PTM: Phosphorylated by PRKDC. Phosphorylation at Ser-329 by PIM2leads to the stabilization of MYC (By similarity). Phosphorylationat Ser-62 by CDK2 prevents Ras-induced senescence. Phosphorylatedat Ser-62 by DYRK2; this primes the protein for subsequentphosphorylation by GSK3B at Thr-58. Phosphorylation at Thr-58 andSer-62 by GSK3 is required for ubiquitination and degradation bythe proteasome. {ECO:0000250, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:19966300,ECO:0000269|PubMed:20713526, ECO:0000269|PubMed:22307329,ECO:0000269|PubMed:8386367}.PTM: Ubiquitinated by the SCF(FBXW7) complex when phosphorylatedat Thr-58 and Ser-62, leading to its degradation by theproteasome. In the nucleoplasm, ubiquitination is counteracted byUSP28, which interacts with isoform 1 of FBXW7 (FBW7alpha),leading to its deubiquitination and preventing degradation. In thenucleolus, however, ubiquitination is not counteracted by USP28,due to the lack of interaction between isoform 4 of FBXW7(FBW7gamma) and USP28, explaining the selective MYC degradation inthe nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.Ubiquitinated by TRIM6 in a phosphorylation-independent manner (Bysimilarity). {ECO:0000250|UniProtKB:P01108,ECO:0000269|PubMed:15103331, ECO:0000269|PubMed:17558397,ECO:0000269|PubMed:19966300, ECO:0000269|PubMed:20713526,ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:8386367}.DISEASE: Note=A chromosomal aberration involving MYC may be acause of a form of B-cell chronic lymphocytic leukemia.Translocation t(8;12)(q24;q22) with BTG1.{ECO:0000269|PubMed:2069907}.DISEASE: Burkitt lymphoma (BL) [MIM:113970]: A form ofundifferentiated malignant lymphoma commonly manifested as a largeosteolytic lesion in the jaw or as an abdominal mass.{ECO:0000269|PubMed:2166998, ECO:0000269|PubMed:8220424}. Note=Thegene represented in this entry is involved in diseasepathogenesis. Chromosomal aberrations involving MYC are usuallyfound in Burkitt lymphoma. Translocations t(8;14), t(8;22) ort(2;8) which juxtapose MYC to one of the heavy or light chainimmunoglobulin gene loci.BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the fourYamanaka factors. When combined, these factors are sufficient toreprogram differentiated cells to an embryonic-like statedesignated iPS (induced pluripotent stem) cells. iPS cells exhibitthe morphology and growth properties of ES cells and express EScell marker genes. {ECO:0000269|PubMed:18035408}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MYCID27.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/myc/\";WEB RESOURCE: Name=Wikipedia; Note=Myc entry;URL=\"https://en.wikipedia.org/wiki/Myc\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-28143N_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q02821"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"]]],["bp:evidence",[["bp:displayName","MYC"],["bp:entityReference_http://identifiers.org/uniprot/P01106",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 323 323 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","323"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 58 58 Phosphothreonine; by GSK3; alternate."],["bp:featureLocation",[["bp:sequencePosition","58"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:organism","Myc proto-oncogene protein"],["bp:displayName","MYC_HUMAN"],["bp:name","Proto-oncogene c-Myc"],["bp:name","BHLHE39"],["bp:name","Class E basic helix-loop-helix protein 39"],["bp:name","Transcription factor p64"],["bp:name","bHLHe39"],["bp:name","MYC"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A93_see-also"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/koK01906.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A93_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1EE4_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01818_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P01106_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_947"],["bp:comment","MYC_HUMAN Reviewed; 439 AA."],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_4609"],["bp:comment","FUNCTION: Transcription factor that binds DNA in a non-specificmanner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.SUBUNIT: Efficient DNA binding requires dimerization with anotherbHLH protein. Binds DNA as a heterodimer with MAX. Interacts withTAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A andKDM5B. Interacts (when phosphorylated at Thr-58 and Ser-62) withFBXW7. Interacts with PIM2. Interacts with RIOX1. The heterodimerMYC:MAX interacts with ABI1; the interaction may enhance MYC:MAXtranscriptional activity. Interacts with TRIM6 (By similarity).{ECO:0000250|UniProtKB:P01108, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:15674325, ECO:0000269|PubMed:15723054,ECO:0000269|PubMed:17308053, ECO:0000269|PubMed:17311883,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:17873522,ECO:0000269|PubMed:9680483}.SUBCELLULAR LOCATION: Nucleus, nucleoplasm{ECO:0000269|PubMed:17558397}. Nucleus, nucleolus{ECO:0000269|PubMed:17558397}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P01106-1; Sequence=Displayed;Name=2;IsoId=P01106-2; Sequence=VSP_037813;Note=Initiates from CTG codon. Ref.7 (BAA01374) sequence is inconflict in position: 2:D->N. Ref.7 (BAA01374) sequence is inconflict in position: 6:V->E. {ECO:0000305};PTM: Phosphorylated by PRKDC. Phosphorylation at Ser-329 by PIM2leads to the stabilization of MYC (By similarity). Phosphorylationat Ser-62 by CDK2 prevents Ras-induced senescence. Phosphorylatedat Ser-62 by DYRK2; this primes the protein for subsequentphosphorylation by GSK3B at Thr-58. Phosphorylation at Thr-58 andSer-62 by GSK3 is required for ubiquitination and degradation bythe proteasome. {ECO:0000250, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:19966300,ECO:0000269|PubMed:20713526, ECO:0000269|PubMed:22307329,ECO:0000269|PubMed:8386367}.PTM: Ubiquitinated by the SCF(FBXW7) complex when phosphorylatedat Thr-58 and Ser-62, leading to its degradation by theproteasome. In the nucleoplasm, ubiquitination is counteracted byUSP28, which interacts with isoform 1 of FBXW7 (FBW7alpha),leading to its deubiquitination and preventing degradation. In thenucleolus, however, ubiquitination is not counteracted by USP28,due to the lack of interaction between isoform 4 of FBXW7(FBW7gamma) and USP28, explaining the selective MYC degradation inthe nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.Ubiquitinated by TRIM6 in a phosphorylation-independent manner (Bysimilarity). {ECO:0000250|UniProtKB:P01108,ECO:0000269|PubMed:15103331, ECO:0000269|PubMed:17558397,ECO:0000269|PubMed:19966300, ECO:0000269|PubMed:20713526,ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:8386367}.DISEASE: Note=A chromosomal aberration involving MYC may be acause of a form of B-cell chronic lymphocytic leukemia.Translocation t(8;12)(q24;q22) with BTG1.{ECO:0000269|PubMed:2069907}.DISEASE: Burkitt lymphoma (BL) [MIM:113970]: A form ofundifferentiated malignant lymphoma commonly manifested as a largeosteolytic lesion in the jaw or as an abdominal mass.{ECO:0000269|PubMed:2166998, ECO:0000269|PubMed:8220424}. Note=Thegene represented in this entry is involved in diseasepathogenesis. Chromosomal aberrations involving MYC are usuallyfound in Burkitt lymphoma. Translocations t(8;14), t(8;22) ort(2;8) which juxtapose MYC to one of the heavy or light chainimmunoglobulin gene loci.BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the fourYamanaka factors. When combined, these factors are sufficient toreprogram differentiated cells to an embryonic-like statedesignated iPS (induced pluripotent stem) cells. iPS cells exhibitthe morphology and growth properties of ES cells and express EScell marker genes. {ECO:0000269|PubMed:18035408}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MYCID27.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/myc/\";WEB RESOURCE: Name=Wikipedia; Note=Myc entry;URL=\"https://en.wikipedia.org/wiki/Myc\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-28143N_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q02821"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"]]],["bp:participant",[["bp:displayName","MYC"],["bp:entityReference_http://identifiers.org/uniprot/P01106",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 323 323 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","323"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 58 58 Phosphothreonine; by GSK3; alternate."],["bp:featureLocation",[["bp:sequencePosition","58"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:organism","Myc proto-oncogene protein"],["bp:displayName","MYC_HUMAN"],["bp:name","Proto-oncogene c-Myc"],["bp:name","BHLHE39"],["bp:name","Class E basic helix-loop-helix protein 39"],["bp:name","Transcription factor p64"],["bp:name","bHLHe39"],["bp:name","MYC"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A93_see-also"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/koK01906.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A93_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1EE4_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01818_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P01106_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_947"],["bp:comment","MYC_HUMAN Reviewed; 439 AA."],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_4609"],["bp:comment","FUNCTION: Transcription factor that binds DNA in a non-specificmanner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.SUBUNIT: Efficient DNA binding requires dimerization with anotherbHLH protein. Binds DNA as a heterodimer with MAX. Interacts withTAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A andKDM5B. Interacts (when phosphorylated at Thr-58 and Ser-62) withFBXW7. Interacts with PIM2. Interacts with RIOX1. The heterodimerMYC:MAX interacts with ABI1; the interaction may enhance MYC:MAXtranscriptional activity. Interacts with TRIM6 (By similarity).{ECO:0000250|UniProtKB:P01108, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:15674325, ECO:0000269|PubMed:15723054,ECO:0000269|PubMed:17308053, ECO:0000269|PubMed:17311883,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:17873522,ECO:0000269|PubMed:9680483}.SUBCELLULAR LOCATION: Nucleus, nucleoplasm{ECO:0000269|PubMed:17558397}. Nucleus, nucleolus{ECO:0000269|PubMed:17558397}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P01106-1; Sequence=Displayed;Name=2;IsoId=P01106-2; Sequence=VSP_037813;Note=Initiates from CTG codon. Ref.7 (BAA01374) sequence is inconflict in position: 2:D->N. Ref.7 (BAA01374) sequence is inconflict in position: 6:V->E. {ECO:0000305};PTM: Phosphorylated by PRKDC. Phosphorylation at Ser-329 by PIM2leads to the stabilization of MYC (By similarity). Phosphorylationat Ser-62 by CDK2 prevents Ras-induced senescence. Phosphorylatedat Ser-62 by DYRK2; this primes the protein for subsequentphosphorylation by GSK3B at Thr-58. Phosphorylation at Thr-58 andSer-62 by GSK3 is required for ubiquitination and degradation bythe proteasome. {ECO:0000250, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:19966300,ECO:0000269|PubMed:20713526, ECO:0000269|PubMed:22307329,ECO:0000269|PubMed:8386367}.PTM: Ubiquitinated by the SCF(FBXW7) complex when phosphorylatedat Thr-58 and Ser-62, leading to its degradation by theproteasome. In the nucleoplasm, ubiquitination is counteracted byUSP28, which interacts with isoform 1 of FBXW7 (FBW7alpha),leading to its deubiquitination and preventing degradation. In thenucleolus, however, ubiquitination is not counteracted by USP28,due to the lack of interaction between isoform 4 of FBXW7(FBW7gamma) and USP28, explaining the selective MYC degradation inthe nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.Ubiquitinated by TRIM6 in a phosphorylation-independent manner (Bysimilarity). {ECO:0000250|UniProtKB:P01108,ECO:0000269|PubMed:15103331, ECO:0000269|PubMed:17558397,ECO:0000269|PubMed:19966300, ECO:0000269|PubMed:20713526,ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:8386367}.DISEASE: Note=A chromosomal aberration involving MYC may be acause of a form of B-cell chronic lymphocytic leukemia.Translocation t(8;12)(q24;q22) with BTG1.{ECO:0000269|PubMed:2069907}.DISEASE: Burkitt lymphoma (BL) [MIM:113970]: A form ofundifferentiated malignant lymphoma commonly manifested as a largeosteolytic lesion in the jaw or as an abdominal mass.{ECO:0000269|PubMed:2166998, ECO:0000269|PubMed:8220424}. Note=Thegene represented in this entry is involved in diseasepathogenesis. Chromosomal aberrations involving MYC are usuallyfound in Burkitt lymphoma. Translocations t(8;14), t(8;22) ort(2;8) which juxtapose MYC to one of the heavy or light chainimmunoglobulin gene loci.BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the fourYamanaka factors. When combined, these factors are sufficient toreprogram differentiated cells to an embryonic-like statedesignated iPS (induced pluripotent stem) cells. iPS cells exhibitthe morphology and growth properties of ES cells and express EScell marker genes. {ECO:0000269|PubMed:18035408}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MYCID27.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/myc/\";WEB RESOURCE: Name=Wikipedia; Note=Myc entry;URL=\"https://en.wikipedia.org/wiki/Myc\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-28143N_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q02821"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80682"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80682"]]}},{"data":{"id":"Protein_ccb47936776e9cd8a0d309a51a253d46","class":"macromolecule","label":"EIF2A","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_ccb47936776e9cd8a0d309a51a253d46.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":505.3056,"y":22.61267,"w":48,"h":25},"metadata":[["bp:displayName","eIF2A"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80735"]]],["bp:entityReference_http://identifiers.org/uniprot/Q9BY44",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 506 506 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","506"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 518 518 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","518"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:standardName","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:organism","Eukaryotic translation initiation factor 2A"],["bp:displayName","EIF2A_HUMAN"],["bp:name","65 kDa eukaryotic translation initiation factor 2A"],["bp:name","EIF2A"],["bp:name","eIF-2A"],["bp:name","Eukaryotic translation initiation factor 2A, N-terminally processed"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NFM1"],["bp:comment","EIF2A_HUMAN Reviewed; 585 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_83939"],["bp:comment","FUNCTION: Functions in the early steps of protein synthesis of asmall number of specific mRNAs. Acts by directing the binding ofmethionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF-2 complex, it binds methionyl-tRNAi to 40 S subunits in a codon-dependent manner, whereas the eIF-2 complex binds methionyl-tRNAito 40 S subunits in a GTP-dependent manner. May act by impigingthe expression of specific proteins.{ECO:0000269|PubMed:12133843}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q9BY44-1; Sequence=Displayed;Name=2;IsoId=Q9BY44-2; Sequence=VSP_024975, VSP_024976;Note=No experimental confirmation available.;Name=3;IsoId=Q9BY44-3; Sequence=VSP_056047;Note=No experimental confirmation available.;Name=4;IsoId=Q9BY44-4; Sequence=VSP_056048;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Widely expressed. Expressed at higher level inpancreas, heart, brain and placenta.{ECO:0000269|PubMed:12133843}.SIMILARITY: Belongs to the WD repeat EIF2A family. {ECO:0000305}.CAUTION: Was initially thought to constitute the ortholog ofprokaryotic IF-2 (infB) protein. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAK14926.1; Type=Erroneous initiation; Evidence={ECO:0000305};Sequence=AAM83402.1; Type=Frameshift; Positions=82, 90; Evidence={ECO:0000305};Sequence=AAQ13506.1; Type=Frameshift; Positions=513; Evidence={ECO:0000305};Sequence=AAQ13612.1; Type=Erroneous initiation; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-40272N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011511526"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_83939"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_5355"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9BY44-2"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80734"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80734"]]}},{"data":{"id":"Protein_6f560aa8c1a3e1653a07472a3c63286f","class":"macromolecule","label":"CHUK","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1257.168,"y":404.08038,"w":48,"h":25},"metadata":[["bp:displayName","IKKs"],["bp:entityReference_http://identifiers.org/uniprot/O15111",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 23 23 Phosphothreonine; by PKB/AKT1 and SGK1."],["bp:featureLocation",[["bp:sequencePosition","23"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES O-acetylthreonine"],["bp:term","O-acetylthreonine"]]],["bp:comment","MOD_RES 179 179 O-acetylthreonine; by Yersinia yopJ."],["bp:featureLocation",[["bp:sequencePosition","179"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 180 180 Phosphoserine; by SGK1."],["bp:featureLocation","MOD_RES 180 180 Phosphoserine; by SGK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 180 180 Phosphoserine; by SGK1."],["bp:featureLocation","MOD_RES 180 180 Phosphoserine; by SGK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 180 180 Phosphoserine; by SGK1."],["bp:featureLocation","MOD_RES 180 180 Phosphoserine; by SGK1."]]],["bp:standardName","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:organism","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:displayName","IKKA_HUMAN"],["bp:name","Transcription factor 16"],["bp:name","TCF16"],["bp:name","CHUK"],["bp:name","IKK-alpha"],["bp:name","TCF-16"],["bp:name","Nuclear factor NF-kappa-B inhibitor kinase alpha"],["bp:name","I-kappa-B kinase alpha"],["bp:name","Conserved helix-loop-helix ubiquitous kinase"],["bp:name","IKKA"],["bp:name","I-kappa-B kinase 1"],["bp:name","IkappaB kinase"],["bp:name","IkBKA"],["bp:name","IKK-A"],["bp:name","IKK1"],["bp:name","2.7.11.10"],["bp:name","NFKBIKA"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-27526N_identity"],["bp:comment","IKKA_HUMAN Reviewed; 745 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1147"],["bp:comment","REPLACED ProteinRef_CHUK__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001269"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_461"],["bp:comment","REPLACED http://identifiers.org/ncbigene/1147"],["bp:comment","REPLACED ProteinRef_CHUK__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_O15111_identity"],["bp:comment","FUNCTION: Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimulisuch as inflammatory cytokines, bacterial or viral products, DNAdamages or other cellular stresses. Acts as part of the canonicalIKK complex in the conventional pathway of NF-kappa-B activationand phosphorylates inhibitors of NF-kappa-B on serine residues.These modifications allow polyubiquitination of the inhibitors andsubsequent degradation by the proteasome. In turn, free NF-kappa-Bis translocated into the nucleus and activates the transcriptionof hundreds of genes involved in immune response, growth control,or protection against apoptosis. Negatively regulates the pathwayby phosphorylating the scaffold protein TAXBP1 and thus promotingthe assembly of the A20/TNFAIP3 ubiquitin-editing complex(composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH andRNF11). Therefore, CHUK plays a key role in the negative feedbackof NF-kappa-B canonical signaling to limit inflammatory geneactivation. As part of the non-canonical pathway of NF-kappa-Bactivation, the MAP3K14-activated CHUK/IKKA homodimerphosphorylates NFKB2/p100 associated with RelB, inducing itsproteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genesencoding molecules involved in B-cell survival and lymphoidorganogenesis. Participates also in the negative feedback of thenon-canonical NF-kappa-B signaling pathway by phosphorylating anddestabilizing MAP3K14/NIK. Within the nucleus, phosphorylatesCREBBP and consequently increases both its transcriptional andhistone acetyltransferase activities. Modulates chromatinaccessibility at NF-kappa-B-responsive promoters byphosphorylating histones H3 at 'Ser-10' that are subsequentlyacetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates theCREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 andmay regulate this pro-apoptotic transcription factor(PubMed:15084260). {ECO:0000269|PubMed:12789342,ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:17434128,ECO:0000269|PubMed:20434986, ECO:0000269|PubMed:20501937,ECO:0000269|PubMed:21765415}.CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-Bphosphoprotein].ENZYME REGULATION: Activated when phosphorylated and inactivatedwhen dephosphorylated.SUBUNIT: Component of the I-kappa-B-kinase (IKK) core complexconsisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits.The IKK core complex seems to associate with regulatory or adapterproteins to form a IKK-signalosome holo-complex (PubMed:10195894,PubMed:12612076). The IKK complex associates with TERF2IP/RAP1,leading to promote IKK-mediated phosphorylation of RELA/p65 (Bysimilarity). Part of a complex composed of NCOA2, NCOA3,CHUK/IKKA, IKBKB, IKBKG and CREBBP (PubMed:11971985). Part of a70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA,RELA, IKBKAP and MAP3K14 (PubMed:9751059). Directly interacts withTRPC4AP (By similarity). May interact with TRAF2(PubMed:19150425). Interacts with NALP2 (PubMed:15456791). Mayinteract with MAVS/IPS1 (PubMed:16177806). Interacts with ARRB1and ARRB2 (PubMed:15173580). Interacts with NLRC5; prevents CHUKphosphorylation and kinase activity (PubMed:20434986). Interactswith PIAS1; this interaction induces PIAS1 phosphorylation(PubMed:17540171). Interacts with ZNF268 isoform 2; theinteraction is further increased in a TNF-alpha-dependent manner(PubMed:23091055). Interacts with FOXO3 (PubMed:15084260).Interacts with IFIT5; the interaction synergizes the recruitmentof IKK to MAP3K7 and enhances IKK phosphorylation(PubMed:26334375). {ECO:0000250|UniProtKB:Q60680,ECO:0000269|PubMed:10195894, ECO:0000269|PubMed:11971985,ECO:0000269|PubMed:12612076, ECO:0000269|PubMed:15084260,ECO:0000269|PubMed:15173580, ECO:0000269|PubMed:15456791,ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:17540171,ECO:0000269|PubMed:19150425, ECO:0000269|PubMed:20434986,ECO:0000269|PubMed:23091055, ECO:0000269|PubMed:26334375,ECO:0000269|PubMed:9751059}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12789342}.Nucleus {ECO:0000269|PubMed:12789342}. Note=Shuttles between thecytoplasm and the nucleus.TISSUE SPECIFICITY: Widely expressed.DOMAIN: The kinase domain is located in the N-terminal region. Theleucine zipper is important to allow homo- and hetero-dimerization. At the C-terminal region is located the regionresponsible for the interaction with NEMO/IKBKG.{ECO:0000269|PubMed:18626576}.PTM: Phosphorylated by MAP3K14/NIK, AKT and to a lesser extent byMEKK1, and dephosphorylated by PP2A. Autophosphorylated.PTM: (Microbial infection) Acetylation of Thr-179 by Yersinia yopJprevents phosphorylation and activation, thus blocking the I-kappa-B signaling pathway. {ECO:0000269|PubMed:17116858}.DISEASE: Cocoon syndrome (COCOS) [MIM:613630]: A lethal syndromecharacterized by multiple fetal malformations including defectiveface and seemingly absent limbs, which are bound to the trunk andencased under the skin. {ECO:0000269|PubMed:20961246}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. I-kappa-B kinase subfamily.{ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/chuk/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_CHUK__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1147"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-5773277_identity"]]],["bp:name","IKK alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"]]}},{"data":{"id":"BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":298.21838,"y":644.43396,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MEKK1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2072"],["bp:featureLocation",[["bp:sequencePosition","1412"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2073"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2069"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2070"],["bp:featureLocation",[["bp:sequencePosition","1400"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2071"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2068"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26177"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26175"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_26175"]]}},{"data":{"id":"BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":420.57172,"y":385.35327,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","BAX"],["bp:entityReference_http://identifiers.org/uniprot/Q07812",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis regulator BAX"],["bp:xref",[["bp:relationshipType",null],["bp:id","BAX"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","Q07812"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q07812"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","BAX_HUMAN"],["bp:name","Bcl2-L-4"],["bp:name","Bcl-2-like protein 4"],["bp:name","BCL2L4"],["bp:name","BAX"],["bp:comment","BAX_HUMAN Reviewed; 192 AA."],["bp:comment","FUNCTION: Accelerates programmed cell death by binding to, andantagonizing the apoptosis repressor BCL2 or its adenovirushomolog E1B 19k protein. Under stress conditions, undergoes aconformation change that causes translocation to the mitochondrionmembrane, leading to the release of cytochrome c that thentriggers apoptosis. Promotes activation of CASP3, and therebyapoptosis. {ECO:0000269|PubMed:10772918,ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:18948948,ECO:0000269|PubMed:21199865, ECO:0000269|PubMed:8358790,ECO:0000269|PubMed:8521816}.SUBUNIT: Homodimer. Forms higher oligomers under stressconditions. Interacts with BCL2L11. Interaction with BCL2L11promotes BAX oligomerization and association with mitochondrialmembranes, with subsequent release of cytochrome c. Formsheterodimers with BCL2, E1B 19K protein, BCL2L1 isoform Bcl-X(L),BCL2L2, MCL1 and A1. Interacts with SH3GLB1 and HN. Interacts withSFN and YWHAZ; the interaction occurs in the cytoplasm. Understress conditions, JNK-mediated phosphorylation of SFN and YWHAZ,releases BAX to mitochondria. Isoform Sigma interacts with BCL2A1and BCL2L1 isoform Bcl-X(L). Interacts with RNF144B, whichregulates the ubiquitin-dependent stability of BAX. Interacts withCLU under stress conditions that cause a conformation changeleading to BAX oligomerization and association with mitochondria.Does not interact with CLU in unstressed cells. Interacts withFAIM2/LFG2. Interacts with human cytomegalovirus/HHV-5 proteinvMIA/UL37. Interacts with BOP/C22orf29. Interacts (via a C-terminal 33 residues) with NOL3 (via CARD domain); inhibits BAXactivation and translocation and consequently cytochrome c releasefrom mitochondria. {ECO:0000269|PubMed:10772918,ECO:0000269|PubMed:11106734, ECO:0000269|PubMed:11259440,ECO:0000269|PubMed:12732850, ECO:0000269|PubMed:15004026,ECO:0000269|PubMed:15004034, ECO:0000269|PubMed:15071501,ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:16946732,ECO:0000269|PubMed:16964429, ECO:0000269|PubMed:18948948,ECO:0000269|PubMed:20300062, ECO:0000269|PubMed:21199865,ECO:0000269|PubMed:23055042, ECO:0000269|PubMed:8358790}.SUBCELLULAR LOCATION: Isoform Alpha: Mitochondrion membrane;Single-pass membrane protein. Cytoplasm. Note=Colocalizes with 14-3-3 proteins in the cytoplasm. Under stress conditions, undergoesa conformation change that causes release from JNK-phosphorylated14-3-3 proteins and translocation to the mitochondrion membrane.SUBCELLULAR LOCATION: Isoform Beta: Cytoplasm.SUBCELLULAR LOCATION: Isoform Gamma: Cytoplasm.SUBCELLULAR LOCATION: Isoform Delta: Cytoplasm {ECO:0000305}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=Alpha;IsoId=Q07812-1; Sequence=Displayed;Name=Beta;IsoId=Q07812-2, Q07814-1;Sequence=VSP_031237;Name=Gamma;IsoId=Q07812-3, Q07815-1;Sequence=VSP_031234, VSP_031236;Name=Delta;IsoId=Q07812-4, P55269-1;Sequence=VSP_031235;Name=Epsilon;IsoId=Q07812-5; Sequence=VSP_031240;Name=Zeta;IsoId=Q07812-6; Sequence=VSP_031239;Name=Psi;IsoId=Q07812-7; Sequence=VSP_031238;Name=Sigma;IsoId=Q07812-8; Sequence=VSP_037475;TISSUE SPECIFICITY: Expressed in a wide variety of tissues.Isoform Psi is found in glial tumors. Isoform Alpha is expressedin spleen, breast, ovary, testis, colon and brain, and at lowlevels in skin and lung. Isoform Sigma is expressed in spleen,breast, ovary, testis, lung, colon, brain and at low levels inskin. Isoform Alpha and isoform Sigma are expressed in pro-myelocytic leukemia, histiocytic lymphoma, Burkitt's lymphoma, T-cell lymphoma, lymphoblastic leukemia, breast adenocarcinoma,ovary adenocarcinoma, prostate carcinoma, prostate adenocarcinoma,lung carcinoma, epidermoid carcinoma, small cell lung carcinomaand colon adenocarcinoma cell lines. {ECO:0000269|PubMed:10772918,ECO:0000269|PubMed:11912183}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family. {ECO:0000250}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bax/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BAXID128ch19q13.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_581"],["bp:comment","REPLACED http://identifiers.org/uniprot/P55269"],["bp:comment","REPLACED ProteinRef_BAX__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_581"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-232N_identity"],["bp:comment","REPLACED ProteinRef_BAX__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_620116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004315"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q07812_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016882566"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02498_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4701"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_59845"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84317"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84318"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_84316"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_84316"]]}},{"data":{"id":"SmallMolecule_fb5c04347a4874d9ff2b1ac418abec8e","class":"simple chemical","label":"Free Fatty acid","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":216.4718,"y":263.58716000000004,"w":48,"h":20},"metadata":[["bp:displayName","Free Fatty acid"],["bp:entityReference_#SmallMoleculeReference_1438d1171ba27edc8c609fd96d7b2a8c",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80717"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":594.65845,"y":59.98376,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","EIF2A"],["bp:entityReference_http://identifiers.org/uniprot/Q9BY44",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 506 506 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","506"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 518 518 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","518"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:standardName","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:organism","Eukaryotic translation initiation factor 2A"],["bp:displayName","EIF2A_HUMAN"],["bp:name","65 kDa eukaryotic translation initiation factor 2A"],["bp:name","EIF2A"],["bp:name","eIF-2A"],["bp:name","Eukaryotic translation initiation factor 2A, N-terminally processed"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NFM1"],["bp:comment","EIF2A_HUMAN Reviewed; 585 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_83939"],["bp:comment","FUNCTION: Functions in the early steps of protein synthesis of asmall number of specific mRNAs. Acts by directing the binding ofmethionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF-2 complex, it binds methionyl-tRNAi to 40 S subunits in a codon-dependent manner, whereas the eIF-2 complex binds methionyl-tRNAito 40 S subunits in a GTP-dependent manner. May act by impigingthe expression of specific proteins.{ECO:0000269|PubMed:12133843}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q9BY44-1; Sequence=Displayed;Name=2;IsoId=Q9BY44-2; Sequence=VSP_024975, VSP_024976;Note=No experimental confirmation available.;Name=3;IsoId=Q9BY44-3; Sequence=VSP_056047;Note=No experimental confirmation available.;Name=4;IsoId=Q9BY44-4; Sequence=VSP_056048;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Widely expressed. Expressed at higher level inpancreas, heart, brain and placenta.{ECO:0000269|PubMed:12133843}.SIMILARITY: Belongs to the WD repeat EIF2A family. {ECO:0000305}.CAUTION: Was initially thought to constitute the ortholog ofprokaryotic IF-2 (infB) protein. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAK14926.1; Type=Erroneous initiation; Evidence={ECO:0000305};Sequence=AAM83402.1; Type=Frameshift; Positions=82, 90; Evidence={ECO:0000305};Sequence=AAQ13506.1; Type=Frameshift; Positions=513; Evidence={ECO:0000305};Sequence=AAQ13612.1; Type=Erroneous initiation; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-40272N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011511526"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_83939"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_5355"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9BY44-2"]]],["bp:name","eIF2A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80736"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","EIF2A"],["bp:entityReference_http://identifiers.org/uniprot/Q9BY44",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 506 506 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","506"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 518 518 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","518"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:standardName","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:organism","Eukaryotic translation initiation factor 2A"],["bp:displayName","EIF2A_HUMAN"],["bp:name","65 kDa eukaryotic translation initiation factor 2A"],["bp:name","EIF2A"],["bp:name","eIF-2A"],["bp:name","Eukaryotic translation initiation factor 2A, N-terminally processed"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NFM1"],["bp:comment","EIF2A_HUMAN Reviewed; 585 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_83939"],["bp:comment","FUNCTION: Functions in the early steps of protein synthesis of asmall number of specific mRNAs. Acts by directing the binding ofmethionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF-2 complex, it binds methionyl-tRNAi to 40 S subunits in a codon-dependent manner, whereas the eIF-2 complex binds methionyl-tRNAito 40 S subunits in a GTP-dependent manner. May act by impigingthe expression of specific proteins.{ECO:0000269|PubMed:12133843}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q9BY44-1; Sequence=Displayed;Name=2;IsoId=Q9BY44-2; Sequence=VSP_024975, VSP_024976;Note=No experimental confirmation available.;Name=3;IsoId=Q9BY44-3; Sequence=VSP_056047;Note=No experimental confirmation available.;Name=4;IsoId=Q9BY44-4; Sequence=VSP_056048;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Widely expressed. Expressed at higher level inpancreas, heart, brain and placenta.{ECO:0000269|PubMed:12133843}.SIMILARITY: Belongs to the WD repeat EIF2A family. {ECO:0000305}.CAUTION: Was initially thought to constitute the ortholog ofprokaryotic IF-2 (infB) protein. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAK14926.1; Type=Erroneous initiation; Evidence={ECO:0000305};Sequence=AAM83402.1; Type=Frameshift; Positions=82, 90; Evidence={ECO:0000305};Sequence=AAQ13506.1; Type=Frameshift; Positions=513; Evidence={ECO:0000305};Sequence=AAQ13612.1; Type=Erroneous initiation; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-40272N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011511526"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_83939"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_5355"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9BY44-2"]]],["bp:name","eIF2A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80736"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","EIF2A"],["bp:entityReference_http://identifiers.org/uniprot/Q9BY44",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 506 506 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","506"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 518 518 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","518"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:standardName","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:organism","Eukaryotic translation initiation factor 2A"],["bp:displayName","EIF2A_HUMAN"],["bp:name","65 kDa eukaryotic translation initiation factor 2A"],["bp:name","EIF2A"],["bp:name","eIF-2A"],["bp:name","Eukaryotic translation initiation factor 2A, N-terminally processed"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NFM1"],["bp:comment","EIF2A_HUMAN Reviewed; 585 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_83939"],["bp:comment","FUNCTION: Functions in the early steps of protein synthesis of asmall number of specific mRNAs. Acts by directing the binding ofmethionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF-2 complex, it binds methionyl-tRNAi to 40 S subunits in a codon-dependent manner, whereas the eIF-2 complex binds methionyl-tRNAito 40 S subunits in a GTP-dependent manner. May act by impigingthe expression of specific proteins.{ECO:0000269|PubMed:12133843}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q9BY44-1; Sequence=Displayed;Name=2;IsoId=Q9BY44-2; Sequence=VSP_024975, VSP_024976;Note=No experimental confirmation available.;Name=3;IsoId=Q9BY44-3; Sequence=VSP_056047;Note=No experimental confirmation available.;Name=4;IsoId=Q9BY44-4; Sequence=VSP_056048;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Widely expressed. Expressed at higher level inpancreas, heart, brain and placenta.{ECO:0000269|PubMed:12133843}.SIMILARITY: Belongs to the WD repeat EIF2A family. {ECO:0000305}.CAUTION: Was initially thought to constitute the ortholog ofprokaryotic IF-2 (infB) protein. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAK14926.1; Type=Erroneous initiation; Evidence={ECO:0000305};Sequence=AAM83402.1; Type=Frameshift; Positions=82, 90; Evidence={ECO:0000305};Sequence=AAQ13506.1; Type=Frameshift; Positions=513; Evidence={ECO:0000305};Sequence=AAQ13612.1; Type=Erroneous initiation; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-40272N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011511526"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_83939"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_5355"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9BY44-2"]]],["bp:name","eIF2A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80736"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","EIF2A"],["bp:entityReference_http://identifiers.org/uniprot/Q9BY44",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 506 506 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","506"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 518 518 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","518"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine; in Eukaryotictranslation initiation factor 2A, N-terminally processed."]]],["bp:standardName","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:xref","Eukaryotic translation initiation factor 2A"],["bp:organism","Eukaryotic translation initiation factor 2A"],["bp:displayName","EIF2A_HUMAN"],["bp:name","65 kDa eukaryotic translation initiation factor 2A"],["bp:name","EIF2A"],["bp:name","eIF-2A"],["bp:name","Eukaryotic translation initiation factor 2A, N-terminally processed"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NFM1"],["bp:comment","EIF2A_HUMAN Reviewed; 585 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_83939"],["bp:comment","FUNCTION: Functions in the early steps of protein synthesis of asmall number of specific mRNAs. Acts by directing the binding ofmethionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF-2 complex, it binds methionyl-tRNAi to 40 S subunits in a codon-dependent manner, whereas the eIF-2 complex binds methionyl-tRNAito 40 S subunits in a GTP-dependent manner. May act by impigingthe expression of specific proteins.{ECO:0000269|PubMed:12133843}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q9BY44-1; Sequence=Displayed;Name=2;IsoId=Q9BY44-2; Sequence=VSP_024975, VSP_024976;Note=No experimental confirmation available.;Name=3;IsoId=Q9BY44-3; Sequence=VSP_056047;Note=No experimental confirmation available.;Name=4;IsoId=Q9BY44-4; Sequence=VSP_056048;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Widely expressed. Expressed at higher level inpancreas, heart, brain and placenta.{ECO:0000269|PubMed:12133843}.SIMILARITY: Belongs to the WD repeat EIF2A family. {ECO:0000305}.CAUTION: Was initially thought to constitute the ortholog ofprokaryotic IF-2 (infB) protein. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAK14926.1; Type=Erroneous initiation; Evidence={ECO:0000305};Sequence=AAM83402.1; Type=Frameshift; Positions=82, 90; Evidence={ECO:0000305};Sequence=AAQ13506.1; Type=Frameshift; Positions=513; Evidence={ECO:0000305};Sequence=AAQ13612.1; Type=Erroneous initiation; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-40272N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011511526"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_83939"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_5355"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9BY44-2"]]],["bp:name","eIF2A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_37494"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80736"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80733"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80733"]]}},{"data":{"id":"BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":262.1575,"y":467.1279,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","RB1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80817"]]],["bp:entityReference_http://identifiers.org/uniprot/P06400",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-methyllysine"],["bp:term","MOD_RES N6-methyllysine"]]],["bp:comment","MOD_RES 810 810 N6-methyllysine; by SMYD2."],["bp:featureLocation",[["bp:sequencePosition","810"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:standardName","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:organism","Retinoblastoma-associated protein"],["bp:displayName","RB_HUMAN"],["bp:name","pp110"],["bp:name","Rb"],["bp:name","pRb"],["bp:name","RB1"],["bp:name","p105-Rb"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q5VW46"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5925"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_452"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5925"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000312"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-1208367_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PJM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P06400_identity"],["bp:comment","REPLACED ProteinRef_RB1__9606"],["bp:comment","FUNCTION: Key regulator of entry into cell division that acts as atumor suppressor. Promotes G0-G1 transition when phosphorylated byCDK3/cyclin-C. Acts as a transcription repressor of E2F1 targetgenes. The underphosphorylated, active form of RB1 interacts withE2F1 and represses its transcription activity, leading to cellcycle arrest. Directly involved in heterochromatin formation bymaintaining overall chromatin structure and, in particular, thatof constitutive heterochromatin by stabilizing histonemethylation. Recruits and targets histone methyltransferasesSUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptionalrepression. Controls histone H4 'Lys-20' trimethylation. Inhibitsthe intrinsic kinase activity of TAF1. Mediates transcriptionalrepression by SMARCA4/BRG1 by recruiting a histone deacetylase(HDAC) complex to the c-FOS promoter. In resting neurons,transcription of the c-FOS promoter is inhibited by BRG1-dependentrecruitment of a phospho-RB1-HDAC1 repressor complex. Upon calciuminflux, RB1 is dephosphorylated by calcineurin, which leads torelease of the repressor complex (By similarity). In case of viralinfections, interactions with SV40 large T antigen, HPV E7 proteinor adenovirus E1A protein induce the disassembly of RB1-E2F1complex thereby disrupting RB1's activity. {ECO:0000250,ECO:0000269|PubMed:15084261}.SUBUNIT: Interacts with ATAD5. Interacts with PRMT2, CDK1 and CDK2(By similarity). The hypophosphorylated form interacts with andsequesters the E2F1 transcription factor. Interacts withheterodimeric E2F/DP transcription factor complexes containingTFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. Theunphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1,MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain ofTAF1. Interacts with SNW1, AATF, DNMT1, LIN9, LMNA, KMT5B, KMT5C,PELP1, UHRF2 and TMPO-alpha. May interact with NDC80. Interactswith GRIP1 and UBR4. Interacts with ARID4A and KDM5B. Interactswith E4F1 and LIMD1. Interacts with SMARCA4/BRG1 AND HDAC1 (Bysimilarity). Interacts with PSMA3 and USP4. Interacts (whenmethylated at Lys-860) with L3MBTL1. Interacts with CHEK2;phosphorylates RB1. Interacts with CEBPA (PubMed:15107404).Interacts with adenovirus E1A protein, HPV E7 protein and SV40large T antigen. Interacts with human cytomegalovirus/HHV-5protein UL123. P-TEFB complex interacts with RB1; promotesphosphorylation of RB1 (PubMed:12037672).{ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568,ECO:0000269|PubMed:10409732, ECO:0000269|PubMed:10446990,ECO:0000269|PubMed:10779342, ECO:0000269|PubMed:10869426,ECO:0000269|PubMed:10888886, ECO:0000269|PubMed:11223246,ECO:0000269|PubMed:11484059, ECO:0000269|PubMed:11571652,ECO:0000269|PubMed:12037672, ECO:0000269|PubMed:12450794,ECO:0000269|PubMed:12466551, ECO:0000269|PubMed:12475961,ECO:0000269|PubMed:12682072, ECO:0000269|PubMed:12695505,ECO:0000269|PubMed:1316611, ECO:0000269|PubMed:15107404,ECO:0000269|PubMed:15538385, ECO:0000269|PubMed:15542589,ECO:0000269|PubMed:15803180, ECO:0000269|PubMed:15927959,ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:16214886,ECO:0000269|PubMed:16337594, ECO:0000269|PubMed:16360038,ECO:0000269|PubMed:16645588, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:17974914, ECO:0000269|PubMed:17996702,ECO:0000269|PubMed:20870719, ECO:0000269|PubMed:21952639,ECO:0000269|PubMed:2839300, ECO:0000269|PubMed:7525595,ECO:0000269|PubMed:7935440, ECO:0000269|PubMed:8414517,ECO:0000269|PubMed:8892909, ECO:0000269|PubMed:9858607}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20940255}.TISSUE SPECIFICITY: Expressed in the retina.DOMAIN: The Pocket domain binds to the threonine-phosphorylateddomain C, thereby preventing interaction with heterodimeric E2F/DPtranscription factor complexes.PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 atSer-567 in G1, thereby releasing E2F1 which is then able toactivate cell growth. Dephosphorylated at the late M phase. SV40large T antigen, HPV E7 and adenovirus E1A bind to theunderphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domainC and the Pocket domain, and thereby inhibits interactions withheterodimeric E2F/DP transcription factor complexes.Dephosphorylated at Ser-795 by calcineruin upon calciumstimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 andSer-811 is required for G0-G1 transition. Phosphorylated by CDK1and CDK2 upon TGFB1-mediated apoptosis (By similarity).{ECO:0000250}.PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity).Monomethylation at Lys-810 by SMYD2 enhances phosphorylation atSer-807 and Ser-811, and promotes cell cycle progression.Monomethylation at Lys-860 by SMYD2 promotes interaction withL3MBTL1. {ECO:0000250, ECO:0000269|PubMed:10499802,ECO:0000269|PubMed:15084261, ECO:0000269|PubMed:15809340,ECO:0000269|PubMed:16360038, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:1756735, ECO:0000269|PubMed:20870719,ECO:0000269|PubMed:22787429, ECO:0000269|PubMed:8114739}.PTM: Acetylation at Lys-873 and Lys-874 regulates subcellularlocalization, at least during keratinocytes differentiation.{ECO:0000269|PubMed:20940255}.DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]:Congenital malignant tumor that arises from the nuclear layers ofthe retina. It occurs in about 1:20'000 live births and representsabout 2% of childhood malignancies. It is bilateral in about 30%of cases. Although most RB appear sporadically, about 20% aretransmitted as an autosomal dominant trait with incompletepenetrance. The diagnosis is usually made before the age of 2years when strabismus or a gray to yellow reflex from pupil ('cateye') is investigated. {ECO:0000269|PubMed:10671068,ECO:0000269|PubMed:11524739, ECO:0000269|PubMed:1352883,ECO:0000269|PubMed:2594029, ECO:0000269|PubMed:7704558,ECO:0000269|PubMed:7795591, ECO:0000269|PubMed:7927327,ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116,ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452,ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancyoriginating in tissues of the urinary bladder. It often presentswith multiple tumors appearing at different times and at differentsites in the bladder. Most bladder cancers are transitional cellcarcinomas that begin in cells that normally make up the innerlining of the bladder. Other types of bladder cancer includesquamous cell carcinoma (cancer that begins in thin, flat cells)and adenocarcinoma (cancer that begins in cells that make andrelease mucus and other fluids). Bladder cancer is a complexdisorder with both genetic and environmental influences.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcomaoriginating in bone-forming cells, affecting the ends of longbones. Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the retinoblastoma protein (RB) family.{ECO:0000305}.WEB RESOURCE: Name=RB1base; Note=RB1 mutation db;URL=\"http://rb1-lsdb.d-lohmann.de/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RB1ID90.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/rb1/\";WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry;URL=\"https://en.wikipedia.org/wiki/Retinoblastoma_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5925"],["bp:comment","RB_HUMAN Reviewed; 928 AA."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01574_identity"],["bp:comment","REPLACED ProteinRef_RB1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1GH6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-582N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80819"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","RB1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80817"]]],["bp:entityReference_http://identifiers.org/uniprot/P06400",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-methyllysine"],["bp:term","MOD_RES N6-methyllysine"]]],["bp:comment","MOD_RES 810 810 N6-methyllysine; by SMYD2."],["bp:featureLocation",[["bp:sequencePosition","810"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:standardName","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:organism","Retinoblastoma-associated protein"],["bp:displayName","RB_HUMAN"],["bp:name","pp110"],["bp:name","Rb"],["bp:name","pRb"],["bp:name","RB1"],["bp:name","p105-Rb"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q5VW46"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5925"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_452"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5925"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000312"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-1208367_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PJM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P06400_identity"],["bp:comment","REPLACED ProteinRef_RB1__9606"],["bp:comment","FUNCTION: Key regulator of entry into cell division that acts as atumor suppressor. Promotes G0-G1 transition when phosphorylated byCDK3/cyclin-C. Acts as a transcription repressor of E2F1 targetgenes. The underphosphorylated, active form of RB1 interacts withE2F1 and represses its transcription activity, leading to cellcycle arrest. Directly involved in heterochromatin formation bymaintaining overall chromatin structure and, in particular, thatof constitutive heterochromatin by stabilizing histonemethylation. Recruits and targets histone methyltransferasesSUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptionalrepression. Controls histone H4 'Lys-20' trimethylation. Inhibitsthe intrinsic kinase activity of TAF1. Mediates transcriptionalrepression by SMARCA4/BRG1 by recruiting a histone deacetylase(HDAC) complex to the c-FOS promoter. In resting neurons,transcription of the c-FOS promoter is inhibited by BRG1-dependentrecruitment of a phospho-RB1-HDAC1 repressor complex. Upon calciuminflux, RB1 is dephosphorylated by calcineurin, which leads torelease of the repressor complex (By similarity). In case of viralinfections, interactions with SV40 large T antigen, HPV E7 proteinor adenovirus E1A protein induce the disassembly of RB1-E2F1complex thereby disrupting RB1's activity. {ECO:0000250,ECO:0000269|PubMed:15084261}.SUBUNIT: Interacts with ATAD5. Interacts with PRMT2, CDK1 and CDK2(By similarity). The hypophosphorylated form interacts with andsequesters the E2F1 transcription factor. Interacts withheterodimeric E2F/DP transcription factor complexes containingTFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. Theunphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1,MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain ofTAF1. Interacts with SNW1, AATF, DNMT1, LIN9, LMNA, KMT5B, KMT5C,PELP1, UHRF2 and TMPO-alpha. May interact with NDC80. Interactswith GRIP1 and UBR4. Interacts with ARID4A and KDM5B. Interactswith E4F1 and LIMD1. Interacts with SMARCA4/BRG1 AND HDAC1 (Bysimilarity). Interacts with PSMA3 and USP4. Interacts (whenmethylated at Lys-860) with L3MBTL1. Interacts with CHEK2;phosphorylates RB1. Interacts with CEBPA (PubMed:15107404).Interacts with adenovirus E1A protein, HPV E7 protein and SV40large T antigen. Interacts with human cytomegalovirus/HHV-5protein UL123. P-TEFB complex interacts with RB1; promotesphosphorylation of RB1 (PubMed:12037672).{ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568,ECO:0000269|PubMed:10409732, ECO:0000269|PubMed:10446990,ECO:0000269|PubMed:10779342, ECO:0000269|PubMed:10869426,ECO:0000269|PubMed:10888886, ECO:0000269|PubMed:11223246,ECO:0000269|PubMed:11484059, ECO:0000269|PubMed:11571652,ECO:0000269|PubMed:12037672, ECO:0000269|PubMed:12450794,ECO:0000269|PubMed:12466551, ECO:0000269|PubMed:12475961,ECO:0000269|PubMed:12682072, ECO:0000269|PubMed:12695505,ECO:0000269|PubMed:1316611, ECO:0000269|PubMed:15107404,ECO:0000269|PubMed:15538385, ECO:0000269|PubMed:15542589,ECO:0000269|PubMed:15803180, ECO:0000269|PubMed:15927959,ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:16214886,ECO:0000269|PubMed:16337594, ECO:0000269|PubMed:16360038,ECO:0000269|PubMed:16645588, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:17974914, ECO:0000269|PubMed:17996702,ECO:0000269|PubMed:20870719, ECO:0000269|PubMed:21952639,ECO:0000269|PubMed:2839300, ECO:0000269|PubMed:7525595,ECO:0000269|PubMed:7935440, ECO:0000269|PubMed:8414517,ECO:0000269|PubMed:8892909, ECO:0000269|PubMed:9858607}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20940255}.TISSUE SPECIFICITY: Expressed in the retina.DOMAIN: The Pocket domain binds to the threonine-phosphorylateddomain C, thereby preventing interaction with heterodimeric E2F/DPtranscription factor complexes.PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 atSer-567 in G1, thereby releasing E2F1 which is then able toactivate cell growth. Dephosphorylated at the late M phase. SV40large T antigen, HPV E7 and adenovirus E1A bind to theunderphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domainC and the Pocket domain, and thereby inhibits interactions withheterodimeric E2F/DP transcription factor complexes.Dephosphorylated at Ser-795 by calcineruin upon calciumstimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 andSer-811 is required for G0-G1 transition. Phosphorylated by CDK1and CDK2 upon TGFB1-mediated apoptosis (By similarity).{ECO:0000250}.PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity).Monomethylation at Lys-810 by SMYD2 enhances phosphorylation atSer-807 and Ser-811, and promotes cell cycle progression.Monomethylation at Lys-860 by SMYD2 promotes interaction withL3MBTL1. {ECO:0000250, ECO:0000269|PubMed:10499802,ECO:0000269|PubMed:15084261, ECO:0000269|PubMed:15809340,ECO:0000269|PubMed:16360038, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:1756735, ECO:0000269|PubMed:20870719,ECO:0000269|PubMed:22787429, ECO:0000269|PubMed:8114739}.PTM: Acetylation at Lys-873 and Lys-874 regulates subcellularlocalization, at least during keratinocytes differentiation.{ECO:0000269|PubMed:20940255}.DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]:Congenital malignant tumor that arises from the nuclear layers ofthe retina. It occurs in about 1:20'000 live births and representsabout 2% of childhood malignancies. It is bilateral in about 30%of cases. Although most RB appear sporadically, about 20% aretransmitted as an autosomal dominant trait with incompletepenetrance. The diagnosis is usually made before the age of 2years when strabismus or a gray to yellow reflex from pupil ('cateye') is investigated. {ECO:0000269|PubMed:10671068,ECO:0000269|PubMed:11524739, ECO:0000269|PubMed:1352883,ECO:0000269|PubMed:2594029, ECO:0000269|PubMed:7704558,ECO:0000269|PubMed:7795591, ECO:0000269|PubMed:7927327,ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116,ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452,ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancyoriginating in tissues of the urinary bladder. It often presentswith multiple tumors appearing at different times and at differentsites in the bladder. Most bladder cancers are transitional cellcarcinomas that begin in cells that normally make up the innerlining of the bladder. Other types of bladder cancer includesquamous cell carcinoma (cancer that begins in thin, flat cells)and adenocarcinoma (cancer that begins in cells that make andrelease mucus and other fluids). Bladder cancer is a complexdisorder with both genetic and environmental influences.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcomaoriginating in bone-forming cells, affecting the ends of longbones. Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the retinoblastoma protein (RB) family.{ECO:0000305}.WEB RESOURCE: Name=RB1base; Note=RB1 mutation db;URL=\"http://rb1-lsdb.d-lohmann.de/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RB1ID90.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/rb1/\";WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry;URL=\"https://en.wikipedia.org/wiki/Retinoblastoma_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5925"],["bp:comment","RB_HUMAN Reviewed; 928 AA."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01574_identity"],["bp:comment","REPLACED ProteinRef_RB1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1GH6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-582N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80819"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","RB1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80817"]]],["bp:entityReference_http://identifiers.org/uniprot/P06400",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-methyllysine"],["bp:term","MOD_RES N6-methyllysine"]]],["bp:comment","MOD_RES 810 810 N6-methyllysine; by SMYD2."],["bp:featureLocation",[["bp:sequencePosition","810"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:standardName","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:organism","Retinoblastoma-associated protein"],["bp:displayName","RB_HUMAN"],["bp:name","pp110"],["bp:name","Rb"],["bp:name","pRb"],["bp:name","RB1"],["bp:name","p105-Rb"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q5VW46"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5925"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_452"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5925"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000312"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-1208367_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PJM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P06400_identity"],["bp:comment","REPLACED ProteinRef_RB1__9606"],["bp:comment","FUNCTION: Key regulator of entry into cell division that acts as atumor suppressor. Promotes G0-G1 transition when phosphorylated byCDK3/cyclin-C. Acts as a transcription repressor of E2F1 targetgenes. The underphosphorylated, active form of RB1 interacts withE2F1 and represses its transcription activity, leading to cellcycle arrest. Directly involved in heterochromatin formation bymaintaining overall chromatin structure and, in particular, thatof constitutive heterochromatin by stabilizing histonemethylation. Recruits and targets histone methyltransferasesSUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptionalrepression. Controls histone H4 'Lys-20' trimethylation. Inhibitsthe intrinsic kinase activity of TAF1. Mediates transcriptionalrepression by SMARCA4/BRG1 by recruiting a histone deacetylase(HDAC) complex to the c-FOS promoter. In resting neurons,transcription of the c-FOS promoter is inhibited by BRG1-dependentrecruitment of a phospho-RB1-HDAC1 repressor complex. Upon calciuminflux, RB1 is dephosphorylated by calcineurin, which leads torelease of the repressor complex (By similarity). In case of viralinfections, interactions with SV40 large T antigen, HPV E7 proteinor adenovirus E1A protein induce the disassembly of RB1-E2F1complex thereby disrupting RB1's activity. {ECO:0000250,ECO:0000269|PubMed:15084261}.SUBUNIT: Interacts with ATAD5. Interacts with PRMT2, CDK1 and CDK2(By similarity). The hypophosphorylated form interacts with andsequesters the E2F1 transcription factor. Interacts withheterodimeric E2F/DP transcription factor complexes containingTFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. Theunphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1,MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain ofTAF1. Interacts with SNW1, AATF, DNMT1, LIN9, LMNA, KMT5B, KMT5C,PELP1, UHRF2 and TMPO-alpha. May interact with NDC80. Interactswith GRIP1 and UBR4. Interacts with ARID4A and KDM5B. Interactswith E4F1 and LIMD1. Interacts with SMARCA4/BRG1 AND HDAC1 (Bysimilarity). Interacts with PSMA3 and USP4. Interacts (whenmethylated at Lys-860) with L3MBTL1. Interacts with CHEK2;phosphorylates RB1. Interacts with CEBPA (PubMed:15107404).Interacts with adenovirus E1A protein, HPV E7 protein and SV40large T antigen. Interacts with human cytomegalovirus/HHV-5protein UL123. P-TEFB complex interacts with RB1; promotesphosphorylation of RB1 (PubMed:12037672).{ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568,ECO:0000269|PubMed:10409732, ECO:0000269|PubMed:10446990,ECO:0000269|PubMed:10779342, ECO:0000269|PubMed:10869426,ECO:0000269|PubMed:10888886, ECO:0000269|PubMed:11223246,ECO:0000269|PubMed:11484059, ECO:0000269|PubMed:11571652,ECO:0000269|PubMed:12037672, ECO:0000269|PubMed:12450794,ECO:0000269|PubMed:12466551, ECO:0000269|PubMed:12475961,ECO:0000269|PubMed:12682072, ECO:0000269|PubMed:12695505,ECO:0000269|PubMed:1316611, ECO:0000269|PubMed:15107404,ECO:0000269|PubMed:15538385, ECO:0000269|PubMed:15542589,ECO:0000269|PubMed:15803180, ECO:0000269|PubMed:15927959,ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:16214886,ECO:0000269|PubMed:16337594, ECO:0000269|PubMed:16360038,ECO:0000269|PubMed:16645588, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:17974914, ECO:0000269|PubMed:17996702,ECO:0000269|PubMed:20870719, ECO:0000269|PubMed:21952639,ECO:0000269|PubMed:2839300, ECO:0000269|PubMed:7525595,ECO:0000269|PubMed:7935440, ECO:0000269|PubMed:8414517,ECO:0000269|PubMed:8892909, ECO:0000269|PubMed:9858607}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20940255}.TISSUE SPECIFICITY: Expressed in the retina.DOMAIN: The Pocket domain binds to the threonine-phosphorylateddomain C, thereby preventing interaction with heterodimeric E2F/DPtranscription factor complexes.PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 atSer-567 in G1, thereby releasing E2F1 which is then able toactivate cell growth. Dephosphorylated at the late M phase. SV40large T antigen, HPV E7 and adenovirus E1A bind to theunderphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domainC and the Pocket domain, and thereby inhibits interactions withheterodimeric E2F/DP transcription factor complexes.Dephosphorylated at Ser-795 by calcineruin upon calciumstimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 andSer-811 is required for G0-G1 transition. Phosphorylated by CDK1and CDK2 upon TGFB1-mediated apoptosis (By similarity).{ECO:0000250}.PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity).Monomethylation at Lys-810 by SMYD2 enhances phosphorylation atSer-807 and Ser-811, and promotes cell cycle progression.Monomethylation at Lys-860 by SMYD2 promotes interaction withL3MBTL1. {ECO:0000250, ECO:0000269|PubMed:10499802,ECO:0000269|PubMed:15084261, ECO:0000269|PubMed:15809340,ECO:0000269|PubMed:16360038, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:1756735, ECO:0000269|PubMed:20870719,ECO:0000269|PubMed:22787429, ECO:0000269|PubMed:8114739}.PTM: Acetylation at Lys-873 and Lys-874 regulates subcellularlocalization, at least during keratinocytes differentiation.{ECO:0000269|PubMed:20940255}.DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]:Congenital malignant tumor that arises from the nuclear layers ofthe retina. It occurs in about 1:20'000 live births and representsabout 2% of childhood malignancies. It is bilateral in about 30%of cases. Although most RB appear sporadically, about 20% aretransmitted as an autosomal dominant trait with incompletepenetrance. The diagnosis is usually made before the age of 2years when strabismus or a gray to yellow reflex from pupil ('cateye') is investigated. {ECO:0000269|PubMed:10671068,ECO:0000269|PubMed:11524739, ECO:0000269|PubMed:1352883,ECO:0000269|PubMed:2594029, ECO:0000269|PubMed:7704558,ECO:0000269|PubMed:7795591, ECO:0000269|PubMed:7927327,ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116,ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452,ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancyoriginating in tissues of the urinary bladder. It often presentswith multiple tumors appearing at different times and at differentsites in the bladder. Most bladder cancers are transitional cellcarcinomas that begin in cells that normally make up the innerlining of the bladder. Other types of bladder cancer includesquamous cell carcinoma (cancer that begins in thin, flat cells)and adenocarcinoma (cancer that begins in cells that make andrelease mucus and other fluids). Bladder cancer is a complexdisorder with both genetic and environmental influences.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcomaoriginating in bone-forming cells, affecting the ends of longbones. Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the retinoblastoma protein (RB) family.{ECO:0000305}.WEB RESOURCE: Name=RB1base; Note=RB1 mutation db;URL=\"http://rb1-lsdb.d-lohmann.de/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RB1ID90.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/rb1/\";WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry;URL=\"https://en.wikipedia.org/wiki/Retinoblastoma_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5925"],["bp:comment","RB_HUMAN Reviewed; 928 AA."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01574_identity"],["bp:comment","REPLACED ProteinRef_RB1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1GH6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-582N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80819"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","RB1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80817"]]],["bp:entityReference_http://identifiers.org/uniprot/P06400",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-methyllysine"],["bp:term","MOD_RES N6-methyllysine"]]],["bp:comment","MOD_RES 810 810 N6-methyllysine; by SMYD2."],["bp:featureLocation",[["bp:sequencePosition","810"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation","MOD_RES 788 788 Phosphoserine."]]],["bp:standardName","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:organism","Retinoblastoma-associated protein"],["bp:displayName","RB_HUMAN"],["bp:name","pp110"],["bp:name","Rb"],["bp:name","pRb"],["bp:name","RB1"],["bp:name","p105-Rb"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q5VW46"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5925"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_452"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5925"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000312"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-1208367_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PJM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P06400_identity"],["bp:comment","REPLACED ProteinRef_RB1__9606"],["bp:comment","FUNCTION: Key regulator of entry into cell division that acts as atumor suppressor. Promotes G0-G1 transition when phosphorylated byCDK3/cyclin-C. Acts as a transcription repressor of E2F1 targetgenes. The underphosphorylated, active form of RB1 interacts withE2F1 and represses its transcription activity, leading to cellcycle arrest. Directly involved in heterochromatin formation bymaintaining overall chromatin structure and, in particular, thatof constitutive heterochromatin by stabilizing histonemethylation. Recruits and targets histone methyltransferasesSUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptionalrepression. Controls histone H4 'Lys-20' trimethylation. Inhibitsthe intrinsic kinase activity of TAF1. Mediates transcriptionalrepression by SMARCA4/BRG1 by recruiting a histone deacetylase(HDAC) complex to the c-FOS promoter. In resting neurons,transcription of the c-FOS promoter is inhibited by BRG1-dependentrecruitment of a phospho-RB1-HDAC1 repressor complex. Upon calciuminflux, RB1 is dephosphorylated by calcineurin, which leads torelease of the repressor complex (By similarity). In case of viralinfections, interactions with SV40 large T antigen, HPV E7 proteinor adenovirus E1A protein induce the disassembly of RB1-E2F1complex thereby disrupting RB1's activity. {ECO:0000250,ECO:0000269|PubMed:15084261}.SUBUNIT: Interacts with ATAD5. Interacts with PRMT2, CDK1 and CDK2(By similarity). The hypophosphorylated form interacts with andsequesters the E2F1 transcription factor. Interacts withheterodimeric E2F/DP transcription factor complexes containingTFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. Theunphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1,MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain ofTAF1. Interacts with SNW1, AATF, DNMT1, LIN9, LMNA, KMT5B, KMT5C,PELP1, UHRF2 and TMPO-alpha. May interact with NDC80. Interactswith GRIP1 and UBR4. Interacts with ARID4A and KDM5B. Interactswith E4F1 and LIMD1. Interacts with SMARCA4/BRG1 AND HDAC1 (Bysimilarity). Interacts with PSMA3 and USP4. Interacts (whenmethylated at Lys-860) with L3MBTL1. Interacts with CHEK2;phosphorylates RB1. Interacts with CEBPA (PubMed:15107404).Interacts with adenovirus E1A protein, HPV E7 protein and SV40large T antigen. Interacts with human cytomegalovirus/HHV-5protein UL123. P-TEFB complex interacts with RB1; promotesphosphorylation of RB1 (PubMed:12037672).{ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568,ECO:0000269|PubMed:10409732, ECO:0000269|PubMed:10446990,ECO:0000269|PubMed:10779342, ECO:0000269|PubMed:10869426,ECO:0000269|PubMed:10888886, ECO:0000269|PubMed:11223246,ECO:0000269|PubMed:11484059, ECO:0000269|PubMed:11571652,ECO:0000269|PubMed:12037672, ECO:0000269|PubMed:12450794,ECO:0000269|PubMed:12466551, ECO:0000269|PubMed:12475961,ECO:0000269|PubMed:12682072, ECO:0000269|PubMed:12695505,ECO:0000269|PubMed:1316611, ECO:0000269|PubMed:15107404,ECO:0000269|PubMed:15538385, ECO:0000269|PubMed:15542589,ECO:0000269|PubMed:15803180, ECO:0000269|PubMed:15927959,ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:16214886,ECO:0000269|PubMed:16337594, ECO:0000269|PubMed:16360038,ECO:0000269|PubMed:16645588, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:17974914, ECO:0000269|PubMed:17996702,ECO:0000269|PubMed:20870719, ECO:0000269|PubMed:21952639,ECO:0000269|PubMed:2839300, ECO:0000269|PubMed:7525595,ECO:0000269|PubMed:7935440, ECO:0000269|PubMed:8414517,ECO:0000269|PubMed:8892909, ECO:0000269|PubMed:9858607}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20940255}.TISSUE SPECIFICITY: Expressed in the retina.DOMAIN: The Pocket domain binds to the threonine-phosphorylateddomain C, thereby preventing interaction with heterodimeric E2F/DPtranscription factor complexes.PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 atSer-567 in G1, thereby releasing E2F1 which is then able toactivate cell growth. Dephosphorylated at the late M phase. SV40large T antigen, HPV E7 and adenovirus E1A bind to theunderphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domainC and the Pocket domain, and thereby inhibits interactions withheterodimeric E2F/DP transcription factor complexes.Dephosphorylated at Ser-795 by calcineruin upon calciumstimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 andSer-811 is required for G0-G1 transition. Phosphorylated by CDK1and CDK2 upon TGFB1-mediated apoptosis (By similarity).{ECO:0000250}.PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity).Monomethylation at Lys-810 by SMYD2 enhances phosphorylation atSer-807 and Ser-811, and promotes cell cycle progression.Monomethylation at Lys-860 by SMYD2 promotes interaction withL3MBTL1. {ECO:0000250, ECO:0000269|PubMed:10499802,ECO:0000269|PubMed:15084261, ECO:0000269|PubMed:15809340,ECO:0000269|PubMed:16360038, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:1756735, ECO:0000269|PubMed:20870719,ECO:0000269|PubMed:22787429, ECO:0000269|PubMed:8114739}.PTM: Acetylation at Lys-873 and Lys-874 regulates subcellularlocalization, at least during keratinocytes differentiation.{ECO:0000269|PubMed:20940255}.DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]:Congenital malignant tumor that arises from the nuclear layers ofthe retina. It occurs in about 1:20'000 live births and representsabout 2% of childhood malignancies. It is bilateral in about 30%of cases. Although most RB appear sporadically, about 20% aretransmitted as an autosomal dominant trait with incompletepenetrance. The diagnosis is usually made before the age of 2years when strabismus or a gray to yellow reflex from pupil ('cateye') is investigated. {ECO:0000269|PubMed:10671068,ECO:0000269|PubMed:11524739, ECO:0000269|PubMed:1352883,ECO:0000269|PubMed:2594029, ECO:0000269|PubMed:7704558,ECO:0000269|PubMed:7795591, ECO:0000269|PubMed:7927327,ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116,ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452,ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancyoriginating in tissues of the urinary bladder. It often presentswith multiple tumors appearing at different times and at differentsites in the bladder. Most bladder cancers are transitional cellcarcinomas that begin in cells that normally make up the innerlining of the bladder. Other types of bladder cancer includesquamous cell carcinoma (cancer that begins in thin, flat cells)and adenocarcinoma (cancer that begins in cells that make andrelease mucus and other fluids). Bladder cancer is a complexdisorder with both genetic and environmental influences.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcomaoriginating in bone-forming cells, affecting the ends of longbones. Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the retinoblastoma protein (RB) family.{ECO:0000305}.WEB RESOURCE: Name=RB1base; Note=RB1 mutation db;URL=\"http://rb1-lsdb.d-lohmann.de/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RB1ID90.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/rb1/\";WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry;URL=\"https://en.wikipedia.org/wiki/Retinoblastoma_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5925"],["bp:comment","RB_HUMAN Reviewed; 928 AA."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01574_identity"],["bp:comment","REPLACED ProteinRef_RB1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1GH6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-582N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80819"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80811"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80811"]]}},{"data":{"id":"Protein_e549451165253d4377bcbdda737a9c85","class":"macromolecule","label":"SMPD1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1010.37415,"y":438.07776,"w":48,"h":25},"metadata":[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1200.0616,"y":451.8457,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","IKKs"],["bp:entityReference_http://identifiers.org/uniprot/O15111",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 23 23 Phosphothreonine; by PKB/AKT1 and SGK1."],["bp:featureLocation",[["bp:sequencePosition","23"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES O-acetylthreonine"],["bp:term","O-acetylthreonine"]]],["bp:comment","MOD_RES 179 179 O-acetylthreonine; by Yersinia yopJ."],["bp:featureLocation",[["bp:sequencePosition","179"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:standardName","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:organism","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:displayName","IKKA_HUMAN"],["bp:name","Transcription factor 16"],["bp:name","TCF16"],["bp:name","CHUK"],["bp:name","IKK-alpha"],["bp:name","TCF-16"],["bp:name","Nuclear factor NF-kappa-B inhibitor kinase alpha"],["bp:name","I-kappa-B kinase alpha"],["bp:name","Conserved helix-loop-helix ubiquitous kinase"],["bp:name","IKKA"],["bp:name","I-kappa-B kinase 1"],["bp:name","IkappaB kinase"],["bp:name","IkBKA"],["bp:name","IKK-A"],["bp:name","IKK1"],["bp:name","2.7.11.10"],["bp:name","NFKBIKA"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-27526N_identity"],["bp:comment","IKKA_HUMAN Reviewed; 745 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1147"],["bp:comment","REPLACED ProteinRef_CHUK__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001269"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_461"],["bp:comment","REPLACED http://identifiers.org/ncbigene/1147"],["bp:comment","REPLACED ProteinRef_CHUK__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_O15111_identity"],["bp:comment","FUNCTION: Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimulisuch as inflammatory cytokines, bacterial or viral products, DNAdamages or other cellular stresses. Acts as part of the canonicalIKK complex in the conventional pathway of NF-kappa-B activationand phosphorylates inhibitors of NF-kappa-B on serine residues.These modifications allow polyubiquitination of the inhibitors andsubsequent degradation by the proteasome. In turn, free NF-kappa-Bis translocated into the nucleus and activates the transcriptionof hundreds of genes involved in immune response, growth control,or protection against apoptosis. Negatively regulates the pathwayby phosphorylating the scaffold protein TAXBP1 and thus promotingthe assembly of the A20/TNFAIP3 ubiquitin-editing complex(composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH andRNF11). Therefore, CHUK plays a key role in the negative feedbackof NF-kappa-B canonical signaling to limit inflammatory geneactivation. As part of the non-canonical pathway of NF-kappa-Bactivation, the MAP3K14-activated CHUK/IKKA homodimerphosphorylates NFKB2/p100 associated with RelB, inducing itsproteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genesencoding molecules involved in B-cell survival and lymphoidorganogenesis. Participates also in the negative feedback of thenon-canonical NF-kappa-B signaling pathway by phosphorylating anddestabilizing MAP3K14/NIK. Within the nucleus, phosphorylatesCREBBP and consequently increases both its transcriptional andhistone acetyltransferase activities. Modulates chromatinaccessibility at NF-kappa-B-responsive promoters byphosphorylating histones H3 at 'Ser-10' that are subsequentlyacetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates theCREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 andmay regulate this pro-apoptotic transcription factor(PubMed:15084260). {ECO:0000269|PubMed:12789342,ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:17434128,ECO:0000269|PubMed:20434986, ECO:0000269|PubMed:20501937,ECO:0000269|PubMed:21765415}.CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-Bphosphoprotein].ENZYME REGULATION: Activated when phosphorylated and inactivatedwhen dephosphorylated.SUBUNIT: Component of the I-kappa-B-kinase (IKK) core complexconsisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits.The IKK core complex seems to associate with regulatory or adapterproteins to form a IKK-signalosome holo-complex (PubMed:10195894,PubMed:12612076). The IKK complex associates with TERF2IP/RAP1,leading to promote IKK-mediated phosphorylation of RELA/p65 (Bysimilarity). Part of a complex composed of NCOA2, NCOA3,CHUK/IKKA, IKBKB, IKBKG and CREBBP (PubMed:11971985). Part of a70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA,RELA, IKBKAP and MAP3K14 (PubMed:9751059). Directly interacts withTRPC4AP (By similarity). May interact with TRAF2(PubMed:19150425). Interacts with NALP2 (PubMed:15456791). Mayinteract with MAVS/IPS1 (PubMed:16177806). Interacts with ARRB1and ARRB2 (PubMed:15173580). Interacts with NLRC5; prevents CHUKphosphorylation and kinase activity (PubMed:20434986). Interactswith PIAS1; this interaction induces PIAS1 phosphorylation(PubMed:17540171). Interacts with ZNF268 isoform 2; theinteraction is further increased in a TNF-alpha-dependent manner(PubMed:23091055). Interacts with FOXO3 (PubMed:15084260).Interacts with IFIT5; the interaction synergizes the recruitmentof IKK to MAP3K7 and enhances IKK phosphorylation(PubMed:26334375). {ECO:0000250|UniProtKB:Q60680,ECO:0000269|PubMed:10195894, ECO:0000269|PubMed:11971985,ECO:0000269|PubMed:12612076, ECO:0000269|PubMed:15084260,ECO:0000269|PubMed:15173580, ECO:0000269|PubMed:15456791,ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:17540171,ECO:0000269|PubMed:19150425, ECO:0000269|PubMed:20434986,ECO:0000269|PubMed:23091055, ECO:0000269|PubMed:26334375,ECO:0000269|PubMed:9751059}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12789342}.Nucleus {ECO:0000269|PubMed:12789342}. Note=Shuttles between thecytoplasm and the nucleus.TISSUE SPECIFICITY: Widely expressed.DOMAIN: The kinase domain is located in the N-terminal region. Theleucine zipper is important to allow homo- and hetero-dimerization. At the C-terminal region is located the regionresponsible for the interaction with NEMO/IKBKG.{ECO:0000269|PubMed:18626576}.PTM: Phosphorylated by MAP3K14/NIK, AKT and to a lesser extent byMEKK1, and dephosphorylated by PP2A. Autophosphorylated.PTM: (Microbial infection) Acetylation of Thr-179 by Yersinia yopJprevents phosphorylation and activation, thus blocking the I-kappa-B signaling pathway. {ECO:0000269|PubMed:17116858}.DISEASE: Cocoon syndrome (COCOS) [MIM:613630]: A lethal syndromecharacterized by multiple fetal malformations including defectiveface and seemingly absent limbs, which are bound to the trunk andencased under the skin. {ECO:0000269|PubMed:20961246}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. I-kappa-B kinase subfamily.{ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/chuk/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_CHUK__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1147"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-5773277_identity"]]],["bp:name","IKK alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80778"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","IKKs"],["bp:entityReference_http://identifiers.org/uniprot/O15111",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 23 23 Phosphothreonine; by PKB/AKT1 and SGK1."],["bp:featureLocation",[["bp:sequencePosition","23"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES O-acetylthreonine"],["bp:term","O-acetylthreonine"]]],["bp:comment","MOD_RES 179 179 O-acetylthreonine; by Yersinia yopJ."],["bp:featureLocation",[["bp:sequencePosition","179"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:standardName","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:organism","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:displayName","IKKA_HUMAN"],["bp:name","Transcription factor 16"],["bp:name","TCF16"],["bp:name","CHUK"],["bp:name","IKK-alpha"],["bp:name","TCF-16"],["bp:name","Nuclear factor NF-kappa-B inhibitor kinase alpha"],["bp:name","I-kappa-B kinase alpha"],["bp:name","Conserved helix-loop-helix ubiquitous kinase"],["bp:name","IKKA"],["bp:name","I-kappa-B kinase 1"],["bp:name","IkappaB kinase"],["bp:name","IkBKA"],["bp:name","IKK-A"],["bp:name","IKK1"],["bp:name","2.7.11.10"],["bp:name","NFKBIKA"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-27526N_identity"],["bp:comment","IKKA_HUMAN Reviewed; 745 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1147"],["bp:comment","REPLACED ProteinRef_CHUK__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001269"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_461"],["bp:comment","REPLACED http://identifiers.org/ncbigene/1147"],["bp:comment","REPLACED ProteinRef_CHUK__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_O15111_identity"],["bp:comment","FUNCTION: Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimulisuch as inflammatory cytokines, bacterial or viral products, DNAdamages or other cellular stresses. Acts as part of the canonicalIKK complex in the conventional pathway of NF-kappa-B activationand phosphorylates inhibitors of NF-kappa-B on serine residues.These modifications allow polyubiquitination of the inhibitors andsubsequent degradation by the proteasome. In turn, free NF-kappa-Bis translocated into the nucleus and activates the transcriptionof hundreds of genes involved in immune response, growth control,or protection against apoptosis. Negatively regulates the pathwayby phosphorylating the scaffold protein TAXBP1 and thus promotingthe assembly of the A20/TNFAIP3 ubiquitin-editing complex(composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH andRNF11). Therefore, CHUK plays a key role in the negative feedbackof NF-kappa-B canonical signaling to limit inflammatory geneactivation. As part of the non-canonical pathway of NF-kappa-Bactivation, the MAP3K14-activated CHUK/IKKA homodimerphosphorylates NFKB2/p100 associated with RelB, inducing itsproteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genesencoding molecules involved in B-cell survival and lymphoidorganogenesis. Participates also in the negative feedback of thenon-canonical NF-kappa-B signaling pathway by phosphorylating anddestabilizing MAP3K14/NIK. Within the nucleus, phosphorylatesCREBBP and consequently increases both its transcriptional andhistone acetyltransferase activities. Modulates chromatinaccessibility at NF-kappa-B-responsive promoters byphosphorylating histones H3 at 'Ser-10' that are subsequentlyacetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates theCREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 andmay regulate this pro-apoptotic transcription factor(PubMed:15084260). {ECO:0000269|PubMed:12789342,ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:17434128,ECO:0000269|PubMed:20434986, ECO:0000269|PubMed:20501937,ECO:0000269|PubMed:21765415}.CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-Bphosphoprotein].ENZYME REGULATION: Activated when phosphorylated and inactivatedwhen dephosphorylated.SUBUNIT: Component of the I-kappa-B-kinase (IKK) core complexconsisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits.The IKK core complex seems to associate with regulatory or adapterproteins to form a IKK-signalosome holo-complex (PubMed:10195894,PubMed:12612076). The IKK complex associates with TERF2IP/RAP1,leading to promote IKK-mediated phosphorylation of RELA/p65 (Bysimilarity). Part of a complex composed of NCOA2, NCOA3,CHUK/IKKA, IKBKB, IKBKG and CREBBP (PubMed:11971985). Part of a70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA,RELA, IKBKAP and MAP3K14 (PubMed:9751059). Directly interacts withTRPC4AP (By similarity). May interact with TRAF2(PubMed:19150425). Interacts with NALP2 (PubMed:15456791). Mayinteract with MAVS/IPS1 (PubMed:16177806). Interacts with ARRB1and ARRB2 (PubMed:15173580). Interacts with NLRC5; prevents CHUKphosphorylation and kinase activity (PubMed:20434986). Interactswith PIAS1; this interaction induces PIAS1 phosphorylation(PubMed:17540171). Interacts with ZNF268 isoform 2; theinteraction is further increased in a TNF-alpha-dependent manner(PubMed:23091055). Interacts with FOXO3 (PubMed:15084260).Interacts with IFIT5; the interaction synergizes the recruitmentof IKK to MAP3K7 and enhances IKK phosphorylation(PubMed:26334375). {ECO:0000250|UniProtKB:Q60680,ECO:0000269|PubMed:10195894, ECO:0000269|PubMed:11971985,ECO:0000269|PubMed:12612076, ECO:0000269|PubMed:15084260,ECO:0000269|PubMed:15173580, ECO:0000269|PubMed:15456791,ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:17540171,ECO:0000269|PubMed:19150425, ECO:0000269|PubMed:20434986,ECO:0000269|PubMed:23091055, ECO:0000269|PubMed:26334375,ECO:0000269|PubMed:9751059}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12789342}.Nucleus {ECO:0000269|PubMed:12789342}. Note=Shuttles between thecytoplasm and the nucleus.TISSUE SPECIFICITY: Widely expressed.DOMAIN: The kinase domain is located in the N-terminal region. Theleucine zipper is important to allow homo- and hetero-dimerization. At the C-terminal region is located the regionresponsible for the interaction with NEMO/IKBKG.{ECO:0000269|PubMed:18626576}.PTM: Phosphorylated by MAP3K14/NIK, AKT and to a lesser extent byMEKK1, and dephosphorylated by PP2A. Autophosphorylated.PTM: (Microbial infection) Acetylation of Thr-179 by Yersinia yopJprevents phosphorylation and activation, thus blocking the I-kappa-B signaling pathway. {ECO:0000269|PubMed:17116858}.DISEASE: Cocoon syndrome (COCOS) [MIM:613630]: A lethal syndromecharacterized by multiple fetal malformations including defectiveface and seemingly absent limbs, which are bound to the trunk andencased under the skin. {ECO:0000269|PubMed:20961246}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. I-kappa-B kinase subfamily.{ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/chuk/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_CHUK__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1147"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-5773277_identity"]]],["bp:name","IKK alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80778"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","IKKs"],["bp:entityReference_http://identifiers.org/uniprot/O15111",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 23 23 Phosphothreonine; by PKB/AKT1 and SGK1."],["bp:featureLocation",[["bp:sequencePosition","23"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES O-acetylthreonine"],["bp:term","O-acetylthreonine"]]],["bp:comment","MOD_RES 179 179 O-acetylthreonine; by Yersinia yopJ."],["bp:featureLocation",[["bp:sequencePosition","179"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:standardName","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:organism","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:displayName","IKKA_HUMAN"],["bp:name","Transcription factor 16"],["bp:name","TCF16"],["bp:name","CHUK"],["bp:name","IKK-alpha"],["bp:name","TCF-16"],["bp:name","Nuclear factor NF-kappa-B inhibitor kinase alpha"],["bp:name","I-kappa-B kinase alpha"],["bp:name","Conserved helix-loop-helix ubiquitous kinase"],["bp:name","IKKA"],["bp:name","I-kappa-B kinase 1"],["bp:name","IkappaB kinase"],["bp:name","IkBKA"],["bp:name","IKK-A"],["bp:name","IKK1"],["bp:name","2.7.11.10"],["bp:name","NFKBIKA"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-27526N_identity"],["bp:comment","IKKA_HUMAN Reviewed; 745 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1147"],["bp:comment","REPLACED ProteinRef_CHUK__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001269"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_461"],["bp:comment","REPLACED http://identifiers.org/ncbigene/1147"],["bp:comment","REPLACED ProteinRef_CHUK__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_O15111_identity"],["bp:comment","FUNCTION: Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimulisuch as inflammatory cytokines, bacterial or viral products, DNAdamages or other cellular stresses. Acts as part of the canonicalIKK complex in the conventional pathway of NF-kappa-B activationand phosphorylates inhibitors of NF-kappa-B on serine residues.These modifications allow polyubiquitination of the inhibitors andsubsequent degradation by the proteasome. In turn, free NF-kappa-Bis translocated into the nucleus and activates the transcriptionof hundreds of genes involved in immune response, growth control,or protection against apoptosis. Negatively regulates the pathwayby phosphorylating the scaffold protein TAXBP1 and thus promotingthe assembly of the A20/TNFAIP3 ubiquitin-editing complex(composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH andRNF11). Therefore, CHUK plays a key role in the negative feedbackof NF-kappa-B canonical signaling to limit inflammatory geneactivation. As part of the non-canonical pathway of NF-kappa-Bactivation, the MAP3K14-activated CHUK/IKKA homodimerphosphorylates NFKB2/p100 associated with RelB, inducing itsproteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genesencoding molecules involved in B-cell survival and lymphoidorganogenesis. Participates also in the negative feedback of thenon-canonical NF-kappa-B signaling pathway by phosphorylating anddestabilizing MAP3K14/NIK. Within the nucleus, phosphorylatesCREBBP and consequently increases both its transcriptional andhistone acetyltransferase activities. Modulates chromatinaccessibility at NF-kappa-B-responsive promoters byphosphorylating histones H3 at 'Ser-10' that are subsequentlyacetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates theCREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 andmay regulate this pro-apoptotic transcription factor(PubMed:15084260). {ECO:0000269|PubMed:12789342,ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:17434128,ECO:0000269|PubMed:20434986, ECO:0000269|PubMed:20501937,ECO:0000269|PubMed:21765415}.CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-Bphosphoprotein].ENZYME REGULATION: Activated when phosphorylated and inactivatedwhen dephosphorylated.SUBUNIT: Component of the I-kappa-B-kinase (IKK) core complexconsisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits.The IKK core complex seems to associate with regulatory or adapterproteins to form a IKK-signalosome holo-complex (PubMed:10195894,PubMed:12612076). The IKK complex associates with TERF2IP/RAP1,leading to promote IKK-mediated phosphorylation of RELA/p65 (Bysimilarity). Part of a complex composed of NCOA2, NCOA3,CHUK/IKKA, IKBKB, IKBKG and CREBBP (PubMed:11971985). Part of a70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA,RELA, IKBKAP and MAP3K14 (PubMed:9751059). Directly interacts withTRPC4AP (By similarity). May interact with TRAF2(PubMed:19150425). Interacts with NALP2 (PubMed:15456791). Mayinteract with MAVS/IPS1 (PubMed:16177806). Interacts with ARRB1and ARRB2 (PubMed:15173580). Interacts with NLRC5; prevents CHUKphosphorylation and kinase activity (PubMed:20434986). Interactswith PIAS1; this interaction induces PIAS1 phosphorylation(PubMed:17540171). Interacts with ZNF268 isoform 2; theinteraction is further increased in a TNF-alpha-dependent manner(PubMed:23091055). Interacts with FOXO3 (PubMed:15084260).Interacts with IFIT5; the interaction synergizes the recruitmentof IKK to MAP3K7 and enhances IKK phosphorylation(PubMed:26334375). {ECO:0000250|UniProtKB:Q60680,ECO:0000269|PubMed:10195894, ECO:0000269|PubMed:11971985,ECO:0000269|PubMed:12612076, ECO:0000269|PubMed:15084260,ECO:0000269|PubMed:15173580, ECO:0000269|PubMed:15456791,ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:17540171,ECO:0000269|PubMed:19150425, ECO:0000269|PubMed:20434986,ECO:0000269|PubMed:23091055, ECO:0000269|PubMed:26334375,ECO:0000269|PubMed:9751059}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12789342}.Nucleus {ECO:0000269|PubMed:12789342}. Note=Shuttles between thecytoplasm and the nucleus.TISSUE SPECIFICITY: Widely expressed.DOMAIN: The kinase domain is located in the N-terminal region. Theleucine zipper is important to allow homo- and hetero-dimerization. At the C-terminal region is located the regionresponsible for the interaction with NEMO/IKBKG.{ECO:0000269|PubMed:18626576}.PTM: Phosphorylated by MAP3K14/NIK, AKT and to a lesser extent byMEKK1, and dephosphorylated by PP2A. Autophosphorylated.PTM: (Microbial infection) Acetylation of Thr-179 by Yersinia yopJprevents phosphorylation and activation, thus blocking the I-kappa-B signaling pathway. {ECO:0000269|PubMed:17116858}.DISEASE: Cocoon syndrome (COCOS) [MIM:613630]: A lethal syndromecharacterized by multiple fetal malformations including defectiveface and seemingly absent limbs, which are bound to the trunk andencased under the skin. {ECO:0000269|PubMed:20961246}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. I-kappa-B kinase subfamily.{ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/chuk/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_CHUK__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1147"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-5773277_identity"]]],["bp:name","IKK alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80778"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","IKKs"],["bp:entityReference_http://identifiers.org/uniprot/O15111",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 23 23 Phosphothreonine; by PKB/AKT1 and SGK1."],["bp:featureLocation",[["bp:sequencePosition","23"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES O-acetylthreonine"],["bp:term","O-acetylthreonine"]]],["bp:comment","MOD_RES 179 179 O-acetylthreonine; by Yersinia yopJ."],["bp:featureLocation",[["bp:sequencePosition","179"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_O15111"]]],["bp:standardName","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:xref","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:organism","Inhibitor of nuclear factor kappa-B kinase subunit alpha"],["bp:displayName","IKKA_HUMAN"],["bp:name","Transcription factor 16"],["bp:name","TCF16"],["bp:name","CHUK"],["bp:name","IKK-alpha"],["bp:name","TCF-16"],["bp:name","Nuclear factor NF-kappa-B inhibitor kinase alpha"],["bp:name","I-kappa-B kinase alpha"],["bp:name","Conserved helix-loop-helix ubiquitous kinase"],["bp:name","IKKA"],["bp:name","I-kappa-B kinase 1"],["bp:name","IkappaB kinase"],["bp:name","IkBKA"],["bp:name","IKK-A"],["bp:name","IKK1"],["bp:name","2.7.11.10"],["bp:name","NFKBIKA"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-27526N_identity"],["bp:comment","IKKA_HUMAN Reviewed; 745 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1147"],["bp:comment","REPLACED ProteinRef_CHUK__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001269"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_461"],["bp:comment","REPLACED http://identifiers.org/ncbigene/1147"],["bp:comment","REPLACED ProteinRef_CHUK__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_O15111_identity"],["bp:comment","FUNCTION: Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimulisuch as inflammatory cytokines, bacterial or viral products, DNAdamages or other cellular stresses. Acts as part of the canonicalIKK complex in the conventional pathway of NF-kappa-B activationand phosphorylates inhibitors of NF-kappa-B on serine residues.These modifications allow polyubiquitination of the inhibitors andsubsequent degradation by the proteasome. In turn, free NF-kappa-Bis translocated into the nucleus and activates the transcriptionof hundreds of genes involved in immune response, growth control,or protection against apoptosis. Negatively regulates the pathwayby phosphorylating the scaffold protein TAXBP1 and thus promotingthe assembly of the A20/TNFAIP3 ubiquitin-editing complex(composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH andRNF11). Therefore, CHUK plays a key role in the negative feedbackof NF-kappa-B canonical signaling to limit inflammatory geneactivation. As part of the non-canonical pathway of NF-kappa-Bactivation, the MAP3K14-activated CHUK/IKKA homodimerphosphorylates NFKB2/p100 associated with RelB, inducing itsproteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genesencoding molecules involved in B-cell survival and lymphoidorganogenesis. Participates also in the negative feedback of thenon-canonical NF-kappa-B signaling pathway by phosphorylating anddestabilizing MAP3K14/NIK. Within the nucleus, phosphorylatesCREBBP and consequently increases both its transcriptional andhistone acetyltransferase activities. Modulates chromatinaccessibility at NF-kappa-B-responsive promoters byphosphorylating histones H3 at 'Ser-10' that are subsequentlyacetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates theCREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 andmay regulate this pro-apoptotic transcription factor(PubMed:15084260). {ECO:0000269|PubMed:12789342,ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:17434128,ECO:0000269|PubMed:20434986, ECO:0000269|PubMed:20501937,ECO:0000269|PubMed:21765415}.CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-Bphosphoprotein].ENZYME REGULATION: Activated when phosphorylated and inactivatedwhen dephosphorylated.SUBUNIT: Component of the I-kappa-B-kinase (IKK) core complexconsisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits.The IKK core complex seems to associate with regulatory or adapterproteins to form a IKK-signalosome holo-complex (PubMed:10195894,PubMed:12612076). The IKK complex associates with TERF2IP/RAP1,leading to promote IKK-mediated phosphorylation of RELA/p65 (Bysimilarity). Part of a complex composed of NCOA2, NCOA3,CHUK/IKKA, IKBKB, IKBKG and CREBBP (PubMed:11971985). Part of a70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA,RELA, IKBKAP and MAP3K14 (PubMed:9751059). Directly interacts withTRPC4AP (By similarity). May interact with TRAF2(PubMed:19150425). Interacts with NALP2 (PubMed:15456791). Mayinteract with MAVS/IPS1 (PubMed:16177806). Interacts with ARRB1and ARRB2 (PubMed:15173580). Interacts with NLRC5; prevents CHUKphosphorylation and kinase activity (PubMed:20434986). Interactswith PIAS1; this interaction induces PIAS1 phosphorylation(PubMed:17540171). Interacts with ZNF268 isoform 2; theinteraction is further increased in a TNF-alpha-dependent manner(PubMed:23091055). Interacts with FOXO3 (PubMed:15084260).Interacts with IFIT5; the interaction synergizes the recruitmentof IKK to MAP3K7 and enhances IKK phosphorylation(PubMed:26334375). {ECO:0000250|UniProtKB:Q60680,ECO:0000269|PubMed:10195894, ECO:0000269|PubMed:11971985,ECO:0000269|PubMed:12612076, ECO:0000269|PubMed:15084260,ECO:0000269|PubMed:15173580, ECO:0000269|PubMed:15456791,ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:17540171,ECO:0000269|PubMed:19150425, ECO:0000269|PubMed:20434986,ECO:0000269|PubMed:23091055, ECO:0000269|PubMed:26334375,ECO:0000269|PubMed:9751059}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12789342}.Nucleus {ECO:0000269|PubMed:12789342}. Note=Shuttles between thecytoplasm and the nucleus.TISSUE SPECIFICITY: Widely expressed.DOMAIN: The kinase domain is located in the N-terminal region. Theleucine zipper is important to allow homo- and hetero-dimerization. At the C-terminal region is located the regionresponsible for the interaction with NEMO/IKBKG.{ECO:0000269|PubMed:18626576}.PTM: Phosphorylated by MAP3K14/NIK, AKT and to a lesser extent byMEKK1, and dephosphorylated by PP2A. Autophosphorylated.PTM: (Microbial infection) Acetylation of Thr-179 by Yersinia yopJprevents phosphorylation and activation, thus blocking the I-kappa-B signaling pathway. {ECO:0000269|PubMed:17116858}.DISEASE: Cocoon syndrome (COCOS) [MIM:613630]: A lethal syndromecharacterized by multiple fetal malformations including defectiveface and seemingly absent limbs, which are bound to the trunk andencased under the skin. {ECO:0000269|PubMed:20961246}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. I-kappa-B kinase subfamily.{ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/chuk/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_CHUK__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1147"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-5773277_identity"]]],["bp:name","IKK alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2250"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80778"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80776"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80776"]]}},{"data":{"id":"Protein_14e265016d0859a57c55cecd6ddaea95","class":"macromolecule","label":"PRKRA","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":275.78961000000004,"y":292.55313,"w":48,"h":25},"metadata":[["bp:displayName","RAX"],["bp:entityReference_http://identifiers.org/uniprot/O75569",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 18 18 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","18"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 246 246 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","246"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 287 287 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","287"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:organism","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:displayName","PRKRA_HUMAN"],["bp:name","PACT"],["bp:name","Protein activator of the interferon-induced protein kinase"],["bp:name","RAX"],["bp:name","PKR-associating protein X"],["bp:name","PRKRA"],["bp:name","Protein kinase, interferon-inducible double-stranded RNA-dependent activator"],["bp:name","PKR-associated protein X"],["bp:comment","FUNCTION: Activates EIF2AK2/PKR in the absence of double-strandedRNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha andinhibition of translation and induction of apoptosis. Required forsiRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required forprocessing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53association and sumoylation and phosphorylation of p53/TP53 at'Lys-386' at 'Ser-392' respectively and enhances its activity in aEIF2AK2/PKR-dependent manner (By similarity). {ECO:0000250,ECO:0000269|PubMed:10336432, ECO:0000269|PubMed:11238927,ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:16982605,ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:9687506}.SUBUNIT: Homodimer. Interacts with EIF2AK2/PKR through its DRBMdomains. Interacts with DICER1, AGO2 and TARBP2. Also able tointeract with dsRNA. Interacts with UBC9 (By similarity). Forms acomplex with UBC9 and p53/TP53 (By similarity). Interacts withDUS2L (via DRBM domain). {ECO:0000250,ECO:0000269|PubMed:11238927, ECO:0000269|PubMed:16424907,ECO:0000269|PubMed:16982605, ECO:0000269|PubMed:17452327,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18421256,ECO:0000269|PubMed:9687506}.SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=O75569-1; Sequence=Displayed;Name=2;IsoId=O75569-2; Sequence=VSP_017283;Note=No experimental confirmation available.;Name=3;IsoId=O75569-3; Sequence=VSP_017282;Note=No experimental confirmation available.;DOMAIN: Self-association may occur via interactions between DRBMdomains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 orDRBM 3/DRBM3.PTM: Phosphorylated at Ser-246 in unstressed cells and at Ser-287in stressed cells. Phosphorylation at Ser-246 appears to be aprerequisite for subsequent phosphorylation at Ser-287.Phosphorylation at Ser-246 and Ser-287 are necessary foractivation of EIF2AK2/PKR under conditions of stress.{ECO:0000269|PubMed:16982605}.DISEASE: Dystonia 16 (DYT16) [MIM:612067]: An early-onsetdystonia-parkinsonism disorder. Dystonia is defined by thepresence of sustained involuntary muscle contraction, oftenleading to abnormal postures. DYT16 patients have progressive,generalized dystonia with axial muscle involvement, oro-mandibular(sardonic smile) and laryngeal dystonia and, in some cases,parkinsonian features. {ECO:0000269|PubMed:18243799,ECO:0000269|PubMed:18420150}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the PRKRA family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41809N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04573_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246978"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003681"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8575"],["bp:comment","PRKRA_HUMAN Reviewed; 313 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8575"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"]]}},{"data":{"id":"BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":284.11563,"y":912.22314,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80895"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80895"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80895"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80895"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80894"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80894"]]}},{"data":{"id":"Protein_065c6912b75528c460d6a73e12b20aef","class":"macromolecule","label":"IGF1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_065c6912b75528c460d6a73e12b20aef.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":295.00107,"y":827.78204,"w":48,"h":25},"metadata":[["bp:displayName","IGF1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80807"]]],["bp:entityReference_http://identifiers.org/uniprot/P05019",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P05019"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P05019"]]],["bp:standardName","Insulin-like growth factor I"],["bp:xref",[["bp:id","P05019"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","IGF1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","IGF1"],["bp:db","hgnc symbol"]]],["bp:displayName","IGF1_HUMAN"],["bp:name","Mechano growth factor"],["bp:name","IBP1"],["bp:name","IGF-I"],["bp:name","Somatomedin-C"],["bp:name","IGF1"],["bp:name","MGF"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P05019"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3479"],["bp:comment","FUNCTION: The insulin-like growth factors, isolated from plasma,are structurally and functionally related to insulin but have amuch higher growth-promoting activity. May be a physiologicalregulator of [1-14C]-2-deoxy-D-glucose (2DG) transport andglycogen synthesis in osteoblasts. Stimulates glucose transport inbone-derived osteoblastic (PyMS) cells and is effective at muchlower concentrations than insulin, not only regarding glycogen andDNA synthesis but also with regard to enhancing glucose uptake.May play a role in synapse maturation (PubMed:21076856,PubMed:24132240). Ca(2+)-dependent exocytosis of IGF1 is requiredfor sensory perception of smell in the olfactory bulb (Bysimilarity). Acts as a ligand for IGF1R. Binds to the alphasubunit of IGF1R, leading to the activation of the intrinsictyrosine kinase activity which autophosphorylates tyrosineresidues in the beta subunit thus initiatiating a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKBand the Ras-MAPK pathways. Binds to integrins ITGAV:ITGB3 andITGA6:ITGB4. Its binding to integrins and subsequent ternarycomplex formation with integrins and IGFR1 are essential for IGF1signaling. Induces the phosphorylation and activation of IGFR1,MAPK3/ERK1, MAPK1/ERK2 and AKT1 (PubMed:19578119, PubMed:22351760,PubMed:23696648, PubMed:23243309). {ECO:0000250|UniProtKB:P05017,ECO:0000269|PubMed:19578119, ECO:0000269|PubMed:21076856,ECO:0000269|PubMed:22351760, ECO:0000269|PubMed:23243309,ECO:0000269|PubMed:23696648, ECO:0000269|PubMed:24132240}.SUBUNIT: Forms a ternary complex with IGFR1 and ITGAV:ITGB3(PubMed:19578119). Forms a ternary complex with IGFR1 andITGA6:ITGB4 (PubMed:22351760, PubMed:23696648).{ECO:0000269|PubMed:19578119, ECO:0000269|PubMed:22351760,ECO:0000269|PubMed:23696648}.SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P05017}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=IGF-IB;IsoId=P05019-1; Sequence=Displayed;Name=2; Synonyms=IGF-IA;IsoId=P05019-2; Sequence=VSP_039637;Name=3;IsoId=P05019-3; Sequence=VSP_043317, VSP_039637;Note=Expressed in liver.;Name=4;IsoId=P05019-4; Sequence=VSP_047399;Note=Gene prediction based on EST data.;DISEASE: Insulin-like growth factor I deficiency (IGF1 deficiency)[MIM:608747]: Autosomal recessive disorder characterized by growthretardation, sensorineural deafness and mental retardation.{ECO:0000269|PubMed:8857020}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the insulin family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA27250.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=HLA-DQB1\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/igf1/\";WEB RESOURCE: Name=Wikipedia; Note=Insulin-like growth factor 1entry;URL=\"https://en.wikipedia.org/wiki/Insulin-like_growth_factor_1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1GZY_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-6021N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00936_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/P01343"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P05019-2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41933N_identity"],["bp:comment","IGF1_HUMAN Reviewed; 195 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IMX_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3479"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PMX_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/3479"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80806"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Complex_ddce8736f5a22a8c0af9357a774894ac","class":"complex","label":"TNFR1A/BAG4","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":886.677,"y":132.296295,"w":52,"h":59},"metadata":[["bp:displayName","TNFR1A/BAG4"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80761"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80761"]]}},{"data":{"id":"Protein_12bcf51c75aae38cdb2620e757a2f48e_Complex_ddce8736f5a22a8c0af9357a774894ac","class":"macromolecule","label":"TNFRSF1A","parent":"Complex_ddce8736f5a22a8c0af9357a774894ac","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":886.677,"y":147.2963,"w":48,"h":25},"metadata":[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_89f70a1844b25ec5984cf26a32b0e470_Complex_ddce8736f5a22a8c0af9357a774894ac","class":"macromolecule","label":"BAG4","parent":"Complex_ddce8736f5a22a8c0af9357a774894ac","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":886.677,"y":117.296295,"w":48,"h":25},"metadata":[["bp:displayName","BAG4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95429",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Omega-N-methylarginine"],["bp:term","Omega-N-methylarginine"]]],["bp:comment","MOD_RES 185 185 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 53 53 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","53"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 108 108 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 108 108 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 108 108 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","BAG family molecular chaperone regulator 4"],["bp:xref","BAG family molecular chaperone regulator 4"],["bp:xref","BAG family molecular chaperone regulator 4"],["bp:organism","BAG family molecular chaperone regulator 4"],["bp:displayName","BAG4_HUMAN"],["bp:name","Bcl-2-associated athanogene 4"],["bp:name","BAG-4"],["bp:name","Silencer of death domains"],["bp:name","SODD"],["bp:name","BAG4"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9530"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9530"],["bp:comment","FUNCTION: Inhibits the chaperone activity of HSP70/HSC70 bypromoting substrate release (By similarity). Prevents constitutiveTNFRSF1A signaling. Negative regulator of PRKN translocation todamaged mitochondria. {ECO:0000250, ECO:0000269|PubMed:24270810}.SUBUNIT: Binds to the ATPase domain of HSP/HSC70 chaperones. Bindsto the death domain of TNFRSF1A in the absence of TNF and therebyprevents binding of adapter molecules such as TRADD or TRAF2.Binds to the death domain of TNFRSF12. Interacts with PRKN.{ECO:0000269|PubMed:12058034, ECO:0000269|PubMed:24270810,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=O95429-1; Sequence=Displayed;Name=2;IsoId=O95429-2; Sequence=VSP_042741;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004865"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04861_identity"],["bp:comment","BAG4_HUMAN Reviewed; 457 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80762"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80762"]]}},{"data":{"id":"Protein_f6435e1b4ee58d0cd8b74a85b5d6797f","class":"macromolecule","label":"AIFM1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":629.10187,"y":410.57034,"w":48,"h":25},"metadata":[["bp:displayName","AIF"],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","268"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 371 371 Phosphoserine."],["bp:featureLocation","MOD_RES 371 371 Phosphoserine."]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80522"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80522"]]}},{"data":{"id":"Protein_843869a58602abb6fbfc3961550c55ef","class":"macromolecule","label":"BCL2","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":759.0172,"y":471.8083,"w":48,"h":25},"metadata":[["bp:displayName","BCL2"],["bp:entityReference_http://identifiers.org/uniprot/P10415",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P10415"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10415"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 69 69 Phosphothreonine; by MAPK8."],["bp:featureLocation","MOD_RES 69 69 Phosphothreonine; by MAPK8."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 69 69 Phosphothreonine; by MAPK8."],["bp:featureLocation","MOD_RES 69 69 Phosphothreonine; by MAPK8."]]],["bp:standardName","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:organism","Apoptosis regulator Bcl-2"],["bp:displayName","BCL2_HUMAN"],["bp:name","BCL2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YSW_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10415-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000624"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q07813"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_596"],["bp:comment","REPLACED ProteinRef_BCL2__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01045_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1043N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10415_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_596"],["bp:comment","REPLACED ProteinRef_BCL2__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000648"],["bp:comment","FUNCTION: Suppresses apoptosis in a variety of cell systemsincluding factor-dependent lymphohematopoietic and neural cells.Regulates cell death by controlling the mitochondrial membranepermeability. Appears to function in a feedback loop system withcaspases. Inhibits caspase activity either by preventing therelease of cytochrome c from the mitochondria and/or by binding tothe apoptosis-activating factor (APAF-1). May attenuateinflammation by impairing NLRP1-inflammasome activation, henceCASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18570871}.SUBUNIT: Forms homodimers, and heterodimers with BAX, BAD, BAK andBcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2motifs, and is necessary for anti-apoptotic activity(PubMed:8183370). Interacts with EI24 (By similarity). Alsointeracts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2.Binding to FKBP8 seems to target BCL2 to the mitochondria andprobably interferes with the binding of BCL2 to its targets.Interacts with BAG1 in an ATP-dependent manner. Interacts withRAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts(via the BH4 domain) with EGLN3; the interaction prevents theformation of the BAX-BCL2 complex and inhibits the anti-apoptoticactivity of BCL2. Interacts with G0S2; this interaction alsoprevents the formation of the anti-apoptotic BAX-BCL2 complex.Interacts with BOP. Interacts with the SCF(FBXO10) complex.Interacts (via the loop between motifs BH4 and BH3) with NLRP1(via LRR repeats), but not with NLRP2, NLRP3, NLRP4, PYCARD, norMEFV (PubMed:17418785). {ECO:0000250, ECO:0000269|PubMed:11463391,ECO:0000269|PubMed:12901880, ECO:0000269|PubMed:15547950,ECO:0000269|PubMed:15733859, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:17090549, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:19228691, ECO:0000269|PubMed:19706769,ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:23055042,ECO:0000269|PubMed:23431138, ECO:0000269|PubMed:8183370,ECO:0000269|PubMed:8668206, ECO:0000269|PubMed:9305631}.SUBCELLULAR LOCATION: Mitochondrion outer membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Nucleus membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Alpha;IsoId=P10415-1; Sequence=Displayed;Name=Beta;IsoId=P10415-2; Sequence=VSP_000512;Note=Ref.1 (AAA51814) sequence is in conflict in position:199:L->S. {ECO:0000305};TISSUE SPECIFICITY: Expressed in a variety of tissues.DOMAIN: BH1 and BH2 domains are required for the interaction withBAX and for anti-apoptotic activity. {ECO:0000269|PubMed:8183370}.DOMAIN: The BH4 motif is required for anti-apoptotic activity andfor interaction with RAF1 and EGLN3.DOMAIN: The loop between motifs BH4 and BH3 is required for theinteraction with NLRP1. {ECO:0000269|PubMed:17418785}.PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation onSer-70 by PKC is required for the anti-apoptosis activity andoccurs during the G2/M phase of the cell cycle. In the absence ofgrowth factors, BCL2 appears to be phosphorylated by other proteinkinases such as ERKs and stress-activated kinases. Phosphorylatedby MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulatesstarvation-induced autophagy. Dephosphorylated by proteinphosphatase 2A (PP2A) (By similarity). {ECO:0000250}.PTM: Proteolytically cleaved by caspases during apoptosis. Thecleaved protein, lacking the BH4 motif, has pro-apoptoticactivity, causes the release of cytochrome c into the cytosolpromoting further caspase activity. {ECO:0000269|PubMed:9395403}.PTM: Monoubiquitinated by PRKN, leading to increase its stability.Ubiquitinated by SCF(FBXO10), leading to its degradation by theproteasome. {ECO:0000269|PubMed:20889974,ECO:0000269|PubMed:23431138}.DISEASE: Note=A chromosomal aberration involving BCL2 has beenfound in chronic lymphatic leukemia. Translocationt(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutationsfound in non-Hodgkin lymphomas carrying the chromosomaltranslocation could be attributed to the Ig somatic hypermutationmechanism resulting in nucleotide transitions.{ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL2ID49.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bcl2/\";WEB RESOURCE: Name=Wikipedia; Note=Bcl-2 entry;URL=\"https://en.wikipedia.org/wiki/Bcl-2\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_925"],["bp:comment","REPLACED http://identifiers.org/ncbigene/596"],["bp:comment","BCL2_HUMAN Reviewed; 239 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_59844"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_59844"]]}},{"data":{"id":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8","class":"macromolecule","label":"MAP4K4","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8.info.1","class":"state variable","state":{"variable":"631","value":"opser"}},{"id":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8.state.2","class":"state variable","state":{"variable":"629","value":"opser"}},{"id":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8.info.3","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8.state.4","class":"state variable","state":{"variable":"805","value":"opser"}},{"id":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8.info.5","class":"state variable","state":{"variable":"801","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":1363.0978,"y":476.47812,"w":85,"h":25},"metadata":[["bp:displayName","MAP4K4"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80783"],["bp:featureLocation",[["bp:sequencePosition","631"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63759"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80782"],["bp:featureLocation",[["bp:sequencePosition","629"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12745"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_49023"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80785"],["bp:featureLocation",[["bp:sequencePosition","805"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80786"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80785"],["bp:featureLocation",[["bp:sequencePosition","805"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80786"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O95819",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80785"],["bp:featureLocation",[["bp:sequencePosition","805"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80786"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80781"]]}},{"data":{"id":"Protein_1219a0b0a64c43bb8747e7e459a510da","class":"macromolecule","label":"BAX","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":336.40936,"y":398.88077,"w":48,"h":25},"metadata":[["bp:displayName","BAX"],["bp:entityReference_http://identifiers.org/uniprot/Q07812",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis regulator BAX"],["bp:xref",[["bp:relationshipType",null],["bp:id","BAX"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","Q07812"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q07812"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","BAX_HUMAN"],["bp:name","Bcl2-L-4"],["bp:name","Bcl-2-like protein 4"],["bp:name","BCL2L4"],["bp:name","BAX"],["bp:comment","BAX_HUMAN Reviewed; 192 AA."],["bp:comment","FUNCTION: Accelerates programmed cell death by binding to, andantagonizing the apoptosis repressor BCL2 or its adenovirushomolog E1B 19k protein. Under stress conditions, undergoes aconformation change that causes translocation to the mitochondrionmembrane, leading to the release of cytochrome c that thentriggers apoptosis. Promotes activation of CASP3, and therebyapoptosis. {ECO:0000269|PubMed:10772918,ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:18948948,ECO:0000269|PubMed:21199865, ECO:0000269|PubMed:8358790,ECO:0000269|PubMed:8521816}.SUBUNIT: Homodimer. Forms higher oligomers under stressconditions. Interacts with BCL2L11. Interaction with BCL2L11promotes BAX oligomerization and association with mitochondrialmembranes, with subsequent release of cytochrome c. Formsheterodimers with BCL2, E1B 19K protein, BCL2L1 isoform Bcl-X(L),BCL2L2, MCL1 and A1. Interacts with SH3GLB1 and HN. Interacts withSFN and YWHAZ; the interaction occurs in the cytoplasm. Understress conditions, JNK-mediated phosphorylation of SFN and YWHAZ,releases BAX to mitochondria. Isoform Sigma interacts with BCL2A1and BCL2L1 isoform Bcl-X(L). Interacts with RNF144B, whichregulates the ubiquitin-dependent stability of BAX. Interacts withCLU under stress conditions that cause a conformation changeleading to BAX oligomerization and association with mitochondria.Does not interact with CLU in unstressed cells. Interacts withFAIM2/LFG2. Interacts with human cytomegalovirus/HHV-5 proteinvMIA/UL37. Interacts with BOP/C22orf29. Interacts (via a C-terminal 33 residues) with NOL3 (via CARD domain); inhibits BAXactivation and translocation and consequently cytochrome c releasefrom mitochondria. {ECO:0000269|PubMed:10772918,ECO:0000269|PubMed:11106734, ECO:0000269|PubMed:11259440,ECO:0000269|PubMed:12732850, ECO:0000269|PubMed:15004026,ECO:0000269|PubMed:15004034, ECO:0000269|PubMed:15071501,ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:16946732,ECO:0000269|PubMed:16964429, ECO:0000269|PubMed:18948948,ECO:0000269|PubMed:20300062, ECO:0000269|PubMed:21199865,ECO:0000269|PubMed:23055042, ECO:0000269|PubMed:8358790}.SUBCELLULAR LOCATION: Isoform Alpha: Mitochondrion membrane;Single-pass membrane protein. Cytoplasm. Note=Colocalizes with 14-3-3 proteins in the cytoplasm. Under stress conditions, undergoesa conformation change that causes release from JNK-phosphorylated14-3-3 proteins and translocation to the mitochondrion membrane.SUBCELLULAR LOCATION: Isoform Beta: Cytoplasm.SUBCELLULAR LOCATION: Isoform Gamma: Cytoplasm.SUBCELLULAR LOCATION: Isoform Delta: Cytoplasm {ECO:0000305}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=Alpha;IsoId=Q07812-1; Sequence=Displayed;Name=Beta;IsoId=Q07812-2, Q07814-1;Sequence=VSP_031237;Name=Gamma;IsoId=Q07812-3, Q07815-1;Sequence=VSP_031234, VSP_031236;Name=Delta;IsoId=Q07812-4, P55269-1;Sequence=VSP_031235;Name=Epsilon;IsoId=Q07812-5; Sequence=VSP_031240;Name=Zeta;IsoId=Q07812-6; Sequence=VSP_031239;Name=Psi;IsoId=Q07812-7; Sequence=VSP_031238;Name=Sigma;IsoId=Q07812-8; Sequence=VSP_037475;TISSUE SPECIFICITY: Expressed in a wide variety of tissues.Isoform Psi is found in glial tumors. Isoform Alpha is expressedin spleen, breast, ovary, testis, colon and brain, and at lowlevels in skin and lung. Isoform Sigma is expressed in spleen,breast, ovary, testis, lung, colon, brain and at low levels inskin. Isoform Alpha and isoform Sigma are expressed in pro-myelocytic leukemia, histiocytic lymphoma, Burkitt's lymphoma, T-cell lymphoma, lymphoblastic leukemia, breast adenocarcinoma,ovary adenocarcinoma, prostate carcinoma, prostate adenocarcinoma,lung carcinoma, epidermoid carcinoma, small cell lung carcinomaand colon adenocarcinoma cell lines. {ECO:0000269|PubMed:10772918,ECO:0000269|PubMed:11912183}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family. {ECO:0000250}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bax/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BAXID128ch19q13.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_581"],["bp:comment","REPLACED http://identifiers.org/uniprot/P55269"],["bp:comment","REPLACED ProteinRef_BAX__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_581"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-232N_identity"],["bp:comment","REPLACED ProteinRef_BAX__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_620116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004315"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q07812_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016882566"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02498_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4701"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_59845"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_19bc3f842f918886f021017e52a9c453","class":"macromolecule","label":"RAF1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_19bc3f842f918886f021017e52a9c453.info.1","class":"state variable","state":{"variable":"269","value":"opthr"}},{"id":"Protein_19bc3f842f918886f021017e52a9c453.state.2","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":259.19888000000003,"y":1137.129,"w":48,"h":25},"metadata":[["bp:displayName","RAF1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22432"],["bp:featureLocation",[["bp:sequencePosition","269"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22309"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7947"]]],["bp:entityReference_http://identifiers.org/uniprot/P04049",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P04049"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation","MOD_RES 341 341 Phosphotyrosine; by SRC."]]],["bp:standardName","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:organism","RAF proto-oncogene serine/threonine-protein kinase"],["bp:displayName","RAF1_HUMAN"],["bp:name","Proto-oncogene c-RAF"],["bp:name","RAF"],["bp:name","RAF1"],["bp:name","2.7.11.1"],["bp:name","cRaf"],["bp:name","Raf-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FAQ_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5894"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002871"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5894"],["bp:comment","REPLACED ProteinRef_RAF1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_653"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P04049_identity"],["bp:comment","FUNCTION: Serine/threonine-protein kinase that acts as aregulatory link between the membrane-associated Ras GTPases andthe MAPK/ERK cascade, and this critical regulatory link functionsas a switch determining cell fate decisions includingproliferation, differentiation, apoptosis, survival and oncogenictransformation. RAF1 activation initiates a mitogen-activatedprotein kinase (MAPK) cascade that comprises a sequentialphosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 andMAP2K2/MEK2) and the extracellular signal-regulated kinases(MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (onresidues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylylcyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.Phosphorylates PPP1R12A resulting in inhibition of the phosphataseactivity. Phosphorylates TNNT2/cardiac muscle troponin T. Canpromote NF-kB activation and inhibit signal transducers involvedin motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),proliferation and angiogenesis (RB1). Can protect cells fromapoptosis also by translocating to the mitochondria where it bindsBCL2 and displaces BAD/Bcl2-antagonist of cell death. RegulatesRho signaling and migration, and is required for normal woundhealing. Plays a role in the oncogenic transformation ofepithelial cells via repression of the TJ protein, occludin (OCLN)by inducing the up-regulation of a transcriptional repressorSNAI2/SLUG, which induces down-regulation of OCLN. Restrictscaspase activation in response to selected stimuli, notably Fasstimulation, pathogen-mediated macrophage apoptosis, and erythroiddifferentiation. {ECO:0000269|PubMed:11427728,ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,ECO:0000269|PubMed:9360956}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Note=Binds 2 Zn(2+) ions per subunit.;ENZYME REGULATION: Regulation is a highly complex processinvolving membrane recruitment, protein-protein interactions,dimerization, and phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the membrane, thereby promoting itsactivation. The inactive conformation of RAF1 is maintained byautoinhibitory interactions occurring between the N-terminalregulatory and the C-terminal catalytic domains and by the bindingof a 14-3-3 protein that contacts two phosphorylation sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1Acooperate to release autoinhibition and the subsequentphosphorylation of activating sites: Ser-338, Tyr-341, Thr-491,and Ser-494, yields a fully active kinase. Through a negativefeedback mechanism involving MAPK1/ERK2, RAF1 is phosphorylated onSer-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 byMAPK1/ERK2, which yields an inactive, desensitized kinase. Thesignaling-competent conformation of RAF1 is finally re-establishedby the coordinated action of PIN1, a prolyl isomerase thatconverts pSer and pThr residues from the cis to the transconformation, which is preferentially recognized anddephosphorylated by PPP2R1A. Activated by homodimerization andheterodimerization (with BRAF). Also regulated through associationwith other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP,PHB/prohibitin and SPRY4. PEBP1/RKIP acts by dissociating RAF1from its substrates MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitinfacilitates the displacement of 14-3-3 from RAF1 by activated Ras,thereby promoting cell membrane localization and phosphorylationof RAF1 at the activating Ser-338. SPRY4 inhibits Ras-independent,but not Ras-dependent, activation of RAF1. CNKSR1/CNK1 regulatesSrc-mediated RAF1 activation. {ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12717443,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016}.SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and thisheterodimer possesses a highly increased kinase activity comparedto the respective homodimers or monomers (PubMed:16508002).Heterodimerization is mitogen-regulated and enhanced by 14-3-3proteins (PubMed:16508002). MAPK1/ERK2 activation can induce anegative feedback that promotes the dissociation of theheterodimer (PubMed:16508002). Forms a multiprotein complex withRas (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CBand PPP1CC) (PubMed:16630891). Interacts with Ras proteins; theinteraction is antagonized by RIN1 (PubMed:11784866). Weaklyinteracts with RIT1. Interacts (via N-terminus) with RGS14 (viaRBD domains); the interaction mediates the formation of a ternarycomplex with BRAF, a ternary complex inhibited by GNAI1 (Bysimilarity). Interacts with STK3/MST2; the interaction inhibitsits pro-apoptotic activity (PubMed:15618521). Interacts (whenphosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') (PubMed:9360956). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2(By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) andthis interaction inhibits the proapoptotic function of MAP3K5/ASK1(PubMed:11427728). Interacts with PAK1 (via kinase domain)(PubMed:11733498). The phosphorylated form interacts with PIN1 (Bysimilarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIPand this interaction is enhanced if RAF1 is phosphorylated onresidues Ser-338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816).Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A,PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 andPHB/prohibitin (PubMed:10801873, PubMed:11719507, PubMed:12717443,PubMed:15385642, PubMed:15935327, PubMed:19710016,PubMed:10576742). Interacts with ROCK2 (By similarity). In itsactive form, interacts with PRMT5 (PubMed:21917714). Interactswith FAM83B; displaces 14-3-3 proteins from RAF1 and activatesRAF1 (PubMed:22886302). Interacts with PDE8A; the interactionpromotes RAF1 activity (PubMed:23509299).{ECO:0000250|UniProtKB:P11345, ECO:0000250|UniProtKB:Q99N57,ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11784866,ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:15935327, ECO:0000269|PubMed:16508002,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:22886302, ECO:0000269|PubMed:23509299,ECO:0000269|PubMed:9360956}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion.Nucleus. Note=Colocalizes with RGS14 and BRAF in both thecytoplasm and membranes. Phosphorylation at Ser-259 impairs itsmembrane accumulation. Recruited to the cell membrane by theactive Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantlylocalized at the nucleus.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=6C;IsoId=P04049-1; Sequence=Displayed;Name=2; Synonyms=1A;IsoId=P04049-2; Sequence=VSP_034649;TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundantthan isoform 2. {ECO:0000269|PubMed:1886707}.PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 andSer-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results inits inactivation. Phosphorylation at Ser-259 induces theinteraction with YWHAZ and inactivates kinase activity.Dephosphorylation of Ser-259 by the complex containing proteinphosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leadingto stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 andPAK5 and Ser-339 by PAK1 is required for its mitochondriallocalization. Phosphorylation at Ser-621 in response to growthfactor treatment stabilizes the protein, possibly by preventingproteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, Ser-338 and Ser-621 are somehow linked to the methylationpotential of cells. Treatment of cells with HGF in the presence ofthe methylation inhibitor 5'-methylthioadenosine (MTA) results inincreased phosphorylation at Ser-338 and Ser-621 and decreasedphosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylationat Ser-338 by PPP5C results in a activity decrease.{ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,ECO:0000269|PubMed:11756411, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16093354,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:16892053,ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614,ECO:0000269|PubMed:9823899}.PTM: Methylated at Arg-563 in response to EGF treatment. Thismodification leads to destabilization of the protein, possiblythrough proteasomal degradation. {ECO:0000269|PubMed:21917714}.DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonansyndrome, a disease characterized by short stature, facialdysmorphic features such as hypertelorism, a downward eyeslant andlow-set posteriorly rotated ears, and a high incidence ofcongenital heart defects and hypertrophic cardiomyopathy. Otherfeatures can include a short neck with webbing or redundancy ofskin, deafness, motor delay, variable intellectual deficits,multiple skeletal defects, cryptorchidism, and bleeding diathesis.Individuals with Noonan syndrome are at risk of juvenilemyelomonocytic leukemia, a myeloproliferative disordercharacterized by excessive production of myelomonocytic cells.{ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483,ECO:0000269|PubMed:20683980}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disordercharacterized by lentigines, electrocardiographic conductionabnormalities, ocular hypertelorism, pulmonic stenosis,abnormalities of genitalia, retardation of growth, andsensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: Adisorder characterized by ventricular dilation and impairedsystolic function, resulting in congestive heart failure andarrhythmia. Patients are at risk of premature death.{ECO:0000269|PubMed:24777450}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. RAF subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/raf1/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","RAF1_HUMAN Reviewed; 648 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1048N_identity"],["bp:comment","REPLACED ProteinRef_RAF1__9606"],["bp:comment","REPLACED ProteinRef_RAF1__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5894"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04049-1"],["bp:comment","REPLACED ProteinRef_RAF1__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80594"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80594"]]}},{"data":{"id":"Protein_b2f0b61da0d4489c9bae7e3394902b11","class":"macromolecule","label":"KSR1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":152.71783,"y":607.89856,"w":48,"h":25},"metadata":[["bp:displayName","KSR"],["bp:entityReference_http://identifiers.org/uniprot/Q8IVT5",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","274"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 311 311 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","311"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 425 425 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","425"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 406 406 Phosphoserine."],["bp:featureLocation","MOD_RES 406 406 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 406 406 Phosphoserine."],["bp:featureLocation","MOD_RES 406 406 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 406 406 Phosphoserine."],["bp:featureLocation","MOD_RES 406 406 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 406 406 Phosphoserine."],["bp:featureLocation","MOD_RES 406 406 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 406 406 Phosphoserine."],["bp:featureLocation","MOD_RES 406 406 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 406 406 Phosphoserine."],["bp:featureLocation","MOD_RES 406 406 Phosphoserine."]]],["bp:standardName","Kinase suppressor of Ras 1"],["bp:xref","Kinase suppressor of Ras 1"],["bp:xref","Kinase suppressor of Ras 1"],["bp:organism","Kinase suppressor of Ras 1"],["bp:displayName","KSR1_HUMAN"],["bp:name","KSR1"],["bp:name","KSR"],["bp:comment","KSR1_HUMAN Reviewed; 923 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_18980_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_055053"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8844"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32619N_identity"],["bp:comment","FUNCTION: Scaffolding protein that is part of a multiproteinsignaling complex. Promotes phosphorylation of Raf family membersand activation of downstream MAP kinases. Promotes activation ofMAPK1 and/or MAPK3, both in response to EGF and to cAMP. Does nothave kinase activity by itself. {ECO:0000250|UniProtKB:Q61097}.SUBUNIT: Interacts with HSP90AA1/HSP90, YWHAE/14-3-3, CDC37,MAP2K1/MEK-1 and MAP2K2/MEK-2 (PubMed:10409742). Interacts withMARK3, PPP2R1A and PPP2CA. Also interacts with RAF and MAPK/ERK,in a Ras-dependent manner. The binding of 14-3-3 proteins tophosphorylated KSR prevents the membrane localization (Bysimilarity). Interacts with isoform 1 of VRK2 (PubMed:20679487).Interacts with AKAP13 and BRAF (PubMed:21102438). Identified in acomplex with AKAP13, MAP2K1 and BRAF (By similarity).{ECO:0000250|UniProtKB:Q61097, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:20679487, ECO:0000269|PubMed:21102438}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20679487}.Membrane {ECO:0000269|PubMed:20679487}; Peripheral membraneprotein {ECO:0000269|PubMed:20679487}. Cell membrane{ECO:0000250|UniProtKB:Q61097}; Peripheral membrane protein{ECO:0000250|UniProtKB:Q61097}. Cell projection, ruffle membrane{ECO:0000250|UniProtKB:Q61097}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:20679487}. Note=In unstimulated cells, wherethe phosphorylated form is bound to a 14-3-3 protein,sequestration in the cytoplasm occurs. Following growth factortreatment, the protein is free for membrane translocation, and itmoves from the cytoplasm to the cell periphery.{ECO:0000305|PubMed:12007434}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q8IVT5-1; Sequence=Displayed;Name=2;IsoId=Q8IVT5-2; Sequence=VSP_055656, VSP_055657;Note=No experimental confirmation available.;Name=3;IsoId=Q8IVT5-3; Sequence=VSP_055655;Note=No experimental confirmation available.;Name=4;IsoId=Q8IVT5-4; Sequence=VSP_055655, VSP_055657;Note=No experimental confirmation available.;DOMAIN: The protein kinase domain is predicted to be catalyticallyinactive. The domain is sufficient for KSR1 and KSR1-mediatedMAP2K1 and MAP2K2 membrane localization. The domain is requiredbut not sufficient for MAP kinase-mediated inhibition of ELK1phosphorylation (PubMed:10409742). {ECO:0000255,ECO:0000269|PubMed:10409742}.DOMAIN: The protein kinase domain is predicted to be catalyticallyinactive. The domain is sufficient for KSR1 and KSR1-mediatedMAP2K1 and MAP2K2 membrane localization. The domain is requiredbut not sufficient for MAP kinase-mediated inhibition of ELK1phosphorylation. {ECO:0000250|UniProtKB:Q61097, ECO:0000255}.DOMAIN: The N-terminal region mediates interaction with BRAF andwith membranes. {ECO:0000250|UniProtKB:Q61097}.PTM: Phosphorylated on Ser-311 and, to a higher extent, on Ser-406by MARK3. Dephosphorylated on Ser-406 by PPP2CA. In resting cells,phosphorylated KSR1 is cytoplasmic and in stimulated cells,dephosphorylated KSR1 is membrane-associated. Phosphorylated byPKA at Ser-888. Phosphorylation at Ser-888 is required for cAMP-dependent activation of MAPK1 and/or MAPK3 (By similarity).{ECO:0000250|UniProtKB:Q61097}.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/KSR1ID41107ch17q11.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_2001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80849"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80849"]]}},{"data":{"id":"Protein_1860f53d1b97dd11d29408c4f2f846d8","class":"macromolecule","label":"TRADD","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1193.0432,"y":386.8101,"w":48,"h":25},"metadata":[["bp:displayName","TRADD"],["bp:entityReference_http://identifiers.org/uniprot/Q15628",[["bp:standardName","Tumor necrosis factor receptor type 1-associated DEATH domain protein"],["bp:xref",[["bp:relationshipType",null],["bp:id","TRADD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","Q15628"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q15628"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TRADD_HUMAN"],["bp:name","TNFRSF1A-associated via death domain"],["bp:name","TNFR1-associated DEATH domain protein"],["bp:name","TRADD"],["bp:comment","REPLACED ProteinRef_TRADD__10116"],["bp:comment","REPLACED ProteinRef_TRADD__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016879304"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003780"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04610_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_8717_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-285N_identity"],["bp:comment","REPLACED ProteinRef_TRADD__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8717"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8717"],["bp:comment","FUNCTION: The nuclear form acts as a tumor suppressor bypreventing ubiquitination and degradation of isoform p19ARF/ARF ofCDKN2A by TRIP12: acts by interacting with TRIP12, leading todisrupt interaction between TRIP12 and isoform p19ARF/ARF ofCDKN2A (By similarity). Adapter molecule for TNFRSF1A/TNFR1 thatspecifically associates with the cytoplasmic domain of activatedTNFRSF1A/TNFR1 mediating its interaction with FADD. Overexpressionof TRADD leads to two major TNF-induced responses, apoptosis andactivation of NF-kappa-B. {ECO:0000250}.SUBUNIT: Interacts with TRIP12 (By similarity). Heterodimer withTNFRSF1A/TNFR1. Interacts with DAB2IP, FADD, HIPK2, KRT14, KRT16,KRT17, KRT18, RIPK1, SQSTM1, TRAF1, TRAF2 and TRPC4AP.{ECO:0000250, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10892748, ECO:0000269|PubMed:11032752,ECO:0000269|PubMed:11684708, ECO:0000269|PubMed:15310755,ECO:0000269|PubMed:8612133}.SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm{ECO:0000250}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:11684708}. Note=Shuttles between the cytoplasmand the nucleus. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q15628-1; Sequence=Displayed;Name=2;IsoId=Q15628-2; Sequence=VSP_056526;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Found in all examined tissues.DOMAIN: Requires the intact death domain to associate withTNFRSF1A/TNFR1.SEQUENCE CAUTION:Sequence=AAA98482.1; Type=Erroneous initiation; Evidence={ECO:0000305};WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tradd/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TRADD_HUMAN Reviewed; 312 AA."],["bp:comment","REPLACED ProteinRef_TRADD__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1577"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_be2b2e3f29a22891062321b977132b86_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":961.97943,"y":342.00598,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80822"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80822"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Acid Sphingomyelinase"],["bp:entityReference_http://identifiers.org/uniprot/P17405",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P17405"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P17405"]]],["bp:standardName","Sphingomyelin phosphodiesterase"],["bp:xref",[["bp:id","P17405"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","SMPD1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASM_HUMAN"],["bp:name","3.1.4.12"],["bp:name","aSMase"],["bp:name","SMPD1"],["bp:name","ASM"],["bp:name","Acid sphingomyelinase"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_18320"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06353_identity"],["bp:comment","FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,PubMed:18815062, PubMed:27659707, PubMed:25920558). Also hasphospholipase C activities toward 1,2-diacylglycerolphosphocholineand 1,2-diacylglycerolphosphoglycerol.{ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000305}.FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)and has no enzyme activity. {ECO:0000269|PubMed:1840600,ECO:0000305}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine. {ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Evidence={ECO:0000269|PubMed:8702487};Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,PubMed:27725636). Zn(2+) is particularly important for enzymeactivity at neutral pH (PubMed:8702487).{ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,ECO:0000269|PubMed:8702487};SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,ECO:0000269|PubMed:27659707}. Secreted{ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,ECO:0000269|PubMed:8702487}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=ASM-1;IsoId=P17405-1; Sequence=Displayed;Note=Most abundant (90%).;Name=2; Synonyms=ASM-2;IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;Note=Intermediate abundance (10%).;Name=3; Synonyms=ASM-3;IsoId=P17405-3; Sequence=VSP_000333;Note=Low abundance (<1%).;Name=4;IsoId=P17405-4; Sequence=VSP_046964;POLYMORPHISM: A common polymorphism arises from a variable numberof hexanucleotide repeat sequence within the signal peptideregion.DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-onset lysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Niemann-Pick disease type A is a primarilyneurodegenerative disorder characterized by onset within the firstyear of life, mental retardation, digestive disorders, failure tothrive, major hepatosplenomegaly, and severe neurologic symptoms.The severe neurological disorders and pulmonary infections lead toan early death, often around the age of four. Clinical featuresare variable. A phenotypic continuum exists between type A (basicneurovisceral) and type B (purely visceral) forms of Niemann-Pickdisease, and the intermediate types encompass a cluster ofvariants combining clinical features of both types A and B.{ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onsetlysosomal storage disorder caused by failure to hydrolyzesphingomyelin to ceramide. It results in the accumulation ofsphingomyelin and other metabolically related lipids inreticuloendothelial and other cell types throughout the body,leading to cell death. Clinical signs involve only visceralorgans. The most constant sign is hepatosplenomegaly which can beassociated with pulmonary symptoms. Patients remain free ofneurologic manifestations. However, a phenotypic continuum existsbetween type A (basic neurovisceral) and type B (purely visceral)forms of Niemann-Pick disease, and the intermediate typesencompass a cluster of variants combining clinical features ofboth types A and B. In Niemann-Pick disease type B, onset of thefirst symptoms occurs in early childhood and patients can surviveinto adulthood. {ECO:0000269|PubMed:12369017,ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,ECO:0000269|PubMed:8664904}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: There are two types of sphingomyelinases: ASM(acid), and NSM (neutral).SIMILARITY: Belongs to the acid sphingomyelinase family.{ECO:0000305}.CAUTION: Variants Gln-294 and Val-485 have been originallyreported as disease-causing mutations in NPDA and NPDB(PubMed:12369017, PubMed:15221801). These variants have beenreclassified as benign polymorphisms (PubMed:23430512).{ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,ECO:0000269|PubMed:23430512}.WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database(LOVD);URL=\"http://www.lovd.nl/SMPD1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASM_HUMAN Reviewed; 629 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6609"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6609"]]],["bp:name","ASM"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19884"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80822"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80821"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80821"]]}},{"data":{"id":"SmallMolecule_4b5c686c031a54a8226c87afaaa8e98b","class":"simple chemical","label":"PHOSPHOCHOLINE","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":412.66736,"y":523.0475,"w":48,"h":20},"metadata":[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Complex_52a595175addc44c86246899debd8454","class":"complex","label":"TNF-alpha/TNFR1A/FAN","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1105.5542,"y":222.00607,"w":52,"h":89},"metadata":[["bp:displayName","TNF-alpha/TNFR1A/FAN"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"]]}},{"data":{"id":"Protein_12ce91dd41f0737ffb0898c71af2f854_Complex_52a595175addc44c86246899debd8454","class":"macromolecule","label":"TNF","parent":"Complex_52a595175addc44c86246899debd8454","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1105.5542,"y":252.00607,"w":48,"h":25},"metadata":[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNF"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P01375"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P01375"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]}},{"data":{"id":"Protein_12bcf51c75aae38cdb2620e757a2f48e_Complex_52a595175addc44c86246899debd8454","class":"macromolecule","label":"TNFRSF1A","parent":"Complex_52a595175addc44c86246899debd8454","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1105.5542,"y":222.00607,"w":48,"h":25},"metadata":[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_be0a2c4a2b3747d87c5a2d76568a200b_Complex_52a595175addc44c86246899debd8454","class":"macromolecule","label":"NSMAF","parent":"Complex_52a595175addc44c86246899debd8454","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1105.5542,"y":192.00607,"w":48,"h":25},"metadata":[["bp:displayName","FAN"],["bp:entityReference_http://identifiers.org/uniprot/Q92636",[["bp:standardName","Protein FAN"],["bp:xref",[["bp:id","Q92636"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","NSMAF"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","NSMAF"],["bp:db","hgnc symbol"]]],["bp:displayName","FAN_HUMAN"],["bp:name","Factor associated with N-SMase activation"],["bp:name","FAN"],["bp:name","NSMAF"],["bp:name","Factor associated with neutral sphingomyelinase activation"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8439"],["bp:comment","REPLACED ProteinRef_NSMAF__40674"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8IW26"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-44106N_identity"],["bp:comment","FAN_HUMAN Reviewed; 917 AA."],["bp:comment","FUNCTION: Couples the p55 TNF-receptor (TNF-R55 / TNFR1) toneutral sphingomyelinase (N-SMASE). Specifically binds to the N-smase activation domain of TNF-R55. May regulate ceramideproduction by N-SMASE.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q92636-1; Sequence=Displayed;Name=2;IsoId=Q92636-2; Sequence=VSP_042036;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_09117_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8439"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003571"],["bp:comment","REPLACED ProteinRef_NSMAF__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21820"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_686db9912dfec92be002705e4fb86b1d","class":"macromolecule","label":"MAP3K1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":228.26848,"y":600.1564,"w":48,"h":25},"metadata":[["bp:displayName","MEKK1"],["bp:entityReference_http://identifiers.org/uniprot/Q13233",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 1043 1043 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","1043"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 300 300 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","300"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 297 297 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 275 275 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 1"],["bp:xref","Mitogen-activated protein kinase kinase kinase 1"],["bp:xref","Mitogen-activated protein kinase kinase kinase 1"],["bp:organism","Mitogen-activated protein kinase kinase kinase 1"],["bp:displayName","M3K1_HUMAN"],["bp:name","MAP3K1"],["bp:name","MAPKKK1"],["bp:name","MEKK1"],["bp:name","MEK kinase 1"],["bp:name","2.7.11.25"],["bp:name","MEKK"],["bp:name","MAPK/ERK kinase kinase 1"],["bp:name","MEKK 1"],["bp:comment","REPLACED ProteinRef_MAP3K1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4214"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005912"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_AAC97073_see-also"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1736"],["bp:comment","REPLACED ProteinRef_MAP3K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-27520N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_19599_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_042066"],["bp:comment","REPLACED ProteinRef_MAP3K1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13233_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4214"],["bp:comment","M3K1_HUMAN Reviewed; 1512 AA."],["bp:comment","FUNCTION: Component of a protein kinase signal transductioncascade. Activates the ERK and JNK kinase pathways byphosphorylation of MAP2K1 and MAP2K4. Activates CHUK and IKBKB,the central protein kinases of the NF-kappa-B pathway.{ECO:0000269|PubMed:9808624}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by autophosphorylation on Thr-1400and Thr-1412 following oligomerization.SUBUNIT: Binds both upstream activators and downstream substratesin multimolecular complexes through its N-terminus. Oligomerizesafter binding MAP4K2 or TRAF2. Interacts with AXIN1. Interacts(via the kinase catalytic domain) with STK38.{ECO:0000269|PubMed:12223491, ECO:0000269|PubMed:15262978,ECO:0000269|PubMed:17906693, ECO:0000269|PubMed:9808624}.PTM: Autophosphorylated. {ECO:0000250}.DISEASE: 46,XY sex reversal 6 (SRXY6) [MIM:613762]: A disorder ofsex development. Affected individuals have a 46,XY karyotype butpresent as phenotypically normal females.{ECO:0000269|PubMed:21129722}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_MAP3K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1482"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1482"]]}},{"data":{"id":"Protein_9ed2672027e26a84801ec82a7e17b642","class":"macromolecule","label":"RAF1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":89.187065,"y":977.9992,"w":48,"h":25},"metadata":[["bp:displayName","RAF1"],["bp:entityReference_http://identifiers.org/uniprot/P04049",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation",[["bp:sequencePosition","341"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 621 621 Phosphoserine."],["bp:featureLocation","MOD_RES 621 621 Phosphoserine."]]],["bp:standardName","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:organism","RAF proto-oncogene serine/threonine-protein kinase"],["bp:displayName","RAF1_HUMAN"],["bp:name","Proto-oncogene c-RAF"],["bp:name","RAF"],["bp:name","RAF1"],["bp:name","2.7.11.1"],["bp:name","cRaf"],["bp:name","Raf-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FAQ_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5894"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002871"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5894"],["bp:comment","REPLACED ProteinRef_RAF1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_653"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P04049_identity"],["bp:comment","FUNCTION: Serine/threonine-protein kinase that acts as aregulatory link between the membrane-associated Ras GTPases andthe MAPK/ERK cascade, and this critical regulatory link functionsas a switch determining cell fate decisions includingproliferation, differentiation, apoptosis, survival and oncogenictransformation. RAF1 activation initiates a mitogen-activatedprotein kinase (MAPK) cascade that comprises a sequentialphosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 andMAP2K2/MEK2) and the extracellular signal-regulated kinases(MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (onresidues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylylcyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.Phosphorylates PPP1R12A resulting in inhibition of the phosphataseactivity. Phosphorylates TNNT2/cardiac muscle troponin T. Canpromote NF-kB activation and inhibit signal transducers involvedin motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),proliferation and angiogenesis (RB1). Can protect cells fromapoptosis also by translocating to the mitochondria where it bindsBCL2 and displaces BAD/Bcl2-antagonist of cell death. RegulatesRho signaling and migration, and is required for normal woundhealing. Plays a role in the oncogenic transformation ofepithelial cells via repression of the TJ protein, occludin (OCLN)by inducing the up-regulation of a transcriptional repressorSNAI2/SLUG, which induces down-regulation of OCLN. Restrictscaspase activation in response to selected stimuli, notably Fasstimulation, pathogen-mediated macrophage apoptosis, and erythroiddifferentiation. {ECO:0000269|PubMed:11427728,ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,ECO:0000269|PubMed:9360956}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Note=Binds 2 Zn(2+) ions per subunit.;ENZYME REGULATION: Regulation is a highly complex processinvolving membrane recruitment, protein-protein interactions,dimerization, and phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the membrane, thereby promoting itsactivation. The inactive conformation of RAF1 is maintained byautoinhibitory interactions occurring between the N-terminalregulatory and the C-terminal catalytic domains and by the bindingof a 14-3-3 protein that contacts two phosphorylation sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1Acooperate to release autoinhibition and the subsequentphosphorylation of activating sites: Ser-338, Tyr-341, Thr-491,and Ser-494, yields a fully active kinase. Through a negativefeedback mechanism involving MAPK1/ERK2, RAF1 is phosphorylated onSer-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 byMAPK1/ERK2, which yields an inactive, desensitized kinase. Thesignaling-competent conformation of RAF1 is finally re-establishedby the coordinated action of PIN1, a prolyl isomerase thatconverts pSer and pThr residues from the cis to the transconformation, which is preferentially recognized anddephosphorylated by PPP2R1A. Activated by homodimerization andheterodimerization (with BRAF). Also regulated through associationwith other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP,PHB/prohibitin and SPRY4. PEBP1/RKIP acts by dissociating RAF1from its substrates MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitinfacilitates the displacement of 14-3-3 from RAF1 by activated Ras,thereby promoting cell membrane localization and phosphorylationof RAF1 at the activating Ser-338. SPRY4 inhibits Ras-independent,but not Ras-dependent, activation of RAF1. CNKSR1/CNK1 regulatesSrc-mediated RAF1 activation. {ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12717443,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016}.SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and thisheterodimer possesses a highly increased kinase activity comparedto the respective homodimers or monomers (PubMed:16508002).Heterodimerization is mitogen-regulated and enhanced by 14-3-3proteins (PubMed:16508002). MAPK1/ERK2 activation can induce anegative feedback that promotes the dissociation of theheterodimer (PubMed:16508002). Forms a multiprotein complex withRas (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CBand PPP1CC) (PubMed:16630891). Interacts with Ras proteins; theinteraction is antagonized by RIN1 (PubMed:11784866). Weaklyinteracts with RIT1. Interacts (via N-terminus) with RGS14 (viaRBD domains); the interaction mediates the formation of a ternarycomplex with BRAF, a ternary complex inhibited by GNAI1 (Bysimilarity). Interacts with STK3/MST2; the interaction inhibitsits pro-apoptotic activity (PubMed:15618521). Interacts (whenphosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') (PubMed:9360956). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2(By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) andthis interaction inhibits the proapoptotic function of MAP3K5/ASK1(PubMed:11427728). Interacts with PAK1 (via kinase domain)(PubMed:11733498). The phosphorylated form interacts with PIN1 (Bysimilarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIPand this interaction is enhanced if RAF1 is phosphorylated onresidues Ser-338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816).Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A,PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 andPHB/prohibitin (PubMed:10801873, PubMed:11719507, PubMed:12717443,PubMed:15385642, PubMed:15935327, PubMed:19710016,PubMed:10576742). Interacts with ROCK2 (By similarity). In itsactive form, interacts with PRMT5 (PubMed:21917714). Interactswith FAM83B; displaces 14-3-3 proteins from RAF1 and activatesRAF1 (PubMed:22886302). Interacts with PDE8A; the interactionpromotes RAF1 activity (PubMed:23509299).{ECO:0000250|UniProtKB:P11345, ECO:0000250|UniProtKB:Q99N57,ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11784866,ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:15935327, ECO:0000269|PubMed:16508002,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:22886302, ECO:0000269|PubMed:23509299,ECO:0000269|PubMed:9360956}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion.Nucleus. Note=Colocalizes with RGS14 and BRAF in both thecytoplasm and membranes. Phosphorylation at Ser-259 impairs itsmembrane accumulation. Recruited to the cell membrane by theactive Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantlylocalized at the nucleus.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=6C;IsoId=P04049-1; Sequence=Displayed;Name=2; Synonyms=1A;IsoId=P04049-2; Sequence=VSP_034649;TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundantthan isoform 2. {ECO:0000269|PubMed:1886707}.PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 andSer-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results inits inactivation. Phosphorylation at Ser-259 induces theinteraction with YWHAZ and inactivates kinase activity.Dephosphorylation of Ser-259 by the complex containing proteinphosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leadingto stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 andPAK5 and Ser-339 by PAK1 is required for its mitochondriallocalization. Phosphorylation at Ser-621 in response to growthfactor treatment stabilizes the protein, possibly by preventingproteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, Ser-338 and Ser-621 are somehow linked to the methylationpotential of cells. Treatment of cells with HGF in the presence ofthe methylation inhibitor 5'-methylthioadenosine (MTA) results inincreased phosphorylation at Ser-338 and Ser-621 and decreasedphosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylationat Ser-338 by PPP5C results in a activity decrease.{ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,ECO:0000269|PubMed:11756411, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16093354,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:16892053,ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614,ECO:0000269|PubMed:9823899}.PTM: Methylated at Arg-563 in response to EGF treatment. Thismodification leads to destabilization of the protein, possiblythrough proteasomal degradation. {ECO:0000269|PubMed:21917714}.DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonansyndrome, a disease characterized by short stature, facialdysmorphic features such as hypertelorism, a downward eyeslant andlow-set posteriorly rotated ears, and a high incidence ofcongenital heart defects and hypertrophic cardiomyopathy. Otherfeatures can include a short neck with webbing or redundancy ofskin, deafness, motor delay, variable intellectual deficits,multiple skeletal defects, cryptorchidism, and bleeding diathesis.Individuals with Noonan syndrome are at risk of juvenilemyelomonocytic leukemia, a myeloproliferative disordercharacterized by excessive production of myelomonocytic cells.{ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483,ECO:0000269|PubMed:20683980}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disordercharacterized by lentigines, electrocardiographic conductionabnormalities, ocular hypertelorism, pulmonic stenosis,abnormalities of genitalia, retardation of growth, andsensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: Adisorder characterized by ventricular dilation and impairedsystolic function, resulting in congestive heart failure andarrhythmia. Patients are at risk of premature death.{ECO:0000269|PubMed:24777450}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. RAF subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/raf1/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","RAF1_HUMAN Reviewed; 648 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1048N_identity"],["bp:comment","REPLACED ProteinRef_RAF1__9606"],["bp:comment","REPLACED ProteinRef_RAF1__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5894"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04049-1"],["bp:comment","REPLACED ProteinRef_RAF1__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"]]}},{"data":{"id":"Protein_0af015ace544274a79f50387d61825ee","class":"macromolecule","label":"MAP2K2","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_0af015ace544274a79f50387d61825ee.info.1","class":"state variable","state":{"variable":"222","value":"opser"}},{"id":"Protein_0af015ace544274a79f50387d61825ee.state.2","class":"state variable","state":{"variable":"226","value":"opser"}},{"id":"Protein_0af015ace544274a79f50387d61825ee.info.3","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":402.63065,"y":1368.1714,"w":85,"h":25},"metadata":[["bp:displayName","MEK2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8446"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8447"],["bp:featureLocation",[["bp:sequencePosition","226"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8448"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22303"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22302"]]}},{"data":{"id":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":503.8445,"y":360.5257,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","sphingomyelin"],["bp:entityReference_#SmallMoleculeReference_218aa1729347498918c05a239eb03b03",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20069"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80950"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80951"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","PHOSPHOCHOLINE"],["bp:entityReference_#SmallMoleculeReference_2ffc4cf3efdb57f4befed3c0f1b8ebf0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80948"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80952"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80947"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80947"]]}},{"data":{"id":"Complex_53e145b04847d664d289afe34fbf89cc","class":"complex","label":"FADD/Caspase 8","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1387.8813,"y":931.93555,"w":52,"h":64},"metadata":[["bp:displayName","FADD/Caspase 8"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","FADD"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80915"],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80916"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13158",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 194 194 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","FAS-associated death domain protein"],["bp:xref","FAS-associated death domain protein"],["bp:xref","FAS-associated death domain protein"],["bp:organism","FAS-associated death domain protein"],["bp:displayName","FADD_HUMAN"],["bp:name","MORT1"],["bp:name","FADD"],["bp:name","FAS-associating death domain-containing protein"],["bp:name","Growth-inhibiting gene 3 protein"],["bp:name","Protein FADD"],["bp:name","Mediator of receptor induced toxicity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003815"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03909_identity"],["bp:comment","FUNCTION: Apoptotic adaptor molecule that recruits caspase-8 orcaspase-10 to the activated Fas (CD95) or TNFR-1 receptors. Theresulting aggregate called the death-inducing signaling complex(DISC) performs caspase-8 proteolytic activation. Active caspase-8initiates the subsequent cascade of caspases mediating apoptosis.Involved in interferon-mediated antiviral immune response, playinga role in the positive regulation of interferon signaling.{ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.SUBUNIT: Can self-associate. Interacts with CFLAR, PEA15 and MBD4.When phosphorylated, part of a complex containing HIPK3 and FAS.May interact with MAVS/IPS1. Interacts with MOCV v-CFLAR proteinand PIDD1. Interacts (via death domain) with FAS (via deathdomain). Interacts with CASP8. Interacts directly (via DED domain)with NOL3 (via CARD domain); inhibits death-inducing signalingcomplex (DISC) assembly by inhibiting the increase in FAS-FADDbinding induced by FAS activation (By similarity).{ECO:0000250|UniProtKB:Q61160, ECO:0000269|PubMed:10442631,ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11034606,ECO:0000269|PubMed:12702765, ECO:0000269|PubMed:16127453,ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues, exceptfor peripheral blood mononuclear leukocytes.DOMAIN: Contains a death domain involved in the binding of thecorresponding domain within Fas receptor.{ECO:0000269|PubMed:19118384}.DOMAIN: The interaction between the FAS and FADD death domains iscrucial for the formation of the death-inducing signaling complex(DISC). {ECO:0000269|PubMed:19118384}.DISEASE: Infections, recurrent, associated with encephalopathy,hepatic dysfunction and cardiovascular malformations (IEHDCM)[MIM:613759]: A condition with biological features of autoimmunelymphoproliferative syndrome such as high-circulatingCD4(-)CD8(-)TCR-alpha-beta(+) T-cell counts, and elevated IL10 andFASL levels. Affected individuals suffer from recurrent,stereotypical episodes of fever, encephalopathy, and mild liverdysfunction sometimes accompanied by generalized seizures. Theepisodes can be triggered by varicella zoster virus (VZV), measlesmumps rubella (MMR) attenuated vaccine, parainfluenza virus, andEpstein-Barr virus (EBV). {ECO:0000269|PubMed:21109225}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/fadd/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8772"],["bp:comment","FADD_HUMAN Reviewed; 208 AA."],["bp:comment","REPLACED ProteinRef_FADD__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-286N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8772"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1124"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25446"],["bp:comment","REPLACED ProteinRef_FADD__10090"],["bp:comment","REPLACED ProteinRef_FADD__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80917"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","FADD"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80915"],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80916"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13158",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 194 194 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","FAS-associated death domain protein"],["bp:xref","FAS-associated death domain protein"],["bp:xref","FAS-associated death domain protein"],["bp:organism","FAS-associated death domain protein"],["bp:displayName","FADD_HUMAN"],["bp:name","MORT1"],["bp:name","FADD"],["bp:name","FAS-associating death domain-containing protein"],["bp:name","Growth-inhibiting gene 3 protein"],["bp:name","Protein FADD"],["bp:name","Mediator of receptor induced toxicity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003815"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03909_identity"],["bp:comment","FUNCTION: Apoptotic adaptor molecule that recruits caspase-8 orcaspase-10 to the activated Fas (CD95) or TNFR-1 receptors. Theresulting aggregate called the death-inducing signaling complex(DISC) performs caspase-8 proteolytic activation. Active caspase-8initiates the subsequent cascade of caspases mediating apoptosis.Involved in interferon-mediated antiviral immune response, playinga role in the positive regulation of interferon signaling.{ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.SUBUNIT: Can self-associate. Interacts with CFLAR, PEA15 and MBD4.When phosphorylated, part of a complex containing HIPK3 and FAS.May interact with MAVS/IPS1. Interacts with MOCV v-CFLAR proteinand PIDD1. Interacts (via death domain) with FAS (via deathdomain). Interacts with CASP8. Interacts directly (via DED domain)with NOL3 (via CARD domain); inhibits death-inducing signalingcomplex (DISC) assembly by inhibiting the increase in FAS-FADDbinding induced by FAS activation (By similarity).{ECO:0000250|UniProtKB:Q61160, ECO:0000269|PubMed:10442631,ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11034606,ECO:0000269|PubMed:12702765, ECO:0000269|PubMed:16127453,ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues, exceptfor peripheral blood mononuclear leukocytes.DOMAIN: Contains a death domain involved in the binding of thecorresponding domain within Fas receptor.{ECO:0000269|PubMed:19118384}.DOMAIN: The interaction between the FAS and FADD death domains iscrucial for the formation of the death-inducing signaling complex(DISC). {ECO:0000269|PubMed:19118384}.DISEASE: Infections, recurrent, associated with encephalopathy,hepatic dysfunction and cardiovascular malformations (IEHDCM)[MIM:613759]: A condition with biological features of autoimmunelymphoproliferative syndrome such as high-circulatingCD4(-)CD8(-)TCR-alpha-beta(+) T-cell counts, and elevated IL10 andFASL levels. Affected individuals suffer from recurrent,stereotypical episodes of fever, encephalopathy, and mild liverdysfunction sometimes accompanied by generalized seizures. Theepisodes can be triggered by varicella zoster virus (VZV), measlesmumps rubella (MMR) attenuated vaccine, parainfluenza virus, andEpstein-Barr virus (EBV). {ECO:0000269|PubMed:21109225}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/fadd/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8772"],["bp:comment","FADD_HUMAN Reviewed; 208 AA."],["bp:comment","REPLACED ProteinRef_FADD__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-286N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8772"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1124"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25446"],["bp:comment","REPLACED ProteinRef_FADD__10090"],["bp:comment","REPLACED ProteinRef_FADD__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80917"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","FADD"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80915"],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80916"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13158",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 194 194 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","FAS-associated death domain protein"],["bp:xref","FAS-associated death domain protein"],["bp:xref","FAS-associated death domain protein"],["bp:organism","FAS-associated death domain protein"],["bp:displayName","FADD_HUMAN"],["bp:name","MORT1"],["bp:name","FADD"],["bp:name","FAS-associating death domain-containing protein"],["bp:name","Growth-inhibiting gene 3 protein"],["bp:name","Protein FADD"],["bp:name","Mediator of receptor induced toxicity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003815"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03909_identity"],["bp:comment","FUNCTION: Apoptotic adaptor molecule that recruits caspase-8 orcaspase-10 to the activated Fas (CD95) or TNFR-1 receptors. Theresulting aggregate called the death-inducing signaling complex(DISC) performs caspase-8 proteolytic activation. Active caspase-8initiates the subsequent cascade of caspases mediating apoptosis.Involved in interferon-mediated antiviral immune response, playinga role in the positive regulation of interferon signaling.{ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.SUBUNIT: Can self-associate. Interacts with CFLAR, PEA15 and MBD4.When phosphorylated, part of a complex containing HIPK3 and FAS.May interact with MAVS/IPS1. Interacts with MOCV v-CFLAR proteinand PIDD1. Interacts (via death domain) with FAS (via deathdomain). Interacts with CASP8. Interacts directly (via DED domain)with NOL3 (via CARD domain); inhibits death-inducing signalingcomplex (DISC) assembly by inhibiting the increase in FAS-FADDbinding induced by FAS activation (By similarity).{ECO:0000250|UniProtKB:Q61160, ECO:0000269|PubMed:10442631,ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11034606,ECO:0000269|PubMed:12702765, ECO:0000269|PubMed:16127453,ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues, exceptfor peripheral blood mononuclear leukocytes.DOMAIN: Contains a death domain involved in the binding of thecorresponding domain within Fas receptor.{ECO:0000269|PubMed:19118384}.DOMAIN: The interaction between the FAS and FADD death domains iscrucial for the formation of the death-inducing signaling complex(DISC). {ECO:0000269|PubMed:19118384}.DISEASE: Infections, recurrent, associated with encephalopathy,hepatic dysfunction and cardiovascular malformations (IEHDCM)[MIM:613759]: A condition with biological features of autoimmunelymphoproliferative syndrome such as high-circulatingCD4(-)CD8(-)TCR-alpha-beta(+) T-cell counts, and elevated IL10 andFASL levels. Affected individuals suffer from recurrent,stereotypical episodes of fever, encephalopathy, and mild liverdysfunction sometimes accompanied by generalized seizures. Theepisodes can be triggered by varicella zoster virus (VZV), measlesmumps rubella (MMR) attenuated vaccine, parainfluenza virus, andEpstein-Barr virus (EBV). {ECO:0000269|PubMed:21109225}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/fadd/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8772"],["bp:comment","FADD_HUMAN Reviewed; 208 AA."],["bp:comment","REPLACED ProteinRef_FADD__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-286N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8772"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1124"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25446"],["bp:comment","REPLACED ProteinRef_FADD__10090"],["bp:comment","REPLACED ProteinRef_FADD__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80917"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","FADD"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80915"],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80916"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13158",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 194 194 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","FAS-associated death domain protein"],["bp:xref","FAS-associated death domain protein"],["bp:xref","FAS-associated death domain protein"],["bp:organism","FAS-associated death domain protein"],["bp:displayName","FADD_HUMAN"],["bp:name","MORT1"],["bp:name","FADD"],["bp:name","FAS-associating death domain-containing protein"],["bp:name","Growth-inhibiting gene 3 protein"],["bp:name","Protein FADD"],["bp:name","Mediator of receptor induced toxicity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003815"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03909_identity"],["bp:comment","FUNCTION: Apoptotic adaptor molecule that recruits caspase-8 orcaspase-10 to the activated Fas (CD95) or TNFR-1 receptors. Theresulting aggregate called the death-inducing signaling complex(DISC) performs caspase-8 proteolytic activation. Active caspase-8initiates the subsequent cascade of caspases mediating apoptosis.Involved in interferon-mediated antiviral immune response, playinga role in the positive regulation of interferon signaling.{ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.SUBUNIT: Can self-associate. Interacts with CFLAR, PEA15 and MBD4.When phosphorylated, part of a complex containing HIPK3 and FAS.May interact with MAVS/IPS1. Interacts with MOCV v-CFLAR proteinand PIDD1. Interacts (via death domain) with FAS (via deathdomain). Interacts with CASP8. Interacts directly (via DED domain)with NOL3 (via CARD domain); inhibits death-inducing signalingcomplex (DISC) assembly by inhibiting the increase in FAS-FADDbinding induced by FAS activation (By similarity).{ECO:0000250|UniProtKB:Q61160, ECO:0000269|PubMed:10442631,ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11034606,ECO:0000269|PubMed:12702765, ECO:0000269|PubMed:16127453,ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues, exceptfor peripheral blood mononuclear leukocytes.DOMAIN: Contains a death domain involved in the binding of thecorresponding domain within Fas receptor.{ECO:0000269|PubMed:19118384}.DOMAIN: The interaction between the FAS and FADD death domains iscrucial for the formation of the death-inducing signaling complex(DISC). {ECO:0000269|PubMed:19118384}.DISEASE: Infections, recurrent, associated with encephalopathy,hepatic dysfunction and cardiovascular malformations (IEHDCM)[MIM:613759]: A condition with biological features of autoimmunelymphoproliferative syndrome such as high-circulatingCD4(-)CD8(-)TCR-alpha-beta(+) T-cell counts, and elevated IL10 andFASL levels. Affected individuals suffer from recurrent,stereotypical episodes of fever, encephalopathy, and mild liverdysfunction sometimes accompanied by generalized seizures. Theepisodes can be triggered by varicella zoster virus (VZV), measlesmumps rubella (MMR) attenuated vaccine, parainfluenza virus, andEpstein-Barr virus (EBV). {ECO:0000269|PubMed:21109225}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/fadd/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8772"],["bp:comment","FADD_HUMAN Reviewed; 208 AA."],["bp:comment","REPLACED ProteinRef_FADD__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-286N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8772"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1124"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25446"],["bp:comment","REPLACED ProteinRef_FADD__10090"],["bp:comment","REPLACED ProteinRef_FADD__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80917"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80913"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80913"]]}},{"data":{"id":"Protein_59946f19a491a0ccdfd10b86bf8a3b2c_Complex_53e145b04847d664d289afe34fbf89cc","class":"macromolecule","label":"CASP8","parent":"Complex_53e145b04847d664d289afe34fbf89cc","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1387.8813,"y":949.43555,"w":48,"h":25},"metadata":[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 224 224 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","224"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 334 334 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 Phosphoserine."],["bp:featureLocation","MOD_RES 211 211 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 Phosphoserine."],["bp:featureLocation","MOD_RES 211 211 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 Phosphoserine."],["bp:featureLocation","MOD_RES 211 211 Phosphoserine."]]],["bp:standardName","Caspase-8"],["bp:xref","Caspase-8"],["bp:xref","Caspase-8"],["bp:organism","Caspase-8"],["bp:displayName","CASP8_HUMAN"],["bp:name","ICE-like apoptotic protease 5"],["bp:name","CAP4"],["bp:name","FADD-homologous ICE/ced-3-like protease"],["bp:name","FLICE"],["bp:name","Apoptotic protease Mch-5"],["bp:name","CASP-8"],["bp:name","Apoptotic cysteine protease"],["bp:name","3.4.22.61"],["bp:name","MORT1-associated ced-3 homolog"],["bp:name","MACH"],["bp:name","FADD-like ICE"],["bp:name","Caspase-8 subunit p10"],["bp:name","MCH5"],["bp:name","Caspase-8 subunit p18"],["bp:name","CASP8"],["bp:comment","REPLACED http://identifiers.org/uniprot/P08160"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q14790_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_841"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-9"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_genbank_indentifier_10835762_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q14790-1"],["bp:comment","FUNCTION: Most upstream protease of the activation cascade ofcaspases responsible for the TNFRSF6/FAS mediated and TNFRSF1Ainduced cell death. Binding to the adapter molecule FADD recruitsit to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolyticactivation. The active dimeric enzyme is then liberated from theDISC and free to activate downstream apoptotic proteases.Proteolytic fragments of the N-terminal propeptide (termed CAP3,CAP5 and CAP6) are likely retained in the DISC. Cleaves andactivates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. Mayparticipate in the GZMB apoptotic pathways. Cleaves ADPRT.Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC.Likely target for the cowpox virus CRMA death inhibitory protein.Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalyticsite and may interfere with the pro-apoptotic activity of thecomplex. {ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9006941}.CATALYTIC ACTIVITY: Strict requirement for Asp at position P1 andhas a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp-|-(Gly/Ser/Ala). {ECO:0000269|PubMed:23516580}.ENZYME REGULATION: Inhibited by the effector protein NleF that isproduced by pathogenic E.coli; this inhibits apoptosis.{ECO:0000269|PubMed:23516580}.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 18 kDa (p18) and a 10kDa (p10) subunit. Interacts with FADD, CFLAR and PEA15. Isoform 9interacts at the endoplasmic reticulum with a complex containingBCAP31, BAP29, BCL2 and/or BCL2L1. Interacts with TNFAIP8L2 (Bysimilarity). Interacts with CASP8AP2. Interacts with RFFL andRNF34; negatively regulate CASP8 through proteasomal degradation.Interacts with human cytomegalovirus/HHV-5 protein vICA/UL36; thisinteraction inhibits CASP8 activation. Interacts with NleF frompathogenic E.coli. Interacts with NOL3; decreases CASP8 activityin a mitochondria localization- and phosphorylation-dependentmanner and this interaction is dissociated by calcium.{ECO:0000250|UniProtKB:O89110, ECO:0000250|UniProtKB:Q9JHX4,ECO:0000269|PubMed:10442631, ECO:0000269|PubMed:10508785,ECO:0000269|PubMed:11427719, ECO:0000269|PubMed:11917123,ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:15509781,ECO:0000269|PubMed:17245429, ECO:0000269|PubMed:23516580,ECO:0000269|PubMed:9334338}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Name=1; Synonyms=Alpha-1;IsoId=Q14790-1; Sequence=Displayed;Name=2; Synonyms=Alpha-2, MCH5-beta;IsoId=Q14790-2; Sequence=VSP_000810;Name=3; Synonyms=Alpha-3;IsoId=Q14790-3; Sequence=VSP_000813;Name=4; Synonyms=Alpha-4;IsoId=Q14790-4; Sequence=VSP_000809, VSP_000810;Name=5; Synonyms=Beta-1;IsoId=Q14790-5; Sequence=VSP_000814, VSP_000815;Name=6; Synonyms=Beta-2;IsoId=Q14790-6; Sequence=VSP_000811, VSP_000812;Name=7; Synonyms=Beta-3, 8L;IsoId=Q14790-7; Sequence=VSP_000816, VSP_000817;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=8; Synonyms=Beta-4;IsoId=Q14790-8; Sequence=VSP_000810, VSP_000816, VSP_000817;Name=9; Synonyms=8L;IsoId=Q14790-9; Sequence=VSP_000808;Note=Ref.8 (AAL87628) sequence is in conflict in position:14:K->R. {ECO:0000305};TISSUE SPECIFICITY: Isoform 1, isoform 5 and isoform 7 areexpressed in a wide variety of tissues. Highest expression inperipheral blood leukocytes, spleen, thymus and liver. Barelydetectable in brain, testis and skeletal muscle.DOMAIN: Isoform 9 contains a N-terminal extension that is requiredfor interaction with the BCAP31 complex.PTM: Generation of the subunits requires association with thedeath-inducing signaling complex (DISC), whereas additionalprocessing is likely due to the autocatalytic activity of theactivated protease. GZMB and CASP10 can be involved in theseprocessing events. {ECO:0000269|PubMed:8962078,ECO:0000269|PubMed:9184224}.PTM: Phosphorylation on Ser-387 during mitosis by CDK1 inhibitsactivation by proteolysis and prevents apoptosis. Thisphosphorylation occurs in cancer cell lines, as well as in primarybreast tissues and lymphocytes. {ECO:0000269|PubMed:20937773}.POLYMORPHISM: Genetic variations in CASP8 are associated withreduced risk of lung cancer [MIM:211980] in a population of HanChinese subjects. Genetic variations are also associated withdecreased risk of cancer of various other forms includingesophageal, gastric, colorectal, cervical, and breast, acting inan allele dose-dependent manner. {ECO:0000269|PubMed:17450141}.DISEASE: Caspase-8 deficiency (CASP8D) [MIM:607271]: Disorderresembling autoimmune lymphoproliferative syndrome (ALPS). It ischaracterized by lymphadenopathy, splenomegaly, and defectiveCD95-induced apoptosis of peripheral blood lymphocytes (PBLs). Itleads to defects in activation of T-lymphocytes, B-lymphocytes,and natural killer cells leading to immunodeficiency characterizedby recurrent sinopulmonary and herpes simplex virus infections andpoor responses to immunization. {ECO:0000269|PubMed:12353035}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA66858.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};Sequence=CAA66859.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};WEB RESOURCE: Name=CASP8base; Note=CASP8 mutation db;URL=\"http://structure.bmc.lu.se/idbase/CASP8base/\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/casp8/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QDU_see-also"],["bp:comment","REPLACED ProteinRef_CASP8__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001219"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203520"],["bp:comment","CASP8_HUMAN Reviewed; 479 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03459_identity"],["bp:comment","REPLACED ProteinRef_CASP8__9606"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_841"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_203519"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1I4E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-30915N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1F9E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QTN_see-also"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4464"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246944"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_36111829"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80669"]]}},{"data":{"id":"Protein_c0184cf78d7f60bf635b44cdd53f9ad3_Complex_53e145b04847d664d289afe34fbf89cc","class":"macromolecule","label":"FADD","parent":"Complex_53e145b04847d664d289afe34fbf89cc","clonemarker":false,"stateVariables":[{"id":"Protein_c0184cf78d7f60bf635b44cdd53f9ad3_Complex_53e145b04847d664d289afe34fbf89cc.info.1","class":"state variable","state":{"variable":"194","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":1387.8813,"y":914.43555,"w":48,"h":25},"metadata":[["bp:displayName","FADD"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80915"],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80916"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13158",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 194 194 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","194"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","FAS-associated death domain protein"],["bp:xref",[["bp:relationshipType",null],["bp:id","FADD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","Q13158"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q13158"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","FADD_HUMAN"],["bp:name","MORT1"],["bp:name","FADD"],["bp:name","FAS-associating death domain-containing protein"],["bp:name","Growth-inhibiting gene 3 protein"],["bp:name","Protein FADD"],["bp:name","Mediator of receptor induced toxicity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003815"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03909_identity"],["bp:comment","FUNCTION: Apoptotic adaptor molecule that recruits caspase-8 orcaspase-10 to the activated Fas (CD95) or TNFR-1 receptors. Theresulting aggregate called the death-inducing signaling complex(DISC) performs caspase-8 proteolytic activation. Active caspase-8initiates the subsequent cascade of caspases mediating apoptosis.Involved in interferon-mediated antiviral immune response, playinga role in the positive regulation of interferon signaling.{ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.SUBUNIT: Can self-associate. Interacts with CFLAR, PEA15 and MBD4.When phosphorylated, part of a complex containing HIPK3 and FAS.May interact with MAVS/IPS1. Interacts with MOCV v-CFLAR proteinand PIDD1. Interacts (via death domain) with FAS (via deathdomain). Interacts with CASP8. Interacts directly (via DED domain)with NOL3 (via CARD domain); inhibits death-inducing signalingcomplex (DISC) assembly by inhibiting the increase in FAS-FADDbinding induced by FAS activation (By similarity).{ECO:0000250|UniProtKB:Q61160, ECO:0000269|PubMed:10442631,ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11034606,ECO:0000269|PubMed:12702765, ECO:0000269|PubMed:16127453,ECO:0000269|PubMed:16762833, ECO:0000269|PubMed:19118384,ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:21109225}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues, exceptfor peripheral blood mononuclear leukocytes.DOMAIN: Contains a death domain involved in the binding of thecorresponding domain within Fas receptor.{ECO:0000269|PubMed:19118384}.DOMAIN: The interaction between the FAS and FADD death domains iscrucial for the formation of the death-inducing signaling complex(DISC). {ECO:0000269|PubMed:19118384}.DISEASE: Infections, recurrent, associated with encephalopathy,hepatic dysfunction and cardiovascular malformations (IEHDCM)[MIM:613759]: A condition with biological features of autoimmunelymphoproliferative syndrome such as high-circulatingCD4(-)CD8(-)TCR-alpha-beta(+) T-cell counts, and elevated IL10 andFASL levels. Affected individuals suffer from recurrent,stereotypical episodes of fever, encephalopathy, and mild liverdysfunction sometimes accompanied by generalized seizures. Theepisodes can be triggered by varicella zoster virus (VZV), measlesmumps rubella (MMR) attenuated vaccine, parainfluenza virus, andEpstein-Barr virus (EBV). {ECO:0000269|PubMed:21109225}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/fadd/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8772"],["bp:comment","FADD_HUMAN Reviewed; 208 AA."],["bp:comment","REPLACED ProteinRef_FADD__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-286N_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8772"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1124"],["bp:comment","REPLACED http://identifiers.org/uniprot/P25446"],["bp:comment","REPLACED ProteinRef_FADD__10090"],["bp:comment","REPLACED ProteinRef_FADD__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80914"]]}},{"data":{"id":"SmallMolecule_e2a17d02eeab58ed31e4539686756323","class":"simple chemical","label":"C11AG","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":507.88568,"y":269.95898,"w":48,"h":20},"metadata":[["bp:displayName","C11AG"],["bp:entityReference_#SmallMoleculeReference_ab3c280f74bc68c7e7f1cd3b6e98af8f",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80960"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_3c451b5cb571d63465f2edc4f88ea7cb","class":"macromolecule","label":"MYC","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":43.619209999999995,"y":705.47186,"w":48,"h":25},"metadata":[["bp:displayName","MYC"],["bp:entityReference_http://identifiers.org/uniprot/P01106",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 323 323 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","323"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 58 58 Phosphothreonine; by GSK3; alternate."],["bp:featureLocation",[["bp:sequencePosition","58"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 143 143 N6-acetyllysine; by PCAF."],["bp:featureLocation",[["bp:sequencePosition","143"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."],["bp:featureLocation","MOD_RES 62 62 Phosphoserine; by DYRK2, GSK3 and CDK2."]]],["bp:standardName","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:xref","Myc proto-oncogene protein"],["bp:organism","Myc proto-oncogene protein"],["bp:displayName","MYC_HUMAN"],["bp:name","Proto-oncogene c-Myc"],["bp:name","BHLHE39"],["bp:name","Class E basic helix-loop-helix protein 39"],["bp:name","Transcription factor p64"],["bp:name","bHLHe39"],["bp:name","MYC"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A93_see-also"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/koK01906.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A93_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002458"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1EE4_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01818_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P01106_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_947"],["bp:comment","MYC_HUMAN Reviewed; 439 AA."],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_4609"],["bp:comment","FUNCTION: Transcription factor that binds DNA in a non-specificmanner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.SUBUNIT: Efficient DNA binding requires dimerization with anotherbHLH protein. Binds DNA as a heterodimer with MAX. Interacts withTAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A andKDM5B. Interacts (when phosphorylated at Thr-58 and Ser-62) withFBXW7. Interacts with PIM2. Interacts with RIOX1. The heterodimerMYC:MAX interacts with ABI1; the interaction may enhance MYC:MAXtranscriptional activity. Interacts with TRIM6 (By similarity).{ECO:0000250|UniProtKB:P01108, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:15674325, ECO:0000269|PubMed:15723054,ECO:0000269|PubMed:17308053, ECO:0000269|PubMed:17311883,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:17873522,ECO:0000269|PubMed:9680483}.SUBCELLULAR LOCATION: Nucleus, nucleoplasm{ECO:0000269|PubMed:17558397}. Nucleus, nucleolus{ECO:0000269|PubMed:17558397}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P01106-1; Sequence=Displayed;Name=2;IsoId=P01106-2; Sequence=VSP_037813;Note=Initiates from CTG codon. Ref.7 (BAA01374) sequence is inconflict in position: 2:D->N. Ref.7 (BAA01374) sequence is inconflict in position: 6:V->E. {ECO:0000305};PTM: Phosphorylated by PRKDC. Phosphorylation at Ser-329 by PIM2leads to the stabilization of MYC (By similarity). Phosphorylationat Ser-62 by CDK2 prevents Ras-induced senescence. Phosphorylatedat Ser-62 by DYRK2; this primes the protein for subsequentphosphorylation by GSK3B at Thr-58. Phosphorylation at Thr-58 andSer-62 by GSK3 is required for ubiquitination and degradation bythe proteasome. {ECO:0000250, ECO:0000269|PubMed:15103331,ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:19966300,ECO:0000269|PubMed:20713526, ECO:0000269|PubMed:22307329,ECO:0000269|PubMed:8386367}.PTM: Ubiquitinated by the SCF(FBXW7) complex when phosphorylatedat Thr-58 and Ser-62, leading to its degradation by theproteasome. In the nucleoplasm, ubiquitination is counteracted byUSP28, which interacts with isoform 1 of FBXW7 (FBW7alpha),leading to its deubiquitination and preventing degradation. In thenucleolus, however, ubiquitination is not counteracted by USP28,due to the lack of interaction between isoform 4 of FBXW7(FBW7gamma) and USP28, explaining the selective MYC degradation inthe nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.Ubiquitinated by TRIM6 in a phosphorylation-independent manner (Bysimilarity). {ECO:0000250|UniProtKB:P01108,ECO:0000269|PubMed:15103331, ECO:0000269|PubMed:17558397,ECO:0000269|PubMed:19966300, ECO:0000269|PubMed:20713526,ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:8386367}.DISEASE: Note=A chromosomal aberration involving MYC may be acause of a form of B-cell chronic lymphocytic leukemia.Translocation t(8;12)(q24;q22) with BTG1.{ECO:0000269|PubMed:2069907}.DISEASE: Burkitt lymphoma (BL) [MIM:113970]: A form ofundifferentiated malignant lymphoma commonly manifested as a largeosteolytic lesion in the jaw or as an abdominal mass.{ECO:0000269|PubMed:2166998, ECO:0000269|PubMed:8220424}. Note=Thegene represented in this entry is involved in diseasepathogenesis. Chromosomal aberrations involving MYC are usuallyfound in Burkitt lymphoma. Translocations t(8;14), t(8;22) ort(2;8) which juxtapose MYC to one of the heavy or light chainimmunoglobulin gene loci.BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the fourYamanaka factors. When combined, these factors are sufficient toreprogram differentiated cells to an embryonic-like statedesignated iPS (induced pluripotent stem) cells. iPS cells exhibitthe morphology and growth properties of ES cells and express EScell marker genes. {ECO:0000269|PubMed:18035408}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MYCID27.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/myc/\";WEB RESOURCE: Name=Wikipedia; Note=Myc entry;URL=\"https://en.wikipedia.org/wiki/Myc\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-28143N_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q02821"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2711"]]}},{"data":{"id":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1035.0857,"y":386.115,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Neutral sphingomyelinase II"],["bp:entityReference_http://identifiers.org/uniprot/Q9NY59",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q9NY59"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 291 291 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:organism","Sphingomyelin phosphodiesterase 3"],["bp:displayName","NSMA2_HUMAN"],["bp:name","Neutral sphingomyelinase 2"],["bp:name","SMPD3"],["bp:name","Neutral sphingomyelinase II"],["bp:name","nSMase-2"],["bp:name","nSMase2"],["bp:name","3.1.4.12"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_55512"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-60431N_identity"],["bp:comment","FUNCTION: Catalyzes the hydrolysis of sphingomyelin to formceramide and phosphocholine. Ceramide mediates numerous cellularfunctions, such as apoptosis and growth arrest, and is capable ofregulating these 2 cellular events independently. Also hydrolyzessphingosylphosphocholine. Regulates the cell cycle by acting as agrowth suppressor in confluent cells. Probably acts as a regulatorof postnatal development and participates in bone and dentinmineralization. {ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:14741383, ECO:0000269|PubMed:15051724}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:15051724};ENZYME REGULATION: Activated by unsaturated fatty acids andphosphatidylserine. {ECO:0000269|PubMed:10823942}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 7.5.;PATHWAY: Lipid metabolism; sphingolipid metabolism.SUBCELLULAR LOCATION: Golgi apparatus membrane{ECO:0000269|PubMed:10823942}; Lipid-anchor{ECO:0000269|PubMed:10823942}. Cell membrane{ECO:0000269|PubMed:15051724}; Lipid-anchor{ECO:0000269|PubMed:15051724}. Note=May localize to detergent-resistant subdomains of Golgi membranes of hypothalamicneurosecretory neurons (PubMed:10823942). Localizes to plasmamembrane in confluent contact-inhaibited cells (PubMed:15051724).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q9NY59-1; Sequence=Displayed;Name=2;IsoId=Q9NY59-2; Sequence=VSP_054334;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Predominantly expressed in brain.{ECO:0000269|PubMed:10823942}.DEVELOPMENTAL STAGE: Up-regulated during G0/G1 phases.PTM: Palmitoylated, palmitoylation-deficient proteins are targetedfor lysosomal degradation. {ECO:0000250}.SIMILARITY: Belongs to the neutral sphingomyelinase family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","NSMA2_HUMAN Reviewed; 655 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_55512"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80701"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Neutral sphingomyelinase II"],["bp:entityReference_http://identifiers.org/uniprot/Q9NY59",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q9NY59"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 291 291 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:organism","Sphingomyelin phosphodiesterase 3"],["bp:displayName","NSMA2_HUMAN"],["bp:name","Neutral sphingomyelinase 2"],["bp:name","SMPD3"],["bp:name","Neutral sphingomyelinase II"],["bp:name","nSMase-2"],["bp:name","nSMase2"],["bp:name","3.1.4.12"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_55512"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-60431N_identity"],["bp:comment","FUNCTION: Catalyzes the hydrolysis of sphingomyelin to formceramide and phosphocholine. Ceramide mediates numerous cellularfunctions, such as apoptosis and growth arrest, and is capable ofregulating these 2 cellular events independently. Also hydrolyzessphingosylphosphocholine. Regulates the cell cycle by acting as agrowth suppressor in confluent cells. Probably acts as a regulatorof postnatal development and participates in bone and dentinmineralization. {ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:14741383, ECO:0000269|PubMed:15051724}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:15051724};ENZYME REGULATION: Activated by unsaturated fatty acids andphosphatidylserine. {ECO:0000269|PubMed:10823942}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 7.5.;PATHWAY: Lipid metabolism; sphingolipid metabolism.SUBCELLULAR LOCATION: Golgi apparatus membrane{ECO:0000269|PubMed:10823942}; Lipid-anchor{ECO:0000269|PubMed:10823942}. Cell membrane{ECO:0000269|PubMed:15051724}; Lipid-anchor{ECO:0000269|PubMed:15051724}. Note=May localize to detergent-resistant subdomains of Golgi membranes of hypothalamicneurosecretory neurons (PubMed:10823942). Localizes to plasmamembrane in confluent contact-inhaibited cells (PubMed:15051724).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q9NY59-1; Sequence=Displayed;Name=2;IsoId=Q9NY59-2; Sequence=VSP_054334;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Predominantly expressed in brain.{ECO:0000269|PubMed:10823942}.DEVELOPMENTAL STAGE: Up-regulated during G0/G1 phases.PTM: Palmitoylated, palmitoylation-deficient proteins are targetedfor lysosomal degradation. {ECO:0000250}.SIMILARITY: Belongs to the neutral sphingomyelinase family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","NSMA2_HUMAN Reviewed; 655 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_55512"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80701"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Neutral sphingomyelinase II"],["bp:entityReference_http://identifiers.org/uniprot/Q9NY59",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q9NY59"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 291 291 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:organism","Sphingomyelin phosphodiesterase 3"],["bp:displayName","NSMA2_HUMAN"],["bp:name","Neutral sphingomyelinase 2"],["bp:name","SMPD3"],["bp:name","Neutral sphingomyelinase II"],["bp:name","nSMase-2"],["bp:name","nSMase2"],["bp:name","3.1.4.12"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_55512"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-60431N_identity"],["bp:comment","FUNCTION: Catalyzes the hydrolysis of sphingomyelin to formceramide and phosphocholine. Ceramide mediates numerous cellularfunctions, such as apoptosis and growth arrest, and is capable ofregulating these 2 cellular events independently. Also hydrolyzessphingosylphosphocholine. Regulates the cell cycle by acting as agrowth suppressor in confluent cells. Probably acts as a regulatorof postnatal development and participates in bone and dentinmineralization. {ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:14741383, ECO:0000269|PubMed:15051724}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:15051724};ENZYME REGULATION: Activated by unsaturated fatty acids andphosphatidylserine. {ECO:0000269|PubMed:10823942}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 7.5.;PATHWAY: Lipid metabolism; sphingolipid metabolism.SUBCELLULAR LOCATION: Golgi apparatus membrane{ECO:0000269|PubMed:10823942}; Lipid-anchor{ECO:0000269|PubMed:10823942}. Cell membrane{ECO:0000269|PubMed:15051724}; Lipid-anchor{ECO:0000269|PubMed:15051724}. Note=May localize to detergent-resistant subdomains of Golgi membranes of hypothalamicneurosecretory neurons (PubMed:10823942). Localizes to plasmamembrane in confluent contact-inhaibited cells (PubMed:15051724).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q9NY59-1; Sequence=Displayed;Name=2;IsoId=Q9NY59-2; Sequence=VSP_054334;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Predominantly expressed in brain.{ECO:0000269|PubMed:10823942}.DEVELOPMENTAL STAGE: Up-regulated during G0/G1 phases.PTM: Palmitoylated, palmitoylation-deficient proteins are targetedfor lysosomal degradation. {ECO:0000250}.SIMILARITY: Belongs to the neutral sphingomyelinase family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","NSMA2_HUMAN Reviewed; 655 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_55512"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80701"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Neutral sphingomyelinase II"],["bp:entityReference_http://identifiers.org/uniprot/Q9NY59",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q9NY59"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 291 291 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:organism","Sphingomyelin phosphodiesterase 3"],["bp:displayName","NSMA2_HUMAN"],["bp:name","Neutral sphingomyelinase 2"],["bp:name","SMPD3"],["bp:name","Neutral sphingomyelinase II"],["bp:name","nSMase-2"],["bp:name","nSMase2"],["bp:name","3.1.4.12"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_55512"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-60431N_identity"],["bp:comment","FUNCTION: Catalyzes the hydrolysis of sphingomyelin to formceramide and phosphocholine. Ceramide mediates numerous cellularfunctions, such as apoptosis and growth arrest, and is capable ofregulating these 2 cellular events independently. Also hydrolyzessphingosylphosphocholine. Regulates the cell cycle by acting as agrowth suppressor in confluent cells. Probably acts as a regulatorof postnatal development and participates in bone and dentinmineralization. {ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:14741383, ECO:0000269|PubMed:15051724}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:15051724};ENZYME REGULATION: Activated by unsaturated fatty acids andphosphatidylserine. {ECO:0000269|PubMed:10823942}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 7.5.;PATHWAY: Lipid metabolism; sphingolipid metabolism.SUBCELLULAR LOCATION: Golgi apparatus membrane{ECO:0000269|PubMed:10823942}; Lipid-anchor{ECO:0000269|PubMed:10823942}. Cell membrane{ECO:0000269|PubMed:15051724}; Lipid-anchor{ECO:0000269|PubMed:15051724}. Note=May localize to detergent-resistant subdomains of Golgi membranes of hypothalamicneurosecretory neurons (PubMed:10823942). Localizes to plasmamembrane in confluent contact-inhaibited cells (PubMed:15051724).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q9NY59-1; Sequence=Displayed;Name=2;IsoId=Q9NY59-2; Sequence=VSP_054334;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Predominantly expressed in brain.{ECO:0000269|PubMed:10823942}.DEVELOPMENTAL STAGE: Up-regulated during G0/G1 phases.PTM: Palmitoylated, palmitoylation-deficient proteins are targetedfor lysosomal degradation. {ECO:0000250}.SIMILARITY: Belongs to the neutral sphingomyelinase family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","NSMA2_HUMAN Reviewed; 655 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_55512"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80701"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Neutral sphingomyelinase II"],["bp:entityReference_http://identifiers.org/uniprot/Q9NY59",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q9NY59"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 291 291 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:organism","Sphingomyelin phosphodiesterase 3"],["bp:displayName","NSMA2_HUMAN"],["bp:name","Neutral sphingomyelinase 2"],["bp:name","SMPD3"],["bp:name","Neutral sphingomyelinase II"],["bp:name","nSMase-2"],["bp:name","nSMase2"],["bp:name","3.1.4.12"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_55512"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-60431N_identity"],["bp:comment","FUNCTION: Catalyzes the hydrolysis of sphingomyelin to formceramide and phosphocholine. Ceramide mediates numerous cellularfunctions, such as apoptosis and growth arrest, and is capable ofregulating these 2 cellular events independently. Also hydrolyzessphingosylphosphocholine. Regulates the cell cycle by acting as agrowth suppressor in confluent cells. Probably acts as a regulatorof postnatal development and participates in bone and dentinmineralization. {ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:14741383, ECO:0000269|PubMed:15051724}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:15051724};ENZYME REGULATION: Activated by unsaturated fatty acids andphosphatidylserine. {ECO:0000269|PubMed:10823942}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 7.5.;PATHWAY: Lipid metabolism; sphingolipid metabolism.SUBCELLULAR LOCATION: Golgi apparatus membrane{ECO:0000269|PubMed:10823942}; Lipid-anchor{ECO:0000269|PubMed:10823942}. Cell membrane{ECO:0000269|PubMed:15051724}; Lipid-anchor{ECO:0000269|PubMed:15051724}. Note=May localize to detergent-resistant subdomains of Golgi membranes of hypothalamicneurosecretory neurons (PubMed:10823942). Localizes to plasmamembrane in confluent contact-inhaibited cells (PubMed:15051724).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q9NY59-1; Sequence=Displayed;Name=2;IsoId=Q9NY59-2; Sequence=VSP_054334;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Predominantly expressed in brain.{ECO:0000269|PubMed:10823942}.DEVELOPMENTAL STAGE: Up-regulated during G0/G1 phases.PTM: Palmitoylated, palmitoylation-deficient proteins are targetedfor lysosomal degradation. {ECO:0000250}.SIMILARITY: Belongs to the neutral sphingomyelinase family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","NSMA2_HUMAN Reviewed; 655 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_55512"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80701"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Neutral sphingomyelinase II"],["bp:entityReference_http://identifiers.org/uniprot/Q9NY59",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q9NY59"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 291 291 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:organism","Sphingomyelin phosphodiesterase 3"],["bp:displayName","NSMA2_HUMAN"],["bp:name","Neutral sphingomyelinase 2"],["bp:name","SMPD3"],["bp:name","Neutral sphingomyelinase II"],["bp:name","nSMase-2"],["bp:name","nSMase2"],["bp:name","3.1.4.12"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_55512"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-60431N_identity"],["bp:comment","FUNCTION: Catalyzes the hydrolysis of sphingomyelin to formceramide and phosphocholine. Ceramide mediates numerous cellularfunctions, such as apoptosis and growth arrest, and is capable ofregulating these 2 cellular events independently. Also hydrolyzessphingosylphosphocholine. Regulates the cell cycle by acting as agrowth suppressor in confluent cells. Probably acts as a regulatorof postnatal development and participates in bone and dentinmineralization. {ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:14741383, ECO:0000269|PubMed:15051724}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:15051724};ENZYME REGULATION: Activated by unsaturated fatty acids andphosphatidylserine. {ECO:0000269|PubMed:10823942}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 7.5.;PATHWAY: Lipid metabolism; sphingolipid metabolism.SUBCELLULAR LOCATION: Golgi apparatus membrane{ECO:0000269|PubMed:10823942}; Lipid-anchor{ECO:0000269|PubMed:10823942}. Cell membrane{ECO:0000269|PubMed:15051724}; Lipid-anchor{ECO:0000269|PubMed:15051724}. Note=May localize to detergent-resistant subdomains of Golgi membranes of hypothalamicneurosecretory neurons (PubMed:10823942). Localizes to plasmamembrane in confluent contact-inhaibited cells (PubMed:15051724).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q9NY59-1; Sequence=Displayed;Name=2;IsoId=Q9NY59-2; Sequence=VSP_054334;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Predominantly expressed in brain.{ECO:0000269|PubMed:10823942}.DEVELOPMENTAL STAGE: Up-regulated during G0/G1 phases.PTM: Palmitoylated, palmitoylation-deficient proteins are targetedfor lysosomal degradation. {ECO:0000250}.SIMILARITY: Belongs to the neutral sphingomyelinase family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","NSMA2_HUMAN Reviewed; 655 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_55512"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80701"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Neutral sphingomyelinase II"],["bp:entityReference_http://identifiers.org/uniprot/Q9NY59",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q9NY59"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 291 291 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","291"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 178 178 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","178"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:xref","Sphingomyelin phosphodiesterase 3"],["bp:organism","Sphingomyelin phosphodiesterase 3"],["bp:displayName","NSMA2_HUMAN"],["bp:name","Neutral sphingomyelinase 2"],["bp:name","SMPD3"],["bp:name","Neutral sphingomyelinase II"],["bp:name","nSMase-2"],["bp:name","nSMase2"],["bp:name","3.1.4.12"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_55512"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_061137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-60431N_identity"],["bp:comment","FUNCTION: Catalyzes the hydrolysis of sphingomyelin to formceramide and phosphocholine. Ceramide mediates numerous cellularfunctions, such as apoptosis and growth arrest, and is capable ofregulating these 2 cellular events independently. Also hydrolyzessphingosylphosphocholine. Regulates the cell cycle by acting as agrowth suppressor in confluent cells. Probably acts as a regulatorof postnatal development and participates in bone and dentinmineralization. {ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:14741383, ECO:0000269|PubMed:15051724}.CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +phosphocholine.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10823942,ECO:0000269|PubMed:15051724};ENZYME REGULATION: Activated by unsaturated fatty acids andphosphatidylserine. {ECO:0000269|PubMed:10823942}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 7.5.;PATHWAY: Lipid metabolism; sphingolipid metabolism.SUBCELLULAR LOCATION: Golgi apparatus membrane{ECO:0000269|PubMed:10823942}; Lipid-anchor{ECO:0000269|PubMed:10823942}. Cell membrane{ECO:0000269|PubMed:15051724}; Lipid-anchor{ECO:0000269|PubMed:15051724}. Note=May localize to detergent-resistant subdomains of Golgi membranes of hypothalamicneurosecretory neurons (PubMed:10823942). Localizes to plasmamembrane in confluent contact-inhaibited cells (PubMed:15051724).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q9NY59-1; Sequence=Displayed;Name=2;IsoId=Q9NY59-2; Sequence=VSP_054334;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Predominantly expressed in brain.{ECO:0000269|PubMed:10823942}.DEVELOPMENTAL STAGE: Up-regulated during G0/G1 phases.PTM: Palmitoylated, palmitoylation-deficient proteins are targetedfor lysosomal degradation. {ECO:0000250}.SIMILARITY: Belongs to the neutral sphingomyelinase family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","NSMA2_HUMAN Reviewed; 655 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_55512"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80696"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80701"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80695"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80695"]]}},{"data":{"id":"Protein_42267d34042f1581692c87987313ebb5","class":"macromolecule","label":"BAX","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_42267d34042f1581692c87987313ebb5.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":566.5064,"y":420.0568,"w":48,"h":25},"metadata":[["bp:displayName","BAX"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1076"]]],["bp:entityReference_http://identifiers.org/uniprot/Q07812",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis regulator BAX"],["bp:xref",[["bp:relationshipType",null],["bp:id","BAX"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","Q07812"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q07812"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","BAX_HUMAN"],["bp:name","Bcl2-L-4"],["bp:name","Bcl-2-like protein 4"],["bp:name","BCL2L4"],["bp:name","BAX"],["bp:comment","BAX_HUMAN Reviewed; 192 AA."],["bp:comment","FUNCTION: Accelerates programmed cell death by binding to, andantagonizing the apoptosis repressor BCL2 or its adenovirushomolog E1B 19k protein. Under stress conditions, undergoes aconformation change that causes translocation to the mitochondrionmembrane, leading to the release of cytochrome c that thentriggers apoptosis. Promotes activation of CASP3, and therebyapoptosis. {ECO:0000269|PubMed:10772918,ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:18948948,ECO:0000269|PubMed:21199865, ECO:0000269|PubMed:8358790,ECO:0000269|PubMed:8521816}.SUBUNIT: Homodimer. Forms higher oligomers under stressconditions. Interacts with BCL2L11. Interaction with BCL2L11promotes BAX oligomerization and association with mitochondrialmembranes, with subsequent release of cytochrome c. Formsheterodimers with BCL2, E1B 19K protein, BCL2L1 isoform Bcl-X(L),BCL2L2, MCL1 and A1. Interacts with SH3GLB1 and HN. Interacts withSFN and YWHAZ; the interaction occurs in the cytoplasm. Understress conditions, JNK-mediated phosphorylation of SFN and YWHAZ,releases BAX to mitochondria. Isoform Sigma interacts with BCL2A1and BCL2L1 isoform Bcl-X(L). Interacts with RNF144B, whichregulates the ubiquitin-dependent stability of BAX. Interacts withCLU under stress conditions that cause a conformation changeleading to BAX oligomerization and association with mitochondria.Does not interact with CLU in unstressed cells. Interacts withFAIM2/LFG2. Interacts with human cytomegalovirus/HHV-5 proteinvMIA/UL37. Interacts with BOP/C22orf29. Interacts (via a C-terminal 33 residues) with NOL3 (via CARD domain); inhibits BAXactivation and translocation and consequently cytochrome c releasefrom mitochondria. {ECO:0000269|PubMed:10772918,ECO:0000269|PubMed:11106734, ECO:0000269|PubMed:11259440,ECO:0000269|PubMed:12732850, ECO:0000269|PubMed:15004026,ECO:0000269|PubMed:15004034, ECO:0000269|PubMed:15071501,ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:16946732,ECO:0000269|PubMed:16964429, ECO:0000269|PubMed:18948948,ECO:0000269|PubMed:20300062, ECO:0000269|PubMed:21199865,ECO:0000269|PubMed:23055042, ECO:0000269|PubMed:8358790}.SUBCELLULAR LOCATION: Isoform Alpha: Mitochondrion membrane;Single-pass membrane protein. Cytoplasm. Note=Colocalizes with 14-3-3 proteins in the cytoplasm. Under stress conditions, undergoesa conformation change that causes release from JNK-phosphorylated14-3-3 proteins and translocation to the mitochondrion membrane.SUBCELLULAR LOCATION: Isoform Beta: Cytoplasm.SUBCELLULAR LOCATION: Isoform Gamma: Cytoplasm.SUBCELLULAR LOCATION: Isoform Delta: Cytoplasm {ECO:0000305}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=Alpha;IsoId=Q07812-1; Sequence=Displayed;Name=Beta;IsoId=Q07812-2, Q07814-1;Sequence=VSP_031237;Name=Gamma;IsoId=Q07812-3, Q07815-1;Sequence=VSP_031234, VSP_031236;Name=Delta;IsoId=Q07812-4, P55269-1;Sequence=VSP_031235;Name=Epsilon;IsoId=Q07812-5; Sequence=VSP_031240;Name=Zeta;IsoId=Q07812-6; Sequence=VSP_031239;Name=Psi;IsoId=Q07812-7; Sequence=VSP_031238;Name=Sigma;IsoId=Q07812-8; Sequence=VSP_037475;TISSUE SPECIFICITY: Expressed in a wide variety of tissues.Isoform Psi is found in glial tumors. Isoform Alpha is expressedin spleen, breast, ovary, testis, colon and brain, and at lowlevels in skin and lung. Isoform Sigma is expressed in spleen,breast, ovary, testis, lung, colon, brain and at low levels inskin. Isoform Alpha and isoform Sigma are expressed in pro-myelocytic leukemia, histiocytic lymphoma, Burkitt's lymphoma, T-cell lymphoma, lymphoblastic leukemia, breast adenocarcinoma,ovary adenocarcinoma, prostate carcinoma, prostate adenocarcinoma,lung carcinoma, epidermoid carcinoma, small cell lung carcinomaand colon adenocarcinoma cell lines. {ECO:0000269|PubMed:10772918,ECO:0000269|PubMed:11912183}.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family. {ECO:0000250}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bax/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BAXID128ch19q13.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_581"],["bp:comment","REPLACED http://identifiers.org/uniprot/P55269"],["bp:comment","REPLACED ProteinRef_BAX__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_581"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-232N_identity"],["bp:comment","REPLACED ProteinRef_BAX__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_620116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004315"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q07812_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016882566"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02498_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4701"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80529"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":181.95634,"y":975.0778,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","RAF1"],["bp:entityReference_http://identifiers.org/uniprot/P04049",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation",[["bp:sequencePosition","341"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:standardName","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:organism","RAF proto-oncogene serine/threonine-protein kinase"],["bp:displayName","RAF1_HUMAN"],["bp:name","Proto-oncogene c-RAF"],["bp:name","RAF"],["bp:name","RAF1"],["bp:name","2.7.11.1"],["bp:name","cRaf"],["bp:name","Raf-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FAQ_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5894"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002871"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5894"],["bp:comment","REPLACED ProteinRef_RAF1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_653"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P04049_identity"],["bp:comment","FUNCTION: Serine/threonine-protein kinase that acts as aregulatory link between the membrane-associated Ras GTPases andthe MAPK/ERK cascade, and this critical regulatory link functionsas a switch determining cell fate decisions includingproliferation, differentiation, apoptosis, survival and oncogenictransformation. RAF1 activation initiates a mitogen-activatedprotein kinase (MAPK) cascade that comprises a sequentialphosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 andMAP2K2/MEK2) and the extracellular signal-regulated kinases(MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (onresidues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylylcyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.Phosphorylates PPP1R12A resulting in inhibition of the phosphataseactivity. Phosphorylates TNNT2/cardiac muscle troponin T. Canpromote NF-kB activation and inhibit signal transducers involvedin motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),proliferation and angiogenesis (RB1). Can protect cells fromapoptosis also by translocating to the mitochondria where it bindsBCL2 and displaces BAD/Bcl2-antagonist of cell death. RegulatesRho signaling and migration, and is required for normal woundhealing. Plays a role in the oncogenic transformation ofepithelial cells via repression of the TJ protein, occludin (OCLN)by inducing the up-regulation of a transcriptional repressorSNAI2/SLUG, which induces down-regulation of OCLN. Restrictscaspase activation in response to selected stimuli, notably Fasstimulation, pathogen-mediated macrophage apoptosis, and erythroiddifferentiation. {ECO:0000269|PubMed:11427728,ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,ECO:0000269|PubMed:9360956}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Note=Binds 2 Zn(2+) ions per subunit.;ENZYME REGULATION: Regulation is a highly complex processinvolving membrane recruitment, protein-protein interactions,dimerization, and phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the membrane, thereby promoting itsactivation. The inactive conformation of RAF1 is maintained byautoinhibitory interactions occurring between the N-terminalregulatory and the C-terminal catalytic domains and by the bindingof a 14-3-3 protein that contacts two phosphorylation sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1Acooperate to release autoinhibition and the subsequentphosphorylation of activating sites: Ser-338, Tyr-341, Thr-491,and Ser-494, yields a fully active kinase. Through a negativefeedback mechanism involving MAPK1/ERK2, RAF1 is phosphorylated onSer-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 byMAPK1/ERK2, which yields an inactive, desensitized kinase. Thesignaling-competent conformation of RAF1 is finally re-establishedby the coordinated action of PIN1, a prolyl isomerase thatconverts pSer and pThr residues from the cis to the transconformation, which is preferentially recognized anddephosphorylated by PPP2R1A. Activated by homodimerization andheterodimerization (with BRAF). Also regulated through associationwith other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP,PHB/prohibitin and SPRY4. PEBP1/RKIP acts by dissociating RAF1from its substrates MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitinfacilitates the displacement of 14-3-3 from RAF1 by activated Ras,thereby promoting cell membrane localization and phosphorylationof RAF1 at the activating Ser-338. SPRY4 inhibits Ras-independent,but not Ras-dependent, activation of RAF1. CNKSR1/CNK1 regulatesSrc-mediated RAF1 activation. {ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12717443,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016}.SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and thisheterodimer possesses a highly increased kinase activity comparedto the respective homodimers or monomers (PubMed:16508002).Heterodimerization is mitogen-regulated and enhanced by 14-3-3proteins (PubMed:16508002). MAPK1/ERK2 activation can induce anegative feedback that promotes the dissociation of theheterodimer (PubMed:16508002). Forms a multiprotein complex withRas (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CBand PPP1CC) (PubMed:16630891). Interacts with Ras proteins; theinteraction is antagonized by RIN1 (PubMed:11784866). Weaklyinteracts with RIT1. Interacts (via N-terminus) with RGS14 (viaRBD domains); the interaction mediates the formation of a ternarycomplex with BRAF, a ternary complex inhibited by GNAI1 (Bysimilarity). Interacts with STK3/MST2; the interaction inhibitsits pro-apoptotic activity (PubMed:15618521). Interacts (whenphosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') (PubMed:9360956). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2(By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) andthis interaction inhibits the proapoptotic function of MAP3K5/ASK1(PubMed:11427728). Interacts with PAK1 (via kinase domain)(PubMed:11733498). The phosphorylated form interacts with PIN1 (Bysimilarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIPand this interaction is enhanced if RAF1 is phosphorylated onresidues Ser-338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816).Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A,PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 andPHB/prohibitin (PubMed:10801873, PubMed:11719507, PubMed:12717443,PubMed:15385642, PubMed:15935327, PubMed:19710016,PubMed:10576742). Interacts with ROCK2 (By similarity). In itsactive form, interacts with PRMT5 (PubMed:21917714). Interactswith FAM83B; displaces 14-3-3 proteins from RAF1 and activatesRAF1 (PubMed:22886302). Interacts with PDE8A; the interactionpromotes RAF1 activity (PubMed:23509299).{ECO:0000250|UniProtKB:P11345, ECO:0000250|UniProtKB:Q99N57,ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11784866,ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:15935327, ECO:0000269|PubMed:16508002,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:22886302, ECO:0000269|PubMed:23509299,ECO:0000269|PubMed:9360956}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion.Nucleus. Note=Colocalizes with RGS14 and BRAF in both thecytoplasm and membranes. Phosphorylation at Ser-259 impairs itsmembrane accumulation. Recruited to the cell membrane by theactive Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantlylocalized at the nucleus.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=6C;IsoId=P04049-1; Sequence=Displayed;Name=2; Synonyms=1A;IsoId=P04049-2; Sequence=VSP_034649;TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundantthan isoform 2. {ECO:0000269|PubMed:1886707}.PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 andSer-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results inits inactivation. Phosphorylation at Ser-259 induces theinteraction with YWHAZ and inactivates kinase activity.Dephosphorylation of Ser-259 by the complex containing proteinphosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leadingto stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 andPAK5 and Ser-339 by PAK1 is required for its mitochondriallocalization. Phosphorylation at Ser-621 in response to growthfactor treatment stabilizes the protein, possibly by preventingproteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, Ser-338 and Ser-621 are somehow linked to the methylationpotential of cells. Treatment of cells with HGF in the presence ofthe methylation inhibitor 5'-methylthioadenosine (MTA) results inincreased phosphorylation at Ser-338 and Ser-621 and decreasedphosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylationat Ser-338 by PPP5C results in a activity decrease.{ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,ECO:0000269|PubMed:11756411, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16093354,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:16892053,ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614,ECO:0000269|PubMed:9823899}.PTM: Methylated at Arg-563 in response to EGF treatment. Thismodification leads to destabilization of the protein, possiblythrough proteasomal degradation. {ECO:0000269|PubMed:21917714}.DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonansyndrome, a disease characterized by short stature, facialdysmorphic features such as hypertelorism, a downward eyeslant andlow-set posteriorly rotated ears, and a high incidence ofcongenital heart defects and hypertrophic cardiomyopathy. Otherfeatures can include a short neck with webbing or redundancy ofskin, deafness, motor delay, variable intellectual deficits,multiple skeletal defects, cryptorchidism, and bleeding diathesis.Individuals with Noonan syndrome are at risk of juvenilemyelomonocytic leukemia, a myeloproliferative disordercharacterized by excessive production of myelomonocytic cells.{ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483,ECO:0000269|PubMed:20683980}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disordercharacterized by lentigines, electrocardiographic conductionabnormalities, ocular hypertelorism, pulmonic stenosis,abnormalities of genitalia, retardation of growth, andsensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: Adisorder characterized by ventricular dilation and impairedsystolic function, resulting in congestive heart failure andarrhythmia. Patients are at risk of premature death.{ECO:0000269|PubMed:24777450}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. RAF subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/raf1/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","RAF1_HUMAN Reviewed; 648 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1048N_identity"],["bp:comment","REPLACED ProteinRef_RAF1__9606"],["bp:comment","REPLACED ProteinRef_RAF1__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5894"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04049-1"],["bp:comment","REPLACED ProteinRef_RAF1__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80595"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","RAF1"],["bp:entityReference_http://identifiers.org/uniprot/P04049",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation",[["bp:sequencePosition","341"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:standardName","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:organism","RAF proto-oncogene serine/threonine-protein kinase"],["bp:displayName","RAF1_HUMAN"],["bp:name","Proto-oncogene c-RAF"],["bp:name","RAF"],["bp:name","RAF1"],["bp:name","2.7.11.1"],["bp:name","cRaf"],["bp:name","Raf-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FAQ_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5894"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002871"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5894"],["bp:comment","REPLACED ProteinRef_RAF1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_653"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P04049_identity"],["bp:comment","FUNCTION: Serine/threonine-protein kinase that acts as aregulatory link between the membrane-associated Ras GTPases andthe MAPK/ERK cascade, and this critical regulatory link functionsas a switch determining cell fate decisions includingproliferation, differentiation, apoptosis, survival and oncogenictransformation. RAF1 activation initiates a mitogen-activatedprotein kinase (MAPK) cascade that comprises a sequentialphosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 andMAP2K2/MEK2) and the extracellular signal-regulated kinases(MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (onresidues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylylcyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.Phosphorylates PPP1R12A resulting in inhibition of the phosphataseactivity. Phosphorylates TNNT2/cardiac muscle troponin T. Canpromote NF-kB activation and inhibit signal transducers involvedin motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),proliferation and angiogenesis (RB1). Can protect cells fromapoptosis also by translocating to the mitochondria where it bindsBCL2 and displaces BAD/Bcl2-antagonist of cell death. RegulatesRho signaling and migration, and is required for normal woundhealing. Plays a role in the oncogenic transformation ofepithelial cells via repression of the TJ protein, occludin (OCLN)by inducing the up-regulation of a transcriptional repressorSNAI2/SLUG, which induces down-regulation of OCLN. Restrictscaspase activation in response to selected stimuli, notably Fasstimulation, pathogen-mediated macrophage apoptosis, and erythroiddifferentiation. {ECO:0000269|PubMed:11427728,ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,ECO:0000269|PubMed:9360956}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Note=Binds 2 Zn(2+) ions per subunit.;ENZYME REGULATION: Regulation is a highly complex processinvolving membrane recruitment, protein-protein interactions,dimerization, and phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the membrane, thereby promoting itsactivation. The inactive conformation of RAF1 is maintained byautoinhibitory interactions occurring between the N-terminalregulatory and the C-terminal catalytic domains and by the bindingof a 14-3-3 protein that contacts two phosphorylation sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1Acooperate to release autoinhibition and the subsequentphosphorylation of activating sites: Ser-338, Tyr-341, Thr-491,and Ser-494, yields a fully active kinase. Through a negativefeedback mechanism involving MAPK1/ERK2, RAF1 is phosphorylated onSer-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 byMAPK1/ERK2, which yields an inactive, desensitized kinase. Thesignaling-competent conformation of RAF1 is finally re-establishedby the coordinated action of PIN1, a prolyl isomerase thatconverts pSer and pThr residues from the cis to the transconformation, which is preferentially recognized anddephosphorylated by PPP2R1A. Activated by homodimerization andheterodimerization (with BRAF). Also regulated through associationwith other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP,PHB/prohibitin and SPRY4. PEBP1/RKIP acts by dissociating RAF1from its substrates MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitinfacilitates the displacement of 14-3-3 from RAF1 by activated Ras,thereby promoting cell membrane localization and phosphorylationof RAF1 at the activating Ser-338. SPRY4 inhibits Ras-independent,but not Ras-dependent, activation of RAF1. CNKSR1/CNK1 regulatesSrc-mediated RAF1 activation. {ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12717443,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016}.SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and thisheterodimer possesses a highly increased kinase activity comparedto the respective homodimers or monomers (PubMed:16508002).Heterodimerization is mitogen-regulated and enhanced by 14-3-3proteins (PubMed:16508002). MAPK1/ERK2 activation can induce anegative feedback that promotes the dissociation of theheterodimer (PubMed:16508002). Forms a multiprotein complex withRas (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CBand PPP1CC) (PubMed:16630891). Interacts with Ras proteins; theinteraction is antagonized by RIN1 (PubMed:11784866). Weaklyinteracts with RIT1. Interacts (via N-terminus) with RGS14 (viaRBD domains); the interaction mediates the formation of a ternarycomplex with BRAF, a ternary complex inhibited by GNAI1 (Bysimilarity). Interacts with STK3/MST2; the interaction inhibitsits pro-apoptotic activity (PubMed:15618521). Interacts (whenphosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') (PubMed:9360956). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2(By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) andthis interaction inhibits the proapoptotic function of MAP3K5/ASK1(PubMed:11427728). Interacts with PAK1 (via kinase domain)(PubMed:11733498). The phosphorylated form interacts with PIN1 (Bysimilarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIPand this interaction is enhanced if RAF1 is phosphorylated onresidues Ser-338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816).Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A,PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 andPHB/prohibitin (PubMed:10801873, PubMed:11719507, PubMed:12717443,PubMed:15385642, PubMed:15935327, PubMed:19710016,PubMed:10576742). Interacts with ROCK2 (By similarity). In itsactive form, interacts with PRMT5 (PubMed:21917714). Interactswith FAM83B; displaces 14-3-3 proteins from RAF1 and activatesRAF1 (PubMed:22886302). Interacts with PDE8A; the interactionpromotes RAF1 activity (PubMed:23509299).{ECO:0000250|UniProtKB:P11345, ECO:0000250|UniProtKB:Q99N57,ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11784866,ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:15935327, ECO:0000269|PubMed:16508002,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:22886302, ECO:0000269|PubMed:23509299,ECO:0000269|PubMed:9360956}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion.Nucleus. Note=Colocalizes with RGS14 and BRAF in both thecytoplasm and membranes. Phosphorylation at Ser-259 impairs itsmembrane accumulation. Recruited to the cell membrane by theactive Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantlylocalized at the nucleus.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=6C;IsoId=P04049-1; Sequence=Displayed;Name=2; Synonyms=1A;IsoId=P04049-2; Sequence=VSP_034649;TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundantthan isoform 2. {ECO:0000269|PubMed:1886707}.PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 andSer-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results inits inactivation. Phosphorylation at Ser-259 induces theinteraction with YWHAZ and inactivates kinase activity.Dephosphorylation of Ser-259 by the complex containing proteinphosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leadingto stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 andPAK5 and Ser-339 by PAK1 is required for its mitochondriallocalization. Phosphorylation at Ser-621 in response to growthfactor treatment stabilizes the protein, possibly by preventingproteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, Ser-338 and Ser-621 are somehow linked to the methylationpotential of cells. Treatment of cells with HGF in the presence ofthe methylation inhibitor 5'-methylthioadenosine (MTA) results inincreased phosphorylation at Ser-338 and Ser-621 and decreasedphosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylationat Ser-338 by PPP5C results in a activity decrease.{ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,ECO:0000269|PubMed:11756411, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16093354,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:16892053,ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614,ECO:0000269|PubMed:9823899}.PTM: Methylated at Arg-563 in response to EGF treatment. Thismodification leads to destabilization of the protein, possiblythrough proteasomal degradation. {ECO:0000269|PubMed:21917714}.DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonansyndrome, a disease characterized by short stature, facialdysmorphic features such as hypertelorism, a downward eyeslant andlow-set posteriorly rotated ears, and a high incidence ofcongenital heart defects and hypertrophic cardiomyopathy. Otherfeatures can include a short neck with webbing or redundancy ofskin, deafness, motor delay, variable intellectual deficits,multiple skeletal defects, cryptorchidism, and bleeding diathesis.Individuals with Noonan syndrome are at risk of juvenilemyelomonocytic leukemia, a myeloproliferative disordercharacterized by excessive production of myelomonocytic cells.{ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483,ECO:0000269|PubMed:20683980}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disordercharacterized by lentigines, electrocardiographic conductionabnormalities, ocular hypertelorism, pulmonic stenosis,abnormalities of genitalia, retardation of growth, andsensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: Adisorder characterized by ventricular dilation and impairedsystolic function, resulting in congestive heart failure andarrhythmia. Patients are at risk of premature death.{ECO:0000269|PubMed:24777450}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. RAF subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/raf1/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","RAF1_HUMAN Reviewed; 648 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1048N_identity"],["bp:comment","REPLACED ProteinRef_RAF1__9606"],["bp:comment","REPLACED ProteinRef_RAF1__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5894"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04049-1"],["bp:comment","REPLACED ProteinRef_RAF1__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80595"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","RAF1"],["bp:entityReference_http://identifiers.org/uniprot/P04049",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation",[["bp:sequencePosition","341"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:standardName","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:organism","RAF proto-oncogene serine/threonine-protein kinase"],["bp:displayName","RAF1_HUMAN"],["bp:name","Proto-oncogene c-RAF"],["bp:name","RAF"],["bp:name","RAF1"],["bp:name","2.7.11.1"],["bp:name","cRaf"],["bp:name","Raf-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FAQ_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5894"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002871"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5894"],["bp:comment","REPLACED ProteinRef_RAF1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_653"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P04049_identity"],["bp:comment","FUNCTION: Serine/threonine-protein kinase that acts as aregulatory link between the membrane-associated Ras GTPases andthe MAPK/ERK cascade, and this critical regulatory link functionsas a switch determining cell fate decisions includingproliferation, differentiation, apoptosis, survival and oncogenictransformation. RAF1 activation initiates a mitogen-activatedprotein kinase (MAPK) cascade that comprises a sequentialphosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 andMAP2K2/MEK2) and the extracellular signal-regulated kinases(MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (onresidues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylylcyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.Phosphorylates PPP1R12A resulting in inhibition of the phosphataseactivity. Phosphorylates TNNT2/cardiac muscle troponin T. Canpromote NF-kB activation and inhibit signal transducers involvedin motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),proliferation and angiogenesis (RB1). Can protect cells fromapoptosis also by translocating to the mitochondria where it bindsBCL2 and displaces BAD/Bcl2-antagonist of cell death. RegulatesRho signaling and migration, and is required for normal woundhealing. Plays a role in the oncogenic transformation ofepithelial cells via repression of the TJ protein, occludin (OCLN)by inducing the up-regulation of a transcriptional repressorSNAI2/SLUG, which induces down-regulation of OCLN. Restrictscaspase activation in response to selected stimuli, notably Fasstimulation, pathogen-mediated macrophage apoptosis, and erythroiddifferentiation. {ECO:0000269|PubMed:11427728,ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,ECO:0000269|PubMed:9360956}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Note=Binds 2 Zn(2+) ions per subunit.;ENZYME REGULATION: Regulation is a highly complex processinvolving membrane recruitment, protein-protein interactions,dimerization, and phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the membrane, thereby promoting itsactivation. The inactive conformation of RAF1 is maintained byautoinhibitory interactions occurring between the N-terminalregulatory and the C-terminal catalytic domains and by the bindingof a 14-3-3 protein that contacts two phosphorylation sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1Acooperate to release autoinhibition and the subsequentphosphorylation of activating sites: Ser-338, Tyr-341, Thr-491,and Ser-494, yields a fully active kinase. Through a negativefeedback mechanism involving MAPK1/ERK2, RAF1 is phosphorylated onSer-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 byMAPK1/ERK2, which yields an inactive, desensitized kinase. Thesignaling-competent conformation of RAF1 is finally re-establishedby the coordinated action of PIN1, a prolyl isomerase thatconverts pSer and pThr residues from the cis to the transconformation, which is preferentially recognized anddephosphorylated by PPP2R1A. Activated by homodimerization andheterodimerization (with BRAF). Also regulated through associationwith other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP,PHB/prohibitin and SPRY4. PEBP1/RKIP acts by dissociating RAF1from its substrates MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitinfacilitates the displacement of 14-3-3 from RAF1 by activated Ras,thereby promoting cell membrane localization and phosphorylationof RAF1 at the activating Ser-338. SPRY4 inhibits Ras-independent,but not Ras-dependent, activation of RAF1. CNKSR1/CNK1 regulatesSrc-mediated RAF1 activation. {ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12717443,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016}.SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and thisheterodimer possesses a highly increased kinase activity comparedto the respective homodimers or monomers (PubMed:16508002).Heterodimerization is mitogen-regulated and enhanced by 14-3-3proteins (PubMed:16508002). MAPK1/ERK2 activation can induce anegative feedback that promotes the dissociation of theheterodimer (PubMed:16508002). Forms a multiprotein complex withRas (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CBand PPP1CC) (PubMed:16630891). Interacts with Ras proteins; theinteraction is antagonized by RIN1 (PubMed:11784866). Weaklyinteracts with RIT1. Interacts (via N-terminus) with RGS14 (viaRBD domains); the interaction mediates the formation of a ternarycomplex with BRAF, a ternary complex inhibited by GNAI1 (Bysimilarity). Interacts with STK3/MST2; the interaction inhibitsits pro-apoptotic activity (PubMed:15618521). Interacts (whenphosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') (PubMed:9360956). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2(By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) andthis interaction inhibits the proapoptotic function of MAP3K5/ASK1(PubMed:11427728). Interacts with PAK1 (via kinase domain)(PubMed:11733498). The phosphorylated form interacts with PIN1 (Bysimilarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIPand this interaction is enhanced if RAF1 is phosphorylated onresidues Ser-338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816).Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A,PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 andPHB/prohibitin (PubMed:10801873, PubMed:11719507, PubMed:12717443,PubMed:15385642, PubMed:15935327, PubMed:19710016,PubMed:10576742). Interacts with ROCK2 (By similarity). In itsactive form, interacts with PRMT5 (PubMed:21917714). Interactswith FAM83B; displaces 14-3-3 proteins from RAF1 and activatesRAF1 (PubMed:22886302). Interacts with PDE8A; the interactionpromotes RAF1 activity (PubMed:23509299).{ECO:0000250|UniProtKB:P11345, ECO:0000250|UniProtKB:Q99N57,ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11784866,ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:15935327, ECO:0000269|PubMed:16508002,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:22886302, ECO:0000269|PubMed:23509299,ECO:0000269|PubMed:9360956}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion.Nucleus. Note=Colocalizes with RGS14 and BRAF in both thecytoplasm and membranes. Phosphorylation at Ser-259 impairs itsmembrane accumulation. Recruited to the cell membrane by theactive Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantlylocalized at the nucleus.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=6C;IsoId=P04049-1; Sequence=Displayed;Name=2; Synonyms=1A;IsoId=P04049-2; Sequence=VSP_034649;TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundantthan isoform 2. {ECO:0000269|PubMed:1886707}.PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 andSer-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results inits inactivation. Phosphorylation at Ser-259 induces theinteraction with YWHAZ and inactivates kinase activity.Dephosphorylation of Ser-259 by the complex containing proteinphosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leadingto stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 andPAK5 and Ser-339 by PAK1 is required for its mitochondriallocalization. Phosphorylation at Ser-621 in response to growthfactor treatment stabilizes the protein, possibly by preventingproteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, Ser-338 and Ser-621 are somehow linked to the methylationpotential of cells. Treatment of cells with HGF in the presence ofthe methylation inhibitor 5'-methylthioadenosine (MTA) results inincreased phosphorylation at Ser-338 and Ser-621 and decreasedphosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylationat Ser-338 by PPP5C results in a activity decrease.{ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,ECO:0000269|PubMed:11756411, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16093354,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:16892053,ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614,ECO:0000269|PubMed:9823899}.PTM: Methylated at Arg-563 in response to EGF treatment. Thismodification leads to destabilization of the protein, possiblythrough proteasomal degradation. {ECO:0000269|PubMed:21917714}.DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonansyndrome, a disease characterized by short stature, facialdysmorphic features such as hypertelorism, a downward eyeslant andlow-set posteriorly rotated ears, and a high incidence ofcongenital heart defects and hypertrophic cardiomyopathy. Otherfeatures can include a short neck with webbing or redundancy ofskin, deafness, motor delay, variable intellectual deficits,multiple skeletal defects, cryptorchidism, and bleeding diathesis.Individuals with Noonan syndrome are at risk of juvenilemyelomonocytic leukemia, a myeloproliferative disordercharacterized by excessive production of myelomonocytic cells.{ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483,ECO:0000269|PubMed:20683980}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disordercharacterized by lentigines, electrocardiographic conductionabnormalities, ocular hypertelorism, pulmonic stenosis,abnormalities of genitalia, retardation of growth, andsensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: Adisorder characterized by ventricular dilation and impairedsystolic function, resulting in congestive heart failure andarrhythmia. Patients are at risk of premature death.{ECO:0000269|PubMed:24777450}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. RAF subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/raf1/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","RAF1_HUMAN Reviewed; 648 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1048N_identity"],["bp:comment","REPLACED ProteinRef_RAF1__9606"],["bp:comment","REPLACED ProteinRef_RAF1__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5894"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04049-1"],["bp:comment","REPLACED ProteinRef_RAF1__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80595"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","RAF1"],["bp:entityReference_http://identifiers.org/uniprot/P04049",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation",[["bp:sequencePosition","341"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:standardName","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:organism","RAF proto-oncogene serine/threonine-protein kinase"],["bp:displayName","RAF1_HUMAN"],["bp:name","Proto-oncogene c-RAF"],["bp:name","RAF"],["bp:name","RAF1"],["bp:name","2.7.11.1"],["bp:name","cRaf"],["bp:name","Raf-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FAQ_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5894"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002871"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5894"],["bp:comment","REPLACED ProteinRef_RAF1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_653"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P04049_identity"],["bp:comment","FUNCTION: Serine/threonine-protein kinase that acts as aregulatory link between the membrane-associated Ras GTPases andthe MAPK/ERK cascade, and this critical regulatory link functionsas a switch determining cell fate decisions includingproliferation, differentiation, apoptosis, survival and oncogenictransformation. RAF1 activation initiates a mitogen-activatedprotein kinase (MAPK) cascade that comprises a sequentialphosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 andMAP2K2/MEK2) and the extracellular signal-regulated kinases(MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (onresidues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylylcyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.Phosphorylates PPP1R12A resulting in inhibition of the phosphataseactivity. Phosphorylates TNNT2/cardiac muscle troponin T. Canpromote NF-kB activation and inhibit signal transducers involvedin motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),proliferation and angiogenesis (RB1). Can protect cells fromapoptosis also by translocating to the mitochondria where it bindsBCL2 and displaces BAD/Bcl2-antagonist of cell death. RegulatesRho signaling and migration, and is required for normal woundhealing. Plays a role in the oncogenic transformation ofepithelial cells via repression of the TJ protein, occludin (OCLN)by inducing the up-regulation of a transcriptional repressorSNAI2/SLUG, which induces down-regulation of OCLN. Restrictscaspase activation in response to selected stimuli, notably Fasstimulation, pathogen-mediated macrophage apoptosis, and erythroiddifferentiation. {ECO:0000269|PubMed:11427728,ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,ECO:0000269|PubMed:9360956}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Note=Binds 2 Zn(2+) ions per subunit.;ENZYME REGULATION: Regulation is a highly complex processinvolving membrane recruitment, protein-protein interactions,dimerization, and phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the membrane, thereby promoting itsactivation. The inactive conformation of RAF1 is maintained byautoinhibitory interactions occurring between the N-terminalregulatory and the C-terminal catalytic domains and by the bindingof a 14-3-3 protein that contacts two phosphorylation sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1Acooperate to release autoinhibition and the subsequentphosphorylation of activating sites: Ser-338, Tyr-341, Thr-491,and Ser-494, yields a fully active kinase. Through a negativefeedback mechanism involving MAPK1/ERK2, RAF1 is phosphorylated onSer-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 byMAPK1/ERK2, which yields an inactive, desensitized kinase. Thesignaling-competent conformation of RAF1 is finally re-establishedby the coordinated action of PIN1, a prolyl isomerase thatconverts pSer and pThr residues from the cis to the transconformation, which is preferentially recognized anddephosphorylated by PPP2R1A. Activated by homodimerization andheterodimerization (with BRAF). Also regulated through associationwith other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP,PHB/prohibitin and SPRY4. PEBP1/RKIP acts by dissociating RAF1from its substrates MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitinfacilitates the displacement of 14-3-3 from RAF1 by activated Ras,thereby promoting cell membrane localization and phosphorylationof RAF1 at the activating Ser-338. SPRY4 inhibits Ras-independent,but not Ras-dependent, activation of RAF1. CNKSR1/CNK1 regulatesSrc-mediated RAF1 activation. {ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12717443,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016}.SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and thisheterodimer possesses a highly increased kinase activity comparedto the respective homodimers or monomers (PubMed:16508002).Heterodimerization is mitogen-regulated and enhanced by 14-3-3proteins (PubMed:16508002). MAPK1/ERK2 activation can induce anegative feedback that promotes the dissociation of theheterodimer (PubMed:16508002). Forms a multiprotein complex withRas (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CBand PPP1CC) (PubMed:16630891). Interacts with Ras proteins; theinteraction is antagonized by RIN1 (PubMed:11784866). Weaklyinteracts with RIT1. Interacts (via N-terminus) with RGS14 (viaRBD domains); the interaction mediates the formation of a ternarycomplex with BRAF, a ternary complex inhibited by GNAI1 (Bysimilarity). Interacts with STK3/MST2; the interaction inhibitsits pro-apoptotic activity (PubMed:15618521). Interacts (whenphosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') (PubMed:9360956). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2(By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) andthis interaction inhibits the proapoptotic function of MAP3K5/ASK1(PubMed:11427728). Interacts with PAK1 (via kinase domain)(PubMed:11733498). The phosphorylated form interacts with PIN1 (Bysimilarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIPand this interaction is enhanced if RAF1 is phosphorylated onresidues Ser-338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816).Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A,PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 andPHB/prohibitin (PubMed:10801873, PubMed:11719507, PubMed:12717443,PubMed:15385642, PubMed:15935327, PubMed:19710016,PubMed:10576742). Interacts with ROCK2 (By similarity). In itsactive form, interacts with PRMT5 (PubMed:21917714). Interactswith FAM83B; displaces 14-3-3 proteins from RAF1 and activatesRAF1 (PubMed:22886302). Interacts with PDE8A; the interactionpromotes RAF1 activity (PubMed:23509299).{ECO:0000250|UniProtKB:P11345, ECO:0000250|UniProtKB:Q99N57,ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11784866,ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:15935327, ECO:0000269|PubMed:16508002,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:22886302, ECO:0000269|PubMed:23509299,ECO:0000269|PubMed:9360956}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion.Nucleus. Note=Colocalizes with RGS14 and BRAF in both thecytoplasm and membranes. Phosphorylation at Ser-259 impairs itsmembrane accumulation. Recruited to the cell membrane by theactive Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantlylocalized at the nucleus.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=6C;IsoId=P04049-1; Sequence=Displayed;Name=2; Synonyms=1A;IsoId=P04049-2; Sequence=VSP_034649;TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundantthan isoform 2. {ECO:0000269|PubMed:1886707}.PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 andSer-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results inits inactivation. Phosphorylation at Ser-259 induces theinteraction with YWHAZ and inactivates kinase activity.Dephosphorylation of Ser-259 by the complex containing proteinphosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leadingto stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 andPAK5 and Ser-339 by PAK1 is required for its mitochondriallocalization. Phosphorylation at Ser-621 in response to growthfactor treatment stabilizes the protein, possibly by preventingproteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, Ser-338 and Ser-621 are somehow linked to the methylationpotential of cells. Treatment of cells with HGF in the presence ofthe methylation inhibitor 5'-methylthioadenosine (MTA) results inincreased phosphorylation at Ser-338 and Ser-621 and decreasedphosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylationat Ser-338 by PPP5C results in a activity decrease.{ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,ECO:0000269|PubMed:11756411, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16093354,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:16892053,ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614,ECO:0000269|PubMed:9823899}.PTM: Methylated at Arg-563 in response to EGF treatment. Thismodification leads to destabilization of the protein, possiblythrough proteasomal degradation. {ECO:0000269|PubMed:21917714}.DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonansyndrome, a disease characterized by short stature, facialdysmorphic features such as hypertelorism, a downward eyeslant andlow-set posteriorly rotated ears, and a high incidence ofcongenital heart defects and hypertrophic cardiomyopathy. Otherfeatures can include a short neck with webbing or redundancy ofskin, deafness, motor delay, variable intellectual deficits,multiple skeletal defects, cryptorchidism, and bleeding diathesis.Individuals with Noonan syndrome are at risk of juvenilemyelomonocytic leukemia, a myeloproliferative disordercharacterized by excessive production of myelomonocytic cells.{ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483,ECO:0000269|PubMed:20683980}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disordercharacterized by lentigines, electrocardiographic conductionabnormalities, ocular hypertelorism, pulmonic stenosis,abnormalities of genitalia, retardation of growth, andsensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: Adisorder characterized by ventricular dilation and impairedsystolic function, resulting in congestive heart failure andarrhythmia. Patients are at risk of premature death.{ECO:0000269|PubMed:24777450}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. RAF subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/raf1/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","RAF1_HUMAN Reviewed; 648 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1048N_identity"],["bp:comment","REPLACED ProteinRef_RAF1__9606"],["bp:comment","REPLACED ProteinRef_RAF1__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5894"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04049-1"],["bp:comment","REPLACED ProteinRef_RAF1__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80595"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","RAF1"],["bp:entityReference_http://identifiers.org/uniprot/P04049",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation",[["bp:sequencePosition","341"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:standardName","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:organism","RAF proto-oncogene serine/threonine-protein kinase"],["bp:displayName","RAF1_HUMAN"],["bp:name","Proto-oncogene c-RAF"],["bp:name","RAF"],["bp:name","RAF1"],["bp:name","2.7.11.1"],["bp:name","cRaf"],["bp:name","Raf-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FAQ_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5894"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002871"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5894"],["bp:comment","REPLACED ProteinRef_RAF1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_653"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P04049_identity"],["bp:comment","FUNCTION: Serine/threonine-protein kinase that acts as aregulatory link between the membrane-associated Ras GTPases andthe MAPK/ERK cascade, and this critical regulatory link functionsas a switch determining cell fate decisions includingproliferation, differentiation, apoptosis, survival and oncogenictransformation. RAF1 activation initiates a mitogen-activatedprotein kinase (MAPK) cascade that comprises a sequentialphosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 andMAP2K2/MEK2) and the extracellular signal-regulated kinases(MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (onresidues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylylcyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.Phosphorylates PPP1R12A resulting in inhibition of the phosphataseactivity. Phosphorylates TNNT2/cardiac muscle troponin T. Canpromote NF-kB activation and inhibit signal transducers involvedin motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),proliferation and angiogenesis (RB1). Can protect cells fromapoptosis also by translocating to the mitochondria where it bindsBCL2 and displaces BAD/Bcl2-antagonist of cell death. RegulatesRho signaling and migration, and is required for normal woundhealing. Plays a role in the oncogenic transformation ofepithelial cells via repression of the TJ protein, occludin (OCLN)by inducing the up-regulation of a transcriptional repressorSNAI2/SLUG, which induces down-regulation of OCLN. Restrictscaspase activation in response to selected stimuli, notably Fasstimulation, pathogen-mediated macrophage apoptosis, and erythroiddifferentiation. {ECO:0000269|PubMed:11427728,ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,ECO:0000269|PubMed:9360956}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Note=Binds 2 Zn(2+) ions per subunit.;ENZYME REGULATION: Regulation is a highly complex processinvolving membrane recruitment, protein-protein interactions,dimerization, and phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the membrane, thereby promoting itsactivation. The inactive conformation of RAF1 is maintained byautoinhibitory interactions occurring between the N-terminalregulatory and the C-terminal catalytic domains and by the bindingof a 14-3-3 protein that contacts two phosphorylation sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1Acooperate to release autoinhibition and the subsequentphosphorylation of activating sites: Ser-338, Tyr-341, Thr-491,and Ser-494, yields a fully active kinase. Through a negativefeedback mechanism involving MAPK1/ERK2, RAF1 is phosphorylated onSer-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 byMAPK1/ERK2, which yields an inactive, desensitized kinase. Thesignaling-competent conformation of RAF1 is finally re-establishedby the coordinated action of PIN1, a prolyl isomerase thatconverts pSer and pThr residues from the cis to the transconformation, which is preferentially recognized anddephosphorylated by PPP2R1A. Activated by homodimerization andheterodimerization (with BRAF). Also regulated through associationwith other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP,PHB/prohibitin and SPRY4. PEBP1/RKIP acts by dissociating RAF1from its substrates MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitinfacilitates the displacement of 14-3-3 from RAF1 by activated Ras,thereby promoting cell membrane localization and phosphorylationof RAF1 at the activating Ser-338. SPRY4 inhibits Ras-independent,but not Ras-dependent, activation of RAF1. CNKSR1/CNK1 regulatesSrc-mediated RAF1 activation. {ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12717443,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016}.SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and thisheterodimer possesses a highly increased kinase activity comparedto the respective homodimers or monomers (PubMed:16508002).Heterodimerization is mitogen-regulated and enhanced by 14-3-3proteins (PubMed:16508002). MAPK1/ERK2 activation can induce anegative feedback that promotes the dissociation of theheterodimer (PubMed:16508002). Forms a multiprotein complex withRas (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CBand PPP1CC) (PubMed:16630891). Interacts with Ras proteins; theinteraction is antagonized by RIN1 (PubMed:11784866). Weaklyinteracts with RIT1. Interacts (via N-terminus) with RGS14 (viaRBD domains); the interaction mediates the formation of a ternarycomplex with BRAF, a ternary complex inhibited by GNAI1 (Bysimilarity). Interacts with STK3/MST2; the interaction inhibitsits pro-apoptotic activity (PubMed:15618521). Interacts (whenphosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') (PubMed:9360956). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2(By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) andthis interaction inhibits the proapoptotic function of MAP3K5/ASK1(PubMed:11427728). Interacts with PAK1 (via kinase domain)(PubMed:11733498). The phosphorylated form interacts with PIN1 (Bysimilarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIPand this interaction is enhanced if RAF1 is phosphorylated onresidues Ser-338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816).Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A,PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 andPHB/prohibitin (PubMed:10801873, PubMed:11719507, PubMed:12717443,PubMed:15385642, PubMed:15935327, PubMed:19710016,PubMed:10576742). Interacts with ROCK2 (By similarity). In itsactive form, interacts with PRMT5 (PubMed:21917714). Interactswith FAM83B; displaces 14-3-3 proteins from RAF1 and activatesRAF1 (PubMed:22886302). Interacts with PDE8A; the interactionpromotes RAF1 activity (PubMed:23509299).{ECO:0000250|UniProtKB:P11345, ECO:0000250|UniProtKB:Q99N57,ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11784866,ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:15935327, ECO:0000269|PubMed:16508002,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:22886302, ECO:0000269|PubMed:23509299,ECO:0000269|PubMed:9360956}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion.Nucleus. Note=Colocalizes with RGS14 and BRAF in both thecytoplasm and membranes. Phosphorylation at Ser-259 impairs itsmembrane accumulation. Recruited to the cell membrane by theactive Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantlylocalized at the nucleus.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=6C;IsoId=P04049-1; Sequence=Displayed;Name=2; Synonyms=1A;IsoId=P04049-2; Sequence=VSP_034649;TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundantthan isoform 2. {ECO:0000269|PubMed:1886707}.PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 andSer-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results inits inactivation. Phosphorylation at Ser-259 induces theinteraction with YWHAZ and inactivates kinase activity.Dephosphorylation of Ser-259 by the complex containing proteinphosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leadingto stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 andPAK5 and Ser-339 by PAK1 is required for its mitochondriallocalization. Phosphorylation at Ser-621 in response to growthfactor treatment stabilizes the protein, possibly by preventingproteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, Ser-338 and Ser-621 are somehow linked to the methylationpotential of cells. Treatment of cells with HGF in the presence ofthe methylation inhibitor 5'-methylthioadenosine (MTA) results inincreased phosphorylation at Ser-338 and Ser-621 and decreasedphosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylationat Ser-338 by PPP5C results in a activity decrease.{ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,ECO:0000269|PubMed:11756411, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16093354,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:16892053,ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614,ECO:0000269|PubMed:9823899}.PTM: Methylated at Arg-563 in response to EGF treatment. Thismodification leads to destabilization of the protein, possiblythrough proteasomal degradation. {ECO:0000269|PubMed:21917714}.DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonansyndrome, a disease characterized by short stature, facialdysmorphic features such as hypertelorism, a downward eyeslant andlow-set posteriorly rotated ears, and a high incidence ofcongenital heart defects and hypertrophic cardiomyopathy. Otherfeatures can include a short neck with webbing or redundancy ofskin, deafness, motor delay, variable intellectual deficits,multiple skeletal defects, cryptorchidism, and bleeding diathesis.Individuals with Noonan syndrome are at risk of juvenilemyelomonocytic leukemia, a myeloproliferative disordercharacterized by excessive production of myelomonocytic cells.{ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483,ECO:0000269|PubMed:20683980}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disordercharacterized by lentigines, electrocardiographic conductionabnormalities, ocular hypertelorism, pulmonic stenosis,abnormalities of genitalia, retardation of growth, andsensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: Adisorder characterized by ventricular dilation and impairedsystolic function, resulting in congestive heart failure andarrhythmia. Patients are at risk of premature death.{ECO:0000269|PubMed:24777450}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. RAF subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/raf1/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","RAF1_HUMAN Reviewed; 648 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1048N_identity"],["bp:comment","REPLACED ProteinRef_RAF1__9606"],["bp:comment","REPLACED ProteinRef_RAF1__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5894"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04049-1"],["bp:comment","REPLACED ProteinRef_RAF1__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80595"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","RAF1"],["bp:entityReference_http://identifiers.org/uniprot/P04049",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 341 341 Phosphotyrosine; by SRC."],["bp:featureLocation",[["bp:sequencePosition","341"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P04049"]]],["bp:standardName","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:xref","RAF proto-oncogene serine/threonine-protein kinase"],["bp:organism","RAF proto-oncogene serine/threonine-protein kinase"],["bp:displayName","RAF1_HUMAN"],["bp:name","Proto-oncogene c-RAF"],["bp:name","RAF"],["bp:name","RAF1"],["bp:name","2.7.11.1"],["bp:name","cRaf"],["bp:name","Raf-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FAQ_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5894"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002871"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5894"],["bp:comment","REPLACED ProteinRef_RAF1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_653"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P04049_identity"],["bp:comment","FUNCTION: Serine/threonine-protein kinase that acts as aregulatory link between the membrane-associated Ras GTPases andthe MAPK/ERK cascade, and this critical regulatory link functionsas a switch determining cell fate decisions includingproliferation, differentiation, apoptosis, survival and oncogenictransformation. RAF1 activation initiates a mitogen-activatedprotein kinase (MAPK) cascade that comprises a sequentialphosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 andMAP2K2/MEK2) and the extracellular signal-regulated kinases(MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (onresidues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylylcyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.Phosphorylates PPP1R12A resulting in inhibition of the phosphataseactivity. Phosphorylates TNNT2/cardiac muscle troponin T. Canpromote NF-kB activation and inhibit signal transducers involvedin motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),proliferation and angiogenesis (RB1). Can protect cells fromapoptosis also by translocating to the mitochondria where it bindsBCL2 and displaces BAD/Bcl2-antagonist of cell death. RegulatesRho signaling and migration, and is required for normal woundhealing. Plays a role in the oncogenic transformation ofepithelial cells via repression of the TJ protein, occludin (OCLN)by inducing the up-regulation of a transcriptional repressorSNAI2/SLUG, which induces down-regulation of OCLN. Restrictscaspase activation in response to selected stimuli, notably Fasstimulation, pathogen-mediated macrophage apoptosis, and erythroiddifferentiation. {ECO:0000269|PubMed:11427728,ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,ECO:0000269|PubMed:9360956}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Zn(2+); Xref=ChEBI:CHEBI:29105;Note=Binds 2 Zn(2+) ions per subunit.;ENZYME REGULATION: Regulation is a highly complex processinvolving membrane recruitment, protein-protein interactions,dimerization, and phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the membrane, thereby promoting itsactivation. The inactive conformation of RAF1 is maintained byautoinhibitory interactions occurring between the N-terminalregulatory and the C-terminal catalytic domains and by the bindingof a 14-3-3 protein that contacts two phosphorylation sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1Acooperate to release autoinhibition and the subsequentphosphorylation of activating sites: Ser-338, Tyr-341, Thr-491,and Ser-494, yields a fully active kinase. Through a negativefeedback mechanism involving MAPK1/ERK2, RAF1 is phosphorylated onSer-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 byMAPK1/ERK2, which yields an inactive, desensitized kinase. Thesignaling-competent conformation of RAF1 is finally re-establishedby the coordinated action of PIN1, a prolyl isomerase thatconverts pSer and pThr residues from the cis to the transconformation, which is preferentially recognized anddephosphorylated by PPP2R1A. Activated by homodimerization andheterodimerization (with BRAF). Also regulated through associationwith other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP,PHB/prohibitin and SPRY4. PEBP1/RKIP acts by dissociating RAF1from its substrates MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitinfacilitates the displacement of 14-3-3 from RAF1 by activated Ras,thereby promoting cell membrane localization and phosphorylationof RAF1 at the activating Ser-338. SPRY4 inhibits Ras-independent,but not Ras-dependent, activation of RAF1. CNKSR1/CNK1 regulatesSrc-mediated RAF1 activation. {ECO:0000269|PubMed:10576742,ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12717443,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016}.SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and thisheterodimer possesses a highly increased kinase activity comparedto the respective homodimers or monomers (PubMed:16508002).Heterodimerization is mitogen-regulated and enhanced by 14-3-3proteins (PubMed:16508002). MAPK1/ERK2 activation can induce anegative feedback that promotes the dissociation of theheterodimer (PubMed:16508002). Forms a multiprotein complex withRas (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CBand PPP1CC) (PubMed:16630891). Interacts with Ras proteins; theinteraction is antagonized by RIN1 (PubMed:11784866). Weaklyinteracts with RIT1. Interacts (via N-terminus) with RGS14 (viaRBD domains); the interaction mediates the formation of a ternarycomplex with BRAF, a ternary complex inhibited by GNAI1 (Bysimilarity). Interacts with STK3/MST2; the interaction inhibitsits pro-apoptotic activity (PubMed:15618521). Interacts (whenphosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') (PubMed:9360956). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2(By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) andthis interaction inhibits the proapoptotic function of MAP3K5/ASK1(PubMed:11427728). Interacts with PAK1 (via kinase domain)(PubMed:11733498). The phosphorylated form interacts with PIN1 (Bysimilarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIPand this interaction is enhanced if RAF1 is phosphorylated onresidues Ser-338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816).Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A,PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 andPHB/prohibitin (PubMed:10801873, PubMed:11719507, PubMed:12717443,PubMed:15385642, PubMed:15935327, PubMed:19710016,PubMed:10576742). Interacts with ROCK2 (By similarity). In itsactive form, interacts with PRMT5 (PubMed:21917714). Interactswith FAM83B; displaces 14-3-3 proteins from RAF1 and activatesRAF1 (PubMed:22886302). Interacts with PDE8A; the interactionpromotes RAF1 activity (PubMed:23509299).{ECO:0000250|UniProtKB:P11345, ECO:0000250|UniProtKB:Q99N57,ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507,ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11784866,ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:15935327, ECO:0000269|PubMed:16508002,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:18294816,ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:22886302, ECO:0000269|PubMed:23509299,ECO:0000269|PubMed:9360956}.SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion.Nucleus. Note=Colocalizes with RGS14 and BRAF in both thecytoplasm and membranes. Phosphorylation at Ser-259 impairs itsmembrane accumulation. Recruited to the cell membrane by theactive Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantlylocalized at the nucleus.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=6C;IsoId=P04049-1; Sequence=Displayed;Name=2; Synonyms=1A;IsoId=P04049-2; Sequence=VSP_034649;TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundantthan isoform 2. {ECO:0000269|PubMed:1886707}.PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 andSer-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results inits inactivation. Phosphorylation at Ser-259 induces theinteraction with YWHAZ and inactivates kinase activity.Dephosphorylation of Ser-259 by the complex containing proteinphosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leadingto stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 andPAK5 and Ser-339 by PAK1 is required for its mitochondriallocalization. Phosphorylation at Ser-621 in response to growthfactor treatment stabilizes the protein, possibly by preventingproteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, Ser-338 and Ser-621 are somehow linked to the methylationpotential of cells. Treatment of cells with HGF in the presence ofthe methylation inhibitor 5'-methylthioadenosine (MTA) results inincreased phosphorylation at Ser-338 and Ser-621 and decreasedphosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylationat Ser-338 by PPP5C results in a activity decrease.{ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,ECO:0000269|PubMed:11756411, ECO:0000269|PubMed:15047712,ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16093354,ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:16892053,ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714,ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614,ECO:0000269|PubMed:9823899}.PTM: Methylated at Arg-563 in response to EGF treatment. Thismodification leads to destabilization of the protein, possiblythrough proteasomal degradation. {ECO:0000269|PubMed:21917714}.DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonansyndrome, a disease characterized by short stature, facialdysmorphic features such as hypertelorism, a downward eyeslant andlow-set posteriorly rotated ears, and a high incidence ofcongenital heart defects and hypertrophic cardiomyopathy. Otherfeatures can include a short neck with webbing or redundancy ofskin, deafness, motor delay, variable intellectual deficits,multiple skeletal defects, cryptorchidism, and bleeding diathesis.Individuals with Noonan syndrome are at risk of juvenilemyelomonocytic leukemia, a myeloproliferative disordercharacterized by excessive production of myelomonocytic cells.{ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483,ECO:0000269|PubMed:20683980}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disordercharacterized by lentigines, electrocardiographic conductionabnormalities, ocular hypertelorism, pulmonic stenosis,abnormalities of genitalia, retardation of growth, andsensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: Adisorder characterized by ventricular dilation and impairedsystolic function, resulting in congestive heart failure andarrhythmia. Patients are at risk of premature death.{ECO:0000269|PubMed:24777450}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. RAF subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/raf1/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","RAF1_HUMAN Reviewed; 648 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1048N_identity"],["bp:comment","REPLACED ProteinRef_RAF1__9606"],["bp:comment","REPLACED ProteinRef_RAF1__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5894"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04049-1"],["bp:comment","REPLACED ProteinRef_RAF1__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8262"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80595"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80593"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80593"]]}},{"data":{"id":"Protein_08df74199f1b23a420ba0b04166df60e","class":"macromolecule","label":"KSR1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_08df74199f1b23a420ba0b04166df60e.info.1","class":"state variable","state":{"variable":"404","value":"opser"}},{"id":"Protein_08df74199f1b23a420ba0b04166df60e.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_08df74199f1b23a420ba0b04166df60e.info.3","class":"state variable","state":{"variable":"309","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":174.72081,"y":816.83276,"w":85,"h":25},"metadata":[["bp:displayName","KSR"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80600"],["bp:featureLocation",[["bp:sequencePosition","404"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16686"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22317"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q8IVT5",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation","MOD_RES 274 274 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation","MOD_RES 274 274 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation","MOD_RES 274 274 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation","MOD_RES 274 274 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation","MOD_RES 274 274 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation","MOD_RES 274 274 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation","MOD_RES 274 274 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation","MOD_RES 274 274 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 274 274 Phosphothreonine."],["bp:featureLocation","MOD_RES 274 274 Phosphothreonine."]]],["bp:standardName","Kinase suppressor of Ras 1"],["bp:xref","Kinase suppressor of Ras 1"],["bp:xref","Kinase suppressor of Ras 1"],["bp:organism","Kinase suppressor of Ras 1"],["bp:displayName","KSR1_HUMAN"],["bp:name","KSR1"],["bp:name","KSR"],["bp:comment","KSR1_HUMAN Reviewed; 923 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_18980_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_055053"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8844"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32619N_identity"],["bp:comment","FUNCTION: Scaffolding protein that is part of a multiproteinsignaling complex. Promotes phosphorylation of Raf family membersand activation of downstream MAP kinases. Promotes activation ofMAPK1 and/or MAPK3, both in response to EGF and to cAMP. Does nothave kinase activity by itself. {ECO:0000250|UniProtKB:Q61097}.SUBUNIT: Interacts with HSP90AA1/HSP90, YWHAE/14-3-3, CDC37,MAP2K1/MEK-1 and MAP2K2/MEK-2 (PubMed:10409742). Interacts withMARK3, PPP2R1A and PPP2CA. Also interacts with RAF and MAPK/ERK,in a Ras-dependent manner. The binding of 14-3-3 proteins tophosphorylated KSR prevents the membrane localization (Bysimilarity). Interacts with isoform 1 of VRK2 (PubMed:20679487).Interacts with AKAP13 and BRAF (PubMed:21102438). Identified in acomplex with AKAP13, MAP2K1 and BRAF (By similarity).{ECO:0000250|UniProtKB:Q61097, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:20679487, ECO:0000269|PubMed:21102438}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20679487}.Membrane {ECO:0000269|PubMed:20679487}; Peripheral membraneprotein {ECO:0000269|PubMed:20679487}. Cell membrane{ECO:0000250|UniProtKB:Q61097}; Peripheral membrane protein{ECO:0000250|UniProtKB:Q61097}. Cell projection, ruffle membrane{ECO:0000250|UniProtKB:Q61097}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:20679487}. Note=In unstimulated cells, wherethe phosphorylated form is bound to a 14-3-3 protein,sequestration in the cytoplasm occurs. Following growth factortreatment, the protein is free for membrane translocation, and itmoves from the cytoplasm to the cell periphery.{ECO:0000305|PubMed:12007434}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=Q8IVT5-1; Sequence=Displayed;Name=2;IsoId=Q8IVT5-2; Sequence=VSP_055656, VSP_055657;Note=No experimental confirmation available.;Name=3;IsoId=Q8IVT5-3; Sequence=VSP_055655;Note=No experimental confirmation available.;Name=4;IsoId=Q8IVT5-4; Sequence=VSP_055655, VSP_055657;Note=No experimental confirmation available.;DOMAIN: The protein kinase domain is predicted to be catalyticallyinactive. The domain is sufficient for KSR1 and KSR1-mediatedMAP2K1 and MAP2K2 membrane localization. The domain is requiredbut not sufficient for MAP kinase-mediated inhibition of ELK1phosphorylation (PubMed:10409742). {ECO:0000255,ECO:0000269|PubMed:10409742}.DOMAIN: The protein kinase domain is predicted to be catalyticallyinactive. The domain is sufficient for KSR1 and KSR1-mediatedMAP2K1 and MAP2K2 membrane localization. The domain is requiredbut not sufficient for MAP kinase-mediated inhibition of ELK1phosphorylation. {ECO:0000250|UniProtKB:Q61097, ECO:0000255}.DOMAIN: The N-terminal region mediates interaction with BRAF andwith membranes. {ECO:0000250|UniProtKB:Q61097}.PTM: Phosphorylated on Ser-311 and, to a higher extent, on Ser-406by MARK3. Dephosphorylated on Ser-406 by PPP2CA. In resting cells,phosphorylated KSR1 is cytoplasmic and in stimulated cells,dephosphorylated KSR1 is membrane-associated. Phosphorylated byPKA at Ser-888. Phosphorylation at Ser-888 is required for cAMP-dependent activation of MAPK1 and/or MAPK3 (By similarity).{ECO:0000250|UniProtKB:Q61097}.SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thrprotein kinase family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/KSR1ID41107ch17q11.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_2001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"]]}},{"data":{"id":"Complex_dceae21100bab7ef8ef90d2fb262a17f","class":"complex","label":"PKC zeta/PAR4","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":500.81883500000004,"y":651.9525,"w":52.00003,"h":64},"metadata":[["bp:displayName","PKC zeta/PAR4"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PAR4"],["bp:entityReference_http://identifiers.org/uniprot/Q96IZ0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 163 163 Phosphothreonine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","163"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 108 108 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 231 231 Phosphoserine."],["bp:featureLocation","MOD_RES 231 231 Phosphoserine."]]],["bp:standardName","PRKC apoptosis WT1 regulator protein"],["bp:xref","PRKC apoptosis WT1 regulator protein"],["bp:xref","PRKC apoptosis WT1 regulator protein"],["bp:organism","PRKC apoptosis WT1 regulator protein"],["bp:displayName","PAWR_HUMAN"],["bp:name","Prostate apoptosis response 4 protein"],["bp:name","PAWR"],["bp:name","PAR4"],["bp:name","Par-4"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_8332"],["bp:comment","FUNCTION: Pro-apoptopic protein capable of selectively inducingapoptosis in cancer cells, sensitizing the cells to diverseapoptotic stimuli and causing regression of tumors in animalmodels. Induces apoptosis in certain cancer cells by activation ofthe Fas prodeath pathway and coparallel inhibition of NF-kappa-Btranscriptional activity. Inhibits the transcriptional activationand augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction withWT1. Seems also to be a transcriptional repressor by itself. Maybe directly involved in regulating the amyloid precursor protein(APP) cleavage activity of BACE1. {ECO:0000269|PubMed:11585763}.SUBUNIT: Interacts with WT1, via the C-terminal region.Homooligomer. Interacts also with a wide variety of proteins, suchas atypical PKCs, p62, DAPK3 kinase and THAP1. Interacts withactin, AATF, BACE1, SPSB1, SPSB2 AND SPSB4. Component of a ternarycomplex composed of SQSTM1 and PRKCZ.{ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:12717420,ECO:0000269|PubMed:14627703, ECO:0000269|PubMed:15671026,ECO:0000269|PubMed:17189197, ECO:0000269|PubMed:8943350}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Mainly cytoplasmicin absence of apoptosis signal and in normal cells. Nuclear inmost cancer cell lines. Nuclear entry seems to be essential butnot sufficient for apoptosis (By similarity). Nuclear localizationincludes nucleoplasm and PML nuclear bodies. {ECO:0000250}.TISSUE SPECIFICITY: Widely expressed. Expression is elevated invarious neurodegenerative diseases such as amyotrophic lateralsclerosis, Alzheimer, Parkinson and Huntington diseases andstroke. Down-regulated in several cancers.{ECO:0000269|PubMed:8943350}.INDUCTION: By apoptosis.DOMAIN: The leucine-zipper domain is not essential for apoptosis,but is required for sensitization of cells to exogenous apoptoticinsults and for interaction with its partners. {ECO:0000250}.DOMAIN: The SAC domain is a death-inducing domain selective forapoptosis induction in cancer cells. This domain is essential fornuclear entry, Fas activation, inhibition of NF-kappa-B activityand induction of apoptosis in cancer cells (By similarity).{ECO:0000250}.PTM: Preferentially phosphorylated at the Thr-163 by PKC in cancercells. {ECO:0000250}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PAWRID41641ch12q21.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pawr/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5074"],["bp:comment","PAWR_HUMAN Reviewed; 340 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29003N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5074"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80633"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PAR4"],["bp:entityReference_http://identifiers.org/uniprot/Q96IZ0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 163 163 Phosphothreonine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","163"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 108 108 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 231 231 Phosphoserine."],["bp:featureLocation","MOD_RES 231 231 Phosphoserine."]]],["bp:standardName","PRKC apoptosis WT1 regulator protein"],["bp:xref","PRKC apoptosis WT1 regulator protein"],["bp:xref","PRKC apoptosis WT1 regulator protein"],["bp:organism","PRKC apoptosis WT1 regulator protein"],["bp:displayName","PAWR_HUMAN"],["bp:name","Prostate apoptosis response 4 protein"],["bp:name","PAWR"],["bp:name","PAR4"],["bp:name","Par-4"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_8332"],["bp:comment","FUNCTION: Pro-apoptopic protein capable of selectively inducingapoptosis in cancer cells, sensitizing the cells to diverseapoptotic stimuli and causing regression of tumors in animalmodels. Induces apoptosis in certain cancer cells by activation ofthe Fas prodeath pathway and coparallel inhibition of NF-kappa-Btranscriptional activity. Inhibits the transcriptional activationand augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction withWT1. Seems also to be a transcriptional repressor by itself. Maybe directly involved in regulating the amyloid precursor protein(APP) cleavage activity of BACE1. {ECO:0000269|PubMed:11585763}.SUBUNIT: Interacts with WT1, via the C-terminal region.Homooligomer. Interacts also with a wide variety of proteins, suchas atypical PKCs, p62, DAPK3 kinase and THAP1. Interacts withactin, AATF, BACE1, SPSB1, SPSB2 AND SPSB4. Component of a ternarycomplex composed of SQSTM1 and PRKCZ.{ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:12717420,ECO:0000269|PubMed:14627703, ECO:0000269|PubMed:15671026,ECO:0000269|PubMed:17189197, ECO:0000269|PubMed:8943350}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Mainly cytoplasmicin absence of apoptosis signal and in normal cells. Nuclear inmost cancer cell lines. Nuclear entry seems to be essential butnot sufficient for apoptosis (By similarity). Nuclear localizationincludes nucleoplasm and PML nuclear bodies. {ECO:0000250}.TISSUE SPECIFICITY: Widely expressed. Expression is elevated invarious neurodegenerative diseases such as amyotrophic lateralsclerosis, Alzheimer, Parkinson and Huntington diseases andstroke. Down-regulated in several cancers.{ECO:0000269|PubMed:8943350}.INDUCTION: By apoptosis.DOMAIN: The leucine-zipper domain is not essential for apoptosis,but is required for sensitization of cells to exogenous apoptoticinsults and for interaction with its partners. {ECO:0000250}.DOMAIN: The SAC domain is a death-inducing domain selective forapoptosis induction in cancer cells. This domain is essential fornuclear entry, Fas activation, inhibition of NF-kappa-B activityand induction of apoptosis in cancer cells (By similarity).{ECO:0000250}.PTM: Preferentially phosphorylated at the Thr-163 by PKC in cancercells. {ECO:0000250}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PAWRID41641ch12q21.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pawr/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5074"],["bp:comment","PAWR_HUMAN Reviewed; 340 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29003N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5074"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80633"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PAR4"],["bp:entityReference_http://identifiers.org/uniprot/Q96IZ0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 163 163 Phosphothreonine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","163"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 108 108 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 231 231 Phosphoserine."],["bp:featureLocation","MOD_RES 231 231 Phosphoserine."]]],["bp:standardName","PRKC apoptosis WT1 regulator protein"],["bp:xref","PRKC apoptosis WT1 regulator protein"],["bp:xref","PRKC apoptosis WT1 regulator protein"],["bp:organism","PRKC apoptosis WT1 regulator protein"],["bp:displayName","PAWR_HUMAN"],["bp:name","Prostate apoptosis response 4 protein"],["bp:name","PAWR"],["bp:name","PAR4"],["bp:name","Par-4"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_8332"],["bp:comment","FUNCTION: Pro-apoptopic protein capable of selectively inducingapoptosis in cancer cells, sensitizing the cells to diverseapoptotic stimuli and causing regression of tumors in animalmodels. Induces apoptosis in certain cancer cells by activation ofthe Fas prodeath pathway and coparallel inhibition of NF-kappa-Btranscriptional activity. Inhibits the transcriptional activationand augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction withWT1. Seems also to be a transcriptional repressor by itself. Maybe directly involved in regulating the amyloid precursor protein(APP) cleavage activity of BACE1. {ECO:0000269|PubMed:11585763}.SUBUNIT: Interacts with WT1, via the C-terminal region.Homooligomer. Interacts also with a wide variety of proteins, suchas atypical PKCs, p62, DAPK3 kinase and THAP1. Interacts withactin, AATF, BACE1, SPSB1, SPSB2 AND SPSB4. Component of a ternarycomplex composed of SQSTM1 and PRKCZ.{ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:12717420,ECO:0000269|PubMed:14627703, ECO:0000269|PubMed:15671026,ECO:0000269|PubMed:17189197, ECO:0000269|PubMed:8943350}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Mainly cytoplasmicin absence of apoptosis signal and in normal cells. Nuclear inmost cancer cell lines. Nuclear entry seems to be essential butnot sufficient for apoptosis (By similarity). Nuclear localizationincludes nucleoplasm and PML nuclear bodies. {ECO:0000250}.TISSUE SPECIFICITY: Widely expressed. Expression is elevated invarious neurodegenerative diseases such as amyotrophic lateralsclerosis, Alzheimer, Parkinson and Huntington diseases andstroke. Down-regulated in several cancers.{ECO:0000269|PubMed:8943350}.INDUCTION: By apoptosis.DOMAIN: The leucine-zipper domain is not essential for apoptosis,but is required for sensitization of cells to exogenous apoptoticinsults and for interaction with its partners. {ECO:0000250}.DOMAIN: The SAC domain is a death-inducing domain selective forapoptosis induction in cancer cells. This domain is essential fornuclear entry, Fas activation, inhibition of NF-kappa-B activityand induction of apoptosis in cancer cells (By similarity).{ECO:0000250}.PTM: Preferentially phosphorylated at the Thr-163 by PKC in cancercells. {ECO:0000250}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PAWRID41641ch12q21.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pawr/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5074"],["bp:comment","PAWR_HUMAN Reviewed; 340 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29003N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5074"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80633"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PAR4"],["bp:entityReference_http://identifiers.org/uniprot/Q96IZ0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 163 163 Phosphothreonine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","163"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 108 108 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 231 231 Phosphoserine."],["bp:featureLocation","MOD_RES 231 231 Phosphoserine."]]],["bp:standardName","PRKC apoptosis WT1 regulator protein"],["bp:xref","PRKC apoptosis WT1 regulator protein"],["bp:xref","PRKC apoptosis WT1 regulator protein"],["bp:organism","PRKC apoptosis WT1 regulator protein"],["bp:displayName","PAWR_HUMAN"],["bp:name","Prostate apoptosis response 4 protein"],["bp:name","PAWR"],["bp:name","PAR4"],["bp:name","Par-4"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_8332"],["bp:comment","FUNCTION: Pro-apoptopic protein capable of selectively inducingapoptosis in cancer cells, sensitizing the cells to diverseapoptotic stimuli and causing regression of tumors in animalmodels. Induces apoptosis in certain cancer cells by activation ofthe Fas prodeath pathway and coparallel inhibition of NF-kappa-Btranscriptional activity. Inhibits the transcriptional activationand augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction withWT1. Seems also to be a transcriptional repressor by itself. Maybe directly involved in regulating the amyloid precursor protein(APP) cleavage activity of BACE1. {ECO:0000269|PubMed:11585763}.SUBUNIT: Interacts with WT1, via the C-terminal region.Homooligomer. Interacts also with a wide variety of proteins, suchas atypical PKCs, p62, DAPK3 kinase and THAP1. Interacts withactin, AATF, BACE1, SPSB1, SPSB2 AND SPSB4. Component of a ternarycomplex composed of SQSTM1 and PRKCZ.{ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:12717420,ECO:0000269|PubMed:14627703, ECO:0000269|PubMed:15671026,ECO:0000269|PubMed:17189197, ECO:0000269|PubMed:8943350}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Mainly cytoplasmicin absence of apoptosis signal and in normal cells. Nuclear inmost cancer cell lines. Nuclear entry seems to be essential butnot sufficient for apoptosis (By similarity). Nuclear localizationincludes nucleoplasm and PML nuclear bodies. {ECO:0000250}.TISSUE SPECIFICITY: Widely expressed. Expression is elevated invarious neurodegenerative diseases such as amyotrophic lateralsclerosis, Alzheimer, Parkinson and Huntington diseases andstroke. Down-regulated in several cancers.{ECO:0000269|PubMed:8943350}.INDUCTION: By apoptosis.DOMAIN: The leucine-zipper domain is not essential for apoptosis,but is required for sensitization of cells to exogenous apoptoticinsults and for interaction with its partners. {ECO:0000250}.DOMAIN: The SAC domain is a death-inducing domain selective forapoptosis induction in cancer cells. This domain is essential fornuclear entry, Fas activation, inhibition of NF-kappa-B activityand induction of apoptosis in cancer cells (By similarity).{ECO:0000250}.PTM: Preferentially phosphorylated at the Thr-163 by PKC in cancercells. {ECO:0000250}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PAWRID41641ch12q21.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pawr/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5074"],["bp:comment","PAWR_HUMAN Reviewed; 340 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29003N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5074"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80633"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80630"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80630"]]}},{"data":{"id":"Protein_f4e18304ab85045807625cb28b2fa4d3_Complex_dceae21100bab7ef8ef90d2fb262a17f","class":"macromolecule","label":"PRKCZ","parent":"Complex_dceae21100bab7ef8ef90d2fb262a17f","clonemarker":false,"stateVariables":[{"id":"Protein_f4e18304ab85045807625cb28b2fa4d3_Complex_dceae21100bab7ef8ef90d2fb262a17f.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":500.81882,"y":634.4525,"w":48,"h":25},"metadata":[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80632"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q05513"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 591 591 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","591"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 591 591 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","591"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 591 591 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","591"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:organism","Protein kinase C zeta type"],["bp:displayName","KPCZ_HUMAN"],["bp:name","nPKC-zeta"],["bp:name","PRKCZ"],["bp:name","2.7.11.13"],["bp:name","PKC2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_457"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01504_identity"],["bp:comment","REPLACED ProteinRef_PRKCZ__9606"],["bp:comment","FUNCTION: Calcium- and diacylglycerol-independentserine/threonine-protein kinase that functions inphosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activatedprotein (MAP) kinase cascade, and is involved in NF-kappa-Bactivation, mitogenic signaling, cell proliferation, cellpolarity, inflammatory response and maintenance of long-termpotentiation (LTP). Upon lipopolysaccharide (LPS) treatment inmacrophages, or following mitogenic stimuli, functions downstreamof PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascadeindependently of RAF1 activation. Required for insulin-dependentactivation of AKT3, but may function as an adapter rather than adirect activator. Upon insulin treatment may act as a downstreameffector of PI3K and contribute to the activation of translocationof the glucose transporter SLC2A4/GLUT4 and subsequent glucosetransport in adipocytes. In EGF-induced cells, binds and activatesMAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity andcan activate JUN promoter through MEF2C. Through binding withSQSTM1/p62, functions in interleukin-1 signaling and activation ofNF-kappa-B with the specific adapters RIPK1 and TRAF6.Participates in TNF-dependent transactivation of NF-kappa-B byphosphorylating and activating IKBKB kinase, which in turn leadsto the degradation of NF-kappa-B inhibitors. In migratingastrocytes, forms a cytoplasmic complex with PARD6A and isrecruited by CDC42 to function in the establishment of cellpolarity along with the microtubule motor and dynein. Inassociation with FEZ1, stimulates neuronal differentiation in PC12cells. In the inflammatory response, is required for the T-helper2 (Th2) differentiation process, including interleukin production,efficient activation of JAK1 and the subsequent phosphorylationand nuclear translocation of STAT6. May be involved in developmentof allergic airway inflammation (asthma), a process dependent onTh2 immune response. In the NF-kappa-B-mediated inflammatoryresponse, can relieve SETD6-dependent repression of NF-kappa-Btarget genes by phosphorylating the RELA subunit at 'Ser-311'.Necessary and sufficient for LTP maintenance in hippocampal CA1pyramidal cells. In vein endothelial cells treated with theoxidant peroxynitrite, phosphorylates STK11 leading to nuclearexport of STK11, subsequent inhibition of PI3K/Akt signaling, andincreased apoptosis. Phosphorylates VAMP2 in vitro(PubMed:17313651). {ECO:0000269|PubMed:11035106,ECO:0000269|PubMed:12162751, ECO:0000269|PubMed:15084291,ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:9447975}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit anelevated basal enzymatic activity (that may be due to theinteraction with SMG1 or SQSTM1) and are not regulated bydiacylglycerol, phosphatidylserine, phorbol esters or calciumions. Two specific sites, Thr-410 (activation loop of the kinasedomain) and Thr-560 (turn motif), need to be phosphorylated forits full activation. Phosphatidylinositol 3,4,5-trisphosphatemight be a physiological activator (By similarity). {ECO:0000250}.SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Formsanother ternary complex with SQSTM1 and GABRR3. Forms a complexwith SQSTM1 and MAP2K5 (By similarity). Interacts with PARD6A,PARD6B, PARD6G and SQSTM1. Part of a complex with PARD3, PARD6A orPARD6B or PARD6G and CDC42 or RAC1. Interacts with ADAP1/CENTA1.Forms a ternary complex composed of SQSTM1 and PAWR. Interactsdirectly with SQSTM1 (Probable). Interacts with IKBKB. Interacts(via the protein kinase domain) with WWC1. Forms a tripartitecomplex with WWC1 and DDR1, but predominantly in the absence ofcollagen. Component of the Par polarity complex, composed of atleast phosphorylated PRKCZ, PARD3 and TIAM1. Interacts with PDPK1(via N-terminal region). Interacts with WDFY2 (via WD repeats 1-3)(PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). Forms acomplex with WDFY2 and VAMP2 (PubMed:17313651).{ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:11260256, ECO:0000269|PubMed:11755531,ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:12234671,ECO:0000269|PubMed:12887891, ECO:0000269|PubMed:12893243,ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:20332120,ECO:0000269|PubMed:9566925, ECO:0000305}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:9566925}. Endosome{ECO:0000269|PubMed:9566925}. Cell junction{ECO:0000269|PubMed:7597083}. Note=In the retina, localizes in theterminals of the rod bipolar cells. Associates with endosomes.Presence of KRIT1, CDH5 and RAP1B is required for its localizationto the cell junction. Colocalizes with VAMP2 and WDFY2 inintracellular vesicles. {ECO:0000269|PubMed:17313651}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=Q05513-1; Sequence=Displayed;Name=2;IsoId=Q05513-2; Sequence=VSP_041904;Name=3;IsoId=Q05513-3; Sequence=VSP_046347;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent inlung, kidney and testis.DOMAIN: The PB1 domain mediate mutually exclusive interactionswith SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}.DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).{ECO:0000269|PubMed:12887891}.PTM: CDH5 is required for its phosphorylation at Thr-410.Phosphorylated by protein kinase PDPK1; phosphorylation isinhibited by the apoptotic C-terminal cleavage product of PKN2.Phosphorylation at Thr-410 by PI3K activates the kinase.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15314172,ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361}.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA78813.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5590"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002735"],["bp:comment","REPLACED ProteinRef_PRKCZ__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5590"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-1"],["bp:comment","REPLACED ProteinRef_PRKCZ__40674"],["bp:comment","KPCZ_HUMAN Reviewed; 592 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80631"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80631"]]}},{"data":{"id":"Protein_f576ffc59d4746653266a7daef180870_Complex_dceae21100bab7ef8ef90d2fb262a17f","class":"macromolecule","label":"PAWR","parent":"Complex_dceae21100bab7ef8ef90d2fb262a17f","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":500.81882,"y":669.4525,"w":48,"h":25},"metadata":[["bp:displayName","PAR4"],["bp:entityReference_http://identifiers.org/uniprot/Q96IZ0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 163 163 Phosphothreonine; by PKA."],["bp:featureLocation",[["bp:sequencePosition","163"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 108 108 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 231 231 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","231"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","PRKC apoptosis WT1 regulator protein"],["bp:xref",[["bp:id","Q96IZ0"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q96IZ0"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q96IZ0"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","PAWR_HUMAN"],["bp:name","Prostate apoptosis response 4 protein"],["bp:name","PAWR"],["bp:name","PAR4"],["bp:name","Par-4"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_8332"],["bp:comment","FUNCTION: Pro-apoptopic protein capable of selectively inducingapoptosis in cancer cells, sensitizing the cells to diverseapoptotic stimuli and causing regression of tumors in animalmodels. Induces apoptosis in certain cancer cells by activation ofthe Fas prodeath pathway and coparallel inhibition of NF-kappa-Btranscriptional activity. Inhibits the transcriptional activationand augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction withWT1. Seems also to be a transcriptional repressor by itself. Maybe directly involved in regulating the amyloid precursor protein(APP) cleavage activity of BACE1. {ECO:0000269|PubMed:11585763}.SUBUNIT: Interacts with WT1, via the C-terminal region.Homooligomer. Interacts also with a wide variety of proteins, suchas atypical PKCs, p62, DAPK3 kinase and THAP1. Interacts withactin, AATF, BACE1, SPSB1, SPSB2 AND SPSB4. Component of a ternarycomplex composed of SQSTM1 and PRKCZ.{ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:12717420,ECO:0000269|PubMed:14627703, ECO:0000269|PubMed:15671026,ECO:0000269|PubMed:17189197, ECO:0000269|PubMed:8943350}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Mainly cytoplasmicin absence of apoptosis signal and in normal cells. Nuclear inmost cancer cell lines. Nuclear entry seems to be essential butnot sufficient for apoptosis (By similarity). Nuclear localizationincludes nucleoplasm and PML nuclear bodies. {ECO:0000250}.TISSUE SPECIFICITY: Widely expressed. Expression is elevated invarious neurodegenerative diseases such as amyotrophic lateralsclerosis, Alzheimer, Parkinson and Huntington diseases andstroke. Down-regulated in several cancers.{ECO:0000269|PubMed:8943350}.INDUCTION: By apoptosis.DOMAIN: The leucine-zipper domain is not essential for apoptosis,but is required for sensitization of cells to exogenous apoptoticinsults and for interaction with its partners. {ECO:0000250}.DOMAIN: The SAC domain is a death-inducing domain selective forapoptosis induction in cancer cells. This domain is essential fornuclear entry, Fas activation, inhibition of NF-kappa-B activityand induction of apoptosis in cancer cells (By similarity).{ECO:0000250}.PTM: Preferentially phosphorylated at the Thr-163 by PKC in cancercells. {ECO:0000250}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PAWRID41641ch12q21.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pawr/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5074"],["bp:comment","PAWR_HUMAN Reviewed; 340 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29003N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5074"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_33394"]]}},{"data":{"id":"Protein_fb84c22837d2432ab826b5c993599b3e","class":"macromolecule","label":"MAPK8","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_fb84c22837d2432ab826b5c993599b3e.info.1","class":"state variable","state":{"variable":"377","value":"opser"}},{"id":"Protein_fb84c22837d2432ab826b5c993599b3e.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_fb84c22837d2432ab826b5c993599b3e.info.3","class":"state variable","state":{"variable":"185","value":"optyr"}},{"id":"Protein_fb84c22837d2432ab826b5c993599b3e.state.4","class":"state variable","state":{"variable":"183","value":"opthr"}}],"unitsOfInformation":[],"bbox":{"x":205.22101,"y":1083.612,"w":85,"h":25},"metadata":[["bp:displayName","Jnk1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_51997"],["bp:featureLocation",[["bp:sequencePosition","377"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1107"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2060"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P45983",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:name","JNK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"]]}},{"data":{"id":"SmallMolecule_278a5cea7704dc16dc95245a209ff208","class":"simple chemical","label":"GD3","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":403.66473,"y":316.4238,"w":48,"h":20},"metadata":[["bp:displayName","GD3"],["bp:entityReference_#SmallMoleculeReference_5dafc4f64c7ee3b35f20ba9598242a0d",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80566"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad","class":"macromolecule","label":"MAP2K4","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad.info.1","class":"state variable","state":{"variable":"","value":"opthr"}},{"id":"Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad.info.3","class":"state variable","state":{"variable":"","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":280.69399999999996,"y":994.23737,"w":85,"h":25},"metadata":[["bp:displayName","MKK4"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80615"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15301"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80614"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80613"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80613"]]}},{"data":{"id":"BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":494.56824,"y":430.26614,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","BAD"],["bp:entityReference_http://identifiers.org/uniprot/Q92934",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 91 91 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","91"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 97 97 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","97"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:organism","Bcl2-associated agonist of cell death"],["bp:displayName","BAD_HUMAN"],["bp:name","Bcl2 antagonist of cell death"],["bp:name","Bcl2-L-8"],["bp:name","Bcl-2-like protein 8"],["bp:name","Bcl-2-binding component 6"],["bp:name","BCL2L8"],["bp:name","BBC6"],["bp:name","BAD"],["bp:name","Bcl-xL/Bcl-2-associated death promoter"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_572"],["bp:comment","FUNCTION: Promotes cell death. Successfully competes for thebinding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the levelof heterodimerization of these proteins with BAX. Can reverse thedeath repressor activity of Bcl-X(L), but not that of Bcl-2 (Bysimilarity). Appears to act as a link between growth factorreceptor signaling and the apoptotic pathways. {ECO:0000250}.SUBUNIT: Forms heterodimers with the anti-apoptotic proteins, Bcl-X(L), Bcl-2 and Bcl-W. Also binds protein S100A10 (By similarity).The Ser-75/Ser-99 phosphorylated form binds 14-3-3 proteins (Bysimilarity). Interacts with AKT1 and PIM3. Interacts (via BH3domain) with NOL3 (via CARD domain); preventing the association ofBAD with BCL2 (By similarity). Interacts with HIF3A (via C-terminus domain); the interaction reduces the binding between BADand BAX (By similarity). {ECO:0000250|UniProtKB:O35147,ECO:0000250|UniProtKB:Q61337, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:17270021}.SUBCELLULAR LOCATION: Mitochondrion outer membrane. Cytoplasm{ECO:0000250|UniProtKB:Q61337}. Note=Colocalizes with HIF3A in thecytoplasm (By similarity). Upon phosphorylation, locates to thecytoplasm. {ECO:0000250|UniProtKB:Q61337}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: Phosphorylated on one or more of Ser-75, Ser-99, Ser-118 andSer-134 in response to survival stimuli, which blocks its pro-apoptotic activity. Phosphorylation on Ser-99 or Ser-75 promotesheterodimerization with 14-3-3 proteins. This interaction thenfacilitates the phosphorylation at Ser-118, a site within the BH3motif, leading to the release of Bcl-X(L) and the promotion ofcell survival. Ser-99 is the major site of AKT/PKBphosphorylation, Ser-118 the major site of protein kinase A (CAPK)phosphorylation. Phosphorylation at Ser-99 by PKB/AKT1 is almostcompletely blocked by the apoptotic C-terminus cleavage product ofPKN2 generated by caspases-3 activity during apoptosis.{ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:11278822,ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16818649}.PTM: Methylation at Arg-94 and Arg-96 by PRMT1 inhibits Akt-mediated phosphorylation at Ser-99. {ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:21444773}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.CAUTION: The protein name 'Bcl2 antagonist of cell death' may bemisleading. The protein antagonises Bcl2-mediated repression ofcell death, hence it promotes apoptosis. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB36516.1; Type=Frameshift; Positions=64, 91; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BADID130ch11q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Bcl 2-associated death promoterentry;URL=\"https://en.wikipedia.org/wiki/Bcl-2-associated_death_promoter\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/572"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_572_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_116784"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29184N_identity"],["bp:comment","REPLACED ProteinRef_BAD__9606"],["bp:comment","REPLACED ProteinRef_BAD__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1156"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_572"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004313"],["bp:comment","BAD_HUMAN Reviewed; 168 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80626"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","BAD"],["bp:entityReference_http://identifiers.org/uniprot/Q92934",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 91 91 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","91"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 97 97 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","97"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:organism","Bcl2-associated agonist of cell death"],["bp:displayName","BAD_HUMAN"],["bp:name","Bcl2 antagonist of cell death"],["bp:name","Bcl2-L-8"],["bp:name","Bcl-2-like protein 8"],["bp:name","Bcl-2-binding component 6"],["bp:name","BCL2L8"],["bp:name","BBC6"],["bp:name","BAD"],["bp:name","Bcl-xL/Bcl-2-associated death promoter"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_572"],["bp:comment","FUNCTION: Promotes cell death. Successfully competes for thebinding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the levelof heterodimerization of these proteins with BAX. Can reverse thedeath repressor activity of Bcl-X(L), but not that of Bcl-2 (Bysimilarity). Appears to act as a link between growth factorreceptor signaling and the apoptotic pathways. {ECO:0000250}.SUBUNIT: Forms heterodimers with the anti-apoptotic proteins, Bcl-X(L), Bcl-2 and Bcl-W. Also binds protein S100A10 (By similarity).The Ser-75/Ser-99 phosphorylated form binds 14-3-3 proteins (Bysimilarity). Interacts with AKT1 and PIM3. Interacts (via BH3domain) with NOL3 (via CARD domain); preventing the association ofBAD with BCL2 (By similarity). Interacts with HIF3A (via C-terminus domain); the interaction reduces the binding between BADand BAX (By similarity). {ECO:0000250|UniProtKB:O35147,ECO:0000250|UniProtKB:Q61337, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:17270021}.SUBCELLULAR LOCATION: Mitochondrion outer membrane. Cytoplasm{ECO:0000250|UniProtKB:Q61337}. Note=Colocalizes with HIF3A in thecytoplasm (By similarity). Upon phosphorylation, locates to thecytoplasm. {ECO:0000250|UniProtKB:Q61337}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: Phosphorylated on one or more of Ser-75, Ser-99, Ser-118 andSer-134 in response to survival stimuli, which blocks its pro-apoptotic activity. Phosphorylation on Ser-99 or Ser-75 promotesheterodimerization with 14-3-3 proteins. This interaction thenfacilitates the phosphorylation at Ser-118, a site within the BH3motif, leading to the release of Bcl-X(L) and the promotion ofcell survival. Ser-99 is the major site of AKT/PKBphosphorylation, Ser-118 the major site of protein kinase A (CAPK)phosphorylation. Phosphorylation at Ser-99 by PKB/AKT1 is almostcompletely blocked by the apoptotic C-terminus cleavage product ofPKN2 generated by caspases-3 activity during apoptosis.{ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:11278822,ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16818649}.PTM: Methylation at Arg-94 and Arg-96 by PRMT1 inhibits Akt-mediated phosphorylation at Ser-99. {ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:21444773}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.CAUTION: The protein name 'Bcl2 antagonist of cell death' may bemisleading. The protein antagonises Bcl2-mediated repression ofcell death, hence it promotes apoptosis. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB36516.1; Type=Frameshift; Positions=64, 91; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BADID130ch11q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Bcl 2-associated death promoterentry;URL=\"https://en.wikipedia.org/wiki/Bcl-2-associated_death_promoter\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/572"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_572_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_116784"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29184N_identity"],["bp:comment","REPLACED ProteinRef_BAD__9606"],["bp:comment","REPLACED ProteinRef_BAD__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1156"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_572"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004313"],["bp:comment","BAD_HUMAN Reviewed; 168 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80626"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","BAD"],["bp:entityReference_http://identifiers.org/uniprot/Q92934",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 91 91 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","91"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 97 97 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","97"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:organism","Bcl2-associated agonist of cell death"],["bp:displayName","BAD_HUMAN"],["bp:name","Bcl2 antagonist of cell death"],["bp:name","Bcl2-L-8"],["bp:name","Bcl-2-like protein 8"],["bp:name","Bcl-2-binding component 6"],["bp:name","BCL2L8"],["bp:name","BBC6"],["bp:name","BAD"],["bp:name","Bcl-xL/Bcl-2-associated death promoter"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_572"],["bp:comment","FUNCTION: Promotes cell death. Successfully competes for thebinding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the levelof heterodimerization of these proteins with BAX. Can reverse thedeath repressor activity of Bcl-X(L), but not that of Bcl-2 (Bysimilarity). Appears to act as a link between growth factorreceptor signaling and the apoptotic pathways. {ECO:0000250}.SUBUNIT: Forms heterodimers with the anti-apoptotic proteins, Bcl-X(L), Bcl-2 and Bcl-W. Also binds protein S100A10 (By similarity).The Ser-75/Ser-99 phosphorylated form binds 14-3-3 proteins (Bysimilarity). Interacts with AKT1 and PIM3. Interacts (via BH3domain) with NOL3 (via CARD domain); preventing the association ofBAD with BCL2 (By similarity). Interacts with HIF3A (via C-terminus domain); the interaction reduces the binding between BADand BAX (By similarity). {ECO:0000250|UniProtKB:O35147,ECO:0000250|UniProtKB:Q61337, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:17270021}.SUBCELLULAR LOCATION: Mitochondrion outer membrane. Cytoplasm{ECO:0000250|UniProtKB:Q61337}. Note=Colocalizes with HIF3A in thecytoplasm (By similarity). Upon phosphorylation, locates to thecytoplasm. {ECO:0000250|UniProtKB:Q61337}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: Phosphorylated on one or more of Ser-75, Ser-99, Ser-118 andSer-134 in response to survival stimuli, which blocks its pro-apoptotic activity. Phosphorylation on Ser-99 or Ser-75 promotesheterodimerization with 14-3-3 proteins. This interaction thenfacilitates the phosphorylation at Ser-118, a site within the BH3motif, leading to the release of Bcl-X(L) and the promotion ofcell survival. Ser-99 is the major site of AKT/PKBphosphorylation, Ser-118 the major site of protein kinase A (CAPK)phosphorylation. Phosphorylation at Ser-99 by PKB/AKT1 is almostcompletely blocked by the apoptotic C-terminus cleavage product ofPKN2 generated by caspases-3 activity during apoptosis.{ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:11278822,ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16818649}.PTM: Methylation at Arg-94 and Arg-96 by PRMT1 inhibits Akt-mediated phosphorylation at Ser-99. {ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:21444773}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.CAUTION: The protein name 'Bcl2 antagonist of cell death' may bemisleading. The protein antagonises Bcl2-mediated repression ofcell death, hence it promotes apoptosis. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB36516.1; Type=Frameshift; Positions=64, 91; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BADID130ch11q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Bcl 2-associated death promoterentry;URL=\"https://en.wikipedia.org/wiki/Bcl-2-associated_death_promoter\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/572"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_572_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_116784"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29184N_identity"],["bp:comment","REPLACED ProteinRef_BAD__9606"],["bp:comment","REPLACED ProteinRef_BAD__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1156"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_572"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004313"],["bp:comment","BAD_HUMAN Reviewed; 168 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80626"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","BAD"],["bp:entityReference_http://identifiers.org/uniprot/Q92934",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 91 91 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","91"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 97 97 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","97"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:organism","Bcl2-associated agonist of cell death"],["bp:displayName","BAD_HUMAN"],["bp:name","Bcl2 antagonist of cell death"],["bp:name","Bcl2-L-8"],["bp:name","Bcl-2-like protein 8"],["bp:name","Bcl-2-binding component 6"],["bp:name","BCL2L8"],["bp:name","BBC6"],["bp:name","BAD"],["bp:name","Bcl-xL/Bcl-2-associated death promoter"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_572"],["bp:comment","FUNCTION: Promotes cell death. Successfully competes for thebinding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the levelof heterodimerization of these proteins with BAX. Can reverse thedeath repressor activity of Bcl-X(L), but not that of Bcl-2 (Bysimilarity). Appears to act as a link between growth factorreceptor signaling and the apoptotic pathways. {ECO:0000250}.SUBUNIT: Forms heterodimers with the anti-apoptotic proteins, Bcl-X(L), Bcl-2 and Bcl-W. Also binds protein S100A10 (By similarity).The Ser-75/Ser-99 phosphorylated form binds 14-3-3 proteins (Bysimilarity). Interacts with AKT1 and PIM3. Interacts (via BH3domain) with NOL3 (via CARD domain); preventing the association ofBAD with BCL2 (By similarity). Interacts with HIF3A (via C-terminus domain); the interaction reduces the binding between BADand BAX (By similarity). {ECO:0000250|UniProtKB:O35147,ECO:0000250|UniProtKB:Q61337, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:17270021}.SUBCELLULAR LOCATION: Mitochondrion outer membrane. Cytoplasm{ECO:0000250|UniProtKB:Q61337}. Note=Colocalizes with HIF3A in thecytoplasm (By similarity). Upon phosphorylation, locates to thecytoplasm. {ECO:0000250|UniProtKB:Q61337}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: Phosphorylated on one or more of Ser-75, Ser-99, Ser-118 andSer-134 in response to survival stimuli, which blocks its pro-apoptotic activity. Phosphorylation on Ser-99 or Ser-75 promotesheterodimerization with 14-3-3 proteins. This interaction thenfacilitates the phosphorylation at Ser-118, a site within the BH3motif, leading to the release of Bcl-X(L) and the promotion ofcell survival. Ser-99 is the major site of AKT/PKBphosphorylation, Ser-118 the major site of protein kinase A (CAPK)phosphorylation. Phosphorylation at Ser-99 by PKB/AKT1 is almostcompletely blocked by the apoptotic C-terminus cleavage product ofPKN2 generated by caspases-3 activity during apoptosis.{ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:11278822,ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16818649}.PTM: Methylation at Arg-94 and Arg-96 by PRMT1 inhibits Akt-mediated phosphorylation at Ser-99. {ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:21444773}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.CAUTION: The protein name 'Bcl2 antagonist of cell death' may bemisleading. The protein antagonises Bcl2-mediated repression ofcell death, hence it promotes apoptosis. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB36516.1; Type=Frameshift; Positions=64, 91; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BADID130ch11q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Bcl 2-associated death promoterentry;URL=\"https://en.wikipedia.org/wiki/Bcl-2-associated_death_promoter\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/572"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_572_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_116784"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29184N_identity"],["bp:comment","REPLACED ProteinRef_BAD__9606"],["bp:comment","REPLACED ProteinRef_BAD__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1156"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_572"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004313"],["bp:comment","BAD_HUMAN Reviewed; 168 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80626"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80623"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80623"]]}},{"data":{"id":"Complex_d772c3d87a8f32f2dc14b2e83086db93","class":"complex","label":"Cathepsin D/ceramide","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":639.9854,"y":636.0608,"w":52,"h":59},"metadata":[["bp:displayName","Cathepsin D/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80582"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80580"]]],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref","Cathepsin D"],["bp:xref","Cathepsin D"],["bp:organism","Cathepsin D"],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80579"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80579"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80581"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80580"]]],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref","Cathepsin D"],["bp:xref","Cathepsin D"],["bp:organism","Cathepsin D"],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80579"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80579"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80581"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Cathepsin D"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80580"]]],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref","Cathepsin D"],["bp:xref","Cathepsin D"],["bp:organism","Cathepsin D"],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80579"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80579"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80581"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80578"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80578"]]}},{"data":{"id":"Protein_4ddc3353a90cc50ccf66dd60dbfd04b1_Complex_d772c3d87a8f32f2dc14b2e83086db93","class":"macromolecule","label":"CTSD","parent":"Complex_d772c3d87a8f32f2dc14b2e83086db93","clonemarker":false,"stateVariables":[{"id":"Protein_4ddc3353a90cc50ccf66dd60dbfd04b1_Complex_d772c3d87a8f32f2dc14b2e83086db93.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":639.9854,"y":621.0608,"w":48,"h":25},"metadata":[["bp:displayName","Cathepsin D"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80580"]]],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref",[["bp:relationshipType",null],["bp:id","CTSD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80579"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0_Complex_d772c3d87a8f32f2dc14b2e83086db93","class":"simple chemical","label":"ceramide","parent":"Complex_d772c3d87a8f32f2dc14b2e83086db93","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":639.9854,"y":653.5608,"w":48,"h":20},"metadata":[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"SmallMolecule_424cd1f4f369b64bb79c706574eb0d16","class":"simple chemical","label":"GW4869","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":460.73257,"y":294.1292,"w":48,"h":20},"metadata":[["bp:displayName","GW4869"],["bp:entityReference_#SmallMoleculeReference_35d4aa85989138669cedac68fd5d8869",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80957"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1000.12286,"y":142.11617,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","FAN"],["bp:entityReference_http://identifiers.org/uniprot/Q92636",[["bp:standardName","Protein FAN"],["bp:xref",[["bp:id","Q92636"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","NSMAF"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","NSMAF"],["bp:db","hgnc symbol"]]],["bp:displayName","FAN_HUMAN"],["bp:name","Factor associated with N-SMase activation"],["bp:name","FAN"],["bp:name","NSMAF"],["bp:name","Factor associated with neutral sphingomyelinase activation"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8439"],["bp:comment","REPLACED ProteinRef_NSMAF__40674"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8IW26"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-44106N_identity"],["bp:comment","FAN_HUMAN Reviewed; 917 AA."],["bp:comment","FUNCTION: Couples the p55 TNF-receptor (TNF-R55 / TNFR1) toneutral sphingomyelinase (N-SMASE). Specifically binds to the N-smase activation domain of TNF-R55. May regulate ceramideproduction by N-SMASE.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q92636-1; Sequence=Displayed;Name=2;IsoId=Q92636-2; Sequence=VSP_042036;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_09117_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8439"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003571"],["bp:comment","REPLACED ProteinRef_NSMAF__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21820"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80588"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha/TNFR1A/FAN"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80590"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha/TNFR1A/FAN"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80590"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha/TNFR1A/FAN"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80590"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","TNF-alpha/TNFR1A/FAN"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80590"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","TNF-alpha/TNFR1A/FAN"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80590"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","TNF-alpha/TNFR1A/FAN"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80590"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","TNF-alpha/TNFR1A/FAN"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438","TNFR1A"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80554"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80550"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80590"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:left","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80586"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80586"]]}},{"data":{"id":"Protein_45fd195b8986611e93ee1d05c54c5867","class":"macromolecule","label":"RB1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_45fd195b8986611e93ee1d05c54c5867.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":292.7889,"y":548.99347,"w":48,"h":25},"metadata":[["bp:displayName","RB1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80817"]]],["bp:entityReference_http://identifiers.org/uniprot/P06400",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-methyllysine"],["bp:term","MOD_RES N6-methyllysine"]]],["bp:comment","MOD_RES 810 810 N6-methyllysine; by SMYD2."],["bp:featureLocation",[["bp:sequencePosition","810"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","788"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:standardName","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:organism","Retinoblastoma-associated protein"],["bp:displayName","RB_HUMAN"],["bp:name","pp110"],["bp:name","Rb"],["bp:name","pRb"],["bp:name","RB1"],["bp:name","p105-Rb"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q5VW46"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5925"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_452"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5925"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000312"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-1208367_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PJM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P06400_identity"],["bp:comment","REPLACED ProteinRef_RB1__9606"],["bp:comment","FUNCTION: Key regulator of entry into cell division that acts as atumor suppressor. Promotes G0-G1 transition when phosphorylated byCDK3/cyclin-C. Acts as a transcription repressor of E2F1 targetgenes. The underphosphorylated, active form of RB1 interacts withE2F1 and represses its transcription activity, leading to cellcycle arrest. Directly involved in heterochromatin formation bymaintaining overall chromatin structure and, in particular, thatof constitutive heterochromatin by stabilizing histonemethylation. Recruits and targets histone methyltransferasesSUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptionalrepression. Controls histone H4 'Lys-20' trimethylation. Inhibitsthe intrinsic kinase activity of TAF1. Mediates transcriptionalrepression by SMARCA4/BRG1 by recruiting a histone deacetylase(HDAC) complex to the c-FOS promoter. In resting neurons,transcription of the c-FOS promoter is inhibited by BRG1-dependentrecruitment of a phospho-RB1-HDAC1 repressor complex. Upon calciuminflux, RB1 is dephosphorylated by calcineurin, which leads torelease of the repressor complex (By similarity). In case of viralinfections, interactions with SV40 large T antigen, HPV E7 proteinor adenovirus E1A protein induce the disassembly of RB1-E2F1complex thereby disrupting RB1's activity. {ECO:0000250,ECO:0000269|PubMed:15084261}.SUBUNIT: Interacts with ATAD5. Interacts with PRMT2, CDK1 and CDK2(By similarity). The hypophosphorylated form interacts with andsequesters the E2F1 transcription factor. Interacts withheterodimeric E2F/DP transcription factor complexes containingTFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. Theunphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1,MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain ofTAF1. Interacts with SNW1, AATF, DNMT1, LIN9, LMNA, KMT5B, KMT5C,PELP1, UHRF2 and TMPO-alpha. May interact with NDC80. Interactswith GRIP1 and UBR4. Interacts with ARID4A and KDM5B. Interactswith E4F1 and LIMD1. Interacts with SMARCA4/BRG1 AND HDAC1 (Bysimilarity). Interacts with PSMA3 and USP4. Interacts (whenmethylated at Lys-860) with L3MBTL1. Interacts with CHEK2;phosphorylates RB1. Interacts with CEBPA (PubMed:15107404).Interacts with adenovirus E1A protein, HPV E7 protein and SV40large T antigen. Interacts with human cytomegalovirus/HHV-5protein UL123. P-TEFB complex interacts with RB1; promotesphosphorylation of RB1 (PubMed:12037672).{ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568,ECO:0000269|PubMed:10409732, ECO:0000269|PubMed:10446990,ECO:0000269|PubMed:10779342, ECO:0000269|PubMed:10869426,ECO:0000269|PubMed:10888886, ECO:0000269|PubMed:11223246,ECO:0000269|PubMed:11484059, ECO:0000269|PubMed:11571652,ECO:0000269|PubMed:12037672, ECO:0000269|PubMed:12450794,ECO:0000269|PubMed:12466551, ECO:0000269|PubMed:12475961,ECO:0000269|PubMed:12682072, ECO:0000269|PubMed:12695505,ECO:0000269|PubMed:1316611, ECO:0000269|PubMed:15107404,ECO:0000269|PubMed:15538385, ECO:0000269|PubMed:15542589,ECO:0000269|PubMed:15803180, ECO:0000269|PubMed:15927959,ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:16214886,ECO:0000269|PubMed:16337594, ECO:0000269|PubMed:16360038,ECO:0000269|PubMed:16645588, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:17974914, ECO:0000269|PubMed:17996702,ECO:0000269|PubMed:20870719, ECO:0000269|PubMed:21952639,ECO:0000269|PubMed:2839300, ECO:0000269|PubMed:7525595,ECO:0000269|PubMed:7935440, ECO:0000269|PubMed:8414517,ECO:0000269|PubMed:8892909, ECO:0000269|PubMed:9858607}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20940255}.TISSUE SPECIFICITY: Expressed in the retina.DOMAIN: The Pocket domain binds to the threonine-phosphorylateddomain C, thereby preventing interaction with heterodimeric E2F/DPtranscription factor complexes.PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 atSer-567 in G1, thereby releasing E2F1 which is then able toactivate cell growth. Dephosphorylated at the late M phase. SV40large T antigen, HPV E7 and adenovirus E1A bind to theunderphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domainC and the Pocket domain, and thereby inhibits interactions withheterodimeric E2F/DP transcription factor complexes.Dephosphorylated at Ser-795 by calcineruin upon calciumstimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 andSer-811 is required for G0-G1 transition. Phosphorylated by CDK1and CDK2 upon TGFB1-mediated apoptosis (By similarity).{ECO:0000250}.PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity).Monomethylation at Lys-810 by SMYD2 enhances phosphorylation atSer-807 and Ser-811, and promotes cell cycle progression.Monomethylation at Lys-860 by SMYD2 promotes interaction withL3MBTL1. {ECO:0000250, ECO:0000269|PubMed:10499802,ECO:0000269|PubMed:15084261, ECO:0000269|PubMed:15809340,ECO:0000269|PubMed:16360038, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:1756735, ECO:0000269|PubMed:20870719,ECO:0000269|PubMed:22787429, ECO:0000269|PubMed:8114739}.PTM: Acetylation at Lys-873 and Lys-874 regulates subcellularlocalization, at least during keratinocytes differentiation.{ECO:0000269|PubMed:20940255}.DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]:Congenital malignant tumor that arises from the nuclear layers ofthe retina. It occurs in about 1:20'000 live births and representsabout 2% of childhood malignancies. It is bilateral in about 30%of cases. Although most RB appear sporadically, about 20% aretransmitted as an autosomal dominant trait with incompletepenetrance. The diagnosis is usually made before the age of 2years when strabismus or a gray to yellow reflex from pupil ('cateye') is investigated. {ECO:0000269|PubMed:10671068,ECO:0000269|PubMed:11524739, ECO:0000269|PubMed:1352883,ECO:0000269|PubMed:2594029, ECO:0000269|PubMed:7704558,ECO:0000269|PubMed:7795591, ECO:0000269|PubMed:7927327,ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116,ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452,ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancyoriginating in tissues of the urinary bladder. It often presentswith multiple tumors appearing at different times and at differentsites in the bladder. Most bladder cancers are transitional cellcarcinomas that begin in cells that normally make up the innerlining of the bladder. Other types of bladder cancer includesquamous cell carcinoma (cancer that begins in thin, flat cells)and adenocarcinoma (cancer that begins in cells that make andrelease mucus and other fluids). Bladder cancer is a complexdisorder with both genetic and environmental influences.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcomaoriginating in bone-forming cells, affecting the ends of longbones. Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the retinoblastoma protein (RB) family.{ECO:0000305}.WEB RESOURCE: Name=RB1base; Note=RB1 mutation db;URL=\"http://rb1-lsdb.d-lohmann.de/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RB1ID90.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/rb1/\";WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry;URL=\"https://en.wikipedia.org/wiki/Retinoblastoma_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5925"],["bp:comment","RB_HUMAN Reviewed; 928 AA."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01574_identity"],["bp:comment","REPLACED ProteinRef_RB1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1GH6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-582N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80816"]]}},{"data":{"id":"Protein_5c1911b3d33a783b3c8db3d2cfbba1e6","class":"macromolecule","label":"PRKRA","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_5c1911b3d33a783b3c8db3d2cfbba1e6.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":432.17685,"y":245.04646,"w":48,"h":25},"metadata":[["bp:displayName","RAX"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80659"]]],["bp:entityReference_http://identifiers.org/uniprot/O75569",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 18 18 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","18"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 246 246 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","246"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:organism","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:displayName","PRKRA_HUMAN"],["bp:name","PACT"],["bp:name","Protein activator of the interferon-induced protein kinase"],["bp:name","RAX"],["bp:name","PKR-associating protein X"],["bp:name","PRKRA"],["bp:name","Protein kinase, interferon-inducible double-stranded RNA-dependent activator"],["bp:name","PKR-associated protein X"],["bp:comment","FUNCTION: Activates EIF2AK2/PKR in the absence of double-strandedRNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha andinhibition of translation and induction of apoptosis. Required forsiRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required forprocessing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53association and sumoylation and phosphorylation of p53/TP53 at'Lys-386' at 'Ser-392' respectively and enhances its activity in aEIF2AK2/PKR-dependent manner (By similarity). {ECO:0000250,ECO:0000269|PubMed:10336432, ECO:0000269|PubMed:11238927,ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:16982605,ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:9687506}.SUBUNIT: Homodimer. Interacts with EIF2AK2/PKR through its DRBMdomains. Interacts with DICER1, AGO2 and TARBP2. Also able tointeract with dsRNA. Interacts with UBC9 (By similarity). Forms acomplex with UBC9 and p53/TP53 (By similarity). Interacts withDUS2L (via DRBM domain). {ECO:0000250,ECO:0000269|PubMed:11238927, ECO:0000269|PubMed:16424907,ECO:0000269|PubMed:16982605, ECO:0000269|PubMed:17452327,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18421256,ECO:0000269|PubMed:9687506}.SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=O75569-1; Sequence=Displayed;Name=2;IsoId=O75569-2; Sequence=VSP_017283;Note=No experimental confirmation available.;Name=3;IsoId=O75569-3; Sequence=VSP_017282;Note=No experimental confirmation available.;DOMAIN: Self-association may occur via interactions between DRBMdomains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 orDRBM 3/DRBM3.PTM: Phosphorylated at Ser-246 in unstressed cells and at Ser-287in stressed cells. Phosphorylation at Ser-246 appears to be aprerequisite for subsequent phosphorylation at Ser-287.Phosphorylation at Ser-246 and Ser-287 are necessary foractivation of EIF2AK2/PKR under conditions of stress.{ECO:0000269|PubMed:16982605}.DISEASE: Dystonia 16 (DYT16) [MIM:612067]: An early-onsetdystonia-parkinsonism disorder. Dystonia is defined by thepresence of sustained involuntary muscle contraction, oftenleading to abnormal postures. DYT16 patients have progressive,generalized dystonia with axial muscle involvement, oro-mandibular(sardonic smile) and laryngeal dystonia and, in some cases,parkinsonian features. {ECO:0000269|PubMed:18243799,ECO:0000269|PubMed:18420150}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the PRKRA family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41809N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04573_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246978"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003681"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8575"],["bp:comment","PRKRA_HUMAN Reviewed; 313 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8575"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80658"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80658"]]}},{"data":{"id":"Protein_12bcf51c75aae38cdb2620e757a2f48e","class":"macromolecule","label":"TNFRSF1A","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":951.7813,"y":75.50607,"w":48,"h":25},"metadata":[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_186a48824d7ef8afa6c6ead978884be7","class":"macromolecule","label":"RB1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_186a48824d7ef8afa6c6ead978884be7.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":271.49144,"y":406.69812,"w":48,"h":25},"metadata":[["bp:displayName","RB1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80815"]]],["bp:entityReference_http://identifiers.org/uniprot/P06400",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-methyllysine"],["bp:term","MOD_RES N6-methyllysine"]]],["bp:comment","MOD_RES 810 810 N6-methyllysine; by SMYD2."],["bp:featureLocation",[["bp:sequencePosition","810"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 788 788 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","788"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 373 373 Phosphothreonine; by CDK1."],["bp:featureLocation","MOD_RES 373 373 Phosphothreonine; by CDK1."]]],["bp:standardName","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:xref","Retinoblastoma-associated protein"],["bp:organism","Retinoblastoma-associated protein"],["bp:displayName","RB_HUMAN"],["bp:name","pp110"],["bp:name","Rb"],["bp:name","pRb"],["bp:name","RB1"],["bp:name","p105-Rb"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q5VW46"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5925"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_452"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5925"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000312"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_intact_EBI-1208367_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PJM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P06400_identity"],["bp:comment","REPLACED ProteinRef_RB1__9606"],["bp:comment","FUNCTION: Key regulator of entry into cell division that acts as atumor suppressor. Promotes G0-G1 transition when phosphorylated byCDK3/cyclin-C. Acts as a transcription repressor of E2F1 targetgenes. The underphosphorylated, active form of RB1 interacts withE2F1 and represses its transcription activity, leading to cellcycle arrest. Directly involved in heterochromatin formation bymaintaining overall chromatin structure and, in particular, thatof constitutive heterochromatin by stabilizing histonemethylation. Recruits and targets histone methyltransferasesSUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptionalrepression. Controls histone H4 'Lys-20' trimethylation. Inhibitsthe intrinsic kinase activity of TAF1. Mediates transcriptionalrepression by SMARCA4/BRG1 by recruiting a histone deacetylase(HDAC) complex to the c-FOS promoter. In resting neurons,transcription of the c-FOS promoter is inhibited by BRG1-dependentrecruitment of a phospho-RB1-HDAC1 repressor complex. Upon calciuminflux, RB1 is dephosphorylated by calcineurin, which leads torelease of the repressor complex (By similarity). In case of viralinfections, interactions with SV40 large T antigen, HPV E7 proteinor adenovirus E1A protein induce the disassembly of RB1-E2F1complex thereby disrupting RB1's activity. {ECO:0000250,ECO:0000269|PubMed:15084261}.SUBUNIT: Interacts with ATAD5. Interacts with PRMT2, CDK1 and CDK2(By similarity). The hypophosphorylated form interacts with andsequesters the E2F1 transcription factor. Interacts withheterodimeric E2F/DP transcription factor complexes containingTFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. Theunphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1,MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain ofTAF1. Interacts with SNW1, AATF, DNMT1, LIN9, LMNA, KMT5B, KMT5C,PELP1, UHRF2 and TMPO-alpha. May interact with NDC80. Interactswith GRIP1 and UBR4. Interacts with ARID4A and KDM5B. Interactswith E4F1 and LIMD1. Interacts with SMARCA4/BRG1 AND HDAC1 (Bysimilarity). Interacts with PSMA3 and USP4. Interacts (whenmethylated at Lys-860) with L3MBTL1. Interacts with CHEK2;phosphorylates RB1. Interacts with CEBPA (PubMed:15107404).Interacts with adenovirus E1A protein, HPV E7 protein and SV40large T antigen. Interacts with human cytomegalovirus/HHV-5protein UL123. P-TEFB complex interacts with RB1; promotesphosphorylation of RB1 (PubMed:12037672).{ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568,ECO:0000269|PubMed:10409732, ECO:0000269|PubMed:10446990,ECO:0000269|PubMed:10779342, ECO:0000269|PubMed:10869426,ECO:0000269|PubMed:10888886, ECO:0000269|PubMed:11223246,ECO:0000269|PubMed:11484059, ECO:0000269|PubMed:11571652,ECO:0000269|PubMed:12037672, ECO:0000269|PubMed:12450794,ECO:0000269|PubMed:12466551, ECO:0000269|PubMed:12475961,ECO:0000269|PubMed:12682072, ECO:0000269|PubMed:12695505,ECO:0000269|PubMed:1316611, ECO:0000269|PubMed:15107404,ECO:0000269|PubMed:15538385, ECO:0000269|PubMed:15542589,ECO:0000269|PubMed:15803180, ECO:0000269|PubMed:15927959,ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:16214886,ECO:0000269|PubMed:16337594, ECO:0000269|PubMed:16360038,ECO:0000269|PubMed:16645588, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:17974914, ECO:0000269|PubMed:17996702,ECO:0000269|PubMed:20870719, ECO:0000269|PubMed:21952639,ECO:0000269|PubMed:2839300, ECO:0000269|PubMed:7525595,ECO:0000269|PubMed:7935440, ECO:0000269|PubMed:8414517,ECO:0000269|PubMed:8892909, ECO:0000269|PubMed:9858607}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20940255}.TISSUE SPECIFICITY: Expressed in the retina.DOMAIN: The Pocket domain binds to the threonine-phosphorylateddomain C, thereby preventing interaction with heterodimeric E2F/DPtranscription factor complexes.PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 atSer-567 in G1, thereby releasing E2F1 which is then able toactivate cell growth. Dephosphorylated at the late M phase. SV40large T antigen, HPV E7 and adenovirus E1A bind to theunderphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domainC and the Pocket domain, and thereby inhibits interactions withheterodimeric E2F/DP transcription factor complexes.Dephosphorylated at Ser-795 by calcineruin upon calciumstimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 andSer-811 is required for G0-G1 transition. Phosphorylated by CDK1and CDK2 upon TGFB1-mediated apoptosis (By similarity).{ECO:0000250}.PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity).Monomethylation at Lys-810 by SMYD2 enhances phosphorylation atSer-807 and Ser-811, and promotes cell cycle progression.Monomethylation at Lys-860 by SMYD2 promotes interaction withL3MBTL1. {ECO:0000250, ECO:0000269|PubMed:10499802,ECO:0000269|PubMed:15084261, ECO:0000269|PubMed:15809340,ECO:0000269|PubMed:16360038, ECO:0000269|PubMed:17380128,ECO:0000269|PubMed:1756735, ECO:0000269|PubMed:20870719,ECO:0000269|PubMed:22787429, ECO:0000269|PubMed:8114739}.PTM: Acetylation at Lys-873 and Lys-874 regulates subcellularlocalization, at least during keratinocytes differentiation.{ECO:0000269|PubMed:20940255}.DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]:Congenital malignant tumor that arises from the nuclear layers ofthe retina. It occurs in about 1:20'000 live births and representsabout 2% of childhood malignancies. It is bilateral in about 30%of cases. Although most RB appear sporadically, about 20% aretransmitted as an autosomal dominant trait with incompletepenetrance. The diagnosis is usually made before the age of 2years when strabismus or a gray to yellow reflex from pupil ('cateye') is investigated. {ECO:0000269|PubMed:10671068,ECO:0000269|PubMed:11524739, ECO:0000269|PubMed:1352883,ECO:0000269|PubMed:2594029, ECO:0000269|PubMed:7704558,ECO:0000269|PubMed:7795591, ECO:0000269|PubMed:7927327,ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116,ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452,ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancyoriginating in tissues of the urinary bladder. It often presentswith multiple tumors appearing at different times and at differentsites in the bladder. Most bladder cancers are transitional cellcarcinomas that begin in cells that normally make up the innerlining of the bladder. Other types of bladder cancer includesquamous cell carcinoma (cancer that begins in thin, flat cells)and adenocarcinoma (cancer that begins in cells that make andrelease mucus and other fluids). Bladder cancer is a complexdisorder with both genetic and environmental influences.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcomaoriginating in bone-forming cells, affecting the ends of longbones. Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the retinoblastoma protein (RB) family.{ECO:0000305}.WEB RESOURCE: Name=RB1base; Note=RB1 mutation db;URL=\"http://rb1-lsdb.d-lohmann.de/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RB1ID90.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/rb1/\";WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry;URL=\"https://en.wikipedia.org/wiki/Retinoblastoma_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5925"],["bp:comment","RB_HUMAN Reviewed; 928 AA."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01574_identity"],["bp:comment","REPLACED ProteinRef_RB1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1GH6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-582N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80812"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80812"]]}},{"data":{"id":"Protein_63c92eb75b3e167900133d4669e0f283","class":"macromolecule","label":"PDGFA","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":153.86406,"y":288.06265,"w":48,"h":25},"metadata":[["bp:displayName","PDGFA"],["bp:entityReference_http://identifiers.org/uniprot/P04085",[["bp:standardName","Platelet-derived growth factor subunit A"],["bp:xref",[["bp:id","P04085"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","PDGFA"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","PDGFA"],["bp:db","hgnc symbol"]]],["bp:displayName","PDGFA_HUMAN"],["bp:name","PDGF1"],["bp:name","PDGF subunit A"],["bp:name","PDGFA"],["bp:name","PDGF-1"],["bp:name","Platelet-derived growth factor alpha polypeptide"],["bp:name","Platelet-derived growth factor A chain"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01424_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P04085"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5735N_identity"],["bp:comment","PDGFA_HUMAN Reviewed; 211 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5154"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5154"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04085-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04085-1"],["bp:comment","FUNCTION: Growth factor that plays an essential role in theregulation of embryonic development, cell proliferation, cellmigration, survival and chemotaxis. Potent mitogen for cells ofmesenchymal origin. Required for normal lung alveolar septumformation during embryogenesis, normal development of thegastrointestinal tract, normal development of Leydig cells andspermatogenesis. Required for normal oligodendrocyte developmentand normal myelination in the spinal cord and cerebellum. Plays animportant role in wound healing. Signaling is modulated by theformation of heterodimers with PDGFB (By similarity).{ECO:0000250}.SUBUNIT: Homodimer; antiparallel disulfide-linked dimer.Heterodimer with PDGFB; antiparallel disulfide-linked dimer. ThePDGFA homodimer interacts with PDGFRA homodimers, and withheterodimers formed by PDGFRA and PDGFRB. The heterodimer composedof PDGFA and PDGFB interacts with PDGFRA homodimers, and withheterodimers formed by PDGFRA and PDGFRB. Interacts with CSPG4.{ECO:0000269|PubMed:10358027, ECO:0000269|PubMed:20534510}.SUBCELLULAR LOCATION: Secreted. Note=Released by platelets uponwounding.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Long;IsoId=P04085-1; Sequence=Displayed;Name=Short;IsoId=P04085-2; Sequence=VSP_004602, VSP_004603;DOMAIN: The long form contains a basic insert which acts as a cellretention signal.SIMILARITY: Belongs to the PDGF/VEGF growth factor family.{ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_8afb0e3b2e7a807fb983c1fad21e3106","class":"macromolecule","label":"CTSD","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":316.7236,"y":497.88632,"w":48,"h":25},"metadata":[["bp:displayName","Cathepsin D"],["bp:entityReference_http://identifiers.org/uniprot/P07339",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P07339"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P07339"]]],["bp:standardName","Cathepsin D"],["bp:xref",[["bp:relationshipType",null],["bp:id","CTSD"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P07339"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CATD_HUMAN"],["bp:name","CPSD"],["bp:name","CTSD"],["bp:name","Cathepsin D heavy chain"],["bp:name","Cathepsin D light chain"],["bp:name","3.4.23.5"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-43906N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1509"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYB_see-also"],["bp:comment","CATD_HUMAN Reviewed; 412 AA."],["bp:comment","FUNCTION: Acid protease active in intracellular protein breakdown.Plays a role in APP processing following cleavage and activationby ADAM30 which leads to APP degradation (PubMed:27333034).Involved in the pathogenesis of several diseases such as breastcancer and possibly Alzheimer disease.{ECO:0000269|PubMed:27333034}.CATALYTIC ACTIVITY: Specificity similar to, but narrower than,that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in Bchain of insulin.SUBUNIT: Consists of a light chain and a heavy chain(PubMed:8393577, PubMed:1426530). Interacts with ADAM30; thisleads to activation of CTSD (PubMed:27333034).{ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,ECO:0000269|PubMed:8393577}.SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,extracellular space. Note=Identified by mass spectrometry inmelanosome fractions from stage I to stage IV. In aortic samples,detected as an extracellular protein loosely bound to the matrix(PubMed:20551380). {ECO:0000269|PubMed:20551380}.TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (atprotein level) (PubMed:20551380). Expressed in liver (at proteinlevel) (PubMed:1426530). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:20551380}.PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.PTM: Undergoes proteolytic cleavage and activation by ADAM30.{ECO:0000269|PubMed:27333034}.PTM: As well as the major heavy chain which starts at Leu-169, 2minor forms starting at Gly-170 and Gly-171 have been identified(PubMed:1426530). An additional form starting at Ala-168 has alsobeen identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,ECO:0000269|PubMed:27333034}.POLYMORPHISM: The Val-58 allele is significantly overrepresentedin demented patients (11.8%) compared with non-demented controls(4.9%). Carriers of the Val-58 allele have a 3.1-fold increasedrisk for developing AD than non-carriers.DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:A form of neuronal ceroid lipofuscinosis with onset at birth orearly childhood. Neuronal ceroid lipofuscinoses are progressiveneurodegenerative, lysosomal storage diseases characterized byintracellular accumulation of autofluorescent liposomal material,and clinically by seizures, dementia, visual loss, and/or cerebralatrophy. {ECO:0000269|PubMed:16670177,ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinosesmutation db;URL=\"http://www.ucl.ac.uk/ncl/catD.shtml\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001900"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1LYA_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1509"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_23922"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"SAS_For_TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14","class":"source and sink","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1603.6184,"y":946.1979,"w":15,"h":15},"metadata":null}},{"data":{"id":"Protein_4de5660d04065edd714945afa96addc5","class":"macromolecule","label":"SPHK2","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_4de5660d04065edd714945afa96addc5.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":302.03186,"y":122.633125,"w":48,"h":25},"metadata":[["bp:displayName","SPHK2"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80648"]]],["bp:entityReference_http://identifiers.org/uniprot/Q9NRA0",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 399 399 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","399"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 387 387 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","387"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:xref","Sphingosine kinase 2"],["bp:organism","Sphingosine kinase 2"],["bp:displayName","SPHK2_HUMAN"],["bp:name","2.7.1.91"],["bp:name","SPHK2"],["bp:name","SK 2"],["bp:name","SPK 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_56848"],["bp:comment","FUNCTION: Catalyzes the phosphorylation of sphingosine to formsphingosine 1-phosphate (SPP), a lipid mediator with both intra-and extracellular functions. Also acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides.{ECO:0000269|PubMed:19168031}.CATALYTIC ACTIVITY: ATP + a sphingoid base = ADP + a sphingoidbase 1-phosphate. {ECO:0000269|PubMed:10751414}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Inhibited by sulfatide.{ECO:0000269|PubMed:19168031}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=3.4 uM for sphingosine {ECO:0000269|PubMed:10751414};pH dependence:Optimum pH is 7.5. {ECO:0000269|PubMed:10751414};SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Membrane.SUBCELLULAR LOCATION: Isoform 2: Lysosome membrane.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9NRA0-1; Sequence=Displayed;Name=2;IsoId=Q9NRA0-2; Sequence=VSP_006217;Name=3;IsoId=Q9NRA0-3; Sequence=VSP_006217, VSP_006218;Name=4;IsoId=Q9NRA0-4; Sequence=VSP_046910;Note=No experimental confirmation available.;Name=5;IsoId=Q9NRA0-5; Sequence=VSP_047721, VSP_047722; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_06157_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16804"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006723355"],["bp:comment","SPHK2_HUMAN Reviewed; 654 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_56848"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80647"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80647"]]}},{"data":{"id":"BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":323.72253,"y":1075.2764,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Jnk1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_51997"],["bp:featureLocation",[["bp:sequencePosition","377"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1107"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2060"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:entityReference_http://identifiers.org/uniprot/P45983",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:name","JNK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80611"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Jnk1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_51997"],["bp:featureLocation",[["bp:sequencePosition","377"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1107"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2060"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:entityReference_http://identifiers.org/uniprot/P45983",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:name","JNK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80611"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Jnk1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_51997"],["bp:featureLocation",[["bp:sequencePosition","377"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1107"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2060"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:entityReference_http://identifiers.org/uniprot/P45983",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:name","JNK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80611"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Jnk1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_51997"],["bp:featureLocation",[["bp:sequencePosition","377"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1107"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2060"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:entityReference_http://identifiers.org/uniprot/P45983",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:name","JNK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80611"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Jnk1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_51997"],["bp:featureLocation",[["bp:sequencePosition","377"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1107"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2060"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:entityReference_http://identifiers.org/uniprot/P45983",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:name","JNK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80611"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Jnk1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_51997"],["bp:featureLocation",[["bp:sequencePosition","377"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1107"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2060"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:entityReference_http://identifiers.org/uniprot/P45983",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:name","JNK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80611"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Jnk1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_51997"],["bp:featureLocation",[["bp:sequencePosition","377"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1107"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2060"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:entityReference_http://identifiers.org/uniprot/P45983",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2063"]]],["bp:name","JNK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80609"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80611"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80608"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80608"]]}},{"data":{"id":"BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":341.37265,"y":340.5315,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","RAX"],["bp:entityReference_http://identifiers.org/uniprot/O75569",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 18 18 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","18"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 246 246 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","246"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:organism","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:displayName","PRKRA_HUMAN"],["bp:name","PACT"],["bp:name","Protein activator of the interferon-induced protein kinase"],["bp:name","RAX"],["bp:name","PKR-associating protein X"],["bp:name","PRKRA"],["bp:name","Protein kinase, interferon-inducible double-stranded RNA-dependent activator"],["bp:name","PKR-associated protein X"],["bp:comment","FUNCTION: Activates EIF2AK2/PKR in the absence of double-strandedRNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha andinhibition of translation and induction of apoptosis. Required forsiRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required forprocessing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53association and sumoylation and phosphorylation of p53/TP53 at'Lys-386' at 'Ser-392' respectively and enhances its activity in aEIF2AK2/PKR-dependent manner (By similarity). {ECO:0000250,ECO:0000269|PubMed:10336432, ECO:0000269|PubMed:11238927,ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:16982605,ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:9687506}.SUBUNIT: Homodimer. Interacts with EIF2AK2/PKR through its DRBMdomains. Interacts with DICER1, AGO2 and TARBP2. Also able tointeract with dsRNA. Interacts with UBC9 (By similarity). Forms acomplex with UBC9 and p53/TP53 (By similarity). Interacts withDUS2L (via DRBM domain). {ECO:0000250,ECO:0000269|PubMed:11238927, ECO:0000269|PubMed:16424907,ECO:0000269|PubMed:16982605, ECO:0000269|PubMed:17452327,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18421256,ECO:0000269|PubMed:9687506}.SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=O75569-1; Sequence=Displayed;Name=2;IsoId=O75569-2; Sequence=VSP_017283;Note=No experimental confirmation available.;Name=3;IsoId=O75569-3; Sequence=VSP_017282;Note=No experimental confirmation available.;DOMAIN: Self-association may occur via interactions between DRBMdomains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 orDRBM 3/DRBM3.PTM: Phosphorylated at Ser-246 in unstressed cells and at Ser-287in stressed cells. Phosphorylation at Ser-246 appears to be aprerequisite for subsequent phosphorylation at Ser-287.Phosphorylation at Ser-246 and Ser-287 are necessary foractivation of EIF2AK2/PKR under conditions of stress.{ECO:0000269|PubMed:16982605}.DISEASE: Dystonia 16 (DYT16) [MIM:612067]: An early-onsetdystonia-parkinsonism disorder. Dystonia is defined by thepresence of sustained involuntary muscle contraction, oftenleading to abnormal postures. DYT16 patients have progressive,generalized dystonia with axial muscle involvement, oro-mandibular(sardonic smile) and laryngeal dystonia and, in some cases,parkinsonian features. {ECO:0000269|PubMed:18243799,ECO:0000269|PubMed:18420150}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the PRKRA family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41809N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04573_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246978"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003681"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8575"],["bp:comment","PRKRA_HUMAN Reviewed; 313 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8575"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80660"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","RAX"],["bp:entityReference_http://identifiers.org/uniprot/O75569",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 18 18 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","18"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 246 246 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","246"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:organism","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:displayName","PRKRA_HUMAN"],["bp:name","PACT"],["bp:name","Protein activator of the interferon-induced protein kinase"],["bp:name","RAX"],["bp:name","PKR-associating protein X"],["bp:name","PRKRA"],["bp:name","Protein kinase, interferon-inducible double-stranded RNA-dependent activator"],["bp:name","PKR-associated protein X"],["bp:comment","FUNCTION: Activates EIF2AK2/PKR in the absence of double-strandedRNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha andinhibition of translation and induction of apoptosis. Required forsiRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required forprocessing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53association and sumoylation and phosphorylation of p53/TP53 at'Lys-386' at 'Ser-392' respectively and enhances its activity in aEIF2AK2/PKR-dependent manner (By similarity). {ECO:0000250,ECO:0000269|PubMed:10336432, ECO:0000269|PubMed:11238927,ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:16982605,ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:9687506}.SUBUNIT: Homodimer. Interacts with EIF2AK2/PKR through its DRBMdomains. Interacts with DICER1, AGO2 and TARBP2. Also able tointeract with dsRNA. Interacts with UBC9 (By similarity). Forms acomplex with UBC9 and p53/TP53 (By similarity). Interacts withDUS2L (via DRBM domain). {ECO:0000250,ECO:0000269|PubMed:11238927, ECO:0000269|PubMed:16424907,ECO:0000269|PubMed:16982605, ECO:0000269|PubMed:17452327,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18421256,ECO:0000269|PubMed:9687506}.SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=O75569-1; Sequence=Displayed;Name=2;IsoId=O75569-2; Sequence=VSP_017283;Note=No experimental confirmation available.;Name=3;IsoId=O75569-3; Sequence=VSP_017282;Note=No experimental confirmation available.;DOMAIN: Self-association may occur via interactions between DRBMdomains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 orDRBM 3/DRBM3.PTM: Phosphorylated at Ser-246 in unstressed cells and at Ser-287in stressed cells. Phosphorylation at Ser-246 appears to be aprerequisite for subsequent phosphorylation at Ser-287.Phosphorylation at Ser-246 and Ser-287 are necessary foractivation of EIF2AK2/PKR under conditions of stress.{ECO:0000269|PubMed:16982605}.DISEASE: Dystonia 16 (DYT16) [MIM:612067]: An early-onsetdystonia-parkinsonism disorder. Dystonia is defined by thepresence of sustained involuntary muscle contraction, oftenleading to abnormal postures. DYT16 patients have progressive,generalized dystonia with axial muscle involvement, oro-mandibular(sardonic smile) and laryngeal dystonia and, in some cases,parkinsonian features. {ECO:0000269|PubMed:18243799,ECO:0000269|PubMed:18420150}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the PRKRA family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41809N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04573_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246978"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003681"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8575"],["bp:comment","PRKRA_HUMAN Reviewed; 313 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8575"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80660"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","RAX"],["bp:entityReference_http://identifiers.org/uniprot/O75569",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 18 18 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","18"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 246 246 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","246"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:organism","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:displayName","PRKRA_HUMAN"],["bp:name","PACT"],["bp:name","Protein activator of the interferon-induced protein kinase"],["bp:name","RAX"],["bp:name","PKR-associating protein X"],["bp:name","PRKRA"],["bp:name","Protein kinase, interferon-inducible double-stranded RNA-dependent activator"],["bp:name","PKR-associated protein X"],["bp:comment","FUNCTION: Activates EIF2AK2/PKR in the absence of double-strandedRNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha andinhibition of translation and induction of apoptosis. Required forsiRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required forprocessing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53association and sumoylation and phosphorylation of p53/TP53 at'Lys-386' at 'Ser-392' respectively and enhances its activity in aEIF2AK2/PKR-dependent manner (By similarity). {ECO:0000250,ECO:0000269|PubMed:10336432, ECO:0000269|PubMed:11238927,ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:16982605,ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:9687506}.SUBUNIT: Homodimer. Interacts with EIF2AK2/PKR through its DRBMdomains. Interacts with DICER1, AGO2 and TARBP2. Also able tointeract with dsRNA. Interacts with UBC9 (By similarity). Forms acomplex with UBC9 and p53/TP53 (By similarity). Interacts withDUS2L (via DRBM domain). {ECO:0000250,ECO:0000269|PubMed:11238927, ECO:0000269|PubMed:16424907,ECO:0000269|PubMed:16982605, ECO:0000269|PubMed:17452327,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18421256,ECO:0000269|PubMed:9687506}.SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=O75569-1; Sequence=Displayed;Name=2;IsoId=O75569-2; Sequence=VSP_017283;Note=No experimental confirmation available.;Name=3;IsoId=O75569-3; Sequence=VSP_017282;Note=No experimental confirmation available.;DOMAIN: Self-association may occur via interactions between DRBMdomains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 orDRBM 3/DRBM3.PTM: Phosphorylated at Ser-246 in unstressed cells and at Ser-287in stressed cells. Phosphorylation at Ser-246 appears to be aprerequisite for subsequent phosphorylation at Ser-287.Phosphorylation at Ser-246 and Ser-287 are necessary foractivation of EIF2AK2/PKR under conditions of stress.{ECO:0000269|PubMed:16982605}.DISEASE: Dystonia 16 (DYT16) [MIM:612067]: An early-onsetdystonia-parkinsonism disorder. Dystonia is defined by thepresence of sustained involuntary muscle contraction, oftenleading to abnormal postures. DYT16 patients have progressive,generalized dystonia with axial muscle involvement, oro-mandibular(sardonic smile) and laryngeal dystonia and, in some cases,parkinsonian features. {ECO:0000269|PubMed:18243799,ECO:0000269|PubMed:18420150}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the PRKRA family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41809N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04573_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246978"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003681"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8575"],["bp:comment","PRKRA_HUMAN Reviewed; 313 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8575"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80660"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","RAX"],["bp:entityReference_http://identifiers.org/uniprot/O75569",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 18 18 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","18"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 246 246 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","246"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:organism","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:displayName","PRKRA_HUMAN"],["bp:name","PACT"],["bp:name","Protein activator of the interferon-induced protein kinase"],["bp:name","RAX"],["bp:name","PKR-associating protein X"],["bp:name","PRKRA"],["bp:name","Protein kinase, interferon-inducible double-stranded RNA-dependent activator"],["bp:name","PKR-associated protein X"],["bp:comment","FUNCTION: Activates EIF2AK2/PKR in the absence of double-strandedRNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha andinhibition of translation and induction of apoptosis. Required forsiRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required forprocessing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53association and sumoylation and phosphorylation of p53/TP53 at'Lys-386' at 'Ser-392' respectively and enhances its activity in aEIF2AK2/PKR-dependent manner (By similarity). {ECO:0000250,ECO:0000269|PubMed:10336432, ECO:0000269|PubMed:11238927,ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:16982605,ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:9687506}.SUBUNIT: Homodimer. Interacts with EIF2AK2/PKR through its DRBMdomains. Interacts with DICER1, AGO2 and TARBP2. Also able tointeract with dsRNA. Interacts with UBC9 (By similarity). Forms acomplex with UBC9 and p53/TP53 (By similarity). Interacts withDUS2L (via DRBM domain). {ECO:0000250,ECO:0000269|PubMed:11238927, ECO:0000269|PubMed:16424907,ECO:0000269|PubMed:16982605, ECO:0000269|PubMed:17452327,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18421256,ECO:0000269|PubMed:9687506}.SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=O75569-1; Sequence=Displayed;Name=2;IsoId=O75569-2; Sequence=VSP_017283;Note=No experimental confirmation available.;Name=3;IsoId=O75569-3; Sequence=VSP_017282;Note=No experimental confirmation available.;DOMAIN: Self-association may occur via interactions between DRBMdomains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 orDRBM 3/DRBM3.PTM: Phosphorylated at Ser-246 in unstressed cells and at Ser-287in stressed cells. Phosphorylation at Ser-246 appears to be aprerequisite for subsequent phosphorylation at Ser-287.Phosphorylation at Ser-246 and Ser-287 are necessary foractivation of EIF2AK2/PKR under conditions of stress.{ECO:0000269|PubMed:16982605}.DISEASE: Dystonia 16 (DYT16) [MIM:612067]: An early-onsetdystonia-parkinsonism disorder. Dystonia is defined by thepresence of sustained involuntary muscle contraction, oftenleading to abnormal postures. DYT16 patients have progressive,generalized dystonia with axial muscle involvement, oro-mandibular(sardonic smile) and laryngeal dystonia and, in some cases,parkinsonian features. {ECO:0000269|PubMed:18243799,ECO:0000269|PubMed:18420150}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the PRKRA family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41809N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04573_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246978"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003681"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8575"],["bp:comment","PRKRA_HUMAN Reviewed; 313 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8575"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80660"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","RAX"],["bp:entityReference_http://identifiers.org/uniprot/O75569",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 18 18 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","18"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 246 246 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","246"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:organism","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:displayName","PRKRA_HUMAN"],["bp:name","PACT"],["bp:name","Protein activator of the interferon-induced protein kinase"],["bp:name","RAX"],["bp:name","PKR-associating protein X"],["bp:name","PRKRA"],["bp:name","Protein kinase, interferon-inducible double-stranded RNA-dependent activator"],["bp:name","PKR-associated protein X"],["bp:comment","FUNCTION: Activates EIF2AK2/PKR in the absence of double-strandedRNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha andinhibition of translation and induction of apoptosis. Required forsiRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required forprocessing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53association and sumoylation and phosphorylation of p53/TP53 at'Lys-386' at 'Ser-392' respectively and enhances its activity in aEIF2AK2/PKR-dependent manner (By similarity). {ECO:0000250,ECO:0000269|PubMed:10336432, ECO:0000269|PubMed:11238927,ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:16982605,ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:9687506}.SUBUNIT: Homodimer. Interacts with EIF2AK2/PKR through its DRBMdomains. Interacts with DICER1, AGO2 and TARBP2. Also able tointeract with dsRNA. Interacts with UBC9 (By similarity). Forms acomplex with UBC9 and p53/TP53 (By similarity). Interacts withDUS2L (via DRBM domain). {ECO:0000250,ECO:0000269|PubMed:11238927, ECO:0000269|PubMed:16424907,ECO:0000269|PubMed:16982605, ECO:0000269|PubMed:17452327,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18421256,ECO:0000269|PubMed:9687506}.SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=O75569-1; Sequence=Displayed;Name=2;IsoId=O75569-2; Sequence=VSP_017283;Note=No experimental confirmation available.;Name=3;IsoId=O75569-3; Sequence=VSP_017282;Note=No experimental confirmation available.;DOMAIN: Self-association may occur via interactions between DRBMdomains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 orDRBM 3/DRBM3.PTM: Phosphorylated at Ser-246 in unstressed cells and at Ser-287in stressed cells. Phosphorylation at Ser-246 appears to be aprerequisite for subsequent phosphorylation at Ser-287.Phosphorylation at Ser-246 and Ser-287 are necessary foractivation of EIF2AK2/PKR under conditions of stress.{ECO:0000269|PubMed:16982605}.DISEASE: Dystonia 16 (DYT16) [MIM:612067]: An early-onsetdystonia-parkinsonism disorder. Dystonia is defined by thepresence of sustained involuntary muscle contraction, oftenleading to abnormal postures. DYT16 patients have progressive,generalized dystonia with axial muscle involvement, oro-mandibular(sardonic smile) and laryngeal dystonia and, in some cases,parkinsonian features. {ECO:0000269|PubMed:18243799,ECO:0000269|PubMed:18420150}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the PRKRA family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41809N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04573_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246978"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003681"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8575"],["bp:comment","PRKRA_HUMAN Reviewed; 313 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8575"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80660"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","RAX"],["bp:entityReference_http://identifiers.org/uniprot/O75569",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 18 18 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","18"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 246 246 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","246"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:organism","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:displayName","PRKRA_HUMAN"],["bp:name","PACT"],["bp:name","Protein activator of the interferon-induced protein kinase"],["bp:name","RAX"],["bp:name","PKR-associating protein X"],["bp:name","PRKRA"],["bp:name","Protein kinase, interferon-inducible double-stranded RNA-dependent activator"],["bp:name","PKR-associated protein X"],["bp:comment","FUNCTION: Activates EIF2AK2/PKR in the absence of double-strandedRNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha andinhibition of translation and induction of apoptosis. Required forsiRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required forprocessing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53association and sumoylation and phosphorylation of p53/TP53 at'Lys-386' at 'Ser-392' respectively and enhances its activity in aEIF2AK2/PKR-dependent manner (By similarity). {ECO:0000250,ECO:0000269|PubMed:10336432, ECO:0000269|PubMed:11238927,ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:16982605,ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:9687506}.SUBUNIT: Homodimer. Interacts with EIF2AK2/PKR through its DRBMdomains. Interacts with DICER1, AGO2 and TARBP2. Also able tointeract with dsRNA. Interacts with UBC9 (By similarity). Forms acomplex with UBC9 and p53/TP53 (By similarity). Interacts withDUS2L (via DRBM domain). {ECO:0000250,ECO:0000269|PubMed:11238927, ECO:0000269|PubMed:16424907,ECO:0000269|PubMed:16982605, ECO:0000269|PubMed:17452327,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18421256,ECO:0000269|PubMed:9687506}.SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=O75569-1; Sequence=Displayed;Name=2;IsoId=O75569-2; Sequence=VSP_017283;Note=No experimental confirmation available.;Name=3;IsoId=O75569-3; Sequence=VSP_017282;Note=No experimental confirmation available.;DOMAIN: Self-association may occur via interactions between DRBMdomains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 orDRBM 3/DRBM3.PTM: Phosphorylated at Ser-246 in unstressed cells and at Ser-287in stressed cells. Phosphorylation at Ser-246 appears to be aprerequisite for subsequent phosphorylation at Ser-287.Phosphorylation at Ser-246 and Ser-287 are necessary foractivation of EIF2AK2/PKR under conditions of stress.{ECO:0000269|PubMed:16982605}.DISEASE: Dystonia 16 (DYT16) [MIM:612067]: An early-onsetdystonia-parkinsonism disorder. Dystonia is defined by thepresence of sustained involuntary muscle contraction, oftenleading to abnormal postures. DYT16 patients have progressive,generalized dystonia with axial muscle involvement, oro-mandibular(sardonic smile) and laryngeal dystonia and, in some cases,parkinsonian features. {ECO:0000269|PubMed:18243799,ECO:0000269|PubMed:18420150}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the PRKRA family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41809N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04573_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246978"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003681"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8575"],["bp:comment","PRKRA_HUMAN Reviewed; 313 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8575"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80660"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","RAX"],["bp:entityReference_http://identifiers.org/uniprot/O75569",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 18 18 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","18"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 246 246 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","246"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 167 167 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","167"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:xref","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:organism","Interferon-inducible double-stranded RNA-dependent protein kinase activator A"],["bp:displayName","PRKRA_HUMAN"],["bp:name","PACT"],["bp:name","Protein activator of the interferon-induced protein kinase"],["bp:name","RAX"],["bp:name","PKR-associating protein X"],["bp:name","PRKRA"],["bp:name","Protein kinase, interferon-inducible double-stranded RNA-dependent activator"],["bp:name","PKR-associated protein X"],["bp:comment","FUNCTION: Activates EIF2AK2/PKR in the absence of double-strandedRNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha andinhibition of translation and induction of apoptosis. Required forsiRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required forprocessing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53association and sumoylation and phosphorylation of p53/TP53 at'Lys-386' at 'Ser-392' respectively and enhances its activity in aEIF2AK2/PKR-dependent manner (By similarity). {ECO:0000250,ECO:0000269|PubMed:10336432, ECO:0000269|PubMed:11238927,ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:16982605,ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:9687506}.SUBUNIT: Homodimer. Interacts with EIF2AK2/PKR through its DRBMdomains. Interacts with DICER1, AGO2 and TARBP2. Also able tointeract with dsRNA. Interacts with UBC9 (By similarity). Forms acomplex with UBC9 and p53/TP53 (By similarity). Interacts withDUS2L (via DRBM domain). {ECO:0000250,ECO:0000269|PubMed:11238927, ECO:0000269|PubMed:16424907,ECO:0000269|PubMed:16982605, ECO:0000269|PubMed:17452327,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18421256,ECO:0000269|PubMed:9687506}.SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=O75569-1; Sequence=Displayed;Name=2;IsoId=O75569-2; Sequence=VSP_017283;Note=No experimental confirmation available.;Name=3;IsoId=O75569-3; Sequence=VSP_017282;Note=No experimental confirmation available.;DOMAIN: Self-association may occur via interactions between DRBMdomains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 orDRBM 3/DRBM3.PTM: Phosphorylated at Ser-246 in unstressed cells and at Ser-287in stressed cells. Phosphorylation at Ser-246 appears to be aprerequisite for subsequent phosphorylation at Ser-287.Phosphorylation at Ser-246 and Ser-287 are necessary foractivation of EIF2AK2/PKR under conditions of stress.{ECO:0000269|PubMed:16982605}.DISEASE: Dystonia 16 (DYT16) [MIM:612067]: An early-onsetdystonia-parkinsonism disorder. Dystonia is defined by thepresence of sustained involuntary muscle contraction, oftenleading to abnormal postures. DYT16 patients have progressive,generalized dystonia with axial muscle involvement, oro-mandibular(sardonic smile) and laryngeal dystonia and, in some cases,parkinsonian features. {ECO:0000269|PubMed:18243799,ECO:0000269|PubMed:18420150}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the PRKRA family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-41809N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04573_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005246978"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003681"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8575"],["bp:comment","PRKRA_HUMAN Reviewed; 313 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8575"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80655"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80660"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80654"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80654"]]}},{"data":{"id":"Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":705.26465,"y":419.3484,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","AIF"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80527"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","AIF"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80527"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","AIF"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80527"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","AIF"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80527"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","AIF"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80527"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","AIF"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80525"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80527"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80521"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80521"]]}},{"data":{"id":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2","class":"complex","label":"PP2A Heterotrimer","parent":"","clonemarker":false,"stateVariables":[{"id":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":118.928276,"y":541.81824,"w":48,"h":20},"metadata":[["bp:displayName","PP2A Heterotrimer"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80688"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80687"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_c70cc1ccf2cde9639ff181595a85dda3","class":"macromolecule","label":"BAD","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":391.46625,"y":437.42267,"w":48,"h":25},"metadata":[["bp:displayName","BAD"],["bp:entityReference_http://identifiers.org/uniprot/Q92934",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 91 91 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","91"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 97 97 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","97"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 75 75 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:xref","Bcl2-associated agonist of cell death"],["bp:organism","Bcl2-associated agonist of cell death"],["bp:displayName","BAD_HUMAN"],["bp:name","Bcl2 antagonist of cell death"],["bp:name","Bcl2-L-8"],["bp:name","Bcl-2-like protein 8"],["bp:name","Bcl-2-binding component 6"],["bp:name","BCL2L8"],["bp:name","BBC6"],["bp:name","BAD"],["bp:name","Bcl-xL/Bcl-2-associated death promoter"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_572"],["bp:comment","FUNCTION: Promotes cell death. Successfully competes for thebinding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the levelof heterodimerization of these proteins with BAX. Can reverse thedeath repressor activity of Bcl-X(L), but not that of Bcl-2 (Bysimilarity). Appears to act as a link between growth factorreceptor signaling and the apoptotic pathways. {ECO:0000250}.SUBUNIT: Forms heterodimers with the anti-apoptotic proteins, Bcl-X(L), Bcl-2 and Bcl-W. Also binds protein S100A10 (By similarity).The Ser-75/Ser-99 phosphorylated form binds 14-3-3 proteins (Bysimilarity). Interacts with AKT1 and PIM3. Interacts (via BH3domain) with NOL3 (via CARD domain); preventing the association ofBAD with BCL2 (By similarity). Interacts with HIF3A (via C-terminus domain); the interaction reduces the binding between BADand BAX (By similarity). {ECO:0000250|UniProtKB:O35147,ECO:0000250|UniProtKB:Q61337, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:17270021}.SUBCELLULAR LOCATION: Mitochondrion outer membrane. Cytoplasm{ECO:0000250|UniProtKB:Q61337}. Note=Colocalizes with HIF3A in thecytoplasm (By similarity). Upon phosphorylation, locates to thecytoplasm. {ECO:0000250|UniProtKB:Q61337}.TISSUE SPECIFICITY: Expressed in a wide variety of tissues.DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAXfor their pro-apoptotic activity and for their interaction withanti-apoptotic members of the Bcl-2 family.PTM: Phosphorylated on one or more of Ser-75, Ser-99, Ser-118 andSer-134 in response to survival stimuli, which blocks its pro-apoptotic activity. Phosphorylation on Ser-99 or Ser-75 promotesheterodimerization with 14-3-3 proteins. This interaction thenfacilitates the phosphorylation at Ser-118, a site within the BH3motif, leading to the release of Bcl-X(L) and the promotion ofcell survival. Ser-99 is the major site of AKT/PKBphosphorylation, Ser-118 the major site of protein kinase A (CAPK)phosphorylation. Phosphorylation at Ser-99 by PKB/AKT1 is almostcompletely blocked by the apoptotic C-terminus cleavage product ofPKN2 generated by caspases-3 activity during apoptosis.{ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:11278822,ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16818649}.PTM: Methylation at Arg-94 and Arg-96 by PRMT1 inhibits Akt-mediated phosphorylation at Ser-99. {ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:21444773}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.CAUTION: The protein name 'Bcl2 antagonist of cell death' may bemisleading. The protein antagonises Bcl2-mediated repression ofcell death, hence it promotes apoptosis. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB36516.1; Type=Frameshift; Positions=64, 91; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BADID130ch11q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Bcl 2-associated death promoterentry;URL=\"https://en.wikipedia.org/wiki/Bcl-2-associated_death_promoter\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/572"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_572_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_116784"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29184N_identity"],["bp:comment","REPLACED ProteinRef_BAD__9606"],["bp:comment","REPLACED ProteinRef_BAD__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1156"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_572"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004313"],["bp:comment","BAD_HUMAN Reviewed; 168 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_8090"]]}},{"data":{"id":"Complex_8799cc43e9e7f7445aeab812fde3e343","class":"complex","label":"PKC zeta/ceramide","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":402.81793,"y":936.1438,"w":52,"h":59},"metadata":[["bp:displayName","PKC zeta/ceramide"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:standardName","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:organism","Protein kinase C zeta type"],["bp:displayName","KPCZ_HUMAN"],["bp:name","nPKC-zeta"],["bp:name","PRKCZ"],["bp:name","2.7.11.13"],["bp:name","PKC2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_457"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01504_identity"],["bp:comment","REPLACED ProteinRef_PRKCZ__9606"],["bp:comment","FUNCTION: Calcium- and diacylglycerol-independentserine/threonine-protein kinase that functions inphosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activatedprotein (MAP) kinase cascade, and is involved in NF-kappa-Bactivation, mitogenic signaling, cell proliferation, cellpolarity, inflammatory response and maintenance of long-termpotentiation (LTP). Upon lipopolysaccharide (LPS) treatment inmacrophages, or following mitogenic stimuli, functions downstreamof PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascadeindependently of RAF1 activation. Required for insulin-dependentactivation of AKT3, but may function as an adapter rather than adirect activator. Upon insulin treatment may act as a downstreameffector of PI3K and contribute to the activation of translocationof the glucose transporter SLC2A4/GLUT4 and subsequent glucosetransport in adipocytes. In EGF-induced cells, binds and activatesMAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity andcan activate JUN promoter through MEF2C. Through binding withSQSTM1/p62, functions in interleukin-1 signaling and activation ofNF-kappa-B with the specific adapters RIPK1 and TRAF6.Participates in TNF-dependent transactivation of NF-kappa-B byphosphorylating and activating IKBKB kinase, which in turn leadsto the degradation of NF-kappa-B inhibitors. In migratingastrocytes, forms a cytoplasmic complex with PARD6A and isrecruited by CDC42 to function in the establishment of cellpolarity along with the microtubule motor and dynein. Inassociation with FEZ1, stimulates neuronal differentiation in PC12cells. In the inflammatory response, is required for the T-helper2 (Th2) differentiation process, including interleukin production,efficient activation of JAK1 and the subsequent phosphorylationand nuclear translocation of STAT6. May be involved in developmentof allergic airway inflammation (asthma), a process dependent onTh2 immune response. In the NF-kappa-B-mediated inflammatoryresponse, can relieve SETD6-dependent repression of NF-kappa-Btarget genes by phosphorylating the RELA subunit at 'Ser-311'.Necessary and sufficient for LTP maintenance in hippocampal CA1pyramidal cells. In vein endothelial cells treated with theoxidant peroxynitrite, phosphorylates STK11 leading to nuclearexport of STK11, subsequent inhibition of PI3K/Akt signaling, andincreased apoptosis. Phosphorylates VAMP2 in vitro(PubMed:17313651). {ECO:0000269|PubMed:11035106,ECO:0000269|PubMed:12162751, ECO:0000269|PubMed:15084291,ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:9447975}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit anelevated basal enzymatic activity (that may be due to theinteraction with SMG1 or SQSTM1) and are not regulated bydiacylglycerol, phosphatidylserine, phorbol esters or calciumions. Two specific sites, Thr-410 (activation loop of the kinasedomain) and Thr-560 (turn motif), need to be phosphorylated forits full activation. Phosphatidylinositol 3,4,5-trisphosphatemight be a physiological activator (By similarity). {ECO:0000250}.SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Formsanother ternary complex with SQSTM1 and GABRR3. Forms a complexwith SQSTM1 and MAP2K5 (By similarity). Interacts with PARD6A,PARD6B, PARD6G and SQSTM1. Part of a complex with PARD3, PARD6A orPARD6B or PARD6G and CDC42 or RAC1. Interacts with ADAP1/CENTA1.Forms a ternary complex composed of SQSTM1 and PAWR. Interactsdirectly with SQSTM1 (Probable). Interacts with IKBKB. Interacts(via the protein kinase domain) with WWC1. Forms a tripartitecomplex with WWC1 and DDR1, but predominantly in the absence ofcollagen. Component of the Par polarity complex, composed of atleast phosphorylated PRKCZ, PARD3 and TIAM1. Interacts with PDPK1(via N-terminal region). Interacts with WDFY2 (via WD repeats 1-3)(PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). Forms acomplex with WDFY2 and VAMP2 (PubMed:17313651).{ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:11260256, ECO:0000269|PubMed:11755531,ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:12234671,ECO:0000269|PubMed:12887891, ECO:0000269|PubMed:12893243,ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:20332120,ECO:0000269|PubMed:9566925, ECO:0000305}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:9566925}. Endosome{ECO:0000269|PubMed:9566925}. Cell junction{ECO:0000269|PubMed:7597083}. Note=In the retina, localizes in theterminals of the rod bipolar cells. Associates with endosomes.Presence of KRIT1, CDH5 and RAP1B is required for its localizationto the cell junction. Colocalizes with VAMP2 and WDFY2 inintracellular vesicles. {ECO:0000269|PubMed:17313651}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=Q05513-1; Sequence=Displayed;Name=2;IsoId=Q05513-2; Sequence=VSP_041904;Name=3;IsoId=Q05513-3; Sequence=VSP_046347;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent inlung, kidney and testis.DOMAIN: The PB1 domain mediate mutually exclusive interactionswith SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}.DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).{ECO:0000269|PubMed:12887891}.PTM: CDH5 is required for its phosphorylation at Thr-410.Phosphorylated by protein kinase PDPK1; phosphorylation isinhibited by the apoptotic C-terminal cleavage product of PKN2.Phosphorylation at Thr-410 by PI3K activates the kinase.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15314172,ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361}.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA78813.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5590"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002735"],["bp:comment","REPLACED ProteinRef_PRKCZ__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5590"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-1"],["bp:comment","REPLACED ProteinRef_PRKCZ__40674"],["bp:comment","KPCZ_HUMAN Reviewed; 592 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:standardName","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:organism","Protein kinase C zeta type"],["bp:displayName","KPCZ_HUMAN"],["bp:name","nPKC-zeta"],["bp:name","PRKCZ"],["bp:name","2.7.11.13"],["bp:name","PKC2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_457"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01504_identity"],["bp:comment","REPLACED ProteinRef_PRKCZ__9606"],["bp:comment","FUNCTION: Calcium- and diacylglycerol-independentserine/threonine-protein kinase that functions inphosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activatedprotein (MAP) kinase cascade, and is involved in NF-kappa-Bactivation, mitogenic signaling, cell proliferation, cellpolarity, inflammatory response and maintenance of long-termpotentiation (LTP). Upon lipopolysaccharide (LPS) treatment inmacrophages, or following mitogenic stimuli, functions downstreamof PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascadeindependently of RAF1 activation. Required for insulin-dependentactivation of AKT3, but may function as an adapter rather than adirect activator. Upon insulin treatment may act as a downstreameffector of PI3K and contribute to the activation of translocationof the glucose transporter SLC2A4/GLUT4 and subsequent glucosetransport in adipocytes. In EGF-induced cells, binds and activatesMAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity andcan activate JUN promoter through MEF2C. Through binding withSQSTM1/p62, functions in interleukin-1 signaling and activation ofNF-kappa-B with the specific adapters RIPK1 and TRAF6.Participates in TNF-dependent transactivation of NF-kappa-B byphosphorylating and activating IKBKB kinase, which in turn leadsto the degradation of NF-kappa-B inhibitors. In migratingastrocytes, forms a cytoplasmic complex with PARD6A and isrecruited by CDC42 to function in the establishment of cellpolarity along with the microtubule motor and dynein. Inassociation with FEZ1, stimulates neuronal differentiation in PC12cells. In the inflammatory response, is required for the T-helper2 (Th2) differentiation process, including interleukin production,efficient activation of JAK1 and the subsequent phosphorylationand nuclear translocation of STAT6. May be involved in developmentof allergic airway inflammation (asthma), a process dependent onTh2 immune response. In the NF-kappa-B-mediated inflammatoryresponse, can relieve SETD6-dependent repression of NF-kappa-Btarget genes by phosphorylating the RELA subunit at 'Ser-311'.Necessary and sufficient for LTP maintenance in hippocampal CA1pyramidal cells. In vein endothelial cells treated with theoxidant peroxynitrite, phosphorylates STK11 leading to nuclearexport of STK11, subsequent inhibition of PI3K/Akt signaling, andincreased apoptosis. Phosphorylates VAMP2 in vitro(PubMed:17313651). {ECO:0000269|PubMed:11035106,ECO:0000269|PubMed:12162751, ECO:0000269|PubMed:15084291,ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:9447975}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit anelevated basal enzymatic activity (that may be due to theinteraction with SMG1 or SQSTM1) and are not regulated bydiacylglycerol, phosphatidylserine, phorbol esters or calciumions. Two specific sites, Thr-410 (activation loop of the kinasedomain) and Thr-560 (turn motif), need to be phosphorylated forits full activation. Phosphatidylinositol 3,4,5-trisphosphatemight be a physiological activator (By similarity). {ECO:0000250}.SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Formsanother ternary complex with SQSTM1 and GABRR3. Forms a complexwith SQSTM1 and MAP2K5 (By similarity). Interacts with PARD6A,PARD6B, PARD6G and SQSTM1. Part of a complex with PARD3, PARD6A orPARD6B or PARD6G and CDC42 or RAC1. Interacts with ADAP1/CENTA1.Forms a ternary complex composed of SQSTM1 and PAWR. Interactsdirectly with SQSTM1 (Probable). Interacts with IKBKB. Interacts(via the protein kinase domain) with WWC1. Forms a tripartitecomplex with WWC1 and DDR1, but predominantly in the absence ofcollagen. Component of the Par polarity complex, composed of atleast phosphorylated PRKCZ, PARD3 and TIAM1. Interacts with PDPK1(via N-terminal region). Interacts with WDFY2 (via WD repeats 1-3)(PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). Forms acomplex with WDFY2 and VAMP2 (PubMed:17313651).{ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:11260256, ECO:0000269|PubMed:11755531,ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:12234671,ECO:0000269|PubMed:12887891, ECO:0000269|PubMed:12893243,ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:20332120,ECO:0000269|PubMed:9566925, ECO:0000305}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:9566925}. Endosome{ECO:0000269|PubMed:9566925}. Cell junction{ECO:0000269|PubMed:7597083}. Note=In the retina, localizes in theterminals of the rod bipolar cells. Associates with endosomes.Presence of KRIT1, CDH5 and RAP1B is required for its localizationto the cell junction. Colocalizes with VAMP2 and WDFY2 inintracellular vesicles. {ECO:0000269|PubMed:17313651}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=Q05513-1; Sequence=Displayed;Name=2;IsoId=Q05513-2; Sequence=VSP_041904;Name=3;IsoId=Q05513-3; Sequence=VSP_046347;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent inlung, kidney and testis.DOMAIN: The PB1 domain mediate mutually exclusive interactionswith SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}.DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).{ECO:0000269|PubMed:12887891}.PTM: CDH5 is required for its phosphorylation at Thr-410.Phosphorylated by protein kinase PDPK1; phosphorylation isinhibited by the apoptotic C-terminal cleavage product of PKN2.Phosphorylation at Thr-410 by PI3K activates the kinase.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15314172,ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361}.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA78813.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5590"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002735"],["bp:comment","REPLACED ProteinRef_PRKCZ__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5590"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-1"],["bp:comment","REPLACED ProteinRef_PRKCZ__40674"],["bp:comment","KPCZ_HUMAN Reviewed; 592 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:standardName","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:organism","Protein kinase C zeta type"],["bp:displayName","KPCZ_HUMAN"],["bp:name","nPKC-zeta"],["bp:name","PRKCZ"],["bp:name","2.7.11.13"],["bp:name","PKC2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_457"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01504_identity"],["bp:comment","REPLACED ProteinRef_PRKCZ__9606"],["bp:comment","FUNCTION: Calcium- and diacylglycerol-independentserine/threonine-protein kinase that functions inphosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activatedprotein (MAP) kinase cascade, and is involved in NF-kappa-Bactivation, mitogenic signaling, cell proliferation, cellpolarity, inflammatory response and maintenance of long-termpotentiation (LTP). Upon lipopolysaccharide (LPS) treatment inmacrophages, or following mitogenic stimuli, functions downstreamof PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascadeindependently of RAF1 activation. Required for insulin-dependentactivation of AKT3, but may function as an adapter rather than adirect activator. Upon insulin treatment may act as a downstreameffector of PI3K and contribute to the activation of translocationof the glucose transporter SLC2A4/GLUT4 and subsequent glucosetransport in adipocytes. In EGF-induced cells, binds and activatesMAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity andcan activate JUN promoter through MEF2C. Through binding withSQSTM1/p62, functions in interleukin-1 signaling and activation ofNF-kappa-B with the specific adapters RIPK1 and TRAF6.Participates in TNF-dependent transactivation of NF-kappa-B byphosphorylating and activating IKBKB kinase, which in turn leadsto the degradation of NF-kappa-B inhibitors. In migratingastrocytes, forms a cytoplasmic complex with PARD6A and isrecruited by CDC42 to function in the establishment of cellpolarity along with the microtubule motor and dynein. Inassociation with FEZ1, stimulates neuronal differentiation in PC12cells. In the inflammatory response, is required for the T-helper2 (Th2) differentiation process, including interleukin production,efficient activation of JAK1 and the subsequent phosphorylationand nuclear translocation of STAT6. May be involved in developmentof allergic airway inflammation (asthma), a process dependent onTh2 immune response. In the NF-kappa-B-mediated inflammatoryresponse, can relieve SETD6-dependent repression of NF-kappa-Btarget genes by phosphorylating the RELA subunit at 'Ser-311'.Necessary and sufficient for LTP maintenance in hippocampal CA1pyramidal cells. In vein endothelial cells treated with theoxidant peroxynitrite, phosphorylates STK11 leading to nuclearexport of STK11, subsequent inhibition of PI3K/Akt signaling, andincreased apoptosis. Phosphorylates VAMP2 in vitro(PubMed:17313651). {ECO:0000269|PubMed:11035106,ECO:0000269|PubMed:12162751, ECO:0000269|PubMed:15084291,ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:9447975}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit anelevated basal enzymatic activity (that may be due to theinteraction with SMG1 or SQSTM1) and are not regulated bydiacylglycerol, phosphatidylserine, phorbol esters or calciumions. Two specific sites, Thr-410 (activation loop of the kinasedomain) and Thr-560 (turn motif), need to be phosphorylated forits full activation. Phosphatidylinositol 3,4,5-trisphosphatemight be a physiological activator (By similarity). {ECO:0000250}.SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Formsanother ternary complex with SQSTM1 and GABRR3. Forms a complexwith SQSTM1 and MAP2K5 (By similarity). Interacts with PARD6A,PARD6B, PARD6G and SQSTM1. Part of a complex with PARD3, PARD6A orPARD6B or PARD6G and CDC42 or RAC1. Interacts with ADAP1/CENTA1.Forms a ternary complex composed of SQSTM1 and PAWR. Interactsdirectly with SQSTM1 (Probable). Interacts with IKBKB. Interacts(via the protein kinase domain) with WWC1. Forms a tripartitecomplex with WWC1 and DDR1, but predominantly in the absence ofcollagen. Component of the Par polarity complex, composed of atleast phosphorylated PRKCZ, PARD3 and TIAM1. Interacts with PDPK1(via N-terminal region). Interacts with WDFY2 (via WD repeats 1-3)(PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). Forms acomplex with WDFY2 and VAMP2 (PubMed:17313651).{ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:11260256, ECO:0000269|PubMed:11755531,ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:12234671,ECO:0000269|PubMed:12887891, ECO:0000269|PubMed:12893243,ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:20332120,ECO:0000269|PubMed:9566925, ECO:0000305}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:9566925}. Endosome{ECO:0000269|PubMed:9566925}. Cell junction{ECO:0000269|PubMed:7597083}. Note=In the retina, localizes in theterminals of the rod bipolar cells. Associates with endosomes.Presence of KRIT1, CDH5 and RAP1B is required for its localizationto the cell junction. Colocalizes with VAMP2 and WDFY2 inintracellular vesicles. {ECO:0000269|PubMed:17313651}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=Q05513-1; Sequence=Displayed;Name=2;IsoId=Q05513-2; Sequence=VSP_041904;Name=3;IsoId=Q05513-3; Sequence=VSP_046347;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent inlung, kidney and testis.DOMAIN: The PB1 domain mediate mutually exclusive interactionswith SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}.DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).{ECO:0000269|PubMed:12887891}.PTM: CDH5 is required for its phosphorylation at Thr-410.Phosphorylated by protein kinase PDPK1; phosphorylation isinhibited by the apoptotic C-terminal cleavage product of PKN2.Phosphorylation at Thr-410 by PI3K activates the kinase.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15314172,ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361}.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA78813.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5590"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002735"],["bp:comment","REPLACED ProteinRef_PRKCZ__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5590"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-1"],["bp:comment","REPLACED ProteinRef_PRKCZ__40674"],["bp:comment","KPCZ_HUMAN Reviewed; 592 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80618"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80617"]]}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0_Complex_8799cc43e9e7f7445aeab812fde3e343","class":"simple chemical","label":"ceramide","parent":"Complex_8799cc43e9e7f7445aeab812fde3e343","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":402.81793,"y":953.6438,"w":48,"h":20},"metadata":[["bp:displayName","ceramide"],["bp:entityReference_#SmallMoleculeReference_1d280ce6fe2b3517f5f99e34d1cf04aa",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19927"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_59fb117d659897cb0b3ea82ec3e1823d_Complex_8799cc43e9e7f7445aeab812fde3e343","class":"macromolecule","label":"PRKCZ","parent":"Complex_8799cc43e9e7f7445aeab812fde3e343","clonemarker":false,"stateVariables":[{"id":"Protein_59fb117d659897cb0b3ea82ec3e1823d_Complex_8799cc43e9e7f7445aeab812fde3e343.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":402.81793,"y":921.1438,"w":48,"h":25},"metadata":[["bp:displayName","PKC zeta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20868"]]],["bp:entityReference_http://identifiers.org/uniprot/Q05513",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_Q05513"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_Q05513"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 591 591 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","591"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 591 591 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","591"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 591 591 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","591"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:xref","Protein kinase C zeta type"],["bp:organism","Protein kinase C zeta type"],["bp:displayName","KPCZ_HUMAN"],["bp:name","nPKC-zeta"],["bp:name","PRKCZ"],["bp:name","2.7.11.13"],["bp:name","PKC2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_457"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01504_identity"],["bp:comment","REPLACED ProteinRef_PRKCZ__9606"],["bp:comment","FUNCTION: Calcium- and diacylglycerol-independentserine/threonine-protein kinase that functions inphosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activatedprotein (MAP) kinase cascade, and is involved in NF-kappa-Bactivation, mitogenic signaling, cell proliferation, cellpolarity, inflammatory response and maintenance of long-termpotentiation (LTP). Upon lipopolysaccharide (LPS) treatment inmacrophages, or following mitogenic stimuli, functions downstreamof PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascadeindependently of RAF1 activation. Required for insulin-dependentactivation of AKT3, but may function as an adapter rather than adirect activator. Upon insulin treatment may act as a downstreameffector of PI3K and contribute to the activation of translocationof the glucose transporter SLC2A4/GLUT4 and subsequent glucosetransport in adipocytes. In EGF-induced cells, binds and activatesMAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity andcan activate JUN promoter through MEF2C. Through binding withSQSTM1/p62, functions in interleukin-1 signaling and activation ofNF-kappa-B with the specific adapters RIPK1 and TRAF6.Participates in TNF-dependent transactivation of NF-kappa-B byphosphorylating and activating IKBKB kinase, which in turn leadsto the degradation of NF-kappa-B inhibitors. In migratingastrocytes, forms a cytoplasmic complex with PARD6A and isrecruited by CDC42 to function in the establishment of cellpolarity along with the microtubule motor and dynein. Inassociation with FEZ1, stimulates neuronal differentiation in PC12cells. In the inflammatory response, is required for the T-helper2 (Th2) differentiation process, including interleukin production,efficient activation of JAK1 and the subsequent phosphorylationand nuclear translocation of STAT6. May be involved in developmentof allergic airway inflammation (asthma), a process dependent onTh2 immune response. In the NF-kappa-B-mediated inflammatoryresponse, can relieve SETD6-dependent repression of NF-kappa-Btarget genes by phosphorylating the RELA subunit at 'Ser-311'.Necessary and sufficient for LTP maintenance in hippocampal CA1pyramidal cells. In vein endothelial cells treated with theoxidant peroxynitrite, phosphorylates STK11 leading to nuclearexport of STK11, subsequent inhibition of PI3K/Akt signaling, andincreased apoptosis. Phosphorylates VAMP2 in vitro(PubMed:17313651). {ECO:0000269|PubMed:11035106,ECO:0000269|PubMed:12162751, ECO:0000269|PubMed:15084291,ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:9447975}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit anelevated basal enzymatic activity (that may be due to theinteraction with SMG1 or SQSTM1) and are not regulated bydiacylglycerol, phosphatidylserine, phorbol esters or calciumions. Two specific sites, Thr-410 (activation loop of the kinasedomain) and Thr-560 (turn motif), need to be phosphorylated forits full activation. Phosphatidylinositol 3,4,5-trisphosphatemight be a physiological activator (By similarity). {ECO:0000250}.SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Formsanother ternary complex with SQSTM1 and GABRR3. Forms a complexwith SQSTM1 and MAP2K5 (By similarity). Interacts with PARD6A,PARD6B, PARD6G and SQSTM1. Part of a complex with PARD3, PARD6A orPARD6B or PARD6G and CDC42 or RAC1. Interacts with ADAP1/CENTA1.Forms a ternary complex composed of SQSTM1 and PAWR. Interactsdirectly with SQSTM1 (Probable). Interacts with IKBKB. Interacts(via the protein kinase domain) with WWC1. Forms a tripartitecomplex with WWC1 and DDR1, but predominantly in the absence ofcollagen. Component of the Par polarity complex, composed of atleast phosphorylated PRKCZ, PARD3 and TIAM1. Interacts with PDPK1(via N-terminal region). Interacts with WDFY2 (via WD repeats 1-3)(PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). Forms acomplex with WDFY2 and VAMP2 (PubMed:17313651).{ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:11260256, ECO:0000269|PubMed:11755531,ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:12234671,ECO:0000269|PubMed:12887891, ECO:0000269|PubMed:12893243,ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:20332120,ECO:0000269|PubMed:9566925, ECO:0000305}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651,ECO:0000269|PubMed:9566925}. Endosome{ECO:0000269|PubMed:9566925}. Cell junction{ECO:0000269|PubMed:7597083}. Note=In the retina, localizes in theterminals of the rod bipolar cells. Associates with endosomes.Presence of KRIT1, CDH5 and RAP1B is required for its localizationto the cell junction. Colocalizes with VAMP2 and WDFY2 inintracellular vesicles. {ECO:0000269|PubMed:17313651}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=Q05513-1; Sequence=Displayed;Name=2;IsoId=Q05513-2; Sequence=VSP_041904;Name=3;IsoId=Q05513-3; Sequence=VSP_046347;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent inlung, kidney and testis.DOMAIN: The PB1 domain mediate mutually exclusive interactionswith SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}.DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).{ECO:0000269|PubMed:12887891}.PTM: CDH5 is required for its phosphorylation at Thr-410.Phosphorylated by protein kinase PDPK1; phosphorylation isinhibited by the apoptotic C-terminal cleavage product of PKN2.Phosphorylation at Thr-410 by PI3K activates the kinase.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15314172,ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361}.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA78813.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5590"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002735"],["bp:comment","REPLACED ProteinRef_PRKCZ__10090"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5590"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q05513-1"],["bp:comment","REPLACED ProteinRef_PRKCZ__40674"],["bp:comment","KPCZ_HUMAN Reviewed; 592 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_22390"]]}},{"data":{"id":"ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1319.6656,"y":1041.4106,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80921"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80921"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80921"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80921"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80921"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80921"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80921"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80921"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Caspase 8"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80668"],["bp:featureLocation",[["bp:sequencePosition","334"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14221"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14790",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1369"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80667"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80921"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80912"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80912"]]}},{"data":{"id":"Protein_5baa21cbcb67644b7ea848eb02cc8edd","class":"macromolecule","label":"CRADD","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1298.234,"y":340.63287,"w":48,"h":25},"metadata":[["bp:displayName","RAIDD"],["bp:entityReference_http://identifiers.org/uniprot/P78560",[["bp:standardName","Death domain-containing protein CRADD"],["bp:xref",[["bp:id","P78560"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CRADD"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","CRADD"],["bp:db","hgnc symbol"]]],["bp:displayName","CRADD_HUMAN"],["bp:name","CRADD"],["bp:name","RIP-associated protein with a death domain"],["bp:name","RAIDD"],["bp:name","Caspase and RIP adapter with death domain"],["bp:comment","CRADD_HUMAN Reviewed; 199 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003796"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8738"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_8738"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04584_identity"],["bp:comment","FUNCTION: Apoptotic adaptor molecule specific for caspase-2 andFASL/TNF receptor-interacting protein RIP. In the presence of RIPand TRADD, CRADD recruits caspase-2 to the TNFR-1 signallingcomplex.SUBUNIT: Interacts with PIDD. {ECO:0000269|PubMed:15073321,ECO:0000269|PubMed:16652156}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P78560-1; Sequence=Displayed;Name=2;IsoId=P78560-2; Sequence=VSP_056892;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Constitutively expressed in most tissues, withparticularly high expression in adult heart, testis, liver,skeletal muscle, fetal liver and kidney.DOMAIN: Contains a death domain involved in the binding of RIPprotein.DOMAIN: The CARD domain mediates the interaction with caspase-2.DISEASE: Mental retardation, autosomal recessive 34, with variantlissencephaly (MRT34) [MIM:614499]: A disorder characterized bysignificantly below average general intellectual functioningassociated with impairments in adaptive behavior and manifestedduring the developmental period. MRT34 is a non-syndromic form.Affected individuals have mildly delayed development andsignificantly impaired cognitive function, precluding independentliving and self-care. Speech is rudimentary, but articulate;autism is not present. {ECO:0000269|PubMed:22279524}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1556"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":216.83875,"y":673.2974,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","KSR"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80600"],["bp:featureLocation",[["bp:sequencePosition","404"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16686"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22317"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q8IVT5",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80851"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","KSR"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80600"],["bp:featureLocation",[["bp:sequencePosition","404"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16686"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22317"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q8IVT5",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80851"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","KSR"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80600"],["bp:featureLocation",[["bp:sequencePosition","404"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16686"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22317"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q8IVT5",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80851"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","KSR"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80600"],["bp:featureLocation",[["bp:sequencePosition","404"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16686"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22317"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q8IVT5",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80851"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","KSR"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80600"],["bp:featureLocation",[["bp:sequencePosition","404"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16686"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22317"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q8IVT5",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80851"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","KSR"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80600"],["bp:featureLocation",[["bp:sequencePosition","404"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16686"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22317"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q8IVT5",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80599"],["bp:featureLocation",[["bp:sequencePosition","309"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6891"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80598"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80851"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80848"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80848"]]}},{"data":{"id":"ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":392.02,"y":849.3047,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80803"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80803"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80803"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80803"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80803"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80803"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80803"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80803"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80801"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80801"]]}},{"data":{"id":"Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","class":"complex","label":"TNFR1A/BAG4/TNF-alpha","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1204.5607,"y":293.42712,"w":52,"h":89},"metadata":[["bp:displayName","TNFR1A/BAG4/TNF-alpha"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80765"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80765"]]}},{"data":{"id":"Protein_12ce91dd41f0737ffb0898c71af2f854_Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","class":"macromolecule","label":"TNF","parent":"Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1204.5607,"y":323.42712,"w":48,"h":25},"metadata":[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNF"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P01375"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P01375"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]}},{"data":{"id":"Protein_12bcf51c75aae38cdb2620e757a2f48e_Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","class":"macromolecule","label":"TNFRSF1A","parent":"Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1204.5607,"y":293.42712,"w":48,"h":25},"metadata":[["bp:displayName","TNFR1A"],["bp:entityReference_http://identifiers.org/uniprot/P19438",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19438"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19438"]]],["bp:standardName","Tumor necrosis factor receptor superfamily member 1A"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNFRSF1A"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19438"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNR1A_HUMAN"],["bp:name","TNFR1"],["bp:name","TNFRSF1A"],["bp:name","p60"],["bp:name","Tumor necrosis factor receptor type I"],["bp:name","TNF-R1"],["bp:name","TNFAR"],["bp:name","Tumor necrosis factor-binding protein 1"],["bp:name","TBPI"],["bp:name","CD120a"],["bp:name","Tumor necrosis factor receptor 1"],["bp:name","TNFR-I"],["bp:name","p55"],["bp:name","Tumor necrosis factor receptor superfamily member 1A, membrane form"],["bp:name","TNF-RI"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10090"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__40674"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7132"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001056"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_4952"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1FT4_see-also"],["bp:comment","TNR1A_HUMAN Reviewed; 455 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7132"],["bp:comment","REPLACED ProteinRef_TNFRSF1A__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-407N_identity"],["bp:comment","FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimericTNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruitscaspase-8 to the activated receptor. The resulting death-inducingsignaling complex (DISC) performs caspase-8 proteolytic activationwhich initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes tothe induction of non-cytocidal TNF effects including anti-viralstate and activation of the acid sphingomyelinase.SUBUNIT: Binding of TNF to the extracellular domain leads tohomotrimerization. The aggregated death domains provide a novelmolecular interface that interacts specifically with the deathdomain of TRADD. Various TRADD-interacting proteins such as TRAFS,RIPK1 and possibly FADD, are recruited to the complex by theirassociation with TRADD. This complex activates at least twodistinct signaling cascades, apoptosis and NF-kappa-B signaling.Interacts with BAG4, BABAM2, FEM1B, GRB2, SQSTM1 and TRPC4AP.Interacts with HCV core protein. Interacts with humancytomegalovirus/HHV-5 protein UL138. Interacts directly with NOL3(via CARD domain); inhibits TNF-signaling pathway (By similarity).{ECO:0000250|UniProtKB:P25118, ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10359574, ECO:0000269|PubMed:10542291,ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:21976655,ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9557650,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.Secreted {ECO:0000269|PubMed:22801493}. Note=A secreted form isproduced through proteolytic processing.SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Name=1; Synonyms=FL-TNFR1;IsoId=P19438-1; Sequence=Displayed;Name=2;IsoId=P19438-2; Sequence=VSP_037153;Note=No experimental confirmation available.;Name=4; Synonyms=Delta6-TNFR1;IsoId=P19438-4; Sequence=VSP_044949;Note=Disease-associated isoform. Isoform 4 splicing pattern isdriven by a variation in the exon 6/intron 6 boundary regionthat alters exon 6 splicing. Exon 6 skipping introduces aframeshift and the translation of a protein lacking theintracellular, the transmembrane and part of the extracellulardomain.;Name=3;IsoId=P19438-3; Sequence=VSP_037154;Note=No experimental confirmation available.;Name=5;IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;Note=No experimental confirmation available.;DOMAIN: The domain that induces A-SMASE is probably identical tothe death domain. The N-SMASE activation domain (NSD) is bothnecessary and sufficient for activation of N-SMASE.DOMAIN: Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in theinteraction with TRPC4AP. {ECO:0000250}.PTM: The soluble form is produced from the membrane form byproteolytic processing.DISEASE: Familial hibernian fever (FHF) [MIM:142680]: A hereditaryperiodic fever syndrome characterized by recurrent fever,abdominal pain, localized tender skin lesions and myalgia.Reactive amyloidosis is the main complication and occurs in 25% ofcases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757,ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484,ECO:0000269|PubMed:14610673}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: Amultifactorial, inflammatory, demyelinating disease of the centralnervous system. Sclerotic lesions are characterized byperivascular infiltration of monocytes and lymphocytes and appearas indurated areas in pathologic specimens (sclerosis in plaques).The pathological mechanism is regarded as an autoimmune attack ofthe myelin sheath, mediated by both cellular and humoral immunity.Clinical manifestations include visual loss, extra-ocular movementdisorders, paresthesias, loss of sensation, weakness, dysarthria,spasticity, ataxia and bladder dysfunction. Genetic andenvironmental factors influence susceptibility to the disease.{ECO:0000269|PubMed:22801493}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry. An intronic mutation affecting alternative splicing andskipping of exon 6 directs increased expression of isoform 4 atranscript encoding a C-terminally truncated protein which issecreted and may function as a TNF antagonist.WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditaryautoinflammatory disorders mutations;URL=\"http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnfrsf1a/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01861_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1739"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_89f70a1844b25ec5984cf26a32b0e470_Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","class":"macromolecule","label":"BAG4","parent":"Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1204.5607,"y":263.42712,"w":48,"h":25},"metadata":[["bp:displayName","BAG4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O95429",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Omega-N-methylarginine"],["bp:term","Omega-N-methylarginine"]]],["bp:comment","MOD_RES 185 185 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 53 53 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","53"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 108 108 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 108 108 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 108 108 Omega-N-methylarginine."],["bp:featureLocation",[["bp:sequencePosition","108"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","BAG family molecular chaperone regulator 4"],["bp:xref","BAG family molecular chaperone regulator 4"],["bp:xref","BAG family molecular chaperone regulator 4"],["bp:organism","BAG family molecular chaperone regulator 4"],["bp:displayName","BAG4_HUMAN"],["bp:name","Bcl-2-associated athanogene 4"],["bp:name","BAG-4"],["bp:name","Silencer of death domains"],["bp:name","SODD"],["bp:name","BAG4"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9530"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9530"],["bp:comment","FUNCTION: Inhibits the chaperone activity of HSP70/HSC70 bypromoting substrate release (By similarity). Prevents constitutiveTNFRSF1A signaling. Negative regulator of PRKN translocation todamaged mitochondria. {ECO:0000250, ECO:0000269|PubMed:24270810}.SUBUNIT: Binds to the ATPase domain of HSP/HSC70 chaperones. Bindsto the death domain of TNFRSF1A in the absence of TNF and therebyprevents binding of adapter molecules such as TRADD or TRAF2.Binds to the death domain of TNFRSF12. Interacts with PRKN.{ECO:0000269|PubMed:12058034, ECO:0000269|PubMed:24270810,ECO:0000269|PubMed:9915703}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=O95429-1; Sequence=Displayed;Name=2;IsoId=O95429-2; Sequence=VSP_042741;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004865"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04861_identity"],["bp:comment","BAG4_HUMAN Reviewed; 457 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80762"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80762"]]}},{"data":{"id":"Protein_54746a7dd41afff1181c13d616c2ce5a","class":"macromolecule","label":"MADD","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1318.0543,"y":380.3965,"w":48,"h":25},"metadata":[["bp:displayName","MADD"],["bp:entityReference_http://identifiers.org/uniprot/Q8WXG6",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 689 689 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","689"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 916 916 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","916"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 156 156 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","156"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 858 858 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","858"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:xref","MAP kinase-activating death domain protein"],["bp:organism","MAP kinase-activating death domain protein"],["bp:displayName","MADD_HUMAN"],["bp:name","Insulinoma glucagonoma clone 20"],["bp:name","MADD"],["bp:name","Rab3 GDP/GTP exchange factor"],["bp:name","Differentially expressed in normal and neoplastic cells"],["bp:name","DENN"],["bp:name","IG20"],["bp:name","KIAA0358"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_8567"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q8WXG6_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04664_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q8WXG6-3"],["bp:comment","MADD_HUMAN Reviewed; 1647 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005253253"],["bp:comment","FUNCTION: Plays a significant role in regulating cellproliferation, survival and death through alternative mRNAsplicing. Isoform 5 shows increased cell proliferation and isoform2 shows decreased. Converts GDP-bound inactive form of RAB3A,RAB3C and RAB3D to the GTP-bound active forms. Component of theTNFRSF1A signaling complex: MADD links TNFRSF1A with MAP kinaseactivation. Plays an important regulatory role in physiologicalcell death (TNF-alpha-induced, caspase-mediated apoptosis);isoform 1 is susceptible to inducing apoptosis, isoform 5 isresistant and isoform 3 and isoform 4 have no effect.{ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:14735464, ECO:0000269|PubMed:15007167,ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:9115275}.SUBUNIT: Interacts with the death domain of TNFRSF1A through itsown death domain. Interacts with PIDD1.{ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,ECO:0000269|PubMed:9115275}.SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:8988362}.Cytoplasm {ECO:0000269|PubMed:8988362}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=8;Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:11577081}, IG20-FL{ECO:0000269|PubMed:14716293};IsoId=Q8WXG6-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20{ECO:0000269|PubMed:14716293}, IG20-PA{ECO:0000269|PubMed:11577081}, IG20-PASV{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,ECO:0000269|PubMed:9796103}; Synonyms=DENN{ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}, IG20-SV1{ECO:0000269|PubMed:14716293}, MADD {ECO:0000269|PubMed:9115275};IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,VSP_052296;Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296;Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4{ECO:0000269|PubMed:11577081};IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_052296, VSP_052297, VSP_052298;Name=7 {ECO:0000269|PubMed:9205841};IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;Name=8;IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,VSP_044848, VSP_052296;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in fetal brain and kidney;adult testis, ovary, brain and heart. Isoform 5 is constitutivelyexpressed in all tissues. Isoform 7 is expressed in fetal liverand in several cancer cell lines. {ECO:0000269|PubMed:14716293,ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9796103}.MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulatedkinase (ERK). Expression of the MADD death domain stimulates boththe ERK and c-JUN N-terminal kinase MAP kinases and induces thephosphorylation of cytosolic phospholipase A2.{ECO:0000269|PubMed:9115275}.SIMILARITY: Belongs to the MADD family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA20814.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1568"]]}},{"data":{"id":"Protein_0f0869ad9967fc9881a0254f5ab0f721","class":"macromolecule","label":"BCL2","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_0f0869ad9967fc9881a0254f5ab0f721.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":49.901039999999995,"y":365.58258,"w":48,"h":25},"metadata":[["bp:displayName","BCL2"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10287"]]],["bp:entityReference_http://identifiers.org/uniprot/P10415",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 87 87 Phosphoserine; by MAPK8."],["bp:featureLocation",[["bp:sequencePosition","87"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P10415"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10415"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10415"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10415"]]],["bp:standardName","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:xref","Apoptosis regulator Bcl-2"],["bp:organism","Apoptosis regulator Bcl-2"],["bp:displayName","BCL2_HUMAN"],["bp:name","BCL2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YSW_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10415-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000624"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q07813"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_596"],["bp:comment","REPLACED ProteinRef_BCL2__9606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01045_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-1043N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10415_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_596"],["bp:comment","REPLACED ProteinRef_BCL2__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000648"],["bp:comment","FUNCTION: Suppresses apoptosis in a variety of cell systemsincluding factor-dependent lymphohematopoietic and neural cells.Regulates cell death by controlling the mitochondrial membranepermeability. Appears to function in a feedback loop system withcaspases. Inhibits caspase activity either by preventing therelease of cytochrome c from the mitochondria and/or by binding tothe apoptosis-activating factor (APAF-1). May attenuateinflammation by impairing NLRP1-inflammasome activation, henceCASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18570871}.SUBUNIT: Forms homodimers, and heterodimers with BAX, BAD, BAK andBcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2motifs, and is necessary for anti-apoptotic activity(PubMed:8183370). Interacts with EI24 (By similarity). Alsointeracts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2.Binding to FKBP8 seems to target BCL2 to the mitochondria andprobably interferes with the binding of BCL2 to its targets.Interacts with BAG1 in an ATP-dependent manner. Interacts withRAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts(via the BH4 domain) with EGLN3; the interaction prevents theformation of the BAX-BCL2 complex and inhibits the anti-apoptoticactivity of BCL2. Interacts with G0S2; this interaction alsoprevents the formation of the anti-apoptotic BAX-BCL2 complex.Interacts with BOP. Interacts with the SCF(FBXO10) complex.Interacts (via the loop between motifs BH4 and BH3) with NLRP1(via LRR repeats), but not with NLRP2, NLRP3, NLRP4, PYCARD, norMEFV (PubMed:17418785). {ECO:0000250, ECO:0000269|PubMed:11463391,ECO:0000269|PubMed:12901880, ECO:0000269|PubMed:15547950,ECO:0000269|PubMed:15733859, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:17090549, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:19228691, ECO:0000269|PubMed:19706769,ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:23055042,ECO:0000269|PubMed:23431138, ECO:0000269|PubMed:8183370,ECO:0000269|PubMed:8668206, ECO:0000269|PubMed:9305631}.SUBCELLULAR LOCATION: Mitochondrion outer membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Nucleus membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}. Endoplasmic reticulum membrane{ECO:0000269|PubMed:2250705}; Single-pass membrane protein{ECO:0000269|PubMed:2250705}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=Alpha;IsoId=P10415-1; Sequence=Displayed;Name=Beta;IsoId=P10415-2; Sequence=VSP_000512;Note=Ref.1 (AAA51814) sequence is in conflict in position:199:L->S. {ECO:0000305};TISSUE SPECIFICITY: Expressed in a variety of tissues.DOMAIN: BH1 and BH2 domains are required for the interaction withBAX and for anti-apoptotic activity. {ECO:0000269|PubMed:8183370}.DOMAIN: The BH4 motif is required for anti-apoptotic activity andfor interaction with RAF1 and EGLN3.DOMAIN: The loop between motifs BH4 and BH3 is required for theinteraction with NLRP1. {ECO:0000269|PubMed:17418785}.PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation onSer-70 by PKC is required for the anti-apoptosis activity andoccurs during the G2/M phase of the cell cycle. In the absence ofgrowth factors, BCL2 appears to be phosphorylated by other proteinkinases such as ERKs and stress-activated kinases. Phosphorylatedby MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulatesstarvation-induced autophagy. Dephosphorylated by proteinphosphatase 2A (PP2A) (By similarity). {ECO:0000250}.PTM: Proteolytically cleaved by caspases during apoptosis. Thecleaved protein, lacking the BH4 motif, has pro-apoptoticactivity, causes the release of cytochrome c into the cytosolpromoting further caspase activity. {ECO:0000269|PubMed:9395403}.PTM: Monoubiquitinated by PRKN, leading to increase its stability.Ubiquitinated by SCF(FBXO10), leading to its degradation by theproteasome. {ECO:0000269|PubMed:20889974,ECO:0000269|PubMed:23431138}.DISEASE: Note=A chromosomal aberration involving BCL2 has beenfound in chronic lymphatic leukemia. Translocationt(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutationsfound in non-Hodgkin lymphomas carrying the chromosomaltranslocation could be attributed to the Ig somatic hypermutationmechanism resulting in nucleotide transitions.{ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL2ID49.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/bcl2/\";WEB RESOURCE: Name=Wikipedia; Note=Bcl-2 entry;URL=\"https://en.wikipedia.org/wiki/Bcl-2\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_925"],["bp:comment","REPLACED http://identifiers.org/ncbigene/596"],["bp:comment","BCL2_HUMAN Reviewed; 239 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10286"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_10286"]]}},{"data":{"id":"SmallMolecule_8f22a0884f4372e32e806e7aea071f44","class":"simple chemical","label":"sphingomyelin","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":563.7625,"y":264.28975,"w":48,"h":20},"metadata":[["bp:displayName","sphingomyelin"],["bp:entityReference_#SmallMoleculeReference_218aa1729347498918c05a239eb03b03",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20069"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Complex_e31100abd4d98b273704d6bdd2524fee","class":"complex","label":"PP2A Heterotrimer","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":179.75526,"y":448.92728,"w":48,"h":20},"metadata":[["bp:displayName","PP2A Heterotrimer"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80935"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":609.3871,"y":493.7318,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","AIF"],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80522"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80522"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80692"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","AIF"],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80522"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80522"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80692"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","AIF"],["bp:entityReference_http://identifiers.org/uniprot/O95831",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 521 521 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","521"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 105 105 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","105"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 268 268 Phosphoserine."],["bp:featureLocation","MOD_RES 268 268 Phosphoserine."]]],["bp:standardName","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:xref","Apoptosis-inducing factor 1, mitochondrial"],["bp:organism","Apoptosis-inducing factor 1, mitochondrial"],["bp:displayName","AIFM1_HUMAN"],["bp:name","Programmed cell death protein 8"],["bp:name","AIFM1"],["bp:name","AIF"],["bp:name","PDCD8"],["bp:name","1.1.1.-"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1M6I_see-also"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_9131"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_9131"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32975N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02161_identity"],["bp:comment","AIFM1_HUMAN Reviewed; 613 AA."],["bp:comment","FUNCTION: Functions both as NADH oxidoreductase and as regulatorof apoptosis. In response to apoptotic stimuli, it is releasedfrom the mitochondrion intermembrane space into the cytosol and tothe nucleus, where it functions as a proapoptotic factor in acaspase-independent pathway. In contrast, functions as anantiapoptotic factor in normal mitochondria via its NADHoxidoreductase activity. The soluble form (AIFsol) found in thenucleus induces 'parthanatos' i.e. caspase-independentfragmentation of chromosomal DNA. Interacts with EIF3G,and therebyinhibits the EIF3 machinery and protein synthesis, and activatescasapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposedcells. Binds to DNA in a sequence-independent manner.{ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225,ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.COFACTOR:Name=FAD; Xref=ChEBI:CHEBI:57692;Evidence={ECO:0000269|PubMed:23217327};BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.53 mM for NADH {ECO:0000269|PubMed:23217327};KM=26 uM for cytochrome c {ECO:0000269|PubMed:23217327};SUBUNIT: Monomer (oxidized form). Homodimer (reduced form). Alsodimerizes with isoform 3 preventing its release from mitochondria.Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G(via C-terminus). Interacts with PRELID1.{ECO:0000269|PubMed:12198487, ECO:0000269|PubMed:17094969,ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:20111043,ECO:0000269|PubMed:21364629, ECO:0000269|PubMed:23217327}.SUBCELLULAR LOCATION: Mitochondrion intermembrane space.Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm,perinuclear region. Note=Proteolytic cleavage during or just aftertranslocation into the mitochondrial intermembrane space (IMS)results in the formation of an inner-membrane-anchored mature form(AIFmit). During apoptosis, further proteolytic processing leadsto a mature form, which is confined to the mitochondrial IMS in asoluble form (AIFsol). AIFsol is released to the cytoplasm inresponse to specific death signals, and translocated to thenucleus, where it induces nuclear apoptosis. Colocalizes withEIF3G in the nucleus and perinuclear region.SUBCELLULAR LOCATION: Isoform 3: Mitochondrion intermembrane space{ECO:0000269|PubMed:20111043}. Mitochondrion inner membrane{ECO:0000269|PubMed:20111043}. Note=Has a stronger membraneanchorage than isoform 1.SUBCELLULAR LOCATION: Isoform 5: Cytoplasm{ECO:0000269|PubMed:16365034}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Name=1; Synonyms=AIF;IsoId=O95831-1; Sequence=Displayed;Name=2;IsoId=O95831-2; Sequence=VSP_004357;Name=3; Synonyms=AIF-exB, AIF2;IsoId=O95831-3; Sequence=VSP_022953;Note=Brain-specific.;Name=4; Synonyms=AIFsh2;IsoId=O95831-4; Sequence=VSP_043637, VSP_043638;Note=Does not induce nuclear apoptosis.;Name=5; Synonyms=AIFsh;IsoId=O95831-5; Sequence=VSP_046248;Note=Pro-apoptotic isoform, strongly down-regulated in manytumor cells, up-regulated by gamma-irradiation.;Name=6;IsoId=O95831-6; Sequence=VSP_047646, VSP_043637, VSP_043638;TISSUE SPECIFICITY: Detected in muscle and skin fibroblasts (atprotein level). Isoform 5 is frequently down-regulated in humancancers. {ECO:0000269|PubMed:16365034,ECO:0000269|PubMed:23217327}.PTM: Under normal conditions, a 54-residue N-terminal segment isfirst proteolytically removed during or just after translocationinto the mitochondrial intermembrane space (IMS) by themitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it isfurther proteolytically processed at amino-acid position 101leading to the generation of the mature form, which is confined tothe mitochondrial IMS in a soluble form (AIFsol). AIFsol isreleased to the cytoplasm in response to specific death signals,and translocated to the nucleus, where it induces nuclearapoptosis in a caspase-independent manner.{ECO:0000269|PubMed:15775970}.PTM: Ubiquitination by XIAP/BIRC4 does not lead to proteasomaldegradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks itsability to bind DNA and induce chromatin degradation, therebyinhibiting its ability to induce cell death.{ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:22103349}.DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6)[MIM:300816]: A mitochondrial disease resulting in aneurodegenerative disorder characterized by psychomotor delay,hypotonia, areflexia, muscle weakness and wasting. Some patientsmanifest prenatal ventriculomegaly and severe postnatalencephalomyopathy. {ECO:0000269|PubMed:20362274,ECO:0000269|PubMed:22019070}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linkedrecessive neuromuscular disorder characterized by early childhoodonset of a slowly progressive axonal sensorimotor neuropathyassociated in some patients with sensorineural deafness andcognitive impairment. {ECO:0000269|PubMed:23217327}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form ofhearing loss characterized by absent or severely abnormal auditorybrainstem response, abnormal middle ear reflexes, abnormal speechdiscrimination, loss of outer hair cell function, and cochlearnerve hypoplasia. DFNX5 patients manifest auditory neuropathy withchildhood onset, associated with distal sensory impairmentaffecting the peripheral nervous system.{ECO:0000269|PubMed:25986071}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the FAD-dependent oxidoreductase family.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/AIFM1ID44053chXq25.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O95831-3"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80522"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80522"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80692"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80691"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80691"]]}},{"data":{"id":"BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":478.28912,"y":172.85681,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKR"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63229"]]],["bp:entityReference_http://identifiers.org/uniprot/P19525",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 293 293 Phosphotyrosine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","293"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:standardName","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:organism","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:displayName","E2AK2_HUMAN"],["bp:name","PKR"],["bp:name","2.7.11.1"],["bp:name","p68 kinase"],["bp:name","Protein kinase RNA-activated"],["bp:name","Eukaryotic translation initiation factor 2-alpha kinase 2"],["bp:name","Tyrosine-protein kinase EIF2AK2"],["bp:name","EIF2AK2"],["bp:name","Protein kinase R"],["bp:name","PRKR"],["bp:name","P1/eIF-2A protein kinase"],["bp:name","2.7.10.2"],["bp:name","Interferon-inducible RNA-dependent protein kinase"],["bp:name","eIF-2A protein kinase 2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002750"],["bp:comment","E2AK2_HUMAN Reviewed; 551 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P19525_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A19_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5610"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2657N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011531289"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5610"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20459"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01468_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_646"],["bp:comment","FUNCTION: IFN-induced dsRNA-dependent serine/threonine-proteinkinase which plays a key role in the innate immune response toviral infection and is also involved in the regulation of signaltransduction, apoptosis, cell proliferation and differentiation.Exerts its antiviral activity on a wide range of DNA and RNAviruses including hepatitis C virus (HCV), hepatitis B virus(HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1).Inhibits viral replication via phosphorylation of the alphasubunit of eukaryotic initiation factor 2 (EIF2S1), thisphosphorylation impairs the recycling of EIF2S1 between successiverounds of initiation leading to inhibition of translation whicheventually results in shutdown of cellular and viral proteinsynthesis. Also phosphorylates other substrates includingp53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral proteinUS11. In addition to serine/threonine-protein kinase activity,also has tyrosine-protein kinase activity and phosphorylates CDK1at 'Tyr-4' upon DNA damage, facilitating its ubiquitination andproteosomal degradation. Either as an adapter protein and/or viaits kinase activity, can regulate various signaling pathways (p38MAP kinase, NF-kappa-B and insulin signaling pathways) andtranscription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved inthe expression of genes encoding proinflammatory cytokines andIFNs. Activates the NF-kappa-B pathway via interaction with IKBKBand TRAF family of proteins and activates the p38 MAP kinasepathway via interaction with MAP2K6. Can act as both a positiveand negative regulator of the insulin signaling pathway (ISP).Negatively regulates ISP by inducing the inhibitoryphosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5Awhich activates FOXO1, which in turn up-regulates the expressionof insulin receptor substrate 2 (IRS2). Can regulate NLRP3inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 andNLRC4 inflammasomes. Can trigger apoptosis via FADD-mediatedactivation of CASP8. Plays a role in the regulation of thecytoskeleton by binding to gelsolin (GSN), sequestering theprotein in an inactive conformation away from actin.{ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Initially produced in an inactive form and isactivated by binding to viral dsRNA, which causes dimerization andautophosphorylation in the activation loop and stimulation offunction. ISGylation can activate it in the absence of viralinfection. Can also be activated by heparin, proinflammatorystimuli, growth factors, cytokines, oxidative stress and thecellular protein PRKRA. Activity is markedly stimulated bymanganese ions. Activation is blocked by the viral components HIV-1 Tat protein and large amounts of HIV-1 trans-activation response(TAR) RNA element as well as by the cellular proteins TARBP2,DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana virus (TOS)and Rift valley fever virus (RVFV) NSS which promote itsproteasomal degradation. Inhibited by vaccinia virus protein E3,probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.SUBUNIT: Homodimer. Interacts with STRBP (By similarity).Interacts with DNAJC3. Forms a complex with FANCA, FANCC, FANCGand HSP70. Interacts with ADAR/ADAR1. Interacts with IRS1 (Bysimilarity). The inactive form interacts with NCK1 and GSN.Interacts (via the kinase catalytic domain) with STAT3 (via SH2domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1,NLRP3, NLRC4 and AIM2. Interacts (via DRBM 1 domain) with DUS2L(via DRBM domain). Interacts with DHX9 (via N-terminus) and thisinteraction is dependent upon activation of the kinase.{ECO:0000250, ECO:0000269|PubMed:10390359,ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11438532,ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25740987,ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.SUBUNIT: (Microbial infection) Interacts with human herpes simplexvirus 1 (HHV-1) protein US11 in an RNA-dependent manner(PubMed:11836380). The inactive form interacts with Toscana virus(TOS) NSS (PubMed:23325696). Interacts with herpes virus 8 proteinv-IRF2; this interaction inhibits EIF2AK2 activation(PubMed:11160738). Interacts with vaccinia protein E3(PubMed:25740987). {ECO:0000269|PubMed:11160738,ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:23325696,ECO:0000269|PubMed:25740987}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, perinuclearregion. Note=Nuclear localization is elevated in acute leukemia,myelodysplastic syndrome (MDS), melanoma, breast, colon, prostateand lung cancer patient samples or cell lines as well asneurocytes from advanced Creutzfeldt-Jakob disease patients.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P19525-1; Sequence=Displayed;Name=2;IsoId=P19525-2; Sequence=VSP_046177;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bonemarrow compared to non-hematopoietic tissues such as smallintestine, liver, or kidney tissues. Colocalizes with GSK3B andTAU in the Alzheimer disease (AD) brain. Elevated levels seen inbreast and colon carcinomas,and which correlates with tumorprogression and invasiveness or risk of progression.{ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:23403623}.INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.PTM: Autophosphorylated on several Ser, Thr and Tyr residues.Autophosphorylation of Thr-451 is dependent on Thr-446 and isstimulated by dsRNA binding and dimerization. Autophosphorylationapparently leads to the activation of the kinase. Tyrosineautophosphorylation is essential for efficient dsRNA-binding,dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/prkr/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80879"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKR"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63229"]]],["bp:entityReference_http://identifiers.org/uniprot/P19525",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 293 293 Phosphotyrosine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","293"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:standardName","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:organism","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:displayName","E2AK2_HUMAN"],["bp:name","PKR"],["bp:name","2.7.11.1"],["bp:name","p68 kinase"],["bp:name","Protein kinase RNA-activated"],["bp:name","Eukaryotic translation initiation factor 2-alpha kinase 2"],["bp:name","Tyrosine-protein kinase EIF2AK2"],["bp:name","EIF2AK2"],["bp:name","Protein kinase R"],["bp:name","PRKR"],["bp:name","P1/eIF-2A protein kinase"],["bp:name","2.7.10.2"],["bp:name","Interferon-inducible RNA-dependent protein kinase"],["bp:name","eIF-2A protein kinase 2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002750"],["bp:comment","E2AK2_HUMAN Reviewed; 551 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P19525_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A19_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5610"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2657N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011531289"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5610"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20459"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01468_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_646"],["bp:comment","FUNCTION: IFN-induced dsRNA-dependent serine/threonine-proteinkinase which plays a key role in the innate immune response toviral infection and is also involved in the regulation of signaltransduction, apoptosis, cell proliferation and differentiation.Exerts its antiviral activity on a wide range of DNA and RNAviruses including hepatitis C virus (HCV), hepatitis B virus(HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1).Inhibits viral replication via phosphorylation of the alphasubunit of eukaryotic initiation factor 2 (EIF2S1), thisphosphorylation impairs the recycling of EIF2S1 between successiverounds of initiation leading to inhibition of translation whicheventually results in shutdown of cellular and viral proteinsynthesis. Also phosphorylates other substrates includingp53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral proteinUS11. In addition to serine/threonine-protein kinase activity,also has tyrosine-protein kinase activity and phosphorylates CDK1at 'Tyr-4' upon DNA damage, facilitating its ubiquitination andproteosomal degradation. Either as an adapter protein and/or viaits kinase activity, can regulate various signaling pathways (p38MAP kinase, NF-kappa-B and insulin signaling pathways) andtranscription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved inthe expression of genes encoding proinflammatory cytokines andIFNs. Activates the NF-kappa-B pathway via interaction with IKBKBand TRAF family of proteins and activates the p38 MAP kinasepathway via interaction with MAP2K6. Can act as both a positiveand negative regulator of the insulin signaling pathway (ISP).Negatively regulates ISP by inducing the inhibitoryphosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5Awhich activates FOXO1, which in turn up-regulates the expressionof insulin receptor substrate 2 (IRS2). Can regulate NLRP3inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 andNLRC4 inflammasomes. Can trigger apoptosis via FADD-mediatedactivation of CASP8. Plays a role in the regulation of thecytoskeleton by binding to gelsolin (GSN), sequestering theprotein in an inactive conformation away from actin.{ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Initially produced in an inactive form and isactivated by binding to viral dsRNA, which causes dimerization andautophosphorylation in the activation loop and stimulation offunction. ISGylation can activate it in the absence of viralinfection. Can also be activated by heparin, proinflammatorystimuli, growth factors, cytokines, oxidative stress and thecellular protein PRKRA. Activity is markedly stimulated bymanganese ions. Activation is blocked by the viral components HIV-1 Tat protein and large amounts of HIV-1 trans-activation response(TAR) RNA element as well as by the cellular proteins TARBP2,DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana virus (TOS)and Rift valley fever virus (RVFV) NSS which promote itsproteasomal degradation. Inhibited by vaccinia virus protein E3,probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.SUBUNIT: Homodimer. Interacts with STRBP (By similarity).Interacts with DNAJC3. Forms a complex with FANCA, FANCC, FANCGand HSP70. Interacts with ADAR/ADAR1. Interacts with IRS1 (Bysimilarity). The inactive form interacts with NCK1 and GSN.Interacts (via the kinase catalytic domain) with STAT3 (via SH2domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1,NLRP3, NLRC4 and AIM2. Interacts (via DRBM 1 domain) with DUS2L(via DRBM domain). Interacts with DHX9 (via N-terminus) and thisinteraction is dependent upon activation of the kinase.{ECO:0000250, ECO:0000269|PubMed:10390359,ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11438532,ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25740987,ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.SUBUNIT: (Microbial infection) Interacts with human herpes simplexvirus 1 (HHV-1) protein US11 in an RNA-dependent manner(PubMed:11836380). The inactive form interacts with Toscana virus(TOS) NSS (PubMed:23325696). Interacts with herpes virus 8 proteinv-IRF2; this interaction inhibits EIF2AK2 activation(PubMed:11160738). Interacts with vaccinia protein E3(PubMed:25740987). {ECO:0000269|PubMed:11160738,ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:23325696,ECO:0000269|PubMed:25740987}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, perinuclearregion. Note=Nuclear localization is elevated in acute leukemia,myelodysplastic syndrome (MDS), melanoma, breast, colon, prostateand lung cancer patient samples or cell lines as well asneurocytes from advanced Creutzfeldt-Jakob disease patients.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P19525-1; Sequence=Displayed;Name=2;IsoId=P19525-2; Sequence=VSP_046177;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bonemarrow compared to non-hematopoietic tissues such as smallintestine, liver, or kidney tissues. Colocalizes with GSK3B andTAU in the Alzheimer disease (AD) brain. Elevated levels seen inbreast and colon carcinomas,and which correlates with tumorprogression and invasiveness or risk of progression.{ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:23403623}.INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.PTM: Autophosphorylated on several Ser, Thr and Tyr residues.Autophosphorylation of Thr-451 is dependent on Thr-446 and isstimulated by dsRNA binding and dimerization. Autophosphorylationapparently leads to the activation of the kinase. Tyrosineautophosphorylation is essential for efficient dsRNA-binding,dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/prkr/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80879"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PKR"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63229"]]],["bp:entityReference_http://identifiers.org/uniprot/P19525",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 293 293 Phosphotyrosine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","293"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:standardName","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:organism","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:displayName","E2AK2_HUMAN"],["bp:name","PKR"],["bp:name","2.7.11.1"],["bp:name","p68 kinase"],["bp:name","Protein kinase RNA-activated"],["bp:name","Eukaryotic translation initiation factor 2-alpha kinase 2"],["bp:name","Tyrosine-protein kinase EIF2AK2"],["bp:name","EIF2AK2"],["bp:name","Protein kinase R"],["bp:name","PRKR"],["bp:name","P1/eIF-2A protein kinase"],["bp:name","2.7.10.2"],["bp:name","Interferon-inducible RNA-dependent protein kinase"],["bp:name","eIF-2A protein kinase 2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002750"],["bp:comment","E2AK2_HUMAN Reviewed; 551 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P19525_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A19_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5610"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2657N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011531289"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5610"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20459"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01468_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_646"],["bp:comment","FUNCTION: IFN-induced dsRNA-dependent serine/threonine-proteinkinase which plays a key role in the innate immune response toviral infection and is also involved in the regulation of signaltransduction, apoptosis, cell proliferation and differentiation.Exerts its antiviral activity on a wide range of DNA and RNAviruses including hepatitis C virus (HCV), hepatitis B virus(HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1).Inhibits viral replication via phosphorylation of the alphasubunit of eukaryotic initiation factor 2 (EIF2S1), thisphosphorylation impairs the recycling of EIF2S1 between successiverounds of initiation leading to inhibition of translation whicheventually results in shutdown of cellular and viral proteinsynthesis. Also phosphorylates other substrates includingp53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral proteinUS11. In addition to serine/threonine-protein kinase activity,also has tyrosine-protein kinase activity and phosphorylates CDK1at 'Tyr-4' upon DNA damage, facilitating its ubiquitination andproteosomal degradation. Either as an adapter protein and/or viaits kinase activity, can regulate various signaling pathways (p38MAP kinase, NF-kappa-B and insulin signaling pathways) andtranscription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved inthe expression of genes encoding proinflammatory cytokines andIFNs. Activates the NF-kappa-B pathway via interaction with IKBKBand TRAF family of proteins and activates the p38 MAP kinasepathway via interaction with MAP2K6. Can act as both a positiveand negative regulator of the insulin signaling pathway (ISP).Negatively regulates ISP by inducing the inhibitoryphosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5Awhich activates FOXO1, which in turn up-regulates the expressionof insulin receptor substrate 2 (IRS2). Can regulate NLRP3inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 andNLRC4 inflammasomes. Can trigger apoptosis via FADD-mediatedactivation of CASP8. Plays a role in the regulation of thecytoskeleton by binding to gelsolin (GSN), sequestering theprotein in an inactive conformation away from actin.{ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Initially produced in an inactive form and isactivated by binding to viral dsRNA, which causes dimerization andautophosphorylation in the activation loop and stimulation offunction. ISGylation can activate it in the absence of viralinfection. Can also be activated by heparin, proinflammatorystimuli, growth factors, cytokines, oxidative stress and thecellular protein PRKRA. Activity is markedly stimulated bymanganese ions. Activation is blocked by the viral components HIV-1 Tat protein and large amounts of HIV-1 trans-activation response(TAR) RNA element as well as by the cellular proteins TARBP2,DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana virus (TOS)and Rift valley fever virus (RVFV) NSS which promote itsproteasomal degradation. Inhibited by vaccinia virus protein E3,probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.SUBUNIT: Homodimer. Interacts with STRBP (By similarity).Interacts with DNAJC3. Forms a complex with FANCA, FANCC, FANCGand HSP70. Interacts with ADAR/ADAR1. Interacts with IRS1 (Bysimilarity). The inactive form interacts with NCK1 and GSN.Interacts (via the kinase catalytic domain) with STAT3 (via SH2domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1,NLRP3, NLRC4 and AIM2. Interacts (via DRBM 1 domain) with DUS2L(via DRBM domain). Interacts with DHX9 (via N-terminus) and thisinteraction is dependent upon activation of the kinase.{ECO:0000250, ECO:0000269|PubMed:10390359,ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11438532,ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25740987,ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.SUBUNIT: (Microbial infection) Interacts with human herpes simplexvirus 1 (HHV-1) protein US11 in an RNA-dependent manner(PubMed:11836380). The inactive form interacts with Toscana virus(TOS) NSS (PubMed:23325696). Interacts with herpes virus 8 proteinv-IRF2; this interaction inhibits EIF2AK2 activation(PubMed:11160738). Interacts with vaccinia protein E3(PubMed:25740987). {ECO:0000269|PubMed:11160738,ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:23325696,ECO:0000269|PubMed:25740987}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, perinuclearregion. Note=Nuclear localization is elevated in acute leukemia,myelodysplastic syndrome (MDS), melanoma, breast, colon, prostateand lung cancer patient samples or cell lines as well asneurocytes from advanced Creutzfeldt-Jakob disease patients.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P19525-1; Sequence=Displayed;Name=2;IsoId=P19525-2; Sequence=VSP_046177;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bonemarrow compared to non-hematopoietic tissues such as smallintestine, liver, or kidney tissues. Colocalizes with GSK3B andTAU in the Alzheimer disease (AD) brain. Elevated levels seen inbreast and colon carcinomas,and which correlates with tumorprogression and invasiveness or risk of progression.{ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:23403623}.INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.PTM: Autophosphorylated on several Ser, Thr and Tyr residues.Autophosphorylation of Thr-451 is dependent on Thr-446 and isstimulated by dsRNA binding and dimerization. Autophosphorylationapparently leads to the activation of the kinase. Tyrosineautophosphorylation is essential for efficient dsRNA-binding,dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/prkr/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80879"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","PKR"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63229"]]],["bp:entityReference_http://identifiers.org/uniprot/P19525",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 293 293 Phosphotyrosine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","293"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:standardName","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:organism","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:displayName","E2AK2_HUMAN"],["bp:name","PKR"],["bp:name","2.7.11.1"],["bp:name","p68 kinase"],["bp:name","Protein kinase RNA-activated"],["bp:name","Eukaryotic translation initiation factor 2-alpha kinase 2"],["bp:name","Tyrosine-protein kinase EIF2AK2"],["bp:name","EIF2AK2"],["bp:name","Protein kinase R"],["bp:name","PRKR"],["bp:name","P1/eIF-2A protein kinase"],["bp:name","2.7.10.2"],["bp:name","Interferon-inducible RNA-dependent protein kinase"],["bp:name","eIF-2A protein kinase 2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002750"],["bp:comment","E2AK2_HUMAN Reviewed; 551 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P19525_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A19_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5610"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2657N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011531289"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5610"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20459"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01468_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_646"],["bp:comment","FUNCTION: IFN-induced dsRNA-dependent serine/threonine-proteinkinase which plays a key role in the innate immune response toviral infection and is also involved in the regulation of signaltransduction, apoptosis, cell proliferation and differentiation.Exerts its antiviral activity on a wide range of DNA and RNAviruses including hepatitis C virus (HCV), hepatitis B virus(HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1).Inhibits viral replication via phosphorylation of the alphasubunit of eukaryotic initiation factor 2 (EIF2S1), thisphosphorylation impairs the recycling of EIF2S1 between successiverounds of initiation leading to inhibition of translation whicheventually results in shutdown of cellular and viral proteinsynthesis. Also phosphorylates other substrates includingp53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral proteinUS11. In addition to serine/threonine-protein kinase activity,also has tyrosine-protein kinase activity and phosphorylates CDK1at 'Tyr-4' upon DNA damage, facilitating its ubiquitination andproteosomal degradation. Either as an adapter protein and/or viaits kinase activity, can regulate various signaling pathways (p38MAP kinase, NF-kappa-B and insulin signaling pathways) andtranscription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved inthe expression of genes encoding proinflammatory cytokines andIFNs. Activates the NF-kappa-B pathway via interaction with IKBKBand TRAF family of proteins and activates the p38 MAP kinasepathway via interaction with MAP2K6. Can act as both a positiveand negative regulator of the insulin signaling pathway (ISP).Negatively regulates ISP by inducing the inhibitoryphosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5Awhich activates FOXO1, which in turn up-regulates the expressionof insulin receptor substrate 2 (IRS2). Can regulate NLRP3inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 andNLRC4 inflammasomes. Can trigger apoptosis via FADD-mediatedactivation of CASP8. Plays a role in the regulation of thecytoskeleton by binding to gelsolin (GSN), sequestering theprotein in an inactive conformation away from actin.{ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Initially produced in an inactive form and isactivated by binding to viral dsRNA, which causes dimerization andautophosphorylation in the activation loop and stimulation offunction. ISGylation can activate it in the absence of viralinfection. Can also be activated by heparin, proinflammatorystimuli, growth factors, cytokines, oxidative stress and thecellular protein PRKRA. Activity is markedly stimulated bymanganese ions. Activation is blocked by the viral components HIV-1 Tat protein and large amounts of HIV-1 trans-activation response(TAR) RNA element as well as by the cellular proteins TARBP2,DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana virus (TOS)and Rift valley fever virus (RVFV) NSS which promote itsproteasomal degradation. Inhibited by vaccinia virus protein E3,probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.SUBUNIT: Homodimer. Interacts with STRBP (By similarity).Interacts with DNAJC3. Forms a complex with FANCA, FANCC, FANCGand HSP70. Interacts with ADAR/ADAR1. Interacts with IRS1 (Bysimilarity). The inactive form interacts with NCK1 and GSN.Interacts (via the kinase catalytic domain) with STAT3 (via SH2domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1,NLRP3, NLRC4 and AIM2. Interacts (via DRBM 1 domain) with DUS2L(via DRBM domain). Interacts with DHX9 (via N-terminus) and thisinteraction is dependent upon activation of the kinase.{ECO:0000250, ECO:0000269|PubMed:10390359,ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11438532,ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25740987,ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.SUBUNIT: (Microbial infection) Interacts with human herpes simplexvirus 1 (HHV-1) protein US11 in an RNA-dependent manner(PubMed:11836380). The inactive form interacts with Toscana virus(TOS) NSS (PubMed:23325696). Interacts with herpes virus 8 proteinv-IRF2; this interaction inhibits EIF2AK2 activation(PubMed:11160738). Interacts with vaccinia protein E3(PubMed:25740987). {ECO:0000269|PubMed:11160738,ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:23325696,ECO:0000269|PubMed:25740987}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, perinuclearregion. Note=Nuclear localization is elevated in acute leukemia,myelodysplastic syndrome (MDS), melanoma, breast, colon, prostateand lung cancer patient samples or cell lines as well asneurocytes from advanced Creutzfeldt-Jakob disease patients.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P19525-1; Sequence=Displayed;Name=2;IsoId=P19525-2; Sequence=VSP_046177;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bonemarrow compared to non-hematopoietic tissues such as smallintestine, liver, or kidney tissues. Colocalizes with GSK3B andTAU in the Alzheimer disease (AD) brain. Elevated levels seen inbreast and colon carcinomas,and which correlates with tumorprogression and invasiveness or risk of progression.{ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:23403623}.INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.PTM: Autophosphorylated on several Ser, Thr and Tyr residues.Autophosphorylation of Thr-451 is dependent on Thr-446 and isstimulated by dsRNA binding and dimerization. Autophosphorylationapparently leads to the activation of the kinase. Tyrosineautophosphorylation is essential for efficient dsRNA-binding,dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/prkr/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80879"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PKR"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63229"]]],["bp:entityReference_http://identifiers.org/uniprot/P19525",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 293 293 Phosphotyrosine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","293"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:standardName","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:organism","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:displayName","E2AK2_HUMAN"],["bp:name","PKR"],["bp:name","2.7.11.1"],["bp:name","p68 kinase"],["bp:name","Protein kinase RNA-activated"],["bp:name","Eukaryotic translation initiation factor 2-alpha kinase 2"],["bp:name","Tyrosine-protein kinase EIF2AK2"],["bp:name","EIF2AK2"],["bp:name","Protein kinase R"],["bp:name","PRKR"],["bp:name","P1/eIF-2A protein kinase"],["bp:name","2.7.10.2"],["bp:name","Interferon-inducible RNA-dependent protein kinase"],["bp:name","eIF-2A protein kinase 2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002750"],["bp:comment","E2AK2_HUMAN Reviewed; 551 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P19525_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A19_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5610"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2657N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011531289"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5610"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20459"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01468_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_646"],["bp:comment","FUNCTION: IFN-induced dsRNA-dependent serine/threonine-proteinkinase which plays a key role in the innate immune response toviral infection and is also involved in the regulation of signaltransduction, apoptosis, cell proliferation and differentiation.Exerts its antiviral activity on a wide range of DNA and RNAviruses including hepatitis C virus (HCV), hepatitis B virus(HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1).Inhibits viral replication via phosphorylation of the alphasubunit of eukaryotic initiation factor 2 (EIF2S1), thisphosphorylation impairs the recycling of EIF2S1 between successiverounds of initiation leading to inhibition of translation whicheventually results in shutdown of cellular and viral proteinsynthesis. Also phosphorylates other substrates includingp53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral proteinUS11. In addition to serine/threonine-protein kinase activity,also has tyrosine-protein kinase activity and phosphorylates CDK1at 'Tyr-4' upon DNA damage, facilitating its ubiquitination andproteosomal degradation. Either as an adapter protein and/or viaits kinase activity, can regulate various signaling pathways (p38MAP kinase, NF-kappa-B and insulin signaling pathways) andtranscription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved inthe expression of genes encoding proinflammatory cytokines andIFNs. Activates the NF-kappa-B pathway via interaction with IKBKBand TRAF family of proteins and activates the p38 MAP kinasepathway via interaction with MAP2K6. Can act as both a positiveand negative regulator of the insulin signaling pathway (ISP).Negatively regulates ISP by inducing the inhibitoryphosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5Awhich activates FOXO1, which in turn up-regulates the expressionof insulin receptor substrate 2 (IRS2). Can regulate NLRP3inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 andNLRC4 inflammasomes. Can trigger apoptosis via FADD-mediatedactivation of CASP8. Plays a role in the regulation of thecytoskeleton by binding to gelsolin (GSN), sequestering theprotein in an inactive conformation away from actin.{ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Initially produced in an inactive form and isactivated by binding to viral dsRNA, which causes dimerization andautophosphorylation in the activation loop and stimulation offunction. ISGylation can activate it in the absence of viralinfection. Can also be activated by heparin, proinflammatorystimuli, growth factors, cytokines, oxidative stress and thecellular protein PRKRA. Activity is markedly stimulated bymanganese ions. Activation is blocked by the viral components HIV-1 Tat protein and large amounts of HIV-1 trans-activation response(TAR) RNA element as well as by the cellular proteins TARBP2,DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana virus (TOS)and Rift valley fever virus (RVFV) NSS which promote itsproteasomal degradation. Inhibited by vaccinia virus protein E3,probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.SUBUNIT: Homodimer. Interacts with STRBP (By similarity).Interacts with DNAJC3. Forms a complex with FANCA, FANCC, FANCGand HSP70. Interacts with ADAR/ADAR1. Interacts with IRS1 (Bysimilarity). The inactive form interacts with NCK1 and GSN.Interacts (via the kinase catalytic domain) with STAT3 (via SH2domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1,NLRP3, NLRC4 and AIM2. Interacts (via DRBM 1 domain) with DUS2L(via DRBM domain). Interacts with DHX9 (via N-terminus) and thisinteraction is dependent upon activation of the kinase.{ECO:0000250, ECO:0000269|PubMed:10390359,ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11438532,ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25740987,ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.SUBUNIT: (Microbial infection) Interacts with human herpes simplexvirus 1 (HHV-1) protein US11 in an RNA-dependent manner(PubMed:11836380). The inactive form interacts with Toscana virus(TOS) NSS (PubMed:23325696). Interacts with herpes virus 8 proteinv-IRF2; this interaction inhibits EIF2AK2 activation(PubMed:11160738). Interacts with vaccinia protein E3(PubMed:25740987). {ECO:0000269|PubMed:11160738,ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:23325696,ECO:0000269|PubMed:25740987}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, perinuclearregion. Note=Nuclear localization is elevated in acute leukemia,myelodysplastic syndrome (MDS), melanoma, breast, colon, prostateand lung cancer patient samples or cell lines as well asneurocytes from advanced Creutzfeldt-Jakob disease patients.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P19525-1; Sequence=Displayed;Name=2;IsoId=P19525-2; Sequence=VSP_046177;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bonemarrow compared to non-hematopoietic tissues such as smallintestine, liver, or kidney tissues. Colocalizes with GSK3B andTAU in the Alzheimer disease (AD) brain. Elevated levels seen inbreast and colon carcinomas,and which correlates with tumorprogression and invasiveness or risk of progression.{ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:23403623}.INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.PTM: Autophosphorylated on several Ser, Thr and Tyr residues.Autophosphorylation of Thr-451 is dependent on Thr-446 and isstimulated by dsRNA binding and dimerization. Autophosphorylationapparently leads to the activation of the kinase. Tyrosineautophosphorylation is essential for efficient dsRNA-binding,dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/prkr/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80879"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","PKR"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63229"]]],["bp:entityReference_http://identifiers.org/uniprot/P19525",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 293 293 Phosphotyrosine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","293"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 255 255 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 255 255 Phosphothreonine; by autocatalysis."]]],["bp:standardName","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:xref","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:organism","Interferon-induced, double-stranded RNA-activated protein kinase"],["bp:displayName","E2AK2_HUMAN"],["bp:name","PKR"],["bp:name","2.7.11.1"],["bp:name","p68 kinase"],["bp:name","Protein kinase RNA-activated"],["bp:name","Eukaryotic translation initiation factor 2-alpha kinase 2"],["bp:name","Tyrosine-protein kinase EIF2AK2"],["bp:name","EIF2AK2"],["bp:name","Protein kinase R"],["bp:name","PRKR"],["bp:name","P1/eIF-2A protein kinase"],["bp:name","2.7.10.2"],["bp:name","Interferon-inducible RNA-dependent protein kinase"],["bp:name","eIF-2A protein kinase 2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002750"],["bp:comment","E2AK2_HUMAN Reviewed; 551 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P19525_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2A19_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5610"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2657N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011531289"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5610"],["bp:comment","REPLACED http://identifiers.org/uniprot/P20459"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01468_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_646"],["bp:comment","FUNCTION: IFN-induced dsRNA-dependent serine/threonine-proteinkinase which plays a key role in the innate immune response toviral infection and is also involved in the regulation of signaltransduction, apoptosis, cell proliferation and differentiation.Exerts its antiviral activity on a wide range of DNA and RNAviruses including hepatitis C virus (HCV), hepatitis B virus(HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1).Inhibits viral replication via phosphorylation of the alphasubunit of eukaryotic initiation factor 2 (EIF2S1), thisphosphorylation impairs the recycling of EIF2S1 between successiverounds of initiation leading to inhibition of translation whicheventually results in shutdown of cellular and viral proteinsynthesis. Also phosphorylates other substrates includingp53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral proteinUS11. In addition to serine/threonine-protein kinase activity,also has tyrosine-protein kinase activity and phosphorylates CDK1at 'Tyr-4' upon DNA damage, facilitating its ubiquitination andproteosomal degradation. Either as an adapter protein and/or viaits kinase activity, can regulate various signaling pathways (p38MAP kinase, NF-kappa-B and insulin signaling pathways) andtranscription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved inthe expression of genes encoding proinflammatory cytokines andIFNs. Activates the NF-kappa-B pathway via interaction with IKBKBand TRAF family of proteins and activates the p38 MAP kinasepathway via interaction with MAP2K6. Can act as both a positiveand negative regulator of the insulin signaling pathway (ISP).Negatively regulates ISP by inducing the inhibitoryphosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5Awhich activates FOXO1, which in turn up-regulates the expressionof insulin receptor substrate 2 (IRS2). Can regulate NLRP3inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 andNLRC4 inflammasomes. Can trigger apoptosis via FADD-mediatedactivation of CASP8. Plays a role in the regulation of thecytoskeleton by binding to gelsolin (GSN), sequestering theprotein in an inactive conformation away from actin.{ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Initially produced in an inactive form and isactivated by binding to viral dsRNA, which causes dimerization andautophosphorylation in the activation loop and stimulation offunction. ISGylation can activate it in the absence of viralinfection. Can also be activated by heparin, proinflammatorystimuli, growth factors, cytokines, oxidative stress and thecellular protein PRKRA. Activity is markedly stimulated bymanganese ions. Activation is blocked by the viral components HIV-1 Tat protein and large amounts of HIV-1 trans-activation response(TAR) RNA element as well as by the cellular proteins TARBP2,DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana virus (TOS)and Rift valley fever virus (RVFV) NSS which promote itsproteasomal degradation. Inhibited by vaccinia virus protein E3,probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.SUBUNIT: Homodimer. Interacts with STRBP (By similarity).Interacts with DNAJC3. Forms a complex with FANCA, FANCC, FANCGand HSP70. Interacts with ADAR/ADAR1. Interacts with IRS1 (Bysimilarity). The inactive form interacts with NCK1 and GSN.Interacts (via the kinase catalytic domain) with STAT3 (via SH2domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1,NLRP3, NLRC4 and AIM2. Interacts (via DRBM 1 domain) with DUS2L(via DRBM domain). Interacts with DHX9 (via N-terminus) and thisinteraction is dependent upon activation of the kinase.{ECO:0000250, ECO:0000269|PubMed:10390359,ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11438532,ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25740987,ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.SUBUNIT: (Microbial infection) Interacts with human herpes simplexvirus 1 (HHV-1) protein US11 in an RNA-dependent manner(PubMed:11836380). The inactive form interacts with Toscana virus(TOS) NSS (PubMed:23325696). Interacts with herpes virus 8 proteinv-IRF2; this interaction inhibits EIF2AK2 activation(PubMed:11160738). Interacts with vaccinia protein E3(PubMed:25740987). {ECO:0000269|PubMed:11160738,ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:23325696,ECO:0000269|PubMed:25740987}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, perinuclearregion. Note=Nuclear localization is elevated in acute leukemia,myelodysplastic syndrome (MDS), melanoma, breast, colon, prostateand lung cancer patient samples or cell lines as well asneurocytes from advanced Creutzfeldt-Jakob disease patients.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P19525-1; Sequence=Displayed;Name=2;IsoId=P19525-2; Sequence=VSP_046177;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bonemarrow compared to non-hematopoietic tissues such as smallintestine, liver, or kidney tissues. Colocalizes with GSK3B andTAU in the Alzheimer disease (AD) brain. Elevated levels seen inbreast and colon carcinomas,and which correlates with tumorprogression and invasiveness or risk of progression.{ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:23403623}.INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.PTM: Autophosphorylated on several Ser, Thr and Tyr residues.Autophosphorylation of Thr-451 is dependent on Thr-446 and isstimulated by dsRNA binding and dimerization. Autophosphorylationapparently leads to the activation of the kinase. Tyrosineautophosphorylation is essential for efficient dsRNA-binding,dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thrprotein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/prkr/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63228"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80879"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80877"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80877"]]}},{"data":{"id":"Protein_1824beb3bc656b1b24397d77f3e0dc49","class":"macromolecule","label":"BAD","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_1824beb3bc656b1b24397d77f3e0dc49.info.1","class":"state variable","state":{"variable":"99","value":"opser"}},{"id":"Protein_1824beb3bc656b1b24397d77f3e0dc49.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_1824beb3bc656b1b24397d77f3e0dc49.info.3","class":"state variable","state":{"variable":"118","value":"opser"}},{"id":"Protein_1824beb3bc656b1b24397d77f3e0dc49.state.4","class":"state variable","state":{"variable":"75","value":"opser"}},{"id":"Protein_1824beb3bc656b1b24397d77f3e0dc49.info.5","class":"state variable","state":{"variable":"134","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":648.4804,"y":365.81528,"w":85,"h":25},"metadata":[["bp:displayName","BAD"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21218"],["bp:featureLocation",[["bp:sequencePosition","99"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21219"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_48206"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_60512"],["bp:featureLocation",[["bp:sequencePosition","118"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28573"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80625"],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_38017"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80625"],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_38017"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q92934",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80625"],["bp:featureLocation",[["bp:sequencePosition","75"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_38017"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80624"]]}},{"data":{"id":"Complex_6f3f7d29a99ad47d0a106e7986af465c","class":"complex","label":"ERK1/PKC delta","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":371.42834,"y":738.7785,"w":89,"h":64},"metadata":[["bp:displayName","ERK1/PKC delta"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC delta"],["bp:entityReference_http://identifiers.org/uniprot/Q05655",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 654 654 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","654"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 307 307 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","307"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:standardName","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:organism","Protein kinase C delta type"],["bp:displayName","KPCD_HUMAN"],["bp:name","Protein kinase C delta type regulatory subunit"],["bp:name","nPKC-delta"],["bp:name","Protein kinase C delta type catalytic subunit"],["bp:name","2.7.10.2"],["bp:name","2.7.11.13"],["bp:name","Tyrosine-protein kinase PRKCD"],["bp:name","SDK1"],["bp:name","Sphingosine-dependent protein kinase-1"],["bp:name","PRKCD"],["bp:comment","REPLACED ProteinRef_PRKCD__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01501_identity"],["bp:comment","KPCD_HUMAN Reviewed; 676 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_882"],["bp:comment","REPLACED ProteinRef_PRKCD__10090"],["bp:comment","FUNCTION: Calcium-independent, phospholipid- and diacylglycerol(DAG)-dependent serine/threonine-protein kinase that playscontrasting roles in cell death and cell survival by functioningas a pro-apoptotic protein during DNA damage-induced apoptosis,but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well assurvival of several cancers, is required for oxygen radicalproduction by NADPH oxidase and acts as positive or negativeregulator in platelet functional responses. Negatively regulates Bcell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage,activates the promoter of the death-promoting transcription factorBCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcriptionand apoptosis. In response to oxidative stress, interact with andactivate CHUK/IKKA in the nucleus, causing the phosphorylation ofp53/TP53. In the case of ER stress or DNA damage-inducedapoptosis, can form a complex with the tyrosine-protein kinaseABL1 which trigger apoptosis independently of p53/TP53. In cytosolcan trigger apoptosis by activating MAPK11 or MAPK14, inhibitingAKT1 and decreasing the level of X-linked inhibitor of apoptosisprotein (XIAP), whereas in nucleus induces apoptosis via theactivation of MAPK8 or MAPK9. Upon ionizing radiation treatment,is required for the activation of the apoptosis regulators BAX andBAK, which trigger the mitochondrial cell death pathway. Canphosphorylate MCL1 and target it for degradation which issufficient to trigger for BAX activation and apoptosis. Isrequired for the control of cell cycle progression both at G1/Sand G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclinCCNA2 promoter activity. In response to UV irradiation canphosphorylate CDK1, which is important for the G2/M DNA damagecheckpoint activation. Can protect glioma cells from the apoptosisinduced by TNFSF10/TRAIL, probably by inducing increasedphosphorylation and subsequent activation of AKT1. Is highlyexpressed in a number of cancer cells and promotes cell survivaland resistance against chemotherapeutic drugs by inducing cyclinD1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3(ERK1/2). Can also act as tumor suppressor upon mitogenicstimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity,and regulates TNF-elicited superoxide anion production inneutrophils, by direct phosphorylation and activation of NCF1 orindirectly through MAPK1/3 (ERK1/2) signaling pathways. May alsoplay a role in the regulation of NADPH oxidase activity ineosinophil after stimulation with IL5, leukotriene B4 or PMA. Incollagen-induced platelet aggregation, acts a negative regulatorof filopodia formation and actin polymerization by interactingwith and negatively regulating VASP phosphorylation. Downstream ofPAR1, PAR4 and CD36/GP4 receptors, regulates differentiallyplatelet dense granule secretion; acts as a positive regulator inPAR-mediated granule secretion, whereas it negatively regulatesCD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins(YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (Bysimilarity). Phosphorylates ELAVL1 in response to angiotensin-2treatment (PubMed:18285462). {ECO:0000250,ECO:0000269|PubMed:11748588, ECO:0000269|PubMed:11877440,ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:16940418,ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19587372,ECO:0000269|PubMed:19801500}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:18285462}.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) arecalcium-insensitive, but activated by diacylglycerol (DAG) andphosphatidylserine. Three specific sites; Thr-507 (activation loopof the kinase domain), Ser-645 (turn motif) and Ser-664(hydrophobic region), need to be phosphorylated for its fullactivation. Activated by caspase-3 (CASP3) cleavage duringapoptosis. After cleavage, the pseudosubstrate motif in theregulatory subunit is released from the substrate recognition siteof the catalytic subunit, which enables PRKCD to becomeconstitutively activated. The catalytic subunit which displaysproperties of a sphingosine-dependent protein kinase is activatedby D-erythro-sphingosine (Sph) or N,N-dimethyl-D-erythrosphingosine (DMS) or N,N,N-trimethyl-D-erythrosphingosine(TMS), but not by ceramide or Sph-1-P and is strongly inhibited byphosphatidylserine (By similarity). {ECO:0000250}.SUBUNIT: Interacts with PDPK1 (via N-terminal region), RAD9A,CDCP1, MUC1 and VASP. {ECO:0000269|PubMed:11781095,ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12628935,ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16940418}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046, ECO:0000269|PubMed:18285462}.Cytoplasm, perinuclear region {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046}. Nucleus{ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:18285462}. Cell membrane{ECO:0000269|PubMed:17603046}; Peripheral membrane protein{ECO:0000305|PubMed:17603046}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q05655-1; Sequence=Displayed;Name=2; Synonyms=PKCdeltaVIII;IsoId=Q05655-2; Sequence=VSP_043899;Note=Antiapoptotic isoform, resistant to caspase-3 cleavage.;DOMAIN: The C1 domain, containing the phorbol ester/DAG-typeregion 1 (C1A) and 2 (C1B), is the diacylglycerol sensor.DOMAIN: The C2 domain is a non-calcium binding domain. It bindsproteins containing phosphotyrosine in a sequence-specific manner.PTM: Autophosphorylated and/or phosphorylated at Thr-507, withinthe activation loop; phosphorylation at Thr-507 is not aprerequisite for enzymatic activity. Autophosphorylated at Ser-299, Ser-302 and Ser-304. Upon TNFSF10/TRAIL treatment,phosphorylated at Tyr-155; phosphorylation is required for itstranslocation to the endoplasmic reticulum and cleavage bycaspase-3. Phosphorylated at Tyr-313, Tyr-334 and Tyr-567;phosphorylation of Tyr-313 and Tyr-567 following thrombinstimulation potentiates its kinase activity. Phosphorylated byprotein kinase PDPK1; phosphorylation is inhibited by theapoptotic C-terminal cleavage product of PKN2.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17570831, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:19801500}.PTM: Proteolytically cleaved into a catalytic subunit and aregulatory subunit by caspase-3 during apoptosis which results inkinase activation. {ECO:0000250}.DISEASE: Autoimmune lymphoproliferative syndrome 3 (ALPS3)[MIM:615559]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen. Thedefect results from a failure of B-cell differentiation andimpaired secretion of immunoglobulins; the numbers of circulatingB-cells is usually in the normal range, but can be low. CVID9patients have B-cell deficiency and severe autoimmunity.{ECO:0000269|PubMed:23319571}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PRKCDID42901ch3p21.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29954N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_006245"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_ddbj_embl_genbank_BAA01381_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_997704"],["bp:comment","REPLACED ProteinRef_PRKCD__40674"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5580"]]],["bp:name","nPKC-delta"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80774"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PKC delta"],["bp:entityReference_http://identifiers.org/uniprot/Q05655",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 654 654 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","654"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 307 307 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","307"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:standardName","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:organism","Protein kinase C delta type"],["bp:displayName","KPCD_HUMAN"],["bp:name","Protein kinase C delta type regulatory subunit"],["bp:name","nPKC-delta"],["bp:name","Protein kinase C delta type catalytic subunit"],["bp:name","2.7.10.2"],["bp:name","2.7.11.13"],["bp:name","Tyrosine-protein kinase PRKCD"],["bp:name","SDK1"],["bp:name","Sphingosine-dependent protein kinase-1"],["bp:name","PRKCD"],["bp:comment","REPLACED ProteinRef_PRKCD__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01501_identity"],["bp:comment","KPCD_HUMAN Reviewed; 676 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_882"],["bp:comment","REPLACED ProteinRef_PRKCD__10090"],["bp:comment","FUNCTION: Calcium-independent, phospholipid- and diacylglycerol(DAG)-dependent serine/threonine-protein kinase that playscontrasting roles in cell death and cell survival by functioningas a pro-apoptotic protein during DNA damage-induced apoptosis,but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well assurvival of several cancers, is required for oxygen radicalproduction by NADPH oxidase and acts as positive or negativeregulator in platelet functional responses. Negatively regulates Bcell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage,activates the promoter of the death-promoting transcription factorBCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcriptionand apoptosis. In response to oxidative stress, interact with andactivate CHUK/IKKA in the nucleus, causing the phosphorylation ofp53/TP53. In the case of ER stress or DNA damage-inducedapoptosis, can form a complex with the tyrosine-protein kinaseABL1 which trigger apoptosis independently of p53/TP53. In cytosolcan trigger apoptosis by activating MAPK11 or MAPK14, inhibitingAKT1 and decreasing the level of X-linked inhibitor of apoptosisprotein (XIAP), whereas in nucleus induces apoptosis via theactivation of MAPK8 or MAPK9. Upon ionizing radiation treatment,is required for the activation of the apoptosis regulators BAX andBAK, which trigger the mitochondrial cell death pathway. Canphosphorylate MCL1 and target it for degradation which issufficient to trigger for BAX activation and apoptosis. Isrequired for the control of cell cycle progression both at G1/Sand G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclinCCNA2 promoter activity. In response to UV irradiation canphosphorylate CDK1, which is important for the G2/M DNA damagecheckpoint activation. Can protect glioma cells from the apoptosisinduced by TNFSF10/TRAIL, probably by inducing increasedphosphorylation and subsequent activation of AKT1. Is highlyexpressed in a number of cancer cells and promotes cell survivaland resistance against chemotherapeutic drugs by inducing cyclinD1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3(ERK1/2). Can also act as tumor suppressor upon mitogenicstimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity,and regulates TNF-elicited superoxide anion production inneutrophils, by direct phosphorylation and activation of NCF1 orindirectly through MAPK1/3 (ERK1/2) signaling pathways. May alsoplay a role in the regulation of NADPH oxidase activity ineosinophil after stimulation with IL5, leukotriene B4 or PMA. Incollagen-induced platelet aggregation, acts a negative regulatorof filopodia formation and actin polymerization by interactingwith and negatively regulating VASP phosphorylation. Downstream ofPAR1, PAR4 and CD36/GP4 receptors, regulates differentiallyplatelet dense granule secretion; acts as a positive regulator inPAR-mediated granule secretion, whereas it negatively regulatesCD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins(YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (Bysimilarity). Phosphorylates ELAVL1 in response to angiotensin-2treatment (PubMed:18285462). {ECO:0000250,ECO:0000269|PubMed:11748588, ECO:0000269|PubMed:11877440,ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:16940418,ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19587372,ECO:0000269|PubMed:19801500}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:18285462}.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) arecalcium-insensitive, but activated by diacylglycerol (DAG) andphosphatidylserine. Three specific sites; Thr-507 (activation loopof the kinase domain), Ser-645 (turn motif) and Ser-664(hydrophobic region), need to be phosphorylated for its fullactivation. Activated by caspase-3 (CASP3) cleavage duringapoptosis. After cleavage, the pseudosubstrate motif in theregulatory subunit is released from the substrate recognition siteof the catalytic subunit, which enables PRKCD to becomeconstitutively activated. The catalytic subunit which displaysproperties of a sphingosine-dependent protein kinase is activatedby D-erythro-sphingosine (Sph) or N,N-dimethyl-D-erythrosphingosine (DMS) or N,N,N-trimethyl-D-erythrosphingosine(TMS), but not by ceramide or Sph-1-P and is strongly inhibited byphosphatidylserine (By similarity). {ECO:0000250}.SUBUNIT: Interacts with PDPK1 (via N-terminal region), RAD9A,CDCP1, MUC1 and VASP. {ECO:0000269|PubMed:11781095,ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12628935,ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16940418}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046, ECO:0000269|PubMed:18285462}.Cytoplasm, perinuclear region {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046}. Nucleus{ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:18285462}. Cell membrane{ECO:0000269|PubMed:17603046}; Peripheral membrane protein{ECO:0000305|PubMed:17603046}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q05655-1; Sequence=Displayed;Name=2; Synonyms=PKCdeltaVIII;IsoId=Q05655-2; Sequence=VSP_043899;Note=Antiapoptotic isoform, resistant to caspase-3 cleavage.;DOMAIN: The C1 domain, containing the phorbol ester/DAG-typeregion 1 (C1A) and 2 (C1B), is the diacylglycerol sensor.DOMAIN: The C2 domain is a non-calcium binding domain. It bindsproteins containing phosphotyrosine in a sequence-specific manner.PTM: Autophosphorylated and/or phosphorylated at Thr-507, withinthe activation loop; phosphorylation at Thr-507 is not aprerequisite for enzymatic activity. Autophosphorylated at Ser-299, Ser-302 and Ser-304. Upon TNFSF10/TRAIL treatment,phosphorylated at Tyr-155; phosphorylation is required for itstranslocation to the endoplasmic reticulum and cleavage bycaspase-3. Phosphorylated at Tyr-313, Tyr-334 and Tyr-567;phosphorylation of Tyr-313 and Tyr-567 following thrombinstimulation potentiates its kinase activity. Phosphorylated byprotein kinase PDPK1; phosphorylation is inhibited by theapoptotic C-terminal cleavage product of PKN2.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17570831, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:19801500}.PTM: Proteolytically cleaved into a catalytic subunit and aregulatory subunit by caspase-3 during apoptosis which results inkinase activation. {ECO:0000250}.DISEASE: Autoimmune lymphoproliferative syndrome 3 (ALPS3)[MIM:615559]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen. Thedefect results from a failure of B-cell differentiation andimpaired secretion of immunoglobulins; the numbers of circulatingB-cells is usually in the normal range, but can be low. CVID9patients have B-cell deficiency and severe autoimmunity.{ECO:0000269|PubMed:23319571}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PRKCDID42901ch3p21.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29954N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_006245"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_ddbj_embl_genbank_BAA01381_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_997704"],["bp:comment","REPLACED ProteinRef_PRKCD__40674"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5580"]]],["bp:name","nPKC-delta"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80774"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC delta"],["bp:entityReference_http://identifiers.org/uniprot/Q05655",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 654 654 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","654"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 307 307 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","307"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:standardName","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:organism","Protein kinase C delta type"],["bp:displayName","KPCD_HUMAN"],["bp:name","Protein kinase C delta type regulatory subunit"],["bp:name","nPKC-delta"],["bp:name","Protein kinase C delta type catalytic subunit"],["bp:name","2.7.10.2"],["bp:name","2.7.11.13"],["bp:name","Tyrosine-protein kinase PRKCD"],["bp:name","SDK1"],["bp:name","Sphingosine-dependent protein kinase-1"],["bp:name","PRKCD"],["bp:comment","REPLACED ProteinRef_PRKCD__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01501_identity"],["bp:comment","KPCD_HUMAN Reviewed; 676 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_882"],["bp:comment","REPLACED ProteinRef_PRKCD__10090"],["bp:comment","FUNCTION: Calcium-independent, phospholipid- and diacylglycerol(DAG)-dependent serine/threonine-protein kinase that playscontrasting roles in cell death and cell survival by functioningas a pro-apoptotic protein during DNA damage-induced apoptosis,but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well assurvival of several cancers, is required for oxygen radicalproduction by NADPH oxidase and acts as positive or negativeregulator in platelet functional responses. Negatively regulates Bcell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage,activates the promoter of the death-promoting transcription factorBCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcriptionand apoptosis. In response to oxidative stress, interact with andactivate CHUK/IKKA in the nucleus, causing the phosphorylation ofp53/TP53. In the case of ER stress or DNA damage-inducedapoptosis, can form a complex with the tyrosine-protein kinaseABL1 which trigger apoptosis independently of p53/TP53. In cytosolcan trigger apoptosis by activating MAPK11 or MAPK14, inhibitingAKT1 and decreasing the level of X-linked inhibitor of apoptosisprotein (XIAP), whereas in nucleus induces apoptosis via theactivation of MAPK8 or MAPK9. Upon ionizing radiation treatment,is required for the activation of the apoptosis regulators BAX andBAK, which trigger the mitochondrial cell death pathway. Canphosphorylate MCL1 and target it for degradation which issufficient to trigger for BAX activation and apoptosis. Isrequired for the control of cell cycle progression both at G1/Sand G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclinCCNA2 promoter activity. In response to UV irradiation canphosphorylate CDK1, which is important for the G2/M DNA damagecheckpoint activation. Can protect glioma cells from the apoptosisinduced by TNFSF10/TRAIL, probably by inducing increasedphosphorylation and subsequent activation of AKT1. Is highlyexpressed in a number of cancer cells and promotes cell survivaland resistance against chemotherapeutic drugs by inducing cyclinD1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3(ERK1/2). Can also act as tumor suppressor upon mitogenicstimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity,and regulates TNF-elicited superoxide anion production inneutrophils, by direct phosphorylation and activation of NCF1 orindirectly through MAPK1/3 (ERK1/2) signaling pathways. May alsoplay a role in the regulation of NADPH oxidase activity ineosinophil after stimulation with IL5, leukotriene B4 or PMA. Incollagen-induced platelet aggregation, acts a negative regulatorof filopodia formation and actin polymerization by interactingwith and negatively regulating VASP phosphorylation. Downstream ofPAR1, PAR4 and CD36/GP4 receptors, regulates differentiallyplatelet dense granule secretion; acts as a positive regulator inPAR-mediated granule secretion, whereas it negatively regulatesCD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins(YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (Bysimilarity). Phosphorylates ELAVL1 in response to angiotensin-2treatment (PubMed:18285462). {ECO:0000250,ECO:0000269|PubMed:11748588, ECO:0000269|PubMed:11877440,ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:16940418,ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19587372,ECO:0000269|PubMed:19801500}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:18285462}.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) arecalcium-insensitive, but activated by diacylglycerol (DAG) andphosphatidylserine. Three specific sites; Thr-507 (activation loopof the kinase domain), Ser-645 (turn motif) and Ser-664(hydrophobic region), need to be phosphorylated for its fullactivation. Activated by caspase-3 (CASP3) cleavage duringapoptosis. After cleavage, the pseudosubstrate motif in theregulatory subunit is released from the substrate recognition siteof the catalytic subunit, which enables PRKCD to becomeconstitutively activated. The catalytic subunit which displaysproperties of a sphingosine-dependent protein kinase is activatedby D-erythro-sphingosine (Sph) or N,N-dimethyl-D-erythrosphingosine (DMS) or N,N,N-trimethyl-D-erythrosphingosine(TMS), but not by ceramide or Sph-1-P and is strongly inhibited byphosphatidylserine (By similarity). {ECO:0000250}.SUBUNIT: Interacts with PDPK1 (via N-terminal region), RAD9A,CDCP1, MUC1 and VASP. {ECO:0000269|PubMed:11781095,ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12628935,ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16940418}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046, ECO:0000269|PubMed:18285462}.Cytoplasm, perinuclear region {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046}. Nucleus{ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:18285462}. Cell membrane{ECO:0000269|PubMed:17603046}; Peripheral membrane protein{ECO:0000305|PubMed:17603046}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q05655-1; Sequence=Displayed;Name=2; Synonyms=PKCdeltaVIII;IsoId=Q05655-2; Sequence=VSP_043899;Note=Antiapoptotic isoform, resistant to caspase-3 cleavage.;DOMAIN: The C1 domain, containing the phorbol ester/DAG-typeregion 1 (C1A) and 2 (C1B), is the diacylglycerol sensor.DOMAIN: The C2 domain is a non-calcium binding domain. It bindsproteins containing phosphotyrosine in a sequence-specific manner.PTM: Autophosphorylated and/or phosphorylated at Thr-507, withinthe activation loop; phosphorylation at Thr-507 is not aprerequisite for enzymatic activity. Autophosphorylated at Ser-299, Ser-302 and Ser-304. Upon TNFSF10/TRAIL treatment,phosphorylated at Tyr-155; phosphorylation is required for itstranslocation to the endoplasmic reticulum and cleavage bycaspase-3. Phosphorylated at Tyr-313, Tyr-334 and Tyr-567;phosphorylation of Tyr-313 and Tyr-567 following thrombinstimulation potentiates its kinase activity. Phosphorylated byprotein kinase PDPK1; phosphorylation is inhibited by theapoptotic C-terminal cleavage product of PKN2.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17570831, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:19801500}.PTM: Proteolytically cleaved into a catalytic subunit and aregulatory subunit by caspase-3 during apoptosis which results inkinase activation. {ECO:0000250}.DISEASE: Autoimmune lymphoproliferative syndrome 3 (ALPS3)[MIM:615559]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen. Thedefect results from a failure of B-cell differentiation andimpaired secretion of immunoglobulins; the numbers of circulatingB-cells is usually in the normal range, but can be low. CVID9patients have B-cell deficiency and severe autoimmunity.{ECO:0000269|PubMed:23319571}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PRKCDID42901ch3p21.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29954N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_006245"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_ddbj_embl_genbank_BAA01381_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_997704"],["bp:comment","REPLACED ProteinRef_PRKCD__40674"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5580"]]],["bp:name","nPKC-delta"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80774"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PKC delta"],["bp:entityReference_http://identifiers.org/uniprot/Q05655",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 654 654 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","654"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 307 307 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","307"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation","MOD_RES 374 374 Phosphotyrosine."]]],["bp:standardName","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:organism","Protein kinase C delta type"],["bp:displayName","KPCD_HUMAN"],["bp:name","Protein kinase C delta type regulatory subunit"],["bp:name","nPKC-delta"],["bp:name","Protein kinase C delta type catalytic subunit"],["bp:name","2.7.10.2"],["bp:name","2.7.11.13"],["bp:name","Tyrosine-protein kinase PRKCD"],["bp:name","SDK1"],["bp:name","Sphingosine-dependent protein kinase-1"],["bp:name","PRKCD"],["bp:comment","REPLACED ProteinRef_PRKCD__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01501_identity"],["bp:comment","KPCD_HUMAN Reviewed; 676 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_882"],["bp:comment","REPLACED ProteinRef_PRKCD__10090"],["bp:comment","FUNCTION: Calcium-independent, phospholipid- and diacylglycerol(DAG)-dependent serine/threonine-protein kinase that playscontrasting roles in cell death and cell survival by functioningas a pro-apoptotic protein during DNA damage-induced apoptosis,but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well assurvival of several cancers, is required for oxygen radicalproduction by NADPH oxidase and acts as positive or negativeregulator in platelet functional responses. Negatively regulates Bcell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage,activates the promoter of the death-promoting transcription factorBCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcriptionand apoptosis. In response to oxidative stress, interact with andactivate CHUK/IKKA in the nucleus, causing the phosphorylation ofp53/TP53. In the case of ER stress or DNA damage-inducedapoptosis, can form a complex with the tyrosine-protein kinaseABL1 which trigger apoptosis independently of p53/TP53. In cytosolcan trigger apoptosis by activating MAPK11 or MAPK14, inhibitingAKT1 and decreasing the level of X-linked inhibitor of apoptosisprotein (XIAP), whereas in nucleus induces apoptosis via theactivation of MAPK8 or MAPK9. Upon ionizing radiation treatment,is required for the activation of the apoptosis regulators BAX andBAK, which trigger the mitochondrial cell death pathway. Canphosphorylate MCL1 and target it for degradation which issufficient to trigger for BAX activation and apoptosis. Isrequired for the control of cell cycle progression both at G1/Sand G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclinCCNA2 promoter activity. In response to UV irradiation canphosphorylate CDK1, which is important for the G2/M DNA damagecheckpoint activation. Can protect glioma cells from the apoptosisinduced by TNFSF10/TRAIL, probably by inducing increasedphosphorylation and subsequent activation of AKT1. Is highlyexpressed in a number of cancer cells and promotes cell survivaland resistance against chemotherapeutic drugs by inducing cyclinD1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3(ERK1/2). Can also act as tumor suppressor upon mitogenicstimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity,and regulates TNF-elicited superoxide anion production inneutrophils, by direct phosphorylation and activation of NCF1 orindirectly through MAPK1/3 (ERK1/2) signaling pathways. May alsoplay a role in the regulation of NADPH oxidase activity ineosinophil after stimulation with IL5, leukotriene B4 or PMA. Incollagen-induced platelet aggregation, acts a negative regulatorof filopodia formation and actin polymerization by interactingwith and negatively regulating VASP phosphorylation. Downstream ofPAR1, PAR4 and CD36/GP4 receptors, regulates differentiallyplatelet dense granule secretion; acts as a positive regulator inPAR-mediated granule secretion, whereas it negatively regulatesCD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins(YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (Bysimilarity). Phosphorylates ELAVL1 in response to angiotensin-2treatment (PubMed:18285462). {ECO:0000250,ECO:0000269|PubMed:11748588, ECO:0000269|PubMed:11877440,ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:16940418,ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19587372,ECO:0000269|PubMed:19801500}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:18285462}.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) arecalcium-insensitive, but activated by diacylglycerol (DAG) andphosphatidylserine. Three specific sites; Thr-507 (activation loopof the kinase domain), Ser-645 (turn motif) and Ser-664(hydrophobic region), need to be phosphorylated for its fullactivation. Activated by caspase-3 (CASP3) cleavage duringapoptosis. After cleavage, the pseudosubstrate motif in theregulatory subunit is released from the substrate recognition siteof the catalytic subunit, which enables PRKCD to becomeconstitutively activated. The catalytic subunit which displaysproperties of a sphingosine-dependent protein kinase is activatedby D-erythro-sphingosine (Sph) or N,N-dimethyl-D-erythrosphingosine (DMS) or N,N,N-trimethyl-D-erythrosphingosine(TMS), but not by ceramide or Sph-1-P and is strongly inhibited byphosphatidylserine (By similarity). {ECO:0000250}.SUBUNIT: Interacts with PDPK1 (via N-terminal region), RAD9A,CDCP1, MUC1 and VASP. {ECO:0000269|PubMed:11781095,ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12628935,ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16940418}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046, ECO:0000269|PubMed:18285462}.Cytoplasm, perinuclear region {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046}. Nucleus{ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:18285462}. Cell membrane{ECO:0000269|PubMed:17603046}; Peripheral membrane protein{ECO:0000305|PubMed:17603046}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q05655-1; Sequence=Displayed;Name=2; Synonyms=PKCdeltaVIII;IsoId=Q05655-2; Sequence=VSP_043899;Note=Antiapoptotic isoform, resistant to caspase-3 cleavage.;DOMAIN: The C1 domain, containing the phorbol ester/DAG-typeregion 1 (C1A) and 2 (C1B), is the diacylglycerol sensor.DOMAIN: The C2 domain is a non-calcium binding domain. It bindsproteins containing phosphotyrosine in a sequence-specific manner.PTM: Autophosphorylated and/or phosphorylated at Thr-507, withinthe activation loop; phosphorylation at Thr-507 is not aprerequisite for enzymatic activity. Autophosphorylated at Ser-299, Ser-302 and Ser-304. Upon TNFSF10/TRAIL treatment,phosphorylated at Tyr-155; phosphorylation is required for itstranslocation to the endoplasmic reticulum and cleavage bycaspase-3. Phosphorylated at Tyr-313, Tyr-334 and Tyr-567;phosphorylation of Tyr-313 and Tyr-567 following thrombinstimulation potentiates its kinase activity. Phosphorylated byprotein kinase PDPK1; phosphorylation is inhibited by theapoptotic C-terminal cleavage product of PKN2.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17570831, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:19801500}.PTM: Proteolytically cleaved into a catalytic subunit and aregulatory subunit by caspase-3 during apoptosis which results inkinase activation. {ECO:0000250}.DISEASE: Autoimmune lymphoproliferative syndrome 3 (ALPS3)[MIM:615559]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen. Thedefect results from a failure of B-cell differentiation andimpaired secretion of immunoglobulins; the numbers of circulatingB-cells is usually in the normal range, but can be low. CVID9patients have B-cell deficiency and severe autoimmunity.{ECO:0000269|PubMed:23319571}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PRKCDID42901ch3p21.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29954N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_006245"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_ddbj_embl_genbank_BAA01381_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_997704"],["bp:comment","REPLACED ProteinRef_PRKCD__40674"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5580"]]],["bp:name","nPKC-delta"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80774"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80773"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_80773"]]}},{"data":{"id":"Protein_07241ca70aaa064dcd6380a81ff2bc8d_Complex_6f3f7d29a99ad47d0a106e7986af465c","class":"macromolecule","label":"MAPK3","parent":"Complex_6f3f7d29a99ad47d0a106e7986af465c","clonemarker":false,"stateVariables":[{"id":"Protein_07241ca70aaa064dcd6380a81ff2bc8d_Complex_6f3f7d29a99ad47d0a106e7986af465c.info.1","class":"state variable","state":{"variable":"202","value":"opthr"}},{"id":"Protein_07241ca70aaa064dcd6380a81ff2bc8d_Complex_6f3f7d29a99ad47d0a106e7986af465c.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_07241ca70aaa064dcd6380a81ff2bc8d_Complex_6f3f7d29a99ad47d0a106e7986af465c.info.3","class":"state variable","state":{"variable":"204","value":"optyr"}}],"unitsOfInformation":[],"bbox":{"x":371.42834,"y":721.2785,"w":85,"h":25},"metadata":[["bp:displayName","Erk1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28907"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2039"]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28909"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_28909"]]],["bp:entityReference_http://identifiers.org/uniprot/P27361",[["bp:modificationType",[["bp:xref",null],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28909"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_28909"]]],["bp:name","ERK1"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_28906"]]}},{"data":{"id":"Protein_e182e050a948953a2b7fe086f9bf09f1_Complex_6f3f7d29a99ad47d0a106e7986af465c","class":"macromolecule","label":"PRKCD","parent":"Complex_6f3f7d29a99ad47d0a106e7986af465c","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":352.92834,"y":756.2785,"w":48,"h":25},"metadata":[["bp:displayName","PKC delta"],["bp:entityReference_http://identifiers.org/uniprot/Q05655",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 654 654 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","654"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 307 307 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","307"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 374 374 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","374"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 299 299 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 299 299 Phosphoserine; by autocatalysis."]]],["bp:standardName","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:xref","Protein kinase C delta type"],["bp:organism","Protein kinase C delta type"],["bp:displayName","KPCD_HUMAN"],["bp:name","Protein kinase C delta type regulatory subunit"],["bp:name","nPKC-delta"],["bp:name","Protein kinase C delta type catalytic subunit"],["bp:name","2.7.10.2"],["bp:name","2.7.11.13"],["bp:name","Tyrosine-protein kinase PRKCD"],["bp:name","SDK1"],["bp:name","Sphingosine-dependent protein kinase-1"],["bp:name","PRKCD"],["bp:comment","REPLACED ProteinRef_PRKCD__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01501_identity"],["bp:comment","KPCD_HUMAN Reviewed; 676 AA."],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_882"],["bp:comment","REPLACED ProteinRef_PRKCD__10090"],["bp:comment","FUNCTION: Calcium-independent, phospholipid- and diacylglycerol(DAG)-dependent serine/threonine-protein kinase that playscontrasting roles in cell death and cell survival by functioningas a pro-apoptotic protein during DNA damage-induced apoptosis,but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well assurvival of several cancers, is required for oxygen radicalproduction by NADPH oxidase and acts as positive or negativeregulator in platelet functional responses. Negatively regulates Bcell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage,activates the promoter of the death-promoting transcription factorBCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcriptionand apoptosis. In response to oxidative stress, interact with andactivate CHUK/IKKA in the nucleus, causing the phosphorylation ofp53/TP53. In the case of ER stress or DNA damage-inducedapoptosis, can form a complex with the tyrosine-protein kinaseABL1 which trigger apoptosis independently of p53/TP53. In cytosolcan trigger apoptosis by activating MAPK11 or MAPK14, inhibitingAKT1 and decreasing the level of X-linked inhibitor of apoptosisprotein (XIAP), whereas in nucleus induces apoptosis via theactivation of MAPK8 or MAPK9. Upon ionizing radiation treatment,is required for the activation of the apoptosis regulators BAX andBAK, which trigger the mitochondrial cell death pathway. Canphosphorylate MCL1 and target it for degradation which issufficient to trigger for BAX activation and apoptosis. Isrequired for the control of cell cycle progression both at G1/Sand G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclinCCNA2 promoter activity. In response to UV irradiation canphosphorylate CDK1, which is important for the G2/M DNA damagecheckpoint activation. Can protect glioma cells from the apoptosisinduced by TNFSF10/TRAIL, probably by inducing increasedphosphorylation and subsequent activation of AKT1. Is highlyexpressed in a number of cancer cells and promotes cell survivaland resistance against chemotherapeutic drugs by inducing cyclinD1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3(ERK1/2). Can also act as tumor suppressor upon mitogenicstimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity,and regulates TNF-elicited superoxide anion production inneutrophils, by direct phosphorylation and activation of NCF1 orindirectly through MAPK1/3 (ERK1/2) signaling pathways. May alsoplay a role in the regulation of NADPH oxidase activity ineosinophil after stimulation with IL5, leukotriene B4 or PMA. Incollagen-induced platelet aggregation, acts a negative regulatorof filopodia formation and actin polymerization by interactingwith and negatively regulating VASP phosphorylation. Downstream ofPAR1, PAR4 and CD36/GP4 receptors, regulates differentiallyplatelet dense granule secretion; acts as a positive regulator inPAR-mediated granule secretion, whereas it negatively regulatesCD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins(YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (Bysimilarity). Phosphorylates ELAVL1 in response to angiotensin-2treatment (PubMed:18285462). {ECO:0000250,ECO:0000269|PubMed:11748588, ECO:0000269|PubMed:11877440,ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:16940418,ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19587372,ECO:0000269|PubMed:19801500}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:18285462}.CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10027}.ENZYME REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) arecalcium-insensitive, but activated by diacylglycerol (DAG) andphosphatidylserine. Three specific sites; Thr-507 (activation loopof the kinase domain), Ser-645 (turn motif) and Ser-664(hydrophobic region), need to be phosphorylated for its fullactivation. Activated by caspase-3 (CASP3) cleavage duringapoptosis. After cleavage, the pseudosubstrate motif in theregulatory subunit is released from the substrate recognition siteof the catalytic subunit, which enables PRKCD to becomeconstitutively activated. The catalytic subunit which displaysproperties of a sphingosine-dependent protein kinase is activatedby D-erythro-sphingosine (Sph) or N,N-dimethyl-D-erythrosphingosine (DMS) or N,N,N-trimethyl-D-erythrosphingosine(TMS), but not by ceramide or Sph-1-P and is strongly inhibited byphosphatidylserine (By similarity). {ECO:0000250}.SUBUNIT: Interacts with PDPK1 (via N-terminal region), RAD9A,CDCP1, MUC1 and VASP. {ECO:0000269|PubMed:11781095,ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12628935,ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16940418}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046, ECO:0000269|PubMed:18285462}.Cytoplasm, perinuclear region {ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17603046}. Nucleus{ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:18285462}. Cell membrane{ECO:0000269|PubMed:17603046}; Peripheral membrane protein{ECO:0000305|PubMed:17603046}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q05655-1; Sequence=Displayed;Name=2; Synonyms=PKCdeltaVIII;IsoId=Q05655-2; Sequence=VSP_043899;Note=Antiapoptotic isoform, resistant to caspase-3 cleavage.;DOMAIN: The C1 domain, containing the phorbol ester/DAG-typeregion 1 (C1A) and 2 (C1B), is the diacylglycerol sensor.DOMAIN: The C2 domain is a non-calcium binding domain. It bindsproteins containing phosphotyrosine in a sequence-specific manner.PTM: Autophosphorylated and/or phosphorylated at Thr-507, withinthe activation loop; phosphorylation at Thr-507 is not aprerequisite for enzymatic activity. Autophosphorylated at Ser-299, Ser-302 and Ser-304. Upon TNFSF10/TRAIL treatment,phosphorylated at Tyr-155; phosphorylation is required for itstranslocation to the endoplasmic reticulum and cleavage bycaspase-3. Phosphorylated at Tyr-313, Tyr-334 and Tyr-567;phosphorylation of Tyr-313 and Tyr-567 following thrombinstimulation potentiates its kinase activity. Phosphorylated byprotein kinase PDPK1; phosphorylation is inhibited by theapoptotic C-terminal cleavage product of PKN2.{ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15774464,ECO:0000269|PubMed:17570831, ECO:0000269|PubMed:17603046,ECO:0000269|PubMed:19801500}.PTM: Proteolytically cleaved into a catalytic subunit and aregulatory subunit by caspase-3 during apoptosis which results inkinase activation. {ECO:0000250}.DISEASE: Autoimmune lymphoproliferative syndrome 3 (ALPS3)[MIM:615559]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen. Thedefect results from a failure of B-cell differentiation andimpaired secretion of immunoglobulins; the numbers of circulatingB-cells is usually in the normal range, but can be low. CVID9patients have B-cell deficiency and severe autoimmunity.{ECO:0000269|PubMed:23319571}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/PRKCDID42901ch3p21.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5580"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29954N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_006245"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_ddbj_embl_genbank_BAA01381_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_997704"],["bp:comment","REPLACED ProteinRef_PRKCD__40674"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5580"]]],["bp:name","nPKC-delta"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_74022"]]}},{"data":{"id":"Protein_99e95d38b0fe51ecd9919f7603bc0b65","class":"macromolecule","label":"ASAH1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":164.64758,"y":348.94913,"w":48,"h":25},"metadata":[["bp:displayName","Acid Ceramidase"],["bp:entityReference_http://identifiers.org/uniprot/Q13510",[["bp:standardName","Acid ceramidase"],["bp:xref",[["bp:id","Q13510"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ASAH1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ASAH1"],["bp:db","hgnc symbol"]]],["bp:displayName","ASAH1_HUMAN"],["bp:name","Acid ceramidase subunit alpha"],["bp:name","ASAH"],["bp:name","Acid ceramidase subunit beta"],["bp:name","Acylsphingosine deacylase"],["bp:name","3.5.1.23"],["bp:name","ACDase"],["bp:name","N-acylsphingosine amidohydrolase"],["bp:name","PHP32"],["bp:name","AC"],["bp:name","Putative 32 kDa heart protein"],["bp:name","ASAH1"],["bp:name","Acid CDase"],["bp:comment","REPLACED http://identifiers.org/uniprot/E7EMM4"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01969_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_427"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_427"],["bp:comment","FUNCTION: Hydrolyzes the sphingolipid ceramide into sphingosineand free fatty acid. {ECO:0000269|PubMed:7744740}.CATALYTIC ACTIVITY: N-acylsphingosine + H(2)O = a carboxylate +sphingosine. {ECO:0000269|PubMed:7744740}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=149 uM for N-lauroylsphingosine {ECO:0000269|PubMed:7744740};Vmax=136 nmol/h/mg enzyme with N-lauroylsphingosine as substrate{ECO:0000269|PubMed:7744740};pH dependence:Optimum pH is 3.8-4.3 with N-lauroylsphingosine as substrate.{ECO:0000269|PubMed:7744740};SUBUNIT: Heterodimer of one alpha and one beta subunit.{ECO:0000269|PubMed:7744740}.SUBCELLULAR LOCATION: Lysosome.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=Q13510-1; Sequence=Displayed;Name=2;IsoId=Q13510-2; Sequence=VSP_037504;Note=Variant in position: 185:W->R (in FL). Variant in position:382:K->Q (in FL). {ECO:0000269|PubMed:21982811};Name=3;IsoId=Q13510-3; Sequence=VSP_037504, VSP_046284, VSP_046285;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Broadly expressed with highest expression inheart.DISEASE: Farber lipogranulomatosis (FRBRL) [MIM:228000]: Anautosomal recessive lysosomal storage disorder characterized bysubcutaneous lipid-loaded nodules, excruciating pain in the jointsand extremities, and marked accumulation of ceramide in lysosomes.Disease severity is variable. The most severe disease subtype is arare neonatal form with death occurring before 1 year of age.{ECO:0000269|PubMed:10610716, ECO:0000269|PubMed:10993717,ECO:0000269|PubMed:11241842, ECO:0000269|PubMed:12638942,ECO:0000269|PubMed:16951918, ECO:0000269|PubMed:20609603,ECO:0000269|PubMed:21893389, ECO:0000269|PubMed:21982811,ECO:0000269|PubMed:8955159}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Spinal muscular atrophy with progressive myoclonicepilepsy (SMAPME) [MIM:159950]: An autosomal recessiveneuromuscular disorder characterized by childhood onset of motordeficits and progressive myoclonic seizures, after normaldevelopmental milestones. Proximal muscle weakness and generalizedmuscular atrophy are due to degeneration of spinal motor neurons.Myoclonic epilepsy is generally resistant to conventional therapy.The disease course is progressive and leads to respiratory muscleinvolvement and severe handicap or early death from respiratoryinsufficiency. {ECO:0000269|PubMed:22703880,ECO:0000269|PubMed:24164096}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the acid ceramidase family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAC73009.1; Type=Frameshift; Positions=15, 21; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","ASAH1_HUMAN Reviewed; 395 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_80723"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}}],"edges":[{"data":{"id":"Protein_63c92eb75b3e167900133d4669e0f283--to--BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_63c92eb75b3e167900133d4669e0f283","target":"BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_63c92eb75b3e167900133d4669e0f283","portTarget":"BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT-output--to--Protein_41cbba05d068bb578a344033dfd6b9a0","class":"production","cardinality":0,"source":"BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT","target":"Protein_41cbba05d068bb578a344033dfd6b9a0","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT","portTarget":"Protein_41cbba05d068bb578a344033dfd6b9a0"}},{"data":{"id":"SmallMolecule_69913dd701a4c1b21404a2aeee4d3fd9--to--BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"SmallMolecule_69913dd701a4c1b21404a2aeee4d3fd9","target":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_69913dd701a4c1b21404a2aeee4d3fd9","portTarget":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_7469a828ff14fc3ff99290371d6053e0--to--BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_7469a828ff14fc3ff99290371d6053e0","target":"BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_7469a828ff14fc3ff99290371d6053e0","portTarget":"InputPort_BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_42267d34042f1581692c87987313ebb5--to--Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_42267d34042f1581692c87987313ebb5","target":"Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_42267d34042f1581692c87987313ebb5","portTarget":"Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT-output--to--Protein_f5c36b1f964edd8213ea3babcf3d02e1","class":"production","cardinality":0,"source":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","target":"Protein_f5c36b1f964edd8213ea3babcf3d02e1","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","portTarget":"Protein_f5c36b1f964edd8213ea3babcf3d02e1"}},{"data":{"id":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT-output--to--SmallMolecule_4b5c686c031a54a8226c87afaaa8e98b","class":"production","cardinality":0,"source":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","target":"SmallMolecule_4b5c686c031a54a8226c87afaaa8e98b","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","portTarget":"SmallMolecule_4b5c686c031a54a8226c87afaaa8e98b"}},{"data":{"id":"Complex_52a595175addc44c86246899debd8454--to--BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_52a595175addc44c86246899debd8454","target":"BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_52a595175addc44c86246899debd8454","portTarget":"BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_8afb0e3b2e7a807fb983c1fad21e3106--to--ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_8afb0e3b2e7a807fb983c1fad21e3106","target":"ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_8afb0e3b2e7a807fb983c1fad21e3106","portTarget":"InputPort_ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_9ed2672027e26a84801ec82a7e17b642--to--BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_9ed2672027e26a84801ec82a7e17b642","target":"BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_9ed2672027e26a84801ec82a7e17b642","portTarget":"InputPort_BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_42267d34042f1581692c87987313ebb5--to--Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_42267d34042f1581692c87987313ebb5","target":"Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_42267d34042f1581692c87987313ebb5","portTarget":"Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT-output--to--Protein_26c29bc263b3ec949832ea6c307b3fe1","class":"production","cardinality":0,"source":"BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT","target":"Protein_26c29bc263b3ec949832ea6c307b3fe1","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT","portTarget":"Protein_26c29bc263b3ec949832ea6c307b3fe1"}},{"data":{"id":"BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT-output--to--Protein_a0b3d7ab91cab515a09792dabb8361e6","class":"production","cardinality":0,"source":"BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT","target":"Protein_a0b3d7ab91cab515a09792dabb8361e6","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT","portTarget":"Protein_a0b3d7ab91cab515a09792dabb8361e6"}},{"data":{"id":"Protein_057774005557cf4d75730302aebee51c--to--ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_057774005557cf4d75730302aebee51c","target":"ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_057774005557cf4d75730302aebee51c","portTarget":"InputPort_ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_424cd1f4f369b64bb79c706574eb0d16--to--BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"SmallMolecule_424cd1f4f369b64bb79c706574eb0d16","target":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_424cd1f4f369b64bb79c706574eb0d16","portTarget":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_e31100abd4d98b273704d6bdd2524fee--to--BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_e31100abd4d98b273704d6bdd2524fee","target":"BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_e31100abd4d98b273704d6bdd2524fee","portTarget":"InputPort_BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_12bcf51c75aae38cdb2620e757a2f48e--to--ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_12bcf51c75aae38cdb2620e757a2f48e","target":"ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_12bcf51c75aae38cdb2620e757a2f48e","portTarget":"InputPort_ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_df21ab8fde712730f509baed7c0e97f1--to--BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_df21ab8fde712730f509baed7c0e97f1","target":"BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_df21ab8fde712730f509baed7c0e97f1","portTarget":"BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_08df74199f1b23a420ba0b04166df60e--to--BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_08df74199f1b23a420ba0b04166df60e","target":"BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_08df74199f1b23a420ba0b04166df60e","portTarget":"BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_f09a415a974418bd0b6bc65135e60760--to--BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_f09a415a974418bd0b6bc65135e60760","target":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_f09a415a974418bd0b6bc65135e60760","portTarget":"InputPort_BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_7c70f237b0f19ba3db592f0ad84be0fd--to--BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_7c70f237b0f19ba3db592f0ad84be0fd","target":"BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_7c70f237b0f19ba3db592f0ad84be0fd","portTarget":"InputPort_BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_8df6fbb2ccfd27d2ffb2483093c4ad97--to--BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"SmallMolecule_8df6fbb2ccfd27d2ffb2483093c4ad97","target":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_8df6fbb2ccfd27d2ffb2483093c4ad97","portTarget":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT-output--to--Protein_19bc3f842f918886f021017e52a9c453","class":"production","cardinality":0,"source":"BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT","target":"Protein_19bc3f842f918886f021017e52a9c453","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_bc2a10b952c3fd1c141ba8dd2232f9a8_LEFT_TO_RIGHT","portTarget":"Protein_19bc3f842f918886f021017e52a9c453"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT"}},{"data":{"id":"Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT-output--to--Protein_ee92ce16bb5ebd6a4c6ecf0c1e60f011","class":"production","cardinality":0,"source":"Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT","target":"Protein_ee92ce16bb5ebd6a4c6ecf0c1e60f011","bendPointPositions":[],"portSource":"OutputPort_Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT","portTarget":"Protein_ee92ce16bb5ebd6a4c6ecf0c1e60f011"}},{"data":{"id":"Protein_5baa21cbcb67644b7ea848eb02cc8edd--to--ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_5baa21cbcb67644b7ea848eb02cc8edd","target":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_5baa21cbcb67644b7ea848eb02cc8edd","portTarget":"InputPort_ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_f5c36b1f964edd8213ea3babcf3d02e1--to--BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_f5c36b1f964edd8213ea3babcf3d02e1","target":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_f5c36b1f964edd8213ea3babcf3d02e1","portTarget":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT-output--to--Complex_57c85addb9c870fb650f24c45f6cb935","class":"production","cardinality":0,"source":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","target":"Complex_57c85addb9c870fb650f24c45f6cb935","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","portTarget":"Complex_57c85addb9c870fb650f24c45f6cb935"}},{"data":{"id":"Protein_4e99ebac6e0007d47a4838b2ae773d07--to--BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_4e99ebac6e0007d47a4838b2ae773d07","target":"BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_4e99ebac6e0007d47a4838b2ae773d07","portTarget":"InputPort_BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_843869a58602abb6fbfc3961550c55ef--to--Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"Protein_843869a58602abb6fbfc3961550c55ef","target":"Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_843869a58602abb6fbfc3961550c55ef","portTarget":"Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_1860f53d1b97dd11d29408c4f2f846d8--to--ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_1860f53d1b97dd11d29408c4f2f846d8","target":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_1860f53d1b97dd11d29408c4f2f846d8","portTarget":"InputPort_ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_bb8f0cd1124ca58baa10c0830e8a3bd3--to--ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_bb8f0cd1124ca58baa10c0830e8a3bd3","target":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_bb8f0cd1124ca58baa10c0830e8a3bd3","portTarget":"InputPort_ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT-output--to--Complex_6f3f7d29a99ad47d0a106e7986af465c","class":"production","cardinality":0,"source":"ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT","target":"Complex_6f3f7d29a99ad47d0a106e7986af465c","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT","portTarget":"Complex_6f3f7d29a99ad47d0a106e7986af465c"}},{"data":{"id":"Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT-output--to--Protein_cc5c1bfad753f6f8b2a7d5a89e3118b8","class":"production","cardinality":0,"source":"Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT","target":"Protein_cc5c1bfad753f6f8b2a7d5a89e3118b8","bendPointPositions":[],"portSource":"OutputPort_Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT","portTarget":"Protein_cc5c1bfad753f6f8b2a7d5a89e3118b8"}},{"data":{"id":"Protein_b54ed7eb0d63a83fb04431a4f179ecf2--to--BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_b54ed7eb0d63a83fb04431a4f179ecf2","target":"BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_b54ed7eb0d63a83fb04431a4f179ecf2","portTarget":"InputPort_BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT-output--to--Protein_8ef34d76e3b19562a5795cfa5dea9425","class":"production","cardinality":0,"source":"ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT","target":"Protein_8ef34d76e3b19562a5795cfa5dea9425","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT","portTarget":"Protein_8ef34d76e3b19562a5795cfa5dea9425"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"InputPort_ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_4b54a396195a7afb2d66e2623aef4725--to--ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_4b54a396195a7afb2d66e2623aef4725","target":"ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_4b54a396195a7afb2d66e2623aef4725","portTarget":"InputPort_ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_f59c961e9775137e7d6dabedebd36f0a--to--ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_f59c961e9775137e7d6dabedebd36f0a","target":"ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_f59c961e9775137e7d6dabedebd36f0a","portTarget":"InputPort_ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_e549451165253d4377bcbdda737a9c85--to--BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_e549451165253d4377bcbdda737a9c85","target":"BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_e549451165253d4377bcbdda737a9c85","portTarget":"InputPort_BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_7df2a04ff77beff2263dd05591458a72--to--BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_7df2a04ff77beff2263dd05591458a72","target":"BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_7df2a04ff77beff2263dd05591458a72","portTarget":"InputPort_BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_b51a045e32b204d7820ae210c6a55006--to--BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"SmallMolecule_b51a045e32b204d7820ae210c6a55006","target":"BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b51a045e32b204d7820ae210c6a55006","portTarget":"BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT-output--to--Complex_0082d1d47f9d4db10237bfa0b048e1de","class":"production","cardinality":0,"source":"ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT","target":"Complex_0082d1d47f9d4db10237bfa0b048e1de","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT","portTarget":"Complex_0082d1d47f9d4db10237bfa0b048e1de"}},{"data":{"id":"Protein_c150eaef12b60ffe815e4a50b857c496--to--BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_c150eaef12b60ffe815e4a50b857c496","target":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_c150eaef12b60ffe815e4a50b857c496","portTarget":"InputPort_BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_ddce8736f5a22a8c0af9357a774894ac--to--ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_ddce8736f5a22a8c0af9357a774894ac","target":"ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_ddce8736f5a22a8c0af9357a774894ac","portTarget":"InputPort_ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_8f22a0884f4372e32e806e7aea071f44--to--BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"SmallMolecule_8f22a0884f4372e32e806e7aea071f44","target":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_8f22a0884f4372e32e806e7aea071f44","portTarget":"InputPort_BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_278a5cea7704dc16dc95245a209ff208--to--BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_278a5cea7704dc16dc95245a209ff208","target":"BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_278a5cea7704dc16dc95245a209ff208","portTarget":"BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT-output--to--Protein_ffc8d02301b00a4ab030813d2f5fe0e8","class":"production","cardinality":0,"source":"BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT","target":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT","portTarget":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8"}},{"data":{"id":"Protein_f576ffc59d4746653266a7daef180870--to--ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_f576ffc59d4746653266a7daef180870","target":"ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_f576ffc59d4746653266a7daef180870","portTarget":"InputPort_ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_63c92eb75b3e167900133d4669e0f283--to--BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_63c92eb75b3e167900133d4669e0f283","target":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_63c92eb75b3e167900133d4669e0f283","portTarget":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT-output--to--Complex_f59c961e9775137e7d6dabedebd36f0a","class":"production","cardinality":0,"source":"BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT","target":"Complex_f59c961e9775137e7d6dabedebd36f0a","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT","portTarget":"Complex_f59c961e9775137e7d6dabedebd36f0a"}},{"data":{"id":"Complex_8799cc43e9e7f7445aeab812fde3e343--to--BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_8799cc43e9e7f7445aeab812fde3e343","target":"BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_8799cc43e9e7f7445aeab812fde3e343","portTarget":"BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_99e95d38b0fe51ecd9919f7603bc0b65--to--BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_99e95d38b0fe51ecd9919f7603bc0b65","target":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_99e95d38b0fe51ecd9919f7603bc0b65","portTarget":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_468f9ef328c933c629513ba7495bc4d9--to--Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_468f9ef328c933c629513ba7495bc4d9","target":"Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_468f9ef328c933c629513ba7495bc4d9","portTarget":"InputPort_Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT-output--to--Complex_d772c3d87a8f32f2dc14b2e83086db93","class":"production","cardinality":0,"source":"ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT","target":"Complex_d772c3d87a8f32f2dc14b2e83086db93","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT","portTarget":"Complex_d772c3d87a8f32f2dc14b2e83086db93"}},{"data":{"id":"BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT-output--to--Protein_0af015ace544274a79f50387d61825ee","class":"production","cardinality":0,"source":"BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT","target":"Protein_0af015ace544274a79f50387d61825ee","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT","portTarget":"Protein_0af015ace544274a79f50387d61825ee"}},{"data":{"id":"ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT-output--to--Complex_52a595175addc44c86246899debd8454","class":"production","cardinality":0,"source":"ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT","target":"Complex_52a595175addc44c86246899debd8454","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT","portTarget":"Complex_52a595175addc44c86246899debd8454"}},{"data":{"id":"BiochemicalReaction_be2b2e3f29a22891062321b977132b86_LEFT_TO_RIGHT-output--to--Protein_a0b3d7ab91cab515a09792dabb8361e6","class":"production","cardinality":0,"source":"BiochemicalReaction_be2b2e3f29a22891062321b977132b86_LEFT_TO_RIGHT","target":"Protein_a0b3d7ab91cab515a09792dabb8361e6","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_be2b2e3f29a22891062321b977132b86_LEFT_TO_RIGHT","portTarget":"Protein_a0b3d7ab91cab515a09792dabb8361e6"}},{"data":{"id":"Complex_0082d1d47f9d4db10237bfa0b048e1de--to--BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_0082d1d47f9d4db10237bfa0b048e1de","target":"BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_0082d1d47f9d4db10237bfa0b048e1de","portTarget":"BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT-output--to--Protein_461233220923d236025748ff1e4a769d","class":"production","cardinality":0,"source":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","target":"Protein_461233220923d236025748ff1e4a769d","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","portTarget":"Protein_461233220923d236025748ff1e4a769d"}},{"data":{"id":"Complex_57c85addb9c870fb650f24c45f6cb935--to--BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_57c85addb9c870fb650f24c45f6cb935","target":"BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_57c85addb9c870fb650f24c45f6cb935","portTarget":"BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT-output--to--Protein_5c1911b3d33a783b3c8db3d2cfbba1e6","class":"production","cardinality":0,"source":"BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT","target":"Protein_5c1911b3d33a783b3c8db3d2cfbba1e6","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT","portTarget":"Protein_5c1911b3d33a783b3c8db3d2cfbba1e6"}},{"data":{"id":"Protein_468f9ef328c933c629513ba7495bc4d9--to--Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_468f9ef328c933c629513ba7495bc4d9","target":"Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_468f9ef328c933c629513ba7495bc4d9","portTarget":"InputPort_Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT-output--to--Protein_59946f19a491a0ccdfd10b86bf8a3b2c","class":"production","cardinality":0,"source":"BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT","target":"Protein_59946f19a491a0ccdfd10b86bf8a3b2c","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT","portTarget":"Protein_59946f19a491a0ccdfd10b86bf8a3b2c"}},{"data":{"id":"Protein_065c6912b75528c460d6a73e12b20aef--to--ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_065c6912b75528c460d6a73e12b20aef","target":"ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_065c6912b75528c460d6a73e12b20aef","portTarget":"ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_e182e050a948953a2b7fe086f9bf09f1--to--ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_e182e050a948953a2b7fe086f9bf09f1","target":"ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_e182e050a948953a2b7fe086f9bf09f1","portTarget":"InputPort_ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT-output--to--Complex_dceae21100bab7ef8ef90d2fb262a17f","class":"production","cardinality":0,"source":"ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT","target":"Complex_dceae21100bab7ef8ef90d2fb262a17f","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT","portTarget":"Complex_dceae21100bab7ef8ef90d2fb262a17f"}},{"data":{"id":"BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT-output--to--Protein_ccb47936776e9cd8a0d309a51a253d46","class":"production","cardinality":0,"source":"BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT","target":"Protein_ccb47936776e9cd8a0d309a51a253d46","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_367ab7e357e719338a0a8771548e331f_LEFT_TO_RIGHT","portTarget":"Protein_ccb47936776e9cd8a0d309a51a253d46"}},{"data":{"id":"Protein_1824beb3bc656b1b24397d77f3e0dc49--to--Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_1824beb3bc656b1b24397d77f3e0dc49","target":"Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_1824beb3bc656b1b24397d77f3e0dc49","portTarget":"Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_752f949acd24a9eb8567d88a0935b28a--to--BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_752f949acd24a9eb8567d88a0935b28a","target":"BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_752f949acd24a9eb8567d88a0935b28a","portTarget":"BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT-output--to--Protein_0f0869ad9967fc9881a0254f5ab0f721","class":"production","cardinality":0,"source":"BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT","target":"Protein_0f0869ad9967fc9881a0254f5ab0f721","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT","portTarget":"Protein_0f0869ad9967fc9881a0254f5ab0f721"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_57c85addb9c870fb650f24c45f6cb935--to--BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_57c85addb9c870fb650f24c45f6cb935","target":"BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_57c85addb9c870fb650f24c45f6cb935","portTarget":"BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT-output--to--Protein_1824beb3bc656b1b24397d77f3e0dc49","class":"production","cardinality":0,"source":"BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT","target":"Protein_1824beb3bc656b1b24397d77f3e0dc49","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT","portTarget":"Protein_1824beb3bc656b1b24397d77f3e0dc49"}},{"data":{"id":"ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT-output--to--Complex_8799cc43e9e7f7445aeab812fde3e343","class":"production","cardinality":0,"source":"ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT","target":"Complex_8799cc43e9e7f7445aeab812fde3e343","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_2db672d0331734a36bc0cf0520857840_LEFT_TO_RIGHT","portTarget":"Complex_8799cc43e9e7f7445aeab812fde3e343"}},{"data":{"id":"BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT-output--to--Protein_4de5660d04065edd714945afa96addc5","class":"production","cardinality":0,"source":"BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT","target":"Protein_4de5660d04065edd714945afa96addc5","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT","portTarget":"Protein_4de5660d04065edd714945afa96addc5"}},{"data":{"id":"Complex_d772c3d87a8f32f2dc14b2e83086db93--to--BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_d772c3d87a8f32f2dc14b2e83086db93","target":"BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_d772c3d87a8f32f2dc14b2e83086db93","portTarget":"BiochemicalReaction_f4136b1998eddd2b8741319f009fb7c5_LEFT_TO_RIGHT"}},{"data":{"id":"Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT-output--to--Protein_cc5c1bfad753f6f8b2a7d5a89e3118b8","class":"production","cardinality":0,"source":"Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT","target":"Protein_cc5c1bfad753f6f8b2a7d5a89e3118b8","bendPointPositions":[],"portSource":"OutputPort_Transport_6ccf7db09b1beaeb7af61fbbd7a6038d_LEFT_TO_RIGHT","portTarget":"Protein_cc5c1bfad753f6f8b2a7d5a89e3118b8"}},{"data":{"id":"Protein_31a21d7f77c1a788543491fb2b184bbb--to--BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_31a21d7f77c1a788543491fb2b184bbb","target":"BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_31a21d7f77c1a788543491fb2b184bbb","portTarget":"InputPort_BiochemicalReaction_54b3702f006851bd47a435ab1c8e271c_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_bb16116cda922facd7903fd53727b854--to--ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_bb16116cda922facd7903fd53727b854","target":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_bb16116cda922facd7903fd53727b854","portTarget":"InputPort_ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT-output--to--Protein_42267d34042f1581692c87987313ebb5","class":"production","cardinality":0,"source":"BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT","target":"Protein_42267d34042f1581692c87987313ebb5","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT","portTarget":"Protein_42267d34042f1581692c87987313ebb5"}},{"data":{"id":"Complex_b9b86d6dc00e1af3e229fa08aa4ddccb--to--ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","target":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","portTarget":"InputPort_ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_e2861ae7a61f3469a6509614275092e7--to--BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_e2861ae7a61f3469a6509614275092e7","target":"BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_e2861ae7a61f3469a6509614275092e7","portTarget":"InputPort_BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227--to--BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227","target":"BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_c1cf4d2d73d0e40c3a2cc6a2dd636227","portTarget":"InputPort_BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_79cfbeed00aaf2ff3f85c67362751d30--to--BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_79cfbeed00aaf2ff3f85c67362751d30","target":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_79cfbeed00aaf2ff3f85c67362751d30","portTarget":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_5c1911b3d33a783b3c8db3d2cfbba1e6--to--BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_5c1911b3d33a783b3c8db3d2cfbba1e6","target":"BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_5c1911b3d33a783b3c8db3d2cfbba1e6","portTarget":"BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_52a595175addc44c86246899debd8454--to--BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_52a595175addc44c86246899debd8454","target":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_52a595175addc44c86246899debd8454","portTarget":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT-output--to--Protein_df21ab8fde712730f509baed7c0e97f1","class":"production","cardinality":0,"source":"BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT","target":"Protein_df21ab8fde712730f509baed7c0e97f1","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT","portTarget":"Protein_df21ab8fde712730f509baed7c0e97f1"}},{"data":{"id":"Complex_8799cc43e9e7f7445aeab812fde3e343--to--BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"Complex_8799cc43e9e7f7445aeab812fde3e343","target":"BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_8799cc43e9e7f7445aeab812fde3e343","portTarget":"BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT-output--to--SmallMolecule_69913dd701a4c1b21404a2aeee4d3fd9","class":"production","cardinality":0,"source":"BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT","target":"SmallMolecule_69913dd701a4c1b21404a2aeee4d3fd9","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT","portTarget":"SmallMolecule_69913dd701a4c1b21404a2aeee4d3fd9"}},{"data":{"id":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT-output--to--SmallMolecule_fb5c04347a4874d9ff2b1ac418abec8e","class":"production","cardinality":0,"source":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","target":"SmallMolecule_fb5c04347a4874d9ff2b1ac418abec8e","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","portTarget":"SmallMolecule_fb5c04347a4874d9ff2b1ac418abec8e"}},{"data":{"id":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8--to--BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8","target":"BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ffc8d02301b00a4ab030813d2f5fe0e8","portTarget":"BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_a4ea751750dbaec26a64eb323da26369--to--BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"Protein_a4ea751750dbaec26a64eb323da26369","target":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_a4ea751750dbaec26a64eb323da26369","portTarget":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT"}},{"data":{"id":"Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT-output--to--Protein_ee92ce16bb5ebd6a4c6ecf0c1e60f011","class":"production","cardinality":0,"source":"Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT","target":"Protein_ee92ce16bb5ebd6a4c6ecf0c1e60f011","bendPointPositions":[],"portSource":"OutputPort_Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT","portTarget":"Protein_ee92ce16bb5ebd6a4c6ecf0c1e60f011"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"InputPort_ComplexAssembly_b67bc02ee1e275c8c21d135129da26e7_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT-output--to--Protein_08df74199f1b23a420ba0b04166df60e","class":"production","cardinality":0,"source":"BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT","target":"Protein_08df74199f1b23a420ba0b04166df60e","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT","portTarget":"Protein_08df74199f1b23a420ba0b04166df60e"}},{"data":{"id":"ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT-output--to--Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","class":"production","cardinality":0,"source":"ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT","target":"Complex_b9b86d6dc00e1af3e229fa08aa4ddccb","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT","portTarget":"Complex_b9b86d6dc00e1af3e229fa08aa4ddccb"}},{"data":{"id":"Complex_57c85addb9c870fb650f24c45f6cb935--to--BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_57c85addb9c870fb650f24c45f6cb935","target":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_57c85addb9c870fb650f24c45f6cb935","portTarget":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT-output--to--SmallMolecule_b174942622c3e16fcf2959863bcf022d","class":"production","cardinality":0,"source":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","target":"SmallMolecule_b174942622c3e16fcf2959863bcf022d","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","portTarget":"SmallMolecule_b174942622c3e16fcf2959863bcf022d"}},{"data":{"id":"BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT-output--to--Protein_752f949acd24a9eb8567d88a0935b28a","class":"production","cardinality":0,"source":"BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT","target":"Protein_752f949acd24a9eb8567d88a0935b28a","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT","portTarget":"Protein_752f949acd24a9eb8567d88a0935b28a"}},{"data":{"id":"Protein_6f560aa8c1a3e1653a07472a3c63286f--to--BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_6f560aa8c1a3e1653a07472a3c63286f","target":"BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_6f560aa8c1a3e1653a07472a3c63286f","portTarget":"InputPort_BiochemicalReaction_ab0c342e131188ade233190819797875_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_a56ed666236bbdbf9bd991c41754204f--to--BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_a56ed666236bbdbf9bd991c41754204f","target":"BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_a56ed666236bbdbf9bd991c41754204f","portTarget":"InputPort_BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_e549451165253d4377bcbdda737a9c85--to--BiochemicalReaction_be2b2e3f29a22891062321b977132b86_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_e549451165253d4377bcbdda737a9c85","target":"BiochemicalReaction_be2b2e3f29a22891062321b977132b86_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_e549451165253d4377bcbdda737a9c85","portTarget":"InputPort_BiochemicalReaction_be2b2e3f29a22891062321b977132b86_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT-output--to--Protein_07241ca70aaa064dcd6380a81ff2bc8d","class":"production","cardinality":0,"source":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","target":"Protein_07241ca70aaa064dcd6380a81ff2bc8d","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","portTarget":"Protein_07241ca70aaa064dcd6380a81ff2bc8d"}},{"data":{"id":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT-output--to--Protein_89f70a1844b25ec5984cf26a32b0e470","class":"production","cardinality":0,"source":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","target":"Protein_89f70a1844b25ec5984cf26a32b0e470","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","portTarget":"Protein_89f70a1844b25ec5984cf26a32b0e470"}},{"data":{"id":"Protein_686db9912dfec92be002705e4fb86b1d--to--BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_686db9912dfec92be002705e4fb86b1d","target":"BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_686db9912dfec92be002705e4fb86b1d","portTarget":"InputPort_BiochemicalReaction_57a78a5d1a2aa2a2ab3bc044f270f389_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2--to--TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14","class":"inhibition","cardinality":0,"source":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2","target":"TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14","bendPointPositions":[],"portSource":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2","portTarget":"TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14"}},{"data":{"id":"Protein_3c65bb885bc05136445eb41a1409f50c--to--BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_3c65bb885bc05136445eb41a1409f50c","target":"BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_3c65bb885bc05136445eb41a1409f50c","portTarget":"InputPort_BiochemicalReaction_914093026b5a5dd7265e8b1eb2cf3432_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT-output--to--SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","class":"production","cardinality":0,"source":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","target":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","portTarget":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0"}},{"data":{"id":"Protein_48d9d24ed3c5ef9554008bb878f042a8--to--BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_48d9d24ed3c5ef9554008bb878f042a8","target":"BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_48d9d24ed3c5ef9554008bb878f042a8","portTarget":"InputPort_BiochemicalReaction_0ff841d2b01bbfe39cd5df055f5ea88a_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_c70cc1ccf2cde9639ff181595a85dda3--to--BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_c70cc1ccf2cde9639ff181595a85dda3","target":"BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_c70cc1ccf2cde9639ff181595a85dda3","portTarget":"InputPort_BiochemicalReaction_d85de49308ee220341febf17fe687b1c_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT-output--to--Protein_31a21d7f77c1a788543491fb2b184bbb","class":"production","cardinality":0,"source":"ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT","target":"Protein_31a21d7f77c1a788543491fb2b184bbb","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT","portTarget":"Protein_31a21d7f77c1a788543491fb2b184bbb"}},{"data":{"id":"Protein_f6435e1b4ee58d0cd8b74a85b5d6797f--to--Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_f6435e1b4ee58d0cd8b74a85b5d6797f","target":"Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_f6435e1b4ee58d0cd8b74a85b5d6797f","portTarget":"InputPort_Transport_a906787b8c90b96bc335edf11d9fa909_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_1824beb3bc656b1b24397d77f3e0dc49--to--Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_1824beb3bc656b1b24397d77f3e0dc49","target":"Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_1824beb3bc656b1b24397d77f3e0dc49","portTarget":"Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_53e145b04847d664d289afe34fbf89cc--to--ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_53e145b04847d664d289afe34fbf89cc","target":"ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_53e145b04847d664d289afe34fbf89cc","portTarget":"InputPort_ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_dceae21100bab7ef8ef90d2fb262a17f--to--BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"Complex_dceae21100bab7ef8ef90d2fb262a17f","target":"BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_dceae21100bab7ef8ef90d2fb262a17f","portTarget":"BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_be0a2c4a2b3747d87c5a2d76568a200b--to--ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_be0a2c4a2b3747d87c5a2d76568a200b","target":"ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_be0a2c4a2b3747d87c5a2d76568a200b","portTarget":"InputPort_ComplexAssembly_a782971d48f2f1f8961f6963534dcf87_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT-output--to--Protein_45fd195b8986611e93ee1d05c54c5867","class":"production","cardinality":0,"source":"BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT","target":"Protein_45fd195b8986611e93ee1d05c54c5867","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT","portTarget":"Protein_45fd195b8986611e93ee1d05c54c5867"}},{"data":{"id":"ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT-output--to--Protein_01c69bf5214b03bc85d545a5d2e46676","class":"production","cardinality":0,"source":"ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT","target":"Protein_01c69bf5214b03bc85d545a5d2e46676","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_fd316b4e1de861d86b9d48d586e03772_LEFT_TO_RIGHT","portTarget":"Protein_01c69bf5214b03bc85d545a5d2e46676"}},{"data":{"id":"BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT-output--to--Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2","class":"production","cardinality":0,"source":"BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT","target":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT","portTarget":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2"}},{"data":{"id":"Protein_843869a58602abb6fbfc3961550c55ef--to--Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"Protein_843869a58602abb6fbfc3961550c55ef","target":"Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_843869a58602abb6fbfc3961550c55ef","portTarget":"Transport_b92751597ccb7c05b660083cd4718a03_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_4b54a396195a7afb2d66e2623aef4725--to--ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_4b54a396195a7afb2d66e2623aef4725","target":"ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_4b54a396195a7afb2d66e2623aef4725","portTarget":"InputPort_ComplexAssembly_b5a6bb00ff63f647c458b35f209f3198_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad--to--BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad","target":"BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad","portTarget":"BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_54746a7dd41afff1181c13d616c2ce5a--to--ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_54746a7dd41afff1181c13d616c2ce5a","target":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_54746a7dd41afff1181c13d616c2ce5a","portTarget":"InputPort_ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_19bc3f842f918886f021017e52a9c453--to--BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_19bc3f842f918886f021017e52a9c453","target":"BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_19bc3f842f918886f021017e52a9c453","portTarget":"BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_57c85addb9c870fb650f24c45f6cb935--to--ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_57c85addb9c870fb650f24c45f6cb935","target":"ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_57c85addb9c870fb650f24c45f6cb935","portTarget":"ComplexAssembly_9b16cc2d7edbf777aaf9a231a120c0ac_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_a0b3d7ab91cab515a09792dabb8361e6--to--BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_a0b3d7ab91cab515a09792dabb8361e6","target":"BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_a0b3d7ab91cab515a09792dabb8361e6","portTarget":"BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT-output--to--SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","class":"production","cardinality":0,"source":"BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT","target":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT","portTarget":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0"}},{"data":{"id":"BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT-output--to--Protein_79cfbeed00aaf2ff3f85c67362751d30","class":"production","cardinality":0,"source":"BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT","target":"Protein_79cfbeed00aaf2ff3f85c67362751d30","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_49f53f69e846939e9051974045eeaba1_LEFT_TO_RIGHT","portTarget":"Protein_79cfbeed00aaf2ff3f85c67362751d30"}},{"data":{"id":"BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT-output--to--Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad","class":"production","cardinality":0,"source":"BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT","target":"Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_fc4f35af301919683f8988df9e0a72c7_LEFT_TO_RIGHT","portTarget":"Protein_1c62fe14b2d8aa6c5cf2aa7ba3f90aad"}},{"data":{"id":"SmallMolecule_b174942622c3e16fcf2959863bcf022d--to--BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"SmallMolecule_b174942622c3e16fcf2959863bcf022d","target":"BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b174942622c3e16fcf2959863bcf022d","portTarget":"InputPort_BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_26c29bc263b3ec949832ea6c307b3fe1--to--BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_26c29bc263b3ec949832ea6c307b3fe1","target":"BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_26c29bc263b3ec949832ea6c307b3fe1","portTarget":"BiochemicalReaction_2438bac6642a4a62bd174c6a096c20e0_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_6e31848cbf98ad57cabd5419ce8299a5--to--BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_6e31848cbf98ad57cabd5419ce8299a5","target":"BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_6e31848cbf98ad57cabd5419ce8299a5","portTarget":"InputPort_BiochemicalReaction_d4ecfdee127b264818b452afff5d479c_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_57c85addb9c870fb650f24c45f6cb935--to--BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_57c85addb9c870fb650f24c45f6cb935","target":"BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_57c85addb9c870fb650f24c45f6cb935","portTarget":"BiochemicalReaction_721c1301ecde0494b2aeed706c3b63bc_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"BiochemicalReaction_b0e34a77daa4f30005ca94cb13305ab3_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2--to--BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2","target":"BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_2170f548d0d8b4e7c5ec4c3d6e1386a2","portTarget":"BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_e2a17d02eeab58ed31e4539686756323--to--BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"SmallMolecule_e2a17d02eeab58ed31e4539686756323","target":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_e2a17d02eeab58ed31e4539686756323","portTarget":"BiochemicalReaction_403a056157e15f3d66595259e625e1ff_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_0af015ace544274a79f50387d61825ee--to--BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_0af015ace544274a79f50387d61825ee","target":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_0af015ace544274a79f50387d61825ee","portTarget":"BiochemicalReaction_b4d198ab3e5dfbf55ee93535a3af084f_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_07241ca70aaa064dcd6380a81ff2bc8d--to--ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_07241ca70aaa064dcd6380a81ff2bc8d","target":"ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_07241ca70aaa064dcd6380a81ff2bc8d","portTarget":"InputPort_ComplexAssembly_e643f526a246228e88091043c560e6c6_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_b2f0b61da0d4489c9bae7e3394902b11--to--BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_b2f0b61da0d4489c9bae7e3394902b11","target":"BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_b2f0b61da0d4489c9bae7e3394902b11","portTarget":"InputPort_BiochemicalReaction_63f43029fc618f4707c8f69dd795144e_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_a5726d9b0e4bdae718169725939db78d--to--ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_a5726d9b0e4bdae718169725939db78d","target":"ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_a5726d9b0e4bdae718169725939db78d","portTarget":"InputPort_ComplexAssembly_d56190a337908a172c2648810d0bd897_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_1219a0b0a64c43bb8747e7e459a510da--to--BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_1219a0b0a64c43bb8747e7e459a510da","target":"BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_1219a0b0a64c43bb8747e7e459a510da","portTarget":"InputPort_BiochemicalReaction_84bec344ceca88d6bbb28dc470284f5d_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_dec3540e8c049a00271de9871a91f002--to--BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_dec3540e8c049a00271de9871a91f002","target":"BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_dec3540e8c049a00271de9871a91f002","portTarget":"InputPort_BiochemicalReaction_c7bd551b88d069b2d11f0cfb6841ed8b_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_186a48824d7ef8afa6c6ead978884be7--to--BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_186a48824d7ef8afa6c6ead978884be7","target":"BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_186a48824d7ef8afa6c6ead978884be7","portTarget":"InputPort_BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_4de5660d04065edd714945afa96addc5--to--BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_4de5660d04065edd714945afa96addc5","target":"BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_4de5660d04065edd714945afa96addc5","portTarget":"BiochemicalReaction_4161e64339b9397da310a06fa9f92044_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_a4ea751750dbaec26a64eb323da26369--to--BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"Protein_a4ea751750dbaec26a64eb323da26369","target":"BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_a4ea751750dbaec26a64eb323da26369","portTarget":"BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT"}},{"data":{"id":"TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14-output--to--Protein_3c451b5cb571d63465f2edc4f88ea7cb","class":"production","cardinality":0,"source":"TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14","target":"Protein_3c451b5cb571d63465f2edc4f88ea7cb","bendPointPositions":[],"portSource":"OutputPort_TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14","portTarget":"Protein_3c451b5cb571d63465f2edc4f88ea7cb"}},{"data":{"id":"BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT-output--to--Protein_fb84c22837d2432ab826b5c993599b3e","class":"production","cardinality":0,"source":"BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT","target":"Protein_fb84c22837d2432ab826b5c993599b3e","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_e4451e570d2eb6f19e7b02fcb3531aea_LEFT_TO_RIGHT","portTarget":"Protein_fb84c22837d2432ab826b5c993599b3e"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"InputPort_BiochemicalReaction_06e9af6da4ffb53d746c791452f925ee_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0--to--BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","target":"BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_b6f7b3023e67664094526666ad9b1ed0","portTarget":"BiochemicalReaction_148dc98eac6dfe778d1a196ed3b548fd_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT-output--to--Protein_ea4c64305171f853861236d92ecc10b0","class":"production","cardinality":0,"source":"BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT","target":"Protein_ea4c64305171f853861236d92ecc10b0","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_bd85dd418db175e49200656d22d16cee_LEFT_TO_RIGHT","portTarget":"Protein_ea4c64305171f853861236d92ecc10b0"}},{"data":{"id":"SAS_For_TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14--to--TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14-input","class":"interaction","cardinality":0,"source":"SAS_For_TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14","target":"TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14","bendPointPositions":[],"portSource":"SAS_For_TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14","portTarget":"TemplateReaction_08d9a2fb28d25b6fc4b2060cf4925c14"}},{"data":{"id":"SmallMolecule_8f22a0884f4372e32e806e7aea071f44--to--BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"SmallMolecule_8f22a0884f4372e32e806e7aea071f44","target":"BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_8f22a0884f4372e32e806e7aea071f44","portTarget":"InputPort_BiochemicalReaction_beaccaa04276fddcbc66c657e189fb4b_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_f6435e1b4ee58d0cd8b74a85b5d6797f--to--Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_f6435e1b4ee58d0cd8b74a85b5d6797f","target":"Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_f6435e1b4ee58d0cd8b74a85b5d6797f","portTarget":"InputPort_Transport_640f3d7aca8a297cba32cf4e7585f6b0_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_ae6bb14892c00e5f2d82a78899eabf25--to--BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_ae6bb14892c00e5f2d82a78899eabf25","target":"BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ae6bb14892c00e5f2d82a78899eabf25","portTarget":"InputPort_BiochemicalReaction_7ef3d7d6bbd174161d5a15763bc5c0be_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_14e265016d0859a57c55cecd6ddaea95--to--BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_14e265016d0859a57c55cecd6ddaea95","target":"BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_14e265016d0859a57c55cecd6ddaea95","portTarget":"InputPort_BiochemicalReaction_46df10e07317ca62cf41bb61ac8f73bc_LEFT_TO_RIGHT"}}],"pathwayMetadata":{"comments":["REPLACED http://pid.nci.nih.gov/biopax#pid_80520"],"dataSource":["pid"],"title":["Ceramide signaling pathway"]}}